02393000000000481000450099100020000070000020000270600020000470100020000609100090
00081300053000174210030000701510029001000350010001294800053001390300026001929300
00500218117000600223085000300229935001000232031000300242032000200245036000600247
04200020025320000020025506500090025712200030026604800140026904800140028304800240
02970490023003210490033003440490037003770490031004140490025004450490042004700430
06900512043006900581043006900650540038800719540040201107540039601509541000601905
#1#0#i#1#20110324#Arquivos Brasileiros de Endocrinologia & Metabologia#Arq Bras 
Endocrinol Metabol. #Arq. bras. endocrinol. metab#0004-2730#Sociedade Brasileira
 de Endocrinologia e Metabologia#Arq Bras Endocrinol Metab#ABEM#other#nd#0004-27
30#55#1#20111#1#0#20110200#14#^les^hSumario#^lpt^hSumário#^len^hTable of Content
s#^lpt^cABEM020^tRevisão#^lpt^cABEM030^tArtigos Originais#^lpt^cABEM060^tApresen
tação de Casos#^lpt^cABEM080^tCarta ao Editor#^lpt^cABEM200^tEditorial#^lpt^cABE
M430^tCasos Clínicos Moleculares#^les^tArq Bras Endocrinol Metab^vvol.55^nno.1^c
São Paulo^mfeb.^a2011#^lpt^tArq Bras Endocrinol Metab^vvol.55^nno.1^cSão Paulo^m
fev.^a2011#^len^tArq Bras Endocrinol Metab^vvol.55^nno.1^cSão Paulo^mFeb.^a2011#
^t<a rel="license" href="http://creativecommons.org/licenses/by-nc/3.0/"><img al
t="Creative Commons License" style="border-width:0" src="http://i.creativecommon
s.org/l/by-nc/3.0/80x15.png" /></a> Todo el contenido de esta revista, excepto d
ónde está identificado, est&#225; bajo una <a rel="license" href="http://creativ
ecommons.org/licenses/by-nc/3.0/">Licencia Creative Commons</a>^les#^t<a rel="li
cense" href="http://creativecommons.org/licenses/by-nc/3.0/"><img alt="Creative 
Commons License" style="border-width:0" src="http://i.creativecommons.org/l/by-n
c/3.0/80x15.png" /></a> Todo o conteúdo deste periódico, exceto onde est&#225 id
entificado, est&#225; licenciado sob uma <a rel="license" href="http://creativec
ommons.org/licenses/by-nc/3.0/">Licen&#231;a Creative Commons</a>^lpt#^t<a rel="
license" href="http://creativecommons.org/licenses/by-nc/3.0/"><img alt="Creativ
e Commons License" style="border-width:0" src="http://i.creativecommons.org/l/by
-nc/3.0/80x15.png" /></a> All the contents of this journal, except where otherwi
se noted, is licensed under a <a rel="license" href="http://creativecommons.org/
licenses/by-nc/3.0/">Creative Commons Attribution License</a>^len#BY-NC##
00260000000000169000450000400060000070200420000670500020004870600020005070000020
00527010002000547090005000567080002000610910009000630920007000720020007000797030
00400086#v55n1#V:\SciELO\serial\abem\v55n1\markup\01.htm#S#o#1#1#text#1#20110324
#154455#01.htm#121##
00822000000000409000450000400060000070200420000670500020004870600020005070000020
00527010002000547090005000567080002000610710003000630400003000660010006000690420
00200075120000400077038000500081038000400086121000300090049000800093158000300101
03000260010403100030013003200020013306500090013501400070014403500100015112300020
01610120081001630100025002440100027002690700100002961170006003960720003004020020
00700405#v55n1#V:\SciELO\serial\abem\v55n1\markup\01.htm#S#h#2#1#text#1#ed#en#br
1.1#1#4.0#ILUS#GRA#01#ABEM200#nd#Arq Bras Endocrinol Metab#55#1#20110200#^f1^l5#
0004-2730#1#Tissue-specific effects of mutations in the thyroid hormone transpor
ter MCT8^len#^rND^nSimone^sKersseboom#^rND^1A01^nTheo J.^sVisser#Erasmus Univers
ity^iA01^1Medical Cente^2Department of Internal Medicine^cRotterdam^pThe Netherl
ands#other#19#01.htm##
00829000000000409000450000400060000070200420000670500020004870600020005070000020
00527010002000547090005000567080002000610710003000630400003000660010006000690420
00200075120000400077038000500081038000400086121000300090049000800093158000300101
03000260010403100030013003200020013306500090013501400070014403500100015112300020
01610120088001630100025002510100027002760700100003031170006004030720003004090020
00700412#v55n1#V:\SciELO\serial\abem\v55n1\markup\01.htm#S#f#3#1#text#1#ed#en#br
1.1#1#4.0#ILUS#GRA#01#ABEM200#nd#Arq Bras Endocrinol Metab#55#1#20110200#^f1^l5#
0004-2730#1#<b>Tissue-specific effects of mutations in the thyroid hormone trans
porter MCT8</b>^len#^rND^nSimone^sKersseboom#^rND^1A01^nTheo J.^sVisser#Erasmus 
University^iA01^1Medical Cente^2Department of Internal Medicine^cRotterdam^pThe 
Netherlands#other#19#01.htm##
00952000000000433000450000400060000070200420000670500020004870600020005070000020
00527010002000547090005000567080002000610640013000630710003000760400003000790010
00600082042000200088120000400090038000500094038000400099121000300103049000800106
15800030011403000290011703100030014603200020014906500090015101400070016003500100
01671230002001770120081001790100025002600100026002850700102003111170006004130720
00300419002000700422008008900429#v55n1#V:\SciELO\serial\abem\v55n1\markup\01.htm
#S#l#4#1#text#1#^mFeb.^a2011#ed#en#br1.1#1#4.0#ilus#gra#01#ABEM200#nd#Arq. bras.
 endocrinol. metab#55#1#20110200#^f1^l5#0004-2730#1#Tissue-specific effects of m
utations in the thyroid hormone transporter MCT8^len#^rND^nSimone^sKersseboom#^r
ND^1A01^nTheo J^sVisser#^iA01^1Erasmus University^2Medical Cente^3Department of 
Internal Medicine^cRotterdam^pThe Netherlands#other#19#01.htm#Internet^ihttp://w
ww.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27302011000100001##
00330000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000500056708000300061704011300064002000700177#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#5#1#text#97#<p align="right"><font face="Ve
rdana, Arial, Helvetica, sans-serif" size="2"><b>EDITORIAL</b></font></p>     ^c
Y#01.htm##
00239000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000500056708000300061704002200064002000700086#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#6#2#text#97#<p>&nbsp;</p>     ^cY#01.htm##
00404000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000500056708000300061704018700064002000700251#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#7#3#text#97#<p><a name="top"></a><font face
="Verdana, Arial, Helvetica, sans-serif" size="4"><b>Tissue-specific    effects 
of mutations in the thyroid hormone transporter MCT8</b></font></p>     ^cY#01.h
tm##
00239000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000500056708000300061704002200064002000700086#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#8#4#text#97#<p>&nbsp;</p>     ^cY#01.htm##
00239000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000500056708000300061704002200064002000700086#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#9#5#text#97#<p>&nbsp;</p>     ^cY#01.htm##
00369000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000500057708000300062704015100065002000700216#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#10#6#text#97#<p><font face="Verdana, Arial,
 Helvetica, sans-serif" size="2"><b>Simone Kersseboom<sup>I</sup>;    Theo J. Vi
sser<sup>II</sup></b></font></p>     ^cY#01.htm##
00414000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000500057708000300062704019600065002000700261#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#11#7#text#97#<p><font face="Verdana, Arial,
 Helvetica, sans-serif" size="2"><sup>I</sup>PhD    student, Department of Inter
nal Medicine, Erasmus University Medical Center,    Rotterdam, The Netherlands  
  ^cY#01.htm##
00366000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000500057708000300062704014800065002000700213#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#12#8#text#97#<br>   <sup>II</sup>Professor,
 Department of Internal Medicine, Erasmus University    Medical Center, Rotterda
m, The Netherlands</font></p>     ^cY#01.htm##
00341000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000500057708000300062704012300065002000700188#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#13#9#text#97#<p><font face="Verdana, Arial,
 Helvetica, sans-serif" size="2"><a href="#back">Correspondence    to</a></font>
</p>     ^cY#01.htm##
00241000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704002200066002000700088#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#14#10#text#97#<p>&nbsp;</p>     ^cY#01.htm#
#
00241000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704002200066002000700088#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#15#11#text#97#<p>&nbsp;</p>     ^cY#01.htm#
#
00827000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704060800066002000700674#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#16#12#text#97#<p><font face="Verdana, Arial
, Helvetica, sans-serif" size="2">Thyroid hormone    (TH) is important for the d
evelopment of different tissues, in particular the    brain, as well as for the 
regulation of the metabolic activities of the tissues    and thermogenesis throu
ghout life. Most TH actions are initiated by binding    of the active hormone 3,
3',5-triiodothyronine (T3) to its nuclear receptor.    This induces an alteratio
n in proteins associated with the transcription initiation    complex, resulting
 in the stimulation or suppression of the expression of TH    responsive genes.<
/font></p>     ^cY#01.htm##
01313000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704109400066002000701160#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#17#13#text#97#<p><font face="Verdana, Arial
, Helvetica, sans-serif" size="2">The biological    activity of TH is thus deter
mined by the intracellular T3 concentration, which    is only indirectly depende
nt on the function of the thyroid gland which secretes    predominantly the proh
ormone thyroxine (3,3',5,5'-tetraiodothyronine, T4). In    many target tissues, 
T3 availability is regulated in a paracrine manner, where    T3 supply to target
 cells is derived from T4 to T3 conversion in neighbouring    cells. Brain and c
ochlea are examples of tissues with paracrine regulation of    TH action. In oth
er tissues, such as the pituitary and brown adipose tissue    (BAT), T3 may be p
roduced from T4 directly in its target cells, representing    an autocrine mecha
nism of TH action (<a href="#f1">Figure 1</a>). In yet other    tissues such as 
the liver and the kidneys, intracellular T3 is in rapid exchange    with circula
ting T3. This could be regarded as an endocrine action of T3, although    it is 
still largely derived from peripheral conversion of T4 even in these same    tis
sues.</font></p>     ^cY#01.htm##
00252000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704003300066002000700099#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#18#14#text#97#<p><a name="f1"></a></p>     
^cY#01.htm##
00241000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704002200066002000700088#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#19#15#text#97#<p>&nbsp;</p>     ^cY#01.htm#
#
00296000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704007700066002000700143#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#20#16#text#97#<p align="center"><img src="/
img/revistas/abem/v55n1/01f01.jpg"></p>     ^cY#01.htm##
00241000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704002200066002000700088#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#21#17#text#97#<p>&nbsp;</p>     ^cY#01.htm#
#
01679000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704146000066002000701526#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#22#18#text#97#<p><font face="Verdana, Arial
, Helvetica, sans-serif" size="2">In contrast to    the activation of T4 by enzy
matic outer ring deiodination (ORD) to T3, TH is    inactivated by inner ring de
iodination (IRD), which converts T4 to 3,3',5'-triiodothyronine    (reverse T3, 
rT3) and T3 to 3,3'-diiodothyronine (T2) (1). Three iodothyronine    deiodinases
 (D1-3) are involved in these different deiodination reactions (1).    D1 is exp
ressed in liver, kidneys and thyroid and has both ORD and IRD activity.    It is
 thought to contribute importantly to production of serum T3, in particular    i
n eu- and hyperthyroid conditions. D2 has only ORD activity and is expressed    
in brain, pituitary, BAT, thyroid and skeletal muscle. It is essential for local
    production of T3 in brain, pituitary and BAT, but the enzyme in thyroid and 
   muscle may also be an important site for production of serum T3 in eu- and hy
pothyroid    subjects. D3 is highly expressed in different fetal tissues, placen
ta and pregnant    uterus, and also in adult brain and skin. It has only IRD act
ivity and thus    catalyzes the inactivation of TH. Together with D2, D3 has a c
rucial role in    the region-specific and time-dependent regulation of T3 in the
 developing brain.    The deiodinases are homologous selenoprotein embedded in t
he membrane of the    endoplasmic reticulum or the plasma membrane, such that th
e active sites are    located in the cytoplasm (1).</font></p>     ^cY#01.htm##
01153000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704093400066002000701000#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#23#19#text#97#<p><font face="Verdana, Arial
, Helvetica, sans-serif" size="2">TH metabolism and    action are intracellular 
processes that require transport of iodothyronines    across the cell membrane. 
This does not take place by passive diffusion but    requires the involvement of
 specific transporters (2). A number of multi-specific    transporters have been
 identified which are also capable of transporting TH.    In addition, three tra
nsporters have been characterized showing considerable    specificity for iodoth
yronines, namely OATP1C1, MCT8, and MCT10 (2). The pathophysiological    relevan
ce of TH transporters has become clear in particular for MCT8, mutations    in w
hich are the cause of a syndrome of X-linked psychomotor retardation combined   
 with abnormal TH levels (3,4). The clinical characteristics of a patient with  
  a novel mutation in <i>MCT8</i> are described by de Menezes Filho and cols.   
 (5).</font></p>     ^cY#01.htm##
00241000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704002200066002000700088#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#24#20#text#97#<p>&nbsp;</p>     ^cY#01.htm#
#
00345000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704012600066002000700192#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#25#21#text#97#<p><font face="Verdana, Arial
, Helvetica, sans-serif" size="3"><b>MOLECULAR CHARACTERISTICS    OF MCT8</b></f
ont></p>     ^cY#01.htm##
00767000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704054800066002000700614#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#26#22#text#97#<p><font face="Verdana, Arial
, Helvetica, sans-serif" size="2">MCT8 and MCT10    are members of what is calle
d the monocarboxylate transporter (MCT) family,    although only 4 members of th
is family (MCT1-4) are known to transport monocarboxylates    such as lactate an
d pyruvate (6). The function of most of the 14 members of    this family is stil
l enigmatic. In 2001, MCT10 was identified as an aromatic    amino acid transpor
ter and we have subsequently demonstrated that MCT8 and MCT10    are effective T
H transporters (2).</font></p>     ^cY#01.htm##
00985000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704076600066002000700832#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#27#23#text#97#<p><font face="Verdana, Arial
, Helvetica, sans-serif" size="2">The <i>MCT8</i>    gene is located on human ch
r Xq13.2 and has 6 exons and, thus, 5 introns of    which intron 1 is ~100 kb in
 size. <i>MCT8</i> has two possible translation    start sites (TLSs), yielding 
proteins of 613 or 539 amino acids. In many animals    <i>MCT8</i> lacks the fir
st TLS giving rise to only the short MCT8 protein.    If the N-terminal extensio
n of the long human MCT8 protein has specific functions    remains to be determi
ned. The <i>MCT10</i> gene has a very similar structure,    is located on human 
chr 6q21-q22, and codes for a protein of 515 amino acids.    In all species, <i>
MCT10</i> has only one TLS, corresponding to the second TLS    of human MCT8.</f
ont></p>     ^cY#01.htm##
01391000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704117200066002000701238#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#28#24#text#97#<p><font face="Verdana, Arial
, Helvetica, sans-serif" size="2">MCT8 and MCT10    have 12 putative transmembra
ne domains (TMDs), with both N-and C-terminal domains    located intracellularly
. MCT8 and MCT10 show a high degree of homology, especially    in their TMDs, wh
ich fits with their similar functions as TH transporters. Both    MCT8 and MCT10
 transport different iodothyronines; T3 is transported somewhat    better by MCT
10 than by MCT8, whereas the opposite is true for T4 (2). Both    MCT8 and MCT10
 facilitate cellular uptake as well as efflux of iodothyronines.    Expression o
f MCT8 or MCT10 may thus induce only a modest increase in steady-state    intrac
ellular TH levels. However, transfection of cells with MCT8 or MCT10 strongly   
 increases iodothyronine metabolism by D1, D2 or D3-expressing cells, indicating
    that they indeed effectively increase intracellular TH availability (2). Pre
vention    of T4 and T3 efflux by co-transfection with the high-affinity cytopla
smic TH-binding    protein CRYM, allows the proper study of TH uptake facilitate
d by MCT8 and MCT10    (2). TH efflux by MCT8 and MCT10 has been less well studi
ed.</font></p>     ^cY#01.htm##
00913000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704069400066002000700760#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#29#25#text#97#<p><font face="Verdana, Arial
, Helvetica, sans-serif" size="2">MCT8 and MCT10    are expressed in many human 
tissues. MCT8 is highly expressed in liver, kidney,    adrenal, ovary and thyroi
d. Studies in mice have shown that MCT8 is also expressed    importantly in brai
n, in particular in neurons in different brain regions, including    cerebral co
rtex and cerebellum, but also in the choroid plexus, in capillaries    and in ta
nycytes lining the 3<sup>rd</sup> ventricle (7). MCT8 has been localized    in d
ifferent nuclei in the human hypothalamus and in the human pituitary (8),    whe
re it appears to be expressed predominantly apparently in folliculostellate    c
ells.</font></p>     ^cY#01.htm##
00241000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704002200066002000700088#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#30#26#text#97#<p>&nbsp;</p>     ^cY#01.htm#
#
00317000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704009800066002000700164#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#31#27#text#97#<p><font face="Verdana, Arial
, Helvetica, sans-serif" size="3"><b>PATIENTS</b></font></p>     ^cY#01.htm##
01469000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704125000066002000701316#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#32#28#text#97#<p><font face="Verdana, Arial
, Helvetica, sans-serif" size="2">Mutations in MCT8    are associated with X-lin
ked psychomotor retardation and abnormal serum TH levels    (2-4). The neurologi
cal syndrome is also known as the Allan-Herndon-Dudley syndrome    (AHDS) after 
the authors of the first study of a large family with affected    males publishe
d in 1944. AHDS comprises central hypotonia associated with poor    head control
 and initially also peripheral hypotonia that progresses to hypertonia    and sp
asticity. Most AHDS patients are unable to sit, stand or walk independently    a
nd have not developed speech. However, in some families patients have a milder  
  phenotype and are able to walk and/or talk, albeit with great difficulty. All 
   patients have severe mental retardation. AHDS patients are born without appar
ent    abnormality and the disease appears to develop progressively, often assoc
iated    with microcephaly. MRI of the brain usually shows delayed myelination b
efore    the age of 2 years which apparently normalizes with increasing age. For
 a more    detailed description of the clinical characteristics, readers are ref
erred to    Holden and cols. (9) and the paper by de Menezes Filho and cols. (5)
.</font></p>     ^cY#01.htm##
00949000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704073000066002000700796#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#33#29#text#97#<p><font face="Verdana, Arial
, Helvetica, sans-serif" size="2">In addition to    the psychomotor retardation,
 AHDS patients have abnormal serum TH levels. Serum    T4 and FT4 levels vary fr
om low-normal to truly reduced, whereas serum T3 levels    are invariably increa
sed. Like T4, serum rT3 is often decreased, and the serum    T3/rT3 and T3/T4 ra
tios are markedly elevated. Serum TSH varies between normal    and elevated; mea
n TSH levels are about twice the normal mean. In view of the    low (F)T4 and so
mewhat higher TSH levels, many AHDS patients have been treated    with T4 substi
tution without any obvious benefit. This is also the case with    the patient re
ported by de Menezes Filho and cols. (5).</font></p>     ^cY#01.htm##
00938000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704071900066002000700785#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#34#30#text#97#<p><font face="Verdana, Arial
, Helvetica, sans-serif" size="2">TH is crucial for    brain development. In AHD
S patients, brain development is impaired despite the    presence of elevated se
rum T3 levels, indicating some form of TH resistance.    This is explained by th
e lack of T3 uptake in neuronal target cells where T3    action is required for 
optimal brain development (<a href="#f1">Figure 1</a>).    AHDS only occurs in m
ales since the <i>MCT8</i> gene is located on the X chromosome.    However, one 
female has been described with AHDS due to chromosomal translocation    with a b
reakpoint in <i>MCT8</i> on one X chromosome and unfavourable inactivation    of
 the intact X chromosome (10).</font></p>     ^cY#01.htm##
01227000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704100800066002000701074#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#35#31#text#97#<p><font face="Verdana, Arial
, Helvetica, sans-serif" size="2">In over 50 families    with AHDS studied so fa
r various mutations in <i>MCT8</i> have been identified.    These mutations incl
ude large deletions, frame-shift mutations and non-sense    mutations, which obv
iously inactivate MCT8. However, for mutations resulting    in the deletion, ins
ertion or substitution of single amino acids this is less    obvious. The conseq
uences of these mutations have been tested in cells transfected    with wild-typ
e (wt) or mutant MCT8 alone or in combination with cDNA coding    for D3. These 
cells have subsequently been tested for TH uptake or TH metabolism,    respectiv
ely. All tested mutations result in a marked decrease in TH transport,    althou
gh the magnitude of the defect depends on the cell type used for transfection   
 (2,11). The results suggest some correlation between the severity of the clinic
al    phenotype, the changes in serum TH levels and the defect in TH transport.<
/font></p>     ^cY#01.htm##
00241000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704002200066002000700088#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#36#32#text#97#<p>&nbsp;</p>     ^cY#01.htm#
#
00368000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704014900066002000700215#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#37#33#text#97#<p><font face="Verdana, Arial
, Helvetica, sans-serif" size="3"><b>TISSUE AND HORMONE-SPECIFIC    EFFECTS OF M
CT8 INACTIVATION</b></font></p>     ^cY#01.htm##
01174000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704095500066002000701021#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#38#34#text#97#<p><font face="Verdana, Arial
, Helvetica, sans-serif" size="2">Inactivation of    MCT8 appears to have differ
ent effects on TH availability in different tissues.    As mentioned above, the 
neurological phenotype of patients with MCT8 mutations    is explained by the la
ck of T3 uptake in central neurons. This appears to be    supported by observati
ons that brain T3 uptake is almost completely blocked    in Mct8 knockout (ko) m
ice, whereas brain T4 uptake is not affected (12). However,    brain T3 uptake i
s probably largely determined by transport across the blood-brain    barrier (BB
B) and/or the blood-CSF barrier (BCB) and indeed MCT8 is importantly    expresse
d in brain capillaries and in the choroid plexus (7,13). The lack of    effect o
f Mct8 inactivation on brain uptake of T4, which is also a substrate    for MCT8
, may be explained by assuming that T4 is largely transported across    the BBB 
and BCF by OATP1C1 (7,13).</font></p>     ^cY#01.htm##
01235000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704101600066002000701082#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#39#35#text#97#<p><font face="Verdana, Arial
, Helvetica, sans-serif" size="2">In contrast to    the subnormal T3 levels in b
rain, tissue T3 levels may be normal or even increased    in other tissues, depe
nding on the repertoire of TH transporters expressed.    Although MCT8 is highly
 expressed in liver, hepatic T4 and T3 uptake do not    seem to be affected in M
ct8 ko mice (12). As the liver is exposed to increased    serum T3 levels, there
 is increased expression of T3 responsive genes such as    <i>Dio1</i> in the li
ver of Mct8 ko mice (12). This is in agreement with the    elevated serum SHBG l
evels in AHDS patients, knowing that hepatic expression    of SHBG is stimulated
 by T3 and increased in patients with hyperthyroidism (14).    The body composit
ion of AHDS patients also suggest increased metabolic rate    and muscle wasting
 due to tissue hyperthyroidism. This is also reported in the    present study by
 de Menezes Filho and cols (5). Also tachycardia has been observed    in AHDS pa
tients.</font></p>     ^cY#01.htm##
00879000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704066000066002000700726#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#40#36#text#97#<p><font face="Verdana, Arial
, Helvetica, sans-serif" size="2"><i>Mct8</i> ko    have been generated to study
 the pathogenic mechanism of AHDS, but disappointingly    these mice do not show
 any obvious neurological phenotype (12,15). However,    they do show the same c
hanges in serum TH levels as AHDS patients, including    a markedly decreased se
rum T4 and a markedly increased serum T3. Studies into    the mechanisms of thes
e alterations have indicated a) increased D1 expression    in liver and kidney, 
b) increased D2 activity in brain and pituitary, and c)    decreased D3 activity
 in brain of Mct8 ko <i>vs.</i> wt animals (12,16).</font></p>     ^cY#01.htm##
00855000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704063600066002000700702#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#41#37#text#97#<p><font face="Verdana, Arial
, Helvetica, sans-serif" size="2">In contrast to    the impaired brain T3 transp
ort and unaffected hepatic T4 and T3 transport,    renal T4 and T3 accumulation 
is increased in the kidneys of Mct8 ko <i>vs.</i>    wt mice (12,16). This parad
oxical change may suggest that MCT8 is more important    for TH efflux than for 
TH uptake in the kidney. The increased tissue T4 content    together with the hi
gh renal D1 activity may contribute to the large increase    in peripheral T4 to
 T3 conversion, and thus, to the low T4 and high serum T3    levels in Mct8 ko m
ice and AHDS patients (16).</font></p>     ^cY#01.htm##
00882000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704066300066002000700729#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#42#38#text#97#<p><font face="Verdana, Arial
, Helvetica, sans-serif" size="2">Recent studies    have unveiled an important f
unction of MCT8 also in TH secretion (17,18). Thyroidal    T4 and T3 content is 
increased in Mct8 ko <i>vs.</i> wt mice. Furthermore, the    increase in serum T
4 induced by TSH injection is lower, whereas the increase    in serum T3 is high
er in Mct8 ko <i>vs.</i> wt mice (18). This suggests that    MCT8 plays an impor
tant role in T4 secretion by thyroid cells. If MCT8 is inactivated,    T4 accumu
lates in the thyrocyte leading to increased intra-thyroidal T4 to T3    conversi
on, and thus an increase in the T3/T4 secretion ratio.</font></p>     ^cY#01.htm
##
00858000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704063900066002000700705#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#43#39#text#97#<p><font face="Verdana, Arial
, Helvetica, sans-serif" size="2">Finally, MCT8 is    expressed in both the hypo
thalamus and the pituitary, and its inactivation may    thus interfere with the 
negative feedback of TH at both sites (12,18). Indeed,    serum TSH is usually m
odestly increased in AHDS patients, which may be compatible    with the modestly
 decreased serum T4 levels but not with the strongly elevated    serum T3 levels
. In Mct8 ko mice hypothalamic TRH expression is markedly increased    which can
 only be suppressed by very high T3 doses, indicating T3 resistance    particula
rly at the hypothalamic level.</font></p>     ^cY#01.htm##
01124000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704090500066002000700971#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#44#40#text#97#<p><font face="Verdana, Arial
, Helvetica, sans-serif" size="2">The study by de    Menezes Filho and cols. (5)
 reported in this issue presents important information    regarding TH dysregula
tion in AHDS patients. In agreement with previous studies,    their patient exhi
bits low serum FT4 and elevated T3 and TSH levels, in agreement    with an impai
red negative feedback of T3. Because of the decreased T4 and increased    TSH, t
he patient was treated with LT4. This resulted in a decrease in serum    TSH and
, remarkably, also a decrease in serum T3. Plotting their data indicates    that
 serum TSH shows a remarkably strong negative correlation with serum FT4    and 
an equally strong positive correlation with serum T3 (<a href="#f2">Figure    2<
/a>). These results are compatible with the view that thyroidal T3 secretion    
may be an important source of serum T3 in AHDS patients.</font></p>     ^cY#01.h
tm##
00252000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704003300066002000700099#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#45#41#text#97#<p><a name="f2"></a></p>     
^cY#01.htm##
00241000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704002200066002000700088#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#46#42#text#97#<p>&nbsp;</p>     ^cY#01.htm#
#
00296000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704007700066002000700143#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#47#43#text#97#<p align="center"><img src="/
img/revistas/abem/v55n1/01f02.jpg"></p>     ^cY#01.htm##
00241000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704002200066002000700088#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#48#44#text#97#<p>&nbsp;</p>     ^cY#01.htm#
#
00318000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704009900066002000700165#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#49#45#text#97#<p><font face="Verdana, Arial
, Helvetica, sans-serif" size="3"><b>TREATMENT</b></font></p>     ^cY#01.htm##
01049000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704083000066002000700896#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#50#46#text#97#<p><font face="Verdana, Arial
, Helvetica, sans-serif" size="2">The lack of a neurological    phenotype in Mct
8 ko mice precludes their use as a model for development of    an effective trea
tment of AHDS patients. The possible success of such a treatment    will depend 
on a) the extent to which irreversible damage in brain development    has occurr
ed at the time the disease is diagnosed, and b) the possibility to    supply act
ive hormone to important brain targets in the absence of functional    MCT8. TH 
is essential for prenatal brain development, but TH-dependent brain    maturatio
n continues after birth (19). The lack of obvious abnormalities at    birth and 
the progressive nature of AHDS may suggest that early postnatal initiation    of
 an effective therapy may have substantial beneficial effect.</font></p>     ^cY
#01.htm##
01164000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704094500066002000701011#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#51#47#text#97#<p><font face="Verdana, Arial
, Helvetica, sans-serif" size="2">Because of the    low serum T4 in combination 
with a modestly increased serum TSH, many AHDS patients    have been treated wit
h LT4 without obvious benefit. In fact, such treatment    may have detrimental e
ffects as it may further increase T3 exposure of tissues    which do not depend 
on MCT8 for TH uptake. For instance, it may induce or aggravate    tachycardia. 
It could also be hypothesized that the abnormal serum T4 and T3    levels contri
bute importantly to the clinical phenotype and that their normalization    may h
ave beneficial therapeutic effects. Such a study has been carried out in    an a
dolescent AHDS patient in whom serum TH levels were normalized by block-and-repl
ace    therapy with PTU plus LT4. This produced favourable effects on body weigh
t and    heart rate but - as expected - did not result in an obvious mental impr
ovement    (14).</font></p>     ^cY#01.htm##
00734000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704051500066002000700581#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#52#48#text#97#<p><font face="Verdana, Arial
, Helvetica, sans-serif" size="2">Obvious possibilities    for effective therapy
 include early treatment of AHDS patients with a thyromimetic    which is effect
ively transported into the brain even if MCT8 is mutated. The    T3 analogue DIT
PA is currently tested clinically in MCT8 patients (20). Preclinical    studies 
are also in progress to test if the bioactive TH metabolite Triac or    its prec
ursor Tetrac may be used for effective treatment of AHDS patients.</font></p>   
  ^cY#01.htm##
00376000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704015700066002000700223#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#53#49#text#97#<p><font face="Verdana, Arial
, Helvetica, sans-serif" size="2">Acknowledgment:    Simone Kersseboom is suppor
ted by the Smile Foundation.</font></p>     ^cY#01.htm##
00241000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704002200066002000700088#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#54#50#text#97#<p>&nbsp;</p>     ^cY#01.htm#
#
00319000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704010000066002000700166#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#55#51#text#97#<p><font face="Verdana, Arial
, Helvetica, sans-serif" size="3"><b>REFERENCES</b></font></p>     ^cY#01.htm##
00493000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063888000200066704026000068002000700328#v55
n1#V:\SciELO\serial\abem\v55n1\markup\01.htm#S#p#56#52#text#97#1#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="2">1. Gereben B, Zavacki    AM, Rib
ich S, Kim BW, Huang SA, Simonides WS, et al. Cellular and molecular    basis of
 deiodinase-regulated thyroid hormone signaling. Endocr Rev. 2008;29:898-938.   
 ^cY#01.htm##
00239000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704002000066002000700086#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#57#53#text#97#</font></p>     ^cY#01.htm##
00459000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063888000200066704022600068002000700294#v55
n1#V:\SciELO\serial\abem\v55n1\markup\01.htm#S#p#58#54#text#97#2#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="2">2. Visser WE, Friesema    EC, Vi
sser TJ. Minireview: thyroid hormone transporters: the knowns and the    unknown
s. Mol Endocrinol. 2011;25:1-14</font></p>     ^cY#01.htm##
00539000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063888000200066704030600068002000700374#v55
n1#V:\SciELO\serial\abem\v55n1\markup\01.htm#S#p#59#55#text#97#3#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="2">3. Dumitrescu AM,    Liao XH, Be
st TB, Brockmann K, Refetoff S. A novel syndrome combining thyroid    and neurol
ogical abnormalities is associated with mutations in a monocarboxylate    transp
orter gene. Am J Hum Genet. 2004;74:168-75.    ^cY#01.htm##
00239000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704002000066002000700086#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#60#56#text#97#</font></p>     ^cY#01.htm##
00526000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063888000200066704029300068002000700361#v55
n1#V:\SciELO\serial\abem\v55n1\markup\01.htm#S#p#61#57#text#97#4#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="2">4. Friesema EC,    Grueters A, B
iebermann H, Krude H, von Moers A, Reeser M, et al. Association    between mutat
ions in a thyroid hormone transporter and severe X-linked psychomotor    retarda
tion. Lancet. 2004;364:1435-7.    ^cY#01.htm##
00239000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704002000066002000700086#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#62#58#text#97#</font></p>     ^cY#01.htm##
00553000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063888000200066704032000068002000700388#v55
n1#V:\SciELO\serial\abem\v55n1\markup\01.htm#S#p#63#59#text#97#5#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="2">5. Menezes Filho    HC, Marui S,
 Manna TD, Brust ES, Radonsky V, Kuperman H, et al. Novel mutation    in MCT8 ge
ne in a Brazilian boy with thyroid hormone resistance and severe neurologic    a
bnormalities. Arq Bras Endocrinol Metab. 2011;55(1):60-6.    ^cY#01.htm##
00239000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704002000066002000700086#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#64#60#text#97#</font></p>     ^cY#01.htm##
00481000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063888000200066704024800068002000700316#v55
n1#V:\SciELO\serial\abem\v55n1\markup\01.htm#S#p#65#61#text#97#6#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="2">6. Halestrap AP,    Meredith D. 
The SLC16 gene family-from monocarboxylate transporters (MCTs) to    aromatic am
ino acid transporters and beyond. Pflugers Arch. 2004;447:619-28.    ^cY#01.htm#
#
00239000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704002000066002000700086#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#66#62#text#97#</font></p>     ^cY#01.htm##
00558000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063888000200066704032500068002000700393#v55
n1#V:\SciELO\serial\abem\v55n1\markup\01.htm#S#p#67#63#text#97#7#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="2">7. Heuer H, Maier    MK, Iden S,
 Mittag J, Friesema EC, Visser TJ, et al. The monocarboxylate transporter    8 l
inked to human psychomotor retardation is highly expressed in thyroid hormone-se
nsitive    neuron populations. Endocrinology. 2005;146:1701-6.    ^cY#01.htm##
00239000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704002000066002000700086#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#68#64#text#97#</font></p>     ^cY#01.htm##
00492000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063888000200066704025900068002000700327#v55
n1#V:\SciELO\serial\abem\v55n1\markup\01.htm#S#p#69#65#text#97#8#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="2">8. Fliers E, Unmehopa    UA, Alk
emade A. Functional neuroanatomy of thyroid hormone feedback in the human    hyp
othalamus and pituitary gland. Mol Cell Endocrinol. 2006;251:1-8</font></p>     
^cY#01.htm##
00496000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063888000200066704026300068002000700331#v55
n1#V:\SciELO\serial\abem\v55n1\markup\01.htm#S#p#70#66#text#97#9#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="2">9. Holden KR, Zuniga    OF, May 
MM, Su H, Molinero MR, Rogers RC, et al. X-linked MCT8 gene mutations:    charac
terization of the pediatric neurologic phenotype. J Child Neurol. 2005;20:852-7.
    ^cY#01.htm##
00239000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704002000066002000700086#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#71#67#text#97#</font></p>     ^cY#01.htm##
00557000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063888000300066704032300069002000700392#v55
n1#V:\SciELO\serial\abem\v55n1\markup\01.htm#S#p#72#68#text#97#10#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">10. Frints SG,    Lenzner S, Ba
uters M, Jensen LR, Van Esch H, des Portes V, et al. MCT8 mutation    analysis a
nd identification of the first female with Allan-Herndon-Dudley syndrome    due 
to loss of MCT8 expression. Eur J Hum Genet. 2008;16:1029-37.    ^cY#01.htm##
00239000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704002000066002000700086#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#73#69#text#97#</font></p>     ^cY#01.htm##
00502000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063888000300066704026800069002000700337#v55
n1#V:\SciELO\serial\abem\v55n1\markup\01.htm#S#p#74#70#text#97#11#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">11. Kinne A, Roth    S, Bieberm
ann H, Koehrle J, Gruters A, Schweizer U. Surface translocation and    T3 uptake
 of mutant MCT8 proteins are cell type-dependent. J Mol Endocrinol.    2009;43:2
63-71.    ^cY#01.htm##
00239000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704002000066002000700086#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#75#71#text#97#</font></p>     ^cY#01.htm##
00505000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063888000300066704027100069002000700340#v55
n1#V:\SciELO\serial\abem\v55n1\markup\01.htm#S#p#76#72#text#97#12#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">12. Trajkovic M,    Visser TJ, 
Mittag J, Horn S, Lukas J, Darras VM, et al. Abnormal thyroid hormone    metabol
ism in mice lacking the monocarboxylate transporter 8. J Clin Invest.    2007;11
7:627-35.    ^cY#01.htm##
00239000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704002000066002000700086#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#77#73#text#97#</font></p>     ^cY#01.htm##
00532000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063888000300066704029800069002000700367#v55
n1#V:\SciELO\serial\abem\v55n1\markup\01.htm#S#p#78#74#text#97#13#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">13. Roberts LM,    Woodford K, 
Zhou M, Black DS, Haggerty JE, Tate EH, et al. Expression of the    thyroid horm
one transporters MCT8 (SLC16A2) and OATP14 (SLCO1C1) at the blood-brain    barri
er. Endocrinology. 2008;149:6251-61.    ^cY#01.htm##
00239000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704002000066002000700086#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#79#75#text#97#</font></p>     ^cY#01.htm##
00546000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063888000300066704031200069002000700381#v55
n1#V:\SciELO\serial\abem\v55n1\markup\01.htm#S#p#80#76#text#97#14#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">14. Wemeau JL,    Pigeyre M, Pr
oust-Lemoine E, d'Herbomez M, Gottrand F, Jansen J, et al. Beneficial    effects
 of propylthiouracil plus L-thyroxine treatment in a patient with a mutation    
in MCT8. J Clin Endocrinol Metab. 2008;93:2084-88.    ^cY#01.htm##
00239000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704002000066002000700086#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#81#77#text#97#</font></p>     ^cY#01.htm##
00516000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063888000300066704028200069002000700351#v55
n1#V:\SciELO\serial\abem\v55n1\markup\01.htm#S#p#82#78#text#97#15#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">15. Dumitrescu    AM, Liao XH, 
Weiss RE, Millen K, Refetoff S. Tissue-specific thyroid hormone    deprivation a
nd excess in monocarboxylate transporter (mct) 8-deficient mice.    Endocrinolog
y. 2006;147:4036-43.    ^cY#01.htm##
00239000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704002000066002000700086#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#83#79#text#97#</font></p>     ^cY#01.htm##
00521000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063888000300066704028700069002000700356#v55
n1#V:\SciELO\serial\abem\v55n1\markup\01.htm#S#p#84#80#text#97#16#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">16. Trajkovic M,    Visser TJ, 
Darras WM, Friesema ECH, Schlott B, Mittag J, et al. Consequences    of MCT8 def
iciency for renal transport and metabolism of thyroid hormones in    mice. Endoc
rinology. 2009;151:802-9.    ^cY#01.htm##
00239000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704002000066002000700086#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#85#81#text#97#</font></p>     ^cY#01.htm##
00495000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063888000300066704026100069002000700330#v55
n1#V:\SciELO\serial\abem\v55n1\markup\01.htm#S#p#86#82#text#97#17#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">17. Di Cosmo C,    Liao XH, Dum
itrescu AM, Philp NJ, Weiss RE, Refetoff S. Mice deficient in MCT8    reveal a m
echanism regulating thyroid hormone secretion. J Clin Invest. 2010;120:3377-88. 
   ^cY#01.htm##
00239000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704002000066002000700086#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#87#83#text#97#</font></p>     ^cY#01.htm##
00538000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063888000300066704030400069002000700373#v55
n1#V:\SciELO\serial\abem\v55n1\markup\01.htm#S#p#88#84#text#97#18#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">18. Trajkovic-Arsic    M, M&uum
l;ller J, Darras VM, Groba C, Lee S, Weih D, et al. Impact of monocarboxylate   
 transporter (Mct)-8 deficiency on the hypothalamus-pituitary-thyroid axis in   
 mice. Endocrinology. 2010;151(10)5053-62.    ^cY#01.htm##
00239000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704002000066002000700086#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#89#85#text#97#</font></p>     ^cY#01.htm##
00413000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063888000300066704017900069002000700248#v55
n1#V:\SciELO\serial\abem\v55n1\markup\01.htm#S#p#90#86#text#97#19#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">19. Bernal J. Thyroid    hormon
e receptors in brain development and function. Nat Clin Pract. 2007;3:249-59.   
 ^cY#01.htm##
00449000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063888000300066704021500069002000700284#v55
n1#V:\SciELO\serial\abem\v55n1\markup\01.htm#S#p#91#87#text#97#20#    Di Cosmo C
, Liao XH, Dumitrescu AM, Weiss RE, Refetoff S. A thyroid hormone    analog with
 reduced dependence on the monocarboxylate transporter 8 for tissue    transport
. Endocrinology. 2009;150:4450-8.    ^cY#01.htm##
00239000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704002000066002000700086#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#92#88#text#97#</font></p>     ^cY#01.htm##
00241000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704002200066002000700088#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#93#89#text#97#<p>&nbsp;</p>     ^cY#01.htm#
#
00241000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704002200066002000700088#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#94#90#text#97#<p>&nbsp;</p>     ^cY#01.htm#
#
00414000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704019500066002000700261#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#95#91#text#97#<p><font face="Verdana, Arial
, Helvetica, sans-serif" size="2"><a name="back"></a><a href="#top"><img src="/i
mg/revistas/abem/v55n1/seta.jpg" border="0"></a>    <b>Correspondence to:</b>   
  ^cY#01.htm##
00248000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704002900066002000700095#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#96#92#text#97#<br>   Theo J. Visser    ^cY#
01.htm##
00265000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704004600066002000700112#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#97#93#text#97#<br>   Department of Internal
 Medicine    ^cY#01.htm##
00257000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704003800066002000700104#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#98#94#text#97#<br>   Erasmus MC, Room Ee 50
2    ^cY#01.htm##
00251000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704003200066002000700098#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#99#95#text#97#<br>   PO Box 2040, 3000    ^
cY#01.htm##
00264000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000300056709000500059708000300064704004400067002000700111#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#100#96#text#97#<br>   CA Rotterdam, The Net
herlands    ^cY#01.htm##
00315000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000300056709000500059708000300064704009500067002000700162#v55n1#V:\SciELO
\serial\abem\v55n1\markup\01.htm#S#p#101#97#text#97#<br>   <a href="mailto:t.j.v
isser@erasmusmc.nl">t.j.visser@erasmusmc.nl</a></font></p>     ^cY#01.htm##
00669000000000337000450000400060000070200420000670500020004870600020005070000040
00527010002000567090005000587080003000631180002000660100017000680100018000850100
01600103010001400119010001600133010002000149810000600169012008300175030001100258
06500090026906400050027803100030028301400080028686500090029400200070030303500100
0310801001100320#v55n1#V:\SciELO\serial\abem\v55n1\markup\01.htm#S#c#102#1#text#
20#1#^rND^sGereben^nB#^rND^sZavacki^nAM#^rND^sRibich^nS#^rND^sKim^nBW#^rND^sHuan
g^nSA#^rND^sSimonides^nWS#et al#Cellular and molecular basis of deiodinase-regul
ated thyroid hormone signaling^len#Endocr Rev#20080000#2008#29#898-938#20110200#
01.htm#0163-769X#Endocr Rev##
00563000000000289000450000400060000070200420000670500020004870600020005070000040
00527010002000567090005000587080003000631180002000660100017000680100019000850100
01700104012007400121030001500195065000900210064000500219031000300224014000500227
865000900232002000700241035001000248801001500258#v55n1#V:\SciELO\serial\abem\v55
n1\markup\01.htm#S#c#103#2#text#20#2#^rND^sVisser^nWE#^rND^sFriesema^nEC#^rND^sV
isser^nTJ#Minireview: thyroid hormone transporters: the knowns and the unknowns^
len#Mol Endocrinol#20110000#2011#25#1-14#20110200#01.htm#0888-8809#Mol Endocrino
l##
00687000000000313000450000400060000070200420000670500020004870600020005070000040
00527010002000567090005000587080003000631180002000660100021000680100015000890100
01500104010001900119010001800138012013700156030001500293065000900308064000500317
031000300322014000700325865000900332002000700341035001000348801001500358#v55n1#V
:\SciELO\serial\abem\v55n1\markup\01.htm#S#c#104#3#text#20#3#^rND^sDumitrescu^nA
M#^rND^sLiao^nXH#^rND^sBest^nTB#^rND^sBrockmann^nK#^rND^sRefetoff^nS#A novel syn
drome combining thyroid and neurological abnormalities is associated with mutati
ons in a monocarboxylate transporter gene^len#Am J Hum Genet#20040000#2004#74#16
8-75#20110200#01.htm#0002-9297#Am J Hum Genet##
00695000000000337000450000400060000070200420000670500020004870600020005070000040
00527010002000567090005000587080003000631180002000660100019000680100018000870100
02000105010001500125010001900140010001600159810000600175012011100181030000700292
06500090029906400050030803100040031301400070031786500090032400200070033303500100
0340801000700350#v55n1#V:\SciELO\serial\abem\v55n1\markup\01.htm#S#c#105#4#text#
20#4#^rND^sFriesema^nEC#^rND^sGrueters^nA#^rND^sBiebermann^nH#^rND^sKrude^nH#^rN
D^svon Moers^nA#^rND^sReeser^nM#et al#Association between mutations in a thyroid
 hormone transporter and severe X-linked psychomotor retardation^len#Lancet#2004
0000#2004#364#1435-7#20110200#01.htm#0099-5355#Lancet##
00779000000000349000450000400060000070200420000670500020004870600020005070000040
00527010002000567090005000587080003000631180002000660100024000680100015000920100
01600107010001600123010001800139010001800157810000600175012011900181030002600300
06500090032606400050033503100030034003200020034301400050034586500090035000200070
0359035001000366801005300376#v55n1#V:\SciELO\serial\abem\v55n1\markup\01.htm#S#c
#106#5#text#20#5#^rND^sMenezes Filho^nHC#^rND^sMarui^nS#^rND^sManna^nTD#^rND^sBr
ust^nES#^rND^sRadonsky^nV#^rND^sKuperman^nH#et al#Novel mutation in MCT8 gene in
 a Brazilian boy with thyroid hormone resistance and severe neurologic abnormali
ties^len#Arq Bras Endocrinol Metab#20110000#2011#55#1#60-6#20110200#01.htm#0004-
2730#Arquivos Brasileiros de Endocrinologia & Metabologia##
00577000000000277000450000400060000070200420000670500020004870600020005070000040
00527010002000567090005000587080003000631180002000660100020000680100018000880120
11400106030001400220065000900234064000500243031000400248014000700252865000900259
002000700268035001000275801001400285#v55n1#V:\SciELO\serial\abem\v55n1\markup\01
.htm#S#c#107#6#text#20#6#^rND^sHalestrap^nAP#^rND^sMeredith^nD#The SLC16 gene fa
mily-from monocarboxylate transporters (MCTs) to aromatic amino acid transporter
s and beyond^len#Pflugers Arch#20040000#2004#447#619-28#20110200#01.htm#0031-676
8#Pflugers Arch##
00734000000000337000450000400060000070200420000670500020004870600020005070000040
00527010002000567090005000587080003000631180002000660100015000680100016000830100
01400099010001600113010001900129010001700148810000600165012014600171030001400317
06500090033106400050034003100040034501400070034986500090035600200070036503500100
0372801001400382#v55n1#V:\SciELO\serial\abem\v55n1\markup\01.htm#S#c#108#7#text#
20#7#^rND^sHeuer^nH#^rND^sMaier^nMK#^rND^sIden^nS#^rND^sMittag^nJ#^rND^sFriesema
^nEC#^rND^sVisser^nTJ#et al#The monocarboxylate transporter 8 linked to human ps
ychomotor retardation is highly expressed in thyroid hormone-sensitive neuron po
pulations^len#Endocrinology#20050000#2005#146#1701-6#20110200#01.htm#0013-7227#E
ndocrinology##
00601000000000289000450000400060000070200420000670500020004870600020005070000040
00527010002000567090005000587080003000631180002000660100016000680100019000840100
01800103012010200121030002000223065000900243064000500252031000400257014000400261
865000900265002000700274035001000281801002000291#v55n1#V:\SciELO\serial\abem\v55
n1\markup\01.htm#S#c#109#8#text#20#8#^rND^sFliers^nE#^rND^sUnmehopa^nUA#^rND^sAl
kemade^nA#Functional neuroanatomy of thyroid hormone feedback in the human hypot
halamus and pituitary gland^len#Mol Cell Endocrinol#20060000#2006#251#1-8#201102
00#01.htm#0303-7207#Mol Cell Endocrinol##
00676000000000337000450000400060000070200420000670500020004870600020005070000040
00527010002000567090005000587080003000631180002000660100017000680100017000850100
01400102010001200116010001900128010001700147810000600164012008900170030001500259
06500090027406400050028303100030028801400060029186500090029700200070030603500100
0313801001500323#v55n1#V:\SciELO\serial\abem\v55n1\markup\01.htm#S#c#110#9#text#
20#9#^rND^sHolden^nKR#^rND^sZuniga^nOF#^rND^sMay^nMM#^rND^sSu^nH#^rND^sMolinero^
nMR#^rND^sRogers^nRC#et al#X-linked MCT8 gene mutations: characterization of the
 pediatric neurologic phenotype^len#J Child Neurol#20050000#2005#20#852-7#201102
00#01.htm#0883-0738#J Child Neurol##
00735000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090005000597080003000641180003000670100017000700100017000870100
01700104010001700121010001800138010002000156810000600176012013200182030001600314
06500090033006400050033903100030034401400080034786500090035500200070036403500100
0371801001600381#v55n1#V:\SciELO\serial\abem\v55n1\markup\01.htm#S#c#111#10#text
#20#10#^rND^sFrints^nSG#^rND^sLenzner^nS#^rND^sBauters^nM#^rND^sJensen^nLR#^rND^
sVan Esch^nH#^rND^sdes Portes^nV#et al#MCT8 mutation analysis and identification
 of the first female with Allan-Herndon-Dudley syndrome due to loss of MCT8 expr
ession^len#Eur J Hum Genet#20080000#2008#16#1029-37#20110200#01.htm#1018-4813#Eu
r J Hum Genet##
00670000000000325000450000400060000070200420000670500020004870600020005070000040
00527010003000567090005000597080003000641180003000670100015000700100014000850100
02000099010001700119010001700136010001900153012008800172030001700260065000900277
06400050028603100030029101400070029486500090030100200070031003500100031780100170
0327#v55n1#V:\SciELO\serial\abem\v55n1\markup\01.htm#S#c#112#11#text#20#11#^rND^
sKinne^nA#^rND^sRoth^nS#^rND^sBiebermann^nH#^rND^sKoehrle^nJ#^rND^sGruters^nA#^r
ND^sSchweizer^nU#Surface translocation and T3 uptake of mutant MCT8 proteins are
 cell type-dependent^len#J Mol Endocrinol#20090000#2009#43#263-71#20110200#01.ht
m#0952-5041#J Mol Endocrinol##
00681000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090005000597080003000641180003000670100019000700100017000890100
01600106010001400122010001500136010001700151810000600168012009000174030001400264
06500090027806400050028703100040029201400070029686500090030300200070031203500100
0319801001400329#v55n1#V:\SciELO\serial\abem\v55n1\markup\01.htm#S#c#113#12#text
#20#12#^rND^sTrajkovic^nM#^rND^sVisser^nTJ#^rND^sMittag^nJ#^rND^sHorn^nS#^rND^sL
ukas^nJ#^rND^sDarras^nVM#et al#Abnormal thyroid hormone metabolism in mice lacki
ng the monocarboxylate transporter 8^len#J Clin Invest#20070000#2007#117#627-35#
20110200#01.htm#0021-9738#J Clin Invest##
00708000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090005000597080003000641180003000670100018000700100018000880100
01400106010001600120010001900136010001500155810000600170012011400176030001400290
06500090030406400050031303100040031801400080032286500090033000200070033903500100
0346801001400356#v55n1#V:\SciELO\serial\abem\v55n1\markup\01.htm#S#c#114#13#text
#20#13#^rND^sRoberts^nLM#^rND^sWoodford^nK#^rND^sZhou^nM#^rND^sBlack^nDS#^rND^sH
aggerty^nJE#^rND^sTate^nEH#et al#Expression of the thyroid hormone transporters 
MCT8 (SLC16A2) and OATP14 (SLCO1C1) at the blood-brain barrier^len#Endocrinology
#20080000#2008#149#6251-61#20110200#01.htm#0013-7227#Endocrinology##
00732000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090005000597080003000641180003000670100017000700100017000870100
02400104010002000128010001800148010001600166810000600182012010700188030002400295
06500090031906400050032803100030033301400080033686500090034400200070035303500100
0360801002400370#v55n1#V:\SciELO\serial\abem\v55n1\markup\01.htm#S#c#115#14#text
#20#14#^rND^sWemeau^nJL#^rND^sPigeyre^nM#^rND^sProust-Lemoine^nE#^rND^sd'Herbome
z^nM#^rND^sGottrand^nF#^rND^sJansen^nJ#et al#Beneficial effects of propylthioura
cil plus L-thyroxine treatment in a patient with a mutation in MCT8^len#J Clin E
ndocrinol Metab#20080000#2008#93#2084-88#20110200#01.htm#0021-972X#J Clin Endocr
inol Metab##
00663000000000313000450000400060000070200420000670500020004870600020005070000040
00527010003000567090005000597080003000641180003000670100021000700100015000910100
01600106010001600122010001800138012011300156030001400269065000900283064000500292
031000400297014000800301865000900309002000700318035001000325801001400335#v55n1#V
:\SciELO\serial\abem\v55n1\markup\01.htm#S#c#116#15#text#20#15#^rND^sDumitrescu^
nAM#^rND^sLiao^nXH#^rND^sWeiss^nRE#^rND^sMillen^nK#^rND^sRefetoff^nS#Tissue-spec
ific thyroid hormone deprivation and excess in monocarboxylate transporter (mct)
 8-deficient mice^len#Endocrinology#20060000#2006#147#4036-43#20110200#01.htm#00
13-7227#Endocrinology##
00697000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090005000597080003000641180003000670100019000700100017000890100
01700106010002000123010001700143010001600160810000600176012009900182030001400281
06500090029506400050030403100040030901400060031386500090031900200070032803500100
0335801001400345#v55n1#V:\SciELO\serial\abem\v55n1\markup\01.htm#S#c#117#16#text
#20#16#^rND^sTrajkovic^nM#^rND^sVisser^nTJ#^rND^sDarras^nWM#^rND^sFriesema^nECH#
^rND^sSchlott^nB#^rND^sMittag^nJ#et al#Consequences of MCT8 deficiency for renal
 transport and metabolism of thyroid hormones in mice^len#Endocrinology#20090000
#2009#151#802-9#20110200#01.htm#0013-7227#Endocrinology##
00663000000000325000450000400060000070200420000670500020004870600020005070000040
00527010003000567090005000597080003000641180003000670100018000700100015000880100
02100103010001600124010001600140010001800156012008300174030001400257065000900271
06400050028003100040028501400080028986500090029700200070030603500100031380100140
0323#v55n1#V:\SciELO\serial\abem\v55n1\markup\01.htm#S#c#118#17#text#20#17#^rND^
sDi Cosmo^nC#^rND^sLiao^nXH#^rND^sDumitrescu^nAM#^rND^sPhilp^nNJ#^rND^sWeiss^nRE
#^rND^sRefetoff^nS#Mice deficient in MCT8 reveal a mechanism regulating thyroid 
hormone secretion^len#J Clin Invest#20100000#2010#120#3377-88#20110200#01.htm#00
21-9738#J Clin Invest##
00721000000000349000450000400060000070200420000670500020004870600020005070000040
00527010003000567090005000597080003000641180003000670100025000700100016000950100
01700111010001500128010001300143010001400156810000600170012011200176030001400288
06500090030206400050031103100040031603200030032001400080032386500090033100200070
0340035001000347801001400357#v55n1#V:\SciELO\serial\abem\v55n1\markup\01.htm#S#c
#119#18#text#20#18#^rND^sTrajkovic-Arsic^nM#^rND^sMüller^nJ#^rND^sDarras^nVM#^rN
D^sGroba^nC#^rND^sLee^nS#^rND^sWeih^nD#et al#Impact of monocarboxylate transport
er (Mct)-8 deficiency on the hypothalamus-pituitary-thyroid axis in mice^len#End
ocrinology#20100000#2010#151#10#5053-62#20110200#01.htm#0013-7227#Endocrinology#
#
00460000000000253000450000400060000070200420000670500020004870600020005070000040
00527010003000567090005000597080003000641180003000670100016000700120064000860300
01500150710000200165065000900167064000500176031000200181014000700183865000900190
002000700199#v55n1#V:\SciELO\serial\abem\v55n1\markup\01.htm#S#c#120#19#text#20#
19#^rND^sBernal^nJ#Thyroid hormone receptors in brain development and function^l
en#Nat Clin Pract#2#20070000#2007#3#249-59#20110200#01.htm##
00647000000000301000450000400060000070200420000670500020004870600020005070000040
00527010003000567090005000597080003000640100018000670100015000850100021001000100
01600121010001800137012011100155030001400266065000900280064000500289031000400294
014000700298865000900305002000700314035001000321801001400331#v55n1#V:\SciELO\ser
ial\abem\v55n1\markup\01.htm#S#c#121#20#text#20#^rND^sDi Cosmo^nC#^rND^sLiao^nXH
#^rND^sDumitrescu^nAM#^rND^sWeiss^nRE#^rND^sRefetoff^nS#A thyroid hormone analog
 with reduced dependence on the monocarboxylate transporter 8 for tissue transpo
rt^len#Endocrinology#20090000#2009#150#4450-8#20110200#01.htm#0013-7227#Endocrin
ology##
00263000000000169000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640910009000660920007000750020007000827030
00400089#v55n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#o#1#1#article#1#20110
324#154502#02.htm#283##
03431000000000577000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640710003000660400003000690010006000720420
00200078120000400080038000400084121000300088049000800091158000300099030002600102
03100030012803200020013106500090013301400080014203500100015001200820016001200760
02420100042003180100049003600100038004090700090004470831030005370850008015670850
04001575085002301615085004601638083100501684085000802689085003802697085002202735
08500380275711700060279507200030280111200090280411100120281311400090282511300120
2834002000702846#v55n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#h#2#1#article
#1#oa#pt#br1.1#1#4.0#TAB#02#ABEM020#nd#Arq Bras Endocrinol Metab#55#1#20110200#^
f6^l15#0004-2730#Dificuldades e armadilhas no diagnóstico da síndrome dos ovário
s policísticos^lpt#Difficulties and pitfalls in the diagnosis of polycystic ovar
y syndrome^len#^rND^1A01^nJosé Antonio Miguel^sMarcondes#^rND^1A01^nCristiano Ro
berto Grimaldi^sBarcellos#^rND^1A01^nMichelle Patrocínio^sRocha#Hospital das Clí
nicas de São Paulo^iA01^1Serviço de Endocrinologia^cSão Paulo^sSP^pBrasil#^lpt^a
A síndrome dos ovários policísticos é uma das endocrinopatias mais comuns, afeta
ndo aproximadamente 7% das mulheres na idade reprodutiva. Embora tenha sido desc
rita em 1935, somente em 1990 foi elaborado o primeiro consenso com relação ao s
eu diagnóstico. Hoje, a síndrome é considerada também um fator de risco cardiova
scular, com uma alta prevalência de distúrbios metabólicos. Como reflexo dessa n
ova visão da síndrome, vários documentos, entre Consensos, Posicionamentos e Ori
entações, têm sido publicados, abordando diversos aspectos da síndrome. O objeti
vo desta revisão é uma análise crítica desses documentos, obtidos mediante um le
vantamento na base PubMed, por meio dos unitermos polycystic ovary syndrome, hyp
erandrogenism e hirsutism, separadamente, tendo como limitador o termo Type of A
rticle (Practice Guideline, Consensus Development Conference, Guideline), sem li
mitação de data, língua e idade. Foram selecionados apenas os documentos elabora
dos sob patrocínio de Entidades Médicas e com mais de um autor.#^dnd^i1#^tm^lpt^
kSíndromes hiperandrogênicas^i1#^tm^lpt^khirsutismo^i1#^tm^lpt^ksíndrome dos ová
rios policísticos^i1#^len^aThe polycystic ovary syndrome is one of the most comm
on endocrinopathies, affecting approximately 7% of women of reproductive age. Al
though it was described in 1935, only in 1990 was published the first Consensus 
regarding it its diagnosis. Today, the syndrome is also considered a cardiovascu
lar risk factor, with a high prevalence of metabolic disorders. Reflecting this 
new vision of the syndrome, several documents, including Consensus, Statement an
d Guidelines have been published, addressing different aspects of the syndrome. 
This review is an analysis of documents obtained through a survey in the PubMed 
database, using the keywords "polycystic ovary syndrome", "hyperandrogenism" and
 "hirsutism", separately, taking as limiting the term Type of Article (Practice 
Guideline, Consensus Development Conference, Guideline) without limitation of ti
me, language and age, having been selected only those documents prepared under t
he sponsorship of Medical Entities and with more than one author.#^dnd^i2#^tm^le
n^kHyperandrogenic syndromes^i2#^tm^len^khirsutism^i2#^tm^len^kpolycystic ovary 
syndrome^i2#other#60#20101020#20/Out/2010#20110128#28/Jan/2011#02.htm##
03480000000000577000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640710003000660400003000690010006000720420
00200078120000400080038000400084121000300088049000800091158000300099030002600102
03100030012803200020013106500090013301400080014203500100015001200890016001200830
02490100042003320100049003740100038004230700090004610831065005510850008016160850
04001624085002301664085004601687083100501733085000802738085003802746085002202784
08500380280611700060284407200030285011200090285311100120286211400090287411300120
2883002000702895#v55n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#f#3#1#article
#1#oa#pt#br1.1#1#4.0#TAB#02#ABEM020#nd#Arq Bras Endocrinol Metab#55#1#20110200#^
f6^l15#0004-2730#<b>Dificuldades e armadilhas no diagnóstico da síndrome dos ová
rios policísticos</b>^lpt#<b>Difficulties and pitfalls in the diagnosis of polyc
ystic ovary syndrome</b>^len#^rND^1A01^nJosé Antonio Miguel^sMarcondes#^rND^1A01
^nCristiano Roberto Grimaldi^sBarcellos#^rND^1A01^nMichelle Patrocínio^sRocha#Ho
spital das Clínicas de São Paulo^iA01^1Serviço de Endocrinologia^cSão Paulo^sSP^
pBrasil#^lpt^aA síndrome dos ovários policísticos é uma das endocrinopatias mais
 comuns, afetando aproximadamente 7% das mulheres na idade reprodutiva. Embora t
enha sido descrita em 1935, somente em 1990 foi elaborado o primeiro consenso co
m relação ao seu diagnóstico. Hoje, a síndrome é considerada também um fator de 
risco cardiovascular, com uma alta prevalência de distúrbios metabólicos. Como r
eflexo dessa nova visão da síndrome, vários documentos, entre Consensos, Posicio
namentos e Orientações, têm sido publicados, abordando diversos aspectos da sínd
rome. O objetivo desta revisão é uma análise crítica desses documentos, obtidos 
mediante um levantamento na base PubMed, por meio dos unitermos <i>polycystic ov
ary syndrome</i>, <i>hyperandrogenism</i> e <i>hirsutism,</i> separadamente, ten
do como limitador o termo <i>Type of Article</i> (<i>Practice Guideline, Consens
us Development Conference, Guideline</i>), sem limitação de data, língua e idade
. Foram selecionados apenas os documentos elaborados sob patrocínio de Entidades
 Médicas e com mais de um autor.#^dnd^i1#^tm^lpt^kSíndromes hiperandrogênicas^i1
#^tm^lpt^khirsutismo^i1#^tm^lpt^ksíndrome dos ovários policísticos^i1#^len^aThe 
polycystic ovary syndrome is one of the most common endocrinopathies, affecting 
approximately 7% of women of reproductive age. Although it was described in 1935
, only in 1990 was published the first Consensus regarding it its diagnosis. Tod
ay, the syndrome is also considered a cardiovascular risk factor, with a high pr
evalence of metabolic disorders. Reflecting this new vision of the syndrome, sev
eral documents, including Consensus, Statement and Guidelines have been publishe
d, addressing different aspects of the syndrome. This review is an analysis of d
ocuments obtained through a survey in the PubMed database, using the keywords "p
olycystic ovary syndrome", "hyperandrogenism" and "hirsutism", separately, takin
g as limiting the term Type of Article (Practice Guideline, Consensus Developmen
t Conference, Guideline) without limitation of time, language and age, having be
en selected only those documents prepared under the sponsorship of Medical Entit
ies and with more than one author.#^dnd^i2#^tm^len^kHyperandrogenic syndromes^i2
#^tm^len^khirsutism^i2#^tm^len^kpolycystic ovary syndrome^i2#other#60#20101020#2
0/Out/2010#20110128#28/Jan/2011#02.htm##
03578000000000601000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640640013000660710003000790400003000820010
00600085042000200091120000400093038000400097121000300101049000800104158000300112
03000290011503100030014403200020014706500090014901400080015803500100016601200820
01760120076002580100042003340100049003760100038004250700092004630831039005550850
00801594085004001602085002301642085004601665083101201711085000802723085003802731
08500220276908500380279111700060282907200030283511200090283811100120284711400090
2859113001202868002000702880008008902887#v55n1#V:\SciELO\serial\abem\v55n1\marku
p\02.htm#S#l#4#1#article#1#^mfev.^a2011#oa#pt#br1.1#1#4.0#tab#02#ABEM020#nd#Arq.
 bras. endocrinol. metab#55#1#20110200#^f6^l15#0004-2730#Dificuldades e armadilh
as no diagnóstico da síndrome dos ovários policísticos^lpt#Difficulties and pitf
alls in the diagnosis of polycystic ovary syndrome^len#^rND^1A01^nJosé Antonio M
iguel^sMarcondes#^rND^1A01^nCristiano Roberto Grimaldi^sBarcellos#^rND^1A01^nMic
helle Patrocínio^sRocha#^iA01^1Hospital das Clínicas de São Paulo^2Serviço de En
docrinologia^cSão Paulo^sSP^pBrasil#^lpt^aA síndrome dos ovários policísticos é 
uma das endocrinopatias mais comuns, afetando aproximadamente 7 por cento das mu
lheres na idade reprodutiva. Embora tenha sido descrita em 1935, somente em 1990
 foi elaborado o primeiro consenso com relação ao seu diagnóstico. Hoje, a síndr
ome é considerada também um fator de risco cardiovascular, com uma alta prevalên
cia de distúrbios metabólicos. Como reflexo dessa nova visão da síndrome, vários
 documentos, entre Consensos, Posicionamentos e Orientações, têm sido publicados
, abordando diversos aspectos da síndrome. O objetivo desta revisão é uma anális
e crítica desses documentos, obtidos mediante um levantamento na base PubMed, po
r meio dos unitermos polycystic ovary syndrome, hyperandrogenism e hirsutism, se
paradamente, tendo como limitador o termo Type of Article (Practice Guideline, C
onsensus Development Conference, Guideline), sem limitação de data, língua e ida
de. Foram selecionados apenas os documentos elaborados sob patrocínio de Entidad
es Médicas e com mais de um autor.#^dnd^i1#^tm^lpt^kSíndromes hiperandrogênicas^
i1#^tm^lpt^khirsutismo^i1#^tm^lpt^ksíndrome dos ovários policísticos^i1#^len^aTh
e polycystic ovary syndrome is one of the most common endocrinopathies, affectin
g approximately 7 percent of women of reproductive age. Although it was describe
d in 1935, only in 1990 was published the first Consensus regarding it its diagn
osis. Today, the syndrome is also considered a cardiovascular risk factor, with 
a high prevalence of metabolic disorders. Reflecting this new vision of the synd
rome, several documents, including Consensus, Statement and Guidelines have been
 published, addressing different aspects of the syndrome. This review is an anal
ysis of documents obtained through a survey in the PubMed database, using the ke
ywords "polycystic ovary syndrome", "hyperandrogenism" and "hirsutism", separate
ly, taking as limiting the term Type of Article (Practice Guideline, Consensus D
evelopment Conference, Guideline) without limitation of time, language and age, 
having been selected only those documents prepared under the sponsorship of Medi
cal Entities and with more than one author.#^dnd^i2#^tm^len^kHyperandrogenic syn
dromes^i2#^tm^len^khirsutism^i2#^tm^len^kpolycystic ovary syndrome^i2#other#60#2
0101020#20/Out/2010#20110128#28/Jan/2011#02.htm#Internet^ihttp://www.scielo.br/s
cielo.php?script=sci_arttext&pid=S0004-27302011000100002##
00339000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704011800068002000700186#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#5#1#article#219#<p align="right"><font face
="Verdana, Arial, Helvetica, sans-serif" size="2"><b>REVIS&Atilde;O</b></font></
p>     ^cY#02.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704002200068002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#6#2#article#219#<p>&nbsp;</p>     ^cY#02.ht
m##
00437000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704021600068002000700284#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#7#3#article#219#<p><a name="top"></a><font 
face="Verdana, Arial, Helvetica, sans-serif" size="4"><b>Dificuldades    e armad
ilhas no diagn&oacute;stico da s&iacute;ndrome dos ov&aacute;rios polic&iacute;s
ticos</b></font></p>     ^cY#02.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704002200068002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#8#4#article#219#<p>&nbsp;</p>     ^cY#02.ht
m##
00385000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704016400068002000700232#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#9#5#article#219#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="3"><b>Difficulties    and pitfalls in the diagn
osis of polycystic ovary syndrome</b></font></p>     ^cY#02.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000400065704002200069002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#10#6#article#219#<p>&nbsp;</p>     ^cY#02.h
tm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000400065704002200069002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#11#7#article#219#<p>&nbsp;</p>     ^cY#02.h
tm##
00426000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000400065704020400069002000700273#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#12#8#article#219#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>Jos&eacute;    Antonio Miguel Marcondes;
 Cristiano Roberto Grimaldi Barcellos; Michelle Patroc&iacute;nio    Rocha</b></
font></p>     ^cY#02.htm##
00423000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000400065704020100069002000700270#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#13#9#article#219#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Servi&ccedil;o    de Endocrinologia, Hospit
al das Cl&iacute;nicas de S&atilde;o Paulo, S&atilde;o    Paulo, SP, Brasil</fon
t></p>     ^cY#02.htm##
00355000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704013200070002000700202#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#14#10#article#219#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><a href="#back">Correspond&ecirc;ncia    p
ara</a></font></p>     ^cY#02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#15#11#article#219#<p>&nbsp;</p>     ^cY#02.
htm##
00267000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704004400070002000700114#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#16#12#article#219#<p>&nbsp;</p> <hr size="1
" noshade>     ^cY#02.htm##
00327000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704010400070002000700174#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#17#13#article#219#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>SUM&Aacute;RIO</b></font></p>     ^cY#0
2.htm##
01613000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704139000070002000701460#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#18#14#article#219#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">A s&iacute;ndrome    dos ov&aacute;rios po
lic&iacute;sticos &eacute; uma das endocrinopatias mais    comuns, afetando apro
ximadamente 7% das mulheres na idade reprodutiva. Embora    tenha sido descrita 
em 1935, somente em 1990 foi elaborado o primeiro consenso    com rela&ccedil;&a
tilde;o ao seu diagn&oacute;stico. Hoje, a s&iacute;ndrome    &eacute; considera
da tamb&eacute;m um fator de risco cardiovascular, com uma    alta preval&ecirc;
ncia de dist&uacute;rbios metab&oacute;licos. Como reflexo    dessa nova vis&ati
lde;o da s&iacute;ndrome, v&aacute;rios documentos, entre    Consensos, Posicion
amentos e Orienta&ccedil;&otilde;es, t&ecirc;m sido publicados,    abordando div
ersos aspectos da s&iacute;ndrome. O objetivo desta revis&atilde;o    &eacute; u
ma an&aacute;lise cr&iacute;tica desses documentos, obtidos mediante    um levan
tamento na base PubMed, por meio dos unitermos <i>polycystic ovary syndrome</i>,
    <i>hyperandrogenism</i> e <i>hirsutism,</i> separadamente, tendo como limita
dor    o termo <i>Type of Article</i> (<i>Practice Guideline, Consensus Developm
ent    Conference, Guideline</i>), sem limita&ccedil;&atilde;o de data, l&iacute
;ngua    e idade. Foram selecionados apenas os documentos elaborados sob patroc&
iacute;nio    de Entidades M&eacute;dicas e com mais de um autor.</font></p>    
 ^cY#02.htm##
00463000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704024000070002000700310#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#19#15#article#219#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Descritores:    </b> S&iacute;ndromes h
iperandrog&ecirc;nicas; hirsutismo; s&iacute;ndrome dos    ov&aacute;rios polic&
iacute;sticos</font></p> <hr size="1" noshade>     ^cY#02.htm##
00320000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704009700070002000700167#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#20#16#article#219#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>SUMMARY</b></font></p>     ^cY#02.htm##
01343000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704112000070002000701190#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#21#17#article#219#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">The polycystic    ovary syndrome is one of
 the most common endocrinopathies, affecting approximately    7% of women of rep
roductive age. Although it was described in 1935, only in    1990 was published 
the first Consensus regarding it its diagnosis. Today, the    syndrome is also c
onsidered a cardiovascular risk factor, with a high prevalence    of metabolic d
isorders. Reflecting this new vision of the syndrome, several    documents, incl
uding Consensus, Statement and Guidelines have been published,    addressing dif
ferent aspects of the syndrome. This review is an analysis of    documents obtai
ned through a survey in the PubMed database, using the keywords    "polycystic o
vary syndrome", "hyperandrogenism" and "hirsutism", separately,    taking as lim
iting the term Type of Article (Practice Guideline, Consensus Development    Con
ference, Guideline) without limitation of time, language and age, having    been
 selected only those documents prepared under the sponsorship of Medical    Enti
ties and with more than one author.</font></p>     ^cY#02.htm##
00411000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704018800070002000700258#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#22#18#article#219#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Keywords:</b>    Hyperandrogenic syndro
mes; hirsutism; polycystic ovary syndrome</font></p> <hr size="1" noshade>     ^
cY#02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#23#19#article#219#<p>&nbsp;</p>     ^cY#02.
htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#24#20#article#219#<p>&nbsp;</p>     ^cY#02.
htm##
00337000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704011400070002000700184#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#25#21#article#219#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="3"><b>INTRODU&Ccedil;&Atilde;O</b></font></p>
     ^cY#02.htm##
00819000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704059600070002000700666#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#26#22#article#219#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">A s&iacute;ndrome    dos ov&aacute;rios po
lic&iacute;sticos (SOP) foi descrita inicialmente por Stein    e Leventhal, em 1
935 (1), os quais observaram uma associa&ccedil;&atilde;o entre    amenorreia, h
irsutismo e obesidade com ov&aacute;rios de aspecto polic&iacute;stico.    Estes
 eram aumentados de volume bilateralmente, com c&aacute;psulas espessadas    e e
sbranqui&ccedil;adas e com m&uacute;ltiplos cistos de localiza&ccedil;&atilde;o 
   preferencialmente subcapsular e estroma denso e hipertr&oacute;fico.</font></
p>     ^cY#02.htm##
01151000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704092800070002000700998#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#27#23#article#219#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Subsequentemente,    a heterogeneidade dos
 achados histol&oacute;gicos e das caracter&iacute;sticas    cl&iacute;nicas lev
ou &agrave; ado&ccedil;&atilde;o do termo "s&iacute;ndrome    dos ov&aacute;rios
 polic&iacute;sticos". Com a introdu&ccedil;&atilde;o de novas    t&eacute;cnica
s de investiga&ccedil;&atilde;o, o que antes era um diagn&oacute;stico    basead
o apenas em aspectos cl&iacute;nicos e anat&ocirc;micos passou a incorporar    c
rit&eacute;rios bioqu&iacute;micos e ultrassonogr&aacute;ficos (2). Se, por    u
m lado, esses avan&ccedil;os amplificaram o campo de pesquisa, possibilitando   
 novas descobertas que se constituem numa diversidade de achados para essa s&iac
ute;ndrome,    por outro, dificultou a obten&ccedil;&atilde;o de um crit&eacute;
rio diagn&oacute;stico    que fosse aceito universalmente pelos estudiosos do te
ma.</font></p>     ^cY#02.htm##
00614000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704039100070002000700461#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#28#24#article#219#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Nesses &uacute;ltimos    anos, v&aacute;ri
os documentos, entre <i>Consensus</i>, <i>Guidelines</i>, <i>Position    Stateme
nt</i> e <i>Practice Bulletin</i>, foram elaborados por sociedades m&eacute;dica
s    com a finalidade de uniformizar os crit&eacute;rios diagn&oacute;sticos da 
s&iacute;ndrome    (3-15).</font></p>     ^cY#02.htm##
01692000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704146900070002000701539#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#29#25#article#219#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">O objetivo desta    revis&atilde;o &eacute
; o de sintetizar e analisar esses documentos, salientando    as dificuldades e 
armadilhas envolvidas na aplica&ccedil;&atilde;o dos crit&eacute;rios    fundame
ntais para o diagn&oacute;stico da SOP. Para tanto, foram pesquisados    na base
 de dados MEDLINE os unitermos <i>hyperandrogenism</i>, <i>polycystic    ovary s
yndrome</i> e <i>hirsutism</i>, separadamente, tendo como limitador o    termo <
i>Type of Article</i> (<i>Practice Guideline</i>, <i>Consensus Development    Co
nference</i>, <i>Guideline</i>), sem limita&ccedil;&atilde;o de data, l&iacute;n
gua    e idade. Foram selecionados apenas os que foram publicados com aval de So
ciedades    M&eacute;dicas e com mais de um autor. A pesquisa dos termos s&iacut
e;ndrome    dos ov&aacute;rios polic&iacute;sticos e hirsutismo, separadamente, 
na base    de dados SciELO n&atilde;o resultou em nenhum artigo que se enquadras
se nos    unitermos pesquisados na base de dados MEDLINE. Embora n&atilde;o tenh
a sido    identificado no levantamento realizado por meio do PubMed, possivelmen
te por    ter sido publicado sob a forma de cap&iacute;tulo de livro, o document
o elaborado    pelo <i>The National Institute of Health Consensus Conference</i>
 (3) sobre    crit&eacute;rios diagn&oacute;sticos da SOP tamb&eacute;m foi cons
iderado, por    se tratar do primeiro Consenso a abordar o tema.</font></p>     
^cY#02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#30#26#article#219#<p>&nbsp;</p>     ^cY#02.
htm##
00333000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704011000070002000700180#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#31#27#article#219#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="3"><b>CONCEITO E CONSENSOS</b></font></p>    
 ^cY#02.htm##
01129000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704090600070002000700976#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#32#28#article#219#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Um ponto concordante    dos consensos sobr
e crit&eacute;rios diagn&oacute;sticos &eacute; que se trata    de uma s&iacute;
ndrome e n&atilde;o de uma doen&ccedil;a espec&iacute;fica.    De acordo com a r
aiz grega de sua palavra, s&iacute;ndrome &eacute; uma associa&ccedil;&atilde;o 
   de caracter&iacute;sticas (sinais, sintomas e fen&ocirc;menos) que ocorrem fr
equentemente    juntas, sendo que a presen&ccedil;a de uma caracter&iacute;stica
 alerta para    a presen&ccedil;a de outra e a raz&atilde;o pela qual ocorrem em
 conjunto &eacute;    desconhecida. Consequentemente nenhum crit&eacute;rio isol
ado &eacute; suficiente    para seu diagn&oacute;stico cl&iacute;nico, sendo, po
rtanto, um diagn&oacute;stico    de exclus&atilde;o, ou seja, doen&ccedil;as que
 mimetizam seu fen&oacute;tipo    devem ser exclu&iacute;das.</font></p>     ^cY
#02.htm##
00531000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704030800070002000700378#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#33#29#article#219#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">No que se refere    &agrave; SOP, suas car
acter&iacute;sticas fundamentais s&atilde;o constitu&iacute;das    por disfun&cc
edil;&atilde;o menstrual, hiperandrogenismo, hiperandrogenemia    e ov&aacute;ri
os polic&iacute;sticos.</font></p>     ^cY#02.htm##
00857000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704063400070002000700704#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#34#30#article#219#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Uma defini&ccedil;&atilde;o    cl&iacute;n
ica e pr&aacute;tica para a s&iacute;ndrome foi elaborada pelo <i>National    In
stitutes of Health</i> (Consenso do NIH), em 1990 (3) (<a href="#t1">Tabela    1
</a>). De acordo com esse documento, a SOP seria consequente a um quadro de    a
novula&ccedil;&atilde;o cr&ocirc;nica hiperandrog&ecirc;nica, devendo ser defini
da    pela presen&ccedil;a de disfun&ccedil;&atilde;o menstrual e excesso androg
&ecirc;nico,    que pode ser de ordem cl&iacute;nica (hiperandrogenismo) ou labo
ratorial (hiperandrogenemia).</font></p>     ^cY#02.htm##
00256000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704003300070002000700103#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#35#31#article#219#<p><a name="t1"></a></p> 
    ^cY#02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#36#32#article#219#<p>&nbsp;</p>     ^cY#02.
htm##
00300000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704007700070002000700147#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#37#33#article#219#<p align="center"><img sr
c="/img/revistas/abem/v55n1/02t01.jpg"></p>     ^cY#02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#38#34#article#219#<p>&nbsp;</p>     ^cY#02.
htm##
01470000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704124700070002000701317#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#39#35#article#219#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Posteriormente,    dois outros Consensos f
oram elaborados, sendo um deles em 2003 pela <i>European    Society of Human Rep
roduction and Embryology/American Society of Reproductive    Medicine</i> (Conse
nso de Rotterdam) (8,9) e o outro em 2006 pela <i>The Androgen    Excess and PCO
S Society</i> (<i>AE-PCOS Society</i>) (11,12). O Consenso de    Rotterdam consi
derou que a SOP ocorre em virtude da produ&ccedil;&atilde;o aumentada    de andr
&oacute;genos pelo ov&aacute;rio (atresia folicular com anovula&ccedil;&atilde;o
    associada ao hiperandrogenismo e hiperandrogenemia). Al&eacute;m disso, cons
iderou    que a s&iacute;ndrome pode se manifestar pelos fen&oacute;tipos mais a
mplos    do que os contemplados pelo crit&eacute;rio do Consenso do NIH (3). Por
 esse    motivo, &eacute; sugerido nesse consenso que a presen&ccedil;a de dois 
dos tr&ecirc;s    crit&eacute;rios seguintes s&atilde;o suficientes para o diagn
&oacute;stico    da s&iacute;ndrome: 1. Oligo e/ou anovula&ccedil;&atilde;o; 2. 
Evid&ecirc;ncias    cl&iacute;nicas ou laboratoriais de hiperandrogenismo e 3. P
resen&ccedil;a de    ov&aacute;rios polic&iacute;sticos &agrave; ultrassonografi
a.</font></p>     ^cY#02.htm##
00784000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704056100070002000700631#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#40#36#article#219#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">De acordo com esse    crit&eacute;rio, doi
s fen&oacute;tipos passaram a ser compat&iacute;veis com    o diagn&oacute;stico
 da SOP: pacientes com evid&ecirc;ncias cl&iacute;nicas    ou laboratoriais de h
iperandrogenismo associados com ov&aacute;rios polic&iacute;sticos,    mas sem d
isfun&ccedil;&atilde;o menstrual; e pacientes com disfun&ccedil;&atilde;o    men
strual e ov&aacute;rios polic&iacute;sticos, mas sem a presen&ccedil;a de    hip
erandrogenismo ou hiperandrogenemia.</font></p>     ^cY#02.htm##
01050000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704082700070002000700897#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#41#37#article#219#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Enquanto no Consenso    de Rotterdam a mor
fologia ovariana polic&iacute;stica &agrave; ultrassonografia    &eacute; coloca
da como um dos crit&eacute;rios isolados para o diagn&oacute;stico    da s&iacut
e;ndrome, no <i>Position Statement</i> da <i>AE-PCOS Society</i> (11,12)    o ex
cesso androg&ecirc;nico deve estar obrigatoriamente presente, seja pela    hiper
androgenemia, seja pelo hiperandrogenismo. Segundo esse posicionamento    para o
 diagn&oacute;stico da s&iacute;ndrome, s&atilde;o necess&aacute;rios    dois do
s crit&eacute;rios seguintes: 1. Oligo e/ou anovula&ccedil;&atilde;o    ou ov&aa
cute;rios polic&iacute;sticos &agrave; ultrassonografia; 2. Evid&ecirc;ncias    
cl&iacute;nicas ou laboratoriais de excesso androg&ecirc;nico.</font></p>     ^c
Y#02.htm##
00977000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704075400070002000700824#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#42#38#article#219#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Para chegar a esses    crit&eacute;rios, c
onsiderou-se a s&iacute;ndrome como uma desordem de excesso    androg&ecirc;nico
 por todas suas caracter&iacute;sticas fundamentais: disfun&ccedil;&atilde;o    
menstrual ou ovulat&oacute;ria, hiperandrogenemia, hiperandrogenismo e ov&aacute
;rios    polic&iacute;sticos; al&eacute;m disso, o <i>Position Statement</i> da 
<i>AE-PCOS    Society</i> salientou que os fen&oacute;tipos resultantes da combi
na&ccedil;&atilde;o    dessas caracter&iacute;sticas, como grupo, mas n&atilde;o
 necessariamente individualmente,    apresentam risco de resist&ecirc;ncia &agra
ve; insulina e suas consequentes    anormalidades metab&oacute;licas.</font></p>
     ^cY#02.htm##
00667000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704044400070002000700514#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#43#39#article#219#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Na realidade, esses    dois Consensos n&at
ilde;o substituem o Consenso do NIH com seu fen&oacute;tipo    cl&aacute;ssico, 
mas sim expandem o n&uacute;mero de fen&oacute;tipo poss&iacute;vel    para a s&
iacute;ndrome, sendo 6 de acordo com os crit&eacute;rios do Consenso    do NIH (
3), 10 do Consenso de Rotterdam (8,9) e 9 pela <i>AE-PCOS Society</i>    (8,9).<
/font></p>     ^cY#02.htm##
00717000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704049400070002000700564#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#44#40#article#219#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Uma dificuldade    particular no diagn&oac
ute;stico da s&iacute;ndrome dos ov&aacute;rios polic&iacute;sticos    refere-se
 &agrave; aplica&ccedil;&atilde;o desses documentos em pacientes adolescentes.  
  Al&eacute;m de dificuldades de ordem t&eacute;cnica e da aus&ecirc;ncia de dad
os    normativos, alguns dos componentes fundamentais da s&iacute;ndrome podem e
star    presentes, mas serem transit&oacute;rios.</font></p>     ^cY#02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#45#41#article#219#<p>&nbsp;</p>     ^cY#02.
htm##
00346000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704012300070002000700193#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#46#42#article#219#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="3"><b>ASPECTOS DO    DIAGN&Oacute;STICO</b></
font></p>     ^cY#02.htm##
00811000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704058800070002000700658#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#47#43#article#219#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Uma variedade de    combina&ccedil;&atilde
;o de sinais e sintomas, bem como de altera&ccedil;&otilde;es    ultrassonogr&aa
cute;ficas e laboratoriais, &eacute; a regra em pacientes portadoras    da s&iac
ute;ndrome (<a href="/img/revistas/abem/v55n1/02t02.jpg">Tabela 2</a>).    Essas
 diferentes manifesta&ccedil;&otilde;es podem ser decorrentes de caracter&iacute
;sticas    gen&eacute;ticas da popula&ccedil;&atilde;o, da presen&ccedil;a da ob
esidade    e do impacto da resist&ecirc;ncia &agrave; insulina.</font></p>     ^
cY#02.htm##
00330000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704010700070002000700177#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#48#44#article#219#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Hiperandrogenismo</b></font></p>     ^c
Y#02.htm##
01746000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704152300070002000701593#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#49#45#article#219#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Manifesta&ccedil;&otilde;es    cl&iacute;n
icas de hiperandrogenismo encontradas em pacientes com a s&iacute;ndrome    incl
uem o hirsutismo, a acne e a alopecia androg&ecirc;nica. Enquanto o hirsutismo  
  &eacute; reconhecidamente um sinal de excesso androg&ecirc;nico (16,17), o sig
nificado    da acne e da alopecia androg&ecirc;nica n&atilde;o est&aacute; adequ
adamente    estabelecido. Embora a acne possa estar presente em aproximadamente 
20% das    pacientes (18-20), n&atilde;o est&aacute; clara a preval&ecirc;ncia d
e hiperandrogenemia    em pacientes com acne isolada, motivo pelo qual esse sina
l deve ser valorizado    com cautela quando estiver presente isoladamente. Como 
pode se observar na <a href="/img/revistas/abem/v55n1/02t02.jpg">tabela    2</a>
, esse sinal &eacute; valorizado pelos diversos documentos, sendo que a    <i>Am
erican Association of Clinical Endocrinologists</i> (<i>AACE</i>) sugere    que 
deva ser considerado somente em situa&ccedil;&otilde;es especiais (se resistente
    ao tratamento ou ap&oacute;s 20 anos de idade ou associada &agrave; disfun&c
cedil;&atilde;o    menstrual) (4). Uma dificuldade adicional quanto &agrave; val
oriza&ccedil;&atilde;o    da acne como evid&ecirc;ncia de excesso androg&ecirc;n
ico ocorre na adolescente,    na qual este &eacute; um sinal comum, com uma inci
d&ecirc;ncia de quase 90%    (21), com possibilidade de regredir ap&oacute;s a t
erceira d&eacute;cada de    vida (22).</font></p>     ^cY#02.htm##
00706000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704048300070002000700553#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#50#46#article#219#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">A alopecia androg&ecirc;nica    pode ser e
ncontrada em at&eacute; 5% das pacientes com a s&iacute;ndrome, sendo    citada 
como uma manifesta&ccedil;&atilde;o de excesso androg&ecirc;nico por    quatro S
ociedades (3,4,8,9,11,12). Entretanto, o Consenso de Rotterdam salienta    que &
eacute; um marcador pobre para hiperandrogenismo caso n&atilde;o esteja    prese
nte o dist&uacute;rbio menstrual (23).</font></p>     ^cY#02.htm##
01166000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704094300070002000701013#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#51#47#article#219#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Com rela&ccedil;&atilde;o    ao hirsutismo
, sua presen&ccedil;a tem sido identificada pelo emprego da escala    de Ferrima
n e Gallwey (24). De acordo com a publica&ccedil;&atilde;o original,    a presen
&ccedil;a e a quantidade de pelos foram avaliadas em uma escala de 0    a 4 em o
nze &aacute;reas corporais. Esses autores observaram que em mulheres    jovens u
ma quantidade significativa de pelos foi encontrada em bra&ccedil;os    e pernas
, enquanto nas demais &aacute;reas a quantidade foi quase nula. A partir    dess
a observa&ccedil;&atilde;o, propuseram que um escore poderia ser obtido    pela 
quantifica&ccedil;&atilde;o dos pelos em nove das onze &aacute;reas avaliadas   
 (com exclus&atilde;o da perna e bra&ccedil;o). Essa escala que considera apenas
    essas nove &aacute;reas tem sido referida como sendo de Ferriman e Gallwey m
odificada    (25).</font></p>     ^cY#02.htm##
00828000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704060500070002000700675#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#52#48#article#219#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Uma limita&ccedil;&atilde;o    importante 
do emprego da escala de Ferriman e Gallwey diz respeito &agrave;    sua reprodut
ibilidade quando empregada por observadores independentes. Enquanto    a variabi
lidade intraobservador &eacute; menor de 3 pontos (26), a variabilidade    inter
observador chega a 50%, dependendo da &aacute;rea considerada (27). Assim,    es
sa escala dessa ser utilizada por um mesmo observador, sendo desaconselh&aacute;
vel    seu uso quando da avalia&ccedil;&atilde;o por v&aacute;rios observadores.
</font></p>     ^cY#02.htm##
01649000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704142600070002000701496#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#53#49#article#219#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Entretanto, a principal    limita&ccedil;&
atilde;o para o emprego da escala de Ferriman e Gallwey consiste    na determina
&ccedil;&atilde;o do ponto de corte considerado normal, levando-se    em conside
ra&ccedil;&atilde;o inclusive a ra&ccedil;a das mulheres estudadas.    Sabe-se, 
por exemplo, que o hirsutismo &eacute; significativamente menos prevalente    em
 mulheres asi&aacute;ticas e adolescentes (28). Apesar de Ferriman ter proposto,
    em uma publica&ccedil;&atilde;o posterior, que o limite de corte deveria ser
    igual ou maior que 5 (29), o limite de corte utilizado tem sido igual ou mai
or    que 8 (<a href="/img/revistas/abem/v55n1/02t02.jpg">Tabela 2</a>), o que r
epresenta    o percentil 95 dos dados originariamente publicados por Ferriman e 
Gallwey (24).    Mais recentemente, um limite de corte de 3 foi proposto por DeU
garte e cols.    em um estudo realizado em mulheres americanas (30). Al&eacute;m
 de demonstrar    que n&atilde;o houve diferen&ccedil;a entre brancas e negras, 
observaram que    a porcentagem de mulheres com um limite de corte maior ou igua
l a 3 que se queixavam    de excesso de pelos (69,3%) foi igual &agrave; das mul
heres com um limite de    corte maior ou igual a 8 (70%), enquanto a porcentagem
 de mulheres com um limite    de corte menor que 3 que se queixavam de excesso d
e pelos foi de 15,8%.</font></p>     ^cY#02.htm##
00816000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704059300070002000700663#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#54#50#article#219#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Esse dado est&aacute;    de acordo com os 
resultados do estudo de Souter e cols., que observaram que,    em mulheres com u
m escore de 1 a 5, 55% apresentavam uma s&iacute;ndrome de    excesso androg&eci
rc;nico, principalmente SOP (31). Das pacientes com irregularidade    menstrual,
 65% apresentaram uma desordem de excesso androg&ecirc;nico, contra    22% das p
acientes com ciclos menstruais regulares. Das pacientes eumenorreicas,    soment
e 11% apresentaram uma s&iacute;ndrome de excesso androg&ecirc;nico.</font></p> 
    ^cY#02.htm##
01471000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704124800070002000701318#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#55#51#article#219#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Contrariando essa    observa&ccedil;&atild
e;o sobre a conveni&ecirc;ncia da redu&ccedil;&atilde;o    do limite de corte, o
 <i>Guideline</i> da <i>Endocrine Society</i> (13) sugere    que pacientes com h
irsutismo de grau leve (escore de Ferriman e Gallwey &lt;    15) n&atilde;o deva
m ser avaliadas, pois considera que a possibilidade de se    identificar uma eti
ologia que possa modificar a conduta terap&ecirc;utica &eacute;    pequena. O hi
rsutismo seria avaliado se de grau moderado ou severo ou de qualquer    grau qua
ndo de in&iacute;cio s&uacute;bito, rapidamente progressivo ou quando    associa
do &agrave; irregularidade menstrual ou infertilidade, obesidade central,    aca
ntose <i>nigricans</i> ou na presen&ccedil;a de clitoromegalia. Se considerarmos
    que tanto o Consenso de Rotterdam quanto o <i>Position Statement</i> da <i>A
E-PCOS    Society</i> admitem a exist&ecirc;ncia de SOP em pacientes com ciclos 
menstruais    regulares, ovulat&oacute;rios ou n&atilde;o, investigar pacientes 
com hirsutismo    com escore &lt; 15 somente se estiver presente a irregularidad
e menstrual poder&aacute;    deixar de identificar pacientes com a s&iacute;ndro
me.</font></p>     ^cY#02.htm##
00330000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704010700070002000700177#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#56#52#article#219#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Hiperandrogenemia</b></font></p>     ^c
Y#02.htm##
01230000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704100700070002000701077#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#57#53#article#219#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">N&iacute;veis elevados    de andr&oacute;g
enos s&atilde;o encontrados em aproximadamente 60% a 80% das    pacientes com SO
P, sendo representado principalmente por um valor aumentado    de testosterona l
ivre, enquanto a dosagem isolada da testosterona total contribui    pouco para o
 diagn&oacute;stico (32). Concentra&ccedil;&atilde;o aumentada de    DHEAS pode 
ser encontrada em 25% das pacientes (33), podendo ser este o &uacute;nico    and
r&oacute;geno alterado em 10% das pacientes (34). A contribui&ccedil;&atilde;o  
  da dosagem de androstenediona &eacute; discut&iacute;vel, mas ela pode aumenta
r    o n&uacute;mero de pacientes diagnosticadas como hiperandrog&ecirc;nicas em
    10% (34). J&aacute; a dosagem da DHEA tem um valor diagn&oacute;stico limita
do,    n&atilde;o sendo sugerida sua determina&ccedil;&atilde;o na avalia&ccedil
;&atilde;o    rotineira em pacientes com s&iacute;ndromes hiperandrog&ecirc;nica
s.</font></p>     ^cY#02.htm##
00830000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704060700070002000700677#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#58#54#article#219#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Como se pode observar    na <a href="/img/
revistas/abem/v55n1/02t02.jpg">tabela 2</a>, testosterona total    e testosteron
a livre s&atilde;o os principais andr&oacute;genos considerados    como &uacute;
teis para identifica&ccedil;&atilde;o da hiperandrogenemia, sendo    que apenas 
tr&ecirc;s dos oito documentos relacionados sugerem a dosagem de    DHEAS e dois
, a de androstenediona. A dosagem da testosterona livre ou o c&aacute;lculo    d
o &iacute;ndice de testosterona livre s&atilde;o sugeridos em todos os documento
s.</font></p>     ^cY#02.htm##
01176000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704095300070002000701023#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#59#55#article#219#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Segundo o Consenso    de Rotterdam, alguma
s limita&ccedil;&otilde;es devem ser consideradas com rela&ccedil;&atilde;o    &
agrave; dosagem de testosterona (8,9): subst&acirc;ncias esteroides de estrutura
    similar na circula&ccedil;&atilde;o podem levar &agrave; interfer&ecirc;ncia
;    a faixa de normalidade na popula&ccedil;&atilde;o geral &eacute; ampla, da 
ordem    de tr&ecirc;s magnitudes; a concentra&ccedil;&atilde;o de testosterona 
varia    durante o dia; aus&ecirc;ncia de valores de refer&ecirc;ncia estabeleci
dos para    cada popula&ccedil;&atilde;o e sexo, principalmente para adolescente
s e idosos;    a faixa et&aacute;ria e o &iacute;ndice de massa corporal n&atild
e;o t&ecirc;m    sido levados em conta na interpreta&ccedil;&atilde;o dos result
ados; n&atilde;o    h&aacute; um padr&atilde;o universal de refer&ecirc;ncia par
a a dosagem de testosterona.</font></p>     ^cY#02.htm##
00885000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704066200070002000700732#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#60#56#article#219#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">V&aacute;rios m&eacute;todos    encontram-
se dispon&iacute;veis para a dosagem de testosterona total, sendo    os mais uti
lizados o radioimunoensaio e o enzimaimunoensaio. Entretanto, o coeficiente    d
e varia&ccedil;&atilde;o &eacute; significativo (entre 10% e 20%), sendo tanto  
  maior quanto menor a concentra&ccedil;&atilde;o de testosterona, principalment
e    para valores inferiores a 250 ng/dL (35). Para uma mesma amostra, dosadas e
m    laborat&oacute;rios diferentes, pode haver uma varia&ccedil;&atilde;o da co
ncentra&ccedil;&atilde;o    da ordem de 2 a 6 vezes (35).</font></p>     ^cY#02.
htm##
00697000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704047400070002000700544#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#61#57#article#219#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Embora o padr&atilde;o-ouro    para a dosa
gem de testosterona livre seja o m&eacute;todo de di&aacute;lise    de equil&iac
ute;brio, na pr&aacute;tica cl&iacute;nica utiliza-se a f&oacute;rmula    de Ver
meulen (36), por meio da qual se obt&eacute;m a testosterona livre a partir    d
as concentra&ccedil;&otilde;es da testosterona total e da globulina ligadora    
de esteroides sexuais (SHBG).</font></p>     ^cY#02.htm##
00558000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704033500070002000700405#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#62#58#article#219#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Levando-se em considera&ccedil;&atilde;o  
  essas observa&ccedil;&otilde;es, &eacute; preciso cautela para se valorizar   
 um aumento da concentra&ccedil;&atilde;o de testosterona em pacientes sem sinai
s    cl&iacute;nicos de excesso androg&ecirc;nico.</font></p>     ^cY#02.htm##
00349000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704012600070002000700196#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#63#59#article#219#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Disfun&ccedil;&atilde;o    menstrual</b
></font></p>     ^cY#02.htm##
01010000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704078700070002000700857#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#64#60#article#219#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Uma variedade de    termos tem sido empreg
ada pelos documentos para caracterizar a disfun&ccedil;&atilde;o    menstrual na
s pacientes com a s&iacute;ndrome: anovula&ccedil;&atilde;o cr&ocirc;nica    (NI
H) (3), oligo e/ou anovula&ccedil;&atilde;o (Rotterdam) (8,9) e oligoanovula&cce
dil;&atilde;o    (<i>AE-PCOS Society</i>) (11,12). Se para o <i>National Institu
te of Health</i>    a presen&ccedil;a da anovula&ccedil;&atilde;o cr&ocirc;nica 
(amenorreia ou espaniomenorreia)    &eacute; essencial para o diagn&oacute;stico
 da SOP, pacientes com ciclos menstruais    regulares e at&eacute; mesmo ovulat&
oacute;rio podem ser diagnosticadas como    portadoras da s&iacute;ndrome pelos 
dois outros consensos.</font></p>     ^cY#02.htm##
01210000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704098700070002000701057#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#65#61#article#219#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Uma minoria de    pacientes pode apresenta
r uma variante da s&iacute;ndrome caracterizada pela    presen&ccedil;a de ovula
&ccedil;&atilde;o (<i>ovulatory PCOS</i>). Nesta variante,    cuja hist&oacute;r
ia natural n&atilde;o se sabe ao certo, observam-se anormalidades    androg&ecir
c;nicas e dist&uacute;rbios metab&oacute;licos menos intensos (37,38).    Enquan
to uma hist&oacute;ria de ciclos menstruais regulares em uma paciente    com aus
&ecirc;ncia de hiperandrogenismo &eacute; fortemente sugestiva de ovula&ccedil;&
atilde;o,    a presen&ccedil;a de sinais de hiperandrogenismo pode indicar ciclo
s anovulat&oacute;rios.    Nessa situa&ccedil;&atilde;o, tanto o <i>Position Sta
tement</i> da <i>AE-PCOS    Society</i> (11,12) quanto o posicionamento da <i>Am
erican Association of Reproductive    Medicine</i> (10) orientam para a dosagem 
da progesterona entre os 20º e 24º    dias do ciclo menstrual.</font></p>     ^c
Y#02.htm##
01266000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704104300070002000701113#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#66#62#article#219#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Em adolescentes,    altera&ccedil;&otilde;
es menstruais e ciclos anovulat&oacute;rios s&atilde;o    comuns, podendo estar 
presentes em at&eacute; 65% das meninas (39). Embora um    intervalo de 45 dias 
tenha sido considerado como normal at&eacute; dois a tr&ecirc;s    anos ap&oacut
e;s a menarca, um estudo demonstrou que 98% das adolescentes com    ciclos com i
ntervalo de 21 a 34 dias aos 15 anos mantiveram o padr&atilde;o    menstrual reg
ular aos 18 anos de idade. J&aacute; nas adolescentes com ciclos    com interval
o maior que 34 dias aos 15 anos, apenas 49% apresentaram ciclos    menstruais re
gulares aos 18 anos (39). Nesse estudo, o melhor preditor para    dist&uacute;rb
io menstrual aos 18 anos de idade foi a presen&ccedil;a de oligomenorreia    na 
adolesc&ecirc;ncia. Esses dados demonstram a dificuldade na valoriza&ccedil;&ati
lde;o    do dist&uacute;rbio menstrual na adolescente, uma vez que metade pode r
egularizar    o ciclo na idade adulta.</font></p>     ^cY#02.htm##
00350000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704012700070002000700197#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#67#63#article#219#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>O ov&aacute;rio    polic&iacute;stico</
b></font></p>     ^cY#02.htm##
01873000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704165000070002000701720#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#68#64#article#219#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">A identifica&ccedil;&atilde;o    do ov&aac
ute;rio polic&iacute;stico deve obedecer a crit&eacute;rios diagn&oacute;sticos 
   estritos e n&atilde;o somente se apoiar na apar&ecirc;ncia multic&iacute;stic
a    ou polic&iacute;stica do ov&aacute;rio. Isso foi poss&iacute;vel a partir d
o    emprego do ultrassom de alta resolu&ccedil;&atilde;o em tempo real por Swan
son    e cols., em 1981 (40), que permitiu detectar cistos e fol&iacute;culos ov
arianos    em condi&ccedil;&otilde;es normais e patol&oacute;gicas. Segundo esse
s autores,    o ov&aacute;rio polic&iacute;stico &eacute; caracterizado por ov&a
acute;rios    aumentados de volume contendo um grande n&uacute;mero de fol&iacut
e;culos com    2 a 6 mm de di&acirc;metro, n&atilde;o se fazendo refer&ecirc;nci
a ao n&uacute;mero    de fol&iacute;culos nem &agrave;s caracter&iacute;sticas d
o estroma. Posteriormente,    Adams e cols. definiram a morfologia polic&iacute;
stica como sendo a de um ov&aacute;rio    que continha pelo menos 10 fol&iacute;
culos, geralmente entre 2 e 8 mm de di&acirc;metro,    dispostos perifericamente
 ou espalhados em um estroma denso e hipertr&oacute;fico    (41). Alternativamen
te, e menos frequentemente, podem ser identificados m&uacute;ltiplos    cistos, 
com 2 a 4 mm de di&acirc;metro, distribu&iacute;dos em um estroma abundante    (
41). Mais recentemente, a utiliza&ccedil;&atilde;o da via transvaginal se acompa
nhou    de um aumento da sensibilidade do exame, ao permitir uma visualiza&ccedi
l;&atilde;o    mais precisa do ov&aacute;rio, principalmente em mulheres obesas 
(42).</font></p>     ^cY#02.htm##
03113000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704289000070002000702960#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#69#65#article#219#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Como pode ser observado    na <a href="/im
g/revistas/abem/v55n1/02t02.jpg">tabela 2</a>, o crit&eacute;rio    de morfologi
a ovariana polic&iacute;stica no ultrassom diverge entre os v&aacute;rios    doc
umentos. O <i>Guideline</i> da AACE adota o crit&eacute;rio proposto por    Adam
s e cols. (41). Posteriormente, e apesar de o aumento da ecogenicidade do    est
roma ter sido descrito inicialmente como uma das caracter&iacute;sticas do    ov
&aacute;rio polic&iacute;stico, o Consenso de Rotterdam (8,9) adotou a sugest&at
ilde;o    de um Consenso internacional sobre avalia&ccedil;&atilde;o ultrassonog
r&aacute;fica    do ov&aacute;rio polic&iacute;stico de que esse aspecto, assim 
como a distribui&ccedil;&atilde;o    perif&eacute;rica dos cistos, fosse omitido
, considerando dificuldades t&eacute;cnicas    para sua identifica&ccedil;&atild
e;o (7). De fato, n&atilde;o h&aacute; um crit&eacute;rio    definido para defin
ir a hiperplasia do estroma (43), sendo este um crit&eacute;rio    subjetivo (44
). Por outro lado, foi demonstrado que o volume ou &aacute;rea    do ov&aacute;r
io tem uma boa correla&ccedil;&atilde;o com o volume do estroma    (7). De acord
o com esse Consenso Internacional, o ov&aacute;rio polic&iacute;stico    deve se
r definido pela presen&ccedil;a de 12 ou mais fol&iacute;culos medindo    entre 
2 e 9 mm de di&acirc;metro e/ou aumento do volume ovariano (&gt; 10 cm<sup>3</su
p>).    Essa defini&ccedil;&atilde;o &eacute; tamb&eacute;m recomendada pelos do
cumentos    que se seguiram ao do Consenso de Rotterdam (13,14,20,22), n&atilde;
o se aplicando    a mulheres em uso de contraceptivo hormonal oral. Algumas cons
idera&ccedil;&otilde;es    adicionais propostas pelo Consenso de Rotterdam inclu
em: em mulheres com ciclos    menstruais regulares, a ultrassonografia deve ser 
realizada na fase folicular    precoce, enquanto em pacientes com dist&uacute;rb
io menstrual pode ser realizada    aleatoriamente ou ap&oacute;s tr&ecirc;s a ci
nco dias de fluxo menstrual induzido    pela administra&ccedil;&atilde;o de prog
esterona; a via transvaginal deve ser    preferencialmente utilizada, principalm
ente em mulheres obesas; se houver evid&ecirc;ncia    de um fol&iacute;culo domi
nante (&gt; 10 mm), a ultrassonografia deve ser repetida;    o c&aacute;lculo do
 volume ovariano deve ser realizado pela f&oacute;rmula:    0,5&nbsp;x&nbsp;comp
rimento x&nbsp;largura&nbsp;x&nbsp;espessura (40); o n&uacute;mero    de fol&iac
ute;culos deve ser estimado tanto em corte longitudinal quanto transversal;    o
 di&acirc;metro dos fol&iacute;culos deve ser expresso como a m&eacute;dia    de
 tr&ecirc;s di&acirc;metros, longitudinal, transversal e anteroposterior e    a 
ultrassonografia &eacute; uma oportunidade para o rastreamento de hiperplasia   
 endometrial e c&acirc;ncer de ov&aacute;rio.</font></p>     ^cY#02.htm##
00893000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704067000070002000700740#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#70#66#article#219#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">&Eacute; importante    salientar que, embo
ra a morfologia ovariana polic&iacute;stica ao ultrassom    possa ser encontrada
 em aproximadamente 75% das pacientes com SOP (7), o <i>Position    Statement</i
> da <i>AE-PCOS Society</i> (11,12) chama a aten&ccedil;&atilde;o    que essa mo
rfologia pode ser encontrada em at&eacute; 20% de mulheres normais.    O seguime
nto de 24 dessas mulheres por um per&iacute;odo de oito anos demonstrou    que s
omente uma evoluiu para a s&iacute;ndrome, enquanto das restantes metade    mant
eve a morfologia e metade apresentou regress&atilde;o desta (45).</font></p>    
 ^cY#02.htm##
01345000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704112200070002000701192#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#71#67#article#219#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Em adolescentes,    a avalia&ccedil;&atild
e;o morfol&oacute;gica do ov&aacute;rio pela ultrassonografia    &eacute; feita 
em geral pela via transabdominal, com uma perda de sensibilidade    do exame (42
,44). Embora n&atilde;o exista um Consenso espec&iacute;fico sobre    crit&eacut
e;rios para diagn&oacute;stico do ov&aacute;rio polic&iacute;stico    nessa faix
a et&aacute;ria, van Hooff e cols. demonstraram que os melhores par&acirc;metros
    para diferenciar o ov&aacute;rio normal do ov&aacute;rio polic&iacute;stico 
   foram o n&uacute;mero de fol&iacute;culos (10 ou mais cistos em ambos os ov&a
acute;rios)    e o volume ovariano (11,8 cm<sup>3</sup>, correspondente ao perce
ntil 95 de    adolescentes com ciclos menstruais regulares) (39). Esses crit&eac
ute;rios estiveram    presentes em apenas 9% de adolescentes com ciclos menstrua
is regulares, aumentando    sua incid&ecirc;ncia de acordo com a piora do padr&a
tilde;o menstrual (28% na    presen&ccedil;a de irregularidade menstrual e 45% n
a presen&ccedil;a de oligomenorreia).</font></p>     ^cY#02.htm##
00992000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704076900070002000700839#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#72#68#article#219#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Uma dificuldade    adicional na adolescent
e &eacute; a presen&ccedil;a de ov&aacute;rios multic&iacute;sticos,    definido
 por Adams e cols. pela presen&ccedil;a de ov&aacute;rios de tamanho    normal o
u aumentado com 6 a 10 cistos com 4 a 10 mm de di&acirc;metro, sem aumento    do
 volume do estroma (41). Esse aspecto morfol&oacute;gico, que pode ser considera
do    como uma variante do ov&aacute;rio normal, n&atilde;o deve ser confundido 
com    o ov&aacute;rio polic&iacute;stico, o que n&atilde;o &eacute; infrequente
 nessa    faixa et&aacute;ria, em decorr&ecirc;ncia da diminui&ccedil;&atilde;o 
da resolu&ccedil;&atilde;o    do ultrassom quando realizado pela via transabdomi
nal.</font></p>     ^cY#02.htm##
00333000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704011000070002000700180#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#73#69#article#219#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Outras anormalidades</b></font></p>    
 ^cY#02.htm##
00842000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704061900070002000700689#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#74#70#article#219#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Apesar de a obesidade    e de anormalidade
s da concentra&ccedil;&atilde;o de LH e de a rela&ccedil;&atilde;o    entre o LH
 e o horm&ocirc;nio fol&iacute;culo-estimulante (FSH) serem encontradas    com f
requ&ecirc;ncia em pacientes com a SOP (2), nenhum dos documentos as considerou 
   como parte da defini&ccedil;&atilde;o da s&iacute;ndrome. De acordo com o Con
senso    de Rotterdam (8,9), a dosagem de LH pode ser considerada um par&acirc;m
etro    secund&aacute;rio, principalmente para o diagn&oacute;stico diferencial 
de amenorreia.</font></p>     ^cY#02.htm##
00348000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704012500070002000700195#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#75#71#article#219#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Exclus&atilde;o    de outras causas</b>
</font></p>     ^cY#02.htm##
01547000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704132400070002000701394#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#76#72#article#219#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">A SOP, como s&iacute;ndrome,    &eacute; u
m diagn&oacute;stico de exclus&atilde;o, devendo-se pesquisar doen&ccedil;as    
que possam mimetizar seu fen&oacute;tipo. Entretanto, a an&aacute;lise da <a hre
f="/img/revistas/abem/v55n1/02t02.jpg">tabela    2</a> demonstra que h&aacute; d
iverg&ecirc;ncias sobre quais doen&ccedil;as    devem ser exclu&iacute;das e com
o faz&ecirc;-lo. Considerando que a forma n&atilde;o    cl&aacute;ssica de hiper
plasia adrenal cong&ecirc;nita, disfun&ccedil;&otilde;es    tireoidianas, neopla
sias virilizantes da adrenal e do ov&aacute;rio, s&iacute;ndromes    de resist&e
circ;ncia severa &agrave; insulina e hiperprolactinemia podem responder    por 5
% a 10% das s&iacute;ndromes de excesso androg&ecirc;nico (8,9), &eacute;    sug
erido o rastreamento dessas doen&ccedil;as mediante avalia&ccedil;&atilde;o    c
l&iacute;nica e/ou laboratorial. Com rela&ccedil;&atilde;o &agrave; hiperprolact
inemia,    embora estudos iniciais apontassem uma preval&ecirc;ncia elevada nas 
pacientes    com o fen&oacute;tipo da s&iacute;ndrome, recentemente demonstrou-s
e que essa    &eacute; uma situa&ccedil;&atilde;o infrequente, sendo a maior par
te dos casos    decorrente de macroprolactinemia ou do efeito do estresse (46).<
/font></p>     ^cY#02.htm##
01071000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704084800070002000700918#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#77#73#article#219#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Altera&ccedil;&atilde;o    da concentra&cc
edil;&atilde;o de 17hidroxi-progesterona (17OHP) &eacute; encontrada    com freq
u&ecirc;ncia em pacientes portadoras da SOP (47,48). Esse esteroide    &eacute; 
um marcador da presen&ccedil;a da forma n&atilde;o cl&aacute;ssica    de hiperpl
asia adrenal cong&ecirc;nita por defici&ecirc;ncia da 21-hidroxilase    (FNC-21H
AC), uma disfun&ccedil;&atilde;o adrenal que pode apresentar um fen&oacute;tipo 
   semelhante ao da SOP (49). O diagn&oacute;stico diferencial entre essas duas 
   entidades pode ser feito tanto com a concentra&ccedil;&atilde;o basal de 17OH
P    quanto ap&oacute;s est&iacute;mulo com ACTH sint&eacute;tico (250 mg por vi
a    endovenosa, em <i>bolus</i>, com coleta de sangue 60 minutos ap&oacute;s) (
2).</font></p>     ^cY#02.htm##
02051000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704182800070002000701898#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#78#74#article#219#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Na <a href="/img/revistas/abem/v55n1/02t02
.jpg">tabela    2</a>, observa-se que o crit&eacute;rio mais frequentemente adot
ado para o diagn&oacute;stico    da FNC-21HAC &eacute; o de Azziz e cols. (50), 
que considera que uma concentra&ccedil;&atilde;o    basal de 4,0 ng/mL tem a m&a
acute;xima especificidade e valor preditivo positivo    para a presen&ccedil;a d
a FNC-21HAC, se coletada no per&iacute;odo da manh&atilde;    e na fase folicula
r do ciclo menstrual. Para amostras coletadas fora dessas    condi&ccedil;&otild
e;es, um limite de corte menor deve ser considerado (2,0    ou 3,0 ng/mL). Esse 
mesmo grupo demonstrou que uma concentra&ccedil;&atilde;o    basal &lt; 2,0 ng/m
L tem um valor preditivo negativo pr&oacute;ximo a 100% (51).    Entretanto, cas
o se adote a 17OHP basal como crit&eacute;rio diagn&oacute;stico,    deve-se lev
ar em considera&ccedil;&atilde;o a popula&ccedil;&atilde;o estudada.    De fato,
 Escobar-Morreale e cols. demonstraram que, para a popula&ccedil;&atilde;o    es
panhola, o limite de corte &eacute; de 1,7 ng/mL (52). Com rela&ccedil;&atilde;o
    &agrave; concentra&ccedil;&atilde;o ap&oacute;s est&iacute;mulo, somente a <
i>American    Society for Reproductive Medicine</i> sugere um limite de corte (&
gt; 10 ng/mL)    (10). Esse valor tem origem em um normograma publicado por New 
e cols. (53),    no qual o diagn&oacute;stico das pacientes com FNC-21HAC se bas
eou na tipagem    do sistema HLA. Com o advento da biologia molecular, novos val
ores de corte    t&ecirc;m sido propostos, sendo que em nosso meio Bachega e col
s. observaram    que a menor concentra&ccedil;&atilde;o de 17OHP ap&oacute;s est
&iacute;mulo    obtido em pacientes com FNC-21HAC com gen&oacute;tipo definido f
oi de 17 ng/mL    (54).</font></p>     ^cY#02.htm##
01077000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704085400070002000700924#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#79#75#article#219#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Embora disfun&ccedil;&otilde;es    tireoid
ianas possam se acompanhar de anovula&ccedil;&atilde;o cr&ocirc;nica,    o Conse
nso de Rotterdam considera que a avalia&ccedil;&atilde;o rotineira da    fun&cce
dil;&atilde;o tireoidiana em pacientes hiperandrog&ecirc;nicas apresente    valo
r limitado, considerando que a incid&ecirc;ncia dessas disfun&ccedil;&otilde;es 
   em pacientes com a s&iacute;ndrome n&atilde;o &eacute; maior que em mulheres 
   adultas jovens (8,9). Entretanto, o <i>Position Statement</i> da <i>AE-PCOS  
  Society</i> sugere o rastreamento, citando como refer&ecirc;ncia uma preval&ec
irc;ncia    tr&ecirc;s vezes maior de tireoidite autoimune nas pacientes com a s
&iacute;ndrome,    com uma manifesta&ccedil;&atilde;o mais precoce da doen&ccedi
l;a (55).</font></p>     ^cY#02.htm##
01307000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704108400070002000701154#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#80#76#article#219#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Embora exclu&iacute;do    do diagn&oacute;
stico diferencial da SOP pelo Consenso do NIH, por apresentar    ciclos menstrua
is regulares e ovulat&oacute;rios, o hirsutismo idiop&aacute;tico,    com o adve
nto do Consenso de Rotterdam (8,9) e o <i>Position Statement</i> da    <i>AE-PCO
S Society</i> (11,12), deve ser considerado tamb&eacute;m como uma    causa a se
r exclu&iacute;da. O conceito de hirsutismo idiop&aacute;tico tem    se modifica
do ao longo do tempo (56). Inicialmente foi caracterizado como hirsutismo    de 
causa desconhecida, ap&oacute;s a exclus&atilde;o de outras causas de s&iacute;n
dromes    hiperandrog&ecirc;nicas. Um conceito atual e estrito &eacute; aquele q
ue caracteriza    o hirsutismo idiop&aacute;tico pela presen&ccedil;a de hirsuti
smo associado    a ciclos menstruais regulares e ovulat&oacute;rios, na presen&c
cedil;a de normoandrogenemia    e ov&aacute;rios normais &agrave; ultrassonograf
ia, tamb&eacute;m com exclus&atilde;o    de outras causas de hiperandrogenismo.<
/font></p>     ^cY#02.htm##
00746000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704052300070002000700593#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#81#77#article#219#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Finalmente, nas    pacientes cuja apresent
a&ccedil;&atilde;o inicial seja a presen&ccedil;a de    oligo/anovula&ccedil;&at
ilde;o, o Consenso de Rotterdam sugere que sejam realizadas    as dosagens de FS
H e estradiol, com o objetivo de excluir-se o hipogonadismo    hipergonadotr&oac
ute;fico ou fal&ecirc;ncia ovariana prematura, caracterizados    por uma concent
ra&ccedil;&atilde;o aumentada de FSH e diminu&iacute;da de estradiol    (8,9).</
font></p>     ^cY#02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#82#78#article#219#<p>&nbsp;</p>     ^cY#02.
htm##
00350000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704012700070002000700197#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#83#79#article#219#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="3"><b>CONSIDERA&Ccedil;&Otilde;ES    FINAIS</
b></font></p>     ^cY#02.htm##
02097000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704187400070002000701944#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#84#80#article#219#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">O diagn&oacute;stico    da SOP, por se tra
tar de uma s&iacute;ndrome, depende de uma combina&ccedil;&atilde;o    dos seus 
elementos fundamentais, com exclus&atilde;o de outras doen&ccedil;as    que pode
m se manifestar com fen&oacute;tipo semelhante. Basicamente, tr&ecirc;s    Conse
nsos sugerem crit&eacute;rios diagn&oacute;sticos para a s&iacute;ndrome,    a p
artir de suas caracter&iacute;sticas fundamentais, hiperandrogenismo, hiperandro
genemia,    disfun&ccedil;&atilde;o menstrual e ov&aacute;rios polic&iacute;stic
os. O primeiro    Consenso surgiu em 1990 (3), definindo o que se pode chamar do
 fen&oacute;tipo    cl&aacute;ssico da s&iacute;ndrome, caracterizado pelo dist&
uacute;rbio menstrual    e manifesta&ccedil;&otilde;es de excesso androg&ecirc;n
ico. Posteriormente,    em 2003 (Consenso de Rotterdam) (8,9) e 2006 (<i>AE-PCOS
 Society</i>) (8,9),    incorporam tamb&eacute;m como elemento fundamental da s&
iacute;ndrome a morfologia    ovariana polic&iacute;stica, elemento este que n&a
tilde;o foi considerado no    Consenso do NIH (3). A introdu&ccedil;&atilde;o da
 morfologia ovariana polic&iacute;stica    como elemento fundamental da s&iacute
;ndrome pelo Consenso de Rotterdam levou    em considera&ccedil;&atilde;o que pa
cientes que apresentam essa morfologia s&atilde;o    mais sens&iacute;veis &agra
ve; indu&ccedil;&atilde;o de ovula&ccedil;&atilde;o    que mulheres com ciclos m
enstruais regulares (57). Um avan&ccedil;o significativo    foi o de se posicion
ar sobre os crit&eacute;rios para a caracteriza&ccedil;&atilde;o    do ov&aacute
;rio polic&iacute;stico ao ultrassom, tendo sido adotada a sugest&atilde;o    de
 um Consenso Internacional sobre o tema (7), tamb&eacute;m recomendada pelos    
documentos que se seguiram ao do Consenso de Rotterdam (13,14,20,22).</font></p>
     ^cY#02.htm##
01464000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704124100070002000701311#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#85#81#article#219#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Se at&eacute; a    d&eacute;cada de 80 do 
s&eacute;culo passado a SOP era considerada uma desordem    com consequ&ecirc;nc
ias reprodutiva e est&eacute;tica, com risco aumentado para    carcinoma de endo
m&eacute;trio, a partir dessa d&eacute;cada v&aacute;rias evid&ecirc;ncias    de
monstraram tamb&eacute;m um risco tamb&eacute;m aumentado para diabetes tipo    
2, dislipidemia, hipertens&atilde;o arterial e possivelmente doen&ccedil;a cardi
ovascular    (58), possivelmente decorrente da presen&ccedil;a da resist&ecirc;n
cia &agrave;    insulina. O objetivo do Consenso da <i>AE-PCOS Society</i> foi j
ustamente o    de definir fen&oacute;tipos possivelmente relacionados com resist
&ecirc;ncia    &agrave; insulina e consequentes dist&uacute;rbios metab&oacute;l
icos. Considerando    que o tratamento da SOP &eacute; inespec&iacute;fico, a es
colha do crit&eacute;rio    para seu diagn&oacute;stico deve levar em considera&
ccedil;&atilde;o o objetivo    do tratamento, principalmente com rela&ccedil;&at
ilde;o &agrave; preven&ccedil;&atilde;o    da doen&ccedil;a cardiovascular, moti
vo de um posicionamento espec&iacute;fico    da <i>AE-PCOS Society</i> (59).</fo
nt></p>     ^cY#02.htm##
01375000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704115200070002000701222#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#86#82#article#219#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Uma dificuldade    na aplica&ccedil;&atild
e;o dos crit&eacute;rios diagn&oacute;sticos para a SOP    consiste na caracteri
za&ccedil;&atilde;o do excesso androg&ecirc;nico. O hirsutismo    &eacute; aceit
o como um marcador confi&aacute;vel, mas a alopecia androg&ecirc;nica    e a acn
e devem ser aceitos com reserva na aus&ecirc;ncia de dist&uacute;rbio    menstru
al e hiperandrogenemia, principalmente em adolescentes. O mesmo ocorre    com a 
hiperandrogenemia isolada, na aus&ecirc;ncia de sinais de excesso androg&ecirc;n
ico,    devido a limita&ccedil;&otilde;es de ordem t&eacute;cnica relacionadas a
 dosagens    de horm&ocirc;nios esteroides. Essas limita&ccedil;&otilde;es podem
 ser contornadas    pelo emprego da cromatografia l&iacute;quida de alta press&a
tilde;o, que pelo    custo &eacute; invi&aacute;vel rotineiramente. Permanece co
mo op&ccedil;&atilde;o    a demonstra&ccedil;&atilde;o de aumento da testosteron
a livre, seja por meio    da aplica&ccedil;&atilde;o da f&oacute;rmula de Vermeu
len ou do c&aacute;lculo    do &iacute;ndice de testosterona livre.</font></p>  
   ^cY#02.htm##
01096000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704087300070002000700943#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#87#83#article#219#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Finalmente, a dificuldade    est&aacute; c
om rela&ccedil;&atilde;o ao diagn&oacute;stico da SOP em adolescentes,    per&ia
cute;odo no qual algumas das caracter&iacute;sticas fundamentais da s&iacute;ndr
ome    podem estar presentes ou serem um achado transit&oacute;rio. Assim, &eacu
te;    prudente que esse diagn&oacute;stico seja feito somente em adolescentes c
om    a m&aacute;xima probabilidade de apresentar a s&iacute;ndrome. De acordo c
om    uma proposta de Carmina e cols. (60), seria necess&aacute;ria a presen&cce
dil;a    dos tr&ecirc;s crit&eacute;rios do Consenso de Rotterdam (8,9). Adicion
almente,    somente o hirsutismo seria aceito como sinal de excesso androg&ecirc
;nico e    o dist&uacute;rbio menstrual (oligomenorreia) valorizado se presente 
por pelo    menos dois anos.</font></p>     ^cY#02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#88#84#article#219#<p>&nbsp;</p>     ^cY#02.
htm##
00327000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704010400070002000700174#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#89#85#article#219#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="3"><b>AP&Ecirc;NDICE</b></font></p>     ^cY#0
2.htm##
00554000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704033100070002000700401#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#90#86#article#219#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">O c&aacute;lculo    da testosterona livre,
 realizado por meio da f&oacute;rmula de Vermeulen, pode    ser obtido no endere
&ccedil;o eletr&ocirc;nico: <a href="http://www.issam.ch/freetesto.htm" target="
_blank">http://www.issam.ch/freetesto.htm</a>.</font></p>     ^cY#02.htm##
00535000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704031200070002000700382#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#91#87#article#219#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">O c&aacute;lculo    do &iacute;ndice de te
stosterona livre &eacute; realizado pela seguinte f&oacute;rmula,    assumindo-s
e que a concentra&ccedil;&atilde;o de albumina seja normal: Testosterona    tota
l (nM/L)/SHBG (nM/L) X 100.</font></p>     ^cY#02.htm##
00428000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704020500070002000700275#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#92#88#article#219#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Declara&ccedil;&atilde;o:    os autores de
claram n&atilde;o haver conflitos de interesse cient&iacute;fico    neste estudo
</font></p>     ^cY#02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#93#89#article#219#<p>&nbsp;</p>     ^cY#02.
htm##
00330000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704010700070002000700177#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#94#90#article#219#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="3"><b>REFER&Ecirc;NCIAS</b></font></p>     ^c
Y#02.htm##
00434000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704019700072002000700269#v55
n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#p#95#91#article#219#1#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">1. Stein IF, Leventhal    ML
. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol. 
   1935;29:181-91.    ^cY#02.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002000070002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#96#92#article#219#</font></p>     ^cY#02.ht
m##
00548000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704031100072002000700383#v55
n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#p#97#93#article#219#2#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">2. Marcondes JAMM,    Hayash
ida SAY, Bachega TASS. Hirsutismo e s&iacute;ndrome dos ov&aacute;rios    polic&
iacute;sticos. In: Saad MJA, Maciel RMB, Mendon&ccedil;a BB, editors.    Endocri
nologia. S&atilde;o Paulo: Atheneu; 2007. p. 635-82.    ^cY#02.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002000070002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#98#94#article#219#</font></p>     ^cY#02.ht
m##
00520000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704028300072002000700355#v55
n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#p#99#95#article#219#3#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">3. Zawadeski JK,    Dunaif A
. Diagnostic criteria for PCOS: towards a more rational approach. In:    Dunaif 
A, Givens JR, Haseltine FP, Merriam MR, editors. PCOS. Boston: Blackwell    Scie
ntific; 1992. p. 377-84.    ^cY#02.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000300056709000800059708000400067704002000071002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#100#96#article#219#</font></p>     ^cY#02.h
tm##
00590000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000300056709000800059708000400067888000200071704035200073002000700425#v55
n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#p#101#97#article#219#4#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">4. Goodman NF,    Bledsoe M
B, Cobin RH, Futterweit W, Goldzieher JW, Petak SM, et al. American    Associati
on of Clinical Endocrinologists medical guidelines for the clinical    practice 
for the diagnosis and treatment of hyperandrogenic disorders. Endocr    Pract. 2
001;14:120-34.    ^cY#02.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000300056709000800059708000400067704002000071002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#102#98#article#219#</font></p>     ^cY#02.h
tm##
00461000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000300056709000800059708000400067888000200071704022300073002000700296#v55
n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#p#103#99#article#219#5#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">5. American College    of O
bstetricians and Gynecologists. ACOG practice bulletin. Polycycstic ovary    syn
drome. Int J Gynaecol Obstet. 2003;80:335-48.    ^cY#02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#104#100#article#219#</font></p>     ^cY#02.
htm##
00506000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000200072704026700074002000700341#v55
n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#p#105#101#article#219#6#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">6. Schroeder BM.    Americ
an College of Obstetricians and Gynecologists. ACOG releases guidelines    on di
agnosis and management of polycystic ovary syndrome. Am Fam Physician.    2003;6
7:1619-20.    ^cY#02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#106#102#article#219#</font></p>     ^cY#02.
htm##
00476000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000200072704023700074002000700311#v55
n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#p#107#103#article#219#7#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">7. Balen AH, Laven    JS, 
Tan SL, Dewailly D. Ultrasound assessment of the polycystic ovary: International
    consensus definitions. Hum Reprod Update. 2003;9:505-14.    ^cY#02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#108#104#article#219#</font></p>     ^cY#02.
htm##
00527000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000200072704028800074002000700362#v55
n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#p#109#105#article#219#8#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">8. Rotterdam ESHRE/ASRM-Sp
onsored    PCOS consensus workshop group. Revised 2003 consensus on diagnostic c
riteria    and long-term health risks related to polycystic ovary syndrome (PCOS
). Hum    Reprod. 2004;19:41-7.    ^cY#02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#110#106#article#219#</font></p>     ^cY#02.
htm##
00524000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000200072704028500074002000700359#v55
n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#p#111#107#article#219#9#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">9. Rotterdam ESHRE/ASRM-Sp
onsored    PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic c
riteria    and long-term health risks related to polycystic ovary syndrome. Fert
il Steril.    2004;81:19-25.    ^cY#02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#112#108#article#219#</font></p>     ^cY#02.
htm##
00470000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704023000075002000700305#v55
n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#p#113#109#article#219#10#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">10. Practice Committee   
 of the American Society for Reproductive Medicine. The evaluation and treatment
    of androgen excess. Fertil Steril. 2006;86:S241-7.    ^cY#02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#114#110#article#219#</font></p>     ^cY#02.
htm##
00642000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704040200075002000700477#v55
n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#p#115#111#article#219#11#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">11. Azziz R, Carmina    E
, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et    al
. Androgen Excess Society. Positions statement: criteria for defining polycystic
    ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Exce
ss    Society guideline. J Clin Endocrinol Metab. 2006;91:4237-45.    ^cY#02.htm
##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#116#112#article#219#</font></p>     ^cY#02.
htm##
00669000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704042900075002000700504#v55
n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#p#117#113#article#219#12#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">12. Azziz R, Carmina    E
, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et    al
. Task Force on the Phenotype of the Polycystic Ovary Syndrome of The Androgen  
  Excess and PCOS Society. The Androgen Excess and PCOS Society criteria for the
    polycystic ovary syndrome: the complete task force report. Fertil Steril. 20
09;91:456-88.    ^cY#02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#118#114#article#219#</font></p>     ^cY#02.
htm##
00551000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704031100075002000700386#v55
n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#p#119#115#article#219#13#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">13. Martin KA,    Chang R
J, Ehrmann DA, Ibanez L, Lobo RA, Rosenfield RL, et al. Evaluation and    treatm
ent of hirsutism in premenopausal women: an endocrine society clinical    practi
ce guideline. J Clin Endocrinol Metab. 2008;93:1105-20.    ^cY#02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#120#116#article#219#</font></p>     ^cY#02.
htm##
00466000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704022600075002000700301#v55
n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#p#121#117#article#219#14#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">14. ACOG Committee    on 
Practice Bulletins&#151;Gynecology. ACOG Practice Bulletin no. 108: Polycystic  
  ovary syndrome. Obstet Gynecol. 2009;114:936-49.    ^cY#02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#122#118#article#219#</font></p>     ^cY#02.
htm##
00532000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704029200075002000700367#v55
n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#p#123#119#article#219#15#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">15. Blume-Peytavi    U, A
tkin S, Shapiro J, Lavery S, Grimalt R, Hoffmann R, et al. Skin Academy.    Euro
pean Consensus on the evaluation of women presenting with excessive hair    grow
th. Eur J Dermatol. 2009;19:597-602.    ^cY#02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#124#120#article#219#</font></p>     ^cY#02.
htm##
00518000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704027800075002000700353#v55
n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#p#125#121#article#219#16#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">16. Azziz R, Woods    KS,
 Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features    of 
the polycystic ovary syndrome in an unselected population. J Clin Endocrinol    
Metab. 2004;89:2745-9.    ^cY#02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#126#122#article#219#</font></p>     ^cY#02.
htm##
00516000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704027600075002000700351#v55
n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#p#127#123#article#219#17#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">17. Azziz R, Sanchez    L
A, Knochenhauer ES, Moran C, Lazenby J, Stephens KC, et al. Androgen excess    i
n women: experience with over 1000 consecutive patients. J Clin Endocrinol    Me
tab. 2004;89:453-62.    ^cY#02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#128#124#article#219#</font></p>     ^cY#02.
htm##
00439000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704019900075002000700274#v55
n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#p#129#125#article#219#18#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">18. Cunliffe WJ,    Gould
 DJ. Prevalence of facial acne vulgaris in late adolescence and in adults.    Br
 Med J. 1979;1:1109-10.    ^cY#02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#130#126#article#219#</font></p>     ^cY#02.
htm##
00518000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704027800075002000700353#v55
n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#p#131#127#article#219#19#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">19. Dalgard F,    Svensso
n A, Holm JO, Sundby J. Self-reported skin morbidity in Oslo. Associations    wi
th sociodemographic factors among adults in a cross-sectional study. Br J    Der
matol. 2004;151:452-7.    ^cY#02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#132#128#article#219#</font></p>     ^cY#02.
htm##
00536000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704029600075002000700371#v55
n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#p#133#129#article#219#20#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">20. Galobardes    B, Dave
y Smith G, Jefferys M, McCarron P. Has acne increased? Prevalence of    acne his
tory among university students between 1948 and 1968. The Glasgow Alumni    Coho
rt Study. Br J Dermatol. 2005;152:824-5.    ^cY#02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#134#130#article#219#</font></p>     ^cY#02.
htm##
00451000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704021100075002000700286#v55
n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#p#135#131#article#219#21#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">21. Stathakis V,    Kilke
nny M, Marks D. Descriptive epidemiology of acne vulgaris in the community.    A
ustralas J Dermatol. 1997;8:115-23.    ^cY#02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#136#132#article#219#</font></p>     ^cY#02.
htm##
00474000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704023400075002000700309#v55
n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#p#137#133#article#219#22#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">22. Collier CN,    Harper
 JC, Cantrell WC, Wang W, Foster KW, Elewski BE. The prevalence of acne    in ad
ults 20 years and older. J Am Acad Dermatol. 2008;58:56-9.    ^cY#02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#138#134#article#219#</font></p>     ^cY#02.
htm##
00515000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704027500075002000700350#v55
n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#p#139#135#article#219#23#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">23. Futterweit&nbsp;W,   
 Dunaif&nbsp;A, Yeh&nbsp;C, Kingsley&nbsp;P. The prevalence of hyperandrogenism 
   in 109 consecutive female patients with diffuse alopecia. J Med Acad Dermatol
.    1988;19:831-6.    ^cY#02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#140#136#article#219#</font></p>     ^cY#02.
htm##
00430000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704019000075002000700265#v55
n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#p#141#137#article#219#24#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">24. Ferriman DM,    Gallw
ey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol.    1
961;21:1440-7.    ^cY#02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#142#138#article#219#</font></p>     ^cY#02.
htm##
00452000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704021200075002000700287#v55
n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#p#143#139#article#219#25#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">25. Hatch R, Rosenfield  
  RL, Kim MH, Tredway D. Hirsutism: implications, etiology, and management. Am  
  J Obstet Gynecol. 1981;140:815-30.    ^cY#02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#144#140#article#219#</font></p>     ^cY#02.
htm##
00433000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704019300075002000700268#v55
n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#p#145#141#article#219#26#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">26. Barth JH. How    robu
st is the methodology for trials of therapy in hirsute women? Clin Endocrinol.  
  1996;45:379-80.    ^cY#02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#146#142#article#219#</font></p>     ^cY#02.
htm##
00509000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704026900075002000700344#v55
n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#p#147#143#article#219#27#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">27. Wild RA, Vesely    S,
 Beebe L, Whitsett T, Owen W. Ferriman Gallwey self-scoring I: performance    as
sessment in women with polycystic ovary syndrome. J Clin Endocrinol Metab.    20
05;90:4112-4.    ^cY#02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#148#144#article#219#</font></p>     ^cY#02.
htm##
00452000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704021200075002000700287#v55
n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#p#149#145#article#219#28#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">28. Ewing JA, Rouse    BA
. Hirsutism, race and testosterone levels: comparison of East Asians and Euroame
ricans.    Hum Biol. 1978;50:209-15.    ^cY#02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#150#146#article#219#</font></p>     ^cY#02.
htm##
00450000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704021000075002000700285#v55
n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#p#151#147#article#219#29#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">29. Ferriman D,    Purdie
 AW. The aetiology of oligomenorrhoea and/or hirsuties: a study of 467    patien
ts. Postgrad Med J. 1983;59:17-20.    ^cY#02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#152#148#article#219#</font></p>     ^cY#02.
htm##
00543000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704030300075002000700378#v55
n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#p#153#149#article#219#30#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">30. DeUgarte CM,    Woods
 KS, Bartolucci AA, Azziz R. Degree of facial and body terminal hair growth    i
n unselected black and white women: toward a populational definition of hirsutis
m.    J Clin Endocrinol Metab. 2006;91:1345-50.    ^cY#02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#154#150#article#219#</font></p>     ^cY#02.
htm##
00497000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704025700075002000700332#v55
n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#p#155#151#article#219#31#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">31. Souter I, Sanchez    
A, Perez M, Bartolucci AA, Azziz R. The prevalence of androgen excess among    p
atients with minimal unwanted hair growth. Am J Obstet Gynecol. 2004;191:1914-20
.    ^cY#02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#156#152#article#219#</font></p>     ^cY#02.
htm##
00537000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704029700075002000700372#v55
n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#p#157#153#article#219#32#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">32. Chang WY, Knochenhaue
r    ES, Bartolucci AA, Azziz R. Phenotypic spectrum of polycystic ovary syndrom
e:    clinical and biochemical characterization of the three major clinical subg
roups.    Fertil Steril. 2005;83:1717-23.    ^cY#02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#158#154#article#219#</font></p>     ^cY#02.
htm##
00488000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704024800075002000700323#v55
n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#p#159#155#article#219#33#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">33. Kumar A, Woods    KS,
 Bartolucci AA, Azziz R. Prevalence of adrenal androgen excess in patients    wi
th the polycystic ovary syndrome (PCOS). Clin Endocrinol. 2005;62:644-9.    ^cY#
02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#160#156#article#219#</font></p>     ^cY#02.
htm##
00574000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704033400075002000700409#v55
n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#p#161#157#article#219#34#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">34. Knochenhauer    ES, K
ey TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the    poly
cystic ovary syndrome in unselected black and white women of the southeastern   
 United States: a prospective study. J Clin Endocrinol Metab. 1998;83:3078-82.  
  ^cY#02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#162#158#article#219#</font></p>     ^cY#02.
htm##
00535000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704029500075002000700370#v55
n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#p#163#159#article#219#35#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">35. Rosner W, Auchus    R
J, Azziz R, Sluss PM, Raff H. Position statement: utility, limitations, and    p
itfalls in measuring testosterone: an Endocrine Society position statement.    J
 Clin Endocrinol Metab. 2007;92:405-13.    ^cY#02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#164#160#article#219#</font></p>     ^cY#02.
htm##
00489000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704024900075002000700324#v55
n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#p#165#161#article#219#36#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">36. Vermeulen A,    Verdo
nck L, Kaufman JM. A critical evaluation of simple methods for the estimation   
 of free testosterone in serum. J Clin Endocrinol Metab. 1999;84:3666-72.    ^cY
#02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#166#162#article#219#</font></p>     ^cY#02.
htm##
00508000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704026800075002000700343#v55
n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#p#167#163#article#219#37#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">37. Wiltgen D,    Spritze
r PM. Variation in metabolic and cardiovascular risk in women with different    
polycystic ovary syndrome phenotypes. Fertil Steril. 2010;94(6):2493-6. Epub    
2010 Mar 24.    ^cY#02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#168#164#article#219#</font></p>     ^cY#02.
htm##
00500000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704026000075002000700335#v55
n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#p#169#165#article#219#38#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">38. Guastella E,    Longo
 RA, Carmina E. Clinical and endocrine characteristics of the main polycystic   
 ovary syndrome phenotypes. Fertil Steril. 2010;94(6):2197-201. Epub 2010 Mar   
 19.    ^cY#02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#170#166#article#219#</font></p>     ^cY#02.
htm##
00586000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704034600075002000700421#v55
n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#p#171#167#article#219#39#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">39. Van Hooff MH,    Voor
horst FJ, Kaptein MB, Hirasing RA, Koppenaal C, Schoemaker J. Predictive    valu
e of menstrual cycle pattern, body mass index, hormone levels and polycystic    
ovaries at age 15 years for oligo-amenorrhoea at age 18 years. Hum Reprod. 2004;
19:383-92.    ^cY#02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#172#168#article#219#</font></p>     ^cY#02.
htm##
00462000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704022200075002000700297#v55
n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#p#173#169#article#219#40#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">40. Swanson M,    Sauerbr
ei EE, Cooperberg PL. Medical implications of ultrasonically detected    polycys
tic ovaries. J Clin Ultrasound. 1981;9:219-22.    ^cY#02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#174#170#article#219#</font></p>     ^cY#02.
htm##
00533000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704029300075002000700368#v55
n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#p#175#171#article#219#41#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">41. Adams J, Polson    DW
, Abdulwahid N, Morris DV, Franks S, Mason HD, et al. Multifollicular ovaries:  
  clinical and endocrine features and response to pulsatile gonadotropin releasi
ng    hormone. Lancet. 1985;2:1375-9.    ^cY#02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#176#172#article#219#</font></p>     ^cY#02.
htm##
00455000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704021500075002000700290#v55
n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#p#177#173#article#219#42#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">42. Goldstein G.    Incor
porating endovaginal ultrasonography into the overall gynaecologic examination. 
   Am J Obstet Gynecol. 1990;160:625-2.    ^cY#02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#178#174#article#219#</font></p>     ^cY#02.
htm##
00533000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704029300075002000700368#v55
n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#p#179#175#article#219#43#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">43. Pache TD, de    Jong 
FH, Hop WC, Fauser BC. Association between ovarian changes assessed by    transv
aginal sonography and clinical and endocrine signs of the polycystic ovary    sy
ndrome. Fertil Steril. 1993;59:544-9.    ^cY#02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#180#176#article#219#</font></p>     ^cY#02.
htm##
00487000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704024700075002000700322#v55
n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#p#181#177#article#219#44#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">44. Crowley WF    Jr, Hal
l JE, Martin KA, Adams J, Taylor AE. An overview of the diagnostic consideration
s    in polycystic ovarian syndrome. Ann N Y Acad Sci. 1993;687:235-41.    ^cY#0
2.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#182#178#article#219#</font></p>     ^cY#02.
htm##
00520000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704028000075002000700355#v55
n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#p#183#179#article#219#45#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">45. Murphy MK,    Hall JE
, Adams JM, Lee H, Welt CK. Polycystic ovarian morphology in normal women    doe
s not predict the development of polycystic ovary syndrome. J Clin Endocrinol   
 Metab. 2006;91:3878-84.    ^cY#02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#184#180#article#219#</font></p>     ^cY#02.
htm##
00504000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704026400075002000700339#v55
n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#p#185#181#article#219#46#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">46. Escobar-Morreale    H
F. Macroprolactinemia in women presenting with hyperandrogenic symptoms: implica
tions    for the management of polycystic ovary syndrome. Fertil Steril. 2004;82
:1697-9.    ^cY#02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#186#182#article#219#</font></p>     ^cY#02.
htm##
00496000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704025600075002000700331#v55
n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#p#187#183#article#219#47#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">47. Pinheiro SA,    Clapa
uch R. Import&acirc;ncia da dosagem da 17OH-progesterona na s&iacute;ndrome    d
os ov&aacute;rios polic&iacute;sticos. Arq Bras Endocrinol Metab. 2001;45:361-8.
    ^cY#02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#188#184#article#219#</font></p>     ^cY#02.
htm##
00466000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704022600075002000700301#v55
n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#p#189#185#article#219#48#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">48. Chetkowski    RJ, Cha
ng RJ, DeFazio J, Meldrum DR, Judd HL. Origin of serum progestins in    polycyst
ic ovarian disease. Obstet Gynecol. 1984;64:27-31.    ^cY#02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#190#186#article#219#</font></p>     ^cY#02.
htm##
00605000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704036500075002000700440#v55
n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#p#191#187#article#219#49#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">49. Marcondes JAM,    Min
anni SL, Sakamoto LC, Hayashida SY, Halbe HW, Wajchenberg BL. O espectro    cl&i
acute;nico e laboratorial da forma n&atilde;o cl&aacute;ssica de hiperplasia    
adrenal cong&ecirc;nita por defici&ecirc;ncia da 21-hidroxilase. Arq Bras Endocr
inol    Metab. 1995;39:37-43.    ^cY#02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#192#188#article#219#</font></p>     ^cY#02.
htm##
00542000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704030200075002000700377#v55
n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#p#193#189#article#219#50#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">50. Azziz R, Hincapie    
LA, Knochenhauer ES, Dewailly D, Fox L, Boots LR. Sceening for 21-hydroxylaser-d
eficient    nonclassic adrenal hyperplasia among hyperandrogenic women: a prospe
ctive study.    Fertil Steril. 1999;72:915-25.    ^cY#02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#194#190#article#219#</font></p>     ^cY#02.
htm##
00459000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704021900075002000700294#v55
n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#p#195#191#article#219#51#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">51. Azziz R, Zacur    HA.
 21-hydroxylase deficiency in female hyperandrogenism: screening and diagnosis. 
   J Clin Endocrinol Metab. 1989;69:577-84.    ^cY#02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#196#192#article#219#</font></p>     ^cY#02.
htm##
00574000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704033400075002000700409#v55
n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#p#197#193#article#219#52#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">52. Escobar-Morreale    H
F, Sanch&oacute;n R, San Mill&aacute;n JL. A prospective study of the prevalence
    of nonclassical congenital adrenal hyperplasia among women presenting with h
yperandrogenic    symptoms and signs. J Clin Endocrinol Metab. 2008;93:527-33.  
  ^cY#02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#198#194#article#219#</font></p>     ^cY#02.
htm##
00503000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704026300075002000700338#v55
n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#p#199#195#article#219#53#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">53. New MI, Lorenzen    F
, Lerner AJ, Kohn B, Oberfield SE, Pollack MS, et al. Genotyping steroid 21-hydr
oxylase    deficiency: hormonal reference data. J Clin Endocrinol Metab. 1983;57
:320-6.    ^cY#02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#200#196#article#219#</font></p>     ^cY#02.
htm##
00598000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704035800075002000700433#v55
n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#p#201#197#article#219#54#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">54. Bachega TA,    Biller
beck AE, Marcondes JA, Madureira G, Arnhold IJ, Mendonca BB. Influence    of dif
ferent genotypes on 17-hydroxyprogesterone levels in patients with nonclassical 
   congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Clin Endocri
nol.    2000;52:601-7.    ^cY#02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#202#198#article#219#</font></p>     ^cY#02.
htm##
00495000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704025500075002000700330#v55
n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#p#203#199#article#219#55#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">55. Janssen OE,    Mehlma
uer N, Hahn S, Offner AH, Gartner R. High prevalence of autoimmune thyroiditis  
  in patients with polycystic ovary syndrome. Eur J Endocrinol. 2004;150:363-9. 
   ^cY#02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#204#200#article#219#</font></p>     ^cY#02.
htm##
00398000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704015800075002000700233#v55
n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#p#205#201#article#219#56#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">56. Azziz R, Carmina    E
, Sawaya ME. Idiopathic hirsutism. Endocr Rev. 2000;21:347-62.    ^cY#02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#206#202#article#219#</font></p>     ^cY#02.
htm##
00556000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704031600075002000700391#v55
n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#p#207#203#article#219#57#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">57. Van Der Meer    M, Ho
mpes PG, De Boer JA, Schats R, Schoemaker J. Cohort size rather than follicle-st
imulating    hormone threshold level determines ovarian sensitivity in polycysti
c ovary syndrome.    J Clin Endocrinol Metab. 1998;83:423-6.    ^cY#02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#208#204#article#219#</font></p>     ^cY#02.
htm##
00512000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704027200075002000700347#v55
n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#p#209#205#article#219#58#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">58. Azziz R, Marin    C, 
Hoq L, Badamgarav E, Song P. Health care-related economic burden of the polycyst
ic    ovary syndrome during the reproductive life span. J Clin Endocrinol Metab.
 2005;90:4650-8.    ^cY#02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#210#206#article#219#</font></p>     ^cY#02.
htm##
00680000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704044000075002000700515#v55
n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#p#211#207#article#219#59#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">59. Wild RA, Carmina    E
, Diamanti-Kandarakis E, Dokras A, Escobar-Morreale HF, Futterweit W, et al.    
Assessment of cardiovascular risk and prevention of cardiovascular disease in   
 women with the polycystic ovary syndrome: a consensus statement by the Androgen
    Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Me
tab.    2010;95:2038-49.    ^cY#02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#212#208#article#219#</font></p>     ^cY#02.
htm##
00450000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704021000075002000700285#v55
n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#p#213#209#article#219#60#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">60. Carmina E,    Oberfie
ld SE, Lobo RA. The diagnosis of polycystic ovary syndrome in adolescents.    Am
 J Obstet Gynecol. 2010;203:201-6.    ^cY#02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#214#210#article#219#</font></p>     ^cY#02.
htm##
00247000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002200072002000700094#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#215#211#article#219#<p>&nbsp;</p>     ^cY#0
2.htm##
00247000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002200072002000700094#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#216#212#article#219#<p>&nbsp;</p>     ^cY#0
2.htm##
00424000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704019900072002000700271#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#217#213#article#219#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2"><b><a name="back"></a><a href="#top"><im
g src="/img/revistas/abem/v55n1/seta.jpg" border="0"></a>    Correspond&ecirc;nc
ia para:    ^cY#02.htm##
00281000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704005600072002000700128#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#218#214#article#219#<br>   </b> Jos&eacute;
 Antonio Miguel Marcondes    ^cY#02.htm##
00273000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704004800072002000700120#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#219#215#article#219#<br>   Rua Baronesa de 
Itu, 821, ap. 112    ^cY#02.htm##
00279000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704005400072002000700126#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#220#216#article#219#<br>   01231-001 -S&ati
lde;o Paulo, SP, Brasil    ^cY#02.htm##
00318000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704009300072002000700165#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#221#217#article#219#<br>   <a href="mailto:
marcondesmd@uol.com.br">marcondesmd@uol.com.br</a></font></p>     ^cY#02.htm##
00319000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704009400072002000700166#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#222#218#article#219#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2">Recebido em 20/Out/2010    ^cY#02.htm##
00273000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704004800072002000700120#v55n1#V:\SciELO
\serial\abem\v55n1\markup\02.htm#S#p#223#219#article#219#<br>   Aceito em 28/Jan
/2011</font></p>     ^cY#02.htm##
00535000000000277000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100016000710100020000870120
06000107030002000167065000900187064000500196031000300201014000700204865000900211
002000700220035001000227801002000237#v55n1#V:\SciELO\serial\abem\v55n1\markup\02
.htm#S#c#224#1#article#60#1#^rND^sStein^nIF#^rND^sLeventhal^nML#Amenorrhea assoc
iated with bilateral polycystic ovaries^len#Am J Obstet Gynecol#19350000#1935#29
#181-91#20110200#02.htm#0002-9378#Am J Obstet Gynecol##
00626000000000313000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100022000710100021000930100
02000114012005100134016001600185016001800201016001900219018001900238066001000257
062000800267065000900275064000500284014000700289865000900296002000700305#v55n1#V
:\SciELO\serial\abem\v55n1\markup\02.htm#S#c#225#2#article#60#2#^rND^sMarcondes^
nJAMM#^rND^sHayashida^nSAY#^rND^sBachega^nTASS#Hirsutismo e síndrome dos ovários
 policísticos^les#^rED^sSaad^nMJA#^rED^sMaciel^nRMB#^rED^sMendonça^nBB#Endocrino
logia^lpt#São Paulo#Atheneu#20070000#2007#635-82#20110200#02.htm##
00633000000000313000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100020000710100016000910120
06700107016001600174016001700190016002000207016001800227018000900245066000700254
062002100261065000900282064000500291014000700296865000900303002000700312#v55n1#V
:\SciELO\serial\abem\v55n1\markup\02.htm#S#c#226#3#article#60#3#^rND^sZawadeski^
nJK#^rND^sDunaif^nA#Diagnostic criteria for PCOS: towards a more rational approa
ch^len#^rED^sDunaif^nA#^rED^sGivens^nJR#^rED^sHaseltine^nFP#^rED^sMerriam^nMR#PC
OS^len#Boston#Blackwell Scientific#19920000#1992#377-84#20110200#02.htm##
00727000000000325000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100018000710100018000890100
01600107010002000123010002100143010001600164810000600180012016000186030001300346
71000020035906500090036106400050037003100030037501400070037886500090038500200070
0394#v55n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#c#227#4#article#60#4#^rND
^sGoodman^nNF#^rND^sBledsoe^nMB#^rND^sCobin^nRH#^rND^sFutterweit^nW#^rND^sGoldzi
eher^nJW#^rND^sPetak^nSM#et al#American Association of Clinical Endocrinologists
 medical guidelines for the clinical practice for the diagnosis and treatment of
 hyperandrogenic disorders^len#Endocr Pract#2#20010000#2001#14#120-34#20110200#0
2.htm##
00538000000000265000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690110052000710120055001230300
02200178065000900200064000500209031000300214014000700217865000900224002000700233
035001000240801002200250#v55n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#c#228
#5#article#60#5#American College of Obstetricians and Gynecologists#ACOG practic
e bulletin: Polycycstic ovary syndrome^len#Int J Gynaecol Obstet#20030000#2003#8
0#335-48#20110200#02.htm#0020-7292#Int J Gynaecol Obstet##
00581000000000265000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100020000710120139000910300
01700230065000900247064000500256031000300261014000800264865000900272002000700281
035001000288801001700298#v55n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#c#229
#6#article#60#6#^rND^sSchroeder^nBM#American College of Obstetricians and Gyneco
logists: ACOG releases guidelines on diagnosis and management of polycystic ovar
y syndrome^len#Am Fam Physician#20030000#2003#67#1619-20#20110200#02.htm#0002-83
8X#Am Fam Physician##
00609000000000301000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100016000710100016000870100
01400103010001800117012008700135030001800222065000900240064000500249031000200254
014000700256865000900263002000700272035001000279801001800289#v55n1#V:\SciELO\ser
ial\abem\v55n1\markup\02.htm#S#c#230#7#article#60#7#^rND^sBalen^nAH#^rND^sLaven^
nJS#^rND^sTan^nSL#^rND^sDewailly^nD#Ultrasound assessment of the polycystic ovar
y: International consensus definitions^len#Hum Reprod Update#20030000#2003#9#505
-14#20110200#02.htm#1355-4786#Hum Reprod Update##
00601000000000277000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690110016000710110045000870120
12100132030001100253065000900264064000500273031000300278014000500281865000900286
002000700295035001000302801001100312#v55n1#V:\SciELO\serial\abem\v55n1\markup\02
.htm#S#c#231#8#article#60#8#Rotterdam ESHRE#ASRM-Sponsored PCOS consensus worksh
op group#Revised 2003 consensus on diagnostic criteria and long-term health risk
s related to polycystic ovary syndrome (PCOS)^len#Hum Reprod#20040000#2004#19#41
-7#20110200#02.htm#0268-1161#Hum Reprod##
00601000000000277000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690110016000710110045000870120
11400132030001400246065000900260064000500269031000300274014000600277865000900283
002000700292035001000299801001400309#v55n1#V:\SciELO\serial\abem\v55n1\markup\02
.htm#S#c#232#9#article#60#9#Rotterdam ESHRE#ASRM-Sponsored PCOS Consensus Worksh
op Group#Revised 2003 consensus on diagnostic criteria and long-term health risk
s related to polycystic ovary syndrome^len#Fertil Steril#20040000#2004#81#19-25#
20110200#02.htm#0015-0282#Fertil Steril##
00538000000000265000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700110069000730120052001420300
01400194065000900208064000500217031000300222014000700225865000900232002000700241
035001000248801001400258#v55n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#c#233
#10#article#60#10#Practice Committee of the American Society for Reproductive Me
dicine#The evaluation and treatment of androgen excess^len#Fertil Steril#2006000
0#2006#86#S241-7#20110200#02.htm#0015-0282#Fertil Steril##
00797000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100015000730100017000880100
01800105010002900123010002700152010002000179810000600199012015500205030002400360
06500090038406400050039303100030039801400080040186500090040900200070041803500100
0425801002400435#v55n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#c#234#11#arti
cle#60#11#^rND^sAzziz^nR#^rND^sCarmina^nE#^rND^sDewailly^nD#^rND^sDiamanti-Kanda
rakis^nE#^rND^sEscobar-Morreale^nHF#^rND^sFutterweit^nW#et al#Positions statemen
t: criteria for defining polycystic ovary syndrome as a predominantly hyperandro
genic syndrome: an Androgen Excess Society guideline^len#J Clin Endocrinol Metab
#20060000#2006#91#4237-45#20110200#02.htm#0021-972X#J Clin Endocrinol Metab##
00839000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100015000730100017000880100
01800105010002900123010002700152010002000179810000600199012021800205030001400423
06500090043706400050044603100030045101400070045486500090046100200070047003500100
0477801001400487#v55n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#c#235#12#arti
cle#60#12#^rND^sAzziz^nR#^rND^sCarmina^nE#^rND^sDewailly^nD#^rND^sDiamanti-Kanda
rakis^nE#^rND^sEscobar-Morreale^nHF#^rND^sFutterweit^nW#et al#Task Force on the 
Phenotype of the Polycystic Ovary Syndrome of The Androgen Excess and PCOS Socie
ty: The Androgen Excess and PCOS Society criteria for the polycystic ovary syndr
ome: the complete task force report^len#Fertil Steril#20090000#2009#91#456-88#20
110200#02.htm#0015-0282#Fertil Steril##
00734000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730100016000900100
01800106010001600124010001500140010002100155810000600176012011500182030002400297
06500090032106400050033003100030033501400080033886500090034600200070035503500100
0362801002400372#v55n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#c#236#13#arti
cle#60#13#^rND^sMartin^nKA#^rND^sChang^nRJ#^rND^sEhrmann^nDA#^rND^sIbanez^nL#^rN
D^sLobo^nRA#^rND^sRosenfield^nRL#et al#Evaluation and treatment of hirsutism in 
premenopausal women: an endocrine society clinical practice guideline^len#J Clin
 Endocrinol Metab#20080000#2008#93#1105-20#20110200#02.htm#0021-972X#J Clin Endo
crinol Metab##
00530000000000265000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700110048000730120062001210300
01500183065000900198064000500207031000400212014000700216865000900223002000700232
035001000239801001500249#v55n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#c#237
#14#article#60#14#ACOG Committee on Practice Bulletins-Gynecology#ACOG Practice 
Bulletin no. 108: Polycystic ovary syndrome^len#Obstet Gynecol#20090000#2009#114
#936-49#20110200#02.htm#0029-7844#Obstet Gynecol##
00706000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100023000730100015000960100
01700111010001600128010001700144010001800161810000600179012010200185030001500287
06500090030206400050031103100030031601400080031986500090032700200070033603500100
0343801001500353#v55n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#c#238#15#arti
cle#60#15#^rND^sBlume-Peytavi^nU#^rND^sAtkin^nS#^rND^sShapiro^nJ#^rND^sLavery^nS
#^rND^sGrimalt^nR#^rND^sHoffmann^nR#et al#Skin Academy: European Consensus on th
e evaluation of women presenting with excessive hair growth^len#Eur J Dermatol#2
0090000#2009#19#597-602#20110200#02.htm#1167-1122#Eur J Dermatol##
00690000000000325000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100015000730100016000880100
01500104010001400119010002300133010001700156012009300173030002400266065000900290
06400050029903100030030401400070030786500090031400200070032303500100033080100240
0340#v55n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#c#239#16#article#60#16#^r
ND^sAzziz^nR#^rND^sWoods^nKS#^rND^sReyna^nR#^rND^sKey^nTJ#^rND^sKnochenhauer^nES
#^rND^sYildiz^nBO#The prevalence and features of the polycystic ovary syndrome i
n an unselected population^len#J Clin Endocrinol Metab#20040000#2004#89#2745-9#2
0110200#02.htm#0021-972X#J Clin Endocrinol Metab##
00699000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100015000730100018000880100
02300106010001500129010001700144010001900161810000600180012007700186030002400263
06500090028706400050029603100030030101400070030486500090031100200070032003500100
0327801002400337#v55n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#c#240#17#arti
cle#60#17#^rND^sAzziz^nR#^rND^sSanchez^nLA#^rND^sKnochenhauer^nES#^rND^sMoran^nC
#^rND^sLazenby^nJ#^rND^sStephens^nKC#et al#Androgen excess in women: experience 
with over 1000 consecutive patients^len#J Clin Endocrinol Metab#20040000#2004#89
#453-62#20110200#02.htm#0021-972X#J Clin Endocrinol Metab##
00527000000000277000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100019000730100016000920120
07300108030000900181065000900190064000500199031000200204014000800206865000900214
002000700223035001000230801000900240#v55n1#V:\SciELO\serial\abem\v55n1\markup\02
.htm#S#c#241#18#article#60#18#^rND^sCunliffe^nWJ#^rND^sGould^nDJ#Prevalence of f
acial acne vulgaris in late adolescence and in adults^len#Br Med J#19790000#1979
#1#1109-10#20110200#02.htm#0007-1447#Br Med J##
00644000000000301000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730100018000900100
01500108010001600123012012500139030001400264065000900278064000500287031000400292
014000600296865000900302002000700311035001000318801001400328#v55n1#V:\SciELO\ser
ial\abem\v55n1\markup\02.htm#S#c#242#19#article#60#19#^rND^sDalgard^nF#^rND^sSve
nsson^nA#^rND^sHolm^nJO#^rND^sSundby^nJ#Self-reported skin morbidity in Oslo: As
sociations with sociodemographic factors among adults in a cross-sectional study
^len#Br J Dermatol#20040000#2004#151#452-7#20110200#02.htm#0007-0963#Br J Dermat
ol##
00663000000000301000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100020000730100021000930100
01800114010001800132012013300150030001400283065000900297064000500306031000400311
014000600315865000900321002000700330035001000337801001400347#v55n1#V:\SciELO\ser
ial\abem\v55n1\markup\02.htm#S#c#243#20#article#60#20#^rND^sGalobardes^nB#^rND^s
Davey Smith^nG#^rND^sJefferys^nM#^rND^sMcCarron^nP#Has acne increased?: Prevalen
ce of acne history among university students between 1948 and 1968. The Glasgow 
Alumni Cohort Study^len#Br J Dermatol#20050000#2005#152#824-5#20110200#02.htm#00
07-0963#Br J Dermatol##
00569000000000289000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100019000730100018000920100
01500110012006300125030002100188065000900209064000500218031000200223014000700225
865000900232002000700241035001000248801002100258#v55n1#V:\SciELO\serial\abem\v55
n1\markup\02.htm#S#c#244#21#article#60#21#^rND^sStathakis^nV#^rND^sKilkenny^nM#^
rND^sMarks^nD#Descriptive epidemiology of acne vulgaris in the community^len#Aus
tralas J Dermatol#19970000#1997#8#115-23#20110200#02.htm#0004-8380#Australas J D
ermatol##
00644000000000325000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100018000730100017000910100
01900108010001400127010001700141010001800158012005600176030001900232065000900251
06400050026003100030026501400050026886500090027300200070028203500100028980100190
0299#v55n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#c#245#22#article#60#22#^r
ND^sCollier^nCN#^rND^sHarper^nJC#^rND^sCantrell^nWC#^rND^sWang^nW#^rND^sFoster^n
KW#^rND^sElewski^nBE#The prevalence of acne in adults 20 years and older^len#J A
m Acad Dermatol#20080000#2008#58#56-9#20110200#02.htm#0190-9622#J Am Acad Dermat
ol##
00587000000000289000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100020000730100016000930100
01300109010001800122012009600140030002000236710000200256065000900258064000500267
031000300272014000600275865000900281002000700290#v55n1#V:\SciELO\serial\abem\v55
n1\markup\02.htm#S#c#246#23#article#60#23#^rND^sFutterweit^nW#^rND^sDunaif^nA#^r
ND^sYeh^nC#^rND^sKingsley^nP#The prevalence of hyperandrogenism in 109 consecuti
ve female patients with diffuse alopecia^len#J Med Acad Dermatol#2#19880000#1988
#19#831-6#20110200#02.htm##
00489000000000265000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100019000730100018000920120
05300110030001800163710000200181065000900183064000500192031000300197014000700200
865000900207002000700216#v55n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#c#247
#24#article#60#24#^rND^sFerriman^nDM#^rND^sGallwey^nJD#Clinical assessment of bo
dy hair growth in women^len#J Clin Endocrinol#2#19610000#1961#21#1440-7#20110200
#02.htm##
00587000000000301000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100015000730100021000880100
01400109010001700123012005400140030002000194065000900214064000500223031000400228
014000700232865000900239002000700248035001000255801002000265#v55n1#V:\SciELO\ser
ial\abem\v55n1\markup\02.htm#S#c#248#25#article#60#25#^rND^sHatch^nR#^rND^sRosen
field^nRL#^rND^sKim^nMH#^rND^sTredway^nD#Hirsutism: implications, etiology, and 
management^len#Am J Obstet Gynecol#19810000#1981#140#815-30#20110200#02.htm#0002
-9378#Am J Obstet Gynecol##
00475000000000253000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730120074000890300
01600163710000200179065000900181064000500190031000300195014000700198865000900205
002000700214#v55n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#c#249#26#article#
60#26#^rND^sBarth^nJH#How robust is the methodology for trials of therapy in hir
sute women?^len#Clin Endocrinol#2#19960000#1996#45#379-80#20110200#02.htm##
00663000000000313000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100015000730100016000880100
01500104010001800119010001400137012010000151030002400251065000900275064000500284
031000300289014000700292865000900299002000700308035001000315801002400325#v55n1#V
:\SciELO\serial\abem\v55n1\markup\02.htm#S#c#250#27#article#60#27#^rND^sWild^nRA
#^rND^sVesely^nS#^rND^sBeebe^nL#^rND^sWhitsett^nT#^rND^sOwen^nW#Ferriman Gallwey
 self-scoring I: performance assessment in women with polycystic ovary syndrome^
len#J Clin Endocrinol Metab#20050000#2005#90#4112-4#20110200#02.htm#0021-972X#J 
Clin Endocrinol Metab##
00540000000000277000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730100016000890120
08900105030000900194065000900203064000500212031000300217014000700220865000900227
002000700236035001000243801000900253#v55n1#V:\SciELO\serial\abem\v55n1\markup\02
.htm#S#c#251#28#article#60#28#^rND^sEwing^nJA#^rND^sRouse^nBA#Hirsutism, race an
d testosterone levels: comparison of East Asians and Euroamericans^len#Hum Biol#
19780000#1978#50#209-15#20110200#02.htm#0018-7143#Hum Biol##
00544000000000277000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100018000730100017000910120
07900108030001500187065000900202064000500211031000300216014000600219865000900225
002000700234035001000241801001500251#v55n1#V:\SciELO\serial\abem\v55n1\markup\02
.htm#S#c#252#29#article#60#29#^rND^sFerriman^nD#^rND^sPurdie^nAW#The aetiology o
f oligomenorrhoea and/or hirsuties: a study of 467 patients^len#Postgrad Med J#1
9830000#1983#59#17-20#20110200#02.htm#0032-5473#Postgrad Med J##
00679000000000301000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100019000730100016000920100
02100108010001500129012013400144030002400278065000900302064000500311031000300316
014000800319865000900327002000700336035001000343801002400353#v55n1#V:\SciELO\ser
ial\abem\v55n1\markup\02.htm#S#c#253#30#article#60#30#^rND^sDeUgarte^nCM#^rND^sW
oods^nKS#^rND^sBartolucci^nAA#^rND^sAzziz^nR#Degree of facial and body terminal 
hair growth in unselected black and white women: toward a populational definitio
n of hirsutism^len#J Clin Endocrinol Metab#20060000#2006#91#1345-50#20110200#02.
htm#0021-972X#J Clin Endocrinol Metab##
00650000000000313000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730100017000890100
01500106010002100121010001500142012008700157030002000244065000900264064000500273
031000400278014000800282865000900290002000700299035001000306801002000316#v55n1#V
:\SciELO\serial\abem\v55n1\markup\02.htm#S#c#254#31#article#60#31#^rND^sSouter^n
I#^rND^sSanchez^nA#^rND^sPerez^nM#^rND^sBartolucci^nAA#^rND^sAzziz^nR#The preval
ence of androgen excess among patients with minimal unwanted hair growth^len#Am 
J Obstet Gynecol#20040000#2004#191#1914-20#20110200#02.htm#0002-9378#Am J Obstet
 Gynecol##
00663000000000301000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730100023000890100
02100112010001500133012013400148030001400282065000900296064000500305031000300310
014000800313865000900321002000700330035001000337801001400347#v55n1#V:\SciELO\ser
ial\abem\v55n1\markup\02.htm#S#c#255#32#article#60#32#^rND^sChang^nWY#^rND^sKnoc
henhauer^nES#^rND^sBartolucci^nAA#^rND^sAzziz^nR#Phenotypic spectrum of polycyst
ic ovary syndrome: clinical and biochemical characterization of the three major 
clinical subgroups^len#Fertil Steril#20050000#2005#83#1717-23#20110200#02.htm#00
15-0282#Fertil Steril##
00583000000000289000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100015000730100016000880100
02100104010001500125012009600140030001600236710000200252065000900254064000500263
031000300268014000600271865000900277002000700286#v55n1#V:\SciELO\serial\abem\v55
n1\markup\02.htm#S#c#256#33#article#60#33#^rND^sKumar^nA#^rND^sWoods^nKS#^rND^sB
artolucci^nAA#^rND^sAzziz^nR#Prevalence of adrenal androgen excess in patients w
ith the polycystic ovary syndrome (PCOS)^len#Clin Endocrinol#2#20050000#2005#62#
644-9#20110200#02.htm##
00746000000000325000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100023000730100014000960100
02300110010001800133010001600151010001500167012013900182030002400321065000900345
06400050035403100030035901400080036286500090037000200070037903500100038680100240
0396#v55n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#c#257#34#article#60#34#^r
ND^sKnochenhauer^nES#^rND^sKey^nTJ#^rND^sKahsar-Miller^nM#^rND^sWaggoner^nW#^rND
^sBoots^nLR#^rND^sAzziz^nR#Prevalence of the polycystic ovary syndrome in unsele
cted black and white women of the southeastern United States: a prospective stud
y^len#J Clin Endocrinol Metab#19980000#1998#83#3078-82#20110200#02.htm#0021-972X
#J Clin Endocrinol Metab##
00689000000000313000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730100017000890100
01500106010001600121010001400137012012600151030002400277065000900301064000500310
031000300315014000700318865000900325002000700334035001000341801002400351#v55n1#V
:\SciELO\serial\abem\v55n1\markup\02.htm#S#c#258#35#article#60#35#^rND^sRosner^n
W#^rND^sAuchus^nRJ#^rND^sAzziz^nR#^rND^sSluss^nPM#^rND^sRaff^nH#Position stateme
nt: utility, limitations, and pitfalls in measuring testosterone: an Endocrine S
ociety position statement^len#J Clin Endocrinol Metab#20070000#2007#92#405-13#20
110200#02.htm#0021-972X#J Clin Endocrinol Metab##
00610000000000289000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100019000730100018000920100
01800110012009300128030002400221065000900245064000500254031000300259014000800262
865000900270002000700279035001000286801002400296#v55n1#V:\SciELO\serial\abem\v55
n1\markup\02.htm#S#c#259#36#article#60#36#^rND^sVermeulen^nA#^rND^sVerdonck^nL#^
rND^sKaufman^nJM#A critical evaluation of simple methods for the estimation of f
ree testosterone in serum^len#J Clin Endocrinol Metab#19990000#1999#84#3666-72#2
0110200#02.htm#0021-972X#J Clin Endocrinol Metab##
00591000000000289000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730100019000900120
11200109030001400221065000900235064000500244031000300249032000200252014000700254
865000900261002000700270035001000277801001400287#v55n1#V:\SciELO\serial\abem\v55
n1\markup\02.htm#S#c#260#37#article#60#37#^rND^sWiltgen^nD#^rND^sSpritzer^nPM#Va
riation in metabolic and cardiovascular risk in women with different polycystic 
ovary syndrome phenotypes^len#Fertil Steril#20100000#2010#94#6#2493-6#20110200#0
2.htm#0015-0282#Fertil Steril##
00601000000000301000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100019000730100016000920100
01700108012009200125030001400217065000900231064000500240031000300245032000200248
014000900250865000900259002000700268035001000275801001400285#v55n1#V:\SciELO\ser
ial\abem\v55n1\markup\02.htm#S#c#261#38#article#60#38#^rND^sGuastella^nE#^rND^sL
ongo^nRA#^rND^sCarmina^nE#Clinical and endocrine characteristics of the main pol
ycystic ovary syndrome phenotypes^len#Fertil Steril#20100000#2010#94#6#2197-201#
20110200#02.htm#0015-0282#Fertil Steril##
00745000000000325000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100020000730100020000930100
01800113010001900131010001900150010002000169012015800189030001100347065000900358
06400050036703100030037201400070037586500090038200200070039103500100039880100110
0408#v55n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#c#262#39#article#60#39#^r
ND^sVan Hooff^nMH#^rND^sVoorhorst^nFJ#^rND^sKaptein^nMB#^rND^sHirasing^nRA#^rND^
sKoppenaal^nC#^rND^sSchoemaker^nJ#Predictive value of menstrual cycle pattern, b
ody mass index, hormone levels and polycystic ovaries at age 15 years for oligo-
amenorrhoea at age 18 years^len#Hum Reprod#20040000#2004#19#383-92#20110200#02.h
tm#0268-1161#Hum Reprod##
00577000000000289000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730100020000900100
02100110012007100131030001800202065000900220064000500229031000200234014000700236
865000900243002000700252035001000259801001800269#v55n1#V:\SciELO\serial\abem\v55
n1\markup\02.htm#S#c#263#40#article#60#40#^rND^sSwanson^nM#^rND^sSauerbrei^nEE#^
rND^sCooperberg^nPL#Medical implications of ultrasonically detected polycystic o
varies^len#J Clin Ultrasound#19810000#1981#9#219-22#20110200#02.htm#0091-2751#J 
Clin Ultrasound##
00699000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100015000730100017000880100
02000105010001700125010001600142010001600158810000600174012011800180030000700298
06500090030506400050031403100020031901400070032186500090032800200070033703500100
0344801000700354#v55n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#c#264#41#arti
cle#60#41#^rND^sAdams^nJ#^rND^sPolson^nDW#^rND^sAbdulwahid^nN#^rND^sMorris^nDV#^
rND^sFranks^nS#^rND^sMason^nHD#et al#Multifollicular ovaries: clinical and endoc
rine features and response to pulsatile gonadotropin releasing hormone^len#Lance
t#19850000#1985#2#1375-9#20110200#02.htm#0099-5355#Lancet##
00536000000000265000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100019000730120088000920300
02000180065000900200064000500209031000400214014000600218865000900224002000700233
035001000240801002000250#v55n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#c#265
#42#article#60#42#^rND^sGoldstein^nG#Incorporating endovaginal ultrasonography i
nto the overall gynaecologic examination^len#Am J Obstet Gynecol#19900000#1990#1
60#625-2#20110200#02.htm#0002-9378#Am J Obstet Gynecol##
00659000000000301000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730100018000890100
01400107010001700121012014200138030001400280065000900294064000500303031000300308
014000600311865000900317002000700326035001000333801001400343#v55n1#V:\SciELO\ser
ial\abem\v55n1\markup\02.htm#S#c#266#43#article#60#43#^rND^sPache^nTD#^rND^sde J
ong^nFH#^rND^sHop^nWC#^rND^sFauser^nBC#Association between ovarian changes asses
sed by transvaginal sonography and clinical and endocrine signs of the polycysti
c ovary syndrome^len#Fertil Steril#19930000#1993#59#544-9#20110200#02.htm#0015-0
282#Fertil Steril##
00637000000000313000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100021000730100015000940100
01700109010001500126010001700141012008000158030001700238065000900255064000500264
031000400269014000700273865000900280002000700289035001000296801001700306#v55n1#V
:\SciELO\serial\abem\v55n1\markup\02.htm#S#c#267#44#article#60#44#^rND^sCrowley^
nWF Jr#^rND^sHall^nJE#^rND^sMartin^nKA#^rND^sAdams^nJ#^rND^sTaylor^nAE#An overvi
ew of the diagnostic considerations in polycystic ovarian syndrome^len#Ann N Y A
cad Sci#19930000#1993#687#235-41#20110200#02.htm#0077-8923#Ann N Y Acad Sci##
00674000000000313000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730100015000900100
01600105010001300121010001500134012011200149030002400261065000900285064000500294
031000300299014000800302865000900310002000700319035001000326801002400336#v55n1#V
:\SciELO\serial\abem\v55n1\markup\02.htm#S#c#268#45#article#60#45#^rND^sMurphy^n
MK#^rND^sHall^nJE#^rND^sAdams^nJM#^rND^sLee^nH#^rND^sWelt^nCK#Polycystic ovarian
 morphology in normal women does not predict the development of polycystic ovary
 syndrome^len#J Clin Endocrinol Metab#20060000#2006#91#3878-84#20110200#02.htm#0
021-972X#J Clin Endocrinol Metab##
00579000000000265000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100027000730120135001000300
01400235065000900249064000500258031000300263014000700266865000900273002000700282
035001000289801001400299#v55n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#c#269
#46#article#60#46#^rND^sEscobar-Morreale^nHF#Macroprolactinemia in women present
ing with hyperandrogenic symptoms: implications for the management of polycystic
 ovary syndrome^len#Fertil Steril#20040000#2004#82#1697-9#20110200#02.htm#0015-0
282#Fertil Steril##
00601000000000277000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100019000730100018000920120
08500110030002600195065000900221064000500230031000300235014000600238865000900244
002000700253035001000260801005300270#v55n1#V:\SciELO\serial\abem\v55n1\markup\02
.htm#S#c#270#47#article#60#47#^rND^sPinheiro^nSA#^rND^sClapauch^nR#Importância d
a dosagem da 17OH-progesterona na síndrome dos ovários policísticos^lpt#Arq Bras
 Endocrinol Metab#20010000#2001#45#361-8#20110200#02.htm#0004-2730#Arquivos Bras
ileiros de Endocrinologia & Metabologia##
00614000000000313000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100021000730100016000940100
01700110010001800127010001500145012006100160030001500221065000900236064000500245
031000300250014000600253865000900259002000700268035001000275801001500285#v55n1#V
:\SciELO\serial\abem\v55n1\markup\02.htm#S#c#271#48#article#60#48#^rND^sChetkows
ki^nRJ#^rND^sChang^nRJ#^rND^sDeFazio^nJ#^rND^sMeldrum^nDR#^rND^sJudd^nHL#Origin 
of serum progestins in polycystic ovarian disease^len#Obstet Gynecol#19840000#19
84#64#27-31#20110200#02.htm#0029-7844#Obstet Gynecol##
00697000000000313000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100021000730100018000940100
01900112010002000131010001600151010002200167012012700189030002600316710000200342
065000900344064000500353031000300358014000600361865000900367002000700376#v55n1#V
:\SciELO\serial\abem\v55n1\markup\02.htm#S#c#272#49#article#60#49#^rND^sMarconde
s^nJAM#^rND^sMinanni^nSL#^rND^sSakamoto^nLC#^rND^sHayashida^nSY#^rND^sHalbe^nHW#
^rND^sWajchenberg^nBL#O espectro clínico e laboratorial da forma não clássica de
 hiperplasia adrenal congênita por deficiência da 21-hidroxilase^lpt#Arq Bras En
docrinol Metab#2#19950000#1995#39#37-43#20110200#02.htm##
00704000000000325000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100015000730100019000880100
02300107010001800130010001300148010001600161012012300177030001400300065000900314
06400050032303100030032801400070033186500090033800200070034703500100035480100140
0364#v55n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#c#273#50#article#60#50#^r
ND^sAzziz^nR#^rND^sHincapie^nLA#^rND^sKnochenhauer^nES#^rND^sDewailly^nD#^rND^sF
ox^nL#^rND^sBoots^nLR#Sceening for 21-hydroxylaser-deficient nonclassic adrenal 
hyperplasia among hyperandrogenic women: a prospective study^len#Fertil Steril#1
9990000#1999#72#915-25#20110200#02.htm#0015-0282#Fertil Steril##
00562000000000277000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100015000730100016000880120
08200104030002400186065000900210064000500219031000300224014000700227865000900234
002000700243035001000250801002400260#v55n1#V:\SciELO\serial\abem\v55n1\markup\02
.htm#S#c#274#51#article#60#51#^rND^sAzziz^nR#^rND^sZacur^nHA#21-hydroxylase defi
ciency in female hyperandrogenism: screening and diagnosis^len#J Clin Endocrinol
 Metab#19890000#1989#69#577-84#20110200#02.htm#0021-972X#J Clin Endocrinol Metab
##
00678000000000289000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100027000730100017001000100
02100117012015200138030002400290065000900314064000500323031000300328014000700331
865000900338002000700347035001000354801002400364#v55n1#V:\SciELO\serial\abem\v55
n1\markup\02.htm#S#c#275#52#article#60#52#^rND^sEscobar-Morreale^nHF#^rND^sSanch
ón^nR#^rND^sSan Millán^nJL#A prospective study of the prevalence of nonclassical
 congenital adrenal hyperplasia among women presenting with hyperandrogenic symp
toms and signs^len#J Clin Endocrinol Metab#20080000#2008#93#527-33#20110200#02.h
tm#0021-972X#J Clin Endocrinol Metab##
00689000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100014000730100018000870100
01700105010001400122010002000136010001800156810000600174012007400180030002400254
06500090027806400050028703100030029201400060029586500090030100200070031003500100
0317801002400327#v55n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#c#276#53#arti
cle#60#53#^rND^sNew^nMI#^rND^sLorenzen^nF#^rND^sLerner^nAJ#^rND^sKohn^nB#^rND^sO
berfield^nSE#^rND^sPollack^nMS#et al#Genotyping steroid 21-hydroxylase deficienc
y: hormonal reference data^len#J Clin Endocrinol Metab#19830000#1983#57#320-6#20
110200#02.htm#0021-972X#J Clin Endocrinol Metab##
00723000000000313000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100018000730100021000910100
02000112010001900132010001800151010001900169012016400188030001600352710000200368
065000900370064000500379031000300384014000600387865000900393002000700402#v55n1#V
:\SciELO\serial\abem\v55n1\markup\02.htm#S#c#277#54#article#60#54#^rND^sBachega^
nTA#^rND^sBillerbeck^nAE#^rND^sMarcondes^nJA#^rND^sMadureira^nG#^rND^sArnhold^nI
J#^rND^sMendonca^nBB#Influence of different genotypes on 17-hydroxyprogesterone 
levels in patients with nonclassical congenital adrenal hyperplasia due to 21-hy
droxylase deficiency^len#Clin Endocrinol#2#20000000#2000#52#601-7#20110200#02.ht
m##
00645000000000313000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100018000730100019000910100
01400110010001700124010001700141012008900158030001700247065000900264064000500273
031000400278014000600282865000900288002000700297035001000304801001700314#v55n1#V
:\SciELO\serial\abem\v55n1\markup\02.htm#S#c#278#55#article#60#55#^rND^sJanssen^
nOE#^rND^sMehlmauer^nN#^rND^sHahn^nS#^rND^sOffner^nAH#^rND^sGartner^nR#High prev
alence of autoimmune thyroiditis in patients with polycystic ovary syndrome^len#
Eur J Endocrinol#20040000#2004#150#363-9#20110200#02.htm#0804-4643#Eur J Endocri
nol##
00509000000000289000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100015000730100017000880100
01700105012002500122030001100147065000900158064000500167031000300172014000700175
865000900182002000700191035001000198801001100208#v55n1#V:\SciELO\serial\abem\v55
n1\markup\02.htm#S#c#279#56#article#60#56#^rND^sAzziz^nR#^rND^sCarmina^nE#^rND^s
Sawaya^nME#Idiopathic hirsutism^len#Endocr Rev#20000000#2000#21#347-62#20110200#
02.htm#0163-769X#Endocr Rev##
00710000000000313000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100022000730100017000950100
01800112010001600130010002000146012013300166030002400299065000900323064000500332
031000300337014000600340865000900346002000700355035001000362801002400372#v55n1#V
:\SciELO\serial\abem\v55n1\markup\02.htm#S#c#280#57#article#60#57#^rND^sVan Der 
Meer^nM#^rND^sHompes^nPG#^rND^sDe Boer^nJA#^rND^sSchats^nR#^rND^sSchoemaker^nJ#C
ohort size rather than follicle-stimulating hormone threshold level determines o
varian sensitivity in polycystic ovary syndrome^len#J Clin Endocrinol Metab#1998
0000#1998#83#423-6#20110200#02.htm#0021-972X#J Clin Endocrinol Metab##
00669000000000313000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100015000730100015000880100
01300103010002000116010001400136012010700150030002400257065000900281064000500290
031000300295014000700298865000900305002000700314035001000321801002400331#v55n1#V
:\SciELO\serial\abem\v55n1\markup\02.htm#S#c#281#58#article#60#58#^rND^sAzziz^nR
#^rND^sMarin^nC#^rND^sHoq^nL#^rND^sBadamgarav^nE#^rND^sSong^nP#Health care-relat
ed economic burden of the polycystic ovary syndrome during the reproductive life
 span^len#J Clin Endocrinol Metab#20050000#2005#90#4650-8#20110200#02.htm#0021-9
72X#J Clin Endocrinol Metab##
00857000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100015000730100017000880100
02900105010001600134010002700150010002000177810000600197012021700203030002400420
06500090044406400050045303100030045801400080046186500090046900200070047803500100
0485801002400495#v55n1#V:\SciELO\serial\abem\v55n1\markup\02.htm#S#c#282#59#arti
cle#60#59#^rND^sWild^nRA#^rND^sCarmina^nE#^rND^sDiamanti-Kandarakis^nE#^rND^sDok
ras^nA#^rND^sEscobar-Morreale^nHF#^rND^sFutterweit^nW#et al#Assessment of cardio
vascular risk and prevention of cardiovascular disease in women with the polycys
tic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic 
Ovary Syndrome (AE-PCOS) Society^len#J Clin Endocrinol Metab#20100000#2010#95#20
38-49#20110200#02.htm#0021-972X#J Clin Endocrinol Metab##
00567000000000289000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730100020000900100
01500110012006200125030002000187065000900207064000500216031000400221014000600225
865000900231002000700240035001000247801002000257#v55n1#V:\SciELO\serial\abem\v55
n1\markup\02.htm#S#c#283#60#article#60#60#^rND^sCarmina^nE#^rND^sOberfield^nSE#^
rND^sLobo^nRA#The diagnosis of polycystic ovary syndrome in adolescents^len#Am J
 Obstet Gynecol#20100000#2010#203#201-6#20110200#02.htm#0002-9378#Am J Obstet Gy
necol##
00263000000000169000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640910009000660920007000750020007000827030
00400089#v55n1#V:\SciELO\serial\abem\v55n1\markup\03.htm#S#o#1#1#article#1#20110
324#154512#03.htm#296##
03835000000000673000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640710003000660400003000690010006000720420
00200078120000400080038000400084038000400088121000300092049000800095158000300103
03000260010603100030013203200020013506500090013701400090014603500100015501201430
01650120117003080100034004250100031004590100036004900100033005260100026005590700
09100585070010000676083101700776085000801793085003701801085003201838085003001870
08500240190008500250192408310030194908500080295208500370296008500300299708500300
30270850023030570850025030801170006031050720003031111120009031141110011031231140
00903134113001103143002000703154#v55n1#V:\SciELO\serial\abem\v55n1\markup\03.htm
#S#h#2#1#article#1#oa#pt#br1.1#1#4.0#GRA#TAB#03#ABEM030#nd#Arq Bras Endocrinol M
etab#55#1#20110200#^f16^l28#0004-2730#Controle hormonal dos adenomas hipofisário
s pela cirurgia transesfenoidal: evolução dos resultados nos primeiros cinco ano
s de experiência^lpt#Hormonal control of pituitary adenomas by transsphenoidal s
urgery: results of the first five years of experience^len#^rND^1A01^nErika Ribei
ro^sBarbosa#^rND^1A01^nSamuel Tau^sZymberg#^rND^1A01^nRodrigo de Paula^sSantos#^
rND^1A02^nHelio Rubens^sMachado#^rND^1A01^nJulio^sAbucham#Universidade Federal d
e São Paulo^iA01^1Escola Paulista de Medicina^cSão Paulo^sSP^pBrasil#Universidad
e de São Paulo^iA02^1Faculdade de Medicina de Ribeirão Preto^cRibeirão Preto^sSP
^pBrasil#^lpt^aOBJETIVO: Avaliar os resultados iniciais de uma equipe cirúrgica 
no controle hormonal dos adenomas hipofisários secretores. MATERIAIS E MÉTODOS: 
Em cinco anos, foram operados 51 adenomas secretores (31 GH, 14 ACTH, 5 prolacti
na, 1 TSH). O controle hormonal foi GH basal < 2,5 ng/dL, cortisol livre urinári
o normal, redução dos níveis de prolactina, e T3 e T4 livre normais. RESULTADOS:
 As taxas de controle foram 36% na acromegalia e 57% no Cushing. Dois prolactino
mas (40%) normalizaram a prolactina. Os hormônios tiroidianos normalizaram no ad
enoma secretor de TSH. O controle do hipercortisolismo correlacionou-se com o te
mpo de experiência da equipe (p = 0,01). CONCLUSÃO: Nossos resultados, limitados
 aos primeiros anos de experiência cirúrgica, situam-se abaixo da variação repor
tada em grandes casuísticas com maior tempo de experiência. Ao longo do tempo, o
bservou-se melhora progressiva nos níveis de cortisol urinário no pós-operatório
 inicial da doença de Cushing em função da experiência cirúrgica.#^dnd^i1#^tm^lp
t^kCirurgia transesfenoidal^i1#^tm^lpt^kadenoma hipofisário^i1#^tm^lpt^kdoença d
e Cushing^i1#^tm^lpt^kacromegalia^i1#^tm^lpt^kprolactinoma^i1#^len^aOBJECTIVE: T
o evaluate the initial results of a surgical team in the hormonal control of sec
reting pituitary adenomas. MATERIALS AND METHODS: In five years 51 functioning a
denomas were operated (31 GH-secreting, 14 ACTH-secreting, 5 PRL-secreting and 1
 TSH-secreting). Hormonal control was defined as GH < 2,5 ng/mL, normal free-uri
nary cortisol, lower prolactin and normal T3 and FT4. RESULTS: Control rates wer
e 36% in acromegaly, and 57% in Cushing's disease. Two prolactinomas normalized 
prolactin levels. Thyroid hormone levels were normalized in the TSH-secreting ad
enoma. Control of hypercortisolism was positively correlated with years of exper
ience (p = 0.01). CONCLUSION: Our results, although restricted to the beginning 
of our experience, lie below the reported range of other surgical series with mu
ch longer experience. During these years, there was a significant improvement in
 initial post surgery urinary cortisol levels in Cushing's disease as a function
 of surgical experience.#^dnd^i2#^tm^len^kTransesphenoidal surgery^i2#^tm^len^kp
ituitary adenoma^i2#^tm^len^kCushing's disease^i2#^tm^len^kacromegaly^i2#^tm^len
^kprolactinoma^i2#other#40#20100810#10/08/2010#20101116#16/11/2010#03.htm##
03939000000000673000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640710003000660400003000690010006000720420
00200078120000400080038000400084038000400088121000300092049000800095158000300103
03000260010603100030013203200020013506500090013701400090014603500100015501201570
01650120131003220100034004530100031004870100036005180100033005540100026005870700
09100613070010000704083105500804085000801859085003701867085003201904085003001936
08500240196608500250199008310410201508500080305608500370306408500300310108500300
31310850023031610850025031841170006032090720003032151120009032181110011032271140
00903238113001103247002000703258#v55n1#V:\SciELO\serial\abem\v55n1\markup\03.htm
#S#f#3#1#article#1#oa#pt#br1.1#1#4.0#GRA#TAB#03#ABEM030#nd#Arq Bras Endocrinol M
etab#55#1#20110200#^f16^l28#0004-2730#<b>Controle hormonal dos adenomas hipofisá
rios pela cirurgia transesfenoidal</b>: <b>evolução dos resultados nos primeiros
 cinco anos de experiência</b>^lpt#<b>Hormonal control of pituitary adenomas by 
transsphenoidal surgery</b>: <b>results of the first five years of experience</b
>^len#^rND^1A01^nErika Ribeiro^sBarbosa#^rND^1A01^nSamuel Tau^sZymberg#^rND^1A01
^nRodrigo de Paula^sSantos#^rND^1A02^nHelio Rubens^sMachado#^rND^1A01^nJulio^sAb
ucham#Universidade Federal de São Paulo^iA01^1Escola Paulista de Medicina^cSão P
aulo^sSP^pBrasil#Universidade de São Paulo^iA02^1Faculdade de Medicina de Ribeir
ão Preto^cRibeirão Preto^sSP^pBrasil#^lpt^a<b>OBJETIVO:</b> Avaliar os resultado
s iniciais de uma equipe cirúrgica no controle hormonal dos adenomas hipofisário
s secretores. <b>MATERIAIS E MÉTODOS:</b> Em cinco anos, foram operados 51 adeno
mas secretores (31 GH, 14 ACTH, 5 prolactina, 1 TSH). O controle hormonal foi GH
 basal <u>&lt;</u> 2,5 ng/dL, cortisol livre urinário normal, redução dos níveis
 de prolactina, e T3 e T4 livre normais. <b>RESULTADOS:</b> As taxas de controle
 foram 36% na acromegalia e 57% no Cushing. Dois prolactinomas (40%) normalizara
m a prolactina. Os hormônios tiroidianos normalizaram no adenoma secretor de TSH
. O controle do hipercortisolismo correlacionou-se com o tempo de experiência da
 equipe (p = 0,01). <b>CONCLUSÃO:</b> Nossos resultados, limitados aos primeiros
 anos de experiência cirúrgica, situam-se abaixo da variação reportada em grande
s casuísticas com maior tempo de experiência. Ao longo do tempo, observou-se mel
hora progressiva nos níveis de cortisol urinário no pós-operatório inicial da do
ença de Cushing em função da experiência cirúrgica.#^dnd^i1#^tm^lpt^kCirurgia tr
ansesfenoidal^i1#^tm^lpt^kadenoma hipofisário^i1#^tm^lpt^kdoença de Cushing^i1#^
tm^lpt^kacromegalia^i1#^tm^lpt^kprolactinoma^i1#^len^a<b>OBJECTIVE:</b> To evalu
ate the initial results of a surgical team in the hormonal control of secreting 
pituitary adenomas. <b>MATERIALS AND METHODS:</b> In five years 51 functioning a
denomas were operated (31 GH-secreting, 14 ACTH-secreting, 5 PRL-secreting and 1
 TSH-secreting). Hormonal control was defined as GH <u>&lt;</u> 2,5 ng/mL, norma
l free-urinary cortisol, lower prolactin and normal T3 and FT4. <b>RESULTS:</b> 
Control rates were 36% in acromegaly, and 57% in Cushing's disease. Two prolacti
nomas normalized prolactin levels. Thyroid hormone levels were normalized in the
 TSH-secreting adenoma. Control of hypercortisolism was positively correlated wi
th years of experience (p = 0.01). <b>CONCLUSION:</b> Our results, although rest
ricted to the beginning of our experience, lie below the reported range of other
 surgical series with much longer experience. During these years, there was a si
gnificant improvement in initial post surgery urinary cortisol levels in Cushing
's disease as a function of surgical experience.#^dnd^i2#^tm^len^kTransesphenoid
al surgery^i2#^tm^len^kpituitary adenoma^i2#^tm^len^kCushing's disease^i2#^tm^le
n^kacromegaly^i2#^tm^len^kprolactinoma^i2#other#40#20100810#10/08/2010#20101116#
16/11/2010#03.htm##
04009000000000697000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640640013000660710003000790400003000820010
00600085042000200091120000400093038000400097038000400101121000300105049000800108
15800030011603000290011903100030014803200020015106500090015301400090016203500100
01710120143001810120117003240100034004410100031004750100036005060100033005420100
02600575070009300601070010200694083104400796085000801840085003701848085003201885
08500300191708500240194708500250197108310170199608500080301308500370302108500300
30580850030030880850023031180850025031411170006031660720003031721120009031751110
01103184114000903195113001103204002000703215008008903222#v55n1#V:\SciELO\serial\
abem\v55n1\markup\03.htm#S#l#4#1#article#1#^mfev.^a2011#oa#pt#br1.1#1#4.0#gra#ta
b#03#ABEM030#nd#Arq. bras. endocrinol. metab#55#1#20110200#^f16^l28#0004-2730#Co
ntrole hormonal dos adenomas hipofisários pela cirurgia transesfenoidal: evoluçã
o dos resultados nos primeiros cinco anos de experiência^lpt#Hormonal control of
 pituitary adenomas by transsphenoidal surgery: results of the first five years 
of experience^len#^rND^1A01^nErika Ribeiro^sBarbosa#^rND^1A01^nSamuel Tau^sZymbe
rg#^rND^1A01^nRodrigo de Paula^sSantos#^rND^1A02^nHelio Rubens^sMachado#^rND^1A0
1^nJulio^sAbucham#^iA01^1Universidade Federal de São Paulo^2Escola Paulista de M
edicina^cSão Paulo^sSP^pBrasil#^iA02^1Universidade de São Paulo^2Faculdade de Me
dicina de Ribeirão Preto^cRibeirão Preto^sSP^pBrasil#^lpt^aOBJETIVO: Avaliar os 
resultados iniciais de uma equipe cirúrgica no controle hormonal dos adenomas hi
pofisários secretores. MATERIAIS E MÉTODOS: Em cinco anos, foram operados 51 ade
nomas secretores (31 GH, 14 ACTH, 5 prolactina, 1 TSH). O controle hormonal foi 
GH basal < 2,5 ng/dL, cortisol livre urinário normal, redução dos níveis de prol
actina, e T3 e T4 livre normais. RESULTADOS: As taxas de controle foram 36 por c
ento na acromegalia e 57 por cento no Cushing. Dois prolactinomas (40 por cento)
 normalizaram a prolactina. Os hormônios tiroidianos normalizaram no adenoma sec
retor de TSH. O controle do hipercortisolismo correlacionou-se com o tempo de ex
periência da equipe (p = 0,01). CONCLUSÃO: Nossos resultados, limitados aos prim
eiros anos de experiência cirúrgica, situam-se abaixo da variação reportada em g
randes casuísticas com maior tempo de experiência. Ao longo do tempo, observou-s
e melhora progressiva nos níveis de cortisol urinário no pós-operatório inicial 
da doença de Cushing em função da experiência cirúrgica.#^dnd^i1#^tm^lpt^kCirurg
ia transesfenoidal^i1#^tm^lpt^kadenoma hipofisário^i1#^tm^lpt^kdoença de Cushing
^i1#^tm^lpt^kacromegalia^i1#^tm^lpt^kprolactinoma^i1#^len^aOBJECTIVE: To evaluat
e the initial results of a surgical team in the hormonal control of secreting pi
tuitary adenomas. MATERIALS AND METHODS: In five years 51 functioning adenomas w
ere operated (31 GH-secreting, 14 ACTH-secreting, 5 PRL-secreting and 1 TSH-secr
eting). Hormonal control was defined as GH < 2,5 ng/mL, normal free-urinary cort
isol, lower prolactin and normal T3 and FT4. RESULTS: Control rates were 36 perc
ent in acromegaly, and 57 percent in Cushing's disease. Two prolactinomas normal
ized prolactin levels. Thyroid hormone levels were normalized in the TSH-secreti
ng adenoma. Control of hypercortisolism was positively correlated with years of 
experience (p = 0.01). CONCLUSION: Our results, although restricted to the begin
ning of our experience, lie below the reported range of other surgical series wi
th much longer experience. During these years, there was a significant improveme
nt in initial post surgery urinary cortisol levels in Cushing's disease as a fun
ction of surgical experience.#^dnd^i2#^tm^len^kTransesphenoidal surgery^i2#^tm^l
en^kpituitary adenoma^i2#^tm^len^kCushing's disease^i2#^tm^len^kacromegaly^i2#^t
m^len^kprolactinoma^i2#other#40#20100810#10/08/2010#20101116#16/11/2010#03.htm#I
nternet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-2730201100
0100003##
00343000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704012200068002000700190#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#5#1#article#252#<p align="right"><font face
="Verdana, Arial, Helvetica, sans-serif" size="2"><b>ARTIGO    ORIGINAL</b></fon
t></p>     ^cY#03.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704002200068002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#6#2#article#252#<p>&nbsp;</p>     ^cY#03.ht
m##
00500000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704027900068002000700347#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#7#3#article#252#<p><a name="top"></a><font 
face="Verdana, Arial, Helvetica, sans-serif" size="4"><b>Controle    hormonal do
s adenomas hipofis&aacute;rios pela cirurgia transesfenoidal: evolu&ccedil;&atil
de;o    dos resultados nos primeiros cinco anos de experi&ecirc;ncia</b></font><
/p>     ^cY#03.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704002200068002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#8#4#article#252#<p>&nbsp;</p>     ^cY#03.ht
m##
00429000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704020800068002000700276#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#9#5#article#252#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="3"><b>Hormonal control    of pituitary adenomas
 by transsphenoidal surgery: results of the first five    years of experience</b
></font></p>     ^cY#03.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000400065704002200069002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#10#6#article#252#<p>&nbsp;</p>     ^cY#03.h
tm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000400065704002200069002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#11#7#article#252#<p>&nbsp;</p>     ^cY#03.h
tm##
00485000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000400065704026300069002000700332#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#12#8#article#252#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>Erika Ribeiro    Barbosa<sup>I</sup>; Sa
muel Tau Zymberg<sup>II</sup>; Rodrigo de Paula Santos<sup>III</sup>;    Helio R
ubens Machado<sup>IV</sup>; Julio Abucham<sup>I</sup></b></font></p>     ^cY#03.
htm##
00454000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000400065704023200069002000700301#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#13#9#article#252#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><sup>I</sup>Disciplina    de Endocrinologia
, Escola Paulista de Medicina, Universidade Federal de S&atilde;o    Paulo (Unif
esp/EPM), S&atilde;o Paulo, SP, Brasil    ^cY#03.htm##
00303000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704008000070002000700150#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#14#10#article#252#<br>   <sup>II</sup>Disci
plina de Neurocirurgia, Unifesp/EPM, SP, Brasil    ^cY#03.htm##
00311000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704008800070002000700158#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#15#11#article#252#<br>   <sup>III</sup>Disc
iplina de Otorrinolaringologia, Unifesp/EPM, SP, Brasil    ^cY#03.htm##
00424000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704020100070002000700271#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#16#12#article#252#<br>   <sup>IV</sup>Disci
plina de Neurocirurgia, Faculdade de Medicina de Ribeir&atilde;o    Preto, Unive
rsidade de S&atilde;o Paulo (FMRP-USP), Ribeir&atilde;o Preto, SP,    Brasil</fo
nt></p>     ^cY#03.htm##
00355000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704013200070002000700202#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#17#13#article#252#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><a href="#back">Correspond&ecirc;ncia    p
ara</a></font></p>     ^cY#03.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#18#14#article#252#<p>&nbsp;</p>     ^cY#03.
htm##
00267000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704004400070002000700114#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#19#15#article#252#<p>&nbsp;</p> <hr size="1
" noshade>     ^cY#03.htm##
00319000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704009600070002000700166#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#20#16#article#252#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>RESUMO</b></font></p>     ^cY#03.htm##
00444000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704022100070002000700291#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#21#17#article#252#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>OBJETIVO:</b>    Avaliar os resultados 
iniciais de uma equipe cir&uacute;rgica no controle hormonal    dos adenomas hip
ofis&aacute;rios secretores.    ^cY#03.htm##
00548000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704032500070002000700395#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#22#18#article#252#<br>   <b>MATERIAIS E M&E
acute;TODOS:</b> Em cinco anos, foram operados 51 adenomas    secretores (31 GH,
 14 ACTH, 5 prolactina, 1 TSH). O controle hormonal foi GH    basal <u>&lt;</u> 
2,5 ng/dL, cortisol livre urin&aacute;rio normal, redu&ccedil;&atilde;o    dos n
&iacute;veis de prolactina, e T3 e T4 livre normais.    ^cY#03.htm##
00557000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704033400070002000700404#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#23#19#article#252#<br>   <b>RESULTADOS:</b>
 As taxas de controle foram 36% na acromegalia e 57% no Cushing.    Dois prolact
inomas (40%) normalizaram a prolactina. Os horm&ocirc;nios tiroidianos    normal
izaram no adenoma secretor de TSH. O controle do hipercortisolismo correlacionou
-se    com o tempo de experi&ecirc;ncia da equipe (p = 0,01).    ^cY#03.htm##
00725000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704050200070002000700572#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#24#20#article#252#<br>   <b>CONCLUS&Atilde;
O:</b> Nossos resultados, limitados aos primeiros anos de    experi&ecirc;ncia c
ir&uacute;rgica, situam-se abaixo da varia&ccedil;&atilde;o    reportada em gran
des casu&iacute;sticas com maior tempo de experi&ecirc;ncia.    Ao longo do temp
o, observou-se melhora progressiva nos n&iacute;veis de cortisol    urin&aacute;
rio no p&oacute;s-operat&oacute;rio inicial da doen&ccedil;a de    Cushing em fu
n&ccedil;&atilde;o da experi&ecirc;ncia cir&uacute;rgica.</font></p>     ^cY#03.
htm##
00460000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704023700070002000700307#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#25#21#article#252#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Descritores:    </b> Cirurgia transesfe
noidal; adenoma hipofis&aacute;rio; doen&ccedil;a de    Cushing; acromegalia; pr
olactinoma</font></p> <hr size="1" noshade>     ^cY#03.htm##
00321000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704009800070002000700168#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#26#22#article#252#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>ABSTRACT</b></font></p>     ^cY#03.htm#
#
00425000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704020200070002000700272#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#27#23#article#252#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>OBJECTIVE:</b>    To evaluate the initi
al results of a surgical team in the hormonal control of    secreting pituitary 
adenomas.    ^cY#03.htm##
00530000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704030700070002000700377#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#28#24#article#252#<br>   <b>MATERIALS AND M
ETHODS:</b> In five years 51 functioning adenomas were operated    (31 GH-secret
ing, 14 ACTH-secreting, 5 PRL-secreting and 1 TSH-secreting). Hormonal    contro
l was defined as GH <u>&lt;</u> 2,5 ng/mL, normal free-urinary cortisol,    lowe
r prolactin and normal T3 and FT4.    ^cY#03.htm##
00537000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704031400070002000700384#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#29#25#article#252#<br>   <b>RESULTS:</b> Co
ntrol rates were 36% in acromegaly, and 57% in Cushing's disease.    Two prolact
inomas normalized prolactin levels. Thyroid hormone levels were normalized    in
 the TSH-secreting adenoma. Control of hypercortisolism was positively correlate
d    with years of experience (p = 0.01).    ^cY#03.htm##
00595000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704037200070002000700442#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#30#26#article#252#<br>   <b>CONCLUSION:</b>
 Our results, although restricted to the beginning of our    experience, lie bel
ow the reported range of other surgical series with much    longer experience. D
uring these years, there was a significant improvement in    initial post surger
y urinary cortisol levels in Cushing's disease as a function    of surgical expe
rience.</font></p>     ^cY#03.htm##
00439000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704021600070002000700286#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#31#27#article#252#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Keywords:</b>    Transesphenoidal surge
ry; pituitary adenoma; Cushing's disease; acromegaly;    prolactinoma</font></p>
 <hr size="1" noshade>     ^cY#03.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#32#28#article#252#<p>&nbsp;</p>     ^cY#03.
htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#33#29#article#252#<p>&nbsp;</p>     ^cY#03.
htm##
00337000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704011400070002000700184#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#34#30#article#252#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="3"><b>INTRODU&Ccedil;&Atilde;O</b></font></p>
     ^cY#03.htm##
01514000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704129100070002000701361#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#35#31#article#252#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">A primeira cirurgia    por via transesfeno
idal bem-sucedida foi realizada em 1907 por Herman Schloffer    (1). Entre 1910 
e 1925, Harvey Cushing aprimorou a t&eacute;cnica e operou 231    pacientes usan
do incis&atilde;o sublabial e acesso endonasal ap&oacute;s retirada    do septo 
(2). Durante as pr&oacute;ximas d&eacute;cadas, essa t&eacute;cnica    foi subst
itu&iacute;da pela craniotomia frontal, tendo em vista limita&ccedil;&otilde;es 
   como campo operat&oacute;rio estreito, ilumina&ccedil;&atilde;o deficiente e 
   risco de infec&ccedil;&atilde;o. A abordagem transesfenoidal para acesso &agr
ave;    hip&oacute;fise foi retomada na d&eacute;cada de 1960, ap&oacute;s a int
rodu&ccedil;&atilde;o    do microsc&oacute;pio cir&uacute;rgico por Jules Hardy 
(3) e do intensificador    de imagem, para confirma&ccedil;&atilde;o da trajet&o
acute;ria cir&uacute;rgica,    por Gerard Guiot (4). Desde ent&atilde;o, o acess
o transeptal-transesfenoidal    tem sido a abordagem de escolha nas cirurgias da
 regi&atilde;o selar. Mais recentemente,    avan&ccedil;os tecnol&oacute;gicos c
omo microinstrumentos e &oacute;ticas anguladas    t&ecirc;m viabilizado a cirur
gia endosc&oacute;pica da regi&atilde;o selar.</font></p>     ^cY#03.htm##
01465000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704124200070002000701312#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#36#32#article#252#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Al&eacute;m dos    avan&ccedil;os tecnol&o
acute;gicos, as caracter&iacute;sticas do tumor, como    tamanho, consist&ecirc;
ncia e invasividade, e a experi&ecirc;ncia do cirurgi&atilde;o    s&atilde;o fat
ores determinantes no resultado dessa cirurgia. A partir de 2001,    todas as ci
rurgias hipofis&aacute;rias em pacientes da Unidade de Neuroendocrinologia    da
 Disciplina de Endocrinologia da Escola Paulista de Medicina da Universidade    
Federal de S&atilde;o Paulo (EPM-Unifesp) foram executadas por uma equipe compos
ta    por um neurocirurgi&atilde;o e um otorrinolaringologista sob orienta&ccedi
l;&atilde;o    inicial de um neurocirurgi&atilde;o experiente em cirurgia transe
ptal-transesfenoidal    por via sublabial e aux&iacute;lio de microsc&oacute;pio
 cir&uacute;rgico. A    partir de 2003, essa via de acesso foi substitu&iacute;d
a pelo acesso transnasal    endosc&oacute;pico. O objetivo deste trabalho &eacut
e; avaliar a evolu&ccedil;&atilde;o    dos resultados cir&uacute;rgicos dessa eq
uipe no tratamento dos adenomas hipofis&aacute;rios    secretores (GH, ACTH, pro
lactina e TSH) operados entre mar&ccedil;o de 2001    e mar&ccedil;o de 2006.</f
ont></p>     ^cY#03.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#37#33#article#252#<p>&nbsp;</p>     ^cY#03.
htm##
00342000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704011900070002000700189#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#38#34#article#252#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="3"><b>PACIENTES E    M&Eacute;TODOS</b></font
></p>     ^cY#03.htm##
00322000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704009900070002000700169#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#39#35#article#252#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Pacientes</b></font></p>     ^cY#03.htm
##
01024000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704080100070002000700871#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#40#36#article#252#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Entre mar&ccedil;o    de 2001 e mar&ccedil
;o de 2006, o grupo de cirurgia hipofis&aacute;ria da EPM-Unifesp    realizou 18
0 cirurgias em 156 pacientes com patologia da regi&atilde;o selar    (<a href="#
t1">Tabela 1</a>). Desses, foi selecionado para esse estudo um total    de 51 pa
cientes portadores de adenomas secretores de GH (n = 31), ACTH (n =    14), prol
actina (n = 5) e TSH (n = 1), submetidos a uma primeira interven&ccedil;&atilde;
o    cir&uacute;rgica pela equipe, com ou sem cirurgia pr&eacute;via por outra e
quipe.    Ap&oacute;s aprova&ccedil;&atilde;o do Comit&ecirc; de &Eacute;tica e 
Pesquisa    da Universidade de S&atilde;o Paulo, todos os prontu&aacute;rios for
am analisados    retrospectivamente.</font></p>     ^cY#03.htm##
00256000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704003300070002000700103#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#41#37#article#252#<p><a name="t1"></a></p> 
    ^cY#03.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#42#38#article#252#<p>&nbsp;</p>     ^cY#03.
htm##
00300000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704007700070002000700147#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#43#39#article#252#<p align="center"><img sr
c="/img/revistas/abem/v55n1/03t01.jpg"></p>     ^cY#03.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#44#40#article#252#<p>&nbsp;</p>     ^cY#03.
htm##
00349000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704012600070002000700196#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#45#41#article#252#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Diagn&oacute;stico    de acromegalia</b
></font></p>     ^cY#03.htm##
00968000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704074500070002000700815#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#46#42#article#252#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">O diagn&oacute;stico    de acromegalia foi
 baseado na suspeita cl&iacute;nica, confirmado pela presen&ccedil;a    de n&iac
ute;veis elevados de IGF-I com n&iacute;veis elevados de GH e/ou sem    supress&
atilde;o ap&oacute;s sobrecarga de glicose, na presen&ccedil;a de les&atilde;o  
  expansiva hipofis&aacute;ria na resson&acirc;ncia magn&eacute;tica. A campimet
ria    visual foi realizada quando indicado. Os tumores eram classificados como 
microadenomas    (tumor <u>&lt;</u> 10 mm), macroadenomas circunscritos (tumor &
gt; 10 mm, restrito    &agrave; sela) ou macroadenomas invasivos (tumor &gt; 10 
mm com invas&atilde;o    de seio cavernoso e/ou esfenoidal).</font></p>     ^cY#
03.htm##
00362000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704013900070002000700209#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#47#43#article#252#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Diagn&oacute;stico    de doen&ccedil;a 
de Cushing</b></font></p>     ^cY#03.htm##
01675000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704145200070002000701522#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#48#44#article#252#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">O diagn&oacute;stico    de doen&ccedil;a d
e Cushing em um paciente com suspeita cl&iacute;nica de hipercortisolismo    end
&oacute;geno foi estabelecido pela presen&ccedil;a de n&iacute;veis elevados    
de cortisol livre em urina de 24 horas em pelo menos duas amostras, falta de    
supress&atilde;o do cortisol s&eacute;rico matinal (&gt; 1,8 ng/dL) ap&oacute;s 
   1 mg de dexametasona na noite anterior e n&iacute;veis normais ou elevados de
    ACTH pela manh&atilde;. Essa proped&ecirc;utica foi geralmente complementada
    pelo teste do DDAVP para a presen&ccedil;a de resposta do ACTH (&gt; 35%) e 
   do cortisol (&gt; 20%) e pela resson&acirc;ncia magn&eacute;tica da regi&atil
de;o    selar. Durante o per&iacute;odo de cinco anos, o cortisol livre urin&aac
ute;rio    foi dosado por RIA de dois <i>kits</i> diferentes, por isso os valore
s foram    expressos como a raz&atilde;o entre a dosagem e o valor do limite sup
erior da    normalidade. Os tumores foram classificados como microadenomas (tumo
r <u>&lt;</u>    10 mm) ou macroadenomas (tumor &gt; 10 mm). Somente um paciente
 n&atilde;o apresentou    evid&ecirc;ncia de adenoma hipofis&aacute;rio na resso
n&acirc;ncia magn&eacute;tica    e foi submetido ao cateterismo do seio petroso 
inferior para dosagem simult&acirc;nea    de ACTH central e perif&eacute;rico an
tes e ap&oacute;s est&iacute;mulo com    DDAVP.</font></p>     ^cY#03.htm##
00350000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704012700070002000700197#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#49#45#article#252#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Diagn&oacute;stico    de prolactinoma</
b></font></p>     ^cY#03.htm##
00795000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704057200070002000700642#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#50#46#article#252#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">O diagn&oacute;stico    de macroprolactino
ma foi baseado na presen&ccedil;a de n&iacute;veis de prolactina    &gt; 200 ng/
ml em pacientes com les&atilde;o expansiva hipofis&aacute;ria &gt;    1,0 cm na 
resson&acirc;ncia magn&eacute;tica. Pacientes com macroadenomas hipofis&aacute;r
ios    e n&iacute;veis de PRL entre 100 e 200 ng/ml foram confirmados como prola
ctinomas    apenas se a imuno-histoqu&iacute;mica fosse francamente positiva par
a PRL. Nenhum    microprolactinoma foi operado.</font></p>     ^cY#03.htm##
00381000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704015800070002000700228#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#51#47#article#252#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Diagn&oacute;stico    de hipertiroidism
o por adenoma secretor de TSH</b></font></p>     ^cY#03.htm##
00693000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704047000070002000700540#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#52#48#article#252#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Um paciente com    adenoma secretor de TSH
 apresentou quadro cl&iacute;nico compat&iacute;vel com    tirotoxicose, com n&i
acute;veis s&eacute;ricos elevados de TSH, tiroxina livre,    triiodotironina e 
subunidade </font><font size="2">&#945;</font><font face="Verdana, Arial, Helvet
ica, sans-serif" size="2">    e um microadenoma hipofis&aacute;rio na resson&aci
rc;ncia magn&eacute;tica.</font></p>     ^cY#03.htm##
00388000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704016500070002000700235#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#53#49#article#252#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Avalia&ccedil;&atilde;o    da fun&ccedi
l;&atilde;o adeno-hipofis&aacute;ria</b></font></p>     ^cY#03.htm##
00802000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704057900070002000700649#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#54#50#article#252#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">A fun&ccedil;&atilde;o    adeno-hipofis&aa
cute;ria foi investigada em todos os pacientes por meio de dosagens    hormonais
 s&eacute;ricas basais de horm&ocirc;nios perif&eacute;ricos e adeno-hipofis&aac
ute;rios    relacionados aos outros eixos hormonais n&atilde;o primariamente env
olvidos    na hipersecre&ccedil;&atilde;o tumoral (GH, IGF-I, prolactina, TSH, T
4 livre,    cortisol, LH, FSH e testosterona total). Pacientes em amenorreia tam
b&eacute;m    foram consideradas hipogon&aacute;dicas.</font></p>     ^cY#03.htm
##
00356000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704013300070002000700203#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#55#51#article#252#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Indica&ccedil;&atilde;o    cir&uacute;r
gica</b></font></p>     ^cY#03.htm##
00581000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704035800070002000700428#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#56#52#article#252#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Todos os pacientes    tiveram a indica&cce
dil;&atilde;o cir&uacute;rgica definida em reuni&atilde;o    multidisciplinar se
manal da Unidade de Neuroendocrinologia da EPM, da qual participam    endocrinol
ogistas, radiologistas, neurocirurgi&otilde;es e otorrinolaringologistas.</font>
</p>     ^cY#03.htm##
00321000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704009800070002000700168#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#57#53#article#252#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Cirurgia</b></font></p>     ^cY#03.htm#
#
01234000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704101100070002000701081#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#58#54#article#252#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Todas as cirurgias    foram realizadas no 
Hospital S&atilde;o Paulo. Inicialmente, contou-se com a    orienta&ccedil;&atil
de;o do Dr. Helio Rubens Machado, professor do Departamento    de Neurocirurgia 
da Faculdade de Medicina de Ribeir&atilde;o Preto da Universidade    de S&atilde
;o Paulo e professor visitante de Neurocirurgia na Escola Paulista    de Medicin
a da Universidade Federal de S&atilde;o Paulo entre os anos 2001 e    2003. At&e
acute; o in&iacute;cio de 2002, todas as cirurgias (n = 14) foram    realizadas 
com aux&iacute;lio de microsc&oacute;pio cir&uacute;rgico e a via    de acesso f
oi sublabial. Depois, nas 37 cirurgias restantes, a via passou a    ser transnas
al, com aux&iacute;lio de endosc&oacute;pio. No p&oacute;s-operat&oacute;rio    
imediato, todos os pacientes foram encaminhados &agrave; enfermaria de Endocrino
logia,    sem necessidade de interna&ccedil;&atilde;o em Unidade de Terapia Inte
nsiva.</font></p>     ^cY#03.htm##
00408000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704018500070002000700255#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#59#55#article#252#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Avalia&ccedil;&atilde;o    p&oacute;s-o
perat&oacute;ria e crit&eacute;rios de controle hormonal</b></font></p>     ^cY#
03.htm##
01480000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704125700070002000701327#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#60#56#article#252#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Todos os pacientes    foram reavaliados no
 p&oacute;s-operat&oacute;rio por meio de dosagens hormonais    e resson&acirc;n
cia magn&eacute;tica. As dosagens hormonais eram, em m&eacute;dia,    realizadas
 2,4 &plusmn; 1,8 meses ap&oacute;s a cirurgia (mediana: 2 meses;    intervalo: 
1-8 meses). Os n&iacute;veis hormonais considerados para se definir    o control
e hormonal pela cirurgia foram: acromegalia: GH <u>&lt;</u> 2,5 ng/mL    (m&eacu
te;dia de 2 dosagens em dias diferentes) e/ou IGF-I expressa como a raz&atilde;o
    entre a dosagem e o valor do limite superior da normalidade para o sexo e id
ade    (normal: <u>&lt;</u> 1; m&eacute;dia de 2 dosagens em dias diferentes). D
oen&ccedil;a    de Cushing: cortisol livre urin&aacute;rio de 24 horas normal (m
&eacute;dia    de 2 dosagens em dias diferentes), expresso como a raz&atilde;o e
ntre a dosagem    e o valor do limite superior da normalidade (normal: <u>&lt;</
u> 1). Prolactinoma:    normaliza&ccedil;&atilde;o dos n&iacute;veis de prolacti
na com doses iguais    ou menores de agonistas dopamin&eacute;rgicos que as usad
as no pr&eacute;-operat&oacute;rio.    Adenoma secretor de TSH: T3 total e T4 li
vre normais.</font></p>     ^cY#03.htm##
00331000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704010800070002000700178#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#61#57#article#252#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Dosagens hormonais</b></font></p>     ^
cY#03.htm##
03289000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704306600070002000703136#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#62#58#article#252#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Todas as dosagens    hormonais foram reali
zadas em duplicata. GH: ensaio por quimioluminesc&ecirc;ncia    (GH Immulite 200
0). Sensibilidade: 0,01 ng/mL. Coeficientes de varia&ccedil;&atilde;o    intraen
saio e interensaio: 2,9-4,6% e 4,2-6,6%, respectivamente. VN: 0-2,5 ng/mL.    IG
F-I: ensaio imunorradiom&eacute;trico (DSL, Texas, USA). Sensibilidade: 0,8    n
g/mL. Coeficientes de varia&ccedil;&atilde;o intraensaio e interensaio: 1,5-3,4%
    e 1,5-8,2%, respectivamente. TSH: ensaio por quimioluminesc&ecirc;ncia (Advi
a-Centaur).    Sensibilidade: 0,01 ng/mL. Coeficientes de varia&ccedil;&atilde;o
 intraensaio    e interensaio: 2,0-5,3% e 2,1-2,5%, respectivamente. VN: 0,35-5,
5 U/dL. T4 livre:    ensaio imunofluorim&eacute;trico (Delfia Wallac Oy, Turku, 
Finland). Sensibilidade:    0,16 ng/dL. Coeficientes de varia&ccedil;&atilde;o i
ntraensaio e interensaio:    4,4% e 6,1%, respectivamente. VN: 0,7-1,54 ng/dL. C
ortisol s&eacute;rico: ensaio    por quimioluminesc&ecirc;ncia (Advia-Centaur). 
Sensibilidade: 0,2 mcg/dL. Coeficientes    de varia&ccedil;&atilde;o intraensaio
 e interensaio: 2,9-3,8% e 1,9-5,4%, respectivamente.    VN: 4,3-22,4 mcg/dL. Co
rtisol livre urin&aacute;rio: radioimunoensaio (DSL 2100    Active Genese, Texas
, USA). Sensibilidade: 0,3 mcg/dL. Coeficientes de varia&ccedil;&atilde;o    int
raensaio e interensaio: 9,5% e 8,4%, respectivamente. VN: 34-122 mcg/24 h    e e
nsaio quimioluminesc&ecirc;ncia&nbsp;(Advia-Centaur). Sensibilidade: 0,2-75    m
cg/dL. Coeficientes de varia&ccedil;&atilde;o intraensaio e interensaio: 2,9-3,8
%    e 1,9-5,4%, respectivamente. VN: 28,5-213,7 mcg/24 h. ACTH: ensaio imuno-qu
imioluminom&eacute;trico    (Diagnostic Prod. Corporation, Los Angeles, USA). Se
nsibilidade: 5 pg/mL. Coeficientes    de varia&ccedil;&atilde;o intraensaio e in
terensaio: 3,6% e 2,8%, respectivamente.    VN: 20-70 pg/mL. LH: ensaio quimiolu
minesc&ecirc;ncia (Advia-Centaur). Sensibilidade:    0,07UI/L. Coeficientes de v
aria&ccedil;&atilde;o intraensaio e interensaio:    2,3-3,0% e 1,5-2,9%, respect
ivamente. VN: 1,5-9,3 UI/L (homens); 1,9-12,5 UI/L    (fase folicular); 8,7-76,3
 UI/L (pico ovulat&oacute;rio); 0,5-16,9 UI/L (fase    l&uacute;tea). <i>FSH</i>
: ensaio quimioluminesc&ecirc;ncia (Advia-Centaur).    Sensibilidade: 0,3-200 UI
/L. Coeficientes de varia&ccedil;&atilde;o intraensaio    e interensaio: 2,0-2,9
% e 0,3-2,7%, respectivamente. VN: 1,4-18,1 UI/L (homens);    2,5-10,2 UI/L (fas
e folicular); 3,2-33,4 UI/L (pico ovulat&oacute;rio); 1,5-9,1    UI/L (fase l&ua
cute;tea). Testosterona: ensaio imuno-quimioluminom&eacute;trico    (Immulite 20
00). Sensibilidade: 20 ng/dL. Coeficientes de varia&ccedil;&atilde;o    intraens
aio e interensaio: 2,3-3,0% e 1,5-2,9%, respectivamente. VN: 262-1593    ng/dL. 
Prolactina: ensaio por quimioluminesc&ecirc;ncia&nbsp;(Advia-Centaur).    Sensib
ilidade: 0,3 ng/mL. Coeficientes de varia&ccedil;&atilde;o intraensaio    e inte
rensaio: 1,9-4,4% e 2,0-4,9%, respectivamente. VN: 2-30 ng/L.</font></p>     ^cY
#03.htm##
00349000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704012600070002000700196#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#63#59#article#252#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>An&aacute;lise    estat&iacute;stica</b
></font></p>     ^cY#03.htm##
01321000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704109800070002000701168#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#64#60#article#252#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Os resultados foram    expressos em m&eacu
te;dia &plusmn; DP ou mediana &plusmn; DP e percentuais.    A an&aacute;lise est
at&iacute;stica foi realizada com testes param&eacute;tricos    ou n&atilde;o pa
ram&eacute;tricos, de acordo com resultados preliminares dos    testes de normal
idade. Para vari&aacute;veis categ&oacute;ricas, foi usado o    teste exato de F
isher ou o teste do qui-quadrado, conforme indicado. Dados cont&iacute;nuos    c
om distribui&ccedil;&atilde;o normal foram analisados por teste <i>t</i> e    co
rrela&ccedil;&atilde;o de Pearson. Dados cont&iacute;nuos com distribui&ccedil;&
atilde;o    n&atilde;o normal foram analisados por Wilcoxon, Mann-Whitney e corr
ela&ccedil;&atilde;o    de Spearman. Valores de p &lt; 0,05 foram considerados s
ignificantes. A an&aacute;lise    estat&iacute;stica foi realizada usando o prog
rama GraphPad Prism vers&atilde;o    4.03 para Windows (GraphPad Software, San D
iego California USA, <a href="http://www.graphpad.com" target="_blank">www.graph
pad.com</a>.)</font></p>     ^cY#03.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#65#61#article#252#<p>&nbsp;</p>     ^cY#03.
htm##
00323000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704010000070002000700170#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#66#62#article#252#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="3"><b>RESULTADOS</b></font></p>     ^cY#03.ht
m##
00324000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704010100070002000700171#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#67#63#article#252#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Acromegalia</b></font></p>     ^cY#03.h
tm##
01649000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704142600070002000701496#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#68#64#article#252#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Casu&iacute;stica:</b>    foram avaliad
os 31 pacientes com acromegalia, antes da primeira interven&ccedil;&atilde;o    
cir&uacute;rgica no servi&ccedil;o, com m&eacute;dia de idade de 46,4 &plusmn;  
  10,5 anos (mediana: 47,5 anos; intervalo: 20-65 anos), 23 do sexo feminino e  
  8 do sexo masculino. Na RM, cinco apresentaram microadenomas (16%) e 26 aprese
ntaram    macroadenomas (84%), sendo 11 macroadenomas circunscritos (36%) e 15 i
nvasivos    (48%). Quatro pacientes j&aacute; haviam sido submetidos a uma cirur
gia transesfenoidal    em outros servi&ccedil;os. Nenhum paciente havia sido sub
metido &agrave; radioterapia.    Ap&oacute;s avalia&ccedil;&atilde;o hormonal e 
radiol&oacute;gica, dez pacientes    (32%) foram tratados com an&aacute;logos da
 somatostatina no pr&eacute;-operat&oacute;rio:    cinco com octreotida subcut&a
circ;nea e cinco com octreotida de dep&oacute;sito    (Sandostatin-LAR<sup>&reg;
</sup>). Nestes &uacute;ltimos, a reavalia&ccedil;&atilde;o    hormonal foi feit
a ap&oacute;s dois meses ou mais da cirurgia. Todos os 31 pacientes    foram rea
valiados ap&oacute;s uma primeira interven&ccedil;&atilde;o cir&uacute;rgica    
pela equipe de cirurgia hipofis&aacute;ria da Unifesp. O exame anatomopatol&oacu
te;gico    confirmou adenoma com imuno-histoqu&iacute;mica positiva para GH em t
odos os    pacientes.</font></p>     ^cY#03.htm##
00610000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704038700070002000700457#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#69#65#article#252#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>GH:</b> o n&iacute;vel    m&eacute;dio 
de GH basal (<a href="#f1">Figura 1</a>) caiu significativamente    (p &lt; 0,04
) ap&oacute;s a cirurgia, de 32,3 &plusmn; 42,8 ng/mL (mediana:    8,5 ng/mL; in
tervalo: 1,6-223 ng/mL) para 7,8 &plusmn; 10,4 ng/mL (mediana:    3,0 ng/mL; int
ervalo: 0,1-40 ng/mL).</font></p>     ^cY#03.htm##
00256000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704003300070002000700103#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#70#66#article#252#<p><a name="f1"></a></p> 
    ^cY#03.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#71#67#article#252#<p>&nbsp;</p>     ^cY#03.
htm##
00300000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704007700070002000700147#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#72#68#article#252#<p align="center"><img sr
c="/img/revistas/abem/v55n1/03f01.jpg"></p>     ^cY#03.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#73#69#article#252#<p>&nbsp;</p>     ^cY#03.
htm##
00680000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704045700070002000700527#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#74#70#article#252#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>IGF-I:</b> o    n&iacute;vel de IGF-I (
<a href="#f2">Figura 2</a>), calculado em rela&ccedil;&atilde;o    ao limite sup
erior da normalidade (LSN) para sexo e idade (VN: <u>&lt;</u> 1,0),    caiu sign
ificativamente (p &lt; 0,04) ap&oacute;s a cirurgia, de 4,0 &plusmn;    5,0 (med
iana: 2,3; intervalo: 1,2-24,7) para 2,1 &plusmn; 1,3 (mediana: 2,0;    interval
o: 0,6-5,8).</font></p>     ^cY#03.htm##
00256000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704003300070002000700103#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#75#71#article#252#<p><a name="f2"></a></p> 
    ^cY#03.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#76#72#article#252#<p>&nbsp;</p>     ^cY#03.
htm##
00300000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704007700070002000700147#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#77#73#article#252#<p align="center"><img sr
c="/img/revistas/abem/v55n1/03f02.jpg"></p>     ^cY#03.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#78#74#article#252#<p>&nbsp;</p>     ^cY#03.
htm##
01227000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704100400070002000701074#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#79#75#article#252#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Fun&ccedil;&atilde;o    adeno-hipofis&a
acute;ria</b>: antes da cirurgia, um paciente apresentava pan-hipopituitarismo  
  (3%), uma apenas hipotiroidismo central (3%) e nove apresentavam hipogonadismo
    hipogonadotr&oacute;fico (29%). Ap&oacute;s a cirurgia, o &uacute;nico pacie
nte    com pan-hipopituitarismo no pr&eacute;-operat&oacute;rio recuperou totalm
ente    a fun&ccedil;&atilde;o adeno-hipofis&aacute;ria. O &uacute;nico paciente
 com    hipotiroidismo central isolado tamb&eacute;m recuperou a fun&ccedil;&ati
lde;o    tiroidiana. Dos nove pacientes com defici&ecirc;ncia gonadotr&oacute;fi
ca, tr&ecirc;s    recuperaram (33%), cinco mantiveram a defici&ecirc;ncia (55%) 
e um adquiriu    outras defici&ecirc;ncias hormonais (11%). Um paciente com fun&
ccedil;&atilde;o    adeno-hipofis&aacute;ria normal no pr&eacute;-operat&oacute;
rio evoluiu com    hipotiroidismo e hipogonadismo ap&oacute;s a cirurgia (11%).<
/font></p>     ^cY#03.htm##
00792000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704056900070002000700639#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#80#76#article#252#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Vis&atilde;o:</b>    um paciente aprese
ntava amaurose bilateral (3%), tr&ecirc;s apresentavam hemianopsia    bilateral 
(10%) e um, hemianopsia &agrave; direita (3%). Desses 5 pacientes,    dois obtiv
eram recupera&ccedil;&atilde;o parcial (40%) e tr&ecirc;s obtiveram    recupera&
ccedil;&atilde;o total da vis&atilde;o (60%). Um paciente portador    de macroad
enoma invasivo apresentou piora do campo visual no p&oacute;s-operat&oacute;rio,
    com quadrantoanopsia superior bilateral.</font></p>     ^cY#03.htm##
00974000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704075100070002000700821#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#81#77#article#252#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Outras complica&ccedil;&otilde;es</b>: 
   n&atilde;o houve nenhum caso de meningite ou &oacute;bito perioperat&oacute;r
io.    Quatro pacientes apresentaram f&iacute;stula liqu&oacute;rica (13%), mas 
somente    um necessitou drenagem lombar, n&atilde;o sendo necess&aacute;ria a r
einterven&ccedil;&atilde;o    cir&uacute;rgica. Outros tr&ecirc;s pacientes apre
sentaram sangramento nasal    (10%), resolvido apenas com tamponamento nasal ant
erior. Diabetes ins&iacute;pido    transit&oacute;rio ocorreu em quatro paciente
s (13%), todos com resolu&ccedil;&atilde;o    do quadro em at&eacute; 48 horas. 
Nenhum paciente apresentou diabetes ins&iacute;pido    permanente.</font></p>   
  ^cY#03.htm##
00473000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704025000070002000700320#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#82#78#article#252#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Classifica&ccedil;&atilde;o    do contr
ole hormonal ap&oacute;s a cirurgia conforme GH e/ou IGF-I (<a href="/img/revist
as/abem/v55n1/03t02.jpg">Tabela    2</a>)</b></font></p>     ^cY#03.htm##
00372000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704014900070002000700219#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#83#79#article#252#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Grupo I: GH    <u>&lt;</u> 2,5 ng/mL e 
IGF-I normal (n = 5)</b></font></p>     ^cY#03.htm##
00963000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704074000070002000700810#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#84#80#article#252#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Cinco dos 31 pacientes    operados (16%) a
tingiram esse crit&eacute;rio: 1 de 5 com microadenomas (20%)    e 4 de 26 com m
acroadenomas (15%), sendo 3 de 11 com macroadenomas circunscritos    (27%) e 1 d
e 15 com macroadenomas invasivos (7%). Nesse grupo, o GH m&eacute;dio    pr&eacu
te;-operat&oacute;rio foi 12,7 &plusmn; 10,0 ng/mL (mediana: 10,8 ng/mL;    inte
rvalo: 5,0-30 ng/mL) e a IGF-I foi 2,6 &plusmn; 1,4 (mediana: 2,2; intervalo:   
 1,3-4,6), caindo para 0,6 &plusmn; 0,5 ng/mL (mediana: 0,6 ng/mL; intervalo:   
 0,1-1,2 ng/mL; p = 0,03) e 0,8 &plusmn; 0,1 (mediana: 0,8; intervalo: 0,6-0,9; 
   p = 0,008), respectivamente, ap&oacute;s a cirurgia.</font></p>     ^cY#03.ht
m##
00374000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704015100070002000700221#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#85#81#article#252#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Grupo II: GH    <u>&lt;</u> 2,5 ng/mL o
u IGF-I normal (n = 6)</b></font></p>     ^cY#03.htm##
01083000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704086000070002000700930#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#86#82#article#252#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Seis dos 31 pacientes    operados (19%) at
ingiram esse crit&eacute;rio, todos com GH <u>&lt;</u> 2,5    ng/mL e IGF-I aind
a elevada: 1 de 5 com microadenomas (20%) e 5 de 26 com macroadenomas    (19%), 
sendo 3 de 11 com macroadenomas circunscritos (27%) e 2 de 15 com macroadenomas 
   invasivos (13%). Nenhum paciente apresentou IGF-I normal e GH &gt; 2,5 ng/mL.
    Nesse grupo, o GH m&eacute;dio pr&eacute;-operat&oacute;rio foi 13,5 &plusmn
;    14,4 ng/mL (mediana: 9,3 ng/mL; intervalo: 1,6-40 ng/mL) e a IGF-I foi 3,6 
&plusmn;    2,5 (mediana: 2,3; intervalo: 1,8-8,2), caindo para 1,4 &plusmn; 0,6
 ng/mL (mediana:    1,5 ng/mL; intervalo: 0,6-2,0 ng/mL; p = 0,01) e 2,1 &plusmn
; 0,8 (mediana:    2,0; intervalo: 1,3-3,4; p = 0,18), respectivamente, ap&oacut
e;s a cirurgia.</font></p>     ^cY#03.htm##
00395000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704017200070002000700242#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#87#83#article#252#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Grupo III: redu&ccedil;&atilde;o    de 
GH <u>&gt;</u> 50% e IGF-I elevada (n = 13)</b></font></p>     ^cY#03.htm##
00958000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704073500070002000700805#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#88#84#article#252#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Treze dos 31 pacientes    (42%) atingiram 
esse crit&eacute;rio: 1 de 5 com microadenomas (20%) e 12 de    26 com macroaden
omas (46%), sendo 5 de 11 macroadenomas circunscritos (45%)    e 7 de 15 macroad
enomas invasivos (47%). Nesse grupo, o GH m&eacute;dio pr&eacute;-operat&oacute;
rio    foi 54,2 &plusmn; 60,1 ng/mL (mediana: 32,4 ng/mL; intervalo: 7,4-223 ng/
mL)    e a IGF-I foi 3,4 &plusmn; 4,8 (mediana: 2,1; intervalo: 1,2-18,5), caind
o para    8,1 &plusmn; 7,3 ng/mL (mediana: 6,0 ng/mL; intervalo: 2,8-28,8 ng/mL;
 p = 0    &lt; 0,001) e 2,1 &plusmn; 1,0 (mediana: 2,0; intervalo: 1,1-4,3; p = 
0,74),    respectivamente, ap&oacute;s a cirurgia.</font></p>     ^cY#03.htm##
00394000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704017100070002000700241#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#89#85#article#252#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Grupo IV: GH    e IGF-I n&atilde;o atin
gem os crit&eacute;rios anteriores (n = 7)</b></font></p>     ^cY#03.htm##
01039000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704081600070002000700886#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#90#86#article#252#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Sete dos 31 pacientes    (22%) apresentara
m GH &gt; 2,5 ng/dL sem redu&ccedil;&atilde;o de GH <u>&gt;</u>    50% ap&oacute
;s a cirurgia: 2 entre os 5 pacientes com microadenomas (40%) e    5 entre os 26
 com macroadenomas (19%), sendo todos macroadenomas invasivos.    Nenhum desses 
pacientes apresentou IGF-I normal. Neste grupo, o GH m&eacute;dio    pr&eacute;-
operat&oacute;rio foi 26,5 &plusmn; 21,4 ng/mL (mediana: 25,7 ng/mL;    interval
o: 2,4-60 ng/mL) e a IGF-I foi 5,7 &plusmn; 8,5 (mediana: 2,3; intervalo:    1,2
-24,7) caindo para 19,3 &plusmn; 14,6 ng/mL (mediana: 17,9 ng/mL; intervalo:    
2,7-40 ng/mL; p = 0,53) e 3,2 &plusmn; 1,8 (mediana: 2,7; intervalo: 1,2-5,8;   
 p = 0,9), respectivamente, ap&oacute;s a cirurgia.</font></p>     ^cY#03.htm##
00850000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704062700070002000700697#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#91#87#article#252#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Fatores preditivos    da resposta cir&u
acute;rgica (GH)</b>: conforme apresentado na <a href="#t3">tabela    3</a>, com
parando-se os 11 pacientes que atingiram controle hormonal ap&oacute;s    a ciru
rgia (Grupos I e II) com os 20 que n&atilde;o atingiram (Grupos III e    IV), ob
servou-se que o n&iacute;vel de GH no diagn&oacute;stico foi significativamente 
   menor nos pacientes controlados (12,2 &plusmn; 11,9 ng/dL, intervalo: 0,3-40,
0    ng/dL <i>vs.</i> 43,7 &plusmn; 49,9 ng/dL, intervalo: 2,4-223 ng/dL; p = 0,
008;    Mann-Whitney).</font></p>     ^cY#03.htm##
00256000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704003300070002000700103#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#92#88#article#252#<p><a name="t3"></a></p> 
    ^cY#03.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#93#89#article#252#<p>&nbsp;</p>     ^cY#03.
htm##
00300000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704007700070002000700147#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#94#90#article#252#<p align="center"><img sr
c="/img/revistas/abem/v55n1/03t03.jpg"></p>     ^cY#03.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#95#91#article#252#<p>&nbsp;</p>     ^cY#03.
htm##
00984000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704076100070002000700831#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#96#92#article#252#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Al&eacute;m disso,    o controle hormonal 
ap&oacute;s a cirurgia tendeu a ocorrer com maior frequ&ecirc;ncia    nos pacien
tes com tumores circunscritos (8/16 <i>vs.</i> 3/15, p = 0,13). N&atilde;o    ho
uve diferen&ccedil;a significativa em rela&ccedil;&atilde;o aos outros fatores  
  analisados: idade (p = 0,24), tratamento cir&uacute;rgico (p = 0,66) ou farmac
ol&oacute;gico    pr&eacute;vio (p = 0,60), propor&ccedil;&atilde;o de micro/mac
roadenomas (p    = 1,0), t&eacute;cnica cir&uacute;rgica empregada (microscopia 
<i>vs.</i> endoscopia,    p = 0,66) ou ano em que foi realizada a cirurgia (p = 
0,56) entre pacientes    controlados e n&atilde;o controlados pela cirurgia.</fo
nt></p>     ^cY#03.htm##
01538000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704131500070002000701385#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#97#93#article#252#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Evolu&ccedil;&atilde;o    dos resultado
s cir&uacute;rgicos na acromegalia</b>: nessa an&aacute;lise, os    pacientes fo
ram divididos em rela&ccedil;&atilde;o &agrave; &eacute;poca em    que foram ope
rados: 17 entre mar&ccedil;o de 2001 e setembro de 2003 e 14 entre    outubro de
 2003 e mar&ccedil;o de 2006. Foram considerados controlados (GH <u>&lt;</u>    
2,5 ng/mL) 7 dos 17 pacientes (41%) operados na primeira metade desses 5 anos   
 e 4 dos 14 pacientes (29%) operados na segunda metade desse per&iacute;odo (p  
  = 0,7). Analisando-se os resultados conforme o tamanho e a circunscri&ccedil;&
atilde;o    dos adenomas, foram controlados 2 de 4 microadenomas (50%) operados 
na primeira    metade <i>vs.</i> 0 de 1 (0%) na segunda metade do per&iacute;odo
 (p = 1), e    5 de 13 macroadenomas (39%) na primeira metade <i>vs.</i> 4 de 13
 (31%) na segunda    (p = 1), sendo 3 de 5 macroadenomas circunscritos (60%) na 
primeira metade <i>vs.</i>    3 de 6 (50%) na segunda (p = 1), e 2 de 8 macroade
nomas invasivos (25%) na primeira    metade <i>vs.</i> 1 de 7 (14%) na segunda (
p = 1). Nenhuma dessas an&aacute;lises    comparativas mostrou diferen&ccedil;a 
significativa entre os resultados obtidos    nos dois per&iacute;odos.</font></p
>     ^cY#03.htm##
00340000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704011700070002000700187#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#98#94#article#252#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Doen&ccedil;a    de Cushing</b></font><
/p>     ^cY#03.htm##
01459000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704123600070002000701306#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#99#95#article#252#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Casu&iacute;stica:</b>    foram avaliad
os 14 pacientes com doen&ccedil;a de Cushing, antes da primeira    interven&cced
il;&atilde;o por essa equipe cir&uacute;rgica, com idade m&eacute;dia    de 30,2
 &plusmn; 9,3 anos (mediana: 31,5 anos; intervalo: 13-40 anos), 12 do    sexo fe
minino e 2 do sexo masculino. Na RM, 8 pacientes apresentavam microadenomas    (
57%) e 5 macroadenomas (36%). Um &uacute;nico paciente (7%), sem evid&ecirc;ncia
    de les&atilde;o hipofis&aacute;ria, foi submetido a cateterismo bilateral do
    seio petroso inferior para dosagem de ACTH basal e ap&oacute;s est&iacute;mu
lo    com desmopressina. O gradiente central/periferia foi 1,8 (basal) e 40 (ap&
oacute;s    desmopressina), com lateraliza&ccedil;&atilde;o &agrave; direita. Um
 paciente    (7%) j&aacute; havia sido submetido a uma cirurgia transesfenoidal,
 por outro    cirurgi&atilde;o, em outro servi&ccedil;o. Nenhum paciente havia s
ido submetido    &agrave; radioterapia. Nove pacientes (64%) receberam cetoconaz
ol antes da cirurgia.    O estudo anatomopatol&oacute;gico confirmou adenoma com
 imuno-histoqu&iacute;mica    positiva para ACTH em todos os pacientes.</font></
p>     ^cY#03.htm##
00758000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000300056709000800059708000400067704053400071002000700605#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#100#96#article#252#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2"><b>Cortisol livre    urin&aacute;rio:</b>
 no pr&eacute;-operat&oacute;rio, o cortisol livre urin&aacute;rio    foi 4,1 &p
lusmn; 3,3 vezes acima do limite superior da normalidade (mediana:    3,1; inter
valo: 1,1-13,1). Ap&oacute;s a cirurgia, o cortisol livre urin&aacute;rio    cai
u significativamente (p = 0,003) para 1,7 &plusmn; 2,3 vezes acima do limite    
superior da normalidade (mediana: 0,75; intervalo: 0-7,4) (<a href="#f3">Figura 
   3</a>).</font></p>     ^cY#03.htm##
00257000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000300056709000800059708000400067704003300071002000700104#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#101#97#article#252#<p><a name="f3"></a></p>
     ^cY#03.htm##
00246000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000300056709000800059708000400067704002200071002000700093#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#102#98#article#252#<p>&nbsp;</p>     ^cY#03
.htm##
00301000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000300056709000800059708000400067704007700071002000700148#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#103#99#article#252#<p align="center"><img s
rc="/img/revistas/abem/v55n1/03f03.jpg"></p>     ^cY#03.htm##
00247000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002200072002000700094#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#104#100#article#252#<p>&nbsp;</p>     ^cY#0
3.htm##
00583000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704035800072002000700430#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#105#101#article#252#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2"><b>ACTH:</b> no    pr&eacute;-operat&oac
ute;rio, o ACTH foi 91,2 &plusmn; 85,2 (mediana: 63,1 pg/dL;    intervalo: 32,6-
370 pg/dL). Ap&oacute;s a cirurgia, o ACTH reduziu significativamente    (p = 0,
01) para 43,2 &plusmn; 34,1 (mediana: 32,7 pg/dL; intervalo: 11-121 pg/dL).</fon
t></p>     ^cY#03.htm##
00729000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704050400072002000700576#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#106#102#article#252#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2"><b>Fun&ccedil;&atilde;o    adeno-hipofis
&aacute;ria</b>: seis pacientes do sexo feminino apresentaram amenorreia.    Ent
re os dois pacientes do sexo masculino, um apresentou atraso no desenvolvimento 
   puberal aos 15 anos. Nenhum paciente apresentou hipotiroidismo. Ap&oacute;s  
  a cirurgia, 7 pacientes (100%) recuperaram a fun&ccedil;&atilde;o gonadotr&oac
ute;fica    e 4 pacientes (29%) desenvolveram hipotiroidismo.</font></p>     ^cY
#03.htm##
00416000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704019100072002000700263#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#107#103#article#252#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2"><b>Vis&atilde;o:</b>    nenhum paciente 
apresentou defici&ecirc;ncia visual antes ou ap&oacute;s a cirurgia.</font></p> 
    ^cY#03.htm##
00673000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704044800072002000700520#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#108#104#article#252#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2"><b>Complica&ccedil;&otilde;es</b>:    ne
nhum paciente apresentou meningite, sangramento ou f&iacute;stula liqu&oacute;ri
ca.    Quatro pacientes apresentaram diabetes ins&iacute;pido transit&oacute;rio
 (29%),    todos com resolu&ccedil;&atilde;o em at&eacute; 48 horas. Nenhum paci
ente evoluiu    com diabetes ins&iacute;pido permanente. Nenhum &oacute;bito oco
rreu.</font></p>     ^cY#03.htm##
01049000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704082400072002000700896#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#109#105#article#252#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2"><b>Controle hormonal:</b>    o hipercort
isolismo foi controlado pela cirurgia em oito pacientes (57%), conforme    avali
ado pelo cortisol livre urin&aacute;rio. Quando consideradas as caracter&iacute;
sticas    radiol&oacute;gicas do tumor, 5 dos 8 microadenomas (55%) e 3 dos 5 ma
croadenomas    (60%) foram controlados pela cirurgia. O paciente sem evid&ecirc;
ncia radiol&oacute;gica    de tumor hipofis&aacute;rio n&atilde;o foi controlado
 pela cirurgia, apesar    de um microadenoma ter sido visualizado no procediment
o. Entre os 9 pacientes    que usaram cetoconazol no pr&eacute;-operat&oacute;ri
o, 7 foram controlados    pela cirurgia (77%), dos quais 2 apresentaram insufici
&ecirc;ncia adrenal aguda    no p&oacute;s-operat&oacute;rio.</font></p>     ^cY
#03.htm##
00894000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704066900072002000700741#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#110#106#article#252#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2">No grupo considerado    controlado pela 
cirurgia (n = 8), o cortisol urin&aacute;rio caiu de 3,6 &plusmn;    2,7 vezes o
 limite superior da normalidade (mediana: 2,7; intervalo: 1,1-8,6)    no pr&eacu
te;-operat&oacute;rio para 0,4 &plusmn; 0,3 vez o limite superior    da normalid
ade (mediana: 0,5; intervalo: 0-0,8) ap&oacute;s a cirurgia (p &lt;    0,001), e
nquanto o ACTH caiu de 73 &plusmn; 29,6 pg/dL (mediana: 64 pg/dL; intervalo:    
32,6-130 pg/dL) no pr&eacute;-operat&oacute;rio para 28,9 &plusmn; 22,5 (mediana
:    23,9; intervalo: 11,2-80) ap&oacute;s a cirurgia (p = 0,004).</font></p>   
  ^cY#03.htm##
00889000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704066400072002000700736#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#111#107#article#252#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2">No grupo n&atilde;o    controlado pela c
irurgia (n = 6), o cortisol urin&aacute;rio caiu de 4,8 &plusmn;    4,1 vezes o 
limite superior da normalidade (mediana: 3,6; intervalo: 1,9-13,1)    para 3,5 &
plusmn; 2,7 vezes o limite superior da normalidade (mediana: 2,1;    intervalo: 
1,3-7,4) ap&oacute;s a cirurgia (p = 0,3), enquanto o ACTH caiu de    115,5 &plu
smn; 128,1 pg/dL (mediana: 61 pg/dL; intervalo: 34,7-370 pg/dL) para    62,3 &pl
usmn; 39,4 (mediana: 51; intervalo: 12-121) ap&oacute;s a cirurgia (p    = 0,58)
 (<a href="/img/revistas/abem/v55n1/03t04.jpg">Tabela 4</a>).</font></p>     ^cY
#03.htm##
01193000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704096800072002000701040#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#112#108#article#252#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2"><b>Fatores preditivos    da resposta cir
&uacute;rgica</b>: o grupo de pacientes controlados ap&oacute;s    a cirurgia fo
i comparado ao grupo n&atilde;o controlado em rela&ccedil;&atilde;o    a caracte
r&iacute;sticas cl&iacute;nicas e laboratoriais. N&atilde;o houve diferen&ccedil
;a    entre os grupos de pacientes controlados e n&atilde;o controlados em rela&
ccedil;&atilde;o    ao cortisol urin&aacute;rio pr&eacute;-operat&oacute;rio (3,
6 &plusmn; 2,7 <i>vs.</i>    4,8 &plusmn; 4,1; p = 0,34; Mann-Withney), ACTH pr&
eacute;-operat&oacute;rio    (73,0 &plusmn; 29,6 <i>vs.</i> 115,5 &plusmn; 128,1
; p = 0,75; Mann-Withney),    a propor&ccedil;&atilde;o de micro/macroadenomas (
p = 1,0), t&eacute;cnica cir&uacute;rgica    empregada (microscopia <i>vs.</i> e
ndoscopia, p = 0,66) ou idade (34,8 &plusmn;    6,4 anos <i>vs.</i> 24,0 &plusmn
; 9,4 p = 0,07) (<a href="#t5">Tabela 5</a>).</font></p>     ^cY#03.htm##
00258000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704003300072002000700105#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#113#109#article#252#<p><a name="t5"></a></p
>     ^cY#03.htm##
00247000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002200072002000700094#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#114#110#article#252#<p>&nbsp;</p>     ^cY#0
3.htm##
00302000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704007700072002000700149#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#115#111#article#252#<p align="center"><img 
src="/img/revistas/abem/v55n1/03t05.jpg"></p>     ^cY#03.htm##
00247000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002200072002000700094#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#116#112#article#252#<p>&nbsp;</p>     ^cY#0
3.htm##
00698000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704047300072002000700545#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#117#113#article#252#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2"><b>Evolu&ccedil;&atilde;o    dos resulta
dos cir&uacute;rgicos na doen&ccedil;a de Cushing</b>: o &iacute;ndice    de con
trole do hipercortisolismo pela cirurgia (n controlados /n operados) variou    d
e 0 (0/3) no ano 2001 a 1,0 (2/2) no ano 2005, correlacionando-se significativam
ente    com o ano da cirurgia ao longo desses 5 anos (p = 0,01; qui-quadrado) (<
a href="#f4">Figura    4</a>).</font></p>     ^cY#03.htm##
00258000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704003300072002000700105#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#118#114#article#252#<p><a name="f4"></a></p
>     ^cY#03.htm##
00247000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002200072002000700094#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#119#115#article#252#<p>&nbsp;</p>     ^cY#0
3.htm##
00302000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704007700072002000700149#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#120#116#article#252#<p align="center"><img 
src="/img/revistas/abem/v55n1/03f04.jpg"></p>     ^cY#03.htm##
00247000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002200072002000700094#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#121#117#article#252#<p>&nbsp;</p>     ^cY#0
3.htm##
00327000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704010200072002000700174#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#122#118#article#252#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2"><b>Prolactinoma</b></font></p>     ^cY#0
3.htm##
01258000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704103300072002000701105#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#123#119#article#252#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2"><b>Casu&iacute;stica:</b>    foram avali
ados 5 pacientes com prolactinoma, com idade m&eacute;dia de 36 &plusmn;    16,8
 anos (mediana: 32 anos; intervalo: 21-59 anos), sendo 3 do sexo feminino    e 2
 do sexo masculino. Na RM, todos apresentavam macroadenomas invasivos. Tr&ecirc;
s    j&aacute; haviam sido submetidos &agrave; cirurgia por outras equipes (uma 
craniotomia    fronto-orbit&aacute;ria e o restante via transesfenoidal). A indi
ca&ccedil;&atilde;o    cir&uacute;rgica foi resist&ecirc;ncia &agrave; bromocrip
tina em 4 pacientes    e intoler&acirc;ncia &agrave; bromocriptina com crescimen
to tumoral em um paciente.    Resist&ecirc;ncia foi caracterizada pelo uso de 15
 mg/dia ou mais de bromocriptina    por pelo menos 3 meses sem normaliza&ccedil;
&atilde;o da prolactina ou redu&ccedil;&atilde;o    do volume tumoral. O estudo 
anatomopatol&oacute;gico confirmou adenoma com imuno-histoqu&iacute;mica    posi
tiva para prolactina em todos.</font></p>     ^cY#03.htm##
00781000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704055600072002000700628#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#124#120#article#252#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2"><b>Prolactina:</b>    no pr&eacute;-oper
at&oacute;rio, na vig&ecirc;ncia de dose m&aacute;xima de    bromocriptina (15 a
 25 mg/dia), a prolactina foi 1895 &plusmn; 3122 ng/ml (mediana:    410 ng/ml; i
ntervalo: 71-7424 ng/ml). Ap&oacute;s a cirurgia, os n&iacute;veis    de prolact
ina foram reduzidos (p &lt; 0,001) para 583,4 &plusmn; 928 ng/ml (mediana:    11
9 ng/ml; intervalo: 14-2195 ng/ml), ainda em uso de bromocriptina (10-15 mg/dia)
    (<a href="#f5">Figura 5</a>).</font></p>     ^cY#03.htm##
00258000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704003300072002000700105#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#125#121#article#252#<p><a name="f5"></a></p
>     ^cY#03.htm##
00247000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002200072002000700094#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#126#122#article#252#<p>&nbsp;</p>     ^cY#0
3.htm##
00302000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704007700072002000700149#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#127#123#article#252#<p align="center"><img 
src="/img/revistas/abem/v55n1/03f05.jpg"></p>     ^cY#03.htm##
00247000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002200072002000700094#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#128#124#article#252#<p>&nbsp;</p>     ^cY#0
3.htm##
00630000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704040500072002000700477#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#129#125#article#252#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2"><b>Fun&ccedil;&atilde;o    adeno-hipofis
&aacute;ria</b>: entre os pacientes com cirurgia hipofis&aacute;ria    pr&eacute
;via, dois j&aacute; apresentavam pan-hipopituitarismo e mantiveram    as mesmas
 defici&ecirc;ncias hormonais. Nenhum paciente evoluiu com nova defici&ecirc;nci
a    hormonal ap&oacute;s a nova cirurgia.</font></p>     ^cY#03.htm##
00519000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704029400072002000700366#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#130#126#article#252#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2"><b>Vis&atilde;o:</b>    todos os pacient
es apresentavam defici&ecirc;ncia visual parcial antes da cirurgia.    O procedi
mento cir&uacute;rgico n&atilde;o corrigiu ou piorou a defici&ecirc;ncia    em n
enhum caso.</font></p>     ^cY#03.htm##
00559000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704033400072002000700406#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#131#127#article#252#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2"><b>Complica&ccedil;&otilde;es</b>:    ne
nhum paciente apresentou meningite, sangramento ou diabetes ins&iacute;pido.    
Um paciente apresentou f&iacute;stula liqu&oacute;rica, corrigida com repouso   
 e tamponamento nasal. Nenhum &oacute;bito ocorreu.</font></p>     ^cY#03.htm##
00589000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704036400072002000700436#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#132#128#article#252#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2"><b>Controle hormonal:</b>    em 2 casos 
com resist&ecirc;ncia &agrave; bromocriptina (40%), a prolactina    se normalizo
u no p&oacute;s-operat&oacute;rio e se manteve normal mesmo com    redu&ccedil;&
atilde;o das doses de bromocriptina (de 15-20 mg/dia para 10 mg/dia    em ambos)
.</font></p>     ^cY#03.htm##
00341000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704011600072002000700188#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#133#129#article#252#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2"><b>Adenoma secretor    de TSH</b></font>
</p>     ^cY#03.htm##
01592000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704136700072002000701439#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#134#130#article#252#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2"><b>Caso:</b> uma    paciente de 19 anos,
 com tirotoxicose e b&oacute;cio difuso, apresentou TSH    de 34 mU/L (VN: 0,35-
5,5 U/dL); T4 livre de 3,3 ng/dL (VN: 0,7-1,54 ng/dL);    T3 total de 1.132 ng/d
L (VN: 75-220 ng/dL) e rela&ccedil;&atilde;o molar subunidade</font><font size="
2">&#945;</font><font face="Verdana, Arial, Helvetica, sans-serif" size="2">/TSH
    de 1,5 (VN: 1). A resson&acirc;ncia magn&eacute;tica mostrou um microadenoma
    de 0,8 cm, do lado esquerdo, junto ao seio cavernoso. N&atilde;o apresentava
    defici&ecirc;ncia hormonal ou visual. Antes da cirurgia foi tratada com Sand
ostatin    LAR, sem resposta cl&iacute;nica ou laboratorial satisfat&oacute;ria.
 Depois    da cirurgia, apresentou melhora cl&iacute;nica importante, com redu&c
cedil;&atilde;o    do volume do b&oacute;cio e dos n&iacute;veis de TSH para 0,1
 mU/L, de T4 livre    para 0,9 ng/dL e de T3 total para 130 ng/dL, sendo conside
rada controlada. O    exame anatomopatol&oacute;gico confirmou adenoma com imuno
-histoqu&iacute;mica    positiva para TSH. Evoluiu com hipotiroidismo central tr
ansit&oacute;rio, tendo    sido tratada com levotiroxina por 4 meses. No sexto m
&ecirc;s ap&oacute;s a    cirurgia, encontrava-se clinicamente eutiroidiana com 
TSH de 0,5 mUI/L e T4    livre de 1,2 ng/dL.</font></p>     ^cY#03.htm##
00422000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704019700072002000700269#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#135#131#article#252#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2"><b>Complica&ccedil;&otilde;es:</b>    ne
nhuma complica&ccedil;&atilde;o cir&uacute;rgica foi observada neste caso.</font
></p>     ^cY#03.htm##
00247000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002200072002000700094#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#136#132#article#252#<p>&nbsp;</p>     ^cY#0
3.htm##
00331000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704010600072002000700178#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#137#133#article#252#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="3"><b>DISCUSS&Atilde;O</b></font></p>     ^
cY#03.htm##
01014000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704078900072002000700861#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#138#134#article#252#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2">O presente trabalho    analisou os resul
tados obtidos no tratamento cir&uacute;rgico dos adenomas hipofis&aacute;rios   
 secretores pelo grupo de cirurgia hipofis&aacute;ria da Unifesp nos primeiros  
  cinco anos de experi&ecirc;ncia (2001-2005). Experi&ecirc;ncia cir&uacute;rgic
a,    de acordo com as diretrizes para o tratamento da acromegalia (5), &eacute;
 definida    como: publica&ccedil;&atilde;o dos resultados cir&uacute;rgicos em 
revistas    indexadas contendo avalia&ccedil;&atilde;o cir&uacute;rgica, bioqu&i
acute;mica    e seguimento adequado dos pacientes; treinamento em pelo menos 100
 casos de    cirurgia hipofis&aacute;ria e realiza&ccedil;&atilde;o de pelo meno
s 25 cirurgias    por ano.</font></p>     ^cY#03.htm##
01096000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704087100072002000700943#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#139#135#article#252#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2">Este grupo de cirurgi&otilde;es    reali
zou 180 cirurgias hipofis&aacute;rias em 5 anos, resultando em m&eacute;dia    3
6 cirurgias por ano. A maior parte das casu&iacute;sticas cir&uacute;rgicas    p
ublicadas (PubMed) relata resultados de experi&ecirc;ncia acumulada em per&iacut
e;odos    mais longos, raramente se restringindo aos anos iniciais, em que os re
sultados    s&atilde;o relativamente piores, o que dificulta uma compara&ccedil;
&atilde;o    mais equilibrada entre nossos resultados e os dessas s&eacute;ries.
 Outros fatores    de dificuldade nessa an&aacute;lise comparativa s&atilde;o a 
heterogeneidade    dos crit&eacute;rios de "cura" ou de controle hormonal ao lon
go do tempo e a    falta de consenso para esses crit&eacute;rios mesmo entre tra
balhos contempor&acirc;neos.</font></p>     ^cY#03.htm##
00877000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704065200072002000700724#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#140#136#article#252#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2">Nessa avalia&ccedil;&atilde;o,    evitou
-se a classifica&ccedil;&atilde;o dos resultados cir&uacute;rgicos em    curados
 e n&atilde;o curados, posto que uma defini&ccedil;&atilde;o de cura    oncol&oa
cute;gica seria necessariamente probabil&iacute;stica e dependente de    um temp
o m&iacute;nimo de seguimento sem a doen&ccedil;a. Al&eacute;m disso,    essa di
cotomia encarcera os resultados em apenas duas categorias e impede a    avalia&c
cedil;&atilde;o de resultados cir&uacute;rgicos intermedi&aacute;rios    que cer
tamente contribuem para o tratamento do paciente.</font></p>     ^cY#03.htm##
00326000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704010100072002000700173#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#141#137#article#252#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2"><b>Acromegalia</b></font></p>     ^cY#03
.htm##
01725000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704150000072002000701572#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#142#138#article#252#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2">Para a acromegalia,    a defini&ccedil;&
atilde;o de controle hormonal &eacute; controversa e os crit&eacute;rios    t&ec
irc;m variado com o passar do tempo. N&iacute;veis basais de GH, nadir de    GH 
ap&oacute;s glicose e IGF-I t&ecirc;m sido usados, isolados ou em conjunto,    c
omo crit&eacute;rios de controle por diferentes autores. Os primeiros relatos   
 consideravam controlados os pacientes com GH &lt; 10 ng/mL (6), sendo que este 
   valor vem decrescendo progressivamente, acompanhando a evolu&ccedil;&atilde;o
    dos ensaios de GH, mais espec&iacute;ficos e com valores mais baixos do que 
   os ensaios mais antigos. Por outro lado, v&aacute;rios estudos epidemiol&oacu
te;gicos    t&ecirc;m demonstrado que a taxa de mortalidade associada &agrave; a
cromegalia    tratada e com GH <u>&lt;</u> 2,5 ng/mL se iguala &agrave; da popul
a&ccedil;&atilde;o    controle, e esse valor, tamb&eacute;m denominado GH seguro
, tem sido frequentemente    adotado como crit&eacute;rio de controle (7-9). Tam
b&eacute;m a normaliza&ccedil;&atilde;o    dos n&iacute;veis de IGF-I em acromeg
&aacute;licos tem sido associada &agrave;    redu&ccedil;&atilde;o da mortalidad
e em alguns estudos epidemiol&oacute;gicos    (10). Al&eacute;m disso, valores d
e GH e IGF-I s&eacute;ricos que s&atilde;o    discrepantes entre si, sobretudo c
om GH &lt; 2-2,5 ng/mL e IGF-I elevada, s&atilde;o    relatados em at&eacute; 32
% dos casos (11).</font></p>     ^cY#03.htm##
00976000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704075100072002000700823#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#143#139#article#252#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2">Atualmente, conforme    sugerido pelo &u
acute;ltimo consenso publicado em 2010 acerca dos crit&eacute;rios    de cura na
 acromegalia (12), esses seriam normaliza&ccedil;&atilde;o de IGF-I,    GH basal
 <u>&lt;</u> 1,0 ng/mL e GH ap&oacute;s sobrecarga oral de glicose &lt;    0,3 n
g/mL. No presente estudo, foi usado como crit&eacute;rio de controle o    GH bas
al <u>&lt;</u> 2,5 ng/mL (GH seguro) em fun&ccedil;&atilde;o da sua valida&ccedi
l;&atilde;o    epidemiol&oacute;gica, associado ou n&atilde;o &agrave; IGF-I nor
mal para idade    e sexo, visto que o objetivo do estudo foi avaliar a evolu&cce
dil;&atilde;o    dos resultados cir&uacute;rgicos ao longo do tempo.</font></p> 
    ^cY#03.htm##
01166000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704094100072002000701013#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#144#140#article#252#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2">Dessa forma, 36%    de todos os tumores 
secretores de GH operados nesses cinco anos iniciais atingiram    n&iacute;veis 
seguros de GH (<u>&lt;</u> 2,5 ng/mL), sendo, portanto, considerados    controla
dos pela cirurgia. Esse resultado inicial encontra-se abaixo dos 62%    (n = 982
; intervalo: 42%-76%) encontrados numa metan&aacute;lise de pacientes    tratado
s por cirurgia transesfenoidal compilados de 11 casu&iacute;sticas. A    porcent
agem de controle nos macroadenomas circunscritos observada em nossa casu&iacute;
stica    foi de 55%, enquanto a de macroadenomas invasivos foi de apenas 20% e a
 de microadenomas,    40%. Nessa mesma metan&aacute;lise, 57% dos macroadenomas 
(n= 634; 23%-75%),    sem distin&ccedil;&atilde;o entre circunscritos e invasivo
s, e 80% dos microadenomas    (n = 247; intervalo: 71%-100%) foram controlados p
ela cirurgia (13).</font></p>     ^cY#03.htm##
01408000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704118300072002000701255#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#145#141#article#252#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2">A import&acirc;ncia    do tempo de exper
i&ecirc;ncia nos resultados da cirurgia hipofis&aacute;ria    transesfenoidal na
 acromegalia tem sido observada em diversos estudos (14-17).    A evolu&ccedil;&
atilde;o das taxas de sucesso cir&uacute;rgico em 139 pacientes    operados por 
um &uacute;nico cirurgi&atilde;o em 21 anos mostrou que a taxa    de remiss&atil
de;o subiu de 48% nos primeiros oito anos (1974-1981) para 73%    no &uacute;lti
mo per&iacute;odo analisado (1991-1995). A an&aacute;lise comparativa    entre o
 primeiro per&iacute;odo e os per&iacute;odos subsequentes (1981-1985,    1986-1
990 e 1991-1995) mostrou melhora significativa dos resultados, enquanto    a com
para&ccedil;&atilde;o entre esses per&iacute;odos posteriores n&atilde;o    most
ra diferen&ccedil;as, sugerindo uma curva de aprendizado ascendente nos    prime
iros 5-10 anos de experi&ecirc;ncia que se estabiliza nos anos subsequentes    (
17). Assim, espera-se que nossos resultados cir&uacute;rgicos na acromegalia,   
 passado esse per&iacute;odo inicial, sejam significativamente melhores nos pr&o
acute;ximos    anos.</font></p>     ^cY#03.htm##
00342000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704011700072002000700189#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#146#142#article#252#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2"><b>Doen&ccedil;a    de Cushing</b></font
></p>     ^cY#03.htm##
02154000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704192900072002000702001#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#147#143#article#252#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2">Na doen&ccedil;a    de Cushing, utilizam
os a determina&ccedil;&atilde;o do cortisol livre na urina    de 24 horas, colhi
da ap&oacute;s quatro ou mais semanas da cirurgia, como par&acirc;metro    de co
ntrole hormonal ap&oacute;s a adenomectomia transesfenoidal. Esse procedimento  
  foi considerado o mais adequado para avaliar o controle hormonal de nossos pac
ientes    pelas seguintes raz&otilde;es: (I) reflete a produ&ccedil;&atilde;o di
&aacute;ria    de cortisol, (II) estava sempre elevado no diagn&oacute;stico des
ses pacientes,    (III) foi tamb&eacute;m utilizado para avaliar a resposta ao t
ratamento pr&eacute;-operat&oacute;rio    com cetoconazol, (IV) foi realizado fo
ra do per&iacute;odo p&oacute;s-operat&oacute;rio    precoce, quando o efeito bl
oqueador do cetoconazol na s&iacute;ntese de cortisol    ainda poderia estar pre
sente (18) e (V) foi o &uacute;nico exame laboratorial    dispon&iacute;vel no p
r&eacute; e p&oacute;s-operat&oacute;rio em todos os pacientes.    Em contraste,
 outros m&eacute;todos de avalia&ccedil;&atilde;o, como o cortisol    basal entr
e 1 e 7 dias ap&oacute;s a cirurgia, bem como o aparecimento de sinais    e sint
omas de insufici&ecirc;ncia adrenal nesse per&iacute;odo, poderiam ser    inadeq
uados em pacientes pr&eacute;-tratados com cetoconazol. A possibilidade    de ef
eito residual da droga no p&oacute;s-operat&oacute;rio favoreceria o encontro   
 de n&iacute;veis s&eacute;ricos de cortisol baixos em alguns pacientes, enquant
o    o desbloqueio do eixo corticotr&oacute;fico durante o tratamento pr&eacute;
-operat&oacute;rio    impediria o aparecimento de insufici&ecirc;ncia adrenal em
 outros. Na presen&ccedil;a    de ambos os efeitos, alguns pacientes n&atilde;o 
controlados em avalia&ccedil;&otilde;es    mais tardias poderiam desenvolver ins
ufici&ecirc;ncia adrenal nesse per&iacute;odo.</font></p>     ^cY#03.htm##
01104000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704087900072002000700951#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#148#144#article#252#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2">No presente estudo,    50% dos tumores s
ecretores de ACTH operados nesses cinco anos iniciais foram    considerados cont
rolados, sendo 40% dos macroadenomas e 55% dos microadenomas.    Entre as grande
s s&eacute;ries cir&uacute;rgicas publicadas, os &iacute;ndices    de remiss&ati
lde;o variam amplamente, entre 42% e 91% (19). A an&aacute;lise    dos resultado
s de acordo com o ano de cirurgia mostrou aumento significativo    da taxa de co
ntrole com o passar do tempo (r = 0,88; p = 0,04), demonstrando    a exist&ecirc
;ncia de uma curva ascendente de aprendizado cir&uacute;rgico.    Assim, &eacute
; ilustrativo que, no primeiro ano, nenhum dos tr&ecirc;s pacientes    tenha sid
o controlado pela cirurgia, ao passo que no &uacute;ltimo ano os dois    pacient
es operados tenham sido controlados.</font></p>     ^cY#03.htm##
01379000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704115400072002000701226#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#149#145#article#252#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2">Diversos estudos    t&ecirc;m demonstrad
o a import&acirc;ncia do tempo de experi&ecirc;ncia nos    resultados da cirurgi
a hipofis&aacute;ria transesfenoidal na doen&ccedil;a de    Cushing. A taxa de r
emiss&atilde;o ap&oacute;s cirurgia transesfenoidal em 24    pacientes com doen&
ccedil;a de Cushing (18 microadenomas, 3 macroadenomas circunscritos    e 3 macr
oadenomas invasivos) operados por Jules Hardy nos primeiros quinze anos    de su
a experi&ecirc;ncia (1961-1976), relatada em sua primeira publica&ccedil;&atilde
;o    desses resultados (20), mostra uma taxa de remiss&atilde;o de 67% (16/24),
 sendo    72% (13/18) nos microadenomas, 100% (3/3) nos macroadenomas circunscri
tos e    0% (0/3) nos macroadenomas invasivos. Numa publica&ccedil;&atilde;o pos
terior    (21), com 75 pacientes (67 microadenomas, 4 macroadenomas circunscrito
s e 4    macroadenomas invasivos) operados entre 1963 e 1982, a taxa de remiss&a
tilde;o    foi 84% (63/75), sendo 88% (58/67) nos microadenomas, 100% (4/4) nos 
macroadenomas    circunscritos e 25% (1/4) nos macroadenomas invasivos.</font></
p>     ^cY#03.htm##
01517000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704129200072002000701364#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#150#146#article#252#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2">Em 1984, Charles    Wilson publicou uma 
revis&atilde;o sobre a primeira d&eacute;cada de sua experi&ecirc;ncia    em mic
rocirurgia hipofis&aacute;ria (22). Entre 1970 e 1982 foram operados,    por via
 transesfenoidal, 1.000 adenomas hipofis&aacute;rios, sendo 774 adenomas    func
ionantes. Entre estes, 96 eram adenomas secretores de ACTH e 77% (74/96)    fora
m considerados controlados pela cirurgia. Entre os microadenomas, a porcentagem 
   de controle foi 86% (63/73), enquanto nos macroadenomas foi 48% (11/23). Em  
  trabalhos publicados recentemente pelo mesmo grupo, as porcentagens de control
e    da doen&ccedil;a de Cushing s&atilde;o maiores. Em 2004 foi publicada uma s
&eacute;rie    (23) com os resultados cir&uacute;rgicos de 200 casos de doen&cce
dil;a de Cushing,    operados entre 1975 e 1998, sendo exclu&iacute;dos, portant
o, os cinco primeiros    anos de experi&ecirc;ncia. A porcentagem de controle ho
rmonal foi 85% (169/200).    Entre os microadenomas foi 86% (121/140), a mesma d
os primeiros 10 anos de experi&ecirc;ncia.    J&aacute; nos macroadenomas, a por
centagem aumentou para 80% (48/60), sendo    83% (43/52) nos macroadenomas circu
nscritos e 63% (5/8) nos macroadenomas invasivos.</font></p>     ^cY#03.htm##
00985000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704076000072002000700832#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#151#147#article#252#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2">Al&eacute;m da    experi&ecirc;ncia cir&
uacute;rgica, a identifica&ccedil;&atilde;o do adenoma    no pr&eacute;-operat&o
acute;rio e a extens&atilde;o do tumor s&atilde;o preditores    importantes do s
ucesso cir&uacute;rgico na doen&ccedil;a de Cushing (24,25).    Em nossa casu&ia
cute;stica, apenas um adenoma n&atilde;o foi identificado no    pr&eacute;-opera
t&oacute;rio e a porcentagem de macroadenomas (43%) foi maior    que a encontrad
a na literatura. Esses fatores, al&eacute;m da variabilidade    na escolha dos c
rit&eacute;rios para definir controle da doen&ccedil;a, podem    explicar a vari
a&ccedil;&atilde;o das porcentagens de controle entre os diversos    estudos.</f
ont></p>     ^cY#03.htm##
00721000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704049600072002000700568#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#152#148#article#252#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2">A t&eacute;cnica    cir&uacute;rgica emp
regada (microscopia ou endoscopia) n&atilde;o foi determinante    para o aumento
 dos &iacute;ndices de controle hormonal na nossa casu&iacute;stica.    Na maior
 s&eacute;rie publicada de pacientes com doen&ccedil;a de Cushing operados    ex
clusivamente com aux&iacute;lio endosc&oacute;pico, os &iacute;ndices de remiss&
atilde;o    foram semelhantes aos da literatura (26).</font></p>     ^cY#03.htm#
#
00327000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704010200072002000700174#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#153#149#article#252#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2"><b>Prolactinoma</b></font></p>     ^cY#0
3.htm##
01157000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704093200072002000701004#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#154#150#article#252#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2">Os adenomas hipofis&aacute;rios    secre
tores de prolactina (prolactinomas) s&atilde;o os tumores hipofis&aacute;rios   
 mais frequentes. A excelente resposta ao tratamento com agonistas dopamin&eacut
e;rgicos,    com normaliza&ccedil;&atilde;o da prolactina em cerca de 90% dos ca
sos e redu&ccedil;&atilde;o    do tumor em cerca de 60% (27), faz dessa modalida
de a primeira op&ccedil;&atilde;o    terap&ecirc;utica para esses tumores. A int
oler&acirc;ncia ou resist&ecirc;ncia    aos agonistas dopamin&eacute;rgicos cons
tituem as poucas indica&ccedil;&otilde;es    cir&uacute;rgicas para os prolactin
omas. Os resultados cir&uacute;rgicos nos    macroprolactinomas costumam ser ins
atisfat&oacute;rios. Em macroprolactinomas    invasivos, a cirurgia normaliza a 
prolactina em apenas 7%-50% dos casos (28,29)    e com elevada taxa de recorr&ec
irc;ncia.</font></p>     ^cY#03.htm##
01034000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704080900072002000700881#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#155#151#article#252#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2">Nesse estudo, obtivemos    melhora do co
ntrole hormonal em 40% dos casos, com normaliza&ccedil;&atilde;o    da prolactin
a com doses menores de bromocriptina daquelas usadas antes da cirurgia.    Esse 
crit&eacute;rio foi adotado porque todos os pacientes deste estudo retrospectivo
    permaneceram em uso de agonista dopamin&eacute;rgico no p&oacute;s-operat&oa
cute;rio.    Na acromegalia, alguns estudos sugerem que a remo&ccedil;&atilde;o 
incompleta    do tumor melhora a resposta aos an&aacute;logos da somatostatina (
30,31) e dados    preliminares sugerem que o mesmo acontece com macroprolactinom
as em rela&ccedil;&atilde;o    aos agonistas dopamin&eacute;rgicos (32). Nossos 
resultados corroboram essa    hip&oacute;tese.</font></p>     ^cY#03.htm##
00341000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704011600072002000700188#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#156#152#article#252#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2"><b>Adenoma secretor    de TSH</b></font>
</p>     ^cY#03.htm##
01160000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704093500072002000701007#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#157#153#article#252#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2">O adenoma hipofis&aacute;rio    secretor
 de TSH &eacute; uma patologia rara, correspondendo a 0,5% a 2% dos    tumores h
ipofis&aacute;rios. Nos &uacute;ltimos 20 anos, apenas cinco pacientes    portad
ores de adenoma hipofis&aacute;rio secretor de TSH (tirotropinoma) foram    acom
panhados no Ambulat&oacute;rio de Neuroendocrinologia de Unifesp (33), sendo    
todos macroadenomas. Entre esses, 4 foram diagnosticados e operados antes de    
2001 e nenhum deles foi controlado pela cirurgia. O &uacute;nico paciente portad
or    de um adenoma secretor de TSH operado durante o per&iacute;odo deste estud
o    apresentava um microadenoma que obteve controle hormonal pela cirurgia. Num
a    extensa revis&atilde;o da literatura publicada recentemente, dos 129 pacien
tes    compilados, apenas 33% apresentaram controle hormonal ap&oacute;s a cirur
gia    (34).</font></p>     ^cY#03.htm##
00349000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704012400072002000700196#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#158#154#article#252#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2"><b>T&eacute;cnica    cir&uacute;rgica</b
></font></p>     ^cY#03.htm##
02082000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704185700072002000701929#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#159#155#article#252#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2">O acesso endosc&oacute;pico    transnasa
l bilateral foi utilizado em 77% dos casos deste estudo. Nesta t&eacute;cnica,  
  o endosc&oacute;pio &eacute; colocado por uma fossa nasal e manipulado pelo   
 otorrinolaringologista durante todo o procedimento, enquanto os instrumentos   
 cir&uacute;rgicos, colocados pela outra fossa nasal, s&atilde;o manipulados    
pelo neurocirurgi&atilde;o. O uso do endosc&oacute;pio, al&eacute;m de facilitar
    o acesso por via transnasal, permite boa visibilidade da regi&atilde;o selar
    durante todo o procedimento. A explora&ccedil;&atilde;o da regi&atilde;o com
    endosc&oacute;pio, ap&oacute;s a remo&ccedil;&atilde;o do tumor, &eacute; ta
mb&eacute;m    de grande import&acirc;ncia, seja para identificar e remover rest
os tumorais,    seja para procurar e corrigir poss&iacute;veis les&otilde;es do 
diafragma selar    que podem causar f&iacute;stulas liqu&oacute;ricas. Esse proc
edimento explorat&oacute;rio    aumenta a possibilidade de encontrar e ressecar 
res&iacute;duos tumorais n&atilde;o    visualizados com microsc&oacute;pio cir&u
acute;rgico. No entanto, est&aacute;    associado &agrave; maior incid&ecirc;nci
a de f&iacute;stulas liqu&oacute;ricas    no intra-operat&oacute;rio (35,36). Po
r ser uma t&eacute;cnica nova, n&atilde;o    existem ainda evid&ecirc;ncias na l
iteratura de que a melhor visualiza&ccedil;&atilde;o    da regi&atilde;o selar p
elo endosc&oacute;pio resulte em maior chance de cura    cir&uacute;rgica, em co
mpara&ccedil;&atilde;o com a utiliza&ccedil;&atilde;o    do microsc&oacute;pio (
26,37). No presente estudo n&atilde;o houve diferen&ccedil;a    estat&iacute;sti
ca entre os resultados com essa t&eacute;cnica em rela&ccedil;&atilde;o    &agra
ve; cirurgia com aux&iacute;lio do microsc&oacute;pio.</font></p>     ^cY#03.htm
##
00341000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704011600072002000700188#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#160#156#article#252#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2"><b>Complica&ccedil;&otilde;es</b></font>
</p>     ^cY#03.htm##
01603000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704137800072002000701450#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#161#157#article#252#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2">A taxa de mortalidade    estimada na cir
urgia hipofis&aacute;ria por via transesfenoidal &eacute; cerca    de 1%, de aco
rdo com uma revis&atilde;o de 30 s&eacute;ries cir&uacute;rgicas    (38). Nenhum
 &oacute;bito peri-operat&oacute;rio ocorreu em nossa casu&iacute;stica.    A f&
iacute;stula liqu&oacute;rica p&oacute;s-operat&oacute;ria &eacute; uma    compl
ica&ccedil;&atilde;o indesejada, por prolongar o tempo de interna&ccedil;&atilde
;o    e aumentar o risco de meningite. Nesta casu&iacute;stica, 10% dos casos ev
olu&iacute;ram    com f&iacute;stula liqu&oacute;rica n&atilde;o complicada, sen
do todas em macroadenomas.    Nenhum caso teve indica&ccedil;&atilde;o de nova a
bordagem cir&uacute;rgica    ou meningite. A maioria dos autores relata &iacute;
ndices menores dessa complica&ccedil;&atilde;o,    abaixo de 5%. Esse fato pode 
ser explicado pela fase de aquisi&ccedil;&atilde;o    de experi&ecirc;ncia da eq
uipe cir&uacute;rgica. O sangramento nasal, presente    em 7% dos casos, tamb&ea
cute;m foi maior que o relatado na literatura, em torno    de 2%. Todos os casos
 ocorreram em macroadenomas secretores de GH e foram resolvidos    com medidas s
imples, como repouso e tamponamento nasal anterior, n&atilde;o    sendo necess&a
acute;ria reinterven&ccedil;&atilde;o cir&uacute;rgica.</font></p>     ^cY#03.ht
m##
01291000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704106600072002000701138#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#162#158#article#252#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2">O desenvolvimento    de nova defici&ecir
c;ncia hipofis&aacute;ria no p&oacute;s-operat&oacute;rio    &eacute; um crit&ea
cute;rio importante na defini&ccedil;&atilde;o de sucesso    cir&uacute;rgico. N
este estudo, todos os casos de diabetes ins&iacute;pido,    20% dos pacientes op
erados, foram transit&oacute;rios. A incid&ecirc;ncia de    diabetes ins&iacute;
pido permanente ap&oacute;s cirurgia transesfenoidal em    outras s&eacute;ries 
&eacute; 1% a 2% (37,38). Apesar da grande incid&ecirc;ncia    de macroadenomas 
invasivos, o desenvolvimento de nova defici&ecirc;ncia hormonal    adeno-hipofis
&aacute;ria aconteceu em apenas 9% dos casos, semelhante a outras    s&eacute;ri
es (13,39,40). Outra preocupa&ccedil;&atilde;o &eacute; a possibilidade    de pi
ora da perda visual por les&atilde;o do nervo &oacute;ptico durante o procedimen
to    cir&uacute;rgico. Nesta casu&iacute;stica, apenas um paciente (2,5%) apres
entou    piora discreta do campo visual ap&oacute;s a cirurgia.</font></p>     ^
cY#03.htm##
00343000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704011800072002000700190#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#163#159#article#252#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2"><b>Melhora visual    e hormonal</b></fon
t></p>     ^cY#03.htm##
00874000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704064900072002000700721#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#164#160#article#252#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2">O sucesso cir&uacute;rgico    deve consi
derar, al&eacute;m do controle da hiperfun&ccedil;&atilde;o hormonal,    a possi
bilidade de melhora de uma defici&ecirc;ncia hormonal ou perda visual    preexis
tente. Nesta s&eacute;rie, 45% dos pacientes com uma ou mais defici&ecirc;ncias 
   adeno-hipofis&aacute;rias no pr&eacute;-operat&oacute;rio (n = 11) recuperara
m    pelo menos uma dessas fun&ccedil;&otilde;es ap&oacute;s a cirurgia. Foram o
perados    cinco pacientes com perda visual. Destes, 3 recuperaram totalmente (6
0%) e 2,    parcialmente a vis&atilde;o (40%).</font></p>     ^cY#03.htm##
01017000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704079200072002000700864#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#165#161#article#252#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2">Em conclus&atilde;o,    nossos resultado
s iniciais da cirurgia transesfenoidal de adenomas hipofis&aacute;rios    secret
ores no controle hormonal refletem um per&iacute;odo de aquisi&ccedil;&atilde;o 
   de experi&ecirc;ncia. Os dados apresentados demonstram, na doen&ccedil;a de  
  Cushing, melhora progressiva dos n&iacute;veis de cortisol urin&aacute;rio no 
   p&oacute;s-operat&oacute;rio inicial nos primeiros cinco anos, com taxas de  
  complica&ccedil;&otilde;es relativamente baixas. Assim, &eacute; prov&aacute;v
el    que nos pr&oacute;ximos anos os &iacute;ndices de controle ser&atilde;o me
lhores    e compar&aacute;veis aos obtidos em centros especializados com maior t
empo de    experi&ecirc;ncia.</font></p>     ^cY#03.htm##
00431000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704020600072002000700278#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#166#162#article#252#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2">Declara&ccedil;&atilde;o:    os autores 
declaram n&atilde;o haver conflitos de interesse cient&iacute;fico    neste estu
do.</font></p>     ^cY#03.htm##
00247000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002200072002000700094#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#167#163#article#252#<p>&nbsp;</p>     ^cY#0
3.htm##
00332000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704010700072002000700179#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#168#164#article#252#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="3"><b>REFER&Ecirc;NCIAS</b></font></p>     
^cY#03.htm##
00434000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000200072704019500074002000700269#v55
n1#V:\SciELO\serial\abem\v55n1\markup\03.htm#S#p#169#165#article#252#1#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">1. Schloffer H.    Erfolgr
eiche operationen eines hypophysentumors auf nasalem wege. Wien Klin    Wochensc
hr. 1907;20:621-4.    ^cY#03.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#170#166#article#252#</font></p>     ^cY#03.
htm##
00421000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000200072704018200074002000700256#v55
n1#V:\SciELO\serial\abem\v55n1\markup\03.htm#S#p#171#167#article#252#2#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">2. Cushing H. The    Weir 
Mitchell lecture. Surgical experiences with pituitary adenoma. JAMA. 1914;63:151
5-25.    ^cY#03.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#172#168#article#252#</font></p>     ^cY#03.
htm##
00426000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000200072704018700074002000700261#v55
n1#V:\SciELO\serial\abem\v55n1\markup\03.htm#S#p#173#169#article#252#3#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">3. Hardy J. &#91;Excision 
   of pituitary adenomas by trans-sphenoidal approach&#93;. Union Med Can. 1962;
91:933-45.    ^cY#03.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#174#170#article#252#</font></p>     ^cY#03.
htm##
00495000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000200072704025600074002000700330#v55
n1#V:\SciELO\serial\abem\v55n1\markup\03.htm#S#p#175#171#article#252#4#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">4. Guiot G, Thibaut    B, 
Bourreau M. &#91;Extirpation of hypophyseal adenomas by trans-septal and    tran
s-sphenoidal approaches&#93;. Ann Otolaryngol Chir Cervicofac. 1959;76:1017-31. 
   ^cY#03.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#176#172#article#252#</font></p>     ^cY#03.
htm##
00490000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000200072704025100074002000700325#v55
n1#V:\SciELO\serial\abem\v55n1\markup\03.htm#S#p#177#173#article#252#5#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">5. Giustina A,    Barkan A
, Casanueva FF, Cavagnini F, Frohman L, Ho K, et al. Criteria for cure    of acr
omegaly: a consensus statement. J Clin Endocrinol Metab. 2000;85(2):526-9.    ^c
Y#03.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#178#174#article#252#</font></p>     ^cY#03.
htm##
00483000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000200072704024400074002000700318#v55
n1#V:\SciELO\serial\abem\v55n1\markup\03.htm#S#p#179#175#article#252#6#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">6. Tucker HS, Grubb    SR,
 Wigand JP, Watlington CO, Blackard WG, Becker DP. The treatment of acromegaly  
  by transsphenoidal surgery. Arch Intern Med. 1980;140(6):795-802.    ^cY#03.ht
m##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#180#176#article#252#</font></p>     ^cY#03.
htm##
00398000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000200072704015900074002000700233#v55
n1#V:\SciELO\serial\abem\v55n1\markup\03.htm#S#p#181#177#article#252#7#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">7. Holdaway IM,    Rajasoo
rya C. Epidemiology of acromegaly. Pituitary. 1999;2(1):29-41.    ^cY#03.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#182#178#article#252#</font></p>     ^cY#03.
htm##
00586000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000200072704034700074002000700421#v55
n1#V:\SciELO\serial\abem\v55n1\markup\03.htm#S#p#183#179#article#252#8#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">8. Ayuk J, Clayton    RN, 
Holder G, Sheppard MC, Stewart PM, Bates AS. Growth hormone and pituitary    rad
iotherapy, but not serum insulin-like growth factor-I concentrations, predict   
 excess mortality in patients with acromegaly. J Clin Endocrinol Metab. 2004;89(
4):1613-7.    ^cY#03.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#184#180#article#252#</font></p>     ^cY#03.
htm##
00610000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000200072704037100074002000700445#v55
n1#V:\SciELO\serial\abem\v55n1\markup\03.htm#S#p#185#181#article#252#9#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">9. Kaltsas GA,    Isidori 
AM, Florakis D, Trainer PJ, Camacho-Hubner C, Afshar F, et al. Predictors    of 
the outcome of surgical treatment in acromegaly and the value of the mean    gro
wth hormone day curve in assessing postoperative disease activity. J Clin    End
ocrinol Metab. 2001;86(4):1645-52.    ^cY#03.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#186#182#article#252#</font></p>     ^cY#03.
htm##
00486000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704024600075002000700321#v55
n1#V:\SciELO\serial\abem\v55n1\markup\03.htm#S#p#187#183#article#252#10#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">10. Beauregard    C, Truo
ng U, Hardy J, Serri O. Long-term outcome and mortality after transsphenoidal   
 adenomectomy for acromegaly. Clin Endocrinol (Oxf). 2003;58(1):86-91.    ^cY#03
.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#188#184#article#252#</font></p>     ^cY#03.
htm##
00585000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704034500075002000700420#v55
n1#V:\SciELO\serial\abem\v55n1\markup\03.htm#S#p#189#185#article#252#11#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">11. Costa AC, Rossi    A,
 Martinelli CE Jr, Machado HR, Moreira AC. Assessment of disease activity    in 
treated acromegalic patients using a sensitive GH assay: should we achieve    st
rict normal GH levels for a biochemical cure? J Clin Endocrinol Metab. 2002;87(7
):3142-7.    ^cY#03.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#190#186#article#252#</font></p>     ^cY#03.
htm##
00492000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704025200075002000700327#v55
n1#V:\SciELO\serial\abem\v55n1\markup\03.htm#S#p#191#187#article#252#12#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">12. Giustina A,    Chanso
n P, Bronstein MD, Klibanski A, Lamberts S, Casanueva FF, et al. A consensus    
on criteria for cure of acromegaly. J Clin Endocrinol Metab. 2010;95:3141-8.    
^cY#03.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#192#188#article#252#</font></p>     ^cY#03.
htm##
00573000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704033300075002000700408#v55
n1#V:\SciELO\serial\abem\v55n1\markup\03.htm#S#p#193#189#article#252#13#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">13. Boeving A,    Borba L
A, Rodrigues AM, Orichowski EB, Paz Filho GJ, Santos CM, et al. &#91;Outcome    
of surgical treatment for acromegaly performed by a single neurosurgeon and    c
umulative meta-analysis&#93;. Arq Bras Endocrinol Metabol. 2006;50(5):884-92.   
 ^cY#03.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#194#190#article#252#</font></p>     ^cY#03.
htm##
00481000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704024100075002000700316#v55
n1#V:\SciELO\serial\abem\v55n1\markup\03.htm#S#p#195#191#article#252#14#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">14. Gittoes NJ,    Sheppa
rd MC, Johnson AP, Stewart PM. Outcome of surgery for acromegaly&#151;the    exp
erience of a dedicated pituitary surgeon. QJM. 1999;92(12):741-5.    ^cY#03.htm#
#
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#196#192#article#252#</font></p>     ^cY#03.
htm##
00566000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704032600075002000700401#v55
n1#V:\SciELO\serial\abem\v55n1\markup\03.htm#S#p#197#193#article#252#15#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">15. Lissett CA,    Peacey
 SR, Laing I, Tetlow L, Davis JR, Shalet SM. The outcome of surgery for    acrom
egaly: the need for a specialist pituitary surgeon for all types of growth    ho
rmone (GH) secreting adenoma. Clin Endocrinol (Oxf). 1998;49(5):653-7.    ^cY#03
.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#198#194#article#252#</font></p>     ^cY#03.
htm##
00512000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704027200075002000700347#v55
n1#V:\SciELO\serial\abem\v55n1\markup\03.htm#S#p#199#195#article#252#16#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">16. Erturk E, Tuncel    E
, Kiyici S, Ersoy C, Duran C, Imamoglu S. Outcome of surgery for acromegaly    p
erformed by different surgeons: importance of surgical experience. Pituitary.   
 2005;8(2):93-7.    ^cY#03.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#200#196#article#252#</font></p>     ^cY#03.
htm##
00520000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704028000075002000700355#v55
n1#V:\SciELO\serial\abem\v55n1\markup\03.htm#S#p#201#197#article#252#17#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">17. Ahmed S, Elsheikh    
M, Stratton IM, Page RC, Adams CB, Wass JA. Outcome of transphenoidal surgery   
 for acromegaly and its relationship to surgical experience. Clin Endocrinol    
(Oxf). 1999;50(5):561-7.    ^cY#03.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#202#198#article#252#</font></p>     ^cY#03.
htm##
00491000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704025100075002000700326#v55
n1#V:\SciELO\serial\abem\v55n1\markup\03.htm#S#p#203#199#article#252#18#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">18. Sonino N, Boscaro    
M, Paoletta A, Mantero F, Ziliotto D. Ketoconazole treatment in Cushing's syndro
me:    experience in 34 patients. Clin Endocrinol (Oxf). 1991;35(4):347-52.    ^
cY#03.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#204#200#article#252#</font></p>     ^cY#03.
htm##
00583000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704034300075002000700418#v55
n1#V:\SciELO\serial\abem\v55n1\markup\03.htm#S#p#205#201#article#252#19#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">19. Bochicchio    D, Losa
 M, Buchfelder M. Factors influencing the immediate and late outcome    of Cushi
ng's disease treated by transsphenoidal surgery: a retrospective study    by the
 European Cushing's Disease Survey Group. J Clin Endocrinol Metab. 1995;80(11):3
114-20.    ^cY#03.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#206#202#article#252#</font></p>     ^cY#03.
htm##
00509000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704026900075002000700344#v55
n1#V:\SciELO\serial\abem\v55n1\markup\03.htm#S#p#207#203#article#252#20#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">20. Bigos ST, Somma    M,
 Rasio E, Eastman RC, Lanthier A, Johnston HH, et al. Cushing's disease: managem
ent    by transsphenoidal pituitary microsurgery. J Clin Endocrinol Metab. 1980;
50(2):348-54.    ^cY#03.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#208#204#article#252#</font></p>     ^cY#03.
htm##
00471000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704023100075002000700306#v55
n1#V:\SciELO\serial\abem\v55n1\markup\03.htm#S#p#209#205#article#252#21#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">21. Hardy J. Presidential
    address: XVII Canadian Congress of Neurological Sciences. Cushing's disease:
    50 years later. Can J Neurol Sci. 1982;9(4):375-80.    ^cY#03.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#210#206#article#252#</font></p>     ^cY#03.
htm##
00431000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704019100075002000700266#v55
n1#V:\SciELO\serial\abem\v55n1\markup\03.htm#S#p#211#207#article#252#22#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">22. Wilson CB.    A decad
e of pituitary microsurgery. The Herbert Olivecrona lecture. J Neurosurg.    198
4;61(5):814-33.    ^cY#03.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#212#208#article#252#</font></p>     ^cY#03.
htm##
00537000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704029700075002000700372#v55
n1#V:\SciELO\serial\abem\v55n1\markup\03.htm#S#p#213#209#article#252#23#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">23. Hammer GD,    Tyrrell
 JB, Lamborn KR, Applebury CB, Hannegan ET, Bell S, et al. Transsphenoidal    mi
crosurgery for Cushing's disease: initial outcome and long-term results. J    Cl
in Endocrinol Metab. 2004;89(12):6348-57.    ^cY#03.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#214#210#article#252#</font></p>     ^cY#03.
htm##
00523000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704028300075002000700358#v55
n1#V:\SciELO\serial\abem\v55n1\markup\03.htm#S#p#215#211#article#252#24#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">24. Hoybye C, Grenback   
 E, Thoren M, Hulting AL, Lundblad L, von Holst H, et al. Transsphenoidal surger
y    in Cushing disease: 10 years of experience in 34 consecutive cases. J Neuro
surg.    2004;100(4):634-8.    ^cY#03.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#216#212#article#252#</font></p>     ^cY#03.
htm##
00424000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704018400075002000700259#v55
n1#V:\SciELO\serial\abem\v55n1\markup\03.htm#S#p#217#213#article#252#25#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">25. Newell-Price    J, Gr
ossman A. Diagnosis and management of Cushing's syndrome. Lancet. 1999;353(9170)
:2087-8.    ^cY#03.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#218#214#article#252#</font></p>     ^cY#03.
htm##
00574000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704033400075002000700409#v55
n1#V:\SciELO\serial\abem\v55n1\markup\03.htm#S#p#219#215#article#252#26#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">26. Netea-Maier    RT, va
n Lindert EJ, den Heijer M, van der Eerden A, Pieters GF, Sweep CG, et    al. Tr
anssphenoidal pituitary surgery via the endoscopic technique: results    in 35 c
onsecutive patients with Cushing's disease. Eur J Endocrinol. 2006;154:675-84.  
  ^cY#03.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#220#216#article#252#</font></p>     ^cY#03.
htm##
00535000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704029500075002000700370#v55
n1#V:\SciELO\serial\abem\v55n1\markup\03.htm#S#p#221#217#article#252#27#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">27. Colao A, Di    Sarno 
R, Sarnacchiaro F, Ferone D, Di Renzo G, Merola B, et al. Prolactinomas    resis
tant to standart dopamin agonists respond to chronic cabergoline treatment.    J
 Clin Endocrinol Metab. 1997;82:876-83.    ^cY#03.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#222#218#article#252#</font></p>     ^cY#03.
htm##
00410000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704017000075002000700245#v55
n1#V:\SciELO\serial\abem\v55n1\markup\03.htm#S#p#223#219#article#252#28#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">28. Molitch ME.    Medica
l treatment of prolactinomas. Endocrinol Metab Clin North Am. 1999;28:143.    ^c
Y#03.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#224#220#article#252#</font></p>     ^cY#03.
htm##
00459000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704021900075002000700294#v55
n1#V:\SciELO\serial\abem\v55n1\markup\03.htm#S#p#225#221#article#252#29#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">29. Gukalp HZ,    Deda H,
 Attar A, Uur HC, Arasil E, Egemen N. The neurosurgical management of    prolact
inomas. J Neurosurg Sci. 2000;44(3):128-32.    ^cY#03.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#226#222#article#252#</font></p>     ^cY#03.
htm##
00604000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704036400075002000700439#v55
n1#V:\SciELO\serial\abem\v55n1\markup\03.htm#S#p#227#223#article#252#30#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">30. Colao A, Attanasio   
 R, Pivonello R, Cappabianca P, Cavallo LM, Lasio G, et al. Partial surgical    
removal of growth hormone-secreting pituitary tumors enhances the response to   
 somatostatin analogs in acromegaly. J Clin Endocrinol Metab. 2006;91(1):85-92. 
   Epub 2005 Nov</font></p>     ^cY#03.htm##
00560000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704032000075002000700395#v55
n1#V:\SciELO\serial\abem\v55n1\markup\03.htm#S#p#228#224#article#252#31#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">31. Karavitaki    N, Turn
er HE, Adams CB, Cudlip S, Byrne JV, Fazal-Sanderson V, et al. Surgical    debul
king of pituitary macroadenomas causing acromegaly improves control by    lanreo
tide. Clin Endocrinol (Oxf). 2008;68(6):970-5. Epub 2007 Nov 19.    ^cY#03.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#229#225#article#252#</font></p>     ^cY#03.
htm##
00531000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704029100075002000700366#v55
n1#V:\SciELO\serial\abem\v55n1\markup\03.htm#S#p#230#226#article#252#32#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">32. Iguchi D, Glezer    A
, Cescato VAS, et al. Does partial surgery removal of macroprolactinomas improve
    their response to dopamine agonists treatment? The Endocrine Society, 90th A
nnual    Meeting, 2008. OR27-1;111.    ^cY#03.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#231#227#article#252#</font></p>     ^cY#03.
htm##
00483000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704024300075002000700318#v55
n1#V:\SciELO\serial\abem\v55n1\markup\03.htm#S#p#232#228#article#252#33#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">33. Barbosa ER,    Olivei
ra JHA, Abucham J. Adenomas hipofis&aacute;rios secretores de TSH: revis&atilde;
o    de casu&iacute;stica. Arq Bras Endocrinol Metab. 2005;49:S105.    ^cY#03.ht
m##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#233#229#article#252#</font></p>     ^cY#03.
htm##
00437000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704019700075002000700272#v55
n1#V:\SciELO\serial\abem\v55n1\markup\03.htm#S#p#234#230#article#252#34#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">34. Beck-Peccoz    P, Per
sani L. Medical management of thyrotropin-secreting pituitary adenomas.    Pitui
tary. 2002;5(2):83-8.    ^cY#03.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#235#231#article#252#</font></p>     ^cY#03.
htm##
00578000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704033800075002000700413#v55
n1#V:\SciELO\serial\abem\v55n1\markup\03.htm#S#p#236#232#article#252#35#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">35. Baussart B,    Aghakh
ani N, Portier F, Chanson P, Tadie M, Parker F. &#91;Endoscope-assisted    micro
surgery for invasive endo- and suprasellar pituitary macroadenomas: a consecutiv
e    retrospective study with 13 patients&#93;. Neurochirurgie. 2005;51(5):455-6
3.    ^cY#03.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#237#233#article#252#</font></p>     ^cY#03.
htm##
00484000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704024400075002000700319#v55
n1#V:\SciELO\serial\abem\v55n1\markup\03.htm#S#p#238#234#article#252#36#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">36. Santos R, Zymberg    
S, Abucham J, Greg&oacute;rio L, Weckx L. Acesso endosc&oacute;pico transnasal  
  aos tumores selares. Rev Bras Otorrinolaringol. 2007;73(4):463-75.    ^cY#03.h
tm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#239#235#article#252#</font></p>     ^cY#03.
htm##
00487000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704024700075002000700322#v55
n1#V:\SciELO\serial\abem\v55n1\markup\03.htm#S#p#240#236#article#252#37#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">37. Yang I, Wang    MB, B
ergsneider M. Making the transition from neurosurgery to endoscopic trans-spheno
idal    pituitary neurosurgery. Neurosurg Clin N Am. 2010;21(4):643-51.    ^cY#0
3.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#241#237#article#252#</font></p>     ^cY#03.
htm##
00409000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704016900075002000700244#v55
n1#V:\SciELO\serial\abem\v55n1\markup\03.htm#S#p#242#238#article#252#38#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">38. Laws ER Jr,    Thapar
 K. Pituitary surgery. Endocrinol Metab Clin North Am. 1999;28(1):119-31.    ^cY
#03.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#243#239#article#252#</font></p>     ^cY#03.
htm##
00462000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704022200075002000700297#v55
n1#V:\SciELO\serial\abem\v55n1\markup\03.htm#S#p#244#240#article#252#39#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">39. Nomikos P,    Fahlbus
ch R, Buchfelder M. Recent developments in transsphenoidal surgery of    pituita
ry tumors. Hormones (Athens). 2004;3(2):85-91.    ^cY#03.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#245#241#article#252#</font></p>     ^cY#03.
htm##
00530000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704029000075002000700365#v55
n1#V:\SciELO\serial\abem\v55n1\markup\03.htm#S#p#246#242#article#252#40#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">40. Sheaves R,    Jenkins
 P, Blackburn P, Huneidi AH, Afshar F, Medbak S, et al. Outcome of transsphenoid
al    surgery for acromegaly using strict criteria for surgical cure. Clin Endoc
rinol    (Oxf). 1996;45(4):407-13.    ^cY#03.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#247#243#article#252#</font></p>     ^cY#03.
htm##
00247000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002200072002000700094#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#248#244#article#252#<p>&nbsp;</p>     ^cY#0
3.htm##
00247000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002200072002000700094#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#249#245#article#252#<p>&nbsp;</p>     ^cY#0
3.htm##
00424000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704019900072002000700271#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#250#246#article#252#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2"><b><a name="back"></a><a href="#top"><im
g src="/img/revistas/abem/v55n1/seta.jpg" border="0"></a>    Correspond&ecirc;nc
ia para:    ^cY#03.htm##
00258000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704003300072002000700105#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#251#247#article#252#<br>   </b> Julio Abuch
am    ^cY#03.htm##
00264000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704003900072002000700111#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#252#248#article#252#<br>   Rua Pedro de Tol
edo, 910    ^cY#03.htm##
00280000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704005500072002000700127#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#253#249#article#252#<br>   04039-002 - S&at
ilde;o Paulo, SP, Brasil    ^cY#03.htm##
00320000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704009500072002000700167#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#254#250#article#252#<br>   <a href="mailto:
julioabucham@uol.com.br">julioabucham@uol.com.br</a></font></p>     ^cY#03.htm##
00318000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704009300072002000700165#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#255#251#article#252#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2">Recebido em 10/08/2010    ^cY#03.htm##
00272000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704004700072002000700119#v55n1#V:\SciELO
\serial\abem\v55n1\markup\03.htm#S#p#256#252#article#252#<br>   Aceito em 16/11/
2010</font></p>     ^cY#03.htm##
00516000000000265000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100019000710120069000900300
02100159065000900180064000500189031000300194014000600197865000900203002000700212
035001000219801002100229#v55n1#V:\SciELO\serial\abem\v55n1\markup\03.htm#S#c#257
#1#article#40#1#^rND^sSchloffer^nH#Erfolgreiche operationen eines hypophysentumo
rs auf nasalem wege^len#Wien Klin Wochenschr#19070000#1907#20#621-4#20110200#03.
htm#0043-5325#Wien Klin Wochenschr##
00490000000000265000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100017000710120075000880300
00500163065000900168064000500177031000300182014000800185865000900193002000700202
035001000209801000500219#v55n1#V:\SciELO\serial\abem\v55n1\markup\03.htm#S#c#258
#2#article#40#2#^rND^sCushing^nH#The Weir Mitchell lecture: Surgical experiences
 with pituitary adenoma^len#JAMA#19140000#1914#63#1515-25#20110200#03.htm#0098-7
484#JAMA##
00494000000000265000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100015000710120064000860300
01400150065000900164064000500173031000300178014000700181865000900188002000700197
035001000204801001400214#v55n1#V:\SciELO\serial\abem\v55n1\markup\03.htm#S#c#259
#3#article#40#3#^rND^sHardy^nJ#Excision of pituitary adenomas by trans-sphenoida
l approach^len#Union Med Can#19620000#1962#91#933-45#20110200#03.htm#0041-6959#U
nion Med Can##
00614000000000289000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100015000710100017000860100
01800103012008800121030003200209065000900241064000500250031000300255014000800258
865000900266002000700275035001000282801003200292#v55n1#V:\SciELO\serial\abem\v55
n1\markup\03.htm#S#c#260#4#article#40#4#^rND^sGuiot^nG#^rND^sThibaut^nB#^rND^sBo
urreau^nM#Extirpation of hypophyseal adenomas by trans-septal and trans-sphenoid
al approaches^len#Ann Otolaryngol Chir Cervicofac#19590000#1959#76#1017-31#20110
200#03.htm#0003-438X#Ann Otolaryngol Chir Cervicofac##
00687000000000349000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100018000710100016000890100
02000105010001900125010001700144010001200161810000600173012005900179030002400238
06500090026206400050027103100030027603200020027901400060028186500090028700200070
0296035001000303801002400313#v55n1#V:\SciELO\serial\abem\v55n1\markup\03.htm#S#c
#261#5#article#40#5#^rND^sGiustina^nA#^rND^sBarkan^nA#^rND^sCasanueva^nFF#^rND^s
Cavagnini^nF#^rND^sFrohman^nL#^rND^sHo^nK#et al#Criteria for cure of acromegaly:
 a consensus statement^len#J Clin Endocrinol Metab#20000000#2000#85#2#526-9#2011
0200#03.htm#0021-972X#J Clin Endocrinol Metab##
00661000000000337000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100017000710100016000880100
01700104010002100121010001900142010001700161012005900178030001600237065000900253
06400050026203100040026703200020027101400080027386500090028100200070029003500100
0297801001600307#v55n1#V:\SciELO\serial\abem\v55n1\markup\03.htm#S#c#262#6#artic
le#40#6#^rND^sTucker^nHS#^rND^sGrubb^nSR#^rND^sWigand^nJP#^rND^sWatlington^nCO#^
rND^sBlackard^nWG#^rND^sBecker^nDP#The treatment of acromegaly by transsphenoida
l surgery^len#Arch Intern Med#19800000#1980#140#6#795-802#20110200#03.htm#0003-9
926#Arch Intern Med##
00501000000000289000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100019000710100020000900120
03100110030001000141065000900151064000500160031000200165032000200167014000600169
865000900175002000700184035001000191801001000201#v55n1#V:\SciELO\serial\abem\v55
n1\markup\03.htm#S#c#263#7#article#40#7#^rND^sHoldaway^nIM#^rND^sRajasoorya^nC#E
pidemiology of acromegaly^len#Pituitary#19990000#1999#2#1#29-41#20110200#03.htm#
1386-341X#PITUITARY##
00769000000000337000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100014000710100018000850100
01600103010001900119010001800138010001600156012015900172030002400331065000900355
06400050036403100030036903200020037201400070037486500090038100200070039003500100
0397801002400407#v55n1#V:\SciELO\serial\abem\v55n1\markup\03.htm#S#c#264#8#artic
le#40#8#^rND^sAyuk^nJ#^rND^sClayton^nRN#^rND^sHolder^nG#^rND^sSheppard^nMC#^rND^
sStewart^nPM#^rND^sBates^nAS#Growth hormone and pituitary radiotherapy, but not 
serum insulin-like growth factor-I concentrations, predict excess mortality in p
atients with acromegaly^len#J Clin Endocrinol Metab#20040000#2004#89#4#1613-7#20
110200#03.htm#0021-972X#J Clin Endocrinol Metab##
00801000000000349000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100018000710100018000890100
01800107010001800125010002400143010001600167810000600183012016100189030002400350
06500090037406400050038303100030038803200020039101400080039386500090040100200070
0410035001000417801002400427#v55n1#V:\SciELO\serial\abem\v55n1\markup\03.htm#S#c
#265#9#article#40#9#^rND^sKaltsas^nGA#^rND^sIsidori^nAM#^rND^sFlorakis^nD#^rND^s
Trainer^nPJ#^rND^sCamacho-Hubner^nC#^rND^sAfshar^nF#et al#Predictors of the outc
ome of surgical treatment in acromegaly and the value of the mean growth hormone
 day curve in assessing postoperative disease activity^len#J Clin Endocrinol Met
ab#20010000#2001#86#4#1645-52#20110200#03.htm#0021-972X#J Clin Endocrinol Metab#
#
00602000000000313000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100020000730100016000930100
01500109010001500124012008600139030001600225710000200241066000400243065000900247
064000500256031000300261032000200264014000600266865000900272002000700281#v55n1#V
:\SciELO\serial\abem\v55n1\markup\03.htm#S#c#266#10#article#40#10#^rND^sBeaurega
rd^nC#^rND^sTruong^nU#^rND^sHardy^nJ#^rND^sSerri^nO#Long-term outcome and mortal
ity after transsphenoidal adenomectomy for acromegaly^len#Clin Endocrinol#2#Oxf#
20030000#2003#58#1#86-91#20110200#03.htm##
00751000000000325000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730100015000890100
02400104010001800128010001800146012016100164030002400325065000900349064000500358
03100030036303200020036601400070036886500090037500200070038403500100039180100240
0401#v55n1#V:\SciELO\serial\abem\v55n1\markup\03.htm#S#c#267#11#article#40#11#^r
ND^sCosta^nAC#^rND^sRossi^nA#^rND^sMartinelli^nCE Jr#^rND^sMachado^nHR#^rND^sMor
eira^nAC#Assessment of disease activity in treated acromegalic patients using a 
sensitive GH assay: should we achieve strict normal GH levels for a biochemical 
cure?^len#J Clin Endocrinol Metab#20020000#2002#87#7#3142-7#20110200#03.htm#0021
-972X#J Clin Endocrinol Metab##
00678000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100018000730100017000910100
02000108010001900128010001800147010002000165810000600185012005100191030002400242
06500090026606400050027503100030028001400070028386500090029000200070029903500100
0306801002400316#v55n1#V:\SciELO\serial\abem\v55n1\markup\03.htm#S#c#268#12#arti
cle#40#12#^rND^sGiustina^nA#^rND^sChanson^nP#^rND^sBronstein^nMD#^rND^sKlibanski
^nA#^rND^sLamberts^nS#^rND^sCasanueva^nFF#et al#A consensus on criteria for cure
 of acromegaly^len#J Clin Endocrinol Metab#20100000#2010#95#3141-8#20110200#03.h
tm#0021-972X#J Clin Endocrinol Metab##
00761000000000349000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730100016000900100
02000106010002100126010002000147010001700167810000600184012011300190030002800303
06500090033106400050034003100030034503200020034801400070035086500090035700200070
0366035001000373801002800383#v55n1#V:\SciELO\serial\abem\v55n1\markup\03.htm#S#c
#269#13#article#40#13#^rND^sBoeving^nA#^rND^sBorba^nLA#^rND^sRodrigues^nAM#^rND^
sOrichowski^nEB#^rND^sPaz Filho^nGJ#^rND^sSantos^nCM#et al#Outcome of surgical t
reatment for acromegaly performed by a single neurosurgeon and cumulative meta-a
nalysis^len#Arq Bras Endocrinol Metabol#20060000#2006#50#5#884-92#20110200#03.ht
m#0004-2730#Arq Bras Endocrinol Metabol##
00606000000000313000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100018000730100019000910100
01800110010001800128012008600146030000400232065000900236064000500245031000300250
032000300253014000600256865000900262002000700271035001000278801000400288#v55n1#V
:\SciELO\serial\abem\v55n1\markup\03.htm#S#c#270#14#article#40#14#^rND^sGittoes^
nNJ#^rND^sSheppard^nMC#^rND^sJohnson^nAP#^rND^sStewart^nPM#Outcome of surgery fo
r acromegaly-the experience of a dedicated pituitary surgeon^len#QJM#19990000#19
99#92#12#741-5#20110200#03.htm#0033-5622#QJM##
00715000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100018000730100017000910100
01500108010001600123010001600139010001700155012014200172030001600314710000200330
06600040033206500090033606400050034503100030035003200020035301400060035586500090
0361002000700370#v55n1#V:\SciELO\serial\abem\v55n1\markup\03.htm#S#c#271#15#arti
cle#40#15#^rND^sLissett^nCA#^rND^sPeacey^nSR#^rND^sLaing^nI#^rND^sTetlow^nL#^rND
^sDavis^nJR#^rND^sShalet^nSM#The outcome of surgery for acromegaly: the need for
 a specialist pituitary surgeon for all types of growth hormone (GH) secreting a
denoma^len#Clin Endocrinol#2#Oxf#19980000#1998#49#5#653-7#20110200#03.htm##
00681000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730100016000890100
01600105010001500121010001500136010001800151012010500169030001000274065000900284
06400050029303100020029803200020030001400050030286500090030700200070031603500100
0323801001000333#v55n1#V:\SciELO\serial\abem\v55n1\markup\03.htm#S#c#272#16#arti
cle#40#16#^rND^sErturk^nE#^rND^sTuncel^nE#^rND^sKiyici^nS#^rND^sErsoy^nC#^rND^sD
uran^nC#^rND^sImamoglu^nS#Outcome of surgery for acromegaly performed by differe
nt surgeons: importance of surgical experience^len#Pituitary#20050000#2005#8#2#9
3-7#20110200#03.htm#1386-341X#PITUITARY##
00669000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100015000730100018000880100
01900106010001500125010001600140010001500156012009700171030001600268710000200284
06600040028606500090029006400050029903100030030403200020030701400060030986500090
0315002000700324#v55n1#V:\SciELO\serial\abem\v55n1\markup\03.htm#S#c#273#17#arti
cle#40#17#^rND^sAhmed^nS#^rND^sElsheikh^nM#^rND^sStratton^nIM#^rND^sPage^nRC#^rN
D^sAdams^nCB#^rND^sWass^nJA#Outcome of transphenoidal surgery for acromegaly and
 its relationship to surgical experience^len#Clin Endocrinol#2#Oxf#19990000#1999
#50#5#561-7#20110200#03.htm##
00625000000000325000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730100017000890100
01800106010001700124010001800141012007600159030001600235710000200251066000400253
06500090025706400050026603100030027103200020027401400070027686500090028300200070
0292#v55n1#V:\SciELO\serial\abem\v55n1\markup\03.htm#S#c#274#18#article#40#18#^r
ND^sSonino^nN#^rND^sBoscaro^nM#^rND^sPaoletta^nA#^rND^sMantero^nF#^rND^sZiliotto
^nD#Ketoconazole treatment in Cushing's syndrome: experience in 34 patients^len#
Clin Endocrinol#2#Oxf#19910000#1991#35#4#347-52#20110200#03.htm##
00712000000000301000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100020000730100014000930100
02000107012018100127030002400308065000900332064000500341031000300346032000300349
014000800352865000900360002000700369035001000376801002400386#v55n1#V:\SciELO\ser
ial\abem\v55n1\markup\03.htm#S#c#275#19#article#40#19#^rND^sBochicchio^nD#^rND^s
Losa^nM#^rND^sBuchfelder^nM#Factors influencing the immediate and late outcome o
f Cushing's disease treated by transsphenoidal surgery: a retrospective study by
 the European Cushing's Disease Survey Group^len#J Clin Endocrinol Metab#1995000
0#1995#80#11#3114-20#20110200#03.htm#0021-972X#J Clin Endocrinol Metab##
00706000000000349000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730100015000890100
01500104010001800119010001800137010001900155810000600174012007600180030002400256
06500090028006400050028903100030029403200020029701400070029986500090030600200070
0315035001000322801002400332#v55n1#V:\SciELO\serial\abem\v55n1\markup\03.htm#S#c
#276#20#article#40#20#^rND^sBigos^nST#^rND^sSomma^nM#^rND^sRasio^nE#^rND^sEastma
n^nRC#^rND^sLanthier^nA#^rND^sJohnston^nHH#et al#Cushing's disease: management b
y transsphenoidal pituitary microsurgery^len#J Clin Endocrinol Metab#19800000#19
80#50#2#348-54#20110200#03.htm#0021-972X#J Clin Endocrinol Metab##
00560000000000277000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100015000730120109000880300
01700197065000900214064000500223031000200228032000200230014000700232865000900239
002000700248035001000255801001700265#v55n1#V:\SciELO\serial\abem\v55n1\markup\03
.htm#S#c#277#21#article#40#21#^rND^sHardy^nJ#Presidential address: XVII Canadian
 Congress of Neurological Sciences. Cushing's disease: 50 years later^len#Can J 
Neurol Sci#19820000#1982#9#4#375-80#20110200#03.htm#0317-1671#Can J Neurol Sci##
00515000000000277000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730120071000900300
01200161065000900173064000500182031000300187032000200190014000700192865000900199
002000700208035001000215801001200225#v55n1#V:\SciELO\serial\abem\v55n1\markup\03
.htm#S#c#278#22#article#40#22#^rND^sWilson^nCB#A decade of pituitary microsurger
y: The Herbert Olivecrona lecture^len#J Neurosurg#19840000#1984#61#5#814-33#2011
0200#03.htm#0022-3085#J Neurosurg##
00731000000000349000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730100018000900100
01800108010002000126010001900146010001400165810000600179012009400185030002400279
06500090030306400050031203100030031703200030032001400080032386500090033100200070
0340035001000347801002400357#v55n1#V:\SciELO\serial\abem\v55n1\markup\03.htm#S#c
#279#23#article#40#23#^rND^sHammer^nGD#^rND^sTyrrell^nJB#^rND^sLamborn^nKR#^rND^
sApplebury^nCB#^rND^sHannegan^nET#^rND^sBell^nS#et al#Transsphenoidal microsurge
ry for Cushing's disease: initial outcome and long-term results^len#J Clin Endoc
rinol Metab#20040000#2004#89#12#6348-57#20110200#03.htm#0021-972X#J Clin Endocri
nol Metab##
00705000000000349000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730100018000890100
01600107010001800123010001800141010001900159810000600178012009500184030001200279
06500090029106400050030003100040030503200020030901400060031186500090031700200070
0326035001000333801001200343#v55n1#V:\SciELO\serial\abem\v55n1\markup\03.htm#S#c
#280#24#article#40#24#^rND^sHoybye^nC#^rND^sGrenback^nE#^rND^sThoren^nM#^rND^sHu
lting^nAL#^rND^sLundblad^nL#^rND^svon Holst^nH#et al#Transsphenoidal surgery in 
Cushing disease: 10 years of experience in 34 consecutive cases^len#J Neurosurg#
20040000#2004#100#4#634-8#20110200#03.htm#0022-3085#J Neurosurg##
00524000000000289000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100022000730100018000950120
05100113030000700164065000900171064000500180031000400185032000500189014000700194
865000900201002000700210035001000217801000700227#v55n1#V:\SciELO\serial\abem\v55
n1\markup\03.htm#S#c#281#25#article#40#25#^rND^sNewell-Price^nJ#^rND^sGrossman^n
A#Diagnosis and management of Cushing's syndrome^len#Lancet#19990000#1999#353#91
70#2087-8#20110200#03.htm#0099-5355#Lancet##
00750000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100022000730100022000950100
02000117010002400137010001800161010001600179810000600195012012600201030001700327
06500090034406400050035303100040035801400070036286500090036900200070037803500100
0385801001700395#v55n1#V:\SciELO\serial\abem\v55n1\markup\03.htm#S#c#282#26#arti
cle#40#26#^rND^sNetea-Maier^nRT#^rND^svan Lindert^nEJ#^rND^sden Heijer^nM#^rND^s
van der Eerden^nA#^rND^sPieters^nGF#^rND^sSweep^nCG#et al#Transsphenoidal pituit
ary surgery via the endoscopic technique: results in 35 consecutive patients wit
h Cushing's disease^len#Eur J Endocrinol#20060000#2006#154#675-84#20110200#03.ht
m#0804-4643#Eur J Endocrinol##
00718000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100015000730100018000880100
02200106010001600128010001800144010001600162810000600178012009800184030002400282
06500090030606400050031503100030032001400070032386500090033000200070033903500100
0346801002400356#v55n1#V:\SciELO\serial\abem\v55n1\markup\03.htm#S#c#283#27#arti
cle#40#27#^rND^sColao^nA#^rND^sDi Sarno^nR#^rND^sSarnacchiaro^nF#^rND^sFerone^nD
#^rND^sDi Renzo^nG#^rND^sMerola^nB#et al#Prolactinomas resistant to standart dop
amin agonists respond to chronic cabergoline treatment^len#J Clin Endocrinol Met
ab#19970000#1997#82#876-83#20110200#03.htm#0021-972X#J Clin Endocrinol Metab##
00505000000000265000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100018000730120039000910300
03100130065000900161064000500170031000300175014000400178865000900182002000700191
035001000198801003100208#v55n1#V:\SciELO\serial\abem\v55n1\markup\03.htm#S#c#284
#28#article#40#28#^rND^sMolitch^nME#Medical treatment of prolactinomas^len#Endoc
rinol Metab Clin North Am#19990000#1999#28#143#20110200#03.htm#0889-8529#Endocri
nol Metab Clin North Am##
00637000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730100014000900100
01500104010001400119010001600133010001600149012005000165030001600215065000900231
06400050024003100030024503200020024801400070025086500090025700200070026603500100
0273801001600283#v55n1#V:\SciELO\serial\abem\v55n1\markup\03.htm#S#c#285#29#arti
cle#40#29#^rND^sGukalp^nHZ#^rND^sDeda^nH#^rND^sAttar^nA#^rND^sUur^nHC#^rND^sAras
il^nE#^rND^sEgemen^nN#The neurosurgical management of prolactinomas^len#J Neuros
urg Sci#20000000#2000#44#3#128-32#20110200#03.htm#0390-5616#J Neurosurg Sci##
00769000000000349000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100015000730100019000880100
01900107010002100126010001800147010001500165810000600180012013400186030002400320
06500090034406400050035303100030035803200020036101400060036386500090036900200070
0378035001000385801002400395#v55n1#V:\SciELO\serial\abem\v55n1\markup\03.htm#S#c
#286#30#article#40#30#^rND^sColao^nA#^rND^sAttanasio^nR#^rND^sPivonello^nR#^rND^
sCappabianca^nP#^rND^sCavallo^nLM#^rND^sLasio^nG#et al#Partial surgical removal 
of growth hormone-secreting pituitary tumors enhances the response to somatostat
in analogs in acromegaly^len#J Clin Endocrinol Metab#20060000#2006#91#1#85-92#20
110200#03.htm#0021-972X#J Clin Endocrinol Metab##
00702000000000349000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100020000730100017000930100
01600110010001600126010001600142010002500158810000600183012010000189030001600289
71000020030506600040030706500090031106400050032003100030032503200020032801400060
0330865000900336002000700345#v55n1#V:\SciELO\serial\abem\v55n1\markup\03.htm#S#c
#287#31#article#40#31#^rND^sKaravitaki^nN#^rND^sTurner^nHE#^rND^sAdams^nCB#^rND^
sCudlip^nS#^rND^sByrne^nJV#^rND^sFazal-Sanderson^nV#et al#Surgical debulking of 
pituitary macroadenomas causing acromegaly improves control by lanreotide^len#Cl
in Endocrinol#2#Oxf#20080000#2008#68#6#970-5#20110200#03.htm##
00592000000000265000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700160016000730160016000890160
01900105810000600124018011000130052002500240053002500265055001200290054000800302
865000900310002000700319#v55n1#V:\SciELO\serial\abem\v55n1\markup\03.htm#S#c#288
#32#article#40#32#^rND^sIguchi^nD#^rND^sGlezer^nA#^rND^sCescato^nVAS#et al#Does 
partial surgery removal of macroprolactinomas improve their response to dopamine
 agonists treatment?^len#The Endocrine Society^i1#Annual Meeting^n90^i1^i1#20080
000^i1#2008^i1#20110200#03.htm##
00539000000000277000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100018000730100020000910100
01700111012006700128030002600195710000200221065000900223064000500232031000300237
014000500240865000900245002000700254#v55n1#V:\SciELO\serial\abem\v55n1\markup\03
.htm#S#c#289#33#article#40#33#^rND^sBarbosa^nER#^rND^sOliveira^nJHA#^rND^sAbucha
m^nJ#Adenomas hipofisários secretores de TSH: revisão de casuística^lpt#Arq Bras
 Endocrinol Metab#2#20050000#2005#49#S105#20110200#03.htm##
00537000000000289000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100021000730100017000940120
06700111030001000178065000900188064000500197031000200202032000200204014000500206
865000900211002000700220035001000227801001000237#v55n1#V:\SciELO\serial\abem\v55
n1\markup\03.htm#S#c#290#34#article#40#34#^rND^sBeck-Peccoz^nP#^rND^sPersani^nL#
Medical management of thyrotropin-secreting pituitary adenomas^len#Pituitary#200
20000#2002#5#2#83-8#20110200#03.htm#1386-341X#PITUITARY##
00742000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100018000730100019000910100
01700110010001700127010001500144010001600159012014700175030001500322065000900337
06400050034603100030035103200020035401400070035686500090036300200070037203500100
0379801001500389#v55n1#V:\SciELO\serial\abem\v55n1\markup\03.htm#S#c#291#35#arti
cle#40#35#^rND^sBaussart^nB#^rND^sAghakhani^nN#^rND^sPortier^nF#^rND^sChanson^nP
#^rND^sTadie^nM#^rND^sParker^nF#Endoscope-assisted microsurgery for invasive end
o- and suprasellar pituitary macroadenomas: a consecutive retrospective study wi
th 13 patients^len#Neurochirurgie#20050000#2005#51#5#455-63#20110200#03.htm#0028
-3770#Neurochirurgie##
00594000000000313000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730100017000890100
01700106010001800123010001500141012005400156030002600210710000200236065000900238
064000500247031000300252032000200255014000700257865000900264002000700273#v55n1#V
:\SciELO\serial\abem\v55n1\markup\03.htm#S#c#292#36#article#40#36#^rND^sSantos^n
R#^rND^sZymberg^nS#^rND^sAbucham^nJ#^rND^sGregório^nL#^rND^sWeckx^nL#Acesso endo
scópico transnasal aos tumores selares^lpt#Rev Bras Otorrinolaringol#2#20070000#
2007#73#4#463-75#20110200#03.htm##
00615000000000301000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100014000730100015000870100
02100102012009800123030002000221065000900241064000500250031000300255032000200258
014000700260865000900267002000700276035001000283801002000293#v55n1#V:\SciELO\ser
ial\abem\v55n1\markup\03.htm#S#c#293#37#article#40#37#^rND^sYang^nI#^rND^sWang^n
MB#^rND^sBergsneider^nM#Making the transition from neurosurgery to endoscopic tr
ans-sphenoidal pituitary neurosurgery^len#Neurosurg Clin N Am#20100000#2010#21#4
#643-51#20110200#03.htm#1042-3680#Neurosurg Clin N Am##
00533000000000289000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100018000730100016000910120
02200107030003100129065000900160064000500169031000300174032000200177014000700179
865000900186002000700195035001000202801003100212#v55n1#V:\SciELO\serial\abem\v55
n1\markup\03.htm#S#c#294#38#article#40#38#^rND^sLaws^nER Jr#^rND^sThapar^nK#Pitu
itary surgery^len#Endocrinol Metab Clin North Am#19990000#1999#28#1#119-31#20110
200#03.htm#0889-8529#Endocrinol Metab Clin North Am##
00589000000000313000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730100019000900100
02000109012007100129030000900200066000700209065000900216064000500225031000200230
032000200232014000600234865000900240002000700249035001000256801000900266#v55n1#V
:\SciELO\serial\abem\v55n1\markup\03.htm#S#c#295#39#article#40#39#^rND^sNomikos^
nP#^rND^sFahlbusch^nR#^rND^sBuchfelder^nM#Recent developments in transsphenoidal
 surgery of pituitary tumors^len#Hormones#Athens#20040000#2004#3#2#85-91#2011020
0#03.htm#0018-5051#Hormones##
00690000000000349000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730100017000900100
01900107010001800126010001600144010001600160810000600176012009400182030001600276
71000020029206600040029406500090029806400050030703100030031203200020031501400070
0317865000900324002000700333#v55n1#V:\SciELO\serial\abem\v55n1\markup\03.htm#S#c
#296#40#article#40#40#^rND^sSheaves^nR#^rND^sJenkins^nP#^rND^sBlackburn^nP#^rND^
sHuneidi^nAH#^rND^sAfshar^nF#^rND^sMedbak^nS#et al#Outcome of transsphenoidal su
rgery for acromegaly using strict criteria for surgical cure^len#Clin Endocrinol
#2#Oxf#19960000#1996#45#4#407-13#20110200#03.htm##
00263000000000169000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640910009000660920007000750020007000827030
00400089#v55n1#V:\SciELO\serial\abem\v55n1\markup\04.htm#S#o#1#1#article#1#20110
324#154522#04.htm#261##
04237000000000769000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640710003000660400003000690010006000720420
00200078120000400080038000500084038000400089038000400093121000300097049000800100
15800030010803000260011103100030013703200020014006500090014201400090015103500100
01600120119001700120114002890100036004030100046004390100044004850100037005290100
04900566010006300615010003700678010003100715010003600746010005000782010004000832
07000940087207001160096607000520108208310060113408500080214008500300214808500270
21780850018022050850029022230850030022520830984022820850008032660850028032740850
02103302085001603323085002803339085004203367117000603409072000303415112000903418
111001203427114000903439113001203448002000703460#v55n1#V:\SciELO\serial\abem\v55
n1\markup\04.htm#S#h#2#1#article#1#oa#pt#br1.1#1#4.0#ILUS#GRA#TAB#04#ABEM030#nd#
Arq Bras Endocrinol Metab#55#1#20110200#^f29^l37#0004-2730#Avaliação de fatores 
clínicos, laboratoriais e ultrassonográficos preditores de malignidade em nódulo
s tiroidianos^lpt#Evaluation of clinical, laboratorial and ultrasonographic pred
icting factors of malignancy in thyroid nodules^len#^rND^1A01 A02^nAna Luiza Sil
va^sRio#^rND^1A01 A02 A03^nRosa Paula Mello^sBiscolla#^rND^1A01 A02^nDanielle Ma
cellaro^sAndreoni#^rND^1A01 A02^nCléber Pinto^sCamacho#^rND^1A01 A02^nCláudia Cr
istina Doimo^sNakabashi#^rND^1A01 A02^nMaria da Conceição de Oliveira Carneiro^s
Mamone#^rND^1A01 A02^nElza Setsuku^sIkejiri#^rND^1A01^nLuiza K.^sMatsumura#^rND^
1A01 A02^nJairo Tabacow^sHidal#^rND^1A01 A02 A03^nRui Monteiro de Barros^sMaciel
#^rND^1A01^nReinaldo Perrone^sFurlanetto#Universidade Federal de São Paulo^iA01^
1Escola Paulista de Medicina^2Departamento de Medicina#Instituto Israelita de En
sino e Pesquisa Albert Einstein^iA02^1Centro de Doenças Tiroidianas^cSão Paulo^s
SP^pBrasil#Fleury Medicina e Saúde^iA03^cSão Paulo^sSP^pBrasil#^lpt^aOBJETIVO: A
valiar risco de malignidade de nódulos tiroidianos por meio de aspectos clínicos
, laboratoriais, ultrassonográficos e citológicos. PACIENTES E MÉTODOS: 741 nódu
los de 407 pacientes. RESULTADOS: A citologia foi benigna (60,5%), indeterminada
 (23,3%), maligna (8,6%) ou não diagnóstica (7,6%). A prevalência de câncer nas 
citologias indeterminadas foi 18,5% (16% nas lesões foliculares, 44% nas suspeit
as). O diagnóstico de malignidade foi 17,2% (n = 70). A frequência de câncer em 
mulheres (15,2%) foi menor do que em homens (27,9%). Houve uma relação inversa e
ntre idade e risco de câncer. Não houve significância estatística na prevalência
 de câncer de acordo com número, tamanho dos nódulos ou níveis de TSH. Hipoecoge
nicidade e microcalcificações ao ultrassom foram fatores de risco. CONCLUSÃO: O 
risco de malignidade foi maior em homens, nódulos hipoecogênicos, com microcalci
ficações e inversamente relacionado à idade. O nível de TSH não foi um preditor 
independente de malignidade.#^dnd^i1#^tm^lpt^kNódulo de tiroide^i1#^tm^lpt^ksexo
 masculino^i1#^tm^lpt^kidade^i1#^tm^lpt^kultrassonografia^i1#^tm^lpt^kpunção de 
tiroide^i1#^len^aOBJECTIVE: To evaluate the risk of malignancy in thyroid nodule
s through clinical, laboratory, ultrasonographic and cytological aspects. PATIEN
TS AND METHODS: 741 nodules of 407 patients. RESULTS: The cytology was benign (6
0,5%), indeterminate (23,3%), malignant (8,3%) or nondiagnostic (7,6%). The prev
alence of cancer in indeterminate citology was 18,5% (16% in follicular lesions,
 44% in suspicious). The diagnosis of malignancy was 17,2% (n = 70). The frequen
cy of cancer in women (15,2%) was lower than in men (27,9%). There was an invers
e relation between age and cancer risk. There was no statistical significance in
 the prevalence of cancer according to number, size of nodules or TSH levels. Hy
poechogenicity and microcalcifications on ultrasound were risk factors. CONCLUSI
ON: The risk of malignancy was higher in men, hypoechoic nodules, with microcalc
ifications and was inversely related to age. The TSH level was not an independen
t factor predictive of malignancy.#^dnd^i2#^tm^len^kThyroid nodules^i2#^tm^len^k
male sex^i2#^tm^len^kage^i2#^tm^len^kultrasonography^i2#^tm^len^kfine needle asp
iration biopsy^i2#other#39#20100930#30/Set/2010#20110113#13/Jan/2011#04.htm##
04308000000000769000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640710003000660400003000690010006000720420
00200078120000400080038000500084038000400089038000400093121000300097049000800100
15800030010803000260011103100030013703200020014006500090014201400090015103500100
01600120126001700120121002960100036004170100046004530100044004990100037005430100
04900580010006300629010003700692010003100729010003600760010005000796010004000846
07000940088607001160098007000520109608310350114808500080218308500300219108500270
22210850018022480850029022660850030022950831012023250850008033370850028033450850
02103373085001603394085002803410085004203438117000603480072000303486112000903489
111001203498114000903510113001203519002000703531#v55n1#V:\SciELO\serial\abem\v55
n1\markup\04.htm#S#f#3#1#article#1#oa#pt#br1.1#1#4.0#ILUS#GRA#TAB#04#ABEM030#nd#
Arq Bras Endocrinol Metab#55#1#20110200#^f29^l37#0004-2730#<b>Avaliação de fator
es clínicos, laboratoriais e ultrassonográficos preditores de malignidade em nód
ulos tiroidianos</b>^lpt#<b>Evaluation of clinical, laboratorial and ultrasonogr
aphic predicting factors of malignancy in thyroid nodules</b>^len#^rND^1A01 A02^
nAna Luiza Silva^sRio#^rND^1A01 A02 A03^nRosa Paula Mello^sBiscolla#^rND^1A01 A0
2^nDanielle Macellaro^sAndreoni#^rND^1A01 A02^nCléber Pinto^sCamacho#^rND^1A01 A
02^nCláudia Cristina Doimo^sNakabashi#^rND^1A01 A02^nMaria da Conceição de Olive
ira Carneiro^sMamone#^rND^1A01 A02^nElza Setsuku^sIkejiri#^rND^1A01^nLuiza K.^sM
atsumura#^rND^1A01 A02^nJairo Tabacow^sHidal#^rND^1A01 A02 A03^nRui Monteiro de 
Barros^sMaciel#^rND^1A01^nReinaldo Perrone^sFurlanetto#Universidade Federal de S
ão Paulo^iA01^1Escola Paulista de Medicina^2Departamento de Medicina#Instituto I
sraelita de Ensino e Pesquisa Albert Einstein^iA02^1Centro de Doenças Tiroidiana
s^cSão Paulo^sSP^pBrasil#Fleury Medicina e Saúde^iA03^cSão Paulo^sSP^pBrasil#^lp
t^a<b>OBJETIVO:</b> Avaliar risco de malignidade de nódulos tiroidianos por meio
 de aspectos clínicos, laboratoriais, ultrassonográficos e citológicos. <b> PACI
ENTES E MÉTODOS:</b> 741 nódulos de 407 pacientes. <b>RESULTADOS:</b> A citologi
a foi benigna (60,5%), indeterminada (23,3%), maligna (8,6%) ou não diagnóstica 
(7,6%). A prevalência de câncer nas citologias indeterminadas foi 18,5% (16% nas
 lesões foliculares, 44% nas suspeitas). O diagnóstico de malignidade foi 17,2% 
(n = 70). A frequência de câncer em mulheres (15,2%) foi menor do que em homens 
(27,9%). Houve uma relação inversa entre idade e risco de câncer. Não houve sign
ificância estatística na prevalência de câncer de acordo com número, tamanho dos
 nódulos ou níveis de TSH. Hipoecogenicidade e microcalcificações ao ultrassom f
oram fatores de risco. <b>CONCLUSÃO:</b> O risco de malignidade foi maior em hom
ens, nódulos hipoecogênicos, com microcalcificações e inversamente relacionado à
 idade. O nível de TSH não foi um preditor independente de malignidade.#^dnd^i1#
^tm^lpt^kNódulo de tiroide^i1#^tm^lpt^ksexo masculino^i1#^tm^lpt^kidade^i1#^tm^l
pt^kultrassonografia^i1#^tm^lpt^kpunção de tiroide^i1#^len^a<b>OBJECTIVE:</b> To
 evaluate the risk of malignancy in thyroid nodules through clinical, laboratory
, ultrasonographic and cytological aspects. <b>PATIENTS AND METHODS:</b> 741 nod
ules of 407 patients. <b>RESULTS:</b> The cytology was benign (60,5%), indetermi
nate (23,3%), malignant (8,3%) or nondiagnostic (7,6%). The prevalence of cancer
 in indeterminate citology was 18,5% (16% in follicular lesions, 44% in suspicio
us). The diagnosis of malignancy was 17,2% (n = 70). The frequency of cancer in 
women (15,2%) was lower than in men (27,9%). There was an inverse relation betwe
en age and cancer risk. There was no statistical significance in the prevalence 
of cancer according to number, size of nodules or TSH levels. Hypoechogenicity a
nd microcalcifications on ultrasound were risk factors. <b>CONCLUSION:</b> The r
isk of malignancy was higher in men, hypoechoic nodules, with microcalcification
s and was inversely related to age. The TSH level was not an independent factor 
predictive of malignancy.#^dnd^i2#^tm^len^kThyroid nodules^i2#^tm^len^kmale sex^
i2#^tm^len^kage^i2#^tm^len^kultrasonography^i2#^tm^len^kfine needle aspiration b
iopsy^i2#other#39#20100930#30/Set/2010#20110113#13/Jan/2011#04.htm##
04531000000000793000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640640013000660710003000790400003000820010
00600085042000200091120000400093038000500097038000400102038000400106121000300110
04900080011315800030012103000290012403100030015303200020015606500090015801400090
01670350010001760120119001860120114003050100036004190100046004550100044005010100
03700545010004900582010006300631010003700694010003000731010003600761010005000797
01000400084707000960088707001180098307000540110108310960115508500080225108500300
22590850027022890850018023160850029023340850030023630831054023930850008034470850
02803455085002103483085001603504085002803520085004203548117000603590072000303596
112000903599111001203608114000903620113001203629002000703641008008903648#v55n1#V
:\SciELO\serial\abem\v55n1\markup\04.htm#S#l#4#1#article#1#^mfev.^a2011#oa#pt#br
1.1#1#4.0#ilus#gra#tab#04#ABEM030#nd#Arq. bras. endocrinol. metab#55#1#20110200#
^f29^l37#0004-2730#Avaliação de fatores clínicos, laboratoriais e ultrassonográf
icos preditores de malignidade em nódulos tiroidianos^lpt#Evaluation of clinical
, laboratorial and ultrasonographic predicting factors of malignancy in thyroid 
nodules^len#^rND^1A01 A02^nAna Luiza Silva^sRio#^rND^1A01 A02 A03^nRosa Paula Me
llo^sBiscolla#^rND^1A01 A02^nDanielle Macellaro^sAndreoni#^rND^1A01 A02^nCléber 
Pinto^sCamacho#^rND^1A01 A02^nCláudia Cristina Doimo^sNakabashi#^rND^1A01 A02^nM
aria da Conceição de Oliveira Carneiro^sMamone#^rND^1A01 A02^nElza Setsuku^sIkej
iri#^rND^1A01^nLuiza K^sMatsumura#^rND^1A01 A02^nJairo Tabacow^sHidal#^rND^1A01 
A02 A03^nRui Monteiro de Barros^sMaciel#^rND^1A01^nReinaldo Perrone^sFurlanetto#
^iA01^1Universidade Federal de São Paulo^2Escola Paulista de Medicina^3Departame
nto de Medicina#^iA02^1Instituto Israelita de Ensino e Pesquisa Albert Einstein^
2Centro de Doenças Tiroidianas^cSão Paulo^sSP^pBrasil#^iA03^1Fleury Medicina e S
aúde^cSão Paulo^sSP^pBrasil#^lpt^aOBJETIVO: Avaliar risco de malignidade de nódu
los tiroidianos por meio de aspectos clínicos, laboratoriais, ultrassonográficos
 e citológicos. PACIENTES E MÉTODOS: 741 nódulos de 407 pacientes. RESULTADOS: A
 citologia foi benigna (60,5 por cento), indeterminada (23,3 por cento), maligna
 (8,6 por cento) ou não diagnóstica (7,6 por cento). A prevalência de câncer nas
 citologias indeterminadas foi 18,5 por cento (16 por cento nas lesões folicular
es, 44 por cento nas suspeitas). O diagnóstico de malignidade foi 17,2 por cento
 (n = 70). A frequência de câncer em mulheres (15,2 por cento) foi menor do que 
em homens (27,9 por cento). Houve uma relação inversa entre idade e risco de cân
cer. Não houve significância estatística na prevalência de câncer de acordo com 
número, tamanho dos nódulos ou níveis de TSH. Hipoecogenicidade e microcalcifica
ções ao ultrassom foram fatores de risco. CONCLUSÃO: O risco de malignidade foi 
maior em homens, nódulos hipoecogênicos, com microcalcificações e inversamente r
elacionado à idade. O nível de TSH não foi um preditor independente de malignida
de.#^dnd^i1#^tm^lpt^kNódulo de tiroide^i1#^tm^lpt^ksexo masculino^i1#^tm^lpt^kid
ade^i1#^tm^lpt^kultrassonografia^i1#^tm^lpt^kpunção de tiroide^i1#^len^aOBJECTIV
E: To evaluate the risk of malignancy in thyroid nodules through clinical, labor
atory, ultrasonographic and cytological aspects. PATIENTS AND METHODS: 741 nodul
es of 407 patients. RESULTS: The cytology was benign (60,5 percent), indetermina
te (23,3 percent), malignant (8,3 percent) or nondiagnostic (7,6 percent). The p
revalence of cancer in indeterminate citology was 18,5 percent (16 percent in fo
llicular lesions, 44 percent in suspicious). The diagnosis of malignancy was 17,
2 percent (n = 70). The frequency of cancer in women (15,2 percent) was lower th
an in men (27,9 percent). There was an inverse relation between age and cancer r
isk. There was no statistical significance in the prevalence of cancer according
 to number, size of nodules or TSH levels. Hypoechogenicity and microcalcificati
ons on ultrasound were risk factors. CONCLUSION: The risk of malignancy was high
er in men, hypoechoic nodules, with microcalcifications and was inversely relate
d to age. The TSH level was not an independent factor predictive of malignancy.#
^dnd^i2#^tm^len^kThyroid nodules^i2#^tm^len^kmale sex^i2#^tm^len^kage^i2#^tm^len
^kultrasonography^i2#^tm^len^kfine needle aspiration biopsy^i2#other#39#20100930
#30/Set/2010#20110113#13/Jan/2011#04.htm#Internet^ihttp://www.scielo.br/scielo.p
hp?script=sci_arttext&pid=S0004-27302011000100004##
00343000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704012200068002000700190#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#5#1#article#218#<p align="right"><font face
="Verdana, Arial, Helvetica, sans-serif" size="2"><b>ARTIGO    ORIGINAL</b></fon
t></p>     ^cY#04.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704002200068002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#6#2#article#218#<p>&nbsp;</p>     ^cY#04.ht
m##
00484000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704026300068002000700331#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#7#3#article#218#<p><a name="top"></a><font 
face="Verdana, Arial, Helvetica, sans-serif" size="4"><b>Avalia&ccedil;&atilde;o
    de fatores cl&iacute;nicos, laboratoriais e ultrassonogr&aacute;ficos predit
ores    de malignidade em n&oacute;dulos tiroidianos</b></font></p>     ^cY#04.h
tm##
00243000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704002200068002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#8#4#article#218#<p>&nbsp;</p>     ^cY#04.ht
m##
00426000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704020500068002000700273#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#9#5#article#218#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="3"><b>Evaluation of    clinical, laboratorial a
nd ultrasonographic predicting factors of malignancy    in thyroid nodules</b></
font></p>     ^cY#04.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000400065704002200069002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#10#6#article#218#<p>&nbsp;</p>     ^cY#04.h
tm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000400065704002200069002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#11#7#article#218#<p>&nbsp;</p>     ^cY#04.h
tm##
00838000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000400065704061600069002000700685#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#12#8#article#218#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>Ana Luiza Silva    Rio<sup>I, II</sup>; 
Rosa Paula Mello Biscolla<sup>I, II, III</sup>; Danielle    Macellaro Andreoni<s
up>I, II</sup>; Cl&eacute;ber Pinto Camacho<sup>I, II</sup>;    Cl&aacute;udia C
ristina Doimo Nakabashi<sup>I, II</sup>; Maria da Concei&ccedil;&atilde;o    de 
Oliveira Carneiro Mamone<sup>I, II</sup>; Elza Setsuku Ikejiri<sup>I, II</sup>; 
   Luiza K. Matsumura<sup>I</sup>; Jairo Tabacow Hidal<sup>I, II</sup>; Rui Mont
eiro    de Barros Maciel<sup>I, II, III</sup>; Reinaldo Perrone Furlanetto<sup>I
</sup></b></font></p>     ^cY#04.htm##
00480000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000400065704025800069002000700327#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#13#9#article#218#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><sup>I</sup>Disciplina    de Endocrinologia
, Departamento de Medicina, Escola Paulista de Medicina, Universidade    Federal
 de S&atilde;o Paulo (Unifesp/EPM), S&atilde;o Paulo, SP, Brasil    ^cY#04.htm##
00387000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704016400070002000700234#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#14#10#article#218#<br>   <sup>II</sup>Centr
o de Doen&ccedil;as Tiroidianas, Instituto Israelita de Ensino    e Pesquisa Alb
ert Einstein (IIEPAE), S&atilde;o Paulo, SP, Brasil    ^cY#04.htm##
00324000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704010100070002000700171#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#15#11#article#218#<br>   <sup>III</sup>Fleu
ry Medicina e Sa&uacute;de, S&atilde;o Paulo, SP, Brasil</font></p>     ^cY#04.h
tm##
00355000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704013200070002000700202#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#16#12#article#218#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><a href="#back">Correspond&ecirc;ncia    p
ara</a></font></p>     ^cY#04.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#17#13#article#218#<p>&nbsp;</p>     ^cY#04.
htm##
00267000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704004400070002000700114#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#18#14#article#218#<p>&nbsp;</p> <hr size="1
" noshade>     ^cY#04.htm##
00319000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704009600070002000700166#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#19#15#article#218#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>RESUMO</b></font></p>     ^cY#04.htm##
00483000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704026000070002000700330#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#20#16#article#218#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>OBJETIVO:</b>    Avaliar risco de malig
nidade de n&oacute;dulos tiroidianos por meio de aspectos    cl&iacute;nicos, la
boratoriais, ultrassonogr&aacute;ficos e citol&oacute;gicos.    <b>    ^cY#04.ht
m##
00306000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704008300070002000700153#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#21#17#article#218#<br>   PACIENTES E M&Eacu
te;TODOS:</b> 741 n&oacute;dulos de 407 pacientes.    ^cY#04.htm##
01015000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704079200070002000700862#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#22#18#article#218#<br>   <b>RESULTADOS:</b>
 A citologia foi benigna (60,5%), indeterminada (23,3%), maligna    (8,6%) ou n&
atilde;o diagn&oacute;stica (7,6%). A preval&ecirc;ncia de c&acirc;ncer    nas c
itologias indeterminadas foi 18,5% (16% nas les&otilde;es foliculares,    44% na
s suspeitas). O diagn&oacute;stico de malignidade foi 17,2% (n = 70).    A frequ
&ecirc;ncia de c&acirc;ncer em mulheres (15,2%) foi menor do que em homens    (2
7,9%). Houve uma rela&ccedil;&atilde;o inversa entre idade e risco de c&acirc;nc
er.    N&atilde;o houve signific&acirc;ncia estat&iacute;stica na preval&ecirc;n
cia    de c&acirc;ncer de acordo com n&uacute;mero, tamanho dos n&oacute;dulos o
u n&iacute;veis    de TSH. Hipoecogenicidade e microcalcifica&ccedil;&otilde;es 
ao ultrassom foram    fatores de risco.    ^cY#04.htm##
00522000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704029900070002000700369#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#23#19#article#218#<br>   <b>CONCLUS&Atilde;
O:</b> O risco de malignidade foi maior em homens, n&oacute;dulos    hipoecog&ec
irc;nicos, com microcalcifica&ccedil;&otilde;es e inversamente relacionado    &a
grave; idade. O n&iacute;vel de TSH n&atilde;o foi um preditor independente    d
e malignidade.</font></p>     ^cY#04.htm##
00453000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704023000070002000700300#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#24#20#article#218#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Descritores:    </b> N&oacute;dulo de t
iroide; sexo masculino; idade; ultrassonografia, pun&ccedil;&atilde;o    de tiro
ide</font></p> <hr size="1" noshade>     ^cY#04.htm##
00321000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704009800070002000700168#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#25#21#article#218#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>ABSTRACT</b></font></p>     ^cY#04.htm#
#
00443000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704022000070002000700290#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#26#22#article#218#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>OBJECTIVE:</b>    To evaluate the risk 
of malignancy in thyroid nodules through clinical, laboratory,    ultrasonograph
ic and cytological aspects.    ^cY#04.htm##
00295000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704007200070002000700142#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#27#23#article#218#<br>   <b>PATIENTS AND ME
THODS:</b> 741 nodules of 407 patients.    ^cY#04.htm##
00852000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704062900070002000700699#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#28#24#article#218#<br>   <b>RESULTS:</b> Th
e cytology was benign (60,5%), indeterminate (23,3%), malignant    (8,3%) or non
diagnostic (7,6%). The prevalence of cancer in indeterminate citology    was 18,
5% (16% in follicular lesions, 44% in suspicious). The diagnosis of malignancy  
  was 17,2% (n = 70). The frequency of cancer in women (15,2%) was lower than   
 in men (27,9%). There was an inverse relation between age and cancer risk. Ther
e    was no statistical significance in the prevalence of cancer according to nu
mber,    size of nodules or TSH levels. Hypoechogenicity and microcalcifications
 on ultrasound    were risk factors.    ^cY#04.htm##
00465000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704024200070002000700312#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#29#25#article#218#<br>   <b>CONCLUSION:</b>
 The risk of malignancy was higher in men, hypoechoic nodules,    with microcalc
ifications and was inversely related to age. The TSH level was    not an indepen
dent factor predictive of malignancy.</font></p>     ^cY#04.htm##
00426000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704020300070002000700273#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#30#26#article#218#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Keywords:</b>    Thyroid nodules; male 
sex; age; ultrasonography; fine needle aspiration biopsy</font></p> <hr size="1"
 noshade>     ^cY#04.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#31#27#article#218#<p>&nbsp;</p>     ^cY#04.
htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#32#28#article#218#<p>&nbsp;</p>     ^cY#04.
htm##
00337000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704011400070002000700184#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#33#29#article#218#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="3"><b>INTRODU&Ccedil;&Atilde;O</b></font></p>
     ^cY#04.htm##
01371000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704114800070002000701218#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#34#30#article#218#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">De acordo com estudos    epidemiol&oacute;
gicos, n&oacute;dulos tiroidianos (NT) palp&aacute;veis ocorrem    em 3% a 8% da
 popula&ccedil;&atilde;o (1-2). Estudos de aut&oacute;psia demonstram    que met
ade da popula&ccedil;&atilde;o apresenta NT (3). O diagn&oacute;stico    de n&oa
cute;dulos n&atilde;o palp&aacute;veis aumentou em decorr&ecirc;ncia    do uso d
e exames ultrassonogr&aacute;ficos de alta resolu&ccedil;&atilde;o,    podendo s
er encontrados em 19% a 67% da popula&ccedil;&atilde;o (4) com ocorr&ecirc;ncia 
   maior em idosos, indiv&iacute;duos do sexo feminino e &aacute;reas de baixo  
  consumo de iodo (4,5). Em consequ&ecirc;ncia do maior uso de exames de imagem,
    h&aacute; tamb&eacute;m um aumento da preval&ecirc;ncia de microcarcinoma de
    tiroide, definido pela Organiza&ccedil;&atilde;o Mundial da Sa&uacute;de (OM
S)    como c&acirc;ncer de tiroide <u>&lt;</u> 10 mm (6). A import&acirc;ncia de
 se    avaliar um NT encontra-se, principalmente, na necessidade de se excluir c
&acirc;ncer    de tiroide que ocorre em 5%-15% dos casos (2,7).</font></p>     ^
cY#04.htm##
00844000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704062100070002000700691#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#35#31#article#218#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Na literatura,    par&acirc;metros cl&iacu
te;nicos de maior suspeita de malignidade em NT incluem:    idade menor de 20 an
os ou maior de 70 anos, sexo masculino, hist&oacute;ria    familiar de c&acirc;n
cer de tiroide, exposi&ccedil;&atilde;o &agrave; radia&ccedil;&atilde;o    ioniz
ante, sintomas compressivos, n&oacute;dulos de crescimento r&aacute;pido,    di&
acirc;metro maior que 4 cm, n&oacute;dulos endurecidos, aderidos a estruturas   
 adjacentes, presen&ccedil;a de paralisia de cordas vocais e linfadenopatia regi
onal    (4,5,8).</font></p>     ^cY#04.htm##
00666000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704044300070002000700513#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#36#32#article#218#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">O risco de malignidade    em n&oacute;dulo
s m&uacute;ltiplos &eacute; controverso na literatura. Alguns    autores acredit
am que a taxa de malignidade em n&oacute;dulos solit&aacute;rios    &eacute; mai
or do que em b&oacute;cios multinodulares (BMN) (9-10), no entanto,    recenteme
nte, alguns trabalhos mostraram taxas semelhantes nos dois grupos (2,7,11,12).</
font></p>     ^cY#04.htm##
00549000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704032600070002000700396#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#37#33#article#218#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Em rela&ccedil;&atilde;o    aos exames lab
oratoriais, alguns estudos sugerem que o n&iacute;vel de horm&ocirc;nio    tiroe
stimulante (TSH) na apresenta&ccedil;&atilde;o cl&iacute;nica pode ser    um pre
ditor independente de malignidade (9,13).</font></p>     ^cY#04.htm##
00832000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704060900070002000700679#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#38#34#article#218#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Caracter&iacute;sticas    ultrassonogr&aac
ute;ficas podem tamb&eacute;m auxiliar na avalia&ccedil;&atilde;o    do risco de
 malignidade em NT. S&atilde;o considerados n&oacute;dulos suspeitos    aqueles 
hipoecog&ecirc;nicos, s&oacute;lidos ou mistos com componente s&oacute;lido,    
mal delimitados, sem halo e com aumento do fluxo nodular central visto pelo    D
oppler (14-17). No entanto, n&atilde;o &eacute; poss&iacute;vel diferenciar    c
om certeza les&otilde;es malignas de benignas somente pela ultrassonografia    (
US).</font></p>     ^cY#04.htm##
00774000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704055100070002000700621#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#39#35#article#218#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">A pun&ccedil;&atilde;o    aspirativa por a
gulha fina (PAAF) com estudo citol&oacute;gico do material obtido    permanece a
t&eacute; o momento como a t&eacute;cnica "gold-standart" na avalia&ccedil;&atil
de;o    de NT (2,18). V&aacute;rios estudos demonstraram que a PAAF guiada por U
S em    compara&ccedil;&atilde;o com a PAAF guiada pela palpa&ccedil;&atilde;o a
umenta    a sensibilidade e diminui o n&uacute;mero de aspirados n&atilde;o diag
n&oacute;sticos    (9,19).</font></p>     ^cY#04.htm##
00677000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704045400070002000700524#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#40#36#article#218#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Em vista do exposto,    a proposta do estu
do foi avaliar fatores de risco para c&acirc;ncer de tiroide    j&aacute; bem es
tabelecidos como idade, sexo, caracter&iacute;sticas ultrassonogr&aacute;ficas, 
   assim como fatores controversos como TSH, na tentativa de auxiliar na decis&a
tilde;o    de quais NT devem realmente ser encaminhados para tratamento cir&uacu
te;rgico.</font></p>     ^cY#04.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#41#37#article#218#<p>&nbsp;</p>     ^cY#04.
htm##
00342000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704011900070002000700189#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#42#38#article#218#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="3"><b>PACIENTES E    M&Eacute;TODOS</b></font
></p>     ^cY#04.htm##
00322000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704009900070002000700169#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#43#39#article#218#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Pacientes</b></font></p>     ^cY#04.htm
##
00464000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704024100070002000700311#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#44#40#article#218#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Este estudo foi    aprovado pelo Comit&eci
rc; de &Eacute;tica em Pesquisa do Hospital S&atilde;o    Paulo, Universidade Fe
deral de S&atilde;o Paulo (Unifesp).</font></p>     ^cY#04.htm##
01104000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704088100070002000700951#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#45#41#article#218#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Foram analisados    dados referentes &agra
ve;s caracter&iacute;sticas de 741 NT de 407 pacientes    (257 prospectivos e 15
0 retrospectivos) atendidos no per&iacute;odo de outubro    de 2006 a agosto de 
2008 referenciados ao Centro de Doen&ccedil;as Tiroidianas,    uma parceria entr
e a Unifesp e o Instituto Israelita de Ensino e Pesquisa Albert    Einstein (IIE
PAE). O crit&eacute;rio para encaminhamento desses pacientes foi    a presen&cce
dil;a de NT pelo exame f&iacute;sico, n&oacute;dulos diagnosticados    incidenta
lmente por exames de imagem (US, tomografia computadorizada, resson&acirc;ncia  
  nuclear magn&eacute;tica), al&eacute;m de NT previamente conhecidos e que eram
    encaminhados para reavalia&ccedil;&atilde;o. N&atilde;o foram inclu&iacute;d
os    n&oacute;dulos t&oacute;xicos.</font></p>     ^cY#04.htm##
01169000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704094600070002000701016#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#46#42#article#218#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Todos os pacientes    foram submetidos &ag
rave; anamnese detalhada levando-se em considera&ccedil;&atilde;o    a faixa et&
aacute;ria, a presen&ccedil;a de sintomas de disfun&ccedil;&atilde;o    tiroidia
na, a exposi&ccedil;&atilde;o &agrave; radia&ccedil;&atilde;o ionizante    e o e
xame f&iacute;sico, incluindo palpa&ccedil;&atilde;o criteriosa da regi&atilde;o
    cervical. Al&eacute;m do atendimento cl&iacute;nico, os pacientes realizaram
    US de tiroide e dosagem de TSH. Foram analisadas caracter&iacute;sticas ultr
assonogr&aacute;ficas,    tais como n&uacute;mero de n&oacute;dulos, tamanho, pr
esen&ccedil;a de calcifica&ccedil;&otilde;es,    presen&ccedil;a de halo e delim
ita&ccedil;&atilde;o do n&oacute;dulo para correlacion&aacute;-las    com maior 
risco de malignidade. A realiza&ccedil;&atilde;o de US foi feita por    um &uacu
te;nico profissional.</font></p>     ^cY#04.htm##
01006000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704078300070002000700853#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#47#43#article#218#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Pacientes com n&iacute;veis    de TSH dent
ro dos limites da normalidade foram submetidos &agrave; PAAF de n&oacute;dulos  
  maiores ou iguais a 1 cm e/ou com caracter&iacute;sticas suspeitas ao US. Aque
les    com n&iacute;veis de TSH abaixo ou acima do limite da normalidade foram a
valiados    quanto &agrave; presen&ccedil;a de hipertiroidismo ou hipotiroidismo
, respectivamente,    e tratados antes de serem submetidos &agrave; PAAF no intu
ito de minimizar o    risco de altera&ccedil;&otilde;es no resultado da citologi
a aspirativa. Pacientes    com diagn&oacute;stico de hipertiroidismo por b&oacut
e;cio nodular t&oacute;xico    n&atilde;o foram puncionados e foram exclu&iacute
;dos deste estudo.</font></p>     ^cY#04.htm##
01098000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704087500070002000700945#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#48#44#article#218#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Os achados citol&oacute;gicos    foram cla
ssificados em benignos, malignos, indeterminados (incluindo les&atilde;o    foli
cular e les&otilde;es suspeitas) e n&atilde;o diagn&oacute;sticos (incluindo    
material insuficiente e sangue) de acordo com a classifica&ccedil;&atilde;o    d
a American Thyroid Association (2006) (2). A interpreta&ccedil;&atilde;o da    c
itologia aspirativa foi feita sempre pelo mesmo profissional. Pacientes com    P
AAF benigna foram encaminhados para seguimento cl&iacute;nico. N&oacute;dulos   
 com PAAF maligna, indeterminada ou insuficiente em mais de uma ocasi&atilde;o  
  e n&oacute;dulos volumosos com sintomas compressivos foram encaminhados para  
  tiroidectomia. Dados do estudo anatomopatol&oacute;gico foram obtidos para an&
aacute;lise    dos resultados.</font></p>     ^cY#04.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#49#45#article#218#<p>&nbsp;</p>     ^cY#04.
htm##
00327000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704010400070002000700174#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#50#46#article#218#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="3"><b>M&Eacute;TODOS</b></font></p>     ^cY#0
4.htm##
00491000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704026800070002000700338#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#51#47#article#218#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">A dosagem de TSH    foi realizada pelo m&e
acute;todo de quimioluminesc&ecirc;ncia (valores de refer&ecirc;ncia:    0,35 a 
5,5 mcUI/ml com limite de detec&ccedil;&atilde;o 0,01 mcUI/ml).</font></p>     ^
cY#04.htm##
00474000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704025100070002000700321#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#52#48#article#218#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Para a realiza&ccedil;&atilde;o    de US d
e tiroide foi utilizado o aparelho da marca ATL com Doppler colorido    modelo H
DI 3500 e com transdutor linear de 7,5-10 MGz.</font></p>     ^cY#04.htm##
00393000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704017000070002000700240#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#53#49#article#218#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">O material obtido    pela PAAF foi fixado 
e corado pela t&eacute;cnica Pan&oacute;tico.</font></p>     ^cY#04.htm##
00349000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704012600070002000700196#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#54#50#article#218#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>An&aacute;lise    estat&iacute;stica</b
></font></p>     ^cY#04.htm##
00518000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704029500070002000700365#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#55#51#article#218#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Ap&oacute;s an&aacute;lise    das caracter
&iacute;sticas dos NT, realizou-se an&aacute;lise estat&iacute;stica    dos dado
s para avalia&ccedil;&atilde;o dos fatores associados com maior risco    para ma
lignidade.</font></p>     ^cY#04.htm##
00605000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704038200070002000700452#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#56#52#article#218#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Para a compara&ccedil;&atilde;o    de dado
s categ&oacute;ricos, o teste Qui-quadrado (<i>X</i><sup>2</sup>) (sem    a corr
e&ccedil;&atilde;o de Yates) foi utilizado obedecendo-se as restri&ccedil;&otild
e;es    de Cochran e, quando estas estiveram presentes, foi realizado o teste ex
ato    de Fisher.</font></p>     ^cY#04.htm##
00570000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704034700070002000700417#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#57#53#article#218#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Diferen&ccedil;as    entre m&eacute;dias d
e dados cont&iacute;nuos foram testadas utilizando-se os    testes T de Student 
(<i>t</i>) e Mann-Whitney. Como ambos mostraram resultados    similares, somente
 os resultados dos testes param&eacute;tricos foram mostrados.</font></p>     ^c
Y#04.htm##
00972000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704074900070002000700819#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#58#54#article#218#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">A regress&atilde;o    log&iacute;stica m&u
acute;ltipla foi usada para investigar as rela&ccedil;&otilde;es    individuais 
entre as vari&aacute;veis independentes (aspectos cl&iacute;nicos    e de US) e 
dependentes (presen&ccedil;a de malignidade). Usamos o crit&eacute;rio    <i>ste
pwise forward likelihood ratio</i> (SFLR) para a sele&ccedil;&atilde;o    das va
ri&aacute;veis independentes. Os resultados dessas an&aacute;lises foram    calc
ulados pelo teste de Wald (Wald <i>X</i><sup>2</sup>). As suposi&ccedil;&otilde;
es    dessas an&aacute;lises foram verificadas. Os resultados est&atilde;o apres
entados    em Raz&atilde;o das Chances (<i>Odds Ratio</i> - OR).</font></p>     
^cY#04.htm##
00778000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704055500070002000700625#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#59#55#article#218#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">A probabilidade    (<i>p</i>) menor que 0,
05 foi considerada para indicar signific&acirc;ncia estat&iacute;stica;    todos
 os testes foram bicaudados. Noventa e cinco por cento de intervalo de    confia
n&ccedil;a (IC) foram calculados em rela&ccedil;&atilde;o &agrave;s diferen&cced
il;as    entre m&eacute;dias e OR. Toda a an&aacute;lise foi calculada segundo o
 programa    estat&iacute;stico SPSS (<i>Statistical Package for the Social Scie
nce</i>)    13.1 para Windows.</font></p>     ^cY#04.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#60#56#article#218#<p>&nbsp;</p>     ^cY#04.
htm##
00323000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704010000070002000700170#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#61#57#article#218#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="3"><b>RESULTADOS</b></font></p>     ^cY#04.ht
m##
00330000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704010700070002000700177#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#62#58#article#218#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Dados descritivos</b></font></p>     ^c
Y#04.htm##
00842000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704061900070002000700689#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#63#59#article#218#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Foram avaliadas    as caracter&iacute;stic
as de 741 NT de 407 pacientes. Destes, 364 (89%) eram    mulheres (8,5@&amp;: 1B
&amp;). A idade m&eacute;dia dos pacientes foi de 49,9    &plusmn; 14,7 anos (va
ria&ccedil;&atilde;o: 11 a 84 anos). Nenhum paciente referia    hist&oacute;ria 
de exposi&ccedil;&atilde;o &agrave; radia&ccedil;&atilde;o ionizante.    O n&oac
ute;dulo encaminhado para avalia&ccedil;&atilde;o foi percebido pelo    pr&oacut
e;prio paciente (36%), diagnosticado por US de tiroide (32%) ou por    um m&eacu
te;dico (28%).</font></p>     ^cY#04.htm##
00739000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704051600070002000700586#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#64#60#article#218#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Foram avaliados    206 (51%) pacientes com
 b&oacute;cio uninodular e 200 (49%) pacientes com BMN.    Destes, 109 (54%) apr
esentaram dois n&oacute;dulos, 59 (29%), tr&ecirc;s n&oacute;dulos,    21 (10%),
 quatro n&oacute;dulos, 10 (5%), cinco n&oacute;dulos e um paciente    apresento
u seis n&oacute;dulos. Um paciente encaminhado com suspeita cl&iacute;nica    de
 NT apresentava b&oacute;cio difuso ao US (<a href="#f1">Figura 1</a>).</font></
p>     ^cY#04.htm##
00256000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704003300070002000700103#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#65#61#article#218#<p><a name="f1"></a></p> 
    ^cY#04.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#66#62#article#218#<p>&nbsp;</p>     ^cY#04.
htm##
00300000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704007700070002000700147#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#67#63#article#218#<p align="center"><img sr
c="/img/revistas/abem/v55n1/04f01.jpg"></p>     ^cY#04.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#68#64#article#218#<p>&nbsp;</p>     ^cY#04.
htm##
00495000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704027200070002000700342#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#69#65#article#218#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Do total de 741    NT confirmados ao US, 2
06 eram menores que 1 cm, dos quais 59 (28,6%) foram    puncionados. Do total de
 535 NT maiores ou iguais a 1 cm, 453 (84,7%) foram    puncionados.</font></p>  
   ^cY#04.htm##
00366000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704014300070002000700213#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#70#66#article#218#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Dados citol&oacute;gicos    e histopato
l&oacute;gicos</b></font></p>     ^cY#04.htm##
00943000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704072000070002000700790#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#71#67#article#218#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">O resultado citol&oacute;gico    final dos
 NT puncionados foi benigno (60,5%), indeterminado (23,3%), maligno    (8,6%) ou
 n&atilde;o diagn&oacute;stico (7,6%) (<a href="#f2">Figura 2</a>).    Dos n&oac
ute;dulos menores que 1 cm submetidos &agrave; PAAF, 25,4% (15 de 59    NT) fora
m n&atilde;o diagn&oacute;sticos, enquanto 5,3% (24 de 453 NT) dos n&oacute;dulo
s    maiores ou iguais a 1 cm tiveram esse diagn&oacute;stico citol&oacute;gico.
    Portanto, o n&uacute;mero de PAAF com resultado n&atilde;o diagn&oacute;stic
o    em n&oacute;dulos menores que 1 cm foi cinco vezes maior do que em n&oacute
;dulos    maiores ou iguais a 1 cm.</font></p>     ^cY#04.htm##
00256000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704003300070002000700103#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#72#68#article#218#<p><a name="f2"></a></p> 
    ^cY#04.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#73#69#article#218#<p>&nbsp;</p>     ^cY#04.
htm##
00300000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704007700070002000700147#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#74#70#article#218#<p align="center"><img sr
c="/img/revistas/abem/v55n1/04f02.jpg"></p>     ^cY#04.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#75#71#article#218#<p>&nbsp;</p>     ^cY#04.
htm##
01006000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704078300070002000700853#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#76#72#article#218#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Um total de 164    pacientes foi submetido
 &agrave; cirurgia. Dos 40 pacientes com PAAF sugestivas    de carcinoma papil&i
acute;fero submetidos &agrave; cirurgia, dois pacientes    tiveram resultados fa
lso-positivos (b&oacute;cio adenomatoso). Do total de 64    pacientes com PAAF s
ugestivas de benignidade encaminhados para cirurgia, dois    apresentaram result
ados falso-negativos (carcinoma papil&iacute;fero), um deles    associado &agrav
e; tiroidite linfoc&iacute;tica. A acur&aacute;cia da PAAF quando    o resultado
 final era compat&iacute;vel com malignidade foi de 96%, a sensibilidade,    95%
, a especificidade, 97%, o valor preditivo positivo, 95%, e o valor preditivo   
 negativo foi 97%.</font></p>     ^cY#04.htm##
01121000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704089800070002000700968#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#77#73#article#218#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Dos 119 n&oacute;dulos    com PAAF indeter
minadas, 114 foram encaminhados para tratamento cir&uacute;rgico    e cinco tive
ram contraindica&ccedil;&atilde;o para cirurgia. Dos 103 n&oacute;dulos    opera
dos, foram encontradas 94 les&otilde;es foliculares e nove suspeitas. A    preva
l&ecirc;ncia de c&acirc;ncer em NT com PAAF indeterminada foi de 18,5%    (16% n
as les&otilde;es foliculares e de 44% nas les&otilde;es suspeitas). Nos    NT co
m diagn&oacute;stico na PAAF de les&atilde;o folicular, 84% apresentaram    resu
ltado final benigno, 10,7%, carcinoma papil&iacute;fero, 4,3%, carcinoma    foli
cular e 1% apresentou carcinoma medular. J&aacute; os NT com PAAF suspeita    ap
resentaram 55,6% de benignidade, 33,3% de carcinoma papil&iacute;fero e 11,1%   
 de carcinoma folicular (<a href="#f3">Figura 3</a>).</font></p>     ^cY#04.htm#
#
00256000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704003300070002000700103#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#78#74#article#218#<p><a name="f3"></a></p> 
    ^cY#04.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#79#75#article#218#<p>&nbsp;</p>     ^cY#04.
htm##
00300000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704007700070002000700147#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#80#76#article#218#<p align="center"><img sr
c="/img/revistas/abem/v55n1/04f03.jpg"></p>     ^cY#04.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#81#77#article#218#<p>&nbsp;</p>     ^cY#04.
htm##
00540000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704031700070002000700387#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#82#78#article#218#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">A preval&ecirc;ncia    final de malignidad
e em pacientes com NT foi de 17,2% (70/407), sendo o carcinoma    papil&iacute;f
ero o tipo histol&oacute;gico mais frequente de c&acirc;ncer de    tiroide (87,2
%) (<a href="#t1">Tabela 1</a>).</font></p>     ^cY#04.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#83#79#article#218#<p>&nbsp;</p>     ^cY#04.
htm##
00256000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704003300070002000700103#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#84#80#article#218#<p><a name="t1"></a></p> 
    ^cY#04.htm##
00300000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704007700070002000700147#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#85#81#article#218#<p align="center"><img sr
c="/img/revistas/abem/v55n1/04t01.jpg"></p>     ^cY#04.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#86#82#article#218#<p>&nbsp;</p>     ^cY#04.
htm##
00354000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704013100070002000700201#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#87#83#article#218#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Caracter&iacute;sticas    cl&iacute;nic
as</b></font></p>     ^cY#04.htm##
00692000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704046900070002000700539#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#88#84#article#218#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">A frequ&ecirc;ncia    de c&acirc;ncer de t
iroide em mulheres com n&oacute;dulos tiroidianos foi significativamente    meno
r do que a de homens: 15,2% em mulheres e 27,9% homens (p = 0,034). N&atilde;o  
  houve diferen&ccedil;a estat&iacute;stica na preval&ecirc;ncia de c&acirc;ncer
    de tiroide entre pacientes com n&oacute;dulo &uacute;nico (15,6%) ou com BMN
    (17,5%) (p = 0,609).</font></p>     ^cY#04.htm##
00540000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704031700070002000700387#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#89#85#article#218#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">A preval&ecirc;ncia    de microcarcinoma e
m pacientes com c&acirc;ncer de tiroide foi de 25,7% (18/70),    sendo que em to
dos os casos tratava-se de microcarcinoma papil&iacute;fero e    em 94,4% dos ca
sos estava presente em mulheres.</font></p>     ^cY#04.htm##
00860000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704063700070002000700707#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#90#86#article#218#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Em nove casos (50%)    o diagn&oacute;stic
o de microcarcinoma foi incidental e em tr&ecirc;s destes    os n&oacute;dulos n
&atilde;o haviam sido visualizados previamente no US. Os    outros 50% foram pun
cionados anteriormente &agrave; cirurgia por apresentarem    caracter&iacute;sti
cas ultrassonogr&aacute;ficas suspeitas (n = 4) ou di&acirc;metro    maior que 1
 cm ao US (n = 5). O tamanho m&eacute;dio dos microcarcinomas no    histopatol&o
acute;gico foi de 6,6 mm (varia&ccedil;&atilde;o de 3 a 10 mm) com    77,8% dos 
n&oacute;dulos maiores que 5 mm.</font></p>     ^cY#04.htm##
00352000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704012900070002000700199#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#91#87#article#218#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Caracter&iacute;sticas    laboratoriais
</b></font></p>     ^cY#04.htm##
00574000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704035100070002000700421#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#92#88#article#218#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Foram analisados    os valores de TSH de p
acientes submetidos &agrave; cirurgia. Para essa an&aacute;lise,    foram inclu&
iacute;dos pacientes com carcinoma diferenciado de tiroide (CDT)    com valores 
de TSH dentro da normalidade e sem reposi&ccedil;&atilde;o de LT4.</font></p>   
  ^cY#04.htm##
00575000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704035200070002000700422#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#93#89#article#218#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">A m&eacute;dia    de TSH dos pacientes com
 n&oacute;dulos benignos (n = 77) n&atilde;o foi estatisticamente    diferente d
a m&eacute;dia dos pacientes com n&oacute;dulos malignos (n = 60)    (1,57 &plus
mn; 1,06 mcUI/ml <i>vs.</i> 1,77 &plusmn; 1,09 mcUI/ml, p = 0,291).</font></p>  
   ^cY#04.htm##
00762000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704053900070002000700609#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#94#90#article#218#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">A fim de se excluir    uma poss&iacute;vel
 interfer&ecirc;ncia nos valores de TSH, a an&aacute;lise    foi feita excluindo
 os pacientes com tiroidite linfoc&iacute;tica. A m&eacute;dia    de TSH dos pac
ientes com n&oacute;dulos benignos (n = 55) tamb&eacute;m n&atilde;o    foi esta
tisticamente diferente da m&eacute;dia dos pacientes com n&oacute;dulos    malig
nos (n = 48) (1,44 &plusmn; 1,04 mcUI/ml <i>vs</i>. 1,71 &plusmn; 1,11    mcUI/m
l, p = 0,203).</font></p>     ^cY#04.htm##
00751000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704052800070002000700598#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#95#91#article#218#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Foi feita a distribui&ccedil;&atilde;o    
dos pacientes com c&acirc;ncer para avaliar o aumento do risco de malignidade   
 de acordo com os n&iacute;veis de TSH ao diagn&oacute;stico. Essa an&aacute;lis
e    incluiu n&oacute;dulos com histopatologia de benignidade e CDT. Os dados de
    concentra&ccedil;&atilde;o s&eacute;rica de TSH foram subdivididos a partir 
   de valores determinados pela literatura (13,20-22) (<a href="#f4">Figura 4</a
>).</font></p>     ^cY#04.htm##
00256000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704003300070002000700103#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#96#92#article#218#<p><a name="f4"></a></p> 
    ^cY#04.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#97#93#article#218#<p>&nbsp;</p>     ^cY#04.
htm##
00300000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704007700070002000700147#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#98#94#article#218#<p align="center"><img sr
c="/img/revistas/abem/v55n1/04f04.jpg"></p>     ^cY#04.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#99#95#article#218#<p>&nbsp;</p>     ^cY#04.
htm##
00497000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000300056709000800059708000400067704027300071002000700344#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#100#96#article#218#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2">N&atilde;o houve    diferen&ccedil;a sign
ificante entre a preval&ecirc;ncia de malignidade e a concentra&ccedil;&atilde;o
    s&eacute;rica de TSH (teste exato de Fisher; n = 144; p = 0,291).</font></p>
     ^cY#04.htm##
00548000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000300056709000800059708000400067704032400071002000700395#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#101#97#article#218#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2">N&atilde;o houve    diferen&ccedil;a sign
ificativa na preval&ecirc;ncia de CDT em pacientes com    ou sem tiroidite linfo
c&iacute;tica confirmada pela histopatologia (benignos    n = 97 e malignos n = 
66) (31,7% <i>vs</i>. 43,9%, p = 0,185).</font></p>     ^cY#04.htm##
00372000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000300056709000800059708000400067704014800071002000700219#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#102#98#article#218#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2"><b>Rela&ccedil;&atilde;o    entre achados
 de US de CDT nos NT</b></font></p>     ^cY#04.htm##
00736000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000300056709000800059708000400067704051200071002000700583#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#103#99#article#218#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2">Para essa an&aacute;lise    foram inclu&i
acute;dos dados de pacientes com diagn&oacute;stico histopatol&oacute;gico    de
 benignidade, CDT e os com PAAF benignas n&atilde;o submetidos &agrave; cirurgia
.    Os pacientes com neoplasia indiferenciada, linfoma, c&acirc;ncer de mama e 
incidentalomas    (micron&oacute;dulos malignos encontrados na histopatologia n&
atilde;o identificados    previamente ao US) foram exclu&iacute;dos.</font></p> 
    ^cY#04.htm##
00508000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704028300072002000700355#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#104#100#article#218#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2">N&atilde;o houve    diferen&ccedil;a sig
nificativa em rela&ccedil;&atilde;o ao tamanho dos n&oacute;dulos    benignos e 
malignos (22,6 &plusmn; 14,6 mm <i>vs</i>. 24,1 &plusmn; 19,8 mm,    p = 0,431).
</font></p>     ^cY#04.htm##
00711000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704048600072002000700558#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#105#101#article#218#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2">A an&aacute;lise    das caracter&iacute;
sticas ultrassonogr&aacute;ficas dos NT evidenciou que as    les&otilde;es malig
nas em rela&ccedil;&atilde;o &agrave;s benignas eram mais    frequentemente hipo
ecog&ecirc;nicas (p &lt; 0,001), s&oacute;lidas (p = 0,001),    mal delimitadas 
(p = 0,036), sem halo (p &lt; 0,001) e com microcalcifica&ccedil;&otilde;es    (
p &lt; 0,001) (<a href="#t2">Tabela 2</a>).</font></p>     ^cY#04.htm##
00258000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704003300072002000700105#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#106#102#article#218#<p><a name="t2"></a></p
>     ^cY#04.htm##
00247000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002200072002000700094#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#107#103#article#218#<p>&nbsp;</p>     ^cY#0
4.htm##
00302000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704007700072002000700149#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#108#104#article#218#<p align="center"><img 
src="/img/revistas/abem/v55n1/04t02.jpg"></p>     ^cY#04.htm##
00247000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002200072002000700094#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#109#105#article#218#<p>&nbsp;</p>     ^cY#0
4.htm##
00824000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704059900072002000700671#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#110#106#article#218#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2">Com a finalidade    de identificar a com
bina&ccedil;&atilde;o de par&acirc;metros de US (vari&aacute;veis    independent
es) mais relevantes no diagn&oacute;stico de malignidade (vari&aacute;vel    dep
endente) por regress&atilde;o log&iacute;stica, inclu&iacute;mos as vari&aacute;
veis    independentes que foram significantes na an&aacute;lise univariada. Usam
os o    crit&eacute;rio SFLR para a sele&ccedil;&atilde;o das vari&aacute;veis i
ndependentes    (<a href="/img/revistas/abem/v55n1/04t03.jpg">Tabela 3</a>).</fo
nt></p>     ^cY#04.htm##
00600000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704037500072002000700447#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#111#107#article#218#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2">O modelo final    incluiu as vari&aacute
;veis microcalcifica&ccedil;&otilde;es e hipoecogenicidade.    A presen&ccedil;a
 de hipoecogenicidade aumenta em 5,18 vezes a chance de malignidade,    enquanto
 a presen&ccedil;a de microcalcifica&ccedil;&atilde;o aumenta em 15,57    vezes 
essa chance.</font></p>     ^cY#04.htm##
00399000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704017400072002000700246#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#112#108#article#218#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2"><b>Rela&ccedil;&atilde;o    entre CDT e 
os achados cl&iacute;nicos nos pacientes com NT</b></font></p>     ^cY#04.htm##
00749000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704052400072002000700596#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#113#109#article#218#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2">Para essa an&aacute;lise    tamb&eacute;
m inclu&iacute;mos os pacientes com diagn&oacute;stico histopatol&oacute;gico   
 de CDT, benignidade e os pacientes com PAAF benignas n&atilde;o submetidos &agr
ave;    cirurgia. Os pacientes com neoplasia indiferenciada, linfoma, c&acirc;nc
er de    mama e incidentalomas (micron&oacute;dulos malignos encontrados na hist
opatologia    n&atilde;o identificados previamente ao US) foram exclu&iacute;dos
.</font></p>     ^cY#04.htm##
00647000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704042200072002000700494#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#114#110#article#218#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2">Entre os pacientes    com NT, a propor&c
cedil;&atilde;o de CDT foi maior em homens do que em mulheres    (38,2% <i>vs</i
>. 17,4%, n = 332, p = 0,004); em n&oacute;dulos com hipoecogenicidade    (28,2%
 <i>vs</i>. 6,4%, n = 297, p &lt; 0,001) e naqueles com microcalcifica&ccedil;&a
tilde;o    (65,5% <i>vs</i>. 15,2%, n = 332, p &lt; 0,001).</font></p>     ^cY#0
4.htm##
00804000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704057900072002000700651#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#115#111#article#218#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2">N&atilde;o houve    diferen&ccedil;a sig
nificativa em rela&ccedil;&atilde;o ao n&uacute;mero de    n&oacute;dulos entre 
os pacientes com e sem CDT (1,98 &plusmn; 1,26 <i>vs</i>.    1,72 &plusmn; 0,95,
 p = 0,063) e em rela&ccedil;&atilde;o aos valores de TSH    (1,80 &plusmn; 1,18
 mcUI/ml <i>vs</i>. 1,71 &plusmn; 1,19 mcUI/ml, p = 0,615).    Por&eacute;m, os 
pacientes com CDT apresentavam idade menor do que os sem CDT    (44,5 &plusmn; 1
5,3 anos <i>vs</i>. 50,1 &plusmn; 14,2 anos, p = 0,006).</font></p>     ^cY#04.h
tm##
00897000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704067200072002000700744#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#116#112#article#218#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2">Foi feita a an&aacute;lise    por regres
s&atilde;o log&iacute;stica para identificar a combina&ccedil;&atilde;o    de pa
r&acirc;metros cl&iacute;nicos e de US (vari&aacute;veis independentes)    mais 
relevantes no diagn&oacute;stico de malignidade (vari&aacute;vel dependente).   
 Para isso, inclu&iacute;mos as vari&aacute;veis independentes citadas anteriorm
ente    que foram significantes na an&aacute;lise univariada. Foi utilizado o cr
it&eacute;rio    SFLR para a sele&ccedil;&atilde;o das vari&aacute;veis independ
entes (<a href="/img/revistas/abem/v55n1/04t04.jpg">Tabela    4</a>).</font></p>
     ^cY#04.htm##
00787000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704056200072002000700634#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#117#113#article#218#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2">O modelo final    incluiu as vari&aacute
;veis idade, presen&ccedil;a de microcalcifica&ccedil;&otilde;es    e hipoecogen
icidade. A presen&ccedil;a de pelo menos um n&oacute;dulo hipoecog&ecirc;nico   
 aumenta em 4,90 vezes o risco de malignidade, enquanto a presen&ccedil;a de    
pelos menos um n&oacute;dulo com microcalcifica&ccedil;&atilde;o aumenta em    8
,28 vezes o risco de malignidade. Por outro lado, para cada ano de vida o risco 
   de malignidade se reduz em 0,97 vez.</font></p>     ^cY#04.htm##
00247000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002200072002000700094#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#118#114#article#218#<p>&nbsp;</p>     ^cY#0
4.htm##
00331000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704010600072002000700178#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#119#115#article#218#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="3"><b>DISCUSS&Atilde;O</b></font></p>     ^
cY#04.htm##
00900000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704067500072002000700747#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#120#116#article#218#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2">A proposta do presente    estudo foi ava
liar fatores de risco para c&acirc;ncer de tiroide na tentativa    de auxiliar n
a decis&atilde;o de quais NT devem realmente ser encaminhados para    tratamento
 cir&uacute;rgico. Em nossos pacientes com NT, a preval&ecirc;ncia    de c&acirc
;ncer foi de 17,2%, aparentemente maior do que a observada em outros    estudos 
(5%-15%) (2,7,23), provavelmente por tratar-se de um servi&ccedil;o    de refer&
ecirc;ncia em que alguns pacientes encaminhados foram previamente avaliados    p
or endocrinologistas e apresentavam uma maior suspeita para malignidade.</font><
/p>     ^cY#04.htm##
01366000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704114100072002000701213#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#121#117#article#218#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2">Uma revis&atilde;o    de Heged&uuml;s (4
) mostrou que a frequ&ecirc;ncia final dos resultados citol&oacute;gicos    da P
AAF varia de 53% a 90% para n&oacute;dulos benignos, 5% a 23% para indeterminado
s,    1% a 10% para malignos e 15% a 20% para n&atilde;o diagn&oacute;sticos. Em
 nosso    estudo, observamos um menor n&uacute;mero de PAAF n&atilde;o diagn&oac
ute;sticas    (7,6%), provavelmente pela grande experi&ecirc;ncia do puncionador
 e do citologista    que participaram do estudo. Banks e cols. (24), avaliando 6
39 pacientes com    les&otilde;es indeterminadas na PAAF, encontraram 30% e 62% 
de malignidade em    les&otilde;es foliculares e suspeitas de carcinoma, respect
ivamente. Outros    autores mostraram uma preval&ecirc;ncia de malignidade varia
ndo entre 12% e    40% em les&otilde;es indeterminadas pela PAAF (25-26). Em nos
so estudo, os resultados    foram semelhantes: a preval&ecirc;ncia de c&acirc;nc
er em n&oacute;dulos com    PAAF indeterminada foi de 18,5%, sendo 16% nas les&o
tilde;es foliculares e 44%    nas les&otilde;es suspeitas.</font></p>     ^cY#04
.htm##
00938000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704071300072002000700785#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#122#118#article#218#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2">Comparando os nossos    resultados com a
 nova classifica&ccedil;&atilde;o das PAAF pelo Sistema Bethesda    (2009) (27),
 podemos observar que nossas les&otilde;es foliculares apresentam    risco de ma
lignidade (16%) semelhante ao do grupo de les&otilde;es foliculares    de signif
icado indeterminado da classifica&ccedil;&atilde;o atual (5% a 15%).    J&aacute
; os nossos pacientes com les&otilde;es suspeitas (risco de 44% de malignidade) 
   provavelmente englobam pacientes que seriam atualmente classificados nos grup
os    de neoplasia folicular (risco de 20% a 30%) e de suspeitos para malignidad
e    (risco de 50% a 75% (27).</font></p>     ^cY#04.htm##
01704000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704147900072002000701551#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#123#119#article#218#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2">O tipo histopatol&oacute;gico    mais fr
equente de c&acirc;ncer de tiroide &eacute; o carcinoma papil&iacute;fero    (80
% a 87%) (7,13,18) e observamos uma ocorr&ecirc;ncia em nosso estudo de 87,2%.  
  Entre os pacientes com c&acirc;ncer de tiroide, 25,7% apresentavam microcarcin
oma    de tiroide, todos do tipo papil&iacute;fero. O microcarcinoma de tiroide 
em    65% a 99% &eacute; do tipo papil&iacute;fero (28) e sua preval&ecirc;ncia 
tem    aumentado (29); Roti e cols. (28) conclu&iacute;ram que microcarcinoma pa
pil&iacute;fero    est&aacute; presente em um quarto dos casos de malignidade de
 tiroide. O principal    fator associado ao aumento do diagn&oacute;stico de mic
rocarcinoma papil&iacute;fero    &eacute; o uso do US de tiroide. A recomenda&cc
edil;&atilde;o das diversas sociedades    &eacute; que n&oacute;dulos menores qu
e 1 cm sejam puncionados somente na presen&ccedil;a    de caracter&iacute;sticas
 suspeitas, linfadenopatia, hist&oacute;ria de irradia&ccedil;&atilde;o    cervi
cal ou hist&oacute;ria familiar de c&acirc;ncer de tiroide em parentes    de pri
meiro grau (17,18,30). Em nosso estudo, os microcarcinomas papil&iacute;feros   
 que foram diagnosticados pela PAAF apresentavam ao menos duas caracter&iacute;s
ticas    ultrassonogr&aacute;ficas suspeitas, tais como hipoecogenicidade, aus&e
circ;ncia    de halo ou presen&ccedil;a de microcalcifica&ccedil;&otilde;es.</fo
nt></p>     ^cY#04.htm##
00560000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704033500072002000700407#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#124#120#article#218#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2">Em rela&ccedil;&atilde;o    aos dados cl
&iacute;nicos, os indiv&iacute;duos do sexo masculino apresentaram    maior risc
o de malignidade do que as mulheres (27,9% e 15,2%, respectivamente)    conforme
 observado tamb&eacute;m por outros autores (13,23).</font></p>     ^cY#04.htm##
01298000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704107300072002000701145#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#125#121#article#218#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2">Por meio da an&aacute;lise    de regress
&atilde;o m&uacute;ltipla observamos uma rela&ccedil;&atilde;o inversa    entre 
idade e risco de malignidade. Rago e cols. (31) recentemente demonstraram    res
ultados semelhantes na avalia&ccedil;&atilde;o do risco para carcinoma papil&iac
ute;fero    de tiroide. Alguns estudos, no entanto, demonstraram uma maior ocorr
&ecirc;ncia    de c&acirc;ncer de tiroide em pacientes com idade abaixo de 30 an
os e acima    de 70 anos (2,9,13,23,24). Em nosso estudo, por&eacute;m, n&atilde
;o houve um    aumento de risco de c&acirc;ncer com o aumento da faixa et&aacute
;ria. Alguns    dados recentes citados em uma revis&atilde;o de Alexander (23) s
&atilde;o contradit&oacute;rios    em rela&ccedil;&atilde;o ao maior risco de c&
acirc;ncer em indiv&iacute;duos    mais idosos, permanecendo incerto se realment
e esse risco existe, sendo prudente    assumir que, considerando a idade do paci
ente, indiv&iacute;duos mais jovens    apresentam maior risco (11,23).</font></p
>     ^cY#04.htm##
00670000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704044500072002000700517#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#126#122#article#218#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2">Boelaert e cols.    (9) observaram um ri
sco maior de malignidade em n&oacute;dulo &uacute;nico comparado    com paciente
s com b&oacute;cio multinodular e b&oacute;cio difuso (9); no entanto,    observ
amos risco semelhante de malignidade em n&oacute;dulo &uacute;nico e em    b&oac
ute;cio multinodular, de acordo com a maioria dos trabalhos recentes (7,12,14,18
).</font></p>     ^cY#04.htm##
01427000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704120200072002000701274#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#127#123#article#218#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2">A rela&ccedil;&atilde;o    do TSH com CD
T n&atilde;o est&aacute; bem estabelecida. J&aacute; se demonstrou    que no CDT
 n&atilde;o ocorre muta&ccedil;&atilde;o no receptor de TSH associada    com aum
ento de transdu&ccedil;&atilde;o (32); outros fatores como IGF-1 s&atilde;o    i
mportantes para crescimento tumoral e existe uma rela&ccedil;&atilde;o inversa  
  entre n&iacute;vel de RNAm do receptor de TSH e agressividade do tumor (33-34)
.    Por outro lado, h&aacute; evid&ecirc;ncia clara do aumento de sobrevida em 
pacientes    com c&acirc;ncer mantidos com TSH suprimido em uso de LT4 (35). Por
 essa raz&atilde;o,    alguns autores avaliaram a concentra&ccedil;&atilde;o de 
TSH de pacientes com    CDT e observaram maior risco de malignidade com o aument
o dos seus n&iacute;veis    (9,13). Em um desses estudos, a m&eacute;dia de TSH 
no grupo de pacientes com    c&acirc;ncer de tiroide foi mais alta (13). Nossos 
resultados n&atilde;o evidenciaram    um maior risco de CDT com o aumento do TSH
 e n&atilde;o houve diferen&ccedil;a    entre as m&eacute;dias de TSH dos pacien
tes com ou sem c&acirc;ncer de tiroide.</font></p>     ^cY#04.htm##
00802000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704057700072002000700649#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#128#124#article#218#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2">Outros fatores    de risco controversos 
avaliados em estudos recentes, como fatores de risco para    c&acirc;ncer de tir
oide, al&eacute;m do TSH, s&atilde;o: os n&iacute;veis de    leptina que se enco
ntram elevados e diminuem ap&oacute;s a tiroidectomia (36);    o &iacute;ndice d
e massa corporal aumentado (37) e a presen&ccedil;a de resist&ecirc;ncia    insu
l&iacute;nica, que tem se mostrado tamb&eacute;m como importante fator de    ris
co para outros carcinomas n&atilde;o tiroidianos (38).</font></p>     ^cY#04.htm
##
01731000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704150600072002000701578#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#129#125#article#218#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2">Ao analisarmos    as caracter&iacute;sti
cas ultrassonogr&aacute;ficas dos NT de forma univariada,    observamos que a pr
esen&ccedil;a de hipoecogenicidade, aus&ecirc;ncia de halo,    presen&ccedil;a d
e microcalcifica&ccedil;&otilde;es e les&otilde;es mal delimitadas    estavam pr
esentes de forma significativa em NT malignos. N&atilde;o houve diferen&ccedil;a
    significante entre o tamanho dos n&oacute;dulos benignos e malignos. A an&aa
cute;lise    multivariada demonstrou que NT hipoecog&ecirc;nico aumenta em 4,9 v
ezes a chance    de malignidade, enquanto a presen&ccedil;a de pelos menos um n&
oacute;dulo com    microcalcifica&ccedil;&atilde;o aumenta em 8,2 vezes a chance
 de malignidade.    Frates e cols. (7) observaram que a composi&ccedil;&atilde;o
 do n&oacute;dulo    (quanto maior o componente s&oacute;lido maior o risco), a 
hipoecogenicidade    e a presen&ccedil;a de calcifica&ccedil;&otilde;es foram fa
tores de risco para    malignidade, enquanto a presen&ccedil;a de halo e o taman
ho do n&oacute;dulo    n&atilde;o foram de significado progn&oacute;stico. Papin
i e cols. (14) observaram    que a presen&ccedil;a de fluxo vascular intranodula
r avaliado pelo Doppler estava    mais relacionado com malignidade assim como a 
presen&ccedil;a de microcalcifica&ccedil;&otilde;es    e les&otilde;es irregular
es; a hipoecogenicidade e o tamanho do n&oacute;dulo,    no entanto, n&atilde;o 
foram fatores de risco.</font></p>     ^cY#04.htm##
01204000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704097900072002000701051#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#130#126#article#218#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2">Avaliamos a histopatologia    para confi
rmar a presen&ccedil;a ou n&atilde;o de tiroidite linfocit&aacute;ria    cr&ocir
c;nica e n&atilde;o observamos associa&ccedil;&atilde;o com CDT. Para    Boelaer
t e cols. (9), a presen&ccedil;a de anticorpos antitiroidianos n&atilde;o    foi
 considerada um fator de risco independente para malignidade. No entanto,    em 
pacientes com tiroidite de Hashimoto e n&oacute;dulos bem definidos a recomenda&
ccedil;&atilde;o    &eacute; que seja realizada a PAAF tanto para afastar a pres
en&ccedil;a de CDT    quanto de linfoma, embora este seja raro (17). Nosso pacie
nte com diagn&oacute;stico    de linfoma apresentava tiroidite de Hashimoto pr&e
acute;via ao diagn&oacute;stico    de malignidade; a maior ocorr&ecirc;ncia de l
infoma em pacientes com doen&ccedil;a    linfocit&aacute;ria cr&ocirc;nica assoc
iada est&aacute; bem estabelecida na    literatura (39).</font></p>     ^cY#04.h
tm##
00751000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704052600072002000700598#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#131#127#article#218#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2">Conclu&iacute;mos    que o risco de mali
gnidade foi maior no sexo masculino, em n&oacute;dulos hipoecog&ecirc;nicos    e
 com microcalcifica&ccedil;&otilde;es vistos ao US. Houve uma rela&ccedil;&atild
e;o    inversa entre idade e risco de malignidade. O n&uacute;mero de n&oacute;d
ulos,    o n&iacute;vel de TSH e a presen&ccedil;a de tiroidite linfoc&iacute;ti
ca cr&ocirc;nica    n&atilde;o foram fatores de risco para c&acirc;ncer de tiroi
de.</font></p>     ^cY#04.htm##
00468000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704024300072002000700315#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#132#128#article#218#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2">Agradecimentos:    ao apoio da Coordena&
ccedil;&atilde;o de Aperfei&ccedil;oamento de Pessoal de    N&iacute;vel Superio
r (Capes) por meio de bolsa de Mestrado.</font></p>     ^cY#04.htm##
00431000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704020600072002000700278#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#133#129#article#218#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2">Declara&ccedil;&atilde;o:    os autores 
declaram n&atilde;o haver conflitos de interesse cient&iacute;fico    neste estu
do.</font></p>     ^cY#04.htm##
00247000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002200072002000700094#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#134#130#article#218#<p>&nbsp;</p>     ^cY#0
4.htm##
00332000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704010700072002000700179#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#135#131#article#218#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="3"><b>REFER&Ecirc;NCIAS</b></font></p>     
^cY#04.htm##
00526000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000200072704028700074002000700361#v55
n1#V:\SciELO\serial\abem\v55n1\markup\04.htm#S#p#136#132#article#218#1#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">1. Wiest PW, Hartshome    
MF, Inskip PD, Crooks LA, Vela BS, Telepak RJ, et al. Thyroid palpation versus  
  high-resolution thyroid ultrasonography in the detection of nodules. J Ultraso
und    Med. 1998;17(8):487-96.    ^cY#04.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#137#133#article#218#</font></p>     ^cY#04.
htm##
00505000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000200072704026600074002000700340#v55
n1#V:\SciELO\serial\abem\v55n1\markup\04.htm#S#p#138#134#article#218#2#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">2. Cooper DS, Doherty    G
M, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Management guidelines for    p
atients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006;16
(2):1-24.    ^cY#04.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#139#135#article#218#</font></p>     ^cY#04.
htm##
00485000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000200072704024600074002000700320#v55
n1#V:\SciELO\serial\abem\v55n1\markup\04.htm#S#p#140#136#article#218#3#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">3. Tan GH, Gharib    H. Th
yroid incidentalomas: management approaches to nonpalpable nodules discovered   
 incidentally on thyroid imaging. Ann Intern Med. 1997;126(3):226-31.    ^cY#04.
htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#141#137#article#218#</font></p>     ^cY#04.
htm##
00386000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000200072704014700074002000700221#v55
n1#V:\SciELO\serial\abem\v55n1\markup\04.htm#S#p#142#138#article#218#4#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">4. Heged&uuml;s    L. The 
thyroid nodule. N Eng J Med. 2004;351(17):1764-71.    ^cY#04.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#143#139#article#218#</font></p>     ^cY#04.
htm##
00469000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000200072704023000074002000700304#v55
n1#V:\SciELO\serial\abem\v55n1\markup\04.htm#S#p#144#140#article#218#5#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">5. Heged&uuml;s    L, Bonn
ema SJ, Bennedbaek FN. Management of simple nodular goiter: current status    an
d future perspectives. Endocr Ver. 2003;24(1):102-32.    ^cY#04.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#145#141#article#218#</font></p>     ^cY#04.
htm##
00524000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000200072704028500074002000700359#v55
n1#V:\SciELO\serial\abem\v55n1\markup\04.htm#S#p#146#142#article#218#6#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">6. Lloyd R, De    Lellis R
, Heitz P, Eng C. World Health Organization: pathologic and genetics    of tumor
s of endocrine organs. Lyon, Fran&ccedil;a: IARC Press International    Agency f
or Research on Cancer; 2004.    ^cY#04.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#147#143#article#218#</font></p>     ^cY#04.
htm##
00555000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000200072704031600074002000700390#v55
n1#V:\SciELO\serial\abem\v55n1\markup\04.htm#S#p#148#144#article#218#7#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">7. Frates MC, Benson    CB
, Doubilet PM, Kunreuther E, Contreras M, Cibas ES, et al. Prevalence and    dis
tribution of carcinoma in patients with solitary and multiple thyroid nodules   
 on sonography. J Clin Endocrinol Metab. 2006;91(9):3411-7.    ^cY#04.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#149#145#article#218#</font></p>     ^cY#04.
htm##
00469000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000200072704023000074002000700304#v55
n1#V:\SciELO\serial\abem\v55n1\markup\04.htm#S#p#150#146#article#218#8#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">8. Shibata Y, Yamashita   
 S, Masyakin VB, Panasyuk GD, Nagataki S. 15 years after Chernobyl: new evidence
    of thyroid cancer. Lancet. 2001;358(9297):1965-6.    ^cY#04.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#151#147#article#218#</font></p>     ^cY#04.
htm##
00568000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000200072704032900074002000700403#v55
n1#V:\SciELO\serial\abem\v55n1\markup\04.htm#S#p#152#148#article#218#9#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">9. Boelaert K,    Horacek 
J, Holder RL, Watkinson JC, Sheppard MC, Franklyn JA. Serum thyrotropin    conce
ntration as a novel predictor of malignancy in thyroid nodules investigated    b
y fine-needle aspiration. J Clin Endocrinol Metab. 2006;91(11):4295-301.    ^cY#
04.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#153#149#article#218#</font></p>     ^cY#04.
htm##
00406000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704016600075002000700241#v55
n1#V:\SciELO\serial\abem\v55n1\markup\04.htm#S#p#154#150#article#218#10#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">10. Mazzaferri    EL. Man
agement of a solitary thyroid nodule. N Engl J Med. 1993;328(8):553-9.    ^cY#04
.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#155#151#article#218#</font></p>     ^cY#04.
htm##
00536000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704029600075002000700371#v55
n1#V:\SciELO\serial\abem\v55n1\markup\04.htm#S#p#156#152#article#218#11#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">11. Belfiore A,    La Ros
a GL, La Porta GA, Giuffrida D, Milazzo G, Lupo L, et al. Cancer risk    in pati
ents with cold thyroid nodules: relevance of iodine intake, sex, age    and mult
inodularity. Am J Med. 1992;93(4):363-9.    ^cY#04.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#157#153#article#218#</font></p>     ^cY#04.
htm##
00511000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704027100075002000700346#v55
n1#V:\SciELO\serial\abem\v55n1\markup\04.htm#S#p#158#154#article#218#12#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">12. Marqusee E,    Benson
 CB, Frates MC, Doubilet PM, Larsen PR, Cibas ES, et al. Usefulness of    ultras
onography in the management of nodular thyroid disease. Ann Intern Med.    2000;
133(9):696-700.    ^cY#04.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#159#155#article#218#</font></p>     ^cY#04.
htm##
00587000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704034700075002000700422#v55
n1#V:\SciELO\serial\abem\v55n1\markup\04.htm#S#p#160#156#article#218#13#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">13. Haymart MR,    Reppli
nger DJ, Leverson GE, Elson DF, Sippel RS, Jaume JC, et al. Higher serum    TSH 
level in thyroid nodule patients is associated with greater risks of differentia
ted    thyroid cancer and advanced tumor stage. J Clin Endocrinol Metab. 2008;93
(3):809-14.    ^cY#04.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#161#157#article#218#</font></p>     ^cY#04.
htm##
00554000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704031400075002000700389#v55
n1#V:\SciELO\serial\abem\v55n1\markup\04.htm#S#p#162#158#article#218#14#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">14. Papini E, Guglielmi  
  R, Bianchini A, Crescenzi A, Taccogna S, Nardi F, et al. Risk of malignancy   
 in nonpalpable thyroid nodules: predictive value of ultrasound and color-Dopple
r    features. J Clin Endocrinol Metab. 2002;87(5):1941-6.    ^cY#04.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#163#159#article#218#</font></p>     ^cY#04.
htm##
00531000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704029100075002000700366#v55
n1#V:\SciELO\serial\abem\v55n1\markup\04.htm#S#p#164#160#article#218#15#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">15. Nam-Goong IS,    Kim 
HY, Gong G, Lee HK, Hong SJ, Kim WB, et al. Ultrasonography-guided fine-needle  
  aspiration of thyroid incidentaloma: correlation with pathological findings.  
  Clin Endocrinol. 2004;60(1):21-8.    ^cY#04.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#165#161#article#218#</font></p>     ^cY#04.
htm##
00552000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704031200075002000700387#v55
n1#V:\SciELO\serial\abem\v55n1\markup\04.htm#S#p#166#162#article#218#16#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">16. Rago T, Vitti    P, C
hiovato SM, Mazzeo S, DeLiperi A, Miccolo P, et al. Role of conventional    ultr
asonography and color flow-Doppler sonography in predicting malignancy in    "co
ld" thyroid nodules. Eur J Endocrinol. 1998;138(1):41-6.    ^cY#04.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#167#163#article#218#</font></p>     ^cY#04.
htm##
00542000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704030200075002000700377#v55
n1#V:\SciELO\serial\abem\v55n1\markup\04.htm#S#p#168#164#article#218#17#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">17. Maia AL, Ward    LS, 
Carvalho GA, Graf H, Maciel RMB, Maciel LMZ, et al. N&oacute;dulos de tire&oacut
e;ide    e c&acirc;ncer diferenciado de tire&oacute;ide: consenso brasileiro. Ar
q Bras    Endocrinol Metab. 2007;51(5):867-93.    ^cY#04.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#169#165#article#218#</font></p>     ^cY#04.
htm##
00549000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704030900075002000700384#v55
n1#V:\SciELO\serial\abem\v55n1\markup\04.htm#S#p#170#166#article#218#18#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">18. Pacini F, Schlumberge
r    M, Dralle H, Elisei R, Smit JWA, Wiersinga W. European consensus for the ma
nagement    of patients with differentiated thyroid carcinoma of the follicular 
epithelium.    Eur J Endocrinol. 2006;154(6):787-803.    ^cY#04.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#171#167#article#218#</font></p>     ^cY#04.
htm##
00441000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704020100075002000700276#v55
n1#V:\SciELO\serial\abem\v55n1\markup\04.htm#S#p#172#168#article#218#19#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">19. Castro MR,    Gharib 
H. Continuing controversies in the management of thyroid nodules. Ann    Intern 
Med. 2005;142(11):926-31.    ^cY#04.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#173#169#article#218#</font></p>     ^cY#04.
htm##
00601000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704036100075002000700436#v55
n1#V:\SciELO\serial\abem\v55n1\markup\04.htm#S#p#174#170#article#218#20#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">20. Kratzsch J,    Fiedle
r GM, Leichtle A, Br&uuml;gel M, Buchbinder S, Otto L, et al. New reference    i
ntervals for thyrotropin and thyroid hormones based on National Academy of    Cl
inical Biochemistry criteria and regular ultrasonography of the thyroid. Clin   
 Chem. 2005;51(8):1480-6.    ^cY#04.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#175#171#article#218#</font></p>     ^cY#04.
htm##
00599000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704035900075002000700434#v55
n1#V:\SciELO\serial\abem\v55n1\markup\04.htm#S#p#176#172#article#218#21#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">21. Hollowell JG,    Stae
hling NW, Flanders D, Hannon WH, Gunter EW, Spencer CA, et al. Serum TSH,    T4 
and thyroid antibodies in The United States population (1988 to 1994): National 
   Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab
.    2002;87(2):489-99.    ^cY#04.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#177#173#article#218#</font></p>     ^cY#04.
htm##
00504000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704026400075002000700339#v55
n1#V:\SciELO\serial\abem\v55n1\markup\04.htm#S#p#178#174#article#218#22#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">22. Surks MI, Ortiz    E,
 Daniels GH, Sawin CT, Col NF, Cobin RH, et al. Subclinical thyroid disease:    
scientific review and guidelines for diagnosis and management. JAMA. 2004;291(2)
:228-38.    ^cY#04.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#179#175#article#218#</font></p>     ^cY#04.
htm##
00455000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704021500075002000700290#v55
n1#V:\SciELO\serial\abem\v55n1\markup\04.htm#S#p#180#176#article#218#23#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">23. Alexander EK.    Appr
oach to the patient with a cytologically indeterminate thyroid nodule. J    Clin
 Endocrinol Metab. 2008;93(11):4175-82.    ^cY#04.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#181#177#article#218#</font></p>     ^cY#04.
htm##
00503000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704026300075002000700338#v55
n1#V:\SciELO\serial\abem\v55n1\markup\04.htm#S#p#182#178#article#218#24#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">24. Banks ND, Kowalski   
 J, Tsai HL, Somervell H, Tufano R, Dackiw APB, et al. A diagnostic predictor   
 model for indeterminate or suspicious thyroid FNA samples. Thyroid. 2008;18(9):
933-41.    ^cY#04.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#183#179#article#218#</font></p>     ^cY#04.
htm##
00527000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704028700075002000700362#v55
n1#V:\SciELO\serial\abem\v55n1\markup\04.htm#S#p#184#180#article#218#25#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">25. Goldstein RE,    Burk
ey B, Johnson JE. Implications of follicular neoplasms, atypia and lesions    su
spicious of malignancy diagnosed by fine-needle aspiration of thyroid nodules.  
  Ann Surg. 2002;235(5):656-64.    ^cY#04.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#185#181#article#218#</font></p>     ^cY#04.
htm##
00518000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704027800075002000700353#v55
n1#V:\SciELO\serial\abem\v55n1\markup\04.htm#S#p#186#182#article#218#26#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">26. Kelman AS,    Leibowi
tz J, Burstein DE, Haber RS. Thyroid cytology and the risk of malignancy    in t
hyroid nodules: importance of nuclear atypia in indeterminate specimens.    Thyr
oid. 2001;11(3):271-7.    ^cY#04.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#187#183#article#218#</font></p>     ^cY#04.
htm##
00440000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704020000075002000700275#v55
n1#V:\SciELO\serial\abem\v55n1\markup\04.htm#S#p#188#184#article#218#27#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">27. Layfield LJ,    Cibas
 ES, Gharib H, Mandel SJ. Thyroid aspiration cytology. Current Status.    Cancer
 J Clin. 2009;59:99-110.    ^cY#04.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#189#185#article#218#</font></p>     ^cY#04.
htm##
00474000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704023400075002000700309#v55
n1#V:\SciELO\serial\abem\v55n1\markup\04.htm#S#p#190#186#article#218#28#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">28. Roti E, Uberti    EC,
 Bondanelli M, Braverman LE. Thyroid papillary microcarcinoma: a descriptive    
meta-analysis study. Eur J Endocrinol. 2008;159(6):656-73.    ^cY#04.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#191#187#article#218#</font></p>     ^cY#04.
htm##
00545000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704030500075002000700380#v55
n1#V:\SciELO\serial\abem\v55n1\markup\04.htm#S#p#192#188#article#218#29#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">29. Leenhardt L,    Grosc
laude P, Ch&eacute;ri&eacute;-Challine L. Thyroid Cancer Committee. Increase    
incidence of thyroid carcinoma in France: a true epidemic of thyroid nodule    m
anagements effect? Thyroid. 2004;14(12):1056-106.    ^cY#04.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#193#189#article#218#</font></p>     ^cY#04.
htm##
00552000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704031200075002000700387#v55
n1#V:\SciELO\serial\abem\v55n1\markup\04.htm#S#p#194#190#article#218#30#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">30. Cooper DS,    Doherty
 GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American    Thyroid 
Association management guidelines for patients with thyroid nodules    and diffe
rentiated thyroid cancer. Thyroid. 2009;19(11):1167-214.    ^cY#04.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#195#191#article#218#</font></p>     ^cY#04.
htm##
00555000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704031500075002000700390#v55
n1#V:\SciELO\serial\abem\v55n1\markup\04.htm#S#p#196#192#article#218#31#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">31. Rago T, Fiore    E, S
cutari M, Santini F, Di Coscio G, Romani R, et al. Cytology suspicious for    or
 indicative of PTC is associated with younger age, male sex, and solitary    ver
sus multiple nodularity. Eur J Endocrinol. 2010;162:763-70.    ^cY#04.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#197#193#article#218#</font></p>     ^cY#04.
htm##
00661000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704042100075002000700496#v55
n1#V:\SciELO\serial\abem\v55n1\markup\04.htm#S#p#198#194#article#218#32#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">32. Matsuo K, Friedman   
 E, Gejman PV, Fagin JA. The thyrotropin receptor (TSH-R) is not an oncogene    
for thyroid tumors: structural studies of the TSH-R and the </font><font size="2
">&#945;</font><font face="Verdana, Arial, Helvetica, sans-serif" size="2">-subu
nit    of Gs in human thyroid neoplasms. J Clin Endocrinol Metab. 1993;76(6):144
6-51.    ^cY#04.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#199#195#article#218#</font></p>     ^cY#04.
htm##
00487000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704024700075002000700322#v55
n1#V:\SciELO\serial\abem\v55n1\markup\04.htm#S#p#200#196#article#218#33#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">33. Derwahl M,    Broecke
r M, Kraiem Z. Thyrotropin may not be the dominant growth factor in benign    an
d malignant thyroid tumors. J Clin Endocrinol Metab. 1999;84(3):829-34.    ^cY#0
4.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#201#197#article#218#</font></p>     ^cY#04.
htm##
00434000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704019400075002000700269#v55
n1#V:\SciELO\serial\abem\v55n1\markup\04.htm#S#p#202#198#article#218#34#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">34. Mazzaferri    EL. Thy
roid cancer and Graves disease: the controversy ten years later. Endocr    Pract
. 2000;6(2):221-5.    ^cY#04.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#203#199#article#218#</font></p>     ^cY#04.
htm##
00508000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704026800075002000700343#v55
n1#V:\SciELO\serial\abem\v55n1\markup\04.htm#S#p#204#200#article#218#35#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">35. Jonklaas J,    Sarlis
 NJ, Litofsky D, Ain KB, Bigos ST, Bierley JD, et al. Outcomes of patients    wi
th differentiated thyroid carcinoma following initial therapy. Thyroid. 2006;16(
12):1229-42.    ^cY#04.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#205#201#article#218#</font></p>     ^cY#04.
htm##
00440000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704020000075002000700275#v55
n1#V:\SciELO\serial\abem\v55n1\markup\04.htm#S#p#206#202#article#218#36#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">36. Akinci M, Kosova    F
, Cetin B, Aslan S, Ari Z, Cetin A. Leptin levels in thyroid cancer. Asian    J 
Surg. 2009;32(4):216-23.    ^cY#04.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#207#203#article#218#</font></p>     ^cY#04.
htm##
00554000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704031400075002000700389#v55
n1#V:\SciELO\serial\abem\v55n1\markup\04.htm#S#p#208#204#article#218#37#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">37. Paes JE, Hua    K, Na
gy R, Kloos RT, Jarioura D, Ringel MD. The relationship between body mass    ind
ex and thyroid cancer pathology features and outcomes: a clinicopathological    
cohort study. J Clin Endocrinol Metab. 2010;95(9):4244-50.    ^cY#04.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#209#205#article#218#</font></p>     ^cY#04.
htm##
00539000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704029900075002000700374#v55
n1#V:\SciELO\serial\abem\v55n1\markup\04.htm#S#p#210#206#article#218#38#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">38. Rezz&oacute;nico    J
N, Rezz&oacute;nico M, Pusiol E, Pitoia F, Niepomniszcze H. Increases prevalence
    of insulin resistance in patients with differentiated thyroid carcinoma. Met
ab    Syndr Relat Disord. 2009;7(4):375-80.    ^cY#04.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#211#207#article#218#</font></p>     ^cY#04.
htm##
00428000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704018800075002000700263#v55
n1#V:\SciELO\serial\abem\v55n1\markup\04.htm#S#p#212#208#article#218#39#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">39. Pasieka JL.    Hashim
oto's disease and thyroid lymphoma: role of the surgeon. World J Surg.    2000;2
4(8):966-70.    ^cY#04.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#213#209#article#218#</font></p>     ^cY#04.
htm##
00247000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002200072002000700094#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#214#210#article#218#<p>&nbsp;</p>     ^cY#0
4.htm##
00247000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002200072002000700094#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#215#211#article#218#<p>&nbsp;</p>     ^cY#0
4.htm##
00424000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704019900072002000700271#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#216#212#article#218#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2"><b><a name="back"></a><a href="#top"><im
g src="/img/revistas/abem/v55n1/seta.jpg" border="0"></a>    Correspond&ecirc;nc
ia para:    ^cY#04.htm##
00264000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704003900072002000700111#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#217#213#article#218#<br>   </b> Ana Luiza S
ilva Rio    ^cY#04.htm##
00291000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704006600072002000700138#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#218#214#article#218#<br>   Av. Almirante Al
exandrino de Alencar, 1618, ap. 301    ^cY#04.htm##
00269000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704004400072002000700116#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#219#215#article#218#<br>   59015-350 - Nata
l, RN, Brasil    ^cY#04.htm##
00314000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704008900072002000700161#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#220#216#article#218#<br>   <a href="mailto:
anario01@hotmail.com">anario01@hotmail.com</a></font></p>     ^cY#04.htm##
00319000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704009400072002000700166#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#221#217#article#218#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2">Recebido em 30/Set/2010    ^cY#04.htm##
00273000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704004800072002000700120#v55n1#V:\SciELO
\serial\abem\v55n1\markup\04.htm#S#p#222#218#article#218#<br>   Aceito em 13/Jan
/2011</font></p>     ^cY#04.htm##
00713000000000349000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100016000710100020000870100
01700107010001700124010001500141010001800156810000600174012009700180030001700277
06500090029406400050030303100030030803200020031101400070031386500090032000200070
0329035001000336801001700346#v55n1#V:\SciELO\serial\abem\v55n1\markup\04.htm#S#c
#223#1#article#39#1#^rND^sWiest^nPW#^rND^sHartshome^nMF#^rND^sInskip^nPD#^rND^sC
rooks^nLA#^rND^sVela^nBS#^rND^sTelepak^nRJ#et al#Thyroid palpation versus high-r
esolution thyroid ultrasonography in the detection of nodules^len#J Ultrasound M
ed#19980000#1998#17#8#487-96#20110200#04.htm#0278-4297#J Ultrasound Med##
00686000000000349000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100017000710100018000880100
01700106010001600123010001400139010001700153810000600170012009400176030000800270
06500090027806400050028703100030029203200020029501400050029786500090030200200070
0311035001000318801000800328#v55n1#V:\SciELO\serial\abem\v55n1\markup\04.htm#S#c
#224#2#article#39#2#^rND^sCooper^nDS#^rND^sDoherty^nGM#^rND^sHaugen^nBR#^rND^sKl
oos^nRT#^rND^sLee^nSL#^rND^sMandel^nSJ#et al#Management guidelines for patients 
with thyroid nodules and differentiated thyroid cancer^len#Thyroid#20060000#2006
#16#2#1-24#20110200#04.htm#1050-7256#Thyroid##
00590000000000289000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100014000710100016000850120
11600101030001500217065000900232064000500241031000400246032000200250014000700252
865000900259002000700268035001000275801001500285#v55n1#V:\SciELO\serial\abem\v55
n1\markup\04.htm#S#c#225#3#article#39#3#^rND^sTan^nGH#^rND^sGharib^nH#Thyroid in
cidentalomas: management approaches to nonpalpable nodules discovered incidental
ly on thyroid imaging^len#Ann Intern Med#19970000#1997#126#3#226-31#20110200#04.
htm#0003-4819#Ann Intern Med##
00468000000000277000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100017000710120023000880300
01200111065000900123064000500132031000400137032000300141014000800144865000900152
002000700161035001000168801001200178#v55n1#V:\SciELO\serial\abem\v55n1\markup\04
.htm#S#c#226#4#article#39#4#^rND^sHegedüs^nL#The thyroid nodule^len#N Eng J Med#
20040000#2004#351#17#1764-71#20110200#04.htm#0028-4793#N Eng J Med##
00552000000000289000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100017000710100018000880100
02100106012008000127030001100207710000200218065000900220064000500229031000300234
032000200237014000700239865000900246002000700255#v55n1#V:\SciELO\serial\abem\v55
n1\markup\04.htm#S#c#227#5#article#39#5#^rND^sHegedüs^nL#^rND^sBonnema^nSJ#^rND^
sBennedbaek^nFN#Management of simple nodular goiter: current status and future p
erspectives^len#Endocr Ver#2#20030000#2003#24#1#102-32#20110200#04.htm##
00593000000000277000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690160015000710160019000860160
01500105016001300120018008500133066000500218067000700223062005500230065000900285
064000500294865000900299002000700308#v55n1#V:\SciELO\serial\abem\v55n1\markup\04
.htm#S#c#228#6#article#39#6#^rND^sLloyd^nR#^rND^sDe Lellis^nR#^rND^sHeitz^nP#^rN
D^sEng^nC#World Health Organization: pathologic and genetics of tumors of endocr
ine organs^len#Lyon#França#IARC Press International Agency for Research on Cance
r#20040000#2004#20110200#04.htm##
00749000000000349000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100017000710100017000880100
01900105010002000124010001900144010001600163810000600179012011400185030002400299
06500090032306400050033203100030033703200020034001400070034286500090034900200070
0358035001000365801002400375#v55n1#V:\SciELO\serial\abem\v55n1\markup\04.htm#S#c
#229#7#article#39#7#^rND^sFrates^nMC#^rND^sBenson^nCB#^rND^sDoubilet^nPM#^rND^sK
unreuther^nE#^rND^sContreras^nM#^rND^sCibas^nES#et al#Prevalence and distributio
n of carcinoma in patients with solitary and multiple thyroid nodules on sonogra
phy^len#J Clin Endocrinol Metab#20060000#2006#91#9#3411-7#20110200#04.htm#0021-9
72X#J Clin Endocrinol Metab##
00620000000000325000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100017000710100019000880100
01900107010001900126010001800145012006100163030000700224065000900231064000500240
03100040024503200050024901400070025486500090026100200070027003500100027780100070
0287#v55n1#V:\SciELO\serial\abem\v55n1\markup\04.htm#S#c#230#8#article#39#8#^rND
^sShibata^nY#^rND^sYamashita^nS#^rND^sMasyakin^nVB#^rND^sPanasyuk^nGD#^rND^sNaga
taki^nS#15 years after Chernobyl: new evidence of thyroid cancer^len#Lancet#2001
0000#2001#358#9297#1965-6#20110200#04.htm#0099-5355#Lancet##
00751000000000337000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100018000710100017000890100
01700106010002000123010001900143010001900162012012900181030002400310065000900334
06400050034303100030034803200030035101400090035486500090036300200070037203500100
0379801002400389#v55n1#V:\SciELO\serial\abem\v55n1\markup\04.htm#S#c#231#9#artic
le#39#9#^rND^sBoelaert^nK#^rND^sHoracek^nJ#^rND^sHolder^nRL#^rND^sWatkinson^nJC#
^rND^sSheppard^nMC#^rND^sFranklyn^nJA#Serum thyrotropin concentration as a novel
 predictor of malignancy in thyroid nodules investigated by fine-needle aspirati
on^len#J Clin Endocrinol Metab#20060000#2006#91#11#4295-301#20110200#04.htm#0021
-972X#J Clin Endocrinol Metab##
00494000000000277000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100021000730120044000940300
01300138065000900151064000500160031000400165032000200169014000600171865000900177
002000700186035001000193801001300203#v55n1#V:\SciELO\serial\abem\v55n1\markup\04
.htm#S#c#232#10#article#39#10#^rND^sMazzaferri^nEL#Management of a solitary thyr
oid nodule^len#N Engl J Med#19930000#1993#328#8#553-9#20110200#04.htm#0028-4793#
N Engl J Med##
00715000000000349000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100018000730100018000910100
01900109010001900128010001700147010001400164810000600178012011200184030000900296
06500090030506400050031403100030031903200020032201400060032486500090033000200070
0339035001000346801000900356#v55n1#V:\SciELO\serial\abem\v55n1\markup\04.htm#S#c
#233#11#article#39#11#^rND^sBelfiore^nA#^rND^sLa Rosa^nGL#^rND^sLa Porta^nGA#^rN
D^sGiuffrida^nD#^rND^sMilazzo^nG#^rND^sLupo^nL#et al#Cancer risk in patients wit
h cold thyroid nodules: relevance of iodine intake, sex, age and multinodularity
^len#Am J Med#19920000#1992#93#4#363-9#20110200#04.htm#0002-9343#Am J Med##
00696000000000349000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100018000730100017000910100
01700108010001900125010001700144010001600161810000600177012007900183030001500262
06500090027706400050028603100040029103200020029501400080029786500090030500200070
0314035001000321801001500331#v55n1#V:\SciELO\serial\abem\v55n1\markup\04.htm#S#c
#234#12#article#39#12#^rND^sMarqusee^nE#^rND^sBenson^nCB#^rND^sFrates^nMC#^rND^s
Doubilet^nPM#^rND^sLarsen^nPR#^rND^sCibas^nES#et al#Usefulness of ultrasonograph
y in the management of nodular thyroid disease^len#Ann Intern Med#20000000#2000#
133#9#696-700#20110200#04.htm#0003-4819#Ann Intern Med##
00781000000000349000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100018000730100021000910100
01900112010001600131010001700147010001600164810000600180012014500186030002400331
06500090035506400050036403100030036903200020037201400070037486500090038100200070
0390035001000397801002400407#v55n1#V:\SciELO\serial\abem\v55n1\markup\04.htm#S#c
#235#13#article#39#13#^rND^sHaymart^nMR#^rND^sRepplinger^nDJ#^rND^sLeverson^nGE#
^rND^sElson^nDF#^rND^sSippel^nRS#^rND^sJaume^nJC#et al#Higher serum TSH level in
 thyroid nodule patients is associated with greater risks of differentiated thyr
oid cancer and advanced tumor stage^len#J Clin Endocrinol Metab#20080000#2008#93
#3#809-14#20110200#04.htm#0021-972X#J Clin Endocrinol Metab##
00748000000000349000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730100019000890100
01900108010001900127010001800146010001500164810000600179012011300185030002400298
06500090032206400050033103100030033603200020033901400070034186500090034800200070
0357035001000364801002400374#v55n1#V:\SciELO\serial\abem\v55n1\markup\04.htm#S#c
#236#14#article#39#14#^rND^sPapini^nE#^rND^sGuglielmi^nR#^rND^sBianchini^nA#^rND
^sCrescenzi^nA#^rND^sTaccogna^nS#^rND^sNardi^nF#et al#Risk of malignancy in nonp
alpable thyroid nodules: predictive value of ultrasound and color-Doppler featur
es^len#J Clin Endocrinol Metab#20020000#2002#87#5#1941-6#20110200#04.htm#0021-97
2X#J Clin Endocrinol Metab##
00681000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100020000730100014000930100
01400107010001400121010001500135010001400150810000600164012011500170030001600285
71000020030106500090030306400050031203100030031703200020032001400050032286500090
0327002000700336#v55n1#V:\SciELO\serial\abem\v55n1\markup\04.htm#S#c#237#15#arti
cle#39#15#^rND^sNam-Goong^nIS#^rND^sKim^nHY#^rND^sGong^nG#^rND^sLee^nHK#^rND^sHo
ng^nSJ#^rND^sKim^nWB#et al#Ultrasonography-guided fine-needle aspiration of thyr
oid incidentaloma: correlation with pathological findings^len#Clin Endocrinol#2#
20040000#2004#60#1#21-8#20110200#04.htm##
00739000000000349000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100014000730100015000870100
01900102010001600121010001800137010001700155810000600172012012600178030001700304
06500090032106400050033003100040033503200020033901400050034186500090034600200070
0355035001000362801001700372#v55n1#V:\SciELO\serial\abem\v55n1\markup\04.htm#S#c
#238#16#article#39#16#^rND^sRago^nT#^rND^sVitti^nP#^rND^sChiovato^nSM#^rND^sMazz
eo^nS#^rND^sDeLiperi^nA#^rND^sMiccolo^nP#et al#Role of conventional ultrasonogra
phy and color flow-Doppler sonography in predicting malignancy in "cold" thyroid
 nodules^len#Eur J Endocrinol#19980000#1998#138#1#41-6#20110200#04.htm#0804-4643
#Eur J Endocrinol##
00665000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100015000730100015000880100
01900103010001400122010001800136010001800154810000600172012007900178030002600257
71000020028306500090028506400050029403100030029903200020030201400070030486500090
0311002000700320#v55n1#V:\SciELO\serial\abem\v55n1\markup\04.htm#S#c#239#17#arti
cle#39#17#^rND^sMaia^nAL#^rND^sWard^nLS#^rND^sCarvalho^nGA#^rND^sGraf^nH#^rND^sM
aciel^nRMB#^rND^sMaciel^nLMZ#et al#Nódulos de tireóide e câncer diferenciado de 
tireóide: consenso brasileiro^lpt#Arq Bras Endocrinol Metab#2#20070000#2007#51#5
#867-93#20110200#04.htm##
00725000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730100022000890100
01600111010001600127010001600143010001900159012012100178030001700299065000900316
06400050032503100040033003200020033401400080033686500090034400200070035303500100
0360801001700370#v55n1#V:\SciELO\serial\abem\v55n1\markup\04.htm#S#c#240#18#arti
cle#39#18#^rND^sPacini^nF#^rND^sSchlumberger^nM#^rND^sDralle^nH#^rND^sElisei^nR#
^rND^sSmit^nJWA#^rND^sWiersinga^nW#European consensus for the management of pati
ents with differentiated thyroid carcinoma of the follicular epithelium^len#Eur 
J Endocrinol#20060000#2006#154#6#787-803#20110200#04.htm#0804-4643#Eur J Endocri
nol##
00546000000000289000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730100016000900120
06600106030001500172065000900187064000500196031000400201032000300205014000700208
865000900215002000700224035001000231801001500241#v55n1#V:\SciELO\serial\abem\v55
n1\markup\04.htm#S#c#241#19#article#39#19#^rND^sCastro^nMR#^rND^sGharib^nH#Conti
nuing controversies in the management of thyroid nodules^len#Ann Intern Med#2005
0000#2005#142#11#926-31#20110200#04.htm#0003-4819#Ann Intern Med##
00773000000000349000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100018000730100018000910100
01800109010001600127010002000143010001400163810000600177012016800183030001000351
06500090036106400050037003100030037503200020037801400070038086500090038700200070
0396035001000403801001000413#v55n1#V:\SciELO\serial\abem\v55n1\markup\04.htm#S#c
#242#20#article#39#20#^rND^sKratzsch^nJ#^rND^sFiedler^nGM#^rND^sLeichtle^nA#^rND
^sBrügel^nM#^rND^sBuchbinder^nS#^rND^sOtto^nL#et al#New reference intervals for 
thyrotropin and thyroid hormones based on National Academy of Clinical Biochemis
try criteria and regular ultrasonography of the thyroid^len#Clin Chem#20050000#2
005#51#8#1480-6#20110200#04.htm#0009-9147#Clin Chem##
00790000000000349000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100020000730100020000930100
01800113010001700131010001700148010001800165810000600183012015100189030002400340
06500090036406400050037303100030037803200020038101400070038386500090039000200070
0399035001000406801002400416#v55n1#V:\SciELO\serial\abem\v55n1\markup\04.htm#S#c
#243#21#article#39#21#^rND^sHollowell^nJG#^rND^sStaehling^nNW#^rND^sFlanders^nD#
^rND^sHannon^nWH#^rND^sGunter^nEW#^rND^sSpencer^nCA#et al#Serum TSH, T4 and thyr
oid antibodies in The United States population (1988 to 1994): National Health a
nd Nutrition Examination Survey (NHANES III)^len#J Clin Endocrinol Metab#2002000
0#2002#87#2#489-99#20110200#04.htm#0021-972X#J Clin Endocrinol Metab##
00682000000000349000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730100015000890100
01800104010001600122010001400138010001600152810000600168012009500174030000500269
06500090027406400050028303100040028803200020029201400070029486500090030100200070
0310035001000317801000500327#v55n1#V:\SciELO\serial\abem\v55n1\markup\04.htm#S#c
#244#22#article#39#22#^rND^sSurks^nMI#^rND^sOrtiz^nE#^rND^sDaniels^nGH#^rND^sSaw
in^nCT#^rND^sCol^nNF#^rND^sCobin^nRH#et al#Subclinical thyroid disease: scientif
ic review and guidelines for diagnosis and management^len#JAMA#20040000#2004#291
#2#228-38#20110200#04.htm#0098-7484#JAMA##
00551000000000277000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100020000730120078000930300
02400171065000900195064000500204031000300209032000300212014000800215865000900223
002000700232035001000239801002400249#v55n1#V:\SciELO\serial\abem\v55n1\markup\04
.htm#S#c#245#23#article#39#23#^rND^sAlexander^nEK#Approach to the patient with a
 cytologically indeterminate thyroid nodule^len#J Clin Endocrinol Metab#20080000
#2008#93#11#4175-82#20110200#04.htm#0021-972X#J Clin Endocrinol Metab##
00684000000000349000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730100018000890100
01500107010001900122010001600141010001800157810000600175012008500181030000800266
06500090027406400050028303100030028803200020029101400070029386500090030000200070
0309035001000316801000800326#v55n1#V:\SciELO\serial\abem\v55n1\markup\04.htm#S#c
#246#24#article#39#24#^rND^sBanks^nND#^rND^sKowalski^nJ#^rND^sTsai^nHL#^rND^sSom
ervell^nH#^rND^sTufano^nR#^rND^sDackiw^nAPB#et al#A diagnostic predictor model f
or indeterminate or suspicious thyroid FNA samples^len#Thyroid#20080000#2008#18#
9#933-41#20110200#04.htm#1050-7256#Thyroid##
00641000000000301000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100020000730100016000930100
01800109012014100127030000900268065000900277064000500286031000400291032000200295
014000700297865000900304002000700313035001000320801000900330#v55n1#V:\SciELO\ser
ial\abem\v55n1\markup\04.htm#S#c#247#25#article#39#25#^rND^sGoldstein^nRE#^rND^s
Burkey^nB#^rND^sJohnson^nJE#Implications of follicular neoplasms, atypia and les
ions suspicious of malignancy diagnosed by fine-needle aspiration of thyroid nod
ules^len#Ann Surg#20020000#2002#235#5#656-64#20110200#04.htm#0003-4932#Ann Surg#
#
00649000000000313000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730100019000900100
01900109010001600128012012400144030000800268065000900276064000500285031000300290
032000200293014000600295865000900301002000700310035001000317801000800327#v55n1#V
:\SciELO\serial\abem\v55n1\markup\04.htm#S#c#248#26#article#39#26#^rND^sKelman^n
AS#^rND^sLeibowitz^nJ#^rND^sBurstein^nDE#^rND^sHaber^nRS#Thyroid cytology and th
e risk of malignancy in thyroid nodules: importance of nuclear atypia in indeter
minate specimens^len#Thyroid#20010000#2001#11#3#271-7#20110200#04.htm#1050-7256#
Thyroid##
00535000000000289000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100019000730100016000920100
01600108010001700124012004800141030001400189710000200203065000900205064000500214
031000300219014000700222865000900229002000700238#v55n1#V:\SciELO\serial\abem\v55
n1\markup\04.htm#S#c#249#27#article#39#27#^rND^sLayfield^nLJ#^rND^sCibas^nES#^rN
D^sGharib^nH#^rND^sMandel^nSJ#Thyroid aspiration cytology: Current Status^len#Ca
ncer J Clin#2#20090000#2009#59#99-110#20110200#04.htm##
00617000000000313000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100014000730100017000870100
02000104010002000124012007200144030001700216065000900233064000500242031000400247
032000200251014000700253865000900260002000700269035001000276801001700286#v55n1#V
:\SciELO\serial\abem\v55n1\markup\04.htm#S#c#250#28#article#39#28#^rND^sRoti^nE#
^rND^sUberti^nEC#^rND^sBondanelli^nM#^rND^sBraverman^nLE#Thyroid papillary micro
carcinoma: a descriptive meta-analysis study^len#Eur J Endocrinol#20080000#2008#
159#6#656-73#20110200#04.htm#0804-4643#Eur J Endocrinol##
00656000000000313000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100019000730100020000920100
02500112011002500137012010900162030000800271065000900279064000500288031000300293
032000300296014000900299865000900308002000700317035001000324801000800334#v55n1#V
:\SciELO\serial\abem\v55n1\markup\04.htm#S#c#251#29#article#39#29#^rND^sLeenhard
t^nL#^rND^sGrosclaude^nP#^rND^sChérié-Challine^nL#Thyroid Cancer Committee#Incre
ase incidence of thyroid carcinoma in France: a true epidemic of thyroid nodule 
managements effect?^len#Thyroid#20040000#2004#14#12#1056-106#20110200#04.htm#105
0-7256#Thyroid##
00730000000000349000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730100018000900100
01700108010001600125010001400141010001700155810000600172012013100178030000800309
06500090031706400050032603100030033103200030033401400090033786500090034600200070
0355035001000362801000800372#v55n1#V:\SciELO\serial\abem\v55n1\markup\04.htm#S#c
#252#30#article#39#30#^rND^sCooper^nDS#^rND^sDoherty^nGM#^rND^sHaugen^nBR#^rND^s
Kloos^nRT#^rND^sLee^nSL#^rND^sMandel^nSJ#et al#Revised American Thyroid Associat
ion management guidelines for patients with thyroid nodules and differentiated t
hyroid cancer^len#Thyroid#20090000#2009#19#11#1167-214#20110200#04.htm#1050-7256
#Thyroid##
00731000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100014000730100015000870100
01700102010001700119010001900136010001600155810000600171012013100177030001700308
06500090032506400050033403100040033901400070034386500090035000200070035903500100
0366801001700376#v55n1#V:\SciELO\serial\abem\v55n1\markup\04.htm#S#c#253#31#arti
cle#39#31#^rND^sRago^nT#^rND^sFiore^nE#^rND^sScutari^nM#^rND^sSantini^nF#^rND^sD
i Coscio^nG#^rND^sRomani^nR#et al#Cytology suspicious for or indicative of PTC i
s associated with younger age, male sex, and solitary versus multiple nodularity
^len#Eur J Endocrinol#20100000#2010#162#763-70#20110200#04.htm#0804-4643#Eur J E
ndocrinol##
00719000000000313000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730100018000890100
01700107010001600124012016400140030002400304065000900328064000500337031000300342
032000200345014000800347865000900355002000700364035001000371801002400381#v55n1#V
:\SciELO\serial\abem\v55n1\markup\04.htm#S#c#254#32#article#39#32#^rND^sMatsuo^n
K#^rND^sFriedman^nE#^rND^sGejman^nPV#^rND^sFagin^nJA#The thyrotropin receptor (T
SH-R) is not an oncogene for thyroid tumors: structural studies of the TSH-R and
 the &#945;-subunit of Gs in human thyroid neoplasms^len#J Clin Endocrinol Metab
#19930000#1993#76#6#1446-51#20110200#04.htm#0021-972X#J Clin Endocrinol Metab##
00619000000000301000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730100018000900100
01600108012009300124030002400217065000900241064000500250031000300255032000200258
014000700260865000900267002000700276035001000283801002400293#v55n1#V:\SciELO\ser
ial\abem\v55n1\markup\04.htm#S#c#255#33#article#39#33#^rND^sDerwahl^nM#^rND^sBro
ecker^nM#^rND^sKraiem^nZ#Thyrotropin may not be the dominant growth factor in be
nign and malignant thyroid tumors^len#J Clin Endocrinol Metab#19990000#1999#84#3
#829-34#20110200#04.htm#0021-972X#J Clin Endocrinol Metab##
00486000000000265000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100021000730120071000940300
01300165710000200178065000900180064000500189031000200194032000200196014000600198
865000900204002000700213#v55n1#V:\SciELO\serial\abem\v55n1\markup\04.htm#S#c#256
#34#article#39#34#^rND^sMazzaferri^nEL#Thyroid cancer and Graves disease: the co
ntroversy ten years later^len#Endocr Pract#2#20000000#2000#6#2#221-5#20110200#04
.htm##
00689000000000349000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100018000730100017000910100
01800108010001400126010001600140010001800156810000600174012008900180030000800269
06500090027706400050028603100030029103200030029401400080029786500090030500200070
0314035001000321801000800331#v55n1#V:\SciELO\serial\abem\v55n1\markup\04.htm#S#c
#257#35#article#39#35#^rND^sJonklaas^nJ#^rND^sSarlis^nNJ#^rND^sLitofsky^nD#^rND^
sAin^nKB#^rND^sBigos^nST#^rND^sBierley^nJD#et al#Outcomes of patients with diffe
rentiated thyroid carcinoma following initial therapy^len#Thyroid#20060000#2006#
16#12#1229-42#20110200#04.htm#1050-7256#Thyroid##
00582000000000325000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730100016000890100
01500105010001500120010001300135010001500148012003600163030001300199710000200212
06500090021406400050022303100030022803200020023101400070023386500090024000200070
0249#v55n1#V:\SciELO\serial\abem\v55n1\markup\04.htm#S#c#258#36#article#39#36#^r
ND^sAkinci^nM#^rND^sKosova^nF#^rND^sCetin^nB#^rND^sAslan^nS#^rND^sAri^nZ#^rND^sC
etin^nA#Leptin levels in thyroid cancer^len#Asian J Surg#2#20090000#2009#32#4#21
6-23#20110200#04.htm##
00737000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100015000730100013000880100
01400101010001600115010001800131010001700149012013200166030002400298065000900322
06400050033103100030033603200020033901400080034186500090034900200070035803500100
0365801002400375#v55n1#V:\SciELO\serial\abem\v55n1\markup\04.htm#S#c#259#37#arti
cle#39#37#^rND^sPaes^nJE#^rND^sHua^nK#^rND^sNagy^nR#^rND^sKloos^nRT#^rND^sJariou
ra^nD#^rND^sRingel^nMD#The relationship between body mass index and thyroid canc
er pathology features and outcomes: a clinicopathological cohort study^len#J Cli
n Endocrinol Metab#20100000#2010#95#9#4244-50#20110200#04.htm#0021-972X#J Clin E
ndocrinol Metab##
00646000000000313000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100020000730100019000930100
01600112010001600128010002300144012009700167030002500264710000200289065000900291
064000500300031000200305032000200307014000700309865000900316002000700325#v55n1#V
:\SciELO\serial\abem\v55n1\markup\04.htm#S#c#260#38#article#39#38#^rND^sRezzónic
o^nJN#^rND^sRezzónico^nM#^rND^sPusiol^nE#^rND^sPitoia^nF#^rND^sNiepomniszcze^nH#
Increases prevalence of insulin resistance in patients with differentiated thyro
id carcinoma^len#Metab Syndr Relat Disord#2#20090000#2009#7#4#375-80#20110200#04
.htm##
00513000000000277000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100018000730120066000910300
01300157065000900170064000500179031000300184032000200187014000700189865000900196
002000700205035001000212801001300222#v55n1#V:\SciELO\serial\abem\v55n1\markup\04
.htm#S#c#261#39#article#39#39#^rND^sPasieka^nJL#Hashimoto's disease and thyroid 
lymphoma: role of the surgeon^len#World J Surg#20000000#2000#24#8#966-70#2011020
0#04.htm#0364-2313#World J Surg##
00263000000000169000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640910009000660920007000750020007000827030
00400089#v55n1#V:\SciELO\serial\abem\v55n1\markup\05.htm#S#o#1#1#article#1#20110
324#154531#05.htm#198##
04632000000000625000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640710003000660400003000690010006000720420
00200078120000400080038000400084038000400088121000300092049000800095158000300103
03000260010603100030013203200020013506500090013701400090014603500100015501201330
01650120159002980100027004570100039004840100042005230100039005650100025006040700
11500629070008500744083141900829085000802248085002202256085003102278085003002309
08315140233908500080385308500240386108500320388508500320391711700060394907200030
3955112000903958111001103967114000903978113001203987002000703999#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#h#2#1#article#1#oa#en#br1.1#1#4.0#GRA#TAB#05#
ABEM030#nd#Arq Bras Endocrinol Metab#55#1#20110200#^f38^l45#0004-2730#Relation o
f uric acid with components of metabolic syndrome before and after Roux-en-Y gas
tric bypass in morbidly obese subjects^len#Relação do ácido úrico com os compone
ntes da síndrome metabólica antes e após o bypass gástrico com reconstrução em Y
-de-Roux em pacientes obesos mórbidos^lpt#^rND^1A01^nAry^sSerpa Neto#^rND^1A01^n
Felipe Martin Bianco^sRossi#^rND^1A01^nLeonardo Guedes Moreira^sValle#^rND^1A01^
nGabriel Kushiyama^sTeixeira#^rND^1A02^nMarçal^sRossi#Faculdade de Medicina do A
BC^iA01^1Division of Clinical and Surgical Treatment of Obesity^cSanto André^sSP
^pBrazil#Sociedade Brasileira de Cirurgia Bariátrica e Metabólica^iA02^cSão Paul
o^sSP^pBrazil#^len^aOBJECTIVE: The purpose of the study was to investigate the p
revalence of hyperuricemia in morbidly obese subjects before and after Roux-en-Y
 gastric bypass (RYGBP) and its relationship with metabolic syndrome abnormaliti
es. SUBJECTS AND METHOD: We evaluated 420 morbidly obese patients. Pre and posto
perative (8 months after RYGBP) blood samples were drawn. Obese patients underwe
nt laparoscopic RYGBP and after eight months all the tests were repeated. RESULT
S: The overall prevalence of hyperuricemia was 34.28%. Hyperuricemia was more co
mmon in men than in women (51.72 vs. 29.72%; p = 0.0002). Men with hyperuricemia
 were more likely to have diabetes (p = 0.034) and more elevated fasting plasma 
glucose levels (p = 0.027). Women with hyperuricemia were more likely to have hy
pertension (p = 0.003), metabolic syndrome (p = 0.001), elevated triglycerides (
p = 0.001) and GGT (p = 0.009), and decreased HDL (p = 0.011). After surgery, ur
ic acid levels decreased from 5.60 ± 1.28 to 4.23 ± 1.20 (p < 0.0001). The preva
lence of hyperuricemia decreased from 33.6% to 6.4% (p < 0.0001), in men from 48
.3% to 17.2% (p < 0.0001) and in women from 29.7% to 3.6% (p < 0.0001). CONCLUSI
ON: Concentrations of uric acid were associated with the prevalence of metabolic
 abnormalities in this sample of morbidly obese patients. Also, weight loss afte
r RYGBP can reduce uric acid levels and the prevalence of hyperuricemia.#^dnd^i1
#^tm^len^kUric acid^i1#^tm^len^kmetabolic syndrome^i1#^tm^len^kbariatric surgery
^i1#^lpt^aOBJETIVO: O objetivo do estudo foi investigar a prevalência de hiperur
icemia em pacientes obesos mórbidos antes e após o bypass gástrico com reconstru
ção em Y-de-Roux (RYGBP) e sua relação com anormalidades da síndrome metabólica.
 SUJEITOS E MÉTODOS: Foram avaliados 420 pacientes com obesidade mórbida. Amostr
as de sangue pré e pós-operatório (8 meses após RYGBP) foram obtidas. Os pacient
es obesos foram submetidos a RYGBP laparoscópica e após oito meses todos os test
es foram repetidos. RESULTADOS: A prevalência de hiperuricemia foi 34,28%. A hip
eruricemia foi mais comum em homens do que em mulheres (51,72 vs. 29,72%, p = 0,
0002). Homens com hiperuricemia foram mais propensos a ter diabetes (p = 0,034) 
e tinham níveis mais elevados de glicemia de jejum (p = 0,027). Mulheres com hip
eruricemia foram mais propensas a ter hipertensão arterial (p = 0,003), síndrome
 metabólica (p = 0,001), triglicérides elevado (p = 0,001) e GGT (p = 0,009) e d
iminuição de HDL (p = 0,011). Após a cirurgia, os níveis de ácido úrico diminuír
am de 5,60 ± 1,28 para 4,23 ± 1,20 (p < 0,0001). A prevalência de hiperuricemia 
diminuiu 33,6% para 6,4% (p < 0,0001), em homens de 48,3% para 17,2% (p < 0,0001
) e nas mulheres de 29,7% para 3,6% (p < 0,0001). CONCLUSÃO: As concentrações de
 ácido úrico foram associadas com a prevalência de anormalidades metabólicas nes
ta amostra de pacientes com obesidade mórbida. Além disso, a perda de peso após 
RYGBP pode reduzir os níveis de ácido úrico e a prevalência de hiperuricemia.#^d
nd^i2#^tm^lpt^kÁcido úrico^i2#^tm^lpt^ksíndrome metabólica^i2#^tm^lpt^kcirurgia 
bariátrica^i2#other#38#20090612#Dec/6/2009#20101116#Nov/16/2010#05.htm##
04740000000000625000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640710003000660400003000690010006000720420
00200078120000400080038000400084038000400088121000300092049000800095158000300103
03000260010603100030013203200020013506500090013701400090014603500100015501201400
01650120166003050100027004710100039004980100042005370100039005790100025006180700
11500643070008500758083146600843085000802309085002202317085003102339085003002370
08315610240008500080396108500240396908500320399308500320402511700060405707200030
4063112000904066111001104075114000904086113001204095002000704107#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#f#3#1#article#1#oa#en#br1.1#1#4.0#GRA#TAB#05#
ABEM030#nd#Arq Bras Endocrinol Metab#55#1#20110200#^f38^l45#0004-2730#<b>Relatio
n of uric acid with components of metabolic syndrome before and after Roux-en-Y 
gastric bypass in morbidly obese subjects</b>^len#<b>Relação do ácido úrico com 
os componentes da síndrome metabólica antes e após o bypass gástrico com reconst
rução em Y-de-Roux em pacientes obesos mórbidos</b>^lpt#^rND^1A01^nAry^sSerpa Ne
to#^rND^1A01^nFelipe Martin Bianco^sRossi#^rND^1A01^nLeonardo Guedes Moreira^sVa
lle#^rND^1A01^nGabriel Kushiyama^sTeixeira#^rND^1A02^nMarçal^sRossi#Faculdade de
 Medicina do ABC^iA01^1Division of Clinical and Surgical Treatment of Obesity^cS
anto André^sSP^pBrazil#Sociedade Brasileira de Cirurgia Bariátrica e Metabólica^
iA02^cSão Paulo^sSP^pBrazil#^len^a<b>OBJECTIVE:</b> The purpose of the study was
 to investigate the prevalence of hyperuricemia in morbidly obese subjects befor
e and after Roux-en-Y gastric bypass (RYGBP) and its relationship with metabolic
 syndrome abnormalities. <b>SUBJECTS AND METHOD:</b> We evaluated 420 morbidly o
bese patients. Pre and postoperative (8 months after RYGBP) blood samples were d
rawn. Obese patients underwent laparoscopic RYGBP and after eight months all the
 tests were repeated. <b>RESULTS:</b> The overall prevalence of hyperuricemia wa
s 34.28%. Hyperuricemia was more common in men than in women (51.72 <i>vs</i>. 2
9.72%; p = 0.0002). Men with hyperuricemia were more likely to have diabetes (p 
= 0.034) and more elevated fasting plasma glucose levels (p = 0.027). Women with
 hyperuricemia were more likely to have hypertension (p = 0.003), metabolic synd
rome (p = 0.001), elevated triglycerides (p = 0.001) and GGT (p = 0.009), and de
creased HDL (p = 0.011). After surgery, uric acid levels decreased from 5.60 ± 1
.28 to 4.23 ± 1.20 (p &lt; 0.0001). The prevalence of hyperuricemia decreased fr
om 33.6% to 6.4% (p &lt; 0.0001), in men from 48.3% to 17.2% (p &lt; 0.0001) and
 in women from 29.7% to 3.6% (p &lt; 0.0001). <b>CONCLUSION:</b> Concentrations 
of uric acid were associated with the prevalence of metabolic abnormalities in t
his sample of morbidly obese patients. Also, weight loss after RYGBP can reduce 
uric acid levels and the prevalence of hyperuricemia.#^dnd^i1#^tm^len^kUric acid
^i1#^tm^len^kmetabolic syndrome^i1#^tm^len^kbariatric surgery^i1#^lpt^a<b>OBJETI
VO:</b> O objetivo do estudo foi investigar a prevalência de hiperuricemia em pa
cientes obesos mórbidos antes e após o bypass gástrico com reconstrução em Y-de-
Roux (RYGBP) e sua relação com anormalidades da síndrome metabólica. <b>SUJEITOS
 E MÉTODOS:</b> Foram avaliados 420 pacientes com obesidade mórbida. Amostras de
 sangue pré e pós-operatório (8 meses após RYGBP) foram obtidas. Os pacientes ob
esos foram submetidos a RYGBP laparoscópica e após oito meses todos os testes fo
ram repetidos. <b>RESULTADOS:</b> A prevalência de hiperuricemia foi 34,28%. A h
iperuricemia foi mais comum em homens do que em mulheres (51,72 <i>vs.</i> 29,72
%, p = 0,0002). Homens com hiperuricemia foram mais propensos a ter diabetes (p 
= 0,034) e tinham níveis mais elevados de glicemia de jejum (p = 0,027). Mulhere
s com hiperuricemia foram mais propensas a ter hipertensão arterial (p = 0,003),
 síndrome metabólica (p = 0,001), triglicérides elevado (p = 0,001) e GGT (p = 0
,009) e diminuição de HDL (p = 0,011). Após a cirurgia, os níveis de ácido úrico
 diminuíram de 5,60 ± 1,28 para 4,23 ± 1,20 (p &lt; 0,0001). A prevalência de hi
peruricemia diminuiu 33,6% para 6,4% (p &lt; 0,0001), em homens de 48,3% para 17
,2% (p &lt; 0,0001) e nas mulheres de 29,7% para 3,6% (p &lt; 0,0001). <b>CONCLU
SÃO:</b> As concentrações de ácido úrico foram associadas com a prevalência de a
normalidades metabólicas nesta amostra de pacientes com obesidade mórbida. Além 
disso, a perda de peso após RYGBP pode reduzir os níveis de ácido úrico e a prev
alência de hiperuricemia.#^dnd^i2#^tm^lpt^kÁcido úrico^i2#^tm^lpt^ksíndrome meta
bólica^i2#^tm^lpt^kcirurgia bariátrica^i2#other#38#20090612#Dec/6/2009#20101116#
Nov/16/2010#05.htm##
04893000000000649000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640640013000660710003000790400003000820010
00600085042000200091120000400093038000400097038000400101121000300105049000800108
15800030011603000290011903100030014803200020015106500090015301400090016203500100
01710120133001810120159003140100027004730100039005000100042005390100039005810100
02500620070011700645070008700762083147500849085000802324085002202332085003102354
08500300238508315860241508500080400108500240400908500320403308500320406511700060
40970720003041031120009041061110011041151140009041261130012041350020007041470080
08904154#v55n1#V:\SciELO\serial\abem\v55n1\markup\05.htm#S#l#4#1#article#1#^mFeb
.^a2011#oa#en#br1.1#1#4.0#gra#tab#05#ABEM030#nd#Arq. bras. endocrinol. metab#55#
1#20110200#^f38^l45#0004-2730#Relation of uric acid with components of metabolic
 syndrome before and after Roux-en-Y gastric bypass in morbidly obese subjects^l
en#Relação do ácido úrico com os componentes da síndrome metabólica antes e após
 o bypass gástrico com reconstrução em Y-de-Roux em pacientes obesos mórbidos^lp
t#^rND^1A01^nAry^sSerpa Neto#^rND^1A01^nFelipe Martin Bianco^sRossi#^rND^1A01^nL
eonardo Guedes Moreira^sValle#^rND^1A01^nGabriel Kushiyama^sTeixeira#^rND^1A02^n
Marçal^sRossi#^iA01^1Faculdade de Medicina do ABC^2Division of Clinical and Surg
ical Treatment of Obesity^cSanto André^sSP^pBrazil#^iA02^1Sociedade Brasileira d
e Cirurgia Bariátrica e Metabólica^cSão Paulo^sSP^pBrazil#^len^aOBJECTIVE: The p
urpose of the study was to investigate the prevalence of hyperuricemia in morbid
ly obese subjects before and after Roux-en-Y gastric bypass (RYGBP) and its rela
tionship with metabolic syndrome abnormalities. SUBJECTS AND METHOD: We evaluate
d 420 morbidly obese patients. Pre and postoperative (8 months after RYGBP) bloo
d samples were drawn. Obese patients underwent laparoscopic RYGBP and after eigh
t months all the tests were repeated. RESULTS: The overall prevalence of hyperur
icemia was 34.28 percent. Hyperuricemia was more common in men than in women (51
.72 vs. 29.72 percent; p = 0.0002). Men with hyperuricemia were more likely to h
ave diabetes (p = 0.034) and more elevated fasting plasma glucose levels (p = 0.
027). Women with hyperuricemia were more likely to have hypertension (p = 0.003)
, metabolic syndrome (p = 0.001), elevated triglycerides (p = 0.001) and GGT (p 
= 0.009), and decreased HDL (p = 0.011). After surgery, uric acid levels decreas
ed from 5.60 ± 1.28 to 4.23 ± 1.20 (p < 0.0001). The prevalence of hyperuricemia
 decreased from 33.6 percent to 6.4 percent (p < 0.0001), in men from 48.3 perce
nt to 17.2 percent (p < 0.0001) and in women from 29.7 percent to 3.6 percent (p
 < 0.0001). CONCLUSION: Concentrations of uric acid were associated with the pre
valence of metabolic abnormalities in this sample of morbidly obese patients. Al
so, weight loss after RYGBP can reduce uric acid levels and the prevalence of hy
peruricemia.#^dnd^i1#^tm^len^kUric acid^i1#^tm^len^kmetabolic syndrome^i1#^tm^le
n^kbariatric surgery^i1#^lpt^aOBJETIVO: O objetivo do estudo foi investigar a pr
evalência de hiperuricemia em pacientes obesos mórbidos antes e após o bypass gá
strico com reconstrução em Y-de-Roux (RYGBP) e sua relação com anormalidades da 
síndrome metabólica. SUJEITOS E MÉTODOS: Foram avaliados 420 pacientes com obesi
dade mórbida. Amostras de sangue pré e pós-operatório (8 meses após RYGBP) foram
 obtidas. Os pacientes obesos foram submetidos a RYGBP laparoscópica e após oito
 meses todos os testes foram repetidos. RESULTADOS: A prevalência de hiperuricem
ia foi 34,28 por cento. A hiperuricemia foi mais comum em homens do que em mulhe
res (51,72 vs. 29,72 por cento, p = 0,0002). Homens com hiperuricemia foram mais
 propensos a ter diabetes (p = 0,034) e tinham níveis mais elevados de glicemia 
de jejum (p = 0,027). Mulheres com hiperuricemia foram mais propensas a ter hipe
rtensão arterial (p = 0,003), síndrome metabólica (p = 0,001), triglicérides ele
vado (p = 0,001) e GGT (p = 0,009) e diminuição de HDL (p = 0,011). Após a cirur
gia, os níveis de ácido úrico diminuíram de 5,60 ± 1,28 para 4,23 ± 1,20 (p < 0,
0001). A prevalência de hiperuricemia diminuiu 33,6 por cento para 6,4 por cento
 (p < 0,0001), em homens de 48,3 por cento para 17,2 por cento (p < 0,0001) e na
s mulheres de 29,7 por cento para 3,6 por cento (p < 0,0001). CONCLUSÃO: As conc
entrações de ácido úrico foram associadas com a prevalência de anormalidades met
abólicas nesta amostra de pacientes com obesidade mórbida. Além disso, a perda d
e peso após RYGBP pode reduzir os níveis de ácido úrico e a prevalência de hiper
uricemia.#^dnd^i2#^tm^lpt^kÁcido úrico^i2#^tm^lpt^ksíndrome metabólica^i2#^tm^lp
t^kcirurgia bariátrica^i2#other#38#20090612#Dec/6/2009#20101116#Nov/16/2010#05.h
tm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-273020
11000100005##
00344000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704012300068002000700191#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#5#1#article#156#<p align="right"><font face
="Verdana, Arial, Helvetica, sans-serif" size="2"><b>ORIGINAL    ARTICLE</b></fo
nt></p>     ^cY#05.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704002200068002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#6#2#article#156#<p>&nbsp;</p>     ^cY#05.ht
m##
00463000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704024200068002000700310#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#7#3#article#156#<p><a name="top"></a><font 
face="Verdana, Arial, Helvetica, sans-serif" size="4"><b>Relation    of uric aci
d with components of metabolic syndrome before and after Roux-en-Y    gastric by
pass in morbidly obese subjects</b></font></p>     ^cY#05.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704002200068002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#8#4#article#156#<p>&nbsp;</p>     ^cY#05.ht
m##
00551000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704033000068002000700398#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#9#5#article#156#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="3"><b>Rela&ccedil;&atilde;o    do &aacute;cido 
&uacute;rico com os componentes da s&iacute;ndrome metab&oacute;lica    antes e 
ap&oacute;s o bypass g&aacute;strico com reconstru&ccedil;&atilde;o    em Y-de-R
oux em pacientes obesos m&oacute;rbidos</b></font></p>     ^cY#05.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000400065704002200069002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#10#6#article#156#<p>&nbsp;</p>     ^cY#05.h
tm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000400065704002200069002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#11#7#article#156#<p>&nbsp;</p>     ^cY#05.h
tm##
00501000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000400065704027900069002000700348#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#12#8#article#156#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>Ary Serpa Neto<sup>I</sup>;    Felipe Ma
rtin Bianco Rossi<sup>I</sup>; Leonardo Guedes Moreira Valle<sup>I</sup>;    Gab
riel Kushiyama Teixeira<sup>I</sup>; Mar&ccedil;al Rossi<sup>II</sup></b></font>
</p>     ^cY#05.htm##
00435000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000400065704021300069002000700282#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#13#9#article#156#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><sup>I</sup>Division    of Clinical and Sur
gical Treatment of Obesity, Faculdade de Medicina do ABC    (FMABC), Santo Andr&
eacute;, SP, Brazil    ^cY#05.htm##
00374000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704015100070002000700221#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#14#10#article#156#<br>   <sup>II</sup>Socie
dade Brasileira de Cirurgia Bari&aacute;trica e Metab&oacute;lica    (SBCBM), S&
atilde;o Paulo, SP, Brazil</font></p>     ^cY#05.htm##
00346000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704012300070002000700193#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#15#11#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><a href="#back">Correspondence    to</a></
font></p>     ^cY#05.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#16#12#article#156#<p>&nbsp;</p>     ^cY#05.
htm##
00267000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704004400070002000700114#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#17#13#article#156#<p>&nbsp;</p> <hr size="1
" noshade>     ^cY#05.htm##
00321000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704009800070002000700168#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#18#14#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>ABSTRACT</b></font></p>     ^cY#05.htm#
#
00533000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704031000070002000700380#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#19#15#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>OBJECTIVE:</b>    The purpose of the st
udy was to investigate the prevalence of hyperuricemia    in morbidly obese subj
ects before and after Roux-en-Y gastric bypass (RYGBP)    and its relationship w
ith metabolic syndrome abnormalities.    ^cY#05.htm##
00484000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704026100070002000700331#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#20#16#article#156#<br>   <b>SUBJECTS AND ME
THOD:</b> We evaluated 420 morbidly obese patients. Pre and    postoperative (8 
months after RYGBP) blood samples were drawn. Obese patients    underwent laparo
scopic RYGBP and after eight months all the tests were repeated.        ^cY#05.h
tm##
01022000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704079900070002000700869#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#21#17#article#156#<br>   <b>RESULTS:</b> Th
e overall prevalence of hyperuricemia was 34.28%. Hyperuricemia    was more comm
on in men than in women (51.72 <i>vs</i>. 29.72%; p = 0.0002).    Men with hyper
uricemia were more likely to have diabetes (p = 0.034) and more    elevated fast
ing plasma glucose levels (p = 0.027). Women with hyperuricemia    were more lik
ely to have hypertension (p = 0.003), metabolic syndrome (p = 0.001),    elevate
d triglycerides (p = 0.001) and GGT (p = 0.009), and decreased HDL (p    = 0.011
). After surgery, uric acid levels decreased from 5.60 &plusmn; 1.28    to 4.23 
&plusmn; 1.20 (p &lt; 0.0001). The prevalence of hyperuricemia decreased    from
 33.6% to 6.4% (p &lt; 0.0001), in men from 48.3% to 17.2% (p &lt; 0.0001)    an
d in women from 29.7% to 3.6% (p &lt; 0.0001).    ^cY#05.htm##
00503000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704028000070002000700350#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#22#18#article#156#<br>   <b>CONCLUSION:</b>
 Concentrations of uric acid were associated with the prevalence    of metabolic
 abnormalities in this sample of morbidly obese patients. Also,    weight loss a
fter RYGBP can reduce uric acid levels and the prevalence of hyperuricemia.</fon
t></p>     ^cY#05.htm##
00396000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704017300070002000700243#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#23#19#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Keywords:</b>    Uric acid; metabolic s
yndrome; bariatric surgery</font></p> <hr size="1" noshade>     ^cY#05.htm##
00319000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704009600070002000700166#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#24#20#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>RESUMO</b></font></p>     ^cY#05.htm##
00612000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704038900070002000700459#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#25#21#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>OBJETIVO:</b>    O objetivo do estudo f
oi investigar a preval&ecirc;ncia de hiperuricemia em    pacientes obesos m&oacu
te;rbidos antes e ap&oacute;s o bypass g&aacute;strico    com reconstru&ccedil;&
atilde;o em Y-de-Roux (RYGBP) e sua rela&ccedil;&atilde;o    com anormalidades d
a s&iacute;ndrome metab&oacute;lica.    ^cY#05.htm##
00571000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704034800070002000700418#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#26#22#article#156#<br>   <b>SUJEITOS E M&Ea
cute;TODOS:</b> Foram avaliados 420 pacientes com obesidade    m&oacute;rbida. A
mostras de sangue pr&eacute; e p&oacute;s-operat&oacute;rio    (8 meses ap&oacut
e;s RYGBP) foram obtidas. Os pacientes obesos foram submetidos    a RYGBP laparo
sc&oacute;pica e ap&oacute;s oito meses todos os testes foram    repetidos.    ^
cY#05.htm##
01153000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704093000070002000701000#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#27#23#article#156#<br>   <b>RESULTADOS:</b>
 A preval&ecirc;ncia de hiperuricemia foi 34,28%. A hiperuricemia    foi mais co
mum em homens do que em mulheres (51,72 <i>vs.</i> 29,72%, p = 0,0002).    Homen
s com hiperuricemia foram mais propensos a ter diabetes (p = 0,034) e tinham    
n&iacute;veis mais elevados de glicemia de jejum (p = 0,027). Mulheres com hiper
uricemia    foram mais propensas a ter hipertens&atilde;o arterial (p = 0,003), 
s&iacute;ndrome    metab&oacute;lica (p = 0,001), triglic&eacute;rides elevado (
p = 0,001) e GGT    (p = 0,009) e diminui&ccedil;&atilde;o de HDL (p = 0,011). A
p&oacute;s a cirurgia,    os n&iacute;veis de &aacute;cido &uacute;rico diminu&i
acute;ram de 5,60 &plusmn;    1,28 para 4,23 &plusmn; 1,20 (p &lt; 0,0001). A pr
eval&ecirc;ncia de hiperuricemia    diminuiu 33,6% para 6,4% (p &lt; 0,0001), em
 homens de 48,3% para 17,2% (p &lt;    0,0001) e nas mulheres de 29,7% para 3,6%
 (p &lt; 0,0001).    ^cY#05.htm##
00632000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704040900070002000700479#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#28#24#article#156#<br>   <b>CONCLUS&Atilde;
O:</b> As concentra&ccedil;&otilde;es de &aacute;cido &uacute;rico    foram asso
ciadas com a preval&ecirc;ncia de anormalidades metab&oacute;licas    nesta amos
tra de pacientes com obesidade m&oacute;rbida. Al&eacute;m disso,    a perda de 
peso ap&oacute;s RYGBP pode reduzir os n&iacute;veis de &aacute;cido    &uacute;
rico e a preval&ecirc;ncia de hiperuricemia.</font></p>     ^cY#05.htm##
00443000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704022000070002000700290#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#29#25#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Descritores:    </b> &Aacute;cido &uacu
te;rico; s&iacute;ndrome metab&oacute;lica; cirurgia    bari&aacute;trica</font>
</p> <hr size="1" noshade>     ^cY#05.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#30#26#article#156#<p>&nbsp;</p>     ^cY#05.
htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#31#27#article#156#<p>&nbsp;</p>     ^cY#05.
htm##
00325000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704010200070002000700172#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#32#28#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="3"><b>INTRODUCTION</b></font></p>     ^cY#05.
htm##
00738000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704051500070002000700585#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#33#29#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Metabolic syndrome    comprises several ab
normalities that occur together more often than would be    expected by chance. 
Typically, general or central adiposity, elevated blood    pressure, dyslipidemi
a, and hyperglycemia are thought to be part of this syndrome.    In addition, se
veral other abnormalities including those of fibrinolysis, thrombosis,    inflam
mation, and endothelial function are strongly related to the syndrome.</font></p
>     ^cY#05.htm##
01099000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704087600070002000700946#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#34#30#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">There continues    to be a need to better 
understand the pattern of risk factor clustering that    constitutes metabolic s
yndrome and the relationship of the syndrome to emerging    risk factors for car
diovascular disease. The positive association between serum    uric acid and car
diovascular diseases such as stroke or ischemic heart disease    has been recogn
ized since the 1950s and has been confirmed by numerous epidemiological    studi
es (1-3). However, whether uric acid is an independent risk factor for    cardio
vascular mortality is still disputed as several studies have suggested    that h
yperuricemia is merely associated with cardiovascular diseases because    of con
founding factors such as obesity, dyslipidemia, hypertension, use of diuretics  
  and insulin resistance (4,5).</font></p>     ^cY#05.htm##
00887000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704066400070002000700734#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#35#31#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Elevated serum    uric acid levels (UA) ar
e commonly seen in association with glucose intolerance,    hypertension, and dy
slipidemia, a cluster of metabolic and hemodynamic disorders    which characteri
ze the so-called metabolic syndrome (6,7). Studies performed    in healthy volun
teers as well as in subjects with asymptomatic hyperuricemia    have suggested t
hat the link between metabolic syndrome and serum uric acid    is related to the
 ability of insulin to decrease uric acid clearance in the    renal proximal tub
ule resulting in an increase in serum uric acid levels (8).</font></p>     ^cY#0
5.htm##
00535000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704031200070002000700382#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#36#32#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">The purpose of    the present study was to
 investigate the prevalence of hyperuricemia in morbidly    obese subjects befor
e and after Roux-en-Y gastric bypass (RYGBP) and its relationship    with metabo
lic syndrome abnormalities.</font></p>     ^cY#05.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#37#33#article#156#<p>&nbsp;</p>     ^cY#05.
htm##
00335000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704011200070002000700182#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#38#34#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="3"><b>SUBJECTS AND    METHOD</b></font></p>  
   ^cY#05.htm##
00329000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704010600070002000700176#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#39#35#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Study population</b></font></p>     ^cY
#05.htm##
00676000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704045300070002000700523#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#40#36#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Four hundred and    twenty morbidly obese 
patients were considered eligible to participate in this    study according to t
he following inclusion criteria: body mass index (BMI) <u>&gt;</u>    40 kg/m&su
p2;, age between 18 and 60 years, and no history of liver disease.    Most patie
nts (68.5%) were women and the mean body mass index was 47.1 &plusmn;    5.4 kg/
m&sup2;.</font></p>     ^cY#05.htm##
00344000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704012100070002000700191#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#41#37#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Study protocol    and follow-up</b></fo
nt></p>     ^cY#05.htm##
01378000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704115500070002000701225#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#42#38#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Pre and postoperative    (at 8 months afte
r bariatric surgery) blood samples were drawn after a minimum    fasting period 
of 8h. Laboratorial analyses were performed using standard methodologies.    BMI
 is defined as the individual's body weight divided by the square of his/her    
height. To define metabolic syndrome (MS) we used the International Diabetes    
Federation (IDF) criteria: waist circumference <u>&gt;</u> 94 cm in men, <u>&gt;
</u>    80 cm in women or BMI <u>&gt;</u> 30 kg/m&sup2;; triglyceride levels <u>
&gt;</u>    150 mg/dL (1.7 mmol/L) and/or specific treatment; HDL-C levels &lt; 
40 mg/dL    (1 mmol/L) in men, &lt; 50 mg/dL (1.3 mmol/L) in women and/or specif
ic treatment;    fasting glucose <u>&gt;</u> 100 mg/dL (5.6 mmol/L) and/or DM2 p
atient; systolic    blood pressure <u>&gt;</u> 130 mmHg, diastolic blood pressur
e <u>&gt;</u> 85    mmHg and/or specific treatment. An individual must present a
t least three of    the five risk factors to be diagnosed with MS. Hyperuricemia
 was defined as    uric acid &gt; 6 mg/dL (women) and 6.8 mg/dL (men).</font></p
>     ^cY#05.htm##
00687000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704046400070002000700534#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#43#39#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">The obese patients    underwent laparoscop
ic RYGBP and after eight months all the tests were repeated.    RYGBP is a mixed
 technique that uses more of a restrictive and less of a disabsortive    partici
pation. Its main characteristics are the formation of a gastric "pouch"    (15 &
plusmn; 5 mL), an alimentary loop of 100 cm, a biliopancreatic loop of    60 cm,
 and a common loop.</font></p>     ^cY#05.htm##
00403000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704018000070002000700250#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#44#40#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">This retrospective    study was approved b
y the Ethics Committee of Faculdade de Medicina do ABC.</font></p>     ^cY#05.ht
m##
00335000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704011200070002000700182#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#45#41#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Statistical    methods</b></font></p>  
   ^cY#05.htm##
00832000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704060900070002000700679#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#46#42#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Data were first    tested for normal distr
ibution with the Kolmogorov-Smirnov test. For cross-sectional    comparisons, co
ncentration of uric acid between those with and without metabolic    syndrome an
d its components at baseline were compared using ANCOVA adjusted    for age and 
ethnicity. The patients were divided into four equal quarters on    the basis of
 uric acid distributions and linear regression analysis was used    to test for 
trends across the four groups fitting quantitative variables for    the four gro
ups.</font></p>     ^cY#05.htm##
01099000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704087600070002000700946#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#47#43#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">For prospective    analyses baseline means
 (with SDs) were calculated for subjects in follow-up    with <i>t</i> tests, Wi
lcoxon tests or </font><font size="2">&#967;</font><font face="Verdana, Arial, H
elvetica, sans-serif" size="2"><sup>2</sup>    tests. The association of uric ac
id with anthropometric and metabolic variables    was evaluated using Pearson co
rrelation analysis controlled for age and ethnicity.    Multivariate logistic re
gression models were used to assess associations of    uric acid with risk of pr
evalent metabolic syndrome and with the improvement    of it after weight loss, 
taking in account potential confounders. We evaluated    the degree to which uri
c acid predicted improvement of metabolic syndrome after    Roux-en-Y gastric by
pass using logistic regression.</font></p>     ^cY#05.htm##
00504000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704028100070002000700351#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#48#44#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">All statistical    analyses were made with
 the statistical software package SPSS (v16.0; SPSS,    Chicago, IL) and MedCalc
 software. Statistical significance was considered at    <i>p</i> &lt; 0.05.</fo
nt></p>     ^cY#05.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#49#45#article#156#<p>&nbsp;</p>     ^cY#05.
htm##
00320000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704009700070002000700167#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#50#46#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="3"><b>RESULTS</b></font></p>     ^cY#05.htm##
01054000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704083100070002000700901#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#51#47#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">The overall prevalence    of hyperuricemia
 was 34.28%. Hyperuricemia was more common in men than in women    (51.72 <i>vs.
</i> 29.72%; p = 0.0002). Some characteristics of the study population    accord
ing to hyperuricemia status are shown in <a href="/img/revistas/abem/v55n1/05t01
.jpg">table    1</a>. Men with hyperuricemia, as compared with those without the
 condition,    were more likely to have diabetes (p = 0.034) and more elevated f
asting plasma    glucose levels (p = 0.027). Women with hyperuricemia as compare
d with their    counterparts without the condition were more likely to have hype
rtension (p    = 0.003), metabolic syndrome (p = 0.001), elevated triglycerides 
(p = 0.001)    and GGT (p = 0.009), and decreased HDL (p = 0.011).</font></p>   
  ^cY#05.htm##
01628000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704140500070002000701475#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#52#48#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">In men, GGT and    fasting plasma glucose 
showed a graded increase according to uric acid quartiles.    In women we observ
ed an increase in triglyceride levels and hypertension prevalence    (<a href="/
img/revistas/abem/v55n1/05t02.jpg">Table 2</a>). In men, mean GGT    in the four
th quartile was higher than that in the first quartile (p = 0.006),    and in wo
men mean triglycerides in the fourth quartile was higher than that    in the fir
st quartile (p = 0.033). The prevalence of metabolic syndrome in men    was high
er in the second quartile than that in the first quartile (p = 0.023),    and th
e prevalence of hypertension and fasting plasma glucose <u>&gt;</u> 100    mg/dL
 in the second and fourth quartile was higher than that in the first quartile   
 (p = 0.002 for the second quartile and p = 0.009 for the fourth quartile of    
hypertension and p = 0.038 for the second quartile and p = 0.009 for the fourth 
   quartile of fasting plasma glucose <u>&gt;</u> 100 mg/dL). In women the preva
lence    of hypertension was higher in the third and fourth quartile than that i
n the    first quartile (p = 0.030 for the third quartile and p = 0.000 for the 
fourth    quartile), and the prevalence of triglycerides <u>&gt;</u> 150 mg/dL w
as higher    in the fourth quartile than that in the first quartile (p = 0.000).
</font></p>     ^cY#05.htm##
00953000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704073000070002000700800#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#53#49#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Pearson's correlation    coefficients for 
the relationship between uric acid and each variable in women    were significan
t for triglycerides (r = 0.20; p = 0.029) and GGT (r = 0.23;    p = 0.018). In m
en the correlation was significant also for GGT (r = 0.45; p    = 0.013) and for
 fasting plasma glucose (r = 0.38; p = 0.039). As shown in <a href="/img/revista
s/abem/v55n1/05t03.jpg">table    3</a>, elevated triglycerides and hypertension 
were statistically significantly    associated with higher uric acid concentrati
on in women. There was no statistical    significance between metabolic abnormal
ities and uric acid concentrations in    men.</font></p>     ^cY#05.htm##
00516000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704029300070002000700363#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#54#50#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">In men, hyperuricemia    showed sensitivit
y and specificity of 41.1 and 50.0% for the diagnosis of metabolic    syndrome a
nd in women sensitivity was 76.2% and specificity 32.6% (<a href="#f1">Figure   
 1</a>).</font></p>     ^cY#05.htm##
00256000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704003300070002000700103#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#55#51#article#156#<p><a name="f1"></a></p> 
    ^cY#05.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#56#52#article#156#<p>&nbsp;</p>     ^cY#05.
htm##
00300000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704007700070002000700147#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#57#53#article#156#<p align="center"><img sr
c="/img/revistas/abem/v55n1/05f01.jpg"></p>     ^cY#05.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#58#54#article#156#<p>&nbsp;</p>     ^cY#05.
htm##
01223000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704100000070002000701070#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#59#55#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">After surgery,    uric acid levels decreas
ed from 5.60 &plusmn; 1.28 to 4.23 &plusmn; 1.20 (p    &lt; 0.0001). In men this
 decrease was from 6.75 &plusmn; 1.12 to 5.36 &plusmn;    1.42 (p &lt; 0.0001) a
nd in women from 5.31 &plusmn; 1.14 to 3.93 &plusmn; 0.93    (p &lt; 0.0001) (<a
 href="#f2">Figure 2</a>). Prevalence of hyperuricemia decreased    from 33.6% t
o 6.4% (p &lt; 0.0001), in men from 48.3% to 17.2% (p &lt; 0.0001)    and in wom
en from 29.7% to 3.6% (p &lt; 0.0001). In women GGT and metabolic    syndrome an
d hypertension prevalence showed a graded increase according to uric    acid qua
rtiles (<a href="/img/revistas/abem/v55n1/05t04.jpg">Table 4</a>). In    women, 
mean GGT in the fourth quartile was higher than that in the first and    second 
quartile (p = 0.019 and p = 0.004, respectively) and mean triglycerides    in th
e fourth quartile were higher than that in the second quartile (p = 0.005).</fon
t></p>     ^cY#05.htm##
00256000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704003300070002000700103#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#60#56#article#156#<p><a name="f2"></a></p> 
    ^cY#05.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#61#57#article#156#<p>&nbsp;</p>     ^cY#05.
htm##
00300000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704007700070002000700147#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#62#58#article#156#<p align="center"><img sr
c="/img/revistas/abem/v55n1/05f02.jpg"></p>     ^cY#05.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#63#59#article#156#<p>&nbsp;</p>     ^cY#05.
htm##
00763000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704054000070002000700610#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#64#60#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Patients with improvement    of metabolic 
syndrome after RYGBP showed a greater decrease of uric acid levels    than those
 without improvement of MS (- 1.52 &plusmn; 1.10 <i>vs.</i> 1.23 &plusmn;    1.2
3, respectively; p = 0.031). In the group of patients with hyperuricemia    befo
re RYGBP, those who became normouricemic after surgery showed 2.70 more    chanc
e of improvement of metabolic syndrome than those without normalization    of ur
ic acid levels.</font></p>     ^cY#05.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#65#61#article#156#<p>&nbsp;</p>     ^cY#05.
htm##
00323000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704010000070002000700170#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#66#62#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="3"><b>DISCUSSION</b></font></p>     ^cY#05.ht
m##
00765000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704054200070002000700612#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#67#63#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">We showed in the    present study that hyp
eruricemic men have a higher prevalence of diabetes and    higher fasting glucos
e. Women showed a higher prevalence of hypertension, metabolic    syndrome, hype
rtriglyceridemia, and low HDL. In general, elevated levels of    uric acid seem 
to be related to many metabolic abnormalities. Weight loss after    RYGBP is acc
ompanied by reduction in uric acid levels and by reduction in the    prevalence 
of hyperuricemia.</font></p>     ^cY#05.htm##
02043000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704182000070002000701890#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#68#64#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Previous studies    have showed a close re
lation between hyperuricemia and metabolic syndrome in    adults and children (9
,10). Several potential mechanisms could account for the    elevated concentrati
ons of uric acid among those with metabolic abnormalities.    Renal clearance of
 urate is inversely related to the degree of insulin resistance    (7). Furtherm
ore, higher concentrations of insulin are known to reduce the renal    excretion
 of urate (11). For example, exogenous insulin can reduce renal excretion    of 
urate in both healthy and hypertensive subjects. Thus, the reduced renal    excr
etion of urate among patients with metabolic syndrome may explain the increased 
   frequency of hyperuricemia (12). Insulin may enhance renal urate reabsorption
    via stimulation of the urate-anion exchanger URAT1 and/or the Na<sup>+</sup>
-dependent    anion cotransporter in brush border membranes of the renal proxima
l tubule (13,14).    In addition, because serum concentrations of leptin and ura
te tend to rise together,    some investigators have suggested that leptin may a
ffect renal reabsorption    (14,15). Increased consumption of fructose, which is
 associated with obesity,    has been shown to elevate concentrations of uric ac
id (16,17). Finally, in the    metabolic syndrome, impaired oxidative phosphoryl
ation may increase systemic    adenosine concentrations by increasing the intrac
ellular concentrations of coenzyme    A esters of long-chain fatty acids. Increa
sed adenosine, in turn, can result    in renal retention of sodium, urate, and w
ater (18,19). Some have speculated    that chronically increased extracellular a
denosine concentrations may also contribute    to hyperuricemia by increasing ur
ate production.</font></p>     ^cY#05.htm##
01376000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704115300070002000701223#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#69#65#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Although hyperuricemia    is well recogniz
ed as a risk factor for atherosclerotic diseases such as myocardial    infarctio
n and stroke, the independence of this association from other confounding    fac
tors has remained controversial. This is mostly because serum uric acid is    as
sociated with other cardiovascular risk factors, such as hypertension and    dys
lipidemia (20). Several previous studies have analyzed possible associations    
between hyperuricemia and coronary heart disease and their independence. Althoug
h    some studies have reported a positive association between hyperuricemia and
    coronary heart disease (21,22), others have not (23,24). Most studies showin
g    negative results advocated, as expected, that the association between uric 
acid    and coronary heart disease is not truly independent, but it is dependent
 on    other risk factors for coronary heart disease. On the other hand, it is p
ossible    that uric acid is an independent risk factor for coronary heart disea
se in some    selected populations, such as alcohol abstainers (25).</font></p> 
    ^cY#05.htm##
01551000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704132800070002000701398#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#70#66#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">In accordance with    previous studies, we
 found that serum uric acid levels are higher in men than    in women, although 
uric acid levels in women tend to increase above the age    of 50 (26). Consider
ing both genders, these differences in serum uric acid levels    and the increas
e after menopause in females have been reported previously and    attributed to 
the influence of sexual hormones (27). We also found that male    subjects have 
a higher prevalence of hyperuricemia than women. The most striking    associatio
n found in our study is certainly the close relationship between serum    trigly
cerides and serum uric acid levels and hyperuricemia. This observation    was ma
de principally in women. The correlation of triglycerides with uric acid    has 
been previously found in several groups of patients (8,28). The mechanism    for
 the strong association of triglyceride values and serum uric acid levels    has
 still not been elucidated. Although, genetic factors have been associated    wi
th the concurrence of gout and hypertriglyceridemia, most investigators tend    
to conclude that hyperuricemia and hypertriglyceridemia reflect more the lifesty
le    of the patient, as part of the metabolic syndrome, than genetic factors (2
9).</font></p>     ^cY#05.htm##
00836000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704061300070002000700683#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#71#67#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Sustained weight    reduction was accompan
ied by significant decrease in uricemia as showed by other    studies (30,31). S
uch effect may be explained by a correction of uric acid renal    clearance resu
lting from the near-normalization of hyperinsulinemia and insulin    resistance.
 Besides the already known benefits of bariatric surgery on blood    pressure, p
lasmatic lipids and metabolic syndrome (32-37), improvement of hyperuricemia    
may contribute to the improvement of cardiometabolic risk in morbidly obese    p
atients.</font></p>     ^cY#05.htm##
00594000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704037100070002000700441#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#72#68#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">In conclusion,    concentrations of uric a
cid were associated with the prevalence of metabolic    abnormalities in this sa
mple of morbidly obese. Furthermore, weight loss after    RYGBP can reduce uric 
acid levels and the prevalence of hyperuricemia as shown    in other articles (3
0,38).</font></p>     ^cY#05.htm##
00393000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704017000070002000700240#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#73#69#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Disclosure: no    potential conflict of in
terest relevant to this article was reported.</font></p>     ^cY#05.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#74#70#article#156#<p>&nbsp;</p>     ^cY#05.
htm##
00323000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704010000070002000700170#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#75#71#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="3"><b>REFERENCES</b></font></p>     ^cY#05.ht
m##
00467000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704023000072002000700302#v55
n1#V:\SciELO\serial\abem\v55n1\markup\05.htm#S#p#76#72#article#156#1#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">1. Gertler MM,    Garn SM, L
evine SA. Serum uric acid in relation to age and physique in health    and coron
ary heart disease. Ann Intern Med. 1951;54:1421-34.    ^cY#05.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002000070002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#77#73#article#156#</font></p>     ^cY#05.ht
m##
00462000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704022500072002000700297#v55
n1#V:\SciELO\serial\abem\v55n1\markup\05.htm#S#p#78#74#article#156#2#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">2. Fang J, Alderman    MH. S
erum uric acid and cardiovascular mortality. The NHANES I epidemiologic    follo
w-up study, 1971-1992. JAMA. 2000;283:2404-10.    ^cY#05.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002000070002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#79#75#article#156#</font></p>     ^cY#05.ht
m##
00496000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704025900072002000700331#v55
n1#V:\SciELO\serial\abem\v55n1\markup\05.htm#S#p#80#76#article#156#3#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">3. Wang JG, Staessen    JA, 
Fagard RH, Birkenh&auml;ger WH, Gong L, Liu L; for the Systollic Hypertension   
 in China (Syst-China) Trial Collaborative Group. Hypertension. 2001;37:1069-74.
    ^cY#05.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002000070002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#81#77#article#156#</font></p>     ^cY#05.ht
m##
00481000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704024400072002000700316#v55
n1#V:\SciELO\serial\abem\v55n1\markup\05.htm#S#p#82#78#article#156#4#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">4. Culleton BF,    Larson MG
, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease    and 
death: The Framingham Heart Study. Ann Intern Med. 1999;131:7-13.    ^cY#05.htm#
#
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002000070002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#83#79#article#156#</font></p>     ^cY#05.ht
m##
00536000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704029900072002000700371#v55
n1#V:\SciELO\serial\abem\v55n1\markup\05.htm#S#p#84#80#article#156#5#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">5. De Leeuw PW,    Thijs L, 
Birkenh&auml;ger WH, et al. Prognostic significance of renal function    in elde
rly patients with isolated systolic hypertension: results from the Syst-Eur    T
rial. J Am Soc Nephrol. 2002;13:2213-22.    ^cY#05.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002000070002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#85#81#article#156#</font></p>     ^cY#05.ht
m##
00447000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704021000072002000700282#v55
n1#V:\SciELO\serial\abem\v55n1\markup\05.htm#S#p#86#82#article#156#6#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">6. Borges RL, Ribeiro    AB,
 Zanella MT, Batista MC. Uric acid as a factor in the metabolic syndrome.    Cur
r Hypertens Rep. 2010;12:113-9.    ^cY#05.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002000070002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#87#83#article#156#</font></p>     ^cY#05.ht
m##
00527000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704029000072002000700362#v55
n1#V:\SciELO\serial\abem\v55n1\markup\05.htm#S#p#88#84#article#156#7#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">7. Facchini F,    Ida Chen Y
-D, Hollenbeck CB, Reaven GM. Relationship between resistance to insulin-mediate
d    glucose uptake, urinary uric acid clearance and plasma uric acid concentrat
ion.    JAMA. 1991;266:3008-11.    ^cY#05.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002000070002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#89#85#article#156#</font></p>     ^cY#05.ht
m##
00593000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704035600072002000700428#v55
n1#V:\SciELO\serial\abem\v55n1\markup\05.htm#S#p#90#86#article#156#8#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">8. Rathmann W,    Funkhouser
 E, Dyer AR, Roseman JM. Relations of hyperuricemia with the various    componen
ts of the insulin resistance syndrome in young black and white adults:    the CA
RDIA study. Coronary Artery Risk Development in Young Adults. Annals Epidemiol. 
   1998;8:250-61.    ^cY#05.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002000070002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#91#87#article#156#</font></p>     ^cY#05.ht
m##
00475000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704023800072002000700310#v55
n1#V:\SciELO\serial\abem\v55n1\markup\05.htm#S#p#92#88#article#156#9#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">9. Ford ES, Li    C, Cook S,
 Choi HK. Serum concentrations of uric acid and the metabolic syndrome    among 
US children and adolescents. Circulation. 2007;115:2526-32.    ^cY#05.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002000070002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#93#89#article#156#</font></p>     ^cY#05.ht
m##
00532000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000300070704029400073002000700367#v55
n1#V:\SciELO\serial\abem\v55n1\markup\05.htm#S#p#94#90#article#156#10#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">10. Ishizaka N,    Ishizaka
 Y, Toda E, Nagai R, Yamakado M. Association between serum uric acid,    metabol
ic syndrome, and carotid atherosclerosis in Japanese individuals. Arterioscler  
  Thromb Vasc Biol. 2005;25:1038-44.    ^cY#05.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002000070002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#95#91#article#156#</font></p>     ^cY#05.ht
m##
00522000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000300070704028400073002000700357#v55
n1#V:\SciELO\serial\abem\v55n1\markup\05.htm#S#p#96#92#article#156#11#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">11. Ter Maaten    JC, Voorb
urg A, Heine RJ, Ter Wee PM, Donker AJ, Gans RO. Renal handling of    urate and 
sodium during acute physiological hyperinsulinaemia in healthy subjects.    Clin
 Sci (Lond). 1997;92:51-8.    ^cY#05.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002000070002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#97#93#article#156#</font></p>     ^cY#05.ht
m##
00509000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000300070704027100073002000700344#v55
n1#V:\SciELO\serial\abem\v55n1\markup\05.htm#S#p#98#94#article#156#12#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">12. Muscelli E,    Natali A
, Bianchi S, Bigazzi R, Galvan AQ, Sironi AM, et al. Effect of insulin    on ren
al sodium and uric acid handling in essential hypertension. Am J Hypertens.    1
996;9:746-52.    ^cY#05.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002000070002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#99#95#article#156#</font></p>     ^cY#05.ht
m##
00481000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000300056709000800059708000400067888000300071704024200074002000700316#v55
n1#V:\SciELO\serial\abem\v55n1\markup\05.htm#S#p#100#96#article#156#13#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">13. Enomoto A,    Kimura H
, Chairoungdua A, et al. Molecular identification of a renal urate anion    exch
anger that regulates blood urate levels. Nature. 2002;417:447-52.    ^cY#05.htm#
#
00244000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000300056709000800059708000400067704002000071002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#101#97#article#156#</font></p>     ^cY#05.h
tm##
00404000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000300056709000800059708000400067888000300071704016500074002000700239#v55
n1#V:\SciELO\serial\abem\v55n1\markup\05.htm#S#p#102#98#article#156#14#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">14. Choi HK, Mount    DB, 
Reginato AM. Pathogenesis of gout. Ann Intern Med. 2005;143:499-516.    ^cY#05.h
tm##
00244000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000300056709000800059708000400067704002000071002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#103#99#article#156#</font></p>     ^cY#05.h
tm##
00488000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704024800075002000700323#v55
n1#V:\SciELO\serial\abem\v55n1\markup\05.htm#S#p#104#100#article#156#15#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">15. Lin JD, Chiou    WK, 
Chang HY, Liu FH, Weng HF. Serum uric acid and leptin levels in metabolic    syn
drome: a quandary over the role of uric acid. Metabolism. 2007;56:751-6.    ^cY#
05.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#105#101#article#156#</font></p>     ^cY#05.
htm##
00499000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704025900075002000700334#v55
n1#V:\SciELO\serial\abem\v55n1\markup\05.htm#S#p#106#102#article#156#16#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">16. Ludwig DS,    Peterso
n KE, Gortmaker SL. Relation between consumption of sugar-sweetened drinks    an
d childhood obesity: a prospective, observational analysis. Lancet. 2001;357:505
-8.    ^cY#05.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#107#103#article#156#</font></p>     ^cY#05.
htm##
00451000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704021100075002000700286#v55
n1#V:\SciELO\serial\abem\v55n1\markup\05.htm#S#p#108#104#article#156#17#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">17. Heinig M, Johnson    
RJ. Role of uric acid in hypertension, renal disease, and metabolic syndrome.   
 Cleve Clin J Med. 2006;73:1059-64.    ^cY#05.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#109#105#article#156#</font></p>     ^cY#05.
htm##
00556000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704031600075002000700391#v55
n1#V:\SciELO\serial\abem\v55n1\markup\05.htm#S#p#110#106#article#156#18#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">18. Dhalla AK,    Wong MY
, Voshol PJ, Belardinelli L, Reaven GM. A1 adenosine receptor partial    agonist
 lowers plasma FFA and improves insulin resistance induced by high-fat    diet i
n rodents. Am J Physiol Endocrinol Metab. 2007;292:E1358-63.    ^cY#05.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#111#107#article#156#</font></p>     ^cY#05.
htm##
00461000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704022100075002000700296#v55
n1#V:\SciELO\serial\abem\v55n1\markup\05.htm#S#p#112#108#article#156#19#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">19. Castrop H.    Mediato
rs of tubuloglomerular feedback regulation of glomerular filtration:    ATP and 
adenosine. Acta Physiol (Oxf). 2007;189:3-14.    ^cY#05.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#113#109#article#156#</font></p>     ^cY#05.
htm##
00513000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704027300075002000700348#v55
n1#V:\SciELO\serial\abem\v55n1\markup\05.htm#S#p#114#110#article#156#20#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">20. Nagahama K,    Iseki 
K, Inoue T, Touma T, Ikemiya Y, Takishita S. Hyperuricemia and cardiovascular   
 risk factor clustering in a screened cohort in Okinawa, Japan. Hypertens Res.  
  2004;27:227-33.    ^cY#05.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#115#111#article#156#</font></p>     ^cY#05.
htm##
00454000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704021400075002000700289#v55
n1#V:\SciELO\serial\abem\v55n1\markup\05.htm#S#p#116#112#article#156#21#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">21. Tangri N, Weiner    D
E. Uric Acid, CKD, and cardiovascular disease: confounders, culprits, and circle
s.    Am J Kidney Dis. 2010;56:247-50.    ^cY#05.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#117#113#article#156#</font></p>     ^cY#05.
htm##
00481000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704024100075002000700316#v55
n1#V:\SciELO\serial\abem\v55n1\markup\05.htm#S#p#118#114#article#156#22#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">22. Palmer IM,    Schutte
 AE, Huisman HW. Uric acid and the cardiovascular profile of African    and Cauc
asian men. J Hum Hypertens. 2010;24(10):639-45. Epub 2010 Feb 11.    ^cY#05.htm#
#
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#119#115#article#156#</font></p>     ^cY#05.
htm##
00540000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704030000075002000700375#v55
n1#V:\SciELO\serial\abem\v55n1\markup\05.htm#S#p#120#116#article#156#23#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">23. Zoppini G,    Targher
 G, Negri C, Stoico V, Perrone F, Muggeo M, et al. Elevated serum uric    acid c
oncentrations independently predict cardiovascular mortality in type 2    diabet
ic patients. Diabetes Care. 2009;32:1716-20.    ^cY#05.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#121#117#article#156#</font></p>     ^cY#05.
htm##
00441000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704020100075002000700276#v55
n1#V:\SciELO\serial\abem\v55n1\markup\05.htm#S#p#122#118#article#156#24#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">24. Santos RD.    Uric ac
id and cardiovascular disease: how to solve another chicken or egg puzzle.    Ca
rdiology. 2009;114:298-9.    ^cY#05.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#123#119#article#156#</font></p>     ^cY#05.
htm##
00480000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704024000075002000700315#v55
n1#V:\SciELO\serial\abem\v55n1\markup\05.htm#S#p#124#120#article#156#25#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">25. Iribarren C,    Sharp
 DS, Curb JD, Yano K. High uric acid: a metabolic marker of coronary heart    di
sease among alcohol abstainers. J Clin Epidemiol. 1996;49:673-8.    ^cY#05.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#125#121#article#156#</font></p>     ^cY#05.
htm##
00517000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704027700075002000700352#v55
n1#V:\SciELO\serial\abem\v55n1\markup\05.htm#S#p#126#122#article#156#26#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">26. Freedman DS,    Willi
amson DF, Gunter EW, Byers T. Relation of serum uric acid to mortality    and is
chemic heart disease. The NHANES I epidemiologic follow-up study. Am J    Epidem
iol. 1995;141:637-44.    ^cY#05.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#127#123#article#156#</font></p>     ^cY#05.
htm##
00478000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704023800075002000700313#v55
n1#V:\SciELO\serial\abem\v55n1\markup\05.htm#S#p#128#124#article#156#27#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">27. Gordon T, Kannel    W
B. Drinking and its relation to smoking, blood pressure, blood lipids, and    ur
ic acid. The Framingham Study. Arch Int Med. 1983;143:1366-74.    ^cY#05.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#129#125#article#156#</font></p>     ^cY#05.
htm##
00543000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704030300075002000700378#v55
n1#V:\SciELO\serial\abem\v55n1\markup\05.htm#S#p#130#126#article#156#28#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">28. Conen D, Wietlisbach 
   V, Bovet P, Shamlaye C, Riesen W, Paccaud F, et al. Prevalence of hyperuricem
ia    and relation of serum uric acid with cardiovascular risk factors in a deve
loping    country. BMC Public Health. 2004;4:9.    ^cY#05.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#131#127#article#156#</font></p>     ^cY#05.
htm##
00498000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704025800075002000700333#v55
n1#V:\SciELO\serial\abem\v55n1\markup\05.htm#S#p#132#128#article#156#29#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">29. Moriwaki Y,    Tetsuy
a Y, Takahashi S, Tsutsumi Z, Higashino K. Apolipoprotein E phenotypes    in pat
ients with gout: relation with hypertriglyceridemia. Ann Rheum Dis. 1995;54:351-
4.    ^cY#05.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#133#129#article#156#</font></p>     ^cY#05.
htm##
00533000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704029300075002000700368#v55
n1#V:\SciELO\serial\abem\v55n1\markup\05.htm#S#p#134#130#article#156#30#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">30. Sj&ouml;str&ouml;m   
 L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, et al. Lifesty
le,    diabetes, and cardiovascular risk factors 10 years after bariatric surger
y.    N Engl J Med. 2004;351:2683-93.    ^cY#05.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#135#131#article#156#</font></p>     ^cY#05.
htm##
00515000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704027500075002000700350#v55
n1#V:\SciELO\serial\abem\v55n1\markup\05.htm#S#p#136#132#article#156#31#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">31. Luyckx FH,    Scheen 
AJ, Desaive C, Dewe W, Gielen JE, Lefebvre PJ. Effects of gastroplasty    on bod
y weight and related biological abnormalities in morbid obesity. Diabetes    Met
ab. 1998;24:355-61.    ^cY#05.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#137#133#article#156#</font></p>     ^cY#05.
htm##
00546000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704030600075002000700381#v55
n1#V:\SciELO\serial\abem\v55n1\markup\05.htm#S#p#138#134#article#156#32#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">32. Serpa Neto    A, Ross
i FM, Amarante RD, Buriti NA, Rossi M. Impact of plasmatic lipids in    glycemic
 control and its influence in the cardiometabolic risk in morbidly obese    subj
ects. Arq Bras Endocrinol Metabol. 2009;53:747-54.    ^cY#05.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#139#135#article#156#</font></p>     ^cY#05.
htm##
00569000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704032900075002000700404#v55
n1#V:\SciELO\serial\abem\v55n1\markup\05.htm#S#p#140#136#article#156#33#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">33. Serpa Neto    A, Bian
co Rossi FM, Dal Moro Amarante R, Alves Buriti N, Cunha Barbosa Saheb    G, Ross
i M. Effect of weight loss after Roux-en-Y gastric bypass, on renal function    
and blood pressure in morbidly obese patients. J Nephrol. 2009;22:637-46.    ^cY
#05.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#141#137#article#156#</font></p>     ^cY#05.
htm##
00557000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704031700075002000700392#v55
n1#V:\SciELO\serial\abem\v55n1\markup\05.htm#S#p#142#138#article#156#34#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">34. Rossi M, Barretto    
Fereira da Silva R, Chaves Alc&acirc;ntara G Jr, Regina PF, Martin Bianco Rossi 
   F, et al. Remission of metabolic syndrome: a study of 140 patients six months
    after Roux-en-Y gastric bypass. Obes Surg. 2008;18:601-6.    ^cY#05.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#143#139#article#156#</font></p>     ^cY#05.
htm##
00550000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704031000075002000700385#v55
n1#V:\SciELO\serial\abem\v55n1\markup\05.htm#S#p#144#140#article#156#35#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">35. Novais PF,    Rasera 
Junior I, Leite CV, Oliveira MR. Body weight evolution and classification    of 
body weight in relation to the results of bariatric surgery: roux-en-Y gastric  
  bypass. Arq Bras Endocrinol Metabol. 2010;54:303-10.    ^cY#05.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#145#141#article#156#</font></p>     ^cY#05.
htm##
00492000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704025200075002000700327#v55
n1#V:\SciELO\serial\abem\v55n1\markup\05.htm#S#p#146#142#article#156#36#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">36. Carvalho PS,    Morei
ra CL, Barelli Mda C, Oliveira FH, Guzzo MF, Miguel GP, et al. Can bariatric    
surgery cure metabolic syndrome? Arq Bras Endocrinol Metabol. 2007;51:79-85.    
^cY#05.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#147#143#article#156#</font></p>     ^cY#05.
htm##
00439000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704019900075002000700274#v55
n1#V:\SciELO\serial\abem\v55n1\markup\05.htm#S#p#148#144#article#156#37#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">37. Geloneze B,    Pareja
 JC. Does bariatric surgery cure the metabolic syndrome? Arq Bras Endocrinol    
Metabol. 2006;50:400-7.    ^cY#05.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#149#145#article#156#</font></p>     ^cY#05.
htm##
00529000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704028900075002000700364#v55
n1#V:\SciELO\serial\abem\v55n1\markup\05.htm#S#p#150#146#article#156#38#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">38. Nakanishi N,    Nakam
ura K, Suzuki K, Matsuo Y, Tatara K. Relation of body weight change to    change
s in atherogenic traits: a study of middle-aged Japanese obese male office    wo
rkers. Ind Health. 2000;38:233-8.    ^cY#05.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#151#147#article#156#</font></p>     ^cY#05.
htm##
00247000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002200072002000700094#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#152#148#article#156#<p>&nbsp;</p>     ^cY#0
5.htm##
00247000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002200072002000700094#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#153#149#article#156#<p>&nbsp;</p>     ^cY#0
5.htm##
00420000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704019500072002000700267#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#154#150#article#156#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2"><a name="back"></a><a href="#top"><img s
rc="/img/revistas/abem/v55n1/seta.jpg" border="0"></a>    <b>Correspondence to:<
/b>     ^cY#05.htm##
00254000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002900072002000700101#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#155#151#article#156#<br>   Ary Serpa Neto  
  ^cY#05.htm##
00270000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704004500072002000700117#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#156#152#article#156#<br>   Rua Ossian Terce
iro Teles, 220    ^cY#05.htm##
00280000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704005500072002000700127#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#157#153#article#156#<br>   04649-000 - S&at
ilde;o Paulo, SP, Brazil    ^cY#05.htm##
00316000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704009100072002000700163#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#158#154#article#156#<br>   <a href="mailto:
aryserpa@terra.com.br">aryserpa@terra.com.br</a></font></p>     ^cY#05.htm##
00318000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704009300072002000700165#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#159#155#article#156#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2">Received on Dec/6/2009    ^cY#05.htm##
00275000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704005000072002000700122#v55n1#V:\SciELO
\serial\abem\v55n1\markup\05.htm#S#p#160#156#article#156#<br>   Accepted on Nov/
16/2010</font></p>     ^cY#05.htm##
00581000000000289000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100018000710100015000890100
01700104012008900121030001500210065000900225064000500234031000300239014000800242
865000900250002000700259035001000266801001500276#v55n1#V:\SciELO\serial\abem\v55
n1\markup\05.htm#S#c#161#1#article#38#1#^rND^sGertler^nMM#^rND^sGarn^nSM#^rND^sL
evine^nSA#Serum uric acid in relation to age and physique in health and coronary
 heart disease^len#Ann Intern Med#19510000#1951#54#1421-34#20110200#05.htm#0003-
4819#Ann Intern Med##
00559000000000289000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100014000710100019000850120
09300104014001000197030000500207065000900212064000500221031000400226014000800230
865000900238002000700247035001000254801000500264#v55n1#V:\SciELO\serial\abem\v55
n1\markup\05.htm#S#c#162#2#article#38#2#^rND^sFang^nJ#^rND^sAlderman^nMH#Serum u
ric acid and cardiovascular mortality: The NHANES I epidemiologic follow-up stud
y^len#1971-1992#JAMA#20000000#2000#283#2404-10#20110200#05.htm#0098-7484#JAMA##
00657000000000325000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100015000710100019000860100
01700105010002200122010001400144010001300158012008300171030001300254065000900267
06400050027603100030028101400080028486500090029200200070030103500100030880100130
0318#v55n1#V:\SciELO\serial\abem\v55n1\markup\05.htm#S#c#163#3#article#38#3#^rND
^sWang^nJG#^rND^sStaessen^nJA#^rND^sFagard^nRH#^rND^sBirkenhäger^nWH#^rND^sGong^
nL#^rND^sLiu^nL#for the Systollic Hypertension in China (Syst-China) Trial Colla
borative Group^len#Hypertension#20010000#2001#37#1069-74#20110200#05.htm#0194-91
1X#Hypertension##
00613000000000301000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100019000710100017000900100
01700107010001400124012009400138030001500232065000900247064000500256031000400261
014000500265865000900270002000700279035001000286801001500296#v55n1#V:\SciELO\ser
ial\abem\v55n1\markup\05.htm#S#c#164#4#article#38#4#^rND^sCulleton^nBF#^rND^sLar
son^nMG#^rND^sKannel^nWB#^rND^sLevy^nD#Serum uric acid and risk for cardiovascul
ar disease and death: The Framingham Heart Study^len#Ann Intern Med#19990000#199
9#131#7-13#20110200#05.htm#0003-4819#Ann Intern Med##
00655000000000301000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100019000710100015000900100
02200105810000600127012013500133030001700268065000900285064000500294031000300299
014000800302865000900310002000700319035001000326801001700336#v55n1#V:\SciELO\ser
ial\abem\v55n1\markup\05.htm#S#c#165#5#article#38#5#^rND^sDe Leeuw^nPW#^rND^sThi
js^nL#^rND^sBirkenhäger^nWH#et al#Prognostic significance of renal function in e
lderly patients with isolated systolic hypertension: results from the Syst-Eur T
rial^len#J Am Soc Nephrol#20020000#2002#13#2213-22#20110200#05.htm#1046-6673#J A
m Soc Nephrol##
00544000000000289000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100017000710100018000880100
01800106010001800124012005200142030001900194710000200213065000900215064000500224
031000300229014000600232865000900238002000700247#v55n1#V:\SciELO\serial\abem\v55
n1\markup\05.htm#S#c#166#6#article#38#6#^rND^sBorges^nRL#^rND^sRibeiro^nAB#^rND^
sZanella^nMT#^rND^sBatista^nMC#Uric acid as a factor in the metabolic syndrome^l
en#Curr Hypertens Rep#2#20100000#2010#12#113-9#20110200#05.htm##
00646000000000301000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100018000710100020000890100
02100109010001700130012013500147030000500282065000900287064000500296031000400301
014000800305865000900313002000700322035001000329801000500339#v55n1#V:\SciELO\ser
ial\abem\v55n1\markup\05.htm#S#c#167#7#article#38#7#^rND^sFacchini^nF#^rND^sIda 
Chen^nY-D#^rND^sHollenbeck^nCB#^rND^sReaven^nGM#Relationship between resistance 
to insulin-mediated glucose uptake, urinary uric acid clearance and plasma uric 
acid concentration^len#JAMA#19910000#1991#266#3008-11#20110200#05.htm#0098-7484#
JAMA##
00684000000000289000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100018000710100020000890100
01500109010001800124012019400142030001700336710000200353065000900355064000500364
031000200369014000700371865000900378002000700387#v55n1#V:\SciELO\serial\abem\v55
n1\markup\05.htm#S#c#168#8#article#38#8#^rND^sRathmann^nW#^rND^sFunkhouser^nE#^r
ND^sDyer^nAR#^rND^sRoseman^nJM#Relations of hyperuricemia with the various compo
nents of the insulin resistance syndrome in young black and white adults: the CA
RDIA study. Coronary Artery Risk Development in Young Adults^len#Annals Epidemio
l#2#19980000#1998#8#250-61#20110200#05.htm##
00604000000000301000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100015000710100012000860100
01400098010001500112012009900127030001200226065000900238064000500247031000400252
014000800256865000900264002000700273035001000280801001200290#v55n1#V:\SciELO\ser
ial\abem\v55n1\markup\05.htm#S#c#169#9#article#38#9#^rND^sFord^nES#^rND^sLi^nC#^
rND^sCook^nS#^rND^sChoi^nHK#Serum concentrations of uric acid and the metabolic 
syndrome among US children and adolescents^len#Circulation#20070000#2007#115#252
6-32#20110200#05.htm#0009-7322#Circulation##
00694000000000313000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100018000730100018000910100
01400109010001500123010001800138012011300156030003000269065000900299064000500308
031000300313014000800316865000900324002000700333035001000340801003000350#v55n1#V
:\SciELO\serial\abem\v55n1\markup\05.htm#S#c#170#10#article#38#10#^rND^sIshizaka
^nN#^rND^sIshizaka^nY#^rND^sToda^nE#^rND^sNagai^nR#^rND^sYamakado^nM#Association
 between serum uric acid, metabolic syndrome, and carotid atherosclerosis in Jap
anese individuals^len#Arterioscler Thromb Vasc Biol#20050000#2005#25#1038-44#201
10200#05.htm#1079-5642#Arterioscler Thromb Vasc Biol##
00691000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100021000730100018000940100
01600112010001800128010001700146010001500163012010400178030000900282066000500291
06500090029606400050030503100030031001400050031386500090031800200070032703500100
0334801000900344#v55n1#V:\SciELO\serial\abem\v55n1\markup\05.htm#S#c#171#11#arti
cle#38#11#^rND^sTer Maaten^nJC#^rND^sVoorburg^nA#^rND^sHeine^nRJ#^rND^sTer Wee^n
PM#^rND^sDonker^nAJ#^rND^sGans^nRO#Renal handling of urate and sodium during acu
te physiological hyperinsulinaemia in healthy subjects^len#Clin Sci#Lond#1997000
0#1997#92#51-8#20110200#05.htm#0009-9287#Clin Sci##
00685000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100018000730100016000910100
01700107010001700124010001700141010001700158810000600175012008700181030001500268
06500090028306400050029203100020029701400070029986500090030600200070031503500100
0322801001500332#v55n1#V:\SciELO\serial\abem\v55n1\markup\05.htm#S#c#172#12#arti
cle#38#12#^rND^sMuscelli^nE#^rND^sNatali^nA#^rND^sBianchi^nS#^rND^sBigazzi^nR#^r
ND^sGalvan^nAQ#^rND^sSironi^nAM#et al#Effect of insulin on renal sodium and uric
 acid handling in essential hypertension^len#Am J Hypertens#19960000#1996#9#746-
52#20110200#05.htm#0895-7061#Am J Hypertens##
00597000000000301000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730100016000900100
02200106810000600128012009600134030000700230065000900237064000500246031000400251
014000700255865000900262002000700271035001000278801000700288#v55n1#V:\SciELO\ser
ial\abem\v55n1\markup\05.htm#S#c#173#13#article#38#13#^rND^sEnomoto^nA#^rND^sKim
ura^nH#^rND^sChairoungdua^nA#et al#Molecular identification of a renal urate ani
on exchanger that regulates blood urate levels^len#Nature#20020000#2002#417#447-
52#20110200#05.htm#0028-0836#Nature##
00520000000000289000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100015000730100016000880100
01900104012002500123030001500148065000900163064000500172031000400177014000800181
865000900189002000700198035001000205801001500215#v55n1#V:\SciELO\serial\abem\v55
n1\markup\05.htm#S#c#174#14#article#38#14#^rND^sChoi^nHK#^rND^sMount^nDB#^rND^sR
eginato^nAM#Pathogenesis of gout^len#Ann Intern Med#20050000#2005#143#499-516#20
110200#05.htm#0003-4819#Ann Intern Med##
00632000000000313000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100014000730100016000870100
01600103010001400119010001500133012009900148030001100247065000900258064000500267
031000300272014000600275865000900281002000700290035001000297801001100307#v55n1#V
:\SciELO\serial\abem\v55n1\markup\05.htm#S#c#175#15#article#38#15#^rND^sLin^nJD#
^rND^sChiou^nWK#^rND^sChang^nHY#^rND^sLiu^nFH#^rND^sWeng^nHF#Serum uric acid and
 leptin levels in metabolic syndrome: a quandary over the role of uric acid^len#
Metabolism#20070000#2007#56#751-6#20110200#05.htm#0026-0495#Metabolism##
00603000000000289000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730100019000900100
02000109012012000129030000700249065000900256064000500265031000400270014000600274
865000900280002000700289035001000296801000700306#v55n1#V:\SciELO\serial\abem\v55
n1\markup\05.htm#S#c#176#16#article#38#16#^rND^sLudwig^nDS#^rND^sPeterson^nKE#^r
ND^sGortmaker^nSL#Relation between consumption of sugar-sweetened drinks and chi
ldhood obesity: a prospective, observational analysis^len#Lancet#20010000#2001#3
57#505-8#20110200#05.htm#0099-5355#Lancet##
00547000000000277000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730100018000890120
07700107030001700184065000900201064000500210031000300215014000800218865000900226
002000700235035001000242801001700252#v55n1#V:\SciELO\serial\abem\v55n1\markup\05
.htm#S#c#177#17#article#38#17#^rND^sHeinig^nM#^rND^sJohnson^nRJ#Role of uric aci
d in hypertension, renal disease, and metabolic syndrome^len#Cleve Clin J Med#20
060000#2006#73#1059-64#20110200#05.htm#0891-1150#Cleve Clin J Med##
00666000000000301000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730100015000900100
01700105010002200122010001700144012012800161030003000289710000200319065000900321
064000500330031000400335014000900339865000900348002000700357#v55n1#V:\SciELO\ser
ial\abem\v55n1\markup\05.htm#S#c#178#18#article#38#18#^rND^sDhalla^nAK#^rND^sWon
g^nMY#^rND^sVoshol^nPJ#^rND^sBelardinelli^nL#^rND^sReaven^nGM#A1 adenosine recep
tor partial agonist lowers plasma FFA and improves insulin resistance induced by
 high-fat diet in rodents^len#Am J Physiol Endocrinol Metab#2#20070000#2007#292#
E1358-63#20110200#05.htm##
00512000000000265000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730120098000900300
01300188710000200201066000400203065000900207064000500216031000400221014000500225
865000900230002000700239#v55n1#V:\SciELO\serial\abem\v55n1\markup\05.htm#S#c#179
#19#article#38#19#^rND^sCastrop^nH#Mediators of tubuloglomerular feedback regula
tion of glomerular filtration: ATP and adenosine^len#Acta Physiol#2#Oxf#20070000
#2007#189#3-14#20110200#05.htm##
00675000000000325000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100018000730100015000910100
01500106010001500121010001700136010001900153012009900172030001400271065000900285
06400050029403100030029901400070030286500090030900200070031803500100032580100140
0335#v55n1#V:\SciELO\serial\abem\v55n1\markup\05.htm#S#c#180#20#article#38#20#^r
ND^sNagahama^nK#^rND^sIseki^nK#^rND^sInoue^nT#^rND^sTouma^nT#^rND^sIkemiya^nY#^r
ND^sTakishita^nS#Hyperuricemia and cardiovascular risk factor clustering in a sc
reened cohort in Okinawa, Japan^len#Hypertens Res#20040000#2004#27#227-33#201102
00#05.htm#0916-9636#Hypertens Res##
00567000000000289000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730100017000890100
01700106012007200123030001600195065000900211064000500220031000300225014000700228
865000900235002000700244035001000251801001600261#v55n1#V:\SciELO\serial\abem\v55
n1\markup\05.htm#S#c#181#21#article#38#21#^rND^sTangri^nN#^rND^sWeiner^nDE#^rND^
sUric^nAcid#CKD, and cardiovascular disease: confounders, culprits, and circles^
len#Am J Kidney Dis#20100000#2010#56#247-50#20110200#05.htm#0272-6386#Am J Kidne
y Dis##
00587000000000301000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730100018000900100
01800108012007400126030001600200065000900216064000500225031000300230032000300233
014000700236865000900243002000700252035001000259801001600269#v55n1#V:\SciELO\ser
ial\abem\v55n1\markup\05.htm#S#c#182#22#article#38#22#^rND^sPalmer^nIM#^rND^sSch
utte^nAE#^rND^sHuisman^nHW#Uric acid and the cardiovascular profile of African a
nd Caucasian men^len#J Hum Hypertens#20100000#2010#24#10#639-45#20110200#05.htm#
0950-9240#J Hum Hypertens##
00713000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730100017000900100
01500107010001600122010001700138010001600155810000600171012011900177030001400296
06500090031006400050031903100030032401400080032786500090033500200070034403500100
0351801001400361#v55n1#V:\SciELO\serial\abem\v55n1\markup\05.htm#S#c#183#23#arti
cle#38#23#^rND^sZoppini^nG#^rND^sTargher^nG#^rND^sNegri^nC#^rND^sStoico^nV#^rND^
sPerrone^nF#^rND^sMuggeo^nM#et al#Elevated serum uric acid concentrations indepe
ndently predict cardiovascular mortality in type 2 diabetic patients^len#Diabete
s Care#20090000#2009#32#1716-20#20110200#05.htm#0149-5992#Diabetes Care##
00513000000000265000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730120085000900300
01100175065000900186064000500195031000400200014000600204865000900210002000700219
035001000226801001100236#v55n1#V:\SciELO\serial\abem\v55n1\markup\05.htm#S#c#184
#24#article#38#24#^rND^sSantos^nRD#Uric acid and cardiovascular disease: how to 
solve another chicken or egg puzzle^len#Cardiology#20090000#2009#114#298-9#20110
200#05.htm#0008-6312#Cardiology##
00612000000000301000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100019000730100016000920100
01500108010001400123012009000137030001700227065000900244064000500253031000300258
014000600261865000900267002000700276035001000283801001700293#v55n1#V:\SciELO\ser
ial\abem\v55n1\markup\05.htm#S#c#185#25#article#38#25#^rND^sIribarren^nC#^rND^sS
harp^nDS#^rND^sCurb^nJD#^rND^sYano^nK#High uric acid: a metabolic marker of coro
nary heart disease among alcohol abstainers^len#J Clin Epidemiol#19960000#1996#4
9#673-8#20110200#05.htm#0895-4356#J Clin Epidemiol##
00644000000000301000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100019000730100021000920100
01700113010001500130012011600145030001500261065000900276064000500285031000400290
014000700294865000900301002000700310035001000317801001500327#v55n1#V:\SciELO\ser
ial\abem\v55n1\markup\05.htm#S#c#186#26#article#38#26#^rND^sFreedman^nDS#^rND^sW
illiamson^nDF#^rND^sGunter^nEW#^rND^sByers^nT#Relation of serum uric acid to mor
tality and ischemic heart disease: The NHANES I epidemiologic follow-up study^le
n#Am J Epidemiol#19950000#1995#141#637-44#20110200#05.htm#0002-9262#Am J Epidemi
ol##
00537000000000265000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730100017000890120
10800106030001300214710000200227065000900229064000500238031000400243014000800247
865000900255002000700264#v55n1#V:\SciELO\serial\abem\v55n1\markup\05.htm#S#c#187
#27#article#38#27#^rND^sGordon^nT#^rND^sKannel^nWB#Drinking and its relation to 
smoking, blood pressure, blood lipids, and uric acid: The Framingham Study^len#A
rch Int Med#2#19830000#1983#143#1366-74#20110200#05.htm##
00682000000000325000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100015000730100021000880100
01500109010001800124010001600142010001700158810000600175012012100181030001800302
71000020032006500090032206400050033103100020033601400020033886500090034000200070
0349#v55n1#V:\SciELO\serial\abem\v55n1\markup\05.htm#S#c#188#28#article#38#28#^r
ND^sConen^nD#^rND^sWietlisbach^nV#^rND^sBovet^nP#^rND^sShamlaye^nC#^rND^sRiesen^
nW#^rND^sPaccaud^nF#et al#Prevalence of hyperuricemia and relation of serum uric
 acid with cardiovascular risk factors in a developing country^len#BMC Public He
alth#2#20040000#2004#4#9#20110200#05.htm##
00645000000000313000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100018000730100017000910100
01900108010001800127010001900145012009000164030001400254065000900268064000500277
031000300282014000600285865000900291002000700300035001000307801001400317#v55n1#V
:\SciELO\serial\abem\v55n1\markup\05.htm#S#c#189#29#article#38#29#^rND^sMoriwaki
^nY#^rND^sTetsuya^nY#^rND^sTakahashi^nS#^rND^sTsutsumi^nZ#^rND^sHigashino^nK#Apo
lipoprotein E phenotypes in patients with gout: relation with hypertriglyceridem
ia^len#Ann Rheum Dis#19950000#1995#54#351-4#20110200#05.htm#0003-4967#Ann Rheum 
Dis##
00695000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100018000730100019000910100
01800110010001900128010001800147010001800165810000600183012009000189030001300279
06500090029206400050030103100040030601400080031086500090031800200070032703500100
0334801001300344#v55n1#V:\SciELO\serial\abem\v55n1\markup\05.htm#S#c#190#30#arti
cle#38#30#^rND^sSjöström^nL#^rND^sLindroos^nAK#^rND^sPeltonen^nM#^rND^sTorgerson
^nJ#^rND^sBouchard^nC#^rND^sCarlsson^nB#et al#Lifestyle, diabetes, and cardiovas
cular risk factors 10 years after bariatric surgery^len#N Engl J Med#20040000#20
04#351#2683-93#20110200#05.htm#0028-4793#N Engl J Med##
00678000000000325000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730100017000900100
01700107010001400124010001700138010001900155012009800174030001500272065000900287
06400050029603100030030101400070030486500090031100200070032003500100032780100150
0337#v55n1#V:\SciELO\serial\abem\v55n1\markup\05.htm#S#c#191#31#article#38#31#^r
ND^sLuyckx^nFH#^rND^sScheen^nAJ#^rND^sDesaive^nC#^rND^sDewe^nW#^rND^sGielen^nJE#
^rND^sLefebvre^nPJ#Effects of gastroplasty on body weight and related biological
 abnormalities in morbid obesity^len#Diabetes Metab#19980000#1998#24#355-61#2011
0200#05.htm#0338-1684#Diabetes metab##
00704000000000313000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100020000730100016000930100
01900109010001700128010001500145012012400160030002800284065000900312064000500321
031000300326014000700329865000900336002000700345035001000352801002800362#v55n1#V
:\SciELO\serial\abem\v55n1\markup\05.htm#S#c#192#32#article#38#32#^rND^sSerpa Ne
to^nA#^rND^sRossi^nFM#^rND^sAmarante^nRD#^rND^sBuriti^nNA#^rND^sRossi^nM#Impact 
of plasmatic lipids in glycemic control and its influence in the cardiometabolic
 risk in morbidly obese subjects^len#Arq Bras Endocrinol Metabol#20090000#2009#5
3#747-54#20110200#05.htm#0004-2730#Arq Bras Endocrinol Metabol##
00727000000000325000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100020000730100023000930100
02700116010002200143010002900165010001500194012012200209030001000331065000900341
06400050035003100030035501400070035886500090036500200070037403500100038180100100
0391#v55n1#V:\SciELO\serial\abem\v55n1\markup\05.htm#S#c#193#33#article#38#33#^r
ND^sSerpa Neto^nA#^rND^sBianco Rossi^nFM#^rND^sDal Moro Amarante^nR#^rND^sAlves 
Buriti^nN#^rND^sCunha Barbosa Saheb^nG#^rND^sRossi^nM#Effect of weight loss afte
r Roux-en-Y gastric bypass, on renal function and blood pressure in morbidly obe
se patients^len#J Nephrol#20090000#2009#22#637-46#20110200#05.htm#1120-3625#J Ne
phrol##
00702000000000325000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100015000730100035000880100
02900123010001700152010002900169810000600198012010300204030001000307065000900317
06400050032603100030033101400060033486500090034000200070034903500100035680100100
0366#v55n1#V:\SciELO\serial\abem\v55n1\markup\05.htm#S#c#194#34#article#38#34#^r
ND^sRossi^nM#^rND^sBarretto Fereira da Silva^nR#^rND^sChaves Alcântara^nG Jr#^rN
D^sRegina^nPF#^rND^sMartin Bianco Rossi^nF#et al#Remission of metabolic syndrome
: a study of 140 patients six months after Roux-en-Y gastric bypass^len#Obes Sur
g#20080000#2008#18#601-6#20110200#05.htm#0960-8923#Obes Surg##
00690000000000301000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730100023000900100
01600113010001900129012013400148030002800282065000900310064000500319031000300324
014000700327865000900334002000700343035001000350801002800360#v55n1#V:\SciELO\ser
ial\abem\v55n1\markup\05.htm#S#c#195#35#article#38#35#^rND^sNovais^nPF#^rND^sRas
era Junior^nI#^rND^sLeite^nCV#^rND^sOliveira^nMR#Body weight evolution and class
ification of body weight in relation to the results of bariatric surgery: roux-e
n-Y gastric bypass^len#Arq Bras Endocrinol Metabol#20100000#2010#54#303-10#20110
200#05.htm#0004-2730#Arq Bras Endocrinol Metabol##
00683000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100019000730100018000920100
02100110010001900131010001600150010001700166810000600183012005100189030002800240
06500090026806400050027703100030028201400060028586500090029100200070030003500100
0307801002800317#v55n1#V:\SciELO\serial\abem\v55n1\markup\05.htm#S#c#196#36#arti
cle#38#36#^rND^sCarvalho^nPS#^rND^sMoreira^nCL#^rND^sBarelli Mda^nC#^rND^sOlivei
ra^nFH#^rND^sGuzzo^nMF#^rND^sMiguel^nGP#et al#Can bariatric surgery cure metabol
ic syndrome?^len#Arq Bras Endocrinol Metabol#20070000#2007#51#79-85#20110200#05.
htm#0004-2730#Arq Bras Endocrinol Metabol##
00547000000000277000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100018000730100017000910120
05600108030002800164065000900192064000500201031000300206014000600209865000900215
002000700224035001000231801002800241#v55n1#V:\SciELO\serial\abem\v55n1\markup\05
.htm#S#c#197#37#article#38#37#^rND^sGeloneze^nB#^rND^sPareja^nJC#Does bariatric 
surgery cure the metabolic syndrome?^len#Arq Bras Endocrinol Metabol#20060000#20
06#50#400-7#20110200#05.htm#0004-2730#Arq Bras Endocrinol Metabol##
00670000000000313000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100019000730100018000920100
01600110010001600126010001600142012012700158030001100285065000900296064000500305
031000300310014000600313865000900319002000700328035001000335801001100345#v55n1#V
:\SciELO\serial\abem\v55n1\markup\05.htm#S#c#198#38#article#38#38#^rND^sNakanish
i^nN#^rND^sNakamura^nK#^rND^sSuzuki^nK#^rND^sMatsuo^nY#^rND^sTatara^nK#Relation 
of body weight change to changes in atherogenic traits: a study of middle-aged J
apanese obese male office workers^len#Ind Health#20000000#2000#38#233-8#20110200
#05.htm#0019-8366#Ind Health##
00263000000000169000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640910009000660920007000750020007000827030
00400089#v55n1#V:\SciELO\serial\abem\v55n1\markup\06.htm#S#o#1#1#article#1#20110
324#154538#06.htm#235##
03792000000000661000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640710003000660400003000690010006000720420
00200078120000400080038000500084038000400089038000400093121000300097049000800100
15800030010803000260011103100030013703200020014006500090014201400090015103500100
01600120103001700120097002730100024003700100042003940100040004360100036004760700
15800512070006100670070007100731083103100802085000801833085002201841085002901863
08500310189208500260192308310140194908500080296308500210297108500270299208500290
30190850025030481170006030730720003030791120009030821110011030911140009031021130
01203111002000703123#v55n1#V:\SciELO\serial\abem\v55n1\markup\06.htm#S#h#2#1#art
icle#1#oa#pt#br1.1#1#4.0#ILUS#GRA#TAB#06#ABEM030#nd#Arq Bras Endocrinol Metab#55
#1#20110200#^f46^l53#0004-2730#Efeito da estreptozotocina sobre os perfis glicêm
ico e lipídico e o estresse oxidativo em hamsters^lpt#Effect of streptozotocin o
n the glycemic and lipid profiles and oxidative stress in hamsters^len#^rND^1A01
^nMaísa^sSilva#^rND^1A01 A03^nWanderson Geraldo de^sLima#^rND^1A01 A02^nMarcelo 
Eustáquio^sSilva#^rND^1A01 A03^nMaria Lucia^sPedrosa#Universidade Federal de Our
o Preto^iA01^1Programa de Pós-graduação em Ciências Biológicas^2Núcleo de Pesqui
sas em Ciências Biológicas^cOuro Preto^sMG^pBrasil#UFOP^iA02^1Departamento de Al
imentos^cOuro Preto^sMG^pBrasil#UFOP^iA03^1Departamento de Ciências Biológicas^c
Ouro Preto^sMG^pBrasil#^lpt^aOBJETIVO: Este estudo avaliou os efeitos da estrept
ozotocina nos perfis glicêmico e lipídico e marcadores de estresse oxidativo em 
hamsteres. MATERIAIS E MÉTODOS: Hamsteres machos Golden Syrian foram divididos e
m dois grupos: grupo diabético (D), que recebeu uma única injeção de estreptozot
ocina (STZ - 50 mg/kg), e grupo controle (C), que recebeu injeção de tampão citr
ato. Os animais foram eutanasiados após 10 dias de experimento e o sangue, o fíg
ado e rins foram coletados. RESULTADOS: O grupo diabético apresentou níveis maio
res de glicose, triacilgliceróis e colesterol séricos e maior concentração de su
bstâncias reativas ao ácido tiobarbitúrico (TBARs) no fígado e nos rins. Também 
apresentou significativo aumento da concentração de glutationa no fígado e menor
es atividades da paraoxonase e do superóxido dismutase. CONCLUSÃO: Hamsteres for
necem um bom modelo para o diabetes melito do tipo I e estresse oxidativo, simil
ar ao da síndrome humana, e poderão ser adequados para a análise de compostos an
tidiabéticos.#^dnd^i1#^tm^lpt^kHamsteres^i1#^tm^lpt^kestreptozotocina^i1#^tm^lpt
^kestresse oxidativo^i1#^tm^lpt^kantioxidantes^i1#^len^aOBJECTIVE: This study ev
aluated the effects of streptozotocin on glycemic and lipid profiles and oxidati
ve stress status in hamsters. MATERIALS AND METHODS: Male Golden Syrian hamsters
 were divided in diabetic group (D) which received a streptozotocin single injec
tion (STZ - 50 mg/kg), and control group (C) which received a single injection o
f the vehicle citrate buffer. Animals were euthanized after 10 days of experimen
t and blood, liver and kidneys were collected. RESULTS: The diabetic group had h
igher levels of glucose, triacylglycerols and cholesterol in serum and thiobarbi
turic acid reactive substances (TBARS) concentration increased in the liver and 
kidneys. Diabetes induced a significant increase in glutathione concentration in
 the liver and decreased paraoxonase and superoxide dismutase activities. CONCLU
SION: Hamsters provide a novel animal model for diabetes mellitus and oxidative 
stress, similar to the human syndrome, which may be suitable for the testing of 
antidiabetic compounds.#^dnd^i2#^tm^len^kHamsters^i2#^tm^len^kstreptozotocin^i2#
^tm^len^koxidative stress^i2#^tm^len^kantioxidants^i2#other#39#20100706#6/Jul/20
10#20101216#16/Dez/2010#06.htm##
03876000000000661000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640710003000660400003000690010006000720420
00200078120000400080038000500084038000400089038000400093121000300097049000800100
15800030010803000260011103100030013703200020014006500090014201400090015103500100
01600120110001700120104002800100024003840100042004080100040004500100036004900700
15800526070006100684070007100745083106600816085000801882085002201890085002901912
08500310194108500260197208310490199808500080304708500210305508500270307608500290
31030850025031321170006031570720003031631120009031661110011031751140009031861130
01203195002000703207#v55n1#V:\SciELO\serial\abem\v55n1\markup\06.htm#S#f#3#1#art
icle#1#oa#pt#br1.1#1#4.0#ILUS#GRA#TAB#06#ABEM030#nd#Arq Bras Endocrinol Metab#55
#1#20110200#^f46^l53#0004-2730#<b>Efeito da estreptozotocina sobre os perfis gli
cêmico e lipídico e o estresse oxidativo em hamsters</b>^lpt#<b>Effect of strept
ozotocin on the glycemic and lipid profiles and oxidative stress in hamsters</b>
^len#^rND^1A01^nMaísa^sSilva#^rND^1A01 A03^nWanderson Geraldo de^sLima#^rND^1A01
 A02^nMarcelo Eustáquio^sSilva#^rND^1A01 A03^nMaria Lucia^sPedrosa#Universidade 
Federal de Ouro Preto^iA01^1Programa de Pós-graduação em Ciências Biológicas^2Nú
cleo de Pesquisas em Ciências Biológicas^cOuro Preto^sMG^pBrasil#UFOP^iA02^1Depa
rtamento de Alimentos^cOuro Preto^sMG^pBrasil#UFOP^iA03^1Departamento de Ciência
s Biológicas^cOuro Preto^sMG^pBrasil#^lpt^a<b>OBJETIVO:</b> Este estudo avaliou 
os efeitos da estreptozotocina nos perfis glicêmico e lipídico e marcadores de e
stresse oxidativo em hamsteres. <b>MATERIAIS E MÉTODOS:</b> Hamsteres machos <i>
Golden Syrian</i> foram divididos em dois grupos: grupo diabético (D), que receb
eu uma única injeção de estreptozotocina (STZ - 50 mg/kg), e grupo controle (C),
 que recebeu injeção de tampão citrato. Os animais foram eutanasiados após 10 di
as de experimento e o sangue, o fígado e rins foram coletados. <b>RESULTADOS:</b
> O grupo diabético apresentou níveis maiores de glicose, triacilgliceróis e col
esterol séricos e maior concentração de substâncias reativas ao ácido tiobarbitú
rico (TBARs) no fígado e nos rins. Também apresentou significativo aumento da co
ncentração de glutationa no fígado e menores atividades da paraoxonase e do supe
róxido dismutase. <b>CONCLUSÃO:</b> Hamsteres fornecem um bom modelo para o diab
etes melito do tipo I e estresse oxidativo, similar ao da síndrome humana, e pod
erão ser adequados para a análise de compostos antidiabéticos.#^dnd^i1#^tm^lpt^k
Hamsteres^i1#^tm^lpt^kestreptozotocina^i1#^tm^lpt^kestresse oxidativo^i1#^tm^lpt
^kantioxidantes^i1#^len^a<b>OBJECTIVE:</b> This study evaluated the effects of s
treptozotocin on glycemic and lipid profiles and oxidative stress status in hams
ters. <b>MATERIALS AND METHODS:</b> Male Golden Syrian hamsters were divided in 
diabetic group (D) which received a streptozotocin single injection (STZ - 50 mg
/kg), and control group (C) which received a single injection of the vehicle cit
rate buffer. Animals were euthanized after 10 days of experiment and blood, live
r and kidneys were collected. <b>RESULTS:</b> The diabetic group had higher leve
ls of glucose, triacylglycerols and cholesterol in serum and thiobarbituric acid
 reactive substances (TBARS) concentration increased in the liver and kidneys. D
iabetes induced a significant increase in glutathione concentration in the liver
 and decreased paraoxonase and superoxide dismutase activities. <b>CONCLUSION:</
b> Hamsters provide a novel animal model for <i>diabetes mellitus</i> and oxidat
ive stress, similar to the human syndrome, which may be suitable for the testing
 of antidiabetic compounds.#^dnd^i2#^tm^len^kHamsters^i2#^tm^len^kstreptozotocin
^i2#^tm^len^koxidative stress^i2#^tm^len^kantioxidants^i2#other#39#20100706#6/Ju
l/2010#20101216#16/Dez/2010#06.htm##
03927000000000685000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640640013000660710003000790400003000820010
00600085042000200091120000400093038000500097038000400102038000400106121000300110
04900080011315800030012103000290012403100030015303200020015606500090015801400090
01670350010001760120103001860120097002890100024003860100042004100100040004520100
03600492070016000528070006300688070007300751083103100824085000801855085002201863
08500290188508500310191408500260194508310140197108500080298508500210299308500270
30140850029030410850025030701170006030950720003031011120009031041110011031131140
00903124113001203133002000703145008008903152#v55n1#V:\SciELO\serial\abem\v55n1\m
arkup\06.htm#S#l#4#1#article#1#^mfev.^a2011#oa#pt#br1.1#1#4.0#ilus#gra#tab#06#AB
EM030#nd#Arq. bras. endocrinol. metab#55#1#20110200#^f46^l53#0004-2730#Efeito da
 estreptozotocina sobre os perfis glicêmico e lipídico e o estresse oxidativo em
 hamsters^lpt#Effect of streptozotocin on the glycemic and lipid profiles and ox
idative stress in hamsters^len#^rND^1A01^nMaísa^sSilva#^rND^1A01 A03^nWanderson 
Geraldo de^sLima#^rND^1A01 A02^nMarcelo Eustáquio^sSilva#^rND^1A01 A03^nMaria Lu
cia^sPedrosa#^iA01^1Universidade Federal de Ouro Preto^2Programa de Pós-graduaçã
o em Ciências Biológicas^3Núcleo de Pesquisas em Ciências Biológicas^cOuro Preto
^sMG^pBrasil#^iA02^1UFOP^2Departamento de Alimentos^cOuro Preto^sMG^pBrasil#^iA0
3^1UFOP^2Departamento de Ciências Biológicas^cOuro Preto^sMG^pBrasil#^lpt^aOBJET
IVO: Este estudo avaliou os efeitos da estreptozotocina nos perfis glicêmico e l
ipídico e marcadores de estresse oxidativo em hamsteres. MATERIAIS E MÉTODOS: Ha
msteres machos Golden Syrian foram divididos em dois grupos: grupo diabético (D)
, que recebeu uma única injeção de estreptozotocina (STZ - 50 mg/kg), e grupo co
ntrole (C), que recebeu injeção de tampão citrato. Os animais foram eutanasiados
 após 10 dias de experimento e o sangue, o fígado e rins foram coletados. RESULT
ADOS: O grupo diabético apresentou níveis maiores de glicose, triacilgliceróis e
 colesterol séricos e maior concentração de substâncias reativas ao ácido tiobar
bitúrico (TBARs) no fígado e nos rins. Também apresentou significativo aumento d
a concentração de glutationa no fígado e menores atividades da paraoxonase e do 
superóxido dismutase. CONCLUSÃO: Hamsteres fornecem um bom modelo para o diabete
s melito do tipo I e estresse oxidativo, similar ao da síndrome humana, e poderã
o ser adequados para a análise de compostos antidiabéticos.#^dnd^i1#^tm^lpt^kHam
steres^i1#^tm^lpt^kestreptozotocina^i1#^tm^lpt^kestresse oxidativo^i1#^tm^lpt^ka
ntioxidantes^i1#^len^aOBJECTIVE: This study evaluated the effects of streptozoto
cin on glycemic and lipid profiles and oxidative stress status in hamsters. MATE
RIALS AND METHODS: Male Golden Syrian hamsters were divided in diabetic group (D
) which received a streptozotocin single injection (STZ - 50 mg/kg), and control
 group (C) which received a single injection of the vehicle citrate buffer. Anim
als were euthanized after 10 days of experiment and blood, liver and kidneys wer
e collected. RESULTS: The diabetic group had higher levels of glucose, triacylgl
ycerols and cholesterol in serum and thiobarbituric acid reactive substances (TB
ARS) concentration increased in the liver and kidneys. Diabetes induced a signif
icant increase in glutathione concentration in the liver and decreased paraoxona
se and superoxide dismutase activities. CONCLUSION: Hamsters provide a novel ani
mal model for diabetes mellitus and oxidative stress, similar to the human syndr
ome, which may be suitable for the testing of antidiabetic compounds.#^dnd^i2#^t
m^len^kHamsters^i2#^tm^len^kstreptozotocin^i2#^tm^len^koxidative stress^i2#^tm^l
en^kantioxidants^i2#other#39#20100706#6/Jul/2010#20101216#16/Dez/2010#06.htm#Int
ernet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-273020110001
00006##
00343000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704012200068002000700190#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#5#1#article#192#<p align="right"><font face
="Verdana, Arial, Helvetica, sans-serif" size="2"><b>ARTIGO    ORIGINAL</b></fon
t></p>     ^cY#06.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704002200068002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#6#2#article#192#<p>&nbsp;</p>     ^cY#06.ht
m##
00446000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704022500068002000700293#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#7#3#article#192#<p><a name="top"></a><font 
face="Verdana, Arial, Helvetica, sans-serif" size="4"><b>Efeito    da estreptozo
tocina sobre os perfis glic&ecirc;mico e lip&iacute;dico e o estresse    oxidati
vo em hamsters</b></font></p>     ^cY#06.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704002200068002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#8#4#article#192#<p>&nbsp;</p>     ^cY#06.ht
m##
00406000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704018500068002000700253#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#9#5#article#192#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="3"><b>Effect of streptozotocin    on the glycem
ic and lipid profiles and oxidative stress in hamsters</b></font></p>     ^cY#06
.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000400065704002200069002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#10#6#article#192#<p>&nbsp;</p>     ^cY#06.h
tm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000400065704002200069002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#11#7#article#192#<p>&nbsp;</p>     ^cY#06.h
tm##
00478000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000400065704025600069002000700325#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#12#8#article#192#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>Ma&iacute;sa    Silva<sup>I</sup>; Wande
rson Geraldo de Lima<sup>I, III</sup>; Marcelo Eust&aacute;quio    Silva<sup>I, 
II</sup>; Maria Lucia Pedrosa<sup>I, III</sup></b></font></p>     ^cY#06.htm##
00527000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000400065704030500069002000700374#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#13#9#article#192#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><sup>I</sup>N&uacute;cleo    de Pesquisas e
m Ci&ecirc;ncias Biol&oacute;gicas, Programa de P&oacute;s-gradua&ccedil;&atilde
;o    em Ci&ecirc;ncias Biol&oacute;gicas, Universidade Federal de Ouro Preto (U
FOP),    Ouro Preto, MG, Brasil    ^cY#06.htm##
00306000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704008300070002000700153#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#14#10#article#192#<br>   <sup>II</sup>Depar
tamento de Alimentos, UFOP, Ouro Preto, MG, Brasil    ^cY#06.htm##
00345000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704012200070002000700192#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#15#11#article#192#<br>   <sup>III</sup>Depa
rtamento de Ci&ecirc;ncias Biol&oacute;gicas, UFOP, Ouro Preto,    MG, Brasil</f
ont></p>     ^cY#06.htm##
00355000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704013200070002000700202#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#16#12#article#192#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><a href="#back">Correspond&ecirc;ncia    p
ara</a></font></p>     ^cY#06.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#17#13#article#192#<p>&nbsp;</p>     ^cY#06.
htm##
00267000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704004400070002000700114#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#18#14#article#192#<p>&nbsp;</p> <hr size="1
" noshade>     ^cY#06.htm##
00319000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704009600070002000700166#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#19#15#article#192#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>RESUMO</b></font></p>     ^cY#06.htm##
00461000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704023800070002000700308#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#20#16#article#192#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>OBJETIVO:</b>    Este estudo avaliou os
 efeitos da estreptozotocina nos perfis glic&ecirc;mico    e lip&iacute;dico e m
arcadores de estresse oxidativo em hamsteres.    ^cY#06.htm##
00673000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704045000070002000700520#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#21#17#article#192#<br>   <b>MATERIAIS E M&E
acute;TODOS:</b> Hamsteres machos <i>Golden Syrian</i> foram    divididos em doi
s grupos: grupo diab&eacute;tico (D), que recebeu uma &uacute;nica    inje&ccedi
l;&atilde;o de estreptozotocina (STZ - 50 mg/kg), e grupo controle    (C), que r
ecebeu inje&ccedil;&atilde;o de tamp&atilde;o citrato. Os animais    foram eutan
asiados ap&oacute;s 10 dias de experimento e o sangue, o f&iacute;gado    e rins
 foram coletados.    ^cY#06.htm##
00711000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704048800070002000700558#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#22#18#article#192#<br>   <b>RESULTADOS:</b>
 O grupo diab&eacute;tico apresentou n&iacute;veis maiores    de glicose, triaci
lglicer&oacute;is e colesterol s&eacute;ricos e maior concentra&ccedil;&atilde;o
    de subst&acirc;ncias reativas ao &aacute;cido tiobarbit&uacute;rico (TBARs) 
   no f&iacute;gado e nos rins. Tamb&eacute;m apresentou significativo aumento  
  da concentra&ccedil;&atilde;o de glutationa no f&iacute;gado e menores ativida
des    da paraoxonase e do super&oacute;xido dismutase.    ^cY#06.htm##
00495000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704027200070002000700342#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#23#19#article#192#<br>   <b>CONCLUS&Atilde;
O:</b> Hamsteres fornecem um bom modelo para o diabetes melito    do tipo I e es
tresse oxidativo, similar ao da s&iacute;ndrome humana, e poder&atilde;o    ser 
adequados para a an&aacute;lise de compostos antidiab&eacute;ticos.</font></p>  
   ^cY#06.htm##
00414000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704019100070002000700261#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#24#20#article#192#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Descritores:    </b> Hamsteres; estrept
ozotocina; estresse oxidativo; antioxidantes</font></p> <hr size="1" noshade>   
  ^cY#06.htm##
00321000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704009800070002000700168#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#25#21#article#192#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>ABSTRACT</b></font></p>     ^cY#06.htm#
#
00440000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704021700070002000700287#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#26#22#article#192#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>OBJECTIVE:</b>    This study evaluated 
the effects of streptozotocin on glycemic and lipid profiles    and oxidative st
ress status in hamsters.    ^cY#06.htm##
00593000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704037000070002000700440#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#27#23#article#192#<br>   <b>MATERIALS AND M
ETHODS:</b> Male Golden Syrian hamsters were divided in diabetic    group (D) wh
ich received a streptozotocin single injection (STZ - 50 mg/kg),    and control 
group (C) which received a single injection of the vehicle citrate    buffer. An
imals were euthanized after 10 days of experiment and blood, liver    and kidney
s were collected.    ^cY#06.htm##
00603000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704038000070002000700450#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#28#24#article#192#<br>   <b>RESULTS:</b> Th
e diabetic group had higher levels of glucose, triacylglycerols    and cholester
ol in serum and thiobarbituric acid reactive substances (TBARS)    concentration
 increased in the liver and kidneys. Diabetes induced a significant    increase 
in glutathione concentration in the liver and decreased paraoxonase    and super
oxide dismutase activities.    ^cY#06.htm##
00459000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704023600070002000700306#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#29#25#article#192#<br>   <b>CONCLUSION:</b>
 Hamsters provide a novel animal model for <i>diabetes mellitus</i>    and oxida
tive stress, similar to the human syndrome, which may be suitable for    the tes
ting of antidiabetic compounds.</font></p>     ^cY#06.htm##
00404000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704018100070002000700251#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#30#26#article#192#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Keywords:</b>    Hamsters; streptozotoc
in; oxidative stress; antioxidants</font></p> <hr size="1" noshade>     ^cY#06.h
tm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#31#27#article#192#<p>&nbsp;</p>     ^cY#06.
htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#32#28#article#192#<p>&nbsp;</p>     ^cY#06.
htm##
00337000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704011400070002000700184#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#33#29#article#192#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="3"><b>INTRODU&Ccedil;&Atilde;O</b></font></p>
     ^cY#06.htm##
01047000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704082400070002000700894#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#34#30#article#192#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">O termo diabetes    melito (DM) &eacute; u
ma desordem metab&oacute;lica de m&uacute;ltiplas etiologias    caracterizadas p
or hiperglicemia cr&ocirc;nica com dist&uacute;rbios no metabolismo    de carboi
dratos, lip&iacute;dios e prote&iacute;nas, como resultado do defeito    na secr
e&ccedil;&atilde;o de insulina ou em sua a&ccedil;&atilde;o ou ambos    (1). H&a
acute; mais de 250 milh&otilde;es de pessoas em todo o mundo com diabetes    e e
stima-se que a cada 5 segundos surja um novo caso (2). O diabetes pode gerar    
complica&ccedil;&otilde;es como retinopatias, nefropatias, neuropatias e dist&ua
cute;rbios    end&oacute;crinos. O papel do estresse oxidativo nessas complica&c
cedil;&otilde;es    tem sido alvo de muito interesse (3,4).</font></p>     ^cY#0
6.htm##
01413000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704119000070002000701260#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#35#31#article#192#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">O estresse oxidativo    &eacute; um estado
 de desequil&iacute;brio entre a produ&ccedil;&atilde;o de    esp&eacute;cies re
ativas de oxig&ecirc;nio (ROS) e a capacidade antioxidante    end&oacute;gena. A
 gera&ccedil;&atilde;o aumentada de ROS no diabetes pode ser    devida &agrave; 
auto-oxida&ccedil;&atilde;o da glicose, &agrave; forma&ccedil;&atilde;o    de pr
odutos finais de glica&ccedil;&atilde;o avan&ccedil;ada (AGEs), &agrave;    via 
dos poli&oacute;is e tamb&eacute;m &agrave;s mudan&ccedil;as no conte&uacute;do 
   e atividade no sistema de defesas antioxidantes no tecido (5). ROS causam, <i
>in    vitro</i>, danos &agrave; via de sinaliza&ccedil;&atilde;o da insulina (6
),    diminui&ccedil;&atilde;o da transloca&ccedil;&atilde;o dos transportadores
 de    glicose (GLUT-4) nos adip&oacute;citos (7) e redu&ccedil;&atilde;o da int
ernaliza&ccedil;&atilde;o    da insulina nas c&eacute;lulas endoteliais (8). Em 
adi&ccedil;&atilde;o, a oxida&ccedil;&atilde;o    de lip&iacute;dios e de prote&
iacute;nas est&aacute; associada com o desenvolvimento    das complica&ccedil;&o
tilde;es do diabetes (5).</font></p>     ^cY#06.htm##
01112000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704088900070002000700959#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#36#32#article#192#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Modelos animais    com diabetes, que apres
entem o <i>status</i> redox similar ao humano, ser&atilde;o    &uacute;teis para
 analisarmos poss&iacute;veis mecanismos que estejam envolvidos    na rela&ccedi
l;&atilde;o diabetes e estresse oxidativo. O diabetes experimental    pode ser i
nduzido por f&aacute;rmacos, manipula&ccedil;&atilde;o cir&uacute;rgica    ou ge
n&eacute;tica em v&aacute;rias esp&eacute;cies de animais. A maioria dos    expe
rimentos &eacute; realizada em roedores, embora alguns estudos sejam realizados 
   em animais maiores. O modelo murino &eacute; o mais usado em decorr&ecirc;nci
a    da disponibilidade de mais de 200 linhagens bem caracterizadas e da habilid
ade    de deletar ou superexpressar genes espec&iacute;ficos por meio da tecnolo
gia    dos nocaute e transg&ecirc;nicos (9).</font></p>     ^cY#06.htm##
01546000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704132300070002000701393#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#37#33#article#192#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">A estreptozotocina    &eacute; uma glicosa
mina-nitrosureia comumente usada para produzir o diabetes.    A droga &eacute; c
aptada pelas c&eacute;lulas pancre&aacute;ticas que cont&ecirc;m    transportado
res de glicose GLUT-2, ent&atilde;o, c&eacute;lulas produtoras de    insulina qu
e n&atilde;o expressam esse transportador s&atilde;o resistentes    &agrave; est
reptozotocina (STZ) (10). Mecanismos s&atilde;o propostos para a    citotoxicida
de produzida pela STZ. A alcaliniza&ccedil;&atilde;o do DNA celular    e subsequ
ente ativa&ccedil;&atilde;o da poli-ADP ribose sintetase causam deple&ccedil;&at
ilde;o    r&aacute;pida e letal de NAD nas c&eacute;lulas pancre&aacute;ticas, c
om subsequente    redu&ccedil;&atilde;o no n&iacute;vel de ATP e posterior inibi
&ccedil;&atilde;o    da s&iacute;ntese e secre&ccedil;&atilde;o da insulina (11,
12). Por outro lado,    evid&ecirc;ncias indicam que os radicais livres podem te
r um papel essencial    no efeito diabetog&ecirc;nico da STZ (13). Hamsteres des
envolvem diabetes quando    tratados com estreptozotocina (14), por&eacute;m n&a
tilde;o existem trabalhos    na literatura que avaliem v&aacute;rios produtos do
 estresse oxidativo e defesas    antioxidantes em hamsteres diab&eacute;ticos.</
font></p>     ^cY#06.htm##
01289000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704106600070002000701136#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#38#34#article#192#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">O estresse oxidativo    pode ser avaliado 
por meio de atividade de enzimas envolvidas no balan&ccedil;o    redox da c&eacu
te;lula, que incluem a super&oacute;xido dismutase, catalase,    glutationa pero
xidase e glutationa redutase, as quais convertem radicais super&oacute;xido    e
m per&oacute;xidos ou per&oacute;xidos em &aacute;gua e oxig&ecirc;nio. A conver
s&atilde;o    de per&oacute;xido de hidrog&ecirc;nio pela glutationa peroxidase 
ocorre concomitante    com a oxida&ccedil;&atilde;o da glutationa reduzida (GSH)
 para a forma oxidada    (GSSG). O diabetes pode alterar a atividade dessas enzi
mas em v&aacute;rios    tecidos (15). Compostos que podem ser modificados pela a
&ccedil;&atilde;o de    radicais livres, como lip&iacute;dios, prote&iacute;nas 
e grupos sulfidrilas,    s&atilde;o tamb&eacute;m usados como medidas indiretas 
do estresse oxidativo.    O principal objetivo deste trabalho foi avaliar o estr
esse oxidativo em hamsteres    com diabetes induzido por STZ.</font></p>     ^cY
#06.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#39#35#article#192#<p>&nbsp;</p>     ^cY#06.
htm##
00342000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704011900070002000700189#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#40#36#article#192#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="3"><b>MATERIAIS E    M&Eacute;TODOS</b></font
></p>     ^cY#06.htm##
00331000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704010800070002000700178#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#41#37#article#192#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Animais utilizados</b></font></p>     ^
cY#06.htm##
00907000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704068400070002000700754#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#42#38#article#192#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Foram usados 14    Hamsteres Syrian Golden
, machos, de 90 dias de idade, divididos em dois grupos,    com 7 hamsteres cada
. O manuseio dos animais foi realizado em concord&acirc;ncia    com os princ&iac
ute;pios &eacute;ticos para manipula&ccedil;&atilde;o de animais    de experimen
ta&ccedil;&atilde;o (Col&eacute;gio Brasileiro de Experimenta&ccedil;&atilde;o  
  Animal) (16) e os procedimentos com os animais foram aprovados pelo Comit&ecir
c;    de &Eacute;tica em Pesquisa da Universidade Federal de Ouro Preto. Os grup
os    receberam dieta comercial (Labina-Purina) e &aacute;gua &agrave; vontade.<
/font></p>     ^cY#06.htm##
00363000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704014000070002000700210#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#43#39#article#192#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Estabelecimento    do diabetes melito e
xperimental</b></font></p>     ^cY#06.htm##
00429000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704020600070002000700276#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#44#40#article#192#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">O diabetes melito    foi induzido pela adm
inistra&ccedil;&atilde;o intraperitoneal de 50 mg/kg de    estreptozotocina (17)
.</font></p>     ^cY#06.htm##
00756000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704053300070002000700603#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#45#41#article#192#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">O grupo controle    recebeu uma inje&ccedi
l;&atilde;o de tamp&atilde;o citrato, 0,01 M, pH 4,5,    para que o mesmo estres
se fosse provocado. Foram considerados diab&eacute;ticos    os hamsteres que ap&
oacute;s tr&ecirc;s dias da administra&ccedil;&atilde;o    de STZ apresentaram p
erda de peso corporal e n&iacute;veis de glicemia maiores    ou iguais a 250 mg/
dL, em determina&ccedil;&otilde;es com glicos&iacute;metro    digital ACCU-CHEK 
(Roche).</font></p>     ^cY#06.htm##
00372000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704014900070002000700219#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#46#42#article#192#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Eutan&aacute;sia    e prepara&ccedil;&a
tilde;o das amostras</b></font></p>     ^cY#06.htm##
00717000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704049400070002000700564#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#47#43#article#192#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Os animais foram    mortos no d&eacute;cim
o dia de experimento, ap&oacute;s anestesia, por sangria    total pelo plexo bra
quial. Amostras de sangue foram coletadas e centrifugadas    em tubos de 1,5 mL 
para a determina&ccedil;&atilde;o de componentes s&eacute;ricos.    O f&iacute;g
ado e os rins foram removidos, pesados e estocados em nitrog&ecirc;nio    l&iacu
te;quido para an&aacute;lises bioqu&iacute;micas.</font></p>     ^cY#06.htm##
00365000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704014200070002000700212#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#48#44#article#192#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>An&aacute;lises    bioqu&iacute;micas s
&eacute;ricas</b></font></p>     ^cY#06.htm##
00863000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704064000070002000700710#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#49#45#article#192#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">A concentra&ccedil;&atilde;o    de glicose
 e frutosamina e a atividade da amilase foram determinadas utilizando    kits La
btest (Labtest, Lagoa Santa, MG, Brasil), n&deg; 84, 97 e 25, respectivamente.  
  A concentra&ccedil;&atilde;o de prote&iacute;nas totais s&eacute;ricas e album
ina    foi medida utilizando kits Labtest 99 e 19, respectivamente. Os n&iacute;
veis    de triacilglicer&oacute;is e colesterol total foram dosados enzimaticame
nte    usando o kit Labtest, cat 59 e 60, utilizando glicerol ou colesterol como
 padr&atilde;o,    respectivamente.</font></p>     ^cY#06.htm##
00364000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704014100070002000700211#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#50#46#article#192#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Avalia&ccedil;&otilde;es    histopatol&
oacute;gicas</b></font></p>     ^cY#06.htm##
01333000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704111000070002000701180#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#51#47#article#192#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Fragmentos n&atilde;o    excedentes a 4 mm
 de di&acirc;metro de p&acirc;ncreas, fixados em solu&ccedil;&atilde;o    de for
mol a 10%, foram desidratados, diafanizados e embebidos em parafina. Ap&oacute;s
    inclus&atilde;o, os fragmentos foram seccionados em micr&oacute;tomo rotativ
o    para a obten&ccedil;&atilde;o de slides de parafina de aproximadamente 4 </
font><font size="2">&#956;</font><font face="Verdana, Arial, Helvetica, sans-ser
if" size="2">m    e posterior fixa&ccedil;&atilde;o em l&acirc;minas de vidro pr
eviamente limpas    e desengorduradas. As l&acirc;minas foram coradas pela t&eac
ute;cnica histol&oacute;gica    de rotina da Hematoxilina &amp; Eosina, para vis
ualiza&ccedil;&atilde;o das    altera&ccedil;&otilde;es histol&oacute;gicas. As 
an&aacute;lises morfom&eacute;tricas    digitais para a determina&ccedil;&atilde
;o da &aacute;rea das ilhotas pancre&aacute;ticas    foram realizadas no microsc
&oacute;pio &oacute;ptico Leica DM5000 associado    ao <i>software</i> de an&aac
ute;lise Leica Qwin plus.</font></p>     ^cY#06.htm##
00362000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704013900070002000700209#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#52#48#article#192#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Atividade de    enzimas e compostos ant
ioxidantes</b></font></p>     ^cY#06.htm##
01115000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704089200070002000700962#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#53#49#article#192#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">A atividade de    paraoxonase (PON) no sor
o (atividade arilester&aacute;sica) foi determinada    de acordo com Beltowski e
 cols. (18). A atividade arilester&aacute;sica foi    calculada utilizando o coe
ficiente de extin&ccedil;&atilde;o molar do fenilacetato,    que &eacute; de 131
0 L. mol<sup>-1</sup> . cm<sup>-1</sup>. Os resultados foram    expressos em uni
dades por mL, em que 1 U de arilesterase hidrolisa 1 mmol de    fenilacetato por
 minuto. A atividade enzim&aacute;tica da paraoxonase no soro    (atividade sobr
e o paraoxon) foi calculada utilizando o coeficiente de extin&ccedil;&atilde;o  
  molar do substrato, que &eacute; de 18.290 L. mol<sup>-1</sup> . cm<sup>-1</su
p>.    Os resultados foram expressos por unidades por mL, em que 1 U de enzima h
idrolisa    1 mmol de paraoxon por minuto (18).</font></p>     ^cY#06.htm##
00798000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704057500070002000700645#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#54#50#article#192#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Para determinar    a atividade da super&oa
cute;xido dismutase (SOD), usamos o kit Fluka 19160 (Steinheim,    Germany). Ess
e ensaio usa a xantina e a xantina oxidase para gerar radicais    super&oacute;x
idos que reagem com 2-(4-iodofenil)-3-(4-nitrofenol)-5-pfeniltetrazoliumclorido 
   para produzir formazan, um composto que absorve luz a 450 nm. A inibi&ccedil;
&atilde;o    da produ&ccedil;&atilde;o do crom&oacute;geno &eacute; proporcional
 &agrave;    atividade da SOD presente na amostra.</font></p>     ^cY#06.htm##
01477000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704125400070002000701324#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#55#51#article#192#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Os grupos sulfidrilas    totais foram esti
mados usando o reagente de Ellman's de acordo com Sedlak and    Lindsay (19). Br
evemente, 40 </font><font size="2">&#956;</font><font face="Verdana, Arial, Helv
etica, sans-serif" size="2">L    de plasma foram misturados com 150 </font><font
 size="2">&#956;</font><font face="Verdana, Arial, Helvetica, sans-serif" size="
2">L    de 0,2 M de tamp&atilde;o Tris HCl (pH 8,2) contendo 20 mM EDTA e com 50
 </font><font size="2">&#956;</font><font face="Verdana, Arial, Helvetica, sans-
serif" size="2">L    de 5,5 ditiobis-(2-&aacute;cido nitrobenzoico) (DTNB, 10 mM
 solu&ccedil;&atilde;o    em metanol). Ent&atilde;o, 800 </font><font size="2">&
#956;</font><font face="Verdana, Arial, Helvetica, sans-serif" size="2">L    de 
metanol foram adicionados, a amostra foi centrifugada a 10.000 g por 15 minutos 
   e a absorb&acirc;ncia do sobrenadante foi determinada a 412 nm. A absorb&acir
c;ncia    da amostra branco (sem DTNB) e reagente branco (sem plasma) foi subtra
&iacute;da    da concentra&ccedil;&atilde;o de sulfidrilas e calculada pela curv
a padr&atilde;o    preparada com concentra&ccedil;&atilde;o conhecida de ciste&i
acute;na.</font></p>     ^cY#06.htm##
00799000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704057600070002000700646#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#56#52#article#192#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">A concentra&ccedil;&atilde;o    de glutati
ona total (GSH e GSSH) em homogenatos de f&iacute;gado foi determinada    usando
 o <i>kit</i> Sigma CS0260 (EUA). Esse <i>kit</i> utiliza um m&eacute;todo    ci
n&eacute;tico para mensurar os n&iacute;veis de glutationa, por meio da redu&cce
dil;&atilde;o    do DTNB (&aacute;cido 5,5'-Ditio-bis-(2-nitrobenzoico) a TNB, q
ue &eacute; determinado    espectrofotometricamente a 412 nm. Foi utilizado um p
adr&atilde;o de glutationa    reduzida Sigma G4251.</font></p>     ^cY#06.htm##
00375000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704015200070002000700222#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#57#53#article#192#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>An&aacute;lise    de peroxida&ccedil;&a
tilde;o lip&iacute;dica</b></font></p>     ^cY#06.htm##
01550000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704132700070002000701397#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#58#54#article#192#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Amostras de f&iacute;gado    de todos os h
amsteres foram homogeneizadas com tamp&atilde;o Tris-HCl 0,1M pH    7,4 (1:10). 
O conte&uacute;do de lip&iacute;dios peroxidados foi determinado    de acordo co
m Buege e Aust (20). Brevemente, 250 </font><font size="2">&#956;</font><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">L    de tricloroac&eacute;ti
co (TCA) a 28% foram adicionados a 500 </font><font size="2">&#956;</font><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">L    de amostra, 250 </fon
t><font size="2">&#956;</font><font face="Verdana, Arial, Helvetica, sans-serif"
 size="2">L    de &aacute;cido tiobarbit&uacute;rico (TBA) (1% em &aacute;cido a
c&eacute;tico    1:1) e 125 </font><font size="2">&#956;</font><font face="Verda
na, Arial, Helvetica, sans-serif" size="2">L    de hidroxibutiltolueno (BHT) (5 
mM dissolvido em etanol) e incubados a 95&deg;C    por 15 minutos. Subsequenteme
nte, a mistura foi centrifugada a 10.000 g por    15 minutos. A absorb&acirc;nci
a do sobrenadante foi feita a 535 nm usando espectrofot&ocirc;metro.    O conte&
uacute;do de lip&iacute;dio peroxidado foi calculado usando o coeficiente    de 
extin&ccedil;&atilde;o molar do complexo TBA-MDA 1,56 x 10<sup>5</sup> mol-1.cm-
1.</font></p>     ^cY#06.htm##
00365000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704014200070002000700212#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#59#55#article#192#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>An&aacute;lise    da oxida&ccedil;&atil
de;o proteica</b></font></p>     ^cY#06.htm##
01610000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704138700070002000701457#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#60#56#article#192#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Amostras de f&iacute;gado    e rins de tod
os os hamsteres foram homogeneizadas em tamp&atilde;o fosfato 50    mM, pH: 6,7 
(1:10). O conte&uacute;do de grupos carbonilas nesses homogenatos    foi determi
nado pelo m&eacute;todo de Levine modificado (21). Primeiramente,    0,5 mL de a
mostra foi precipitado usando 0,5 mL de TCA 10% e centrifugado a    5.000 g por 
10 minutos, descartando-se o sobrenadante. Foram adicionados a esse    precipita
do 10 mM de difenil-hidrazina (DNPH) HCl2M e incubados &agrave; temperatura    a
mbiente por 30 minutos. Durante a incuba&ccedil;&atilde;o, as amostras foram    
vigorosamente misturadas a cada 15 minutos. Depois da incuba&ccedil;&atilde;o,  
  0,5 mL de TCA 10% foi adicionado e as prote&iacute;nas foram precipitadas e   
 centrifugadas a 5.000 g por 10 minutos. Depois de descartar o sobrenadante,    
o precipitado foi lavado duas vezes com uma mistura de acetato de etila e etanol
    (1:1), centrifugado e o sobrenadante descartado. O precipitado foi dissolvid
o    em SDS 6% e centrifugado a 10.000 g por 10 minutos. O sobrenadante foi lido
    a 370 nm contra HCl 2M. Os n&iacute;veis de prote&iacute;nas carboniladas fo
ram    expressos em nanomoles por mL usando a coeficiente de extin&ccedil;&atild
e;o    molar do DNPH (22000 mol<sup>-1</sup>.cm<sup>-1</sup>).</font></p>     ^c
Y#06.htm##
00351000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704012800070002000700198#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#61#57#article#192#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>An&aacute;lises    estat&iacute;sticas<
/b></font></p>     ^cY#06.htm##
00684000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704046100070002000700531#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#62#58#article#192#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Os dados foram    analisados pelo teste de
 normalidade Kolmogorov-Smirnov. Todos os dados seguiram    uma distribui&ccedil
;&atilde;o normal e foram analisados pelo teste de <i>t</i>    de Student. Os da
dos foram expressos como m&eacute;dia &plusmn; desvio-padr&atilde;o.    Em todos
 os testes, foram considerados significantes os resultados com valores    de p <
u>&lt;</u> 0,05.</font></p>     ^cY#06.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#63#59#article#192#<p>&nbsp;</p>     ^cY#06.
htm##
00323000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704010000070002000700170#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#64#60#article#192#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="3"><b>RESULTADOS</b></font></p>     ^cY#06.ht
m##
00504000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704028100070002000700351#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#65#61#article#192#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Avalia&ccedil;&atilde;o    do efeito da
 inje&ccedil;&atilde;o de estreptozotocina sobre o perfil glic&ecirc;mico,    pe
rfil lip&iacute;dico e fun&ccedil;&atilde;o hep&aacute;tica de hamsteres</b></fo
nt></p>     ^cY#06.htm##
01430000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704120700070002000701277#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#66#62#article#192#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Inicialmente, analisamos    os n&iacute;ve
is de glicose e os n&iacute;veis de frutosamina. Ao analisar os    dados da conc
entra&ccedil;&atilde;o de glicose dos hamsteres que receberam a    inje&ccedil;&
atilde;o de estreptozotocina, na tabela 1, podemos notar que ela    est&aacute; 
aumentada cerca de 7 vezes. A concentra&ccedil;&atilde;o de frutosamina    n&ati
lde;o foi influenciada pelo tratamento com STZ (p &gt; 0,05). A porcentagem    t
otal de &aacute;rea pancre&aacute;tica ocupada pelas ilhotas foi de 8,23% para  
  o grupo C, significativamente maior que a porcentagem da &aacute;rea ocupada  
  pelas ilhotas pancre&aacute;ticas de 2,98% nos animais D (<a href="#f1">Figura
s    1</a> e <a href="#f2">2</a>). As concentra&ccedil;&otilde;es de prote&iacut
e;nas    totais e albumina s&eacute;rica n&atilde;o apresentaram diferen&ccedil;
a significativa    entre os grupos. A an&aacute;lise estat&iacute;stica do peso 
dos f&iacute;gados    n&atilde;o demonstrou diferen&ccedil;as entre os grupos, m
as os pesos dos rins    apresentaram-se 1,5 vez aumentado nos hamsteres diab&eac
ute;ticos (<a href="#t1">Tabela    1</a>).</font></p>     ^cY#06.htm##
00256000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704003300070002000700103#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#67#63#article#192#<p><a name="f1"></a></p> 
    ^cY#06.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#68#64#article#192#<p>&nbsp;</p>     ^cY#06.
htm##
00300000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704007700070002000700147#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#69#65#article#192#<p align="center"><img sr
c="/img/revistas/abem/v55n1/06f01.jpg"></p>     ^cY#06.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#70#66#article#192#<p>&nbsp;</p>     ^cY#06.
htm##
00256000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704003300070002000700103#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#71#67#article#192#<p><a name="f2"></a></p> 
    ^cY#06.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#72#68#article#192#<p>&nbsp;</p>     ^cY#06.
htm##
00300000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704007700070002000700147#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#73#69#article#192#<p align="center"><img sr
c="/img/revistas/abem/v55n1/06f02.jpg"></p>     ^cY#06.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#74#70#article#192#<p>&nbsp;</p>     ^cY#06.
htm##
00256000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704003300070002000700103#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#75#71#article#192#<p><a name="t1"></a></p> 
    ^cY#06.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#76#72#article#192#<p>&nbsp;</p>     ^cY#06.
htm##
00300000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704007700070002000700147#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#77#73#article#192#<p align="center"><img sr
c="/img/revistas/abem/v55n1/06t01.jpg"></p>     ^cY#06.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#78#74#article#192#<p>&nbsp;</p>     ^cY#06.
htm##
00959000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704073600070002000700806#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#79#75#article#192#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">A an&aacute;lise    estat&iacute;stica dos
 dados revelou que a concentra&ccedil;&atilde;o de triacilglicer&oacute;is    ap
resentava-se 2,7 vezes aumentada nos hamsteres diab&eacute;ticos, como mostrado 
   na <a href="#t2">tabela 2</a>. A concentra&ccedil;&atilde;o de colesterol tot
al    foi 4,5 vezes aumentada pelo diabetes. Verificamos que o tratamento com ST
Z    em hamsteres tamb&eacute;m promoveu altera&ccedil;&otilde;es no perfil lip&
iacute;dico,    similares &agrave;s encontradas para humanos. As atividades s&ea
cute;ricas da    PON sobre os substratos fenilacetato e o paraoxon apresentaram-
se 44% e 31%    diminu&iacute;das, respectivamente.</font></p>     ^cY#06.htm##
00256000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704003300070002000700103#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#80#76#article#192#<p><a name="t2"></a></p> 
    ^cY#06.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#81#77#article#192#<p>&nbsp;</p>     ^cY#06.
htm##
00300000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704007700070002000700147#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#82#78#article#192#<p align="center"><img sr
c="/img/revistas/abem/v55n1/06t02.jpg"></p>     ^cY#06.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#83#79#article#192#<p>&nbsp;</p>     ^cY#06.
htm##
00423000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704020000070002000700270#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#84#80#article#192#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>An&aacute;lise    dos efeitos do diabet
es sobre as defesas antioxidantes e marcadores do estresse    oxidativo</b></fon
t></p>     ^cY#06.htm##
01115000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704089200070002000700962#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#85#81#article#192#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">O <i>status</i>    antioxidante foi mensur
ado pela dosagem da concentra&ccedil;&atilde;o de SH    total, atividade da supe
r&oacute;xido dismutase e da concentra&ccedil;&atilde;o    de glutationa total n
o f&iacute;gado e nos rins. A <a href="#t3">tabela 3</a>    mostra que n&atilde;
o h&aacute; diferen&ccedil;as na concentra&ccedil;&atilde;o    de grupos sulfidr
ilas totais no soro entre os grupos. A concentra&ccedil;&atilde;o    de glutatio
na total no f&iacute;gado apresentou-se 8,2 vezes aumentada nos hamsteres    dia
b&eacute;ticos. J&aacute; a concentra&ccedil;&atilde;o de glutationa total    no
s rins n&atilde;o foi modificada. Notamos tamb&eacute;m que a atividade da    en
zima super&oacute;xido dismutase no soro apresentou um aumento de 2,5 vezes    n
o grupo diab&eacute;tico comparado ao controle.</font></p>     ^cY#06.htm##
00256000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704003300070002000700103#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#86#82#article#192#<p><a name="t3"></a></p> 
    ^cY#06.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#87#83#article#192#<p>&nbsp;</p>     ^cY#06.
htm##
00300000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704007700070002000700147#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#88#84#article#192#<p align="center"><img sr
c="/img/revistas/abem/v55n1/06t03.jpg"></p>     ^cY#06.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#89#85#article#192#<p>&nbsp;</p>     ^cY#06.
htm##
00739000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704051600070002000700586#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#90#86#article#192#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">A an&aacute;lise    de nossos dados n&atil
de;o revelou diferen&ccedil;a significativa para a concentra&ccedil;&atilde;o   
 de prote&iacute;na carbonilada no f&iacute;gado e nos rins nos grupos estudados
    (<a href="#t3">Tabela 3</a>). Por&eacute;m, a concentra&ccedil;&atilde;o de 
   TBARS no f&iacute;gado e rim dos hamsteres diab&eacute;ticos revelou-se 2,6  
  vezes e 2,4 vezes aumentada, respectivamente, pelo teste de <i>t</i>.</font></
p>     ^cY#06.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#91#87#article#192#<p>&nbsp;</p>     ^cY#06.
htm##
00329000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704010600070002000700176#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#92#88#article#192#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="3"><b>DISCUSS&Atilde;O</b></font></p>     ^cY
#06.htm##
02241000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704201800070002000702088#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#93#89#article#192#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Animais com diabetes    induzido por subst
&acirc;ncias qu&iacute;micas t&ecirc;m sido usados para estudar    o diabetes de
pendente de insulina. A indu&ccedil;&atilde;o de diabetes em hamsteres    utiliz
ando STZ pode ser conseguida utilizando doses m&uacute;ltiplas de droga    ou em
 uma dose &uacute;nica (17,22). Em nosso trabalho aplicamos uma dose &uacute;nic
a    de 50 mg/kg de STZ e observamos um aumento significativo da concentra&ccedi
l;&atilde;o    de glicose s&eacute;rica desde o terceiro dia ap&oacute;s a aplic
a&ccedil;&atilde;o.    Os animais permaneceram com a glicose significativamente 
aumentada at&eacute;    serem eutanasiados no d&eacute;cimo dia. Possivelmente, 
em decorr&ecirc;ncia    do curto tempo de experimento, a concentra&ccedil;&atild
e;o de frutosamina dos    hamsteres diab&eacute;ticos n&atilde;o foi alterada, p
ois essa reflete a concentra&ccedil;&atilde;o    de prote&iacute;nas que foram g
licadas h&aacute; aproximadamente tr&ecirc;s    semanas e, portanto, no curto pe
r&iacute;odo do experimento n&atilde;o foi poss&iacute;vel    detectar altera&cc
edil;&otilde;es nesse par&acirc;metro. A diminui&ccedil;&atilde;o    da &aacute;
rea ocupada pelas ilhotas pancre&aacute;ticas dos hamsteres do grupo    D confir
ma esse quadro, sugerindo que a dose de STZ aplicada foi capaz de provocar    di
abetes tipo 1 nos animais. Hipercolesterolemia em animais tratados com estreptoz
otocina    resulta da absor&ccedil;&atilde;o intestinal e da s&iacute;ntese aume
ntadas    de colesterol (23). As lipoprote&iacute;nas de ratos diab&eacute;ticos
 s&atilde;o    oxidadas e demonstram citotoxicidade, um aspecto que pode ser pre
venido pela    insulina ou tratamento antioxidante. Trabalhos mostram que o meta
bolismo de    lip&iacute;dios de hamsteres &eacute; influenciado pelo diabetes, 
aumentando    a concentra&ccedil;&atilde;o de triacilglicer&oacute;is e colester
ol (24,25),    corroborando com dados deste trabalho.</font></p>     ^cY#06.htm#
#
00906000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704068300070002000700753#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#94#90#article#192#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Bell e cols. (26)    demonstraram que hams
teres que receberam a mesma concentra&ccedil;&atilde;o    de STZ que os animais 
do presente trabalho apresentaram tumores hep&aacute;ticos.    Assim, avaliamos 
um poss&iacute;vel dano hep&aacute;tico por meio de marcadores    s&eacute;ricos
 e n&atilde;o observamos nenhuma mudan&ccedil;a nas concentra&ccedil;&otilde;es 
   de prote&iacute;nas e albumina. Isso pode indicar que altera&ccedil;&otilde;e
s    em par&acirc;metros bioqu&iacute;micos observados n&atilde;o foram devidas 
&agrave;s    les&otilde;es hep&aacute;ticas e sim pr&oacute;prias do diabetes.</
font></p>     ^cY#06.htm##
00684000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704046100070002000700531#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#95#91#article#192#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Estresse oxidativo    aumentado e mudan&cc
edil;as na capacidade antioxidante s&atilde;o observados    em diabetes melito c
l&iacute;nico e experimental e podem contribuir para complica&ccedil;&otilde;es 
   dessa doen&ccedil;a (5). Corroborando com isso, nossos dados mostram uma dimi
nui&ccedil;&atilde;o    de enzimas antioxidantes e um aumento de produtos do est
resse oxidativo.</font></p>     ^cY#06.htm##
00821000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704059800070002000700668#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#96#92#article#192#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Ocorre aumento    do estresse oxidativo e 
da peroxida&ccedil;&atilde;o lip&iacute;dica em macr&oacute;fagos    e em lipopr
ote&iacute;nas na presen&ccedil;a de hiperglicemia e hipertrigliceridemia    (27
). A enzima PON associada com a HDL protege a LDL e a HDL contra a oxida&ccedil;
&atilde;o    e tamb&eacute;m elimina lip&iacute;dios oxidados das c&eacute;lulas
 (28). A    atividade s&eacute;rica da PON se encontra diminu&iacute;da no diabe
tes melito    (29), o que tamb&eacute;m foi verificado em nosso trabalho.</font>
</p>     ^cY#06.htm##
01335000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704111200070002000701182#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#97#93#article#192#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Esta enzima tamb&eacute;m    pode atuar de
 forma suicida neste processo e ent&atilde;o ser usada para prevenir    a peroxi
da&ccedil;&atilde;o de HDL. Essa teoria &eacute; apoiada pela observa&ccedil;&at
ilde;o    da diminui&ccedil;&atilde;o da atividade da PON quando exposta a per&o
acute;xidos    de lip&iacute;dios. A atividade diminu&iacute;da da PON 1 pode se
r relacionada    &agrave; glica&ccedil;&atilde;o do HDL e consequente perda de f
un&ccedil;&atilde;o,    que ocorre no diabetes. Foi verificado por Hedrick e col
s. (30) uma diminui&ccedil;&atilde;o    de 65% na atividade de PON em HDL glicad
o e uma redu&ccedil;&atilde;o de 40%    na atividade enzim&aacute;tica, quando a
 PON purificada &eacute; exposta diretamente    &agrave; glica&ccedil;&atilde;o.
 N&atilde;o existem trabalhos na literatura    que verifiquem a atividade dessa 
enzima em hamsteres diab&eacute;ticos e isso    se torna mais importante devido 
ao fato de esse animal apresentar o metabolismo    de lipoprote&iacute;nas t&ati
lde;o semelhante ao humano.</font></p>     ^cY#06.htm##
01501000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704127800070002000701348#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#98#94#article#192#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">O radical super&oacute;xido,    o primeiro
 produto da redu&ccedil;&atilde;o da mol&eacute;cula de oxig&ecirc;nio,    tem u
m el&eacute;tron desemparelhado em sua &oacute;rbita externa e isso resulta    e
m uma fonte importante de hidroper&oacute;xidos e de radicais livres t&oacute;xi
cos.    Uma c&eacute;lula normal tem a habilidade de detoxificar radicais super&
oacute;xido    por meio de enzimas como a super&oacute;xido dismutase. A SOD, ju
nto com outras    enzimas como a catalase, glutationa redutase, ajuda a manter a
 concentra&ccedil;&atilde;o    de glutationa e NADPH necess&aacute;rio para a &o
acute;tima fun&ccedil;&atilde;o    dos mecanismos de defesas antioxidantes. V&aa
cute;rios trabalhos com animais    tratados com STZ mostram uma diminui&ccedil;&
atilde;o da atividade de SOD. Mohan    and Das (31) demonstraram uma diminui&cce
dil;&atilde;o da atividade de SOD no    plasma de ratos diab&eacute;ticos; por&e
acute;m, trabalhos demonstrando os efeitos    causados pelo diabetes sobre a ati
vidade de SOD em hamsteres s&atilde;o escassos.    Observamos tamb&eacute;m uma 
atividade diminu&iacute;da em nossos hamsteres,    corroborando com os trabalhos
 em outros modelos experimentais.</font></p>     ^cY#06.htm##
02474000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704225100070002000702321#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#99#95#article#192#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Os dados das enzimas    super&oacute;xido 
dismutase, glutationa peroxidase ou redutase e catalase muitas    vezes s&atilde
;o controversos. Como verificado para diabetes em alguns modelos    experimentai
s ou diferentes tecidos, elas podem se encontrar aumentadas ou diminu&iacute;das
.    O aumento de suas express&otilde;es e, consequentemente, de suas atividades
    pode ser devido a um mecanismo regulado em n&iacute;vel transcricional (32).
    Sob condi&ccedil;&otilde;es fisiol&oacute;gicas normais, a transcri&ccedil;&
atilde;o    do fator Nrf2 &eacute; inibida pela prote&iacute;na repressora Keap1
 localizada    no citoplasma das c&eacute;lulas (33). A prote&iacute;na Keap1 co
nt&eacute;m    res&iacute;duos conservados de ciste&iacute;na, os quais desempen
ham um papel    cr&iacute;tico na manuten&ccedil;&atilde;o do Nrf2 no citoplasma
. Entretanto,    um aumento na produ&ccedil;&atilde;o de EROS no organismo promo
ve no citoplasma    a dissocia&ccedil;&atilde;o desse complexo, fazendo com que 
o Nrf2 fique ativado,    sendo transportado para o n&uacute;cleo (34,35). No n&u
acute;cleo das c&eacute;lulas,    esse fator de transcri&ccedil;&atilde;o se lig
a a elementos de resposta a antioxidantes    (ARE) na regi&atilde;o promotora do
s genes que transcrevem enzimas antioxidantes    end&oacute;genas. A ativa&ccedi
l;&atilde;o Nrf2-ARE induz a produ&ccedil;&atilde;o    da super&oacute;xido dism
utase, catalase, glutationa peroxidase, glutationa    reduzida, peroxiredoxinas,
 nicotinamida adenina dinucleot&iacute;deo fosfato    (NADPH): quinona oxidoredu
tases (NQOs) e hemoxigenases. Juntas, essas enzimas    e pept&iacute;deos repres
entam um potente mecanismo antioxidante de defesa.    Uma vez restabelecido o ba
lan&ccedil;o redox da c&eacute;lula, o Nrf2 &eacute;    dissociado do n&uacute;c
leo pelo Keap1 e subsequentemente transportado para    o citoplasma, onde &eacut
e; ubiquitinado e degradado (32). Essa pode ser uma    explica&ccedil;&atilde;o 
para nosso resultado de concentra&ccedil;&atilde;o    de glutationa total no f&i
acute;gado, que se apresentou aumentado talvez por    esse mecanismo de defesa d
o organismo ativado pelo aumento de oxidantes.</font></p>     ^cY#06.htm##
01303000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000300056709000800059708000400067704107900071002000701150#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#100#96#article#192#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2">Hidroper&oacute;xidos    t&ecirc;m um efe
ito t&oacute;xico nas c&eacute;lulas, diretamente ou por meio    de grande degra
da&ccedil;&atilde;o de radicais hidroxil t&oacute;xicos. Eles    tamb&eacute;m p
odem reagir com metais de transi&ccedil;&atilde;o e formar alde&iacute;dos,    c
omo o malondialde&iacute;do, que causa danos &agrave;s membranas celulares.    O
 aumento de esp&eacute;cies reativas ao &aacute;cido tiobarbit&uacute;rico,    q
ue &eacute; uma evid&ecirc;ncia indireta da intensa produ&ccedil;&atilde;o    de
 radicais livres, &eacute; visto em v&aacute;rios trabalhos com ratos tratados  
  com estreptozotocina e aloxana (36,37). Em hamsteres, Takatori e cols. (38)   
 analisaram a concentra&ccedil;&atilde;o de malondialde&iacute;do e 4-HNE, outro
    alde&iacute;do formado da peroxida&ccedil;&atilde;o lip&iacute;dica, e verif
icaram    tamb&eacute;m um aumento nas suas concentra&ccedil;&otilde;es em anima
is que    receberam uma dose de STZ, o que corrobora com nossos resultados.</fon
t></p>     ^cY#06.htm##
01237000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000300056709000800059708000400067704101300071002000701084#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#101#97#article#192#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2">As principais mudan&ccedil;as    estrutur
ais em prote&iacute;nas podem ser caracterizadas pelas dosagens de prote&iacute;
na    carbonilada (PCO), perda de grupos ti&oacute;is e produtos de oxida&ccedil
;&atilde;o    proteica avan&ccedil;ada (AOPP). O uso da prote&iacute;na carbonil
ada como marcador    possui algumas vantagens em rela&ccedil;&atilde;o a outros 
marcadores, como    sua forma&ccedil;&atilde;o relativamente r&aacute;pida, gran
de estabilidade    e longo tempo de vida. Esses compostos carbonilados podem con
tribuir para as    complica&ccedil;&otilde;es diab&eacute;ticas. Considerando qu
e em nossos animais    est&aacute; ocorrendo um aumento do estresse oxidativo, u
m baixo n&iacute;vel    de danos a prote&iacute;nas pode ser interpretado como u
m resultado da efici&ecirc;ncia    alta do sistema de antioxidantes, o que pode 
estar sendo promovido pela estimula&ccedil;&atilde;o    via Nrf-2, causada pelo 
diabetes.</font></p>     ^cY#06.htm##
00832000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000300056709000800059708000400067704060800071002000700679#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#102#98#article#192#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2">A aus&ecirc;ncia    de mudan&ccedil;as si
gnificativas na concentra&ccedil;&atilde;o de prote&iacute;nas    carboniladas e
 grupos sulfidrilas, combinada com efeito significativo do diabetes    sobre os 
lip&iacute;dios peroxidados, sugere que os substratos bioqu&iacute;micos    dife
rentes possuem suscetibilidade diferente ao estresse produzido pelo diabetes.   
 Isso corrobora com trabalhos realizados em outros roedores, que n&atilde;o obse
rvaram    mudan&ccedil;as em todos os produtos gerados pelo estresse oxidativo (
39).</font></p>     ^cY#06.htm##
00824000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000300056709000800059708000400067704060000071002000700671#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#103#99#article#192#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2">Os mecanismos pelos    quais o estresse o
xidativo aumentado est&aacute; envolvido nas complica&ccedil;&otilde;es    diab&
eacute;ticas s&atilde;o parcialmente conhecidos. Muitas pesquisas com resultados
    positivos em outros roedores n&atilde;o apresentaram os mesmos resultados sa
tisfat&oacute;rios    em humanos diab&eacute;ticos. Este trabalho mostrou o hams
ter como um bom modelo    experimental para ajudar na elucida&ccedil;&atilde;o d
e mecanismos e identificar    terapias adicionais ao tratamento do diabetes.</fo
nt></p>     ^cY#06.htm##
00728000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704050300072002000700575#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#104#100#article#192#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2">Agradecimentos:    este estudo foi finan
ciado pela Funda&ccedil;&atilde;o de Amparo &agrave; Pesquisa    de Minas Gerais
 (Fapemig, Minas Gerais, Brasil n&deg; CDS-APQ 01126-08) e Conselho    Nacional 
de Desenvolvimento Cient&iacute;&ucirc;co e Tecnol&oacute;gico (CNPq,    Brasil;
 no. 475823/2007-9). Agradecemos ao Professor Rinaldo Cardoso dos Santos    pela
s sugest&otilde;es e revis&atilde;o cuidadosa do manuscrito.</font></p>     ^cY#
06.htm##
00431000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704020600072002000700278#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#105#101#article#192#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2">Declara&ccedil;&atilde;o:    os autores 
declaram n&atilde;o haver conflitos de interesse cient&iacute;fico    neste estu
do.</font></p>     ^cY#06.htm##
00247000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002200072002000700094#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#106#102#article#192#<p>&nbsp;</p>     ^cY#0
6.htm##
00325000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704010000072002000700172#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#107#103#article#192#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="3"><b>REFERENCES</b></font></p>     ^cY#06.
htm##
00439000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000200072704020000074002000700274#v55
n1#V:\SciELO\serial\abem\v55n1\markup\06.htm#S#p#108#104#article#192#1#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">1. Conget I. &#91;Diagnosi
s,    classification and cathogenesis of diabetes mellitus&#93;. Rev Esp Cardiol
.    2002;55(5):528-35.    ^cY#06.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#109#105#article#192#</font></p>     ^cY#06.
htm##
00424000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000200072704018500074002000700259#v55
n1#V:\SciELO\serial\abem\v55n1\markup\06.htm#S#p#110#106#article#192#2#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">2. Type 2 diabetes    in c
hildren and adolescents. American Diabetes Association. Diabetes Care. 2000;23(3
):381-9.    ^cY#06.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#111#107#article#192#</font></p>     ^cY#06.
htm##
00406000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000200072704016700074002000700241#v55
n1#V:\SciELO\serial\abem\v55n1\markup\06.htm#S#p#112#108#article#192#3#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">3. Ceriello A.    Oxidativ
e stress and glycemic regulation. Metabolism. 2000;49(2 Suppl 1):27-9.    ^cY#06
.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#113#109#article#192#</font></p>     ^cY#06.
htm##
00513000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000200072704027400074002000700348#v55
n1#V:\SciELO\serial\abem\v55n1\markup\06.htm#S#p#114#110#article#192#4#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">4. Reis JS, Veloso    CA, 
Mattos RT, Purish S, Nogueira-Machado JA. &#91;Oxidative stress: a review    on 
metabolic signaling in type 1 diabetes&#93;. Arq Bras Endocrinol Metabol.    200
8;52(7):1096-105.    ^cY#06.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#115#111#article#192#</font></p>     ^cY#06.
htm##
00424000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000200072704018500074002000700259#v55
n1#V:\SciELO\serial\abem\v55n1\markup\06.htm#S#p#116#112#article#192#5#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">5. Baynes JW. Role    of o
xidative stress in development of complications in diabetes. Diabetes 1991;40(4)
:405-12.    ^cY#06.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#117#113#article#192#</font></p>     ^cY#06.
htm##
00477000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000200072704023800074002000700312#v55
n1#V:\SciELO\serial\abem\v55n1\markup\06.htm#S#p#118#114#article#192#6#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">6. Najib S, Sanchez-Margal
et    V. Homocysteine thiolactone inhibits insulin signaling, and glutathione ha
s    a protective effect. J Mol Endocrinol. 2001;27(1):85-91.    ^cY#06.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#119#115#article#192#</font></p>     ^cY#06.
htm##
00502000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000200072704026300074002000700337#v55
n1#V:\SciELO\serial\abem\v55n1\markup\06.htm#S#p#120#116#article#192#7#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">7. Rudich A, Tirosh    A, 
Potashnik R, Hemi R, Kanety H, Bashan N. Prolonged oxidative stress impairs    i
nsulin-induced GLUT4 translocation in 3T3-L1 adipocytes. Diabetes. 1998;47(10):1
562-9.    ^cY#06.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#121#117#article#192#</font></p>     ^cY#06.
htm##
00468000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000200072704022900074002000700303#v55
n1#V:\SciELO\serial\abem\v55n1\markup\06.htm#S#p#122#118#article#192#8#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">8. Bertelsen M,    Anggard
 EE, Carrier MJ. Oxidative stress impairs insulin internalization in    endothel
ial cells in vitro. Diabetologia. 2001;44(5):605-13.    ^cY#06.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#123#119#article#192#</font></p>     ^cY#06.
htm##
00404000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000200072704016500074002000700239#v55
n1#V:\SciELO\serial\abem\v55n1\markup\06.htm#S#p#124#120#article#192#9#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">9. Rees DA, Alcolado    JC
. Animal models of diabetes mellitus. Diabet Med. 2005;22(4):359-70.    ^cY#06.h
tm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#125#121#article#192#</font></p>     ^cY#06.
htm##
00509000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704026900075002000700344#v55
n1#V:\SciELO\serial\abem\v55n1\markup\06.htm#S#p#126#122#article#192#10#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">10. Elsner M, Guldbakke  
  B, Tiedge M, Munday R, Lenzen S. Relative importance of transport and alkylati
on    for pancreatic beta-cell toxicity of streptozotocin. Diabetologia. 2000;43
(12):1528-33.    ^cY#06.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#127#123#article#192#</font></p>     ^cY#06.
htm##
00450000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704021000075002000700285#v55
n1#V:\SciELO\serial\abem\v55n1\markup\06.htm#S#p#128#124#article#192#11#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">11. Bennett RA,    Pegg A
E. Alkylation of DNA in rat tissues following administration of streptozotocin. 
   Cancer Res. 1981;41(7):2786-90.    ^cY#06.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#129#125#article#192#</font></p>     ^cY#06.
htm##
00405000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704016500075002000700240#v55
n1#V:\SciELO\serial\abem\v55n1\markup\06.htm#S#p#130#126#article#192#12#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">12. Bolzan AD,    Bianchi
 MS. Genotoxicity of streptozotocin. Mutat Res. 2002;512(2-3):121-34.    ^cY#06.
htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#131#127#article#192#</font></p>     ^cY#06.
htm##
00537000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704029700075002000700372#v55
n1#V:\SciELO\serial\abem\v55n1\markup\06.htm#S#p#132#128#article#192#13#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">13. Takasu N, Komiya    I
, Asawa T, Nagasawa Y, Yamada T. Streptozocin- and alloxan-induced H2O2 generati
on    and DNA fragmentation in pancreatic islets. H2O2 as mediator for DNA fragm
entation.    Diabetes. 1991;40(9):1141-5.    ^cY#06.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#133#129#article#192#</font></p>     ^cY#06.
htm##
00446000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704020600075002000700281#v55
n1#V:\SciELO\serial\abem\v55n1\markup\06.htm#S#p#134#130#article#192#14#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">14. Phares CK.    Strepto
zotocin-induced diabetes in Syrian hamsters: new model of diabetes mellitus.    
Experientia. 1980;36(6):681-2.    ^cY#06.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#135#131#article#192#</font></p>     ^cY#06.
htm##
00523000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704028300075002000700358#v55
n1#V:\SciELO\serial\abem\v55n1\markup\06.htm#S#p#136#132#article#192#15#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">15. Rauscher FM,    Sande
rs RA, Watkins JB, III. Effects of new antioxidant compounds PNU-104067F    and 
PNU-74389G on antioxidant defense in normal and diabetic rats. J Biochem    Mol 
Toxicol. 2000;14(4):189-94.    ^cY#06.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#137#133#article#192#</font></p>     ^cY#06.
htm##
00560000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704032000075002000700395#v55
n1#V:\SciELO\serial\abem\v55n1\markup\06.htm#S#p#138#134#article#192#16#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">16. Col&eacute;gio    Bra
sileiro de Experimenta&ccedil;&atilde;o Animal. Princ&iacute;pios &eacute;ticos 
   na experimenta&ccedil;&atilde;o animal do Col&eacute;gio Brasileiro de Experi
menta&ccedil;&atilde;o    Animal. S&atilde;o Paulo: COBEA, 1991.    ^cY#06.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#139#135#article#192#</font></p>     ^cY#06.
htm##
00558000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704031800075002000700393#v55
n1#V:\SciELO\serial\abem\v55n1\markup\06.htm#S#p#140#136#article#192#17#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">17. Simionescu    M, Popo
v D, Sima A, Hasu M, Costache G, Faitar S, et al. Pathobiochemistry of    combin
ed diabetes and atherosclerosis studied on a novel animal model. The hyperlipemi
c-hyperglycemic    hamster. Am J Pathol. 1996;148(3):997-1014.    ^cY#06.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#141#137#article#192#</font></p>     ^cY#06.
htm##
00521000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704028100075002000700356#v55
n1#V:\SciELO\serial\abem\v55n1\markup\06.htm#S#p#142#138#article#192#18#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">18. Beltowski J,    Wojci
cka G, Jamroz A. Differential effect of 3-hydroxy-3-methylglutaryl coenzyme    A
 reductase inhibitors on plasma paraoxonase 1 activity in the rat. Pol J Pharmac
ol.    2002;54(6):661-71.    ^cY#06.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#143#139#article#192#</font></p>     ^cY#06.
htm##
00478000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704023800075002000700313#v55
n1#V:\SciELO\serial\abem\v55n1\markup\06.htm#S#p#144#140#article#192#19#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">19. Sedlak J, Lindsay    
RH. Estimation of total, protein-bound, and nonprotein sulfhydryl groups in    t
issue with Ellman's reagent. Anal Biochem. 1968;25(1):192-205.    ^cY#06.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#145#141#article#192#</font></p>     ^cY#06.
htm##
00400000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704016000075002000700235#v55
n1#V:\SciELO\serial\abem\v55n1\markup\06.htm#S#p#146#142#article#192#20#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">20. Buege JA, Aust    SD.
 Microsomal lipid peroxidation. Methods Enzymol. 1978;52:302-10.    ^cY#06.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#147#143#article#192#</font></p>     ^cY#06.
htm##
00470000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704023000075002000700305#v55
n1#V:\SciELO\serial\abem\v55n1\markup\06.htm#S#p#148#144#article#192#21#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">21. Levine RL,    William
s JA, Stadtman ER, Shacter E. Carbonyl assays for determination of oxidatively  
  modified proteins. Methods Enzymol. 1994;233:346-57.    ^cY#06.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#149#145#article#192#</font></p>     ^cY#06.
htm##
00564000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704032400075002000700399#v55
n1#V:\SciELO\serial\abem\v55n1\markup\06.htm#S#p#150#146#article#192#22#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">22. El-Swefy S,    Schaef
er EJ, Seman LJ, van DD, Sevanian A, Smith DE, et al. The effect of vitamin    E
, probucol, and lovastatin on oxidative status and aortic fatty lesions in    hy
perlipidemic-diabetic hamsters. Atherosclerosis. 2000;149(2):277-86.    ^cY#06.h
tm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#151#147#article#192#</font></p>     ^cY#06.
htm##
00564000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704032400075002000700399#v55
n1#V:\SciELO\serial\abem\v55n1\markup\06.htm#S#p#152#148#article#192#23#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">23. Ebara T, Hirano    T,
 Mamo JC, Sakamaki R, Furukawa S, Nagano S, et al. Hyperlipidemia in streptozoci
n-diabetic    hamsters as a model for human insulin-deficient diabetes: comparis
on to streptozocin-diabetic    rats. Metabolism. 1994;43(3):299-305.    ^cY#06.h
tm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#153#149#article#192#</font></p>     ^cY#06.
htm##
00564000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704032400075002000700399#v55
n1#V:\SciELO\serial\abem\v55n1\markup\06.htm#S#p#154#150#article#192#24#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">24. Ebara T, Hirano    T,
 Mamo JC, Sakamaki R, Furukawa S, Nagano S, et al. Hyperlipidemia in streptozoci
n-diabetic    hamsters as a model for human insulin-deficient diabetes: comparis
on to streptozocin-diabetic    rats. Metabolism. 1994;43(3):299-305.    ^cY#06.h
tm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#155#151#article#192#</font></p>     ^cY#06.
htm##
00402000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704016200075002000700237#v55
n1#V:\SciELO\serial\abem\v55n1\markup\06.htm#S#p#156#152#article#192#25#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">25. Mathe D. Dyslipidemia
    and diabetes: animal models. Diabete Metab. 1995;21(2):106-11.    ^cY#06.htm
##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#157#153#article#192#</font></p>     ^cY#06.
htm##
00443000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704020300075002000700278#v55
n1#V:\SciELO\serial\abem\v55n1\markup\06.htm#S#p#158#154#article#192#26#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">26. Bell Jr RH,    Hye RJ
, Miyai K. Streptozotocin-induced liver tumors in the Syrian hamster.    Carcino
genesis. 1984;5(10):1235-8.    ^cY#06.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#159#155#article#192#</font></p>     ^cY#06.
htm##
00427000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704018700075002000700262#v55
n1#V:\SciELO\serial\abem\v55n1\markup\06.htm#S#p#160#156#article#192#27#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">27. Griendling    KK, Ale
xander RW. Oxidative stress and cardiovascular disease. Circulation.    1997;96(
10):3264-5.    ^cY#06.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#161#157#article#192#</font></p>     ^cY#06.
htm##
00468000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704022800075002000700303#v55
n1#V:\SciELO\serial\abem\v55n1\markup\06.htm#S#p#162#158#article#192#28#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">28. Aviram M. Introductio
n    to the serial review on paraoxonases, oxidative stress, and cardiovascular 
diseases.    Free Radic Biol Med. 2004;37(9):1301-3.    ^cY#06.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#163#159#article#192#</font></p>     ^cY#06.
htm##
00580000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704034000075002000700415#v55
n1#V:\SciELO\serial\abem\v55n1\markup\06.htm#S#p#164#160#article#192#29#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">29. Abbott CA,    Macknes
s MI, Kumar S, Boulton AJ, Durrington PN. Serum paraoxonase activity,    concent
ration, and phenotype distribution in diabetes mellitus and its relationship    
to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol. 1995;15(11):181
2-8.    ^cY#06.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#165#161#article#192#</font></p>     ^cY#06.
htm##
00578000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704033800075002000700413#v55
n1#V:\SciELO\serial\abem\v55n1\markup\06.htm#S#p#166#162#article#192#30#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">30. Hedrick CC,    Hassan
 K, Hough GP, Yoo JH, Simzar S, Quinto CR, et al. Short-term feeding of    ather
ogenic diet to mice results in reduction of HDL and paraoxonase that may    be m
ediated by an immune mechanism. Arterioscler Thromb Vasc Biol. 2000;20(8):1946-5
2.    ^cY#06.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#167#163#article#192#</font></p>     ^cY#06.
htm##
00458000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704021800075002000700293#v55
n1#V:\SciELO\serial\abem\v55n1\markup\06.htm#S#p#168#164#article#192#31#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">31. Mohan IK, Das    UN. 
Effect of L-arginine-nitric oxide system on chemical-induced diabetes mellitus. 
   Free Radic Biol Med. 1998;25(7):757-65.    ^cY#06.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#169#165#article#192#</font></p>     ^cY#06.
htm##
00483000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704024300075002000700318#v55
n1#V:\SciELO\serial\abem\v55n1\markup\06.htm#S#p#170#166#article#192#32#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">32. Kensler TW,    Wakaba
yashi N, Biswal S. Cell survival responses to environmental stresses via    the 
Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol. 2007;47:89-116.    ^cY#06.ht
m##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#171#167#article#192#</font></p>     ^cY#06.
htm##
00524000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704028400075002000700359#v55
n1#V:\SciELO\serial\abem\v55n1\markup\06.htm#S#p#172#168#article#192#33#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">33. Itoh K, Wakabayashi  
  N, Katoh Y, Ishii T, O'Connor T, Yamamoto M. Keap1 regulates both cytoplasmic-
nuclear    shuttling and degradation of Nrf2 in response to electrophiles. Genes
 Cells.    2003;8(4):379-91.    ^cY#06.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#173#169#article#192#</font></p>     ^cY#06.
htm##
00501000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704026100075002000700336#v55
n1#V:\SciELO\serial\abem\v55n1\markup\06.htm#S#p#174#170#article#192#34#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">34. Dahl EL, Mulcahy    R
T. Cell-type specific differences in glutamate cysteine ligase transcriptional  
  regulation demonstrate independent subunit control. Toxicol Sci. 2001;61(2):26
5-72.    ^cY#06.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#175#171#article#192#</font></p>     ^cY#06.
htm##
00565000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704032500075002000700400#v55
n1#V:\SciELO\serial\abem\v55n1\markup\06.htm#S#p#176#172#article#192#35#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">35. de Vries HE,    Witte
 M, Hondius D, Rozemuller AJ, Drukarch B, Hoozemans J, et al. Nrf2-induced    an
tioxidant protection: a promising target to counteract ROS-mediated damage    in
 neurodegenerative disease? Free Radic Biol Med. 2008;45(10):1375-83.    ^cY#06.
htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#177#173#article#192#</font></p>     ^cY#06.
htm##
00537000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704029700075002000700372#v55
n1#V:\SciELO\serial\abem\v55n1\markup\06.htm#S#p#178#174#article#192#36#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">36. Aragno M, Tamagno    
E, Gatto V, Brignardello E, Parola S, Danni O, et al. Dehydroepiandrosterone    
protects tissues of streptozotocin-treated rats against oxidative stress. Free  
  Radic Biol Med. 1999;26(11-12):1467-74.    ^cY#06.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#179#175#article#192#</font></p>     ^cY#06.
htm##
00420000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704018000075002000700255#v55
n1#V:\SciELO\serial\abem\v55n1\markup\06.htm#S#p#180#176#article#192#37#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">37. Jain SK. The    neona
tal erythrocyte and its oxidative susceptibility. Semin Hematol. 1989;26(4):286-
300.    ^cY#06.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#181#177#article#192#</font></p>     ^cY#06.
htm##
00533000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704029300075002000700368#v55
n1#V:\SciELO\serial\abem\v55n1\markup\06.htm#S#p#182#178#article#192#38#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">38. Takatori A,    Ohta E
, Inenaga T, Horiuchi K, Ishii Y, Itagaki S, et al. Protective effects    of pro
bucol treatment on pancreatic beta-cell function of SZ-induced diabetic    APA h
amsters. Exp Anim. 2003;52(4):317-27.    ^cY#06.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#183#179#article#192#</font></p>     ^cY#06.
htm##
00489000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704024900075002000700324#v55
n1#V:\SciELO\serial\abem\v55n1\markup\06.htm#S#p#184#180#article#192#39#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">39. Hase M, Babazono    T
, Karibe S, Kinae N, Iwamoto Y. Renoprotective effects of tea catechin in strept
ozotocin-    induced diabetic rats. Int Urol Nephrol. 2006;38(3-4):693-9.    ^cY
#06.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#185#181#article#192#</font></p>     ^cY#06.
htm##
00247000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002200072002000700094#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#186#182#article#192#<p>&nbsp;</p>     ^cY#0
6.htm##
00247000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002200072002000700094#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#187#183#article#192#<p>&nbsp;</p>     ^cY#0
6.htm##
00424000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704019900072002000700271#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#188#184#article#192#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2"><b><a name="back"></a><a href="#top"><im
g src="/img/revistas/abem/v55n1/seta.jpg" border="0"></a>    Correspond&ecirc;nc
ia para:    ^cY#06.htm##
00263000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704003800072002000700110#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#189#185#article#192#<br>   </b> Ma&iacute;s
a Silva    ^cY#06.htm##
00274000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704004900072002000700121#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#190#186#article#192#<br>   Universidade Fed
eral de Ouro Preto    ^cY#06.htm##
00264000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704003900072002000700111#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#191#187#article#192#<br>   Campus Morro do 
Cruzeiro    ^cY#06.htm##
00297000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704007200072002000700144#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#192#188#article#192#<br>   Departamento de 
Ci&ecirc;ncias Biol&oacute;gicas, Bauxita    ^cY#06.htm##
00274000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704004900072002000700121#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#193#189#article#192#<br>   35400-000 - Ouro
 Preto, MG, Brasil    ^cY#06.htm##
00318000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704009300072002000700165#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#194#190#article#192#<br>   <a href="mailto:
maisasilv@yahoo.com.br">maisasilv@yahoo.com.br</a></font></p>     ^cY#06.htm##
00318000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704009300072002000700165#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#195#191#article#192#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2">Recebido em 6/Jul/2010    ^cY#06.htm##
00273000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704004800072002000700120#v55n1#V:\SciELO
\serial\abem\v55n1\markup\06.htm#S#p#196#192#article#192#<br>   Aceito em 16/Dez
/2010</font></p>     ^cY#06.htm##
00517000000000277000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100016000710120068000870300
01600155065000900171064000500180031000300185032000200188014000700190865000900197
002000700206035001000213801001600223#v55n1#V:\SciELO\serial\abem\v55n1\markup\06
.htm#S#c#197#1#article#39#1#^rND^sConget^nI#Diagnosis, classification and cathog
enesis of diabetes mellitus^len#Rev Esp Cardiol#20020000#2002#55#5#528-35#201102
00#06.htm#0300-8932#Rev Esp Cardiol##
00506000000000277000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690120048000710110030001190300
01400149065000900163064000500172031000300177032000200180014000600182865000900188
002000700197035001000204801001400214#v55n1#V:\SciELO\serial\abem\v55n1\markup\06
.htm#S#c#198#2#article#39#2#Type 2 diabetes in children and adolescents^len#Amer
ican Diabetes Association#Diabetes Care#20000000#2000#23#3#381-9#20110200#06.htm
#0149-5992#Diabetes Care##
00487000000000277000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100018000710120045000890300
01100134065000900145064000500154031000300159032000500162014000500167865000900172
002000700181035001000188801001100198#v55n1#V:\SciELO\serial\abem\v55n1\markup\06
.htm#S#c#199#3#article#39#3#^rND^sCeriello^nA#Oxidative stress and glycemic regu
lation^len#Metabolism#20000000#2000#49#2^s1#27-9#20110200#06.htm#0026-0495#Metab
olism##
00672000000000325000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100015000710100017000860100
01700103010001600120010002700136012007300163030002800236065000900264064000500273
03100030027803200020028101400090028386500090029200200070030103500100030880100280
0318#v55n1#V:\SciELO\serial\abem\v55n1\markup\06.htm#S#c#200#4#article#39#4#^rND
^sReis^nJS#^rND^sVeloso^nCA#^rND^sMattos^nRT#^rND^sPurish^nS#^rND^sNogueira-Mach
ado^nJA#Oxidative stress: a review on metabolic signaling in type 1 diabetes^len
#Arq Bras Endocrinol Metabol#20080000#2008#52#7#1096-105#20110200#06.htm#0004-27
30#Arq Bras Endocrinol Metabol##
00509000000000277000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100017000710120073000880300
00900161065000900170064000500179031000300184032000200187014000700189865000900196
002000700205035001000212801000900222#v55n1#V:\SciELO\serial\abem\v55n1\markup\06
.htm#S#c#201#5#article#39#5#^rND^sBaynes^nJW#Role of oxidative stress in develop
ment of complications in diabetes^len#Diabetes#19910000#1991#40#4#405-12#2011020
0#06.htm#0012-1797#Diabetes##
00584000000000289000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100015000710100026000860120
09700112030001700209065000900226064000500235031000300240032000200243014000600245
865000900251002000700260035001000267801001700277#v55n1#V:\SciELO\serial\abem\v55
n1\markup\06.htm#S#c#202#6#article#39#6#^rND^sNajib^nS#^rND^sSanchez-Margalet^nV
#Homocysteine thiolactone inhibits insulin signaling, and glutathione has a prot
ective effect^len#J Mol Endocrinol#20010000#2001#27#1#85-91#20110200#06.htm#0952
-5041#J Mol Endocrinol##
00673000000000337000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100016000710100016000870100
01900103010001400122010001600136010001600152012009600168030000900264065000900273
06400050028203100030028703200030029001400070029386500090030000200070030903500100
0316801000900326#v55n1#V:\SciELO\serial\abem\v55n1\markup\06.htm#S#c#203#7#artic
le#39#7#^rND^sRudich^nA#^rND^sTirosh^nA#^rND^sPotashnik^nR#^rND^sHemi^nR#^rND^sK
anety^nH#^rND^sBashan^nN#Prolonged oxidative stress impairs insulin-induced GLUT
4 translocation in 3T3-L1 adipocytes^len#Diabetes#19980000#1998#47#10#1562-9#201
10200#06.htm#0012-1797#Diabetes##
00589000000000301000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100019000710100018000900100
01800108012008300126030001300209065000900222064000500231031000300236032000200239
014000700241865000900248002000700257035001000264801001300274#v55n1#V:\SciELO\ser
ial\abem\v55n1\markup\06.htm#S#c#204#8#article#39#8#^rND^sBertelsen^nM#^rND^sAng
gard^nEE#^rND^sCarrier^nMJ#Oxidative stress impairs insulin internalization in e
ndothelial cells in vitro^len#Diabetologia#20010000#2001#44#5#605-13#20110200#06
.htm#0012-186X#Diabetologia##
00508000000000289000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100015000710100019000860120
03900105030001100144065000900155064000500164031000300169032000200172014000700174
865000900181002000700190035001000197801001100207#v55n1#V:\SciELO\serial\abem\v55
n1\markup\06.htm#S#c#205#9#article#39#9#^rND^sRees^nDA#^rND^sAlcolado^nJC#Animal
 models of diabetes mellitus^len#Diabet Med#20050000#2005#22#4#359-70#20110200#0
6.htm#0742-3071#Diabet Med##
00666000000000325000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730100019000890100
01600108010001600124010001600140012010400156030001300260065000900273064000500282
03100030028703200030029001400080029386500090030100200070031003500100031780100130
0327#v55n1#V:\SciELO\serial\abem\v55n1\markup\06.htm#S#c#206#10#article#39#10#^r
ND^sElsner^nM#^rND^sGuldbakke^nB#^rND^sTiedge^nM#^rND^sMunday^nR#^rND^sLenzen^nS
#Relative importance of transport and alkylation for pancreatic beta-cell toxici
ty of streptozotocin^len#Diabetologia#20000000#2000#43#12#1528-33#20110200#06.ht
m#0012-186X#Diabetologia##
00551000000000289000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100018000730100015000910120
08000106030001100186065000900197064000500206031000300211032000200214014000800216
865000900224002000700233035001000240801001100250#v55n1#V:\SciELO\serial\abem\v55
n1\markup\06.htm#S#c#207#11#article#39#11#^rND^sBennett^nRA#^rND^sPegg^nAE#Alkyl
ation of DNA in rat tissues following administration of streptozotocin^len#Cance
r Res#19810000#1981#41#7#2786-90#20110200#06.htm#0008-5472#Cancer res##
00508000000000289000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730100018000900120
03500108030001000143065000900153064000500162031000400167032000400171014000700175
865000900182002000700191035001000198801001000208#v55n1#V:\SciELO\serial\abem\v55
n1\markup\06.htm#S#c#208#12#article#39#12#^rND^sBolzan^nAD#^rND^sBianchi^nMS#Gen
otoxicity of streptozotocin^len#Mutat Res#20020000#2002#512#2-3#121-34#20110200#
06.htm#0027-5107#Mutat Res##
00687000000000325000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730100016000890100
01500105010001800120010001600138012013700154030000900291065000900300064000500309
03100030031403200020031701400070031986500090032600200070033503500100034280100090
0352#v55n1#V:\SciELO\serial\abem\v55n1\markup\06.htm#S#c#209#13#article#39#13#^r
ND^sTakasu^nN#^rND^sKomiya^nI#^rND^sAsawa^nT#^rND^sNagasawa^nY#^rND^sYamada^nT#S
treptozocin- and alloxan-induced H2O2 generation and DNA fragmentation in pancre
atic islets: H2O2 as mediator for DNA fragmentation^len#Diabetes#19910000#1991#4
0#9#1141-5#20110200#06.htm#0012-1797#Diabetes##
00530000000000277000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730120087000900300
01200177065000900189064000500198031000300203032000200206014000600208865000900214
002000700223035001000230801001200240#v55n1#V:\SciELO\serial\abem\v55n1\markup\06
.htm#S#c#210#14#article#39#14#^rND^sPhares^nCK#Streptozotocin-induced diabetes i
n Syrian hamsters: new model of diabetes mellitus^len#Experientia#19800000#1980#
36#6#681-2#20110200#06.htm#0014-4754#Experientia##
00650000000000301000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100019000730100018000920100
01800110012012400128030002200252065000900274064000500283031000300288032000200291
014000700293865000900300002000700309035001000316801002200326#v55n1#V:\SciELO\ser
ial\abem\v55n1\markup\06.htm#S#c#211#15#article#39#15#^rND^sRauscher^nFM#^rND^sS
anders^nRA#^rND^sWatkins^nJB#III. Effects of new antioxidant compounds PNU-10406
7F and PNU-74389G on antioxidant defense in normal and diabetic rats^len#J Bioch
em Mol Toxicol#20000000#2000#14#4#189-94#20110200#06.htm#1095-6670#J Biochem Mol
 Toxicol##
00487000000000229000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700170044000730180094001170660
01000211062000600221065000900227064000500236865000900241002000700250#v55n1#V:\Sc
iELO\serial\abem\v55n1\markup\06.htm#S#c#212#16#article#39#16#Colégio Brasileiro
 de Experimentação Animal#Princípios éticos na experimentação animal do Colégio 
Brasileiro de Experimentação Animal^lpt#São Paulo#COBEA#19910000#1991#20110200#0
6.htm##
00740000000000349000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100020000730100015000930100
01400108010001400122010001800136010001600154810000600170012013500176030001200311
06500090032306400050033203100040033703200020034101400090034386500090035200200070
0361035001000368801001200378#v55n1#V:\SciELO\serial\abem\v55n1\markup\06.htm#S#c
#213#17#article#39#17#^rND^sSimionescu^nM#^rND^sPopov^nD#^rND^sSima^nA#^rND^sHas
u^nM#^rND^sCostache^nG#^rND^sFaitar^nS#et al#Pathobiochemistry of combined diabe
tes and atherosclerosis studied on a novel animal model: The hyperlipemic-hyperg
lycemic hamster^len#Am J Pathol#19960000#1996#148#3#997-1014#20110200#06.htm#000
2-9440#Am J Pathol##
00642000000000301000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100019000730100018000920100
01600110012013000126030001600256065000900272064000500281031000300286032000200289
014000700291865000900298002000700307035001000314801001600324#v55n1#V:\SciELO\ser
ial\abem\v55n1\markup\06.htm#S#c#214#18#article#39#18#^rND^sBeltowski^nJ#^rND^sW
ojcicka^nG#^rND^sJamroz^nA#Differential effect of 3-hydroxy-3-methylglutaryl coe
nzyme A reductase inhibitors on plasma paraoxonase 1 activity in the rat^len#Pol
 J Pharmacol#20020000#2002#54#6#661-71#20110200#06.htm#1230-6002#Pol J Pharmacol
##
00581000000000289000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730100018000890120
10500107030001300212065000900225064000500234031000300239032000200242014000800244
865000900252002000700261035001000268801001300278#v55n1#V:\SciELO\serial\abem\v55
n1\markup\06.htm#S#c#215#19#article#39#19#^rND^sSedlak^nJ#^rND^sLindsay^nRH#Esti
mation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with 
Ellman's reagent^len#Anal Biochem#19680000#1968#25#1#192-205#20110200#06.htm#000
3-2697#Anal Biochem##
00498000000000277000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730100015000890120
03400104030001600138065000900154064000500163031000300168014000700171865000900178
002000700187035001000194801001600204#v55n1#V:\SciELO\serial\abem\v55n1\markup\06
.htm#S#c#216#20#article#39#20#^rND^sBuege^nJA#^rND^sAust^nSD#Microsomal lipid pe
roxidation^len#Methods Enzymol#19780000#1978#52#302-10#20110200#06.htm#0076-6879
#Methods Enzymol##
00601000000000301000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730100019000900100
01900109010001700128012007100145030001600216065000900232064000500241031000400246
014000700250865000900257002000700266035001000273801001600283#v55n1#V:\SciELO\ser
ial\abem\v55n1\markup\06.htm#S#c#217#21#article#39#21#^rND^sLevine^nRL#^rND^sWil
liams^nJA#^rND^sStadtman^nER#^rND^sShacter^nE#Carbonyl assays for determination 
of oxidatively modified proteins^len#Methods Enzymol#19940000#1994#233#346-57#20
110200#06.htm#0076-6879#Methods Enzymol##
00750000000000349000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100018000730100019000910100
01600110010001400126010001800140010001600158810000600174012013500180030001600315
06500090033106400050034003100040034503200020034901400070035186500090035800200070
0367035001000374801001600384#v55n1#V:\SciELO\serial\abem\v55n1\markup\06.htm#S#c
#218#22#article#39#22#^rND^sEl-Swefy^nS#^rND^sSchaefer^nEJ#^rND^sSeman^nLJ#^rND^
svan^nDD#^rND^sSevanian^nA#^rND^sSmith^nDE#et al#The effect of vitamin E, probuc
ol, and lovastatin on oxidative status and aortic fatty lesions in hyperlipidemi
c-diabetic hamsters^len#Atherosclerosis#20000000#2000#149#2#277-86#20110200#06.h
tm#0021-9150#Atherosclerosis##
00745000000000349000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100015000730100016000880100
01500104010001800119010001800137010001600155810000600171012014300177030001100320
06500090033106400050034003100030034503200020034801400080035086500090035800200070
0367035001000374801001100384#v55n1#V:\SciELO\serial\abem\v55n1\markup\06.htm#S#c
#219#23#article#39#23#^rND^sEbara^nT#^rND^sHirano^nT#^rND^sMamo^nJC#^rND^sSakama
ki^nR#^rND^sFurukawa^nS#^rND^sNagano^nS#et al#Hyperlipidemia in streptozocin-dia
betic hamsters as a model for human insulin-deficient diabetes: comparison to st
reptozocin-diabetic rats^len#Metabolism#19940000#1994#43#3#299-305#20110200#06.h
tm#0026-0495#Metabolism##
00745000000000349000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100015000730100016000880100
01500104010001800119010001800137010001600155810000600171012014300177030001100320
06500090033106400050034003100030034503200020034801400080035086500090035800200070
0367035001000374801001100384#v55n1#V:\SciELO\serial\abem\v55n1\markup\06.htm#S#c
#220#24#article#39#24#^rND^sEbara^nT#^rND^sHirano^nT#^rND^sMamo^nJC#^rND^sSakama
ki^nR#^rND^sFurukawa^nS#^rND^sNagano^nS#et al#Hyperlipidemia in streptozocin-dia
betic hamsters as a model for human insulin-deficient diabetes: comparison to st
reptozocin-diabetic rats^len#Metabolism#19940000#1994#43#3#299-305#20110200#06.h
tm#0026-0495#Metabolism##
00491000000000277000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100015000730120045000880300
01400133065000900147064000500156031000300161032000200164014000700166865000900173
002000700182035001000189801001400199#v55n1#V:\SciELO\serial\abem\v55n1\markup\06
.htm#S#c#221#25#article#39#25#^rND^sMathe^nD#Dyslipidemia and diabetes: animal m
odels^len#Diabete Metab#19950000#1995#21#2#106-11#20110200#06.htm#0338-1684#Diab
ete Metab##
00566000000000301000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100018000730100014000910100
01500105012006200120030001500182065000900197064000500206031000200211032000300213
014000700216865000900223002000700232035001000239801001500249#v55n1#V:\SciELO\ser
ial\abem\v55n1\markup\06.htm#S#c#222#26#article#39#26#^rND^sBell Jr^nRH#^rND^sHy
e^nRJ#^rND^sMiyai^nK#Streptozotocin-induced liver tumors in the Syrian hamster^l
en#Carcinogenesis#19840000#1984#5#10#1235-8#20110200#06.htm#0143-3334#Carcinogen
esis##
00529000000000289000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100021000730100020000940120
04800114030001200162065000900174064000500183031000300188032000300191014000700194
865000900201002000700210035001000217801001200227#v55n1#V:\SciELO\serial\abem\v55
n1\markup\06.htm#S#c#223#27#article#39#27#^rND^sGriendling^nKK#^rND^sAlexander^n
RW#Oxidative stress and cardiovascular disease^len#Circulation#19970000#1997#96#
10#3264-5#20110200#06.htm#0009-7322#Circulation##
00560000000000277000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730120101000890300
02000190065000900210064000500219031000300224032000200227014000700229865000900236
002000700245035001000252801002000262#v55n1#V:\SciELO\serial\abem\v55n1\markup\06
.htm#S#c#224#28#article#39#28#^rND^sAviram^nM#Introduction to the serial review 
on paraoxonases, oxidative stress, and cardiovascular diseases^len#Free Radic Bi
ol Med#20040000#2004#37#9#1301-3#20110200#06.htm#0891-5849#Free Radic Biol Med##
00751000000000325000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730100019000900100
01500109010001800124010002100142012014900163030003000312065000900342064000500351
03100030035603200030035901400070036286500090036900200070037803500100038580100300
0395#v55n1#V:\SciELO\serial\abem\v55n1\markup\06.htm#S#c#225#29#article#39#29#^r
ND^sAbbott^nCA#^rND^sMackness^nMI#^rND^sKumar^nS#^rND^sBoulton^nAJ#^rND^sDurring
ton^nPN#Serum paraoxonase activity, concentration, and phenotype distribution in
 diabetes mellitus and its relationship to serum lipids and lipoproteins^len#Art
erioscler Thromb Vasc Biol#19950000#1995#15#11#1812-8#20110200#06.htm#1079-5642#
Arterioscler Thromb Vasc Biol##
00778000000000349000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100018000730100016000910100
01600107010001400123010001600137010001700153810000600170012013900176030003000315
06500090034506400050035403100030035903200020036201400080036486500090037200200070
0381035001000388801003000398#v55n1#V:\SciELO\serial\abem\v55n1\markup\06.htm#S#c
#226#30#article#39#30#^rND^sHedrick^nCC#^rND^sHassan^nK#^rND^sHough^nGP#^rND^sYo
o^nJH#^rND^sSimzar^nS#^rND^sQuinto^nCR#et al#Short-term feeding of atherogenic d
iet to mice results in reduction of HDL and paraoxonase that may be mediated by 
an immune mechanism^len#Arterioscler Thromb Vasc Biol#20000000#2000#20#8#1946-52
#20110200#06.htm#1079-5642#Arterioscler Thromb Vasc Biol##
00568000000000289000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730100014000890120
08300103030002000186065000900206064000500215031000300220032000200223014000700225
865000900232002000700241035001000248801002000258#v55n1#V:\SciELO\serial\abem\v55
n1\markup\06.htm#S#c#227#31#article#39#31#^rND^sMohan^nIK#^rND^sDas^nUN#Effect o
f L-arginine-nitric oxide system on chemical-induced diabetes mellitus^len#Free 
Radic Biol Med#19980000#1998#25#7#757-65#20110200#06.htm#0891-5849#Free Radic Bi
ol Med##
00607000000000289000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100018000730100021000910100
01600112012008500128030002700213065000900240064000500249031000300254014000700257
865000900264002000700273035001000280801002700290#v55n1#V:\SciELO\serial\abem\v55
n1\markup\06.htm#S#c#228#32#article#39#32#^rND^sKensler^nTW#^rND^sWakabayashi^nN
#^rND^sBiswal^nS#Cell survival responses to environmental stresses via the Keap1
-Nrf2-ARE pathway^len#Annu Rev Pharmacol Toxicol#20070000#2007#47#89-116#2011020
0#06.htm#0362-1642#Annu Rev Pharmacol Toxicol##
00695000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100014000730100021000870100
01500108010001500123010001800138010001800156012010800174030001200282065000900294
06400050030303100020030803200020031001400070031286500090031900200070032803500100
0335801001200345#v55n1#V:\SciELO\serial\abem\v55n1\markup\06.htm#S#c#229#33#arti
cle#39#33#^rND^sItoh^nK#^rND^sWakabayashi^nN#^rND^sKatoh^nY#^rND^sIshii^nT#^rND^
sO'Connor^nT#^rND^sYamamoto^nM#Keap1 regulates both cytoplasmic-nuclear shuttlin
g and degradation of Nrf2 in response to electrophiles^len#Genes Cells#20030000#
2003#8#4#379-91#20110200#06.htm#1356-9597#Genes Cells##
00603000000000289000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100015000730100018000880120
13100106030001200237065000900249064000500258031000300263032000200266014000700268
865000900275002000700284035001000291801001200301#v55n1#V:\SciELO\serial\abem\v55
n1\markup\06.htm#S#c#230#34#article#39#34#^rND^sDahl^nEL#^rND^sMulcahy^nRT#Cell-
type specific differences in glutamate cysteine ligase transcriptional regulatio
n demonstrate independent subunit control^len#Toxicol Sci#20010000#2001#61#2#265
-72#20110200#06.htm#1096-6080#Toxicol Sci##
00756000000000349000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100019000730100015000920100
01700107010002100124010001800145010001900163810000600182012012400188030002000312
06500090033206400050034103100030034603200030034901400080035286500090036000200070
0369035001000376801002000386#v55n1#V:\SciELO\serial\abem\v55n1\markup\06.htm#S#c
#231#35#article#39#35#^rND^sde Vries^nHE#^rND^sWitte^nM#^rND^sHondius^nD#^rND^sR
ozemuller^nAJ#^rND^sDrukarch^nB#^rND^sHoozemans^nJ#et al#Nrf2-induced antioxidan
t protection: a promising target to counteract ROS-mediated damage in neurodegen
erative disease?^len#Free Radic Biol Med#20080000#2008#45#10#1375-83#20110200#06
.htm#0891-5849#Free Radic Biol Med##
00727000000000349000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730100017000890100
01500106010002200121010001600143010001500159810000600174012010000180030002000280
06500090030006400050030903100030031403200060031701400080032386500090033100200070
0340035001000347801002000357#v55n1#V:\SciELO\serial\abem\v55n1\markup\06.htm#S#c
#232#36#article#39#36#^rND^sAragno^nM#^rND^sTamagno^nE#^rND^sGatto^nV#^rND^sBrig
nardello^nE#^rND^sParola^nS#^rND^sDanni^nO#et al#Dehydroepiandrosterone protects
 tissues of streptozotocin-treated rats against oxidative stress^len#Free Radic 
Biol Med#19990000#1999#26#11-12#1467-74#20110200#06.htm#0891-5849#Free Radic Bio
l Med##
00509000000000277000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100015000730120062000880300
01400150065000900164064000500173031000300178032000200181014000800183865000900191
002000700200035001000207801001400217#v55n1#V:\SciELO\serial\abem\v55n1\markup\06
.htm#S#c#233#37#article#39#37#^rND^sJain^nSK#The neonatal erythrocyte and its ox
idative susceptibility^len#Semin Hematol#19890000#1989#26#4#286-300#20110200#06.
htm#0037-1963#Semin Hematol##
00712000000000349000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100018000730100014000910100
01700105010001800122010001500140010001700155810000600172012011400178030000900292
06500090030106400050031003100030031503200020031801400070032086500090032700200070
0336035001000343801000900353#v55n1#V:\SciELO\serial\abem\v55n1\markup\06.htm#S#c
#234#38#article#39#38#^rND^sTakatori^nA#^rND^sOhta^nE#^rND^sInenaga^nT#^rND^sHor
iuchi^nK#^rND^sIshii^nY#^rND^sItagaki^nS#et al#Protective effects of probucol tr
eatment on pancreatic beta-cell function of SZ-induced diabetic APA hamsters^len
#Exp Anim#20030000#2003#52#4#317-27#20110200#06.htm#0014-4916#Exp Anim##
00650000000000325000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100014000730100018000870100
01600105010001500121010001700136012008400153030001700237065000900254064000500263
03100030026803200040027101400060027586500090028100200070029003500100029780100170
0307#v55n1#V:\SciELO\serial\abem\v55n1\markup\06.htm#S#c#235#39#article#39#39#^r
ND^sHase^nM#^rND^sBabazono^nT#^rND^sKaribe^nS#^rND^sKinae^nN#^rND^sIwamoto^nY#Re
noprotective effects of tea catechin in streptozotocin- induced diabetic rats^le
n#Int Urol Nephrol#20060000#2006#38#3-4#693-9#20110200#06.htm#0301-1623#Int Urol
 Nephrol##
00263000000000169000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640910009000660920007000750020007000827030
00400089#v55n1#V:\SciELO\serial\abem\v55n1\markup\07.htm#S#o#1#1#article#1#20110
406#124245#07.htm#199##
03600000000000721000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640710003000660400003000690010006000720420
00200078120000400080038000400084121000300088049000800091158000300099030002600102
03100030012803200020013106500090013301400090014203500100015101200860016101200870
02470100031003340100034003650100027003990100025004260100026004510100024004770100
02700501010002700528070012200555070007800677083083200755085000801587085004901595
08500330164408500320167708500350170908500280174408500200177208308240179208500080
26160850049026240850033026730850033027060850031027390850030027700850019028001170
00602819072000302825112000902828111001302837114000902850113001202859002000702871
#v55n1#V:\SciELO\serial\abem\v55n1\markup\07.htm#S#h#2#1#article#1#oa#pt#br1.1#1
#4.0#TAB#07#ABEM030#nd#Arq Bras Endocrinol Metab#55#1#20110200#^f54^l59#0004-273
0#Síndrome de Berardinelli-Seip: descrição genética e metabólica de cinco pacien
tes^lpt#Genetic and metabolic description of five patients with Berardinelli-Sei
p syndrome^len#^rND^1A01^nCristiane B.^sBarra#^rND^1A01^nRoberta D.^sSavoldelli#
^rND^1A01^nThais D.^sManna#^rND^1A01^nChong A.^sKim#^rND^1A02^nJocelyn^sMagre#^r
ND^1A01^nGilda^sPorta#^rND^1A01^nNuvarte^sSetian#^rND^1A01^nDurval^sDamiani#Univ
ersidade de São Paulo^iA01^1Faculdade de Medicina^2Hospital das Clínicas^3Instit
uto da Criança^cSão Paulo^sSP^pBrasil#Institut National de la Santé et de la Rec
herche Médicale^iA02^cParis^pFrance#^lpt^aOBJETIVO: Descrever o perfil genético 
e metabólico de portadores da síndrome de Berardinelli-Seip (BSCL) acompanhados 
no Instituto da Criança do HC-FMUSP. SUJEITOS E MÉTODOS: Pacientes com as caract
erísticas clínicas da BSCL (n = 5), todas do sexo feminino, foram avaliadas com 
dosagens de glicose e insulina, lípides, leptina, enzimas hepáticas, análise de 
DNA, ultrassonografia abdominal. RESULTADOS: A deficiência de leptina e a hipert
rigliceridemia foram constatadas nas cinco pacientes. Três evoluíram para diabet
es melito (DM). Quatro tiveram mutação no gene AGPAT2 e uma no gene CAV1. CONCLU
SÃO: As alterações metabólicas mais precoces foram a hipertrigliceridemia e a re
sistência insulínica, culminando no surgimento do DM à época da puberdade, sendo
 as mutações no gene AGPAT2 as mais frequentes em nossa casuística.#^dnd^i1#^tm^
lpt^kLipodistrofia congênita generalizada^i1#^tm^lpt^khipertrigliceridemia^i1#^t
m^lpt^khipercolesterolemia^i1#^tm^lpt^kresistência à insulina^i1#^tm^lpt^kdiabet
es melito^i1#^tm^lpt^kleptina^i1#^len^aOBJECTIVE: To report the genetic and meta
bolic profile of patients with Berardinelli-Seip syndrome (BSCL) followed at Ins
tituto da Criança, HC-FMUSP. SUBJECTS AND METHODS: Patients with clinical featur
es of BSCL (n = 5), all female, were evaluated through serum levels of glucose, 
insulin, lipids, leptin, and liver enzymes. Abdominal sonography and DNA analysi
s were also performed. RESULTS: Leptin deficiency and hypertriglyceridemia were 
found in all the patients. Three progressed to diabetes mellitus. Four patients 
have mutations in AGPAT2 gene and one have a mutation in CAV1 gene. CONCLUSION: 
The earliest metabolic abnormalities were hypertriglyceridemia and insulin resis
tance, culminating in the onset of diabetes at the time of puberty. Mutations in
 the AGPAT2 gene were the most frequent in our patients.#^dnd^i2#^tm^len^kCongen
ital generalized lipodystrophy^i2#^tm^len^khypertriglyceridemia^i2#^tm^len^khype
rcholesterolemia^i2#^tm^len^kinsulin resistance^i2#^tm^len^kdiabetes mellitus^i2
#^tm^len^kleptin^i2#other#39#20100530#30/Mail/2010#20101227#27/Dez/2010#07.htm##
03746000000000721000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640710003000660400003000690010006000720420
00200078120000400080038000400084121000300088049000800091158000300099030002600102
03100030012803200020013106500090013301400090014203500100015101200930016101200940
02540100031003480100034003790100027004130100025004400100026004650100024004910100
02700515010002700542070012200569070007800691083088700769085000801656085004901664
08500330171308500320174608500350177808500280181308500200184108308800186108500080
27410850049027490850033027980850033028310850031028640850037028950850033029321170
00602965072000302971112000902974111001302983114000902996113001203005002000703017
#v55n1#V:\SciELO\serial\abem\v55n1\markup\07.htm#S#f#3#1#article#1#oa#pt#br1.1#1
#4.0#TAB#07#ABEM030#nd#Arq Bras Endocrinol Metab#55#1#20110200#^f54^l59#0004-273
0#<b>Síndrome de Berardinelli-Seip: descrição genética e metabólica de cinco pac
ientes</b>^lpt#<b>Genetic and metabolic description of five patients with Berard
inelli-Seip syndrome</b>^len#^rND^1A01^nCristiane B.^sBarra#^rND^1A01^nRoberta D
.^sSavoldelli#^rND^1A01^nThais D.^sManna#^rND^1A01^nChong A.^sKim#^rND^1A02^nJoc
elyn^sMagre#^rND^1A01^nGilda^sPorta#^rND^1A01^nNuvarte^sSetian#^rND^1A01^nDurval
^sDamiani#Universidade de São Paulo^iA01^1Faculdade de Medicina^2Hospital das Cl
ínicas^3Instituto da Criança^cSão Paulo^sSP^pBrasil#Institut National de la Sant
é et de la Recherche Médicale^iA02^cParis^pFrance#^lpt^a<b>OBJETIVO:</b> Descrev
er o perfil genético e metabólico de portadores da síndrome de Berardinelli-Seip
 (BSCL) acompanhados no Instituto da Criança do HC-FMUSP. <b>SUJEITOS E MÉTODOS:
</b> Pacientes com as características clínicas da BSCL (n = 5), todas do sexo fe
minino, foram avaliadas com dosagens de glicose e insulina, lípides, leptina, en
zimas hepáticas, análise de DNA, ultrassonografia abdominal. <b>RESULTADOS:</b> 
A deficiência de leptina e a hipertrigliceridemia foram constatadas nas cinco pa
cientes. Três evoluíram para diabetes melito (DM). Quatro tiveram mutação no gen
e <i>AGPAT2</i> e uma no gene <i>CAV1</i>.&nbsp; <b>CONCLUSÃO:</b> As alterações
 metabólicas mais precoces foram a hipertrigliceridemia e a resistência insulíni
ca, culminando no surgimento do DM à época da puberdade, sendo as mutações no ge
ne <i>AGPAT2</i> as mais frequentes em nossa casuística.#^dnd^i1#^tm^lpt^kLipodi
strofia congênita generalizada^i1#^tm^lpt^khipertrigliceridemia^i1#^tm^lpt^khipe
rcolesterolemia^i1#^tm^lpt^kresistência à insulina^i1#^tm^lpt^kdiabetes melito^i
1#^tm^lpt^kleptina^i1#^len^a<b>OBJECTIVE:</b> To report the genetic and metaboli
c profile of patients with Berardinelli-Seip syndrome (BSCL) followed at Institu
to da Criança, HC-FMUSP. <b>SUBJECTS AND METHODS:</b> Patients with clinical fea
tures of BSCL (n = 5), all female, were evaluated through serum levels of glucos
e, insulin, lipids, leptin, and liver enzymes. Abdominal sonography and DNA anal
ysis were also performed. <b>RESULTS:</b> Leptin deficiency and hypertriglycerid
emia were found in all the patients. Three progressed to <i>diabetes mellitus.</
i> Four patients have mutations in <i>AGPAT2</i> gene and one have a mutation in
 <i>CAV1</i> gene. <b>CONCLUSION:</b> The earliest metabolic abnormalities were 
hypertriglyceridemia and insulin resistance, culminating in the onset of diabete
s at the time of puberty. Mutations in the <i>AGPAT2</i> gene were the most freq
uent in our patients.#^dnd^i2#^tm^len^kCongenital generalized lipodystrophy^i2#^
tm^len^khypertriglyceridemia^i2#^tm^len^khypercholesterolemia^i2#^tm^len^kinsuli
n resistance^i2#^tm^len^k<i>diabetes mellitus</i>^i2#^tm^len^k<i></i>leptin<i></
i>^i2#other#39#20100530#30/Mail/2010#20101227#27/Dez/2010#07.htm##
03729000000000745000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640640013000660710003000790400003000820010
00600085042000200091120000400093038000400097121000300101049000800104158000300112
03000290011503100030014403200020014706500090014901400090015803500100016701200860
01770120087002630100030003500100033003800100026004130100024004390100026004630100
02400489010002700513010002700540070012400567070008000691083083200771085000801603
08500490161108500330166008500320169308500350172508500280176008500200178808308240
18080850008026320850049026400850033026890850033027220850031027550850030027860850
01902816117000602835072000302841112000902844111001302853114000902866113001202875
002000702887008008902894#v55n1#V:\SciELO\serial\abem\v55n1\markup\07.htm#S#l#4#1
#article#1#^mfev.^a2011#oa#pt#br1.1#1#4.0#tab#07#ABEM030#nd#Arq. bras. endocrino
l. metab#55#1#20110200#^f54^l59#0004-2730#Síndrome de Berardinelli-Seip: descriç
ão genética e metabólica de cinco pacientes^lpt#Genetic and metabolic descriptio
n of five patients with Berardinelli-Seip syndrome^len#^rND^1A01^nCristiane B^sB
arra#^rND^1A01^nRoberta D^sSavoldelli#^rND^1A01^nThais D^sManna#^rND^1A01^nChong
 A^sKim#^rND^1A02^nJocelyn^sMagre#^rND^1A01^nGilda^sPorta#^rND^1A01^nNuvarte^sSe
tian#^rND^1A01^nDurval^sDamiani#^iA01^1Universidade de São Paulo^2Faculdade de M
edicina^3Hospital das Clínicas. Instituto da Criança^cSão Paulo^sSP^pBrasil#^iA0
2^1Institut National de la Santé et de la Recherche Médicale^cParis^pFrance#^lpt
^aOBJETIVO: Descrever o perfil genético e metabólico de portadores da síndrome d
e Berardinelli-Seip (BSCL) acompanhados no Instituto da Criança do HC-FMUSP. SUJ
EITOS E MÉTODOS: Pacientes com as características clínicas da BSCL (n = 5), toda
s do sexo feminino, foram avaliadas com dosagens de glicose e insulina, lípides,
 leptina, enzimas hepáticas, análise de DNA, ultrassonografia abdominal. RESULTA
DOS: A deficiência de leptina e a hipertrigliceridemia foram constatadas nas cin
co pacientes. Três evoluíram para diabetes melito (DM). Quatro tiveram mutação n
o gene AGPAT2 e uma no gene CAV1. CONCLUSÃO: As alterações metabólicas mais prec
oces foram a hipertrigliceridemia e a resistência insulínica, culminando no surg
imento do DM à época da puberdade, sendo as mutações no gene AGPAT2 as mais freq
uentes em nossa casuística.#^dnd^i1#^tm^lpt^kLipodistrofia congênita generalizad
a^i1#^tm^lpt^khipertrigliceridemia^i1#^tm^lpt^khipercolesterolemia^i1#^tm^lpt^kr
esistência à insulina^i1#^tm^lpt^kdiabetes melito^i1#^tm^lpt^kleptina^i1#^len^aO
BJECTIVE: To report the genetic and metabolic profile of patients with Berardine
lli-Seip syndrome (BSCL) followed at Instituto da Criança, HC-FMUSP. SUBJECTS AN
D METHODS: Patients with clinical features of BSCL (n = 5), all female, were eva
luated through serum levels of glucose, insulin, lipids, leptin, and liver enzym
es. Abdominal sonography and DNA analysis were also performed. RESULTS: Leptin d
eficiency and hypertriglyceridemia were found in all the patients. Three progres
sed to diabetes mellitus. Four patients have mutations in AGPAT2 gene and one ha
ve a mutation in CAV1 gene. CONCLUSION: The earliest metabolic abnormalities wer
e hypertriglyceridemia and insulin resistance, culminating in the onset of diabe
tes at the time of puberty. Mutations in the AGPAT2 gene were the most frequent 
in our patients.#^dnd^i2#^tm^len^kCongenital generalized lipodystrophy^i2#^tm^le
n^khypertriglyceridemia^i2#^tm^len^khypercholesterolemia^i2#^tm^len^kinsulin res
istance^i2#^tm^len^kdiabetes mellitus^i2#^tm^len^kleptin^i2#other#39#20100530#30
/Mail/2010#20101227#27/Dez/2010#07.htm#Internet^ihttp://www.scielo.br/scielo.php
?script=sci_arttext&pid=S0004-27302011000100007##
00343000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704012200068002000700190#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#5#1#article#156#<p align="right"><font face
="Verdana, Arial, Helvetica, sans-serif" size="2"><b>ARTIGO    ORIGINAL</b></fon
t></p>     ^cY#07.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704002200068002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#6#2#article#156#<p>&nbsp;</p>     ^cY#07.ht
m##
00451000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704023000068002000700298#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#7#3#article#156#<p><a name="top"></a><font 
face="Verdana, Arial, Helvetica, sans-serif" size="4"><b>S&iacute;ndrome    de B
erardinelli-Seip: descri&ccedil;&atilde;o gen&eacute;tica e metab&oacute;lica   
 de cinco pacientes</b></font></p>     ^cY#07.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704002200068002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#8#4#article#156#<p>&nbsp;</p>     ^cY#07.ht
m##
00396000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704017500068002000700243#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#9#5#article#156#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="3"><b>Genetic and    metabolic description of f
ive patients with Berardinelli-Seip syndrome</b></font></p>     ^cY#07.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000400065704002200069002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#10#6#article#156#<p>&nbsp;</p>     ^cY#07.h
tm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000400065704002200069002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#11#7#article#156#<p>&nbsp;</p>     ^cY#07.h
tm##
00549000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000400065704032700069002000700396#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#12#8#article#156#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>Cristiane B.    Barra<sup>I</sup>; Rober
ta D. Savoldelli<sup>I</sup>; Thais D. Manna<sup>I</sup>;    Chong A. Kim<sup>I<
/sup>; Jocelyn Magre<sup>II</sup>; Gilda Porta<sup>I</sup>;    Nuvarte Setian<su
p>I</sup>; Durval Damiani<sup>I</sup></b></font></p>     ^cY#07.htm##
00470000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000400065704024800069002000700317#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#13#9#article#156#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><sup>I</sup>Instituto    da Crian&ccedil;a,
 Hospital das Cl&iacute;nicas, Faculdade de Medicina, Universidade    de S&atild
e;o Paulo (ICr-HC-FMUSP), S&atilde;o Paulo, SP, Brasil    ^cY#07.htm##
00360000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704013700070002000700207#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#14#10#article#156#<br>   <sup>II</sup>INSER
M, Institut National de la Sant&eacute; et de la Recherche    M&eacute;dicale, P
aris, France</font></p>     ^cY#07.htm##
00355000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704013200070002000700202#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#15#11#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><a href="#back">Correspond&ecirc;ncia    p
ara</a></font></p>     ^cY#07.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#16#12#article#156#<p>&nbsp;</p>     ^cY#07.
htm##
00267000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704004400070002000700114#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#17#13#article#156#<p>&nbsp;</p> <hr size="1
" noshade>     ^cY#07.htm##
00319000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704009600070002000700166#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#18#14#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>RESUMO</b></font></p>     ^cY#07.htm##
00489000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704026600070002000700336#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#19#15#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>OBJETIVO:</b>    Descrever o perfil gen
&eacute;tico e metab&oacute;lico de portadores da s&iacute;ndrome    de Berardin
elli-Seip (BSCL) acompanhados no Instituto da Crian&ccedil;a do HC-FMUSP.    ^cY
#07.htm##
00531000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704030800070002000700378#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#20#16#article#156#<br>   <b>SUJEITOS E M&Ea
cute;TODOS:</b> Pacientes com as caracter&iacute;sticas cl&iacute;nicas    da BS
CL (n = 5), todas do sexo feminino, foram avaliadas com dosagens de glicose    e
 insulina, l&iacute;pides, leptina, enzimas hep&aacute;ticas, an&aacute;lise    
de DNA, ultrassonografia abdominal.    ^cY#07.htm##
00507000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704028400070002000700354#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#21#17#article#156#<br>   <b>RESULTADOS:</b>
 A defici&ecirc;ncia de leptina e a hipertrigliceridemia foram    constatadas na
s cinco pacientes. Tr&ecirc;s evolu&iacute;ram para diabetes melito    (DM). Qua
tro tiveram muta&ccedil;&atilde;o no gene <i>AGPAT2</i> e uma no gene    <i>CAV1
</i>.&nbsp;    ^cY#07.htm##
00582000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704035900070002000700429#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#22#18#article#156#<br>   <b>CONCLUS&Atilde;
O:</b> As altera&ccedil;&otilde;es metab&oacute;licas mais    precoces foram a h
ipertrigliceridemia e a resist&ecirc;ncia insul&iacute;nica,    culminando no su
rgimento do DM &agrave; &eacute;poca da puberdade, sendo as    muta&ccedil;&otil
de;es no gene <i>AGPAT2</i> as mais frequentes em nossa casu&iacute;stica.</font
></p>     ^cY#07.htm##
00503000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704028000070002000700350#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#23#19#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Descritores:    </b> Lipodistrofia cong
&ecirc;nita generalizada; hipertrigliceridemia; hipercolesterolemia;    resist&e
circ;ncia &agrave; insulina; diabetes melito; leptina</font></p> <hr size="1" no
shade>     ^cY#07.htm##
00321000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704009800070002000700168#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#24#20#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>ABSTRACT</b></font></p>     ^cY#07.htm#
#
00463000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704024000070002000700310#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#25#21#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>OBJECTIVE:</b>    To report the genetic
 and metabolic profile of patients with Berardinelli-Seip    syndrome (BSCL) fol
lowed at Instituto da Crian&ccedil;a, HC-FMUSP.    ^cY#07.htm##
00488000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704026500070002000700335#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#26#22#article#156#<br>   <b>SUBJECTS AND ME
THODS:</b> Patients with clinical features of BSCL (n = 5),    all female, were 
evaluated through serum levels of glucose, insulin, lipids,    leptin, and liver
 enzymes. Abdominal sonography and DNA analysis were also performed.        ^cY#
07.htm##
00480000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704025700070002000700327#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#27#23#article#156#<br>   <b>RESULTS:</b> Le
ptin deficiency and hypertriglyceridemia were found in all    the patients. Thre
e progressed to <i>diabetes mellitus.</i> Four patients have    mutations in <i>
AGPAT2</i> gene and one have a mutation in <i>CAV1</i> gene.        ^cY#07.htm##
00498000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704027500070002000700345#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#28#24#article#156#<br>   <b>CONCLUSION:</b>
 The earliest metabolic abnormalities were hypertriglyceridemia    and insulin r
esistance, culminating in the onset of diabetes at the time of    puberty. Mutat
ions in the <i>AGPAT2</i> gene were the most frequent in our patients.</font></p
>     ^cY#07.htm##
00484000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704026100070002000700331#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#29#25#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Keywords:</b>    Congenital generalized
 lipodystrophy; hypertriglyceridemia; hypercholesterolemia;    insulin resistanc
e;<i>diabetes mellitus</i>; leptin</font></p> <hr size="1" noshade>     ^cY#07.h
tm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#30#26#article#156#<p>&nbsp;</p>     ^cY#07.
htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#31#27#article#156#<p>&nbsp;</p>     ^cY#07.
htm##
00337000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704011400070002000700184#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#32#28#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="3"><b>INTRODU&Ccedil;&Atilde;O</b></font></p>
     ^cY#07.htm##
01022000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704079900070002000700869#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#33#29#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">A s&iacute;ndrome    de Berardinelli-Seip 
ou lipodistrofia cong&ecirc;nita generalizada (BSCL, MIM    #269700) caracteriza
-se clinicamente pela redu&ccedil;&atilde;o extrema da quantidade    de tecido a
diposo, cursando com facies grosseira, hipertrofia muscular, m&atilde;os    e p&
eacute;s grandes, acantose <i>nigricans</i>, hepatomegalia, hipertrigliceridemia
,    esteatose hep&aacute;tica, grave resist&ecirc;ncia &agrave; insulina, toler
&acirc;ncia    alterada &agrave; glicose ou diabetes melito e aterosclerose de i
n&iacute;cio    precoce (1-3). Sua preval&ecirc;ncia &eacute; baixa, de aproxima
damente 1:10.000.000    nascidos vivos, mas acredita-se que, de cada quatro caso
s, apenas um seja relatado    (3).</font></p>     ^cY#07.htm##
01049000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704082600070002000700896#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#34#30#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">A BSCL foi descrita    primeiramente por B
erardinelli em 1954 (2), em um paciente brasileiro de 2 anos    de idade e, post
eriormente em 1959, Seip descreveu tr&ecirc;s pacientes, dois    deles irm&atild
e;os, com as mesmas caracter&iacute;sticas cl&iacute;nicas (4,5).    Brunzell e 
cols. em 1968 (6), observando a recorr&ecirc;ncia de casos em fam&iacute;lias   
 consangu&iacute;neas, sugeriram a exist&ecirc;ncia de uma transmiss&atilde;o   
 autoss&ocirc;mica recessiva e relataram casos que combinavam a lipodistrofia   
 cong&ecirc;nita generalizada, a angiomatose c&iacute;stica no tecido subcut&aci
rc;neo    e em ossos longos, como tamb&eacute;m os ov&aacute;rios polic&iacute;s
ticos,    caracterizando a s&iacute;ndrome de Brunzell (6,7).</font></p>     ^cY
#07.htm##
01086000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704086300070002000700933#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#35#31#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Dos tr&ecirc;s    genes j&aacute; relacion
ados &agrave; BSCL, dois encontram-se mutados em aproximadamente    95% dos caso
s: o gene <i>BSCL1</i> ou <i>AGPAT2</i> localizado em 9q34 (MIM*603100)    codif
ica uma prote&iacute;na da fam&iacute;lia das aciltransferases, que &eacute;    
a enzima 1-acilglicerol-3-fosfato-0-aciltransferase-2, fundamental para a bioss&
iacute;ntese    de glicerofosfolip&iacute;deos e triacilglicerol (8), e o gene <
i>BSCL2</i>    localizado em 11q13 codifica a prote&iacute;na denominada <i>seip
ina</i> (MIM*606158).    Recentemente, a BSCL foi associada a uma nova muta&cced
il;&atilde;o no gene    <i>CAV1</i> localizado em 7q31 (MIM<sup>#</sup>612526), 
que codifica uma prote&iacute;na    constitutiva da membrana plasm&aacute;tica, 
a caveolina-1 (9).</font></p>     ^cY#07.htm##
00723000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704050000070002000700570#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#36#32#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">O d&eacute;ficit    de tecido adiposo e co
nsequentemente da leptina, que &eacute; um horm&ocirc;nio    produzido nos adip&
oacute;citos com importante fun&ccedil;&atilde;o metab&oacute;lica,    parece ex
ercer papel fundamental na fisiopatologia da resist&ecirc;ncia insul&iacute;nica
,    do diabetes melito, da esteatose hep&aacute;tica e da dislipidemia com marc
ante    hipertrigliceridemia presentes na BSCL (10-12).</font></p>     ^cY#07.ht
m##
00791000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704056800070002000700638#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#37#33#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">O objetivo deste    estudo &eacute; descre
ver o perfil gen&eacute;tico e metab&oacute;lico de cinco    pacientes portadora
s da BSCL acompanhadas no ambulat&oacute;rio de Endocrinologia    Pedi&aacute;tr
ica do Instituto da Crian&ccedil;a do Hospital das Cl&iacute;nicas    da Faculda
de de Medicina da Universidade de S&atilde;o Paulo (ICr-HC-FMUSP)    a fim de am
pliar a discuss&atilde;o e o conhecimento sobre essa doen&ccedil;a    grave, rar
a e ainda sem tratamento espec&iacute;fico.</font></p>     ^cY#07.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#38#34#article#156#<p>&nbsp;</p>     ^cY#07.
htm##
00342000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704011900070002000700189#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#39#35#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="3"><b>PACIENTES E    M&Eacute;TODOS</b></font
></p>     ^cY#07.htm##
01267000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704104400070002000701114#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#40#36#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Cinco pacientes,    sendo duas irm&atilde;
s, acompanhados regularmente em nosso ambulat&oacute;rio    com caracter&iacute;
sticas cl&iacute;nicas compat&iacute;veis com BSCL, foram    avaliados laborator
ialmente com dosagens s&eacute;ricas de glicose (hexoquinase    UV, valor de ref
er&ecirc;ncia (VR) entre 70-99 mg/dl) e insulina de jejum (ensaio    imunofluori
m&eacute;trico, VR &lt;25 </font><font size="2">&#956;</font><font face="Verdana
, Arial, Helvetica, sans-serif" size="2">U/ml    - PerkinElmer, Waltham, USA), c
olesterol total e fra&ccedil;&otilde;es, triglic&eacute;rides    (ensaio enzim&a
acute;tico, VR: CT&lt; 200 mg/dl; LDL <u>&lt;</u> 130 mg/dl,    HDL &gt; 40 mg/d
l, TG &lt;150 mg/dl) (13), enzimas hep&aacute;ticas (IFCC UV,    Kinetic - ALT: 
19-44 U/L, AST: 5-26 U/L) e leptina (ensaio imunoenzim&aacute;tico,    VR 3,7-11
,1 ng/ml - Millipore, Billerica, USA). O volume hep&aacute;tico foi    avaliado 
por meio de ultrassonografia de abdome.</font></p>     ^cY#07.htm##
00808000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704058500070002000700655#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#41#37#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Foi considerada    como resist&ecirc;ncia 
insul&iacute;nica uma rela&ccedil;&atilde;o entre glicose    e insulina de jejum
 menor do que 7 (glicemia mg/dl &divide; insulina </font><font size="2">&#956;</
font><font face="Verdana, Arial, Helvetica, sans-serif" size="2">U/ml    &lt; 7)
 (14) e &iacute;ndice de HOMA<sub>IR</sub> &#91;glicose (mmol/L) x insulina    (
</font><font size="2">&#956;</font><font face="Verdana, Arial, Helvetica, sans-s
erif" size="2">U/ml)&#93;    &divide; 22,5 &gt; 2,9 (15,16).</font></p>     ^cY#
07.htm##
00717000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704049400070002000700564#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#42#38#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">O DNA gen&ocirc;mico    extra&iacute;do de
 sangue perif&eacute;rico foi amplificado pela PCR usando    os <i>primers</i> e
spec&iacute;ficos de &eacute;xons dos genes de <i>AGPAT1</i>    e <i>CAV1</i>, s
eguindo a metodologia publicada por Magr&eacute; e cols. em    2003 (17) e por K
im e cols. na primeira descri&ccedil;&atilde;o da paciente    portadora da muta&
ccedil;&atilde;o no gene <i>CAV1</i> em 2008 (9).</font></p>     ^cY#07.htm##
00462000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704023900070002000700309#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#43#39#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Os produtos da    PCR foram purificados us
ando coluna Sephadex e, em seguida, sequenciados pelo    Big Dye Terminator (App
lied Biosystems, Foster City, CA).</font></p>     ^cY#07.htm##
00623000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704040000070002000700470#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#44#40#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Todas as pacientes    ou respons&aacute;ve
is assinaram termo de consentimento livre e esclarecido    para realiza&ccedil;&
atilde;o do estudo gen&eacute;tico e o estudo transcorreu    de acordo com as no
rmas estabelecidas pela Comiss&atilde;o de &Eacute;tica para    An&aacute;lise d
e Projetos de Pesquisa do HC-FMUSP.</font></p>     ^cY#07.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#45#41#article#156#<p>&nbsp;</p>     ^cY#07.
htm##
00323000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704010000070002000700170#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#46#42#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="3"><b>RESULTADOS</b></font></p>     ^cY#07.ht
m##
00610000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704038700070002000700457#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#47#43#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Todas as cinco    pacientes inclu&iacute;d
as eram do sexo feminino. A idade variou entre 8,3 e    23 anos. Os principais a
chados cl&iacute;nicos e laboratoriais s&atilde;o apresentados    nas <a href="/
img/revistas/abem/v55n1/07t01.jpg">tabelas 1</a> e <a href="/img/revistas/abem/v
55n1/07t02.jpg">2</a>.</font></p>     ^cY#07.htm##
00538000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704031500070002000700385#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#48#44#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">As quatro fam&iacute;lias    eram proceden
tes da regi&atilde;o nordeste do Brasil, dos estados da Bahia,    Cear&aacute; e
 Pernambuco, havendo consanguinidade em todas elas; os pais em    todos os casos
 eram primos em primeiro grau.</font></p>     ^cY#07.htm##
00532000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704030900070002000700379#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#49#45#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Todas as pacientes    apresentavam caracte
r&iacute;sticas cl&iacute;nicas evidentes da BSCL, como    escassez de tecido ad
iposo nas regi&otilde;es de tronco, abdome e membros com    hipertrofia muscular
, mesmo nas mais jovens.</font></p>     ^cY#07.htm##
01038000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704081500070002000700885#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#50#46#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">A an&aacute;lise    do DNA evidenciou muta
&ccedil;&atilde;o do gene <i>AGPAT2</i> em quatro casos,    que apresentaram uma
 dele&ccedil;&atilde;o dos &eacute;xons 3 e 4 em homozigose    (del 317-588). Em
 uma paciente, descrita detalhadamente por Kim e cols. em 2008    (9), foi ident
ificada a muta&ccedil;&atilde;o em homozigose do gene <i>CAV1,</i>    na qual um
a troca de nucleot&iacute;deo c.112G</font><font size="2">&#8594;</font><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">T    levou &agrave; substitu
i&ccedil;&atilde;o de um &aacute;cido glut&acirc;mico    na posi&ccedil;&atilde;
o 38 por um stop c&oacute;don (p.Glu38X), sendo essa    a primeira associa&ccedi
l;&atilde;o do gene <i>CAV1</i> &agrave; BSCL (9).</font></p>     ^cY#07.htm##
00881000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704065800070002000700728#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#51#47#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">A defici&ecirc;ncia    de leptina foi obse
rvada em todas as cinco pacientes. Tr&ecirc;s delas evolu&iacute;ram    para dia
betes melito de dif&iacute;cil controle mesmo com uso de altas doses    de insul
ina. A m&eacute;dia de idade ao diagn&oacute;stico do diabetes foi de    13,5 an
os (13a, 13a6m e 14a). As outras duas pacientes apresentaram glicemia    de jeju
m normal, por&eacute;m com rela&ccedil;&atilde;o glicemia/insulina &lt;    7 e &
iacute;ndice HOMA<sub>IR</sub> &gt; 2,9, evidenciando resist&ecirc;ncia    insul
&iacute;nica e hiperinsulinismo compensat&oacute;rio.</font></p>     ^cY#07.htm#
#
01061000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704083800070002000700908#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#52#48#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">A altera&ccedil;&atilde;o    metab&oacute;
lica encontrada em maior frequ&ecirc;ncia foi a hipertrigliceridemia,    evident
e nos cinco casos, com valores variando entre 349 a 3.187 mg/dl (M&plusmn;DP:   
 1148,2 &plusmn; 1168,2). Duas apresentaram n&iacute;veis elevados de LDL (LDL  
  57-175 mg/dl; M &plusmn; DP: 86,5 &plusmn; 62,4) e apenas uma tinha n&iacute;v
eis    normais de HDL (HDL: 20-55 mg/dl; M &plusmn; DP: 34,2 &plusmn; 14,97). A 
ultrassonografia    de abdome mostrou hepatomegalia em um dos casos. Das cinco p
acientes, tr&ecirc;s    j&aacute; foram submetidas &agrave; ultrassonografia com
 Doppler das art&eacute;rias    car&oacute;tidas e n&atilde;o foram evidenciados
 altera&ccedil;&otilde;es vasculares    ou sinais de placas ateromatosas.</font>
</p>     ^cY#07.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#53#49#article#156#<p>&nbsp;</p>     ^cY#07.
htm##
00329000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704010600070002000700176#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#54#50#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="3"><b>DISCUSS&Atilde;O</b></font></p>     ^cY
#07.htm##
01045000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704082200070002000700892#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#55#51#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Muta&ccedil;&otilde;es    no gene <i>AGPAT
2</i> (BSCL1, MIM*603100) foram as mais frequentes em nosso    estudo, sendo enc
ontradas em quatro das cinco pacientes. Esse dado &eacute;    condizente com a l
iteratura que mostra uma maior preval&ecirc;ncia dessa muta&ccedil;&atilde;o    
no sexo feminino (18). A associa&ccedil;&atilde;o de muta&ccedil;&otilde;es    d
o gene <i>AGPAT2</i> com a BSCL foi primeiramente relatada por Agarwal e cols.  
  em 2002 (19), que descreveram dez muta&ccedil;&otilde;es em homozigose e heter
ozigose    composta em 11 fam&iacute;lias de predomin&acirc;ncia afro-americana.
 Por outro    lado, muta&ccedil;&otilde;es no gene da seipina (<i>BSCL2</i>, MIM
 606158) n&atilde;o    foram encontradas em nossos casos.</font></p>     ^cY#07.
htm##
01543000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704132000070002000701390#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#56#52#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Em uma das pacientes,    foi identificada 
uma muta&ccedil;&atilde;o homozig&oacute;tica no gene <i>CAV1</i>    (BSCL3, MIM
<sup>#</sup>601047) (9). Ela evoluiu para diabetes melito aos 13    anos, com di
f&iacute;cil controle glic&ecirc;mico apesar da insulinoterapia    intensiva. At
ualmente com 23 anos, possui tamb&eacute;m uma importante hipertrigliceridemia  
  (610 mg/dl), fazendo uso regular de fibrato e estatina. Alguns trabalhos suger
em    que a muta&ccedil;&atilde;o do <i>CAV1</i> pode estar relacionada &agrave;
 resist&ecirc;ncia    ao IGF-1 (20); apesar de nossa paciente apresentar baixa e
statura (z-score =    -2,81), n&atilde;o houve altera&ccedil;&otilde;es evidente
s no eixo GH-IGF-1.    Ela nasceu a termo com comprimento de 45 cm e peso de 2.5
00 g. A altura da m&atilde;e    &eacute; de 168 cm, n&atilde;o sendo poss&iacute
;vel determinar o alvo familiar,    uma vez que n&atilde;o existe informa&ccedil
;&atilde;o precisa sobre a altura    do pai, j&aacute; falecido. Os n&iacute;vei
s basais de GH = 1,1 ng/ml (m&eacute;todo    imunofluorim&eacute;trico " autoDEL
FIA) e de IGF-1 = 193 ng/ml (valor de refer&ecirc;ncia:    116-358; pelo m&eacut
e;todo imunoquimioluminom&eacute;trico"DPC&nbsp;immulite)    foram normais.</fon
t></p>     ^cY#07.htm##
01150000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704092700070002000700997#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#57#53#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">A muta&ccedil;&atilde;o    encontrada com 
maior frequ&ecirc;ncia em nosso estudo foi a dele&ccedil;&atilde;o    dos &eacut
e;xons 3 e 4 do gene <i>AGPAT2</i> em homozigose (del 317-588), que    j&aacute;
 havia sido previamente descrita na popula&ccedil;&atilde;o brasileira    por Go
mes e cols. (22) em 10 indiv&iacute;duos provenientes de Minas Gerais    e em um
 indiv&iacute;duo estudado por Fu e cols. (23) Anteriormente, Agarwal    e cols.
 (19) j&aacute; haviam descrito a mesma muta&ccedil;&atilde;o em uma    popula&c
cedil;&atilde;o de origem portuguesa. Em nosso estudo, as fam&iacute;lias    das
 tr&ecirc;s pacientes que apresentaram essa muta&ccedil;&atilde;o eram provenien
tes    de estados diferentes, e n&atilde;o foram realizadas an&aacute;lises comp
lementares    que pudessem sugerir um efeito fundador dessa muta&ccedil;&atilde;
o.</font></p>     ^cY#07.htm##
00847000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704062400070002000700694#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#58#54#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Outras muta&ccedil;&otilde;es    no gene <
i>AGPAT2</i> foram descritas em indiv&iacute;duos brasileiros por Fu    e cols. 
(23) em heterozigose composta (IVS3-1G&gt;C e p.Phe189X) e mais recentemente    
por Miranda e cols. (24), que identificaram quatro fam&iacute;lias apresentando 
   a mesma muta&ccedil;&atilde;o em homozigose (IVS3-1G&gt;C), das quais duas ap
resentavam    tamb&eacute;m outra muta&ccedil;&atilde;o no mesmo gene (c.299G&gt
;A), ambas    j&aacute; descritas anteriormente em popula&ccedil;&otilde;es euro
peias e argentinas.</font></p>     ^cY#07.htm##
00976000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704075300070002000700823#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#59#55#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Em seu estudo,    Gomes e cols. (22) avali
aram 22 pacientes provenientes do Rio Grande do Norte    e em todos eles o gene 
da seipina encontrou-se mutado (<i>669insA</i>). Fu e    cols. (23) tamb&eacute;
m avaliaram 18 indiv&iacute;duos de 15 fam&iacute;lias    provenientes de uma re
gi&atilde;o localizada no Rio Grande do Norte e todos    apresentavam a mesma mu
ta&ccedil;&atilde;o no gene da seipina, com grande probabilidade    de que essa 
muta&ccedil;&atilde;o seja decorrente de um gene fundador de origem    portugues
a, o que sugere a exist&ecirc;ncia de uma regionaliza&ccedil;&atilde;o    de alg
umas das diferentes muta&ccedil;&otilde;es associadas &agrave; BSCL.</font></p> 
    ^cY#07.htm##
00726000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704050300070002000700573#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#60#56#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">As altera&ccedil;&otilde;es    metab&oacut
e;licas inicialmente observadas em nossas pacientes foram a hipertrigliceridemia
    e a resist&ecirc;ncia insul&iacute;nica. Das cinco pacientes estudadas, toda
s    apresentaram n&iacute;veis elevados de triglic&eacute;rides (349-3.187 mg/d
l).    Resist&ecirc;ncia insul&iacute;nica com hiperinsulinismo foi observada em
 duas    pacientes e diabetes melito em outras tr&ecirc;s.</font></p>     ^cY#07
.htm##
00965000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704074200070002000700812#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#61#57#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Em estudo publicado    por Beltrand e cols
. (11), das sete crian&ccedil;as estudadas, seis meninos    e uma menina com ida
de que variou de 2,4 a 13,6 anos, todos apresentaram glicemia    de jejum normal
, mas com n&iacute;veis elevados de insulina plasm&aacute;tica    (91,2-307,2 pm
ol/L). A hipertrigliceridemia foi observada nas cinco pacientes.    No Brasil, o
utros grupos descreveram perfis metab&oacute;licos semelhantes em    seus pacien
tes com BSCL. Figueiredo Filho e cols. (25) encontraram hipertrigliceridemia    
em sete dos oito pacientes avaliados com idades entre 3 meses e 19 anos. Todos  
  apresentavam n&iacute;veis baixos de HDL (19-35 mg/dl).</font></p>     ^cY#07.
htm##
00972000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704074900070002000700819#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#62#58#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Na hist&oacute;ria    natural da BSCL, a m
aioria dos pacientes evolui para dislipidemia com hipertrigliceridemia    acentu
ada e resist&ecirc;ncia insul&iacute;nica culminando no quadro de diabetes    me
lito insulinorresistente ao longo do tempo. O in&iacute;cio do desequil&iacute;b
rio    glic&ecirc;mico geralmente ocorre no in&iacute;cio da puberdade, em torno
 dos    8 a 10 anos de idade, com diminui&ccedil;&atilde;o da toler&acirc;ncia &
agrave;    glicose e concomitante aumento da resist&ecirc;ncia insul&iacute;nica
, proporcionalmente    ao avan&ccedil;o da idade. A instala&ccedil;&atilde;o do 
diabetes acontece frequentemente    a partir dos 10 anos (3,25).</font></p>     
^cY#07.htm##
01299000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704107600070002000701146#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#63#59#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Em nossas tr&ecirc;s    pacientes, houve c
oincid&ecirc;ncia entre a instala&ccedil;&atilde;o do diabetes    e a puberdade,
 &eacute;poca em que se desenvolve um processo tempor&aacute;rio    e fisiol&oac
ute;gico de maior resist&ecirc;ncia &agrave; insulina. Isso parece    acontecer,
 pelo menos em parte, em decorr&ecirc;ncia da maior oxida&ccedil;&atilde;o    de
 gordura na puberdade que teria rela&ccedil;&atilde;o com os n&iacute;veis    s&
eacute;ricos aumentados de IGF-1 associados &agrave; maior secre&ccedil;&atilde;
o    de GH. A sensibilidade &agrave; insulina parece ser maior antes do in&iacut
e;cio    da puberdade, atingindo seu nadir na metade do desenvolvimento e retorn
a aos    valores pr&eacute;-puberais ao final da matura&ccedil;&atilde;o sexual 
(26).    O desequil&iacute;brio metab&oacute;lico concomitante a essas altera&cc
edil;&otilde;es    fisiol&oacute;gicas parece ser o gatilho para o aparecimento 
do diabetes melito    nesta faixa et&aacute;ria nas pacientes com BSCL.</font></
p>     ^cY#07.htm##
01225000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704100200070002000701072#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#64#60#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">J&aacute; a origem    das dislipidemias ai
nda &eacute; muito discutida, mas sem d&uacute;vida baseia-se    na adipog&ecirc
;nese deficit&aacute;ria que restringe a capacidade de metabolismo    e armazena
mento lip&iacute;dico dos quais o adip&oacute;cito &eacute; o principal    &oacu
te;rg&atilde;o efetor. Dessa forma, na BSCL, h&aacute; um excesso de l&iacute;pi
des    circulantes que ir&atilde;o se depositar em outros tecidos, como musculoe
squel&eacute;tico,    mioc&aacute;rdio, f&iacute;gado (gordura ect&oacute;pica),
 excedendo sua capacidade    oxidativa e de armazenagem, evidenciados pela inten
sa hipertrigliceridemia e    esteatose hep&aacute;tica. Muitos estudos defendem 
a hip&oacute;tese de que    o ac&uacute;mulo de triglic&eacute;rides nessas c&ea
cute;lulas sens&iacute;veis    &agrave; insulina interfere na sua sinaliza&ccedi
l;&atilde;o e consequentemente    na sensibilidade insul&iacute;nica (27,28).</f
ont></p>     ^cY#07.htm##
00967000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704074400070002000700814#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#65#61#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">As adipocinas,    horm&ocirc;nios pept&iac
ute;dicos secretados pelos adip&oacute;citos, tamb&eacute;m    parecem contribui
r de forma fundamental para a resist&ecirc;ncia insul&iacute;nica    e dislipide
mia. Na avalia&ccedil;&atilde;o das nossas cinco pacientes, todas    apresentara
m valores de leptina abaixo do limite inferior do valor de refer&ecirc;ncia    u
tilizado. Em virtude da escassez de tecido adiposo, a hipoleptinemia est&aacute;
    presente em praticamente todos os portadores da BSCL, independentemente de s
eu    &iacute;ndice da massa corp&oacute;rea (IMC), uma vez que esse &iacute;ndi
ce    reflete tamb&eacute;m a massa corporal magra (10,29).</font></p>     ^cY#0
7.htm##
01500000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704127700070002000701347#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#66#62#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">A leptina funciona    como principal "adip
ostato" na regula&ccedil;&atilde;o da ingesta cal&oacute;rica    e do gasto ener
g&eacute;tico. A ativa&ccedil;&atilde;o de seus receptores no    n&uacute;cleo a
rqueado do hipot&aacute;lamo leva &agrave; repress&atilde;o de    vias orex&iacu
te;genas (neuropept&iacute;deo Y, pept&iacute;deo ligado ao Agouti)    e libera&
ccedil;&atilde;o de vias anorex&iacute;genas (pr&oacute;-opiomelanocortina,    C
ART " transcritos relacionados &agrave; coca&iacute;na e &agrave; anfetamina).  
  Al&eacute;m dessa a&ccedil;&atilde;o regulat&oacute;ria do apetite e termog&ec
irc;nese,    a leptina tamb&eacute;m atua na regula&ccedil;&atilde;o do metaboli
smo de glicose    (via fosfatidil inositol-3-quinase) e reduz o ac&uacute;mulo d
e triglicer&iacute;deos    nos hepat&oacute;citos (30) e c&eacute;lulas muscular
es esquel&eacute;ticas,    melhorando a sensibilidade &agrave; insulina, e parec
e modular a atividade de    c&eacute;lulas beta-pancre&aacute;ticas (31). A manu
ten&ccedil;&atilde;o da    homeostase normal dos &aacute;cidos graxos fora dos a
dip&oacute;citos tamb&eacute;m    pode requerer a conten&ccedil;&atilde;o da lip
og&ecirc;nese pela leptina (32).</font></p>     ^cY#07.htm##
00605000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704038200070002000700452#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#67#63#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Portanto, &eacute;    muito prov&aacute;ve
l que a defici&ecirc;ncia da leptina exer&ccedil;a um papel    muito importante 
na fisiopatologia de aspectos cl&iacute;nicos e metab&oacute;licos    presentes 
na BSCL, como o apetite voraz, a resist&ecirc;ncia insul&iacute;nica    e a hipe
rtrigliceridemia.</font></p>     ^cY#07.htm##
00944000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704072100070002000700791#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#68#64#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">A abordagem terap&ecirc;utica    atual res
ume-se ao controle das complica&ccedil;&otilde;es cr&ocirc;nicas comuns    &agra
ve; BSCL. Drogas como a metformina, estatinas e fibratos podem melhorar    a res
ist&ecirc;ncia insul&iacute;nica, a hipercolesterolemia e a hipertrigliceridemia
,    mas n&atilde;o impedem a evolu&ccedil;&atilde;o para o diabetes melito, a c
irrose    hep&aacute;tica e as complica&ccedil;&otilde;es cardiovasculares, que 
podem    culminar em eventos fatais numa fase precoce da vida. Entretanto, muito
 ainda    se discute quanto &agrave; seguran&ccedil;a das drogas hipolipemiantes
 na inf&acirc;ncia    (33-35).&nbsp;</font></p>     ^cY#07.htm##
02019000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704179600070002000701866#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#69#65#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Tendo em vista    a import&acirc;ncia da l
eptina na fisiopatologia dos principais dist&uacute;rbios    metab&oacute;licos 
encontrados na BSCL, alguns grupos analisaram a reposi&ccedil;&atilde;o    de le
ptina humana recombinante como forma de interferir nesta evolu&ccedil;&atilde;o 
   (11,36-39). Oral e cols. (37) observaram que a reposi&ccedil;&atilde;o da lep
tina    recombinante por doze meses melhorou a sensibilidade &agrave; insulina, 
com    redu&ccedil;&atilde;o da glicemia de jejum e da hemoglobina glicada, have
ndo    tamb&eacute;m uma redu&ccedil;&atilde;o do aporte cal&oacute;rico por mei
o de    um maior controle do apetite. Neste estudo, a melhora da a&ccedil;&atild
e;o    da insulina esteve associada a uma redu&ccedil;&atilde;o importante do co
nte&uacute;do    lip&iacute;dico hep&aacute;tico e muscular. Beltrand e cols. (1
1), utilizando    leptina humana recombinante por 6 meses, em sete crian&ccedil;
as n&atilde;o    diab&eacute;ticas com BSCL, evidenciaram melhora na sensibilida
de insul&iacute;nica,    redu&ccedil;&atilde;o dos n&iacute;veis de triglic&eacu
te;rides e do volume    hep&aacute;tico em 30%, 63% e 20,3% dos casos, respectiv
amente. Chong e cols.    (38) relataram que a reposi&ccedil;&atilde;o de leptina
 recombinante &eacute;    capaz de manter os benef&iacute;cios metab&oacute;lico
s tanto no controle glic&ecirc;mico    quanto na dislipidemia a longo prazo, em 
adultos. Por outro lado, Beltrand e    cols. (39) demonstraram recentemente que 
alguns pacientes podem desenvolver    resist&ecirc;ncia parcial ou total aos efe
itos metab&oacute;licos desse tratamento    devido &agrave; presen&ccedil;a de a
nticorpos neutralizantes direcionados &agrave;    leptina recombinante.</font></
p>     ^cY#07.htm##
00844000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704062100070002000700691#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#70#66#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Neste estudo, conclu&iacute;mos    que o p
erfil metab&oacute;lico das cinco pacientes condiz com os principais    dados da
 literatura referentes &agrave;s caracter&iacute;sticas da BSCL como    a hipole
ptinemia, hipertrigliceridemia associadas a baixos n&iacute;veis de    HDL e imp
ortante resist&ecirc;ncia insul&iacute;nica evoluindo para diabetes    melito na
 fase da puberdade. A del 317-588 no gene <i>AGPAT2</i> foi observada    em quat
ro casos e a muta&ccedil;&atilde;o p.Glu38X no gene <i>CAV1</i> foi descrita    
em uma paciente.</font></p>     ^cY#07.htm##
00408000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704018500070002000700255#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#71#67#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Declara&ccedil;&atilde;o:    Os autores de
claram n&atilde;o haver conflitos de interesse neste estudo.</font></p>     ^cY#
07.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#72#68#article#156#<p>&nbsp;</p>     ^cY#07.
htm##
00330000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704010700070002000700177#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#73#69#article#156#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="3"><b>REFER&Ecirc;NCIAS</b></font></p>     ^c
Y#07.htm##
00438000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704020100072002000700273#v55
n1#V:\SciELO\serial\abem\v55n1\markup\07.htm#S#p#74#70#article#156#1#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">1. Seip M, Trygstad    O. Ge
neralized lipodystrophy, congenital and acquired (lipoatrophy). Acta Paediatr   
 Suppl. 1996;413:2-28.    ^cY#07.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002000070002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#75#71#article#156#</font></p>     ^cY#07.ht
m##
00437000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704020000072002000700272#v55
n1#V:\SciELO\serial\abem\v55n1\markup\07.htm#S#p#76#72#article#156#2#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">2. Berardinelli    W. An und
iagnosed endocrinometabolic syndrome: report of 2 cases. J Clin Endocrinol    Me
tab. 1954;14:193-204.    ^cY#07.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002000070002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#77#73#article#156#</font></p>     ^cY#07.ht
m##
00395000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704015800072002000700230#v55
n1#V:\SciELO\serial\abem\v55n1\markup\07.htm#S#p#78#74#article#156#3#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">3. Garg A. Acquired    and i
nherited lipodystrophies. New Engl J Med. 2004;350:1220-34.    ^cY#07.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002000070002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#79#75#article#156#</font></p>     ^cY#07.ht
m##
00452000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704021500072002000700287#v55
n1#V:\SciELO\serial\abem\v55n1\markup\07.htm#S#p#80#76#article#156#4#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">4. Seip M. Lipodystrophy    
and gigantism with associated endocrine manifestation: a new diencephalic syndro
me?    Acta Pediatr. 1959;48:555-74.    ^cY#07.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002000070002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#81#77#article#156#</font></p>     ^cY#07.ht
m##
00392000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704015500072002000700227#v55
n1#V:\SciELO\serial\abem\v55n1\markup\07.htm#S#p#82#78#article#156#5#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">5. Seip M, Trygstad    O. Ge
neralized lipodystrophy. Arch Dis Child. 1963;38:447-53.    ^cY#07.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002000070002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#83#79#article#156#</font></p>     ^cY#07.ht
m##
00532000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704029500072002000700367#v55
n1#V:\SciELO\serial\abem\v55n1\markup\07.htm#S#p#84#80#article#156#6#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">6. Brunzell JD,    Shankle S
W, Bethune JE. Congenital generalized lipodystrophy and systemic cystic    angio
matosis: the simultaneous occurrence of two unusual syndromes in a single    fam
ily. Ann Intern Med. 1968;69:501-16.    ^cY#07.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002000070002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#85#81#article#156#</font></p>     ^cY#07.ht
m##
00564000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704032700072002000700399#v55
n1#V:\SciELO\serial\abem\v55n1\markup\07.htm#S#p#86#82#article#156#7#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">7. Van Maldergem    L, Bacq 
C, Mommen N, Fourneau C, Hilbert P, Gillerot Y. Total lipodystrophy,    polycyst
ic ovaries and cystic angiomatosis of bones (Brunzell syndrome): confirmation   
 of a separate entity. (Abstract) Am J Hum Genet. 1992;51Suppl A109.    ^cY#07.h
tm##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002000070002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#87#83#article#156#</font></p>     ^cY#07.ht
m##
00543000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704030600072002000700378#v55
n1#V:\SciELO\serial\abem\v55n1\markup\07.htm#S#p#88#84#article#156#8#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">8. Haque W, Garg    A, Agarw
al A. Enzimatic activity of naturally occurring 1-acylglycerol-3-phosphate-O-acy
ltransferase    2 mutants associated with congenital generalized lipodystrophy. 
Biochem Biophys    Res Commun. 2005;327:446-53.    ^cY#07.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002000070002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#89#85#article#156#</font></p>     ^cY#07.ht
m##
00532000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704029500072002000700367#v55
n1#V:\SciELO\serial\abem\v55n1\markup\07.htm#S#p#90#86#article#156#9#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">9. Kim CA, Delepine    M, Bo
utet E, El Mourabit H, Lay SL, Meier M, et al. Association of a homozygous    no
nsense caveolin-1 mutation with Berardinelli-Seip congenital lipodystrophy.    J
 Clin Endocr Metab. 2008;93:1129-34.    ^cY#07.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002000070002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#91#87#article#156#</font></p>     ^cY#07.ht
m##
00501000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000300070704026300073002000700336#v55
n1#V:\SciELO\serial\abem\v55n1\markup\07.htm#S#p#92#88#article#156#10#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">10. Jaquet D, Khallouf    E
, L&eacute;vy-Marchal C, Czernichow P. Extremely low values of serum leptin    i
n children with congenital generalized lipoatrophy. Eur J Endocrinol. 1999;140:1
07-9.    ^cY#07.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002000070002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#93#89#article#156#</font></p>     ^cY#07.ht
m##
00557000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000300070704031900073002000700392#v55
n1#V:\SciELO\serial\abem\v55n1\markup\07.htm#S#p#94#90#article#156#11#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">11. Beltrand J,    Beregsza
szi M, Chevenne D, Sebag G, De Kerdanet M, Huet F, et al. Metabolic    correctio
n induced by leptin replacement treatment in young children with Berardinelli-Se
ip    congenital lipoatrophy. Pediatrics. 2007;120(2):e291-6.    ^cY#07.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002000070002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#95#91#article#156#</font></p>     ^cY#07.ht
m##
00462000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000300070704022400073002000700297#v55
n1#V:\SciELO\serial\abem\v55n1\markup\07.htm#S#p#96#92#article#156#12#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">12. Gomes KB, Pardini    VC
, Fernandes AP. Clinical and molecular aspects of Berardinelli-Seip congenital  
  lipodystrophy. Clin Chim Acta. 2009;402:1-6.    ^cY#07.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002000070002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#97#93#article#156#</font></p>     ^cY#07.ht
m##
00414000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000300070704017600073002000700249#v55
n1#V:\SciELO\serial\abem\v55n1\markup\07.htm#S#p#98#94#article#156#13#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">13. Zappalla FR,    Gidding
 SS. Lipid management in children. Endocrinol Metab Clin N Am. 2009;38:171-83.  
  ^cY#07.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002000070002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#99#95#article#156#</font></p>     ^cY#07.ht
m##
00557000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000300056709000800059708000400067888000300071704031800074002000700392#v55
n1#V:\SciELO\serial\abem\v55n1\markup\07.htm#S#p#100#96#article#156#14#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">14. Ibanez L, Potau    N, 
Zampolli M, Prat N, Virdis R, Vicens-Calvet E, et al. Hyperinsulinemia in    pos
tpubertal girls with a history of premature pubarche and functional ovarian    h
yperandrogenism. J Clin Endocrinol Metab. 1996;81(3):1237-43.    ^cY#07.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000300056709000800059708000400067704002000071002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#101#97#article#156#</font></p>     ^cY#07.h
tm##
00558000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000300056709000800059708000400067888000300071704031900074002000700393#v55
n1#V:\SciELO\serial\abem\v55n1\markup\07.htm#S#p#102#98#article#156#15#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">15. Matthews DR,    Hosker
 JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model    assess
ment: insulin resistance and beta-cell function from fasting plasma glucose    a
nd insulin concentrations in man. Diabetologia. 1985;28:412-9.    ^cY#07.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000300056709000800059708000400067704002000071002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#103#99#article#156#</font></p>     ^cY#07.h
tm##
00396000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704015600075002000700231#v55
n1#V:\SciELO\serial\abem\v55n1\markup\07.htm#S#p#104#100#article#156#16#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">16. Bloomgarden    ZT. Me
asures of insulin sensitivity. Clin Lab Med. 2006;26:611-33.    ^cY#07.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#105#101#article#156#</font></p>     ^cY#07.
htm##
00499000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704025900075002000700334#v55
n1#V:\SciELO\serial\abem\v55n1\markup\07.htm#S#p#106#102#article#156#17#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">17. Magr&eacute;    J, De
l&eacute;pine M, Van Maldergem L, Robert J, Maassen JA, Meier M, et al.    Preva
lence of mutations in AGPAT2 among human lipodystrophies. Diabetes. 2003;52:1573
-8.    ^cY#07.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#107#103#article#156#</font></p>     ^cY#07.
htm##
00531000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704029100075002000700366#v55
n1#V:\SciELO\serial\abem\v55n1\markup\07.htm#S#p#108#104#article#156#18#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">18. Val Maldergem    L, M
agr&eacute; J, Khallouf T, Gedde-Dahl T Jr, Del&eacute;pine M, Trygstad    O, et
 al. Genotype-phenotype relationship in Berardinelli-Seip congenital lipodistrop
hy.    J Med Genet. 2002;39:722-33.    ^cY#07.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#109#105#article#156#</font></p>     ^cY#07.
htm##
00509000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704026900075002000700344#v55
n1#V:\SciELO\serial\abem\v55n1\markup\07.htm#S#p#110#106#article#156#19#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">19. Agarwal A,    Ariougl
u E, De Almeida S, Akkoc N, Taylor SI, Bowcock AM, et al. AGPAT2 is mutated    i
n congenital generalized lipodistrophy linked to chromosome 9q34. Nat Genet.    
2002;31:21-3.    ^cY#07.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#111#107#article#156#</font></p>     ^cY#07.
htm##
00535000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704029500075002000700370#v55
n1#V:\SciELO\serial\abem\v55n1\markup\07.htm#S#p#112#108#article#156#20#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">20. Salani B, Briatore   
 L, Garibaldi S, Cordera R, Maggi D. Caveolin-1 Down-regulation inhibits insulin
-like    growth factor-I receptor signal transduction in H9C2 rat cardiomyoblast
s. Endocrinology.    2008;149(2):461-5.    ^cY#07.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#113#109#article#156#</font></p>     ^cY#07.
htm##
00517000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704027700075002000700352#v55
n1#V:\SciELO\serial\abem\v55n1\markup\07.htm#S#p#114#110#article#156#21#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">21. Payne VA, Grimsey    
N, Tuthill A, Virtue S, Gray SL, Dalla Nora E, et al. The lipodistrophy gene    
BSCL2/seipin may be essential for normal adipocyte differentiantion. Diabetes.  
  2008;57(8):2055-60.    ^cY#07.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#115#111#article#156#</font></p>     ^cY#07.
htm##
00613000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704037300075002000700448#v55
n1#V:\SciELO\serial\abem\v55n1\markup\07.htm#S#p#116#112#article#156#22#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">22. Gomes KB, Fernandes  
  AP, Ferreira AC, Pardini H, Garg A, Magr&eacute; J, et al. Mutations in the   
 seipin and AGPAT2 genes clustering in consanguineous families with Berardinelli
-Seip    congenital lipodystrophy from two separate regions of Brazil. J Clin En
docrinol    Metab. 2004;89(1):357-61.    ^cY#07.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#117#113#article#156#</font></p>     ^cY#07.
htm##
00616000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704037600075002000700451#v55
n1#V:\SciELO\serial\abem\v55n1\markup\07.htm#S#p#118#114#article#156#23#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">23. Fu M, Kazlauskaite   
 R, Baracho MFP, Santos MGN, Brand&atilde;o-Neto J, Villares S, et al. Mutations
    in Gng31g and AGPAT2 in Berardinelli-Seip congenital lipodystrophy and Brunz
ell    syndrome: phenotype variability suggests important modifier effects. J Cl
in    Endocrinol Metab. 2004;89:2916-22.    ^cY#07.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#119#115#article#156#</font></p>     ^cY#07.
htm##
00571000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704033100075002000700406#v55
n1#V:\SciELO\serial\abem\v55n1\markup\07.htm#S#p#120#116#article#156#24#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">24. Miranda DM,    Wajche
nberg BL, Calsolari MR, Aguiar MJ, Silva JMCL, Ribeiro MG, et al. Novel    mutat
ions of the BSCL2 and AGPAT2 genes in 10 families with Berardinelli-Seip    cong
enital generalized lipodystrophy syndrome. Clin Endocrinol. 2009;71: 512-7.    ^
cY#07.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#121#117#article#156#</font></p>     ^cY#07.
htm##
00476000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704023600075002000700311#v55
n1#V:\SciELO\serial\abem\v55n1\markup\07.htm#S#p#122#118#article#156#25#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">25. Figueiredo    Filho P
P, Val AC, Diamante R, Cunha CF, Norton RC, Lamounier JA, et al. Lipodistrofia  
  generalizada cong&ecirc;nita. J Pediatr. 2004;80(4):333-6.    ^cY#07.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#123#119#article#156#</font></p>     ^cY#07.
htm##
00457000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704021700075002000700292#v55
n1#V:\SciELO\serial\abem\v55n1\markup\07.htm#S#p#124#120#article#156#26#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">26. Agarwal A,    Garg A.
 Genetic disorders of adipose tissue development, differenciation, and    death.
 Annu Rev Genom Hum Genet. 2006;7:175-99.    ^cY#07.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#125#121#article#156#</font></p>     ^cY#07.
htm##
00415000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704017500075002000700250#v55
n1#V:\SciELO\serial\abem\v55n1\markup\07.htm#S#p#126#122#article#156#27#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">27. Goran MI, Gower    BA
. Longitudinal study on pubertal insulin resistance. Diabetes. 2001;50:2444-50. 
   ^cY#07.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#127#123#article#156#</font></p>     ^cY#07.
htm##
00507000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704026700075002000700342#v55
n1#V:\SciELO\serial\abem\v55n1\markup\07.htm#S#p#128#124#article#156#28#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">28. Randle PJ,    Garland
 PB, Hales CN, Newsholme EA. The glucose fatty acid cycle: its role in    insuli
n sensitivity and the metabolic disturbances of diabetes mellitus. Lancet.    19
63;1:785-9.    ^cY#07.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#129#125#article#156#</font></p>     ^cY#07.
htm##
00637000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704039700075002000700472#v55
n1#V:\SciELO\serial\abem\v55n1\markup\07.htm#S#p#130#126#article#156#29#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">29. Ryysy L, H&auml;kkine
n    AM, Goto T, Vehkavaara S, Westerbacka J, Halavaara J, et al. Hepatic fat co
ntent    and insulin action on free fat acids and glucose metabolism rather than
 insulin    absorption are associated with insulin requirements during insulin t
herapy in    type 2 diabetic pacients. Diabetes. 2000:740-58.    ^cY#07.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#131#127#article#156#</font></p>     ^cY#07.
htm##
00494000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704025400075002000700329#v55
n1#V:\SciELO\serial\abem\v55n1\markup\07.htm#S#p#132#128#article#156#30#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">30. Storz P, Doppler    H
, Wernig A, Pfizenmaier K, Muller G.Cross-talk mechanisms in the development    
of insulin resistance of skeletal muscle cells. Eur J Biochem. 1999;266:17-25.  
  ^cY#07.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#133#129#article#156#</font></p>     ^cY#07.
htm##
00583000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704034300075002000700418#v55
n1#V:\SciELO\serial\abem\v55n1\markup\07.htm#S#p#134#130#article#156#31#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">31. Pardini VC,    Vict&o
acute;ria IM, Rocha SM, Andrade DG, Rocha AM, Pieroni FB, et al. Leptin    level
s, beta-cell function, and insulin sensitivity in families with congenital    an
d acquired generalized lipoatropic diabetes. J Clin Endocrinol Metab. 1998;83(2)
:503-8.    ^cY#07.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#135#131#article#156#</font></p>     ^cY#07.
htm##
00424000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704018400075002000700259#v55
n1#V:\SciELO\serial\abem\v55n1\markup\07.htm#S#p#136#132#article#156#32#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">32. Rabe K, Lehrke    M, 
Parhofer KG, Broedl U. Adipokines and insulin resistance.Mol Med. 2008;14(11-12)
:741-51.    ^cY#07.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#137#133#article#156#</font></p>     ^cY#07.
htm##
00503000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704026300075002000700338#v55
n1#V:\SciELO\serial\abem\v55n1\markup\07.htm#S#p#138#134#article#156#33#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">33. Belfort R,    Mandari
no L, Kashyap S, Wirfel K, Pratipanawatr T, Berria R, et al. Dose-response    ef
fect of elevated plasma free fatty acid on insulin signaling. Diabetes. 2005;54:
1640-8.    ^cY#07.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#139#135#article#156#</font></p>     ^cY#07.
htm##
00547000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704030700075002000700382#v55
n1#V:\SciELO\serial\abem\v55n1\markup\07.htm#S#p#140#136#article#156#34#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">34. Wiegman A,    Hutten 
BA, de Groot E, Rodenburg J, Bakker HD, B&uuml;ller HR, et al. Efficacy    and s
afety of statin theraphy in children with familial hypercholesterolemia:    a ra
ndomized controlled trial. JAMA. 2004;292(3):331-7.    ^cY#07.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#141#137#article#156#</font></p>     ^cY#07.
htm##
00536000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704029600075002000700371#v55
n1#V:\SciELO\serial\abem\v55n1\markup\07.htm#S#p#142#138#article#156#35#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">35. de Jongh S,    Lilien
 MR, op't Roodt J, Stroes ES, Bakker HD, Kastelein JJ. Early statin theraphy    
restores endothelial function in children with familial hypercholesterolemia.   
 J Am Coll Cardiol. 2002;40(12):2117-21.    ^cY#07.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#143#139#article#156#</font></p>     ^cY#07.
htm##
00460000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704022000075002000700295#v55
n1#V:\SciELO\serial\abem\v55n1\markup\07.htm#S#p#144#140#article#156#36#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">36. Daniels SR,    Greer 
FR; and the Committee on Nutrition. Lipid screening and Cardiovascular    Health
 in Childhood. Pediatrics. 2008;122:198-208.    ^cY#07.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#145#141#article#156#</font></p>     ^cY#07.
htm##
00463000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704022300075002000700298#v55
n1#V:\SciELO\serial\abem\v55n1\markup\07.htm#S#p#146#142#article#156#37#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">37. Oral EA, Simha    V, 
Ruiz E, Andewelt A, Premkumar A, Snell P, et al. Leptin replacement theraphy    
for lipodystrophy. N EnglJ Med. 2002;346:570-8.    ^cY#07.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#147#143#article#156#</font></p>     ^cY#07.
htm##
00466000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704022600075002000700301#v55
n1#V:\SciELO\serial\abem\v55n1\markup\07.htm#S#p#148#144#article#156#38#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">38. Chong AY, Lupsa    BC
, Cochran EK, Gorden P. Efficacy of leptin therapy in the different forms    of 
human lipodystrophy. Diabetologia. 2010; 53:27-35.    ^cY#07.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#149#145#article#156#</font></p>     ^cY#07.
htm##
00553000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704031300075002000700388#v55
n1#V:\SciELO\serial\abem\v55n1\markup\07.htm#S#p#150#146#article#156#39#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">39. Beltrand J,    Lahlou
 N, Le Charpentier T, Sebag G, Leka S, Polak M, et al. Resistance to leptin    r
eplacement theraphy in Berardinelli-Seip congenital lipodystrophy (BSCL): An    
immunological origin. Eur J Endocrinol. 2010;162:1083-91.    ^cY#07.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#151#147#article#156#</font></p>     ^cY#07.
htm##
00247000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002200072002000700094#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#152#148#article#156#<p>&nbsp;</p>     ^cY#0
7.htm##
00247000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002200072002000700094#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#153#149#article#156#<p>&nbsp;</p>     ^cY#0
7.htm##
00424000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704019900072002000700271#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#154#150#article#156#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2"><b><a name="back"></a><a href="#top"><im
g src="/img/revistas/abem/v55n1/seta.jpg" border="0"></a>    Correspond&ecirc;nc
ia para:    ^cY#07.htm##
00263000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704003800072002000700110#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#155#151#article#156#<br>   </b> Cristiane B
. Barra    ^cY#07.htm##
00271000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704004600072002000700118#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#156#152#article#156#<br>   Rua Pedro de Tol
edo, 97, ap. 80    ^cY#07.htm##
00294000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704006900072002000700141#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#157#153#article#156#<br>   12243-740&nbsp;-
 S&atilde;o Jos&eacute; dos Campos, SP    ^cY#07.htm##
00316000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704009100072002000700163#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#158#154#article#156#<br>   <a href="mailto:
crisbbarra@uol.com.br">crisbbarra@uol.com.br</a></font></p>     ^cY#07.htm##
00320000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704009500072002000700167#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#159#155#article#156#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2">Recebido em 30/Mail/2010    ^cY#07.htm##
00273000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704004800072002000700120#v55n1#V:\SciELO
\serial\abem\v55n1\markup\07.htm#S#p#160#156#article#156#<br>   Aceito em 27/Dez
/2010</font></p>     ^cY#07.htm##
00547000000000289000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100014000710100018000850120
06900103030001400172032000800186065000900194064000500203031000400208014000500212
865000900217002000700226035001000233801001400243#v55n1#V:\SciELO\serial\abem\v55
n1\markup\07.htm#S#c#161#1#article#39#1#^rND^sSeip^nM#^rND^sTrygstad^nO#Generali
zed lipodystrophy, congenital and acquired (lipoatrophy)^len#Acta Paediatr#^sSup
pl#19960000#1996#413#2-28#20110200#07.htm#0001-656X#Acta Paediatr##
00524000000000265000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100022000710120066000930300
02400159065000900183064000500192031000300197014000800200865000900208002000700217
035001000224801002400234#v55n1#V:\SciELO\serial\abem\v55n1\markup\07.htm#S#c#162
#2#article#39#2#^rND^sBerardinelli^nW#An undiagnosed endocrinometabolic syndrome
: report of 2 cases^len#J Clin Endocrinol Metab#19540000#1954#14#193-204#2011020
0#07.htm#0021-972X#J Clin Endocrinol Metab##
00441000000000253000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100014000710120043000850300
01500128710000200143065000900145064000500154031000400159014000800163865000900171
002000700180#v55n1#V:\SciELO\serial\abem\v55n1\markup\07.htm#S#c#163#3#article#3
9#3#^rND^sGarg^nA#Acquired and inherited lipodystrophies^len#New Engl J Med#2#20
040000#2004#350#1220-34#20110200#07.htm##
00529000000000265000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100014000710120102000850300
01300187065000900200064000500209031000300214014000700217865000900224002000700233
035001000240801001300250#v55n1#V:\SciELO\serial\abem\v55n1\markup\07.htm#S#c#164
#4#article#39#4#^rND^sSeip^nM#Lipodystrophy and gigantism with associated endocr
ine manifestation: a new diencephalic syndrome?^len#Acta Pediatr#19590000#1959#4
8#555-74#20110200#07.htm#0001-6640#Acta Pediatr##
00491000000000277000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100014000710100018000850120
03000103030001500133065000900148064000500157031000300162014000700165865000900172
002000700181035001000188801001500198#v55n1#V:\SciELO\serial\abem\v55n1\markup\07
.htm#S#c#165#5#article#39#5#^rND^sSeip^nM#^rND^sTrygstad^nO#Generalized lipodyst
rophy^len#Arch Dis Child#19630000#1963#38#447-53#20110200#07.htm#0003-9888#Arch 
Dis Child##
00643000000000289000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100019000710100018000900100
01800108012014700126030001500273065000900288064000500297031000300302014000700305
865000900312002000700321035001000328801001500338#v55n1#V:\SciELO\serial\abem\v55
n1\markup\07.htm#S#c#166#6#article#39#6#^rND^sBrunzell^nJD#^rND^sShankle^nSW#^rN
D^sBethune^nJE#Congenital generalized lipodystrophy and systemic cystic angiomat
osis: the simultaneous occurrence of two unusual syndromes in a single family^le
n#Ann Intern Med#19680000#1968#69#501-16#20110200#07.htm#0003-4819#Ann Intern Me
d##
00691000000000313000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100023000710100014000940100
01600108010001800124010001700142010001800159012013200177030002600309710000200335
065000900337064000500346031000300351032000700354865000900361002000700370#v55n1#V
:\SciELO\serial\abem\v55n1\markup\07.htm#S#c#167#7#article#39#7#^rND^sVan Malder
gem^nL#^rND^sBacq^nC#^rND^sMommen^nN#^rND^sFourneau^nC#^rND^sHilbert^nP#^rND^sGi
llerot^nY#Total lipodystrophy, polycystic ovaries and cystic angiomatosis of bon
es (Brunzell syndrome): confirmation of a separate entity^len#(Abstract) Am J Hu
m Genet#2#19920000#1992#51#^sA109#20110200#07.htm##
00666000000000289000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100015000710100014000860100
01700100012015400117030002700271065000900298064000500307031000400312014000700316
865000900323002000700332035001000339801002700349#v55n1#V:\SciELO\serial\abem\v55
n1\markup\07.htm#S#c#168#8#article#39#8#^rND^sHaque^nW#^rND^sGarg^nA#^rND^sAgarw
al^nA#Enzimatic activity of naturally occurring 1-acylglycerol-3-phosphate-O-acy
ltransferase 2 mutants associated with congenital generalized lipodystrophy^len#
Biochem Biophys Res Commun#20050000#2005#327#446-53#20110200#07.htm#0006-291X#Bi
ochem Biophys Res Commun##
00673000000000325000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100014000710100018000850100
01600103010002100119010001400140010001500154810000600169012010900175030002000284
71000020030406500090030606400050031503100030032001400080032386500090033100200070
0340#v55n1#V:\SciELO\serial\abem\v55n1\markup\07.htm#S#c#169#9#article#39#9#^rND
^sKim^nCA#^rND^sDelepine^nM#^rND^sBoutet^nE#^rND^sEl Mourabit^nH#^rND^sLay^nSL#^
rND^sMeier^nM#et al#Association of a homozygous nonsense caveolin-1 mutation wit
h Berardinelli-Seip congenital lipodystrophy^len#J Clin Endocr Metab#2#20080000#
2008#93#1129-34#20110200#07.htm##
00628000000000301000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730100018000890100
02200107010002000129012009300149030001700242065000900259064000500268031000400273
014000600277865000900283002000700292035001000299801001700309#v55n1#V:\SciELO\ser
ial\abem\v55n1\markup\07.htm#S#c#170#10#article#39#10#^rND^sJaquet^nD#^rND^sKhal
louf^nE#^rND^sLévy-Marchal^nC#^rND^sCzernichow^nP#Extremely low values of serum 
leptin in children with congenital generalized lipoatrophy^len#Eur J Endocrinol#
19990000#1999#140#107-9#20110200#07.htm#0804-4643#Eur J Endocrinol##
00740000000000349000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100018000730100021000910100
01800112010001500130010002100145010001400166810000600180012012900186030001100315
06500090032606400050033503100040034003200020034401400070034686500090035300200070
0362035001000369801001100379#v55n1#V:\SciELO\serial\abem\v55n1\markup\07.htm#S#c
#171#11#article#39#11#^rND^sBeltrand^nJ#^rND^sBeregszaszi^nM#^rND^sChevenne^nD#^
rND^sSebag^nG#^rND^sDe Kerdanet^nM#^rND^sHuet^nF#et al#Metabolic correction indu
ced by leptin replacement treatment in young children with Berardinelli-Seip con
genital lipoatrophy^len#Pediatrics#20070000#2007#120#2#e291-6#20110200#07.htm#00
31-4005#Pediatrics##
00576000000000289000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730100018000890100
02000107012008100127030001500208065000900223064000500232031000400237014000400241
865000900245002000700254035001000261801001500271#v55n1#V:\SciELO\serial\abem\v55
n1\markup\07.htm#S#c#172#12#article#39#12#^rND^sGomes^nKB#^rND^sPardini^nVC#^rND
^sFernandes^nAP#Clinical and molecular aspects of Berardinelli-Seip congenital l
ipodystrophy^len#Clin Chim Acta#20090000#2009#402#1-6#20110200#07.htm#0009-8981#
Clin Chim Acta##
00478000000000265000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100019000730100018000920120
03300110030002700143710000200170065000900172064000500181031000300186014000700189
865000900196002000700205#v55n1#V:\SciELO\serial\abem\v55n1\markup\07.htm#S#c#173
#13#article#39#13#^rND^sZappalla^nFR#^rND^sGidding^nSS#Lipid management in child
ren^len#Endocrinol Metab Clin N Am#2#20090000#2009#38#171-83#20110200#07.htm##
00752000000000349000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730100015000890100
01800104010001400122010001600136010002300152810000600175012012000181030002400301
06500090032506400050033403100030033903200020034201400080034486500090035200200070
0361035001000368801002400378#v55n1#V:\SciELO\serial\abem\v55n1\markup\07.htm#S#c
#174#14#article#39#14#^rND^sIbanez^nL#^rND^sPotau^nN#^rND^sZampolli^nM#^rND^sPra
t^nN#^rND^sVirdis^nR#^rND^sVicens-Calvet^nE#et al#Hyperinsulinemia in postpubert
al girls with a history of premature pubarche and functional ovarian hyperandrog
enism^len#J Clin Endocrinol Metab#19960000#1996#81#3#1237-43#20110200#07.htm#002
1-972X#J Clin Endocrinol Metab##
00720000000000325000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100019000730100017000920100
01900109010001700128010001900145010001700164012013800181030001300319065000900332
06400050034103100030034601400060034986500090035500200070036403500100037180100130
0381#v55n1#V:\SciELO\serial\abem\v55n1\markup\07.htm#S#c#175#15#article#39#15#^r
ND^sMatthews^nDR#^rND^sHosker^nJP#^rND^sRudenski^nAS#^rND^sNaylor^nBA#^rND^sTrea
cher^nDF#^rND^sTurner^nRC#Homeostasis model assessment: insulin resistance and b
eta-cell function from fasting plasma glucose and insulin concentrations in man^
len#Diabetologia#19850000#1985#28#412-9#20110200#07.htm#0012-186X#Diabetologia##
00473000000000265000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100022000730120036000950300
01300131065000900144064000500153031000300158014000700161865000900168002000700177
035001000184801001300194#v55n1#V:\SciELO\serial\abem\v55n1\markup\07.htm#S#c#176
#16#article#39#16#^rND^sBloomgarden^nZT#Measures of insulin sensitivity^len#Clin
 Lab Med#20060000#2006#26#611-33#20110200#07.htm#0272-2712#Clin Lab Med##
00656000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100015000730100018000880100
02300106010001600129010001800145010001500163810000600178012006600184030000900250
06500090025906400050026803100030027301400070027686500090028300200070029203500100
0299801000900309#v55n1#V:\SciELO\serial\abem\v55n1\markup\07.htm#S#c#177#17#arti
cle#39#17#^rND^sMagré^nJ#^rND^sDelépine^nM#^rND^sVan Maldergem^nL#^rND^sRobert^n
J#^rND^sMaassen^nJA#^rND^sMeier^nM#et al#Prevalence of mutations in AGPAT2 among
 human lipodystrophies^len#Diabetes#20030000#2003#52#1573-8#20110200#07.htm#0012
-1797#Diabetes##
00688000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100023000730100015000960100
01800111010002300129010001800152010001800170810000600188012008200194030001200276
06500090028806400050029703100030030201400070030586500090031200200070032103500100
0328801001200338#v55n1#V:\SciELO\serial\abem\v55n1\markup\07.htm#S#c#178#18#arti
cle#39#18#^rND^sVal Maldergem^nL#^rND^sMagré^nJ#^rND^sKhallouf^nT#^rND^sGedde-Da
hl^nT Jr#^rND^sDelépine^nM#^rND^sTrygstad^nO#et al#Genotype-phenotype relationsh
ip in Berardinelli-Seip congenital lipodistrophy^len#J Med Genet#20020000#2002#3
9#722-33#20110200#07.htm#0022-2593#J Med Genet##
00678000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730100018000900100
02000108010001500128010001700143010001800160810000600178012008800184030001000272
06500090028206400050029103100030029601400050029986500090030400200070031303500100
0320801001000330#v55n1#V:\SciELO\serial\abem\v55n1\markup\07.htm#S#c#179#19#arti
cle#39#19#^rND^sAgarwal^nA#^rND^sAriouglu^nE#^rND^sDe Almeida^nS#^rND^sAkkoc^nN#
^rND^sTaylor^nSI#^rND^sBowcock^nAM#et al#AGPAT2 is mutated in congenital general
ized lipodistrophy linked to chromosome 9q34^len#Nat Genet#20020000#2002#31#21-3
#20110200#07.htm#1061-4036#Nat Genet##
00690000000000325000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730100018000890100
01900107010001700126010001500143012012600158030001400284065000900298064000500307
03100040031203200020031601400060031886500090032400200070033303500100034080100140
0350#v55n1#V:\SciELO\serial\abem\v55n1\markup\07.htm#S#c#180#20#article#39#20#^r
ND^sSalani^nB#^rND^sBriatore^nL#^rND^sGaribaldi^nS#^rND^sCordera^nR#^rND^sMaggi^
nD#Caveolin-1 Down-regulation inhibits insulin-like growth factor-I receptor sig
nal transduction in H9C2 rat cardiomyoblasts^len#Endocrinology#20080000#2008#149
#2#461-5#20110200#07.htm#0013-7227#Endocrinology##
00696000000000349000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730100017000890100
01700106010001600123010001500139010002000154810000600174012009500180030000900275
06500090028406400050029303100030029803200020030101400080030386500090031100200070
0320035001000327801000900337#v55n1#V:\SciELO\serial\abem\v55n1\markup\07.htm#S#c
#181#21#article#39#21#^rND^sPayne^nVA#^rND^sGrimsey^nN#^rND^sTuthill^nA#^rND^sVi
rtue^nS#^rND^sGray^nSL#^rND^sDalla Nora^nE#et al#The lipodistrophy gene BSCL2/se
ipin may be essential for normal adipocyte differentiantion^len#Diabetes#2008000
0#2008#57#8#2055-60#20110200#07.htm#0012-1797#Diabetes##
00797000000000349000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730100020000890100
01900109010001700128010001400145010001500159810000600174012016700180030002400347
06500090037106400050038003100030038503200020038801400070039086500090039700200070
0406035001000413801002400423#v55n1#V:\SciELO\serial\abem\v55n1\markup\07.htm#S#c
#182#22#article#39#22#^rND^sGomes^nKB#^rND^sFernandes^nAP#^rND^sFerreira^nAC#^rN
D^sPardini^nH#^rND^sGarg^nA#^rND^sMagré^nJ#et al#Mutations in the seipin and AGP
AT2 genes clustering in consanguineous families with Berardinelli-Seip congenita
l lipodystrophy from two separate regions of Brazil^len#J Clin Endocrinol Metab#
20040000#2004#89#1#357-61#20110200#07.htm#0021-972X#J Clin Endocrinol Metab##
00789000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100012000730100022000850100
01900107010001800126010002200144010001800166810000600184012016200190030002400352
06500090037606400050038503100030039001400080039386500090040100200070041003500100
0417801002400427#v55n1#V:\SciELO\serial\abem\v55n1\markup\07.htm#S#c#183#23#arti
cle#39#23#^rND^sFu^nM#^rND^sKazlauskaite^nR#^rND^sBaracho^nMFP#^rND^sSantos^nMGN
#^rND^sBrandão-Neto^nJ#^rND^sVillares^nS#et al#Mutations in Gng31g and AGPAT2 in
 Berardinelli-Seip congenital lipodystrophy and Brunzell syndrome: phenotype var
iability suggests important modifier effects^len#J Clin Endocrinol Metab#2004000
0#2004#89#2916-22#20110200#07.htm#0021-972X#J Clin Endocrinol Metab##
00709000000000325000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100018000730100022000910100
02000113010001700133010001800150010001800168810000600186012013400192030001600326
71000020034206500090034406400050035303100030035801400060036186500090036700200070
0376#v55n1#V:\SciELO\serial\abem\v55n1\markup\07.htm#S#c#184#24#article#39#24#^r
ND^sMiranda^nDM#^rND^sWajchenberg^nBL#^rND^sCalsolari^nMR#^rND^sAguiar^nMJ#^rND^
sSilva^nJMCL#^rND^sRibeiro^nMG#et al#Novel mutations of the BSCL2 and AGPAT2 gen
es in 10 families with Berardinelli-Seip congenital generalized lipodystrophy sy
ndrome^len#Clin Endocrinol#2#20090000#2009#71#512-7#20110200#07.htm##
00653000000000349000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100027000730100014001000100
01800114010001600132010001700148010002000165810000600185012004100191030001000232
06500090024206400050025103100030025603200020025901400060026186500090026700200070
0276035001000283801001000293#v55n1#V:\SciELO\serial\abem\v55n1\markup\07.htm#S#c
#185#25#article#39#25#^rND^sFigueiredo Filho^nPP#^rND^sVal^nAC#^rND^sDiamante^nR
#^rND^sCunha^nCF#^rND^sNorton^nRC#^rND^sLamounier^nJA#et al#Lipodistrofia genera
lizada congênita^lpt#J Pediatr#20040000#2004#80#4#333-6#20110200#07.htm#0022-347
6#J Pediatr##
00516000000000265000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730100014000900120
08000104030002500184710000200209065000900211064000500220031000200225014000700227
865000900234002000700243#v55n1#V:\SciELO\serial\abem\v55n1\markup\07.htm#S#c#186
#26#article#39#26#^rND^sAgarwal^nA#^rND^sGarg^nA#Genetic disorders of adipose ti
ssue development, differenciation, and death^len#Annu Rev Genom Hum Genet#2#2006
0000#2006#7#175-99#20110200#07.htm##
00506000000000277000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730100016000890120
05400105030000900159065000900168064000500177031000300182014000800185865000900193
002000700202035001000209801000900219#v55n1#V:\SciELO\serial\abem\v55n1\markup\07
.htm#S#c#187#27#article#39#27#^rND^sGoran^nMI#^rND^sGower^nBA#Longitudinal study
 on pubertal insulin resistance^len#Diabetes#20010000#2001#50#2444-50#20110200#0
7.htm#0012-1797#Diabetes##
00626000000000301000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730100018000900100
01600108010002000124012011800144030000700262065000900269064000500278031000200283
014000600285865000900291002000700300035001000307801000700317#v55n1#V:\SciELO\ser
ial\abem\v55n1\markup\07.htm#S#c#188#28#article#39#28#^rND^sRandle^nPJ#^rND^sGar
land^nPB#^rND^sHales^nCN#^rND^sNewsholme^nEA#The glucose fatty acid cycle: its r
ole in insulin sensitivity and the metabolic disturbances of diabetes mellitus^l
en#Lancet#19630000#1963#1#785-9#20110200#07.htm#0099-5355#Lancet##
00785000000000325000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100015000730100019000880100
01400107010002000121010002100141010001900162810000600181012020700187030000900394
06500090040306400050041203100070041786500090042400200070043303500100044080100090
0450#v55n1#V:\SciELO\serial\abem\v55n1\markup\07.htm#S#c#189#29#article#39#29#^r
ND^sRyysy^nL#^rND^sHäkkinen^nAM#^rND^sGoto^nT#^rND^sVehkavaara^nS#^rND^sWesterba
cka^nJ#^rND^sHalavaara^nJ#et al#Hepatic fat content and insulin action on free f
at acids and glucose metabolism rather than insulin absorption are associated wi
th insulin requirements during insulin therapy in type 2 diabetic pacients^len#D
iabetes#20000000#2000#740-58#20110200#07.htm#0012-1797#Diabetes##
00642000000000313000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100015000730100017000880100
01600105010002100121010001600142012009200158030001400250065000900264064000500273
031000400278014000600282865000900288002000700297035001000304801001400314#v55n1#V
:\SciELO\serial\abem\v55n1\markup\07.htm#S#c#190#30#article#39#30#^rND^sStorz^nP
#^rND^sDoppler^nH#^rND^sWernig^nA#^rND^sPfizenmaier^nK#^rND^sMuller^nG#Cross-tal
k mechanisms in the development of insulin resistance of skeletal muscle cells^l
en#Eur J Biochem#19990000#1999#266#17-25#20110200#07.htm#0014-2956#Eur J Biochem
##
00770000000000349000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100018000730100019000910100
01600110010001800126010001600144010001800160810000600178012013700184030002400321
06500090034506400050035403100030035903200020036201400060036486500090037000200070
0379035001000386801002400396#v55n1#V:\SciELO\serial\abem\v55n1\markup\07.htm#S#c
#191#31#article#39#31#^rND^sPardini^nVC#^rND^sVictória^nIM#^rND^sRocha^nSM#^rND^
sAndrade^nDG#^rND^sRocha^nAM#^rND^sPieroni^nFB#et al#Leptin levels, beta-cell fu
nction, and insulin sensitivity in families with congenital and acquired general
ized lipoatropic diabetes^len#J Clin Endocrinol Metab#19980000#1998#83#2#503-8#2
0110200#07.htm#0021-972X#J Clin Endocrinol Metab##
00562000000000313000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100014000730100016000870100
01900103010001600122012003800138030000800176065000900184064000500193031000300198
032000600201014000700207865000900214002000700223035001000230801000800240#v55n1#V
:\SciELO\serial\abem\v55n1\markup\07.htm#S#c#192#32#article#39#32#^rND^sRabe^nK#
^rND^sLehrke^nM#^rND^sParhofer^nKG#^rND^sBroedl^nU#Adipokines and insulin resist
ance^len#Mol Med#20080000#2008#14#11-12#741-51#20110200#07.htm#1076-1551#Mol Med
##
00674000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730100019000900100
01700109010001600126010002300142010001600165810000600181012008100187030000900268
06500090027706400050028603100030029101400070029486500090030100200070031003500100
0317801000900327#v55n1#V:\SciELO\serial\abem\v55n1\markup\07.htm#S#c#193#33#arti
cle#39#33#^rND^sBelfort^nR#^rND^sMandarino^nL#^rND^sKashyap^nS#^rND^sWirfel^nK#^
rND^sPratipanawatr^nT#^rND^sBerria^nR#et al#Dose-response effect of elevated pla
sma free fatty acid on insulin signaling^len#Diabetes#20050000#2005#54#1640-8#20
110200#07.htm#0012-1797#Diabetes##
00717000000000349000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730100017000900100
01800107010001900125010001700144010001700161810000600178012012100184030000500305
06500090031006400050031903100040032403200020032801400060033086500090033600200070
0345035001000352801000500362#v55n1#V:\SciELO\serial\abem\v55n1\markup\07.htm#S#c
#194#34#article#39#34#^rND^sWiegman^nA#^rND^sHutten^nBA#^rND^sde Groot^nE#^rND^s
Rodenburg^nJ#^rND^sBakker^nHD#^rND^sBüller^nHR#et al#Efficacy and safety of stat
in theraphy in children with familial hypercholesterolemia: a randomized control
led trial^len#JAMA#20040000#2004#292#3#331-7#20110200#07.htm#0098-7484#JAMA##
00713000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100018000730100017000910100
02000108010001700128010001700145010002000162012010300182030001800285065000900303
06400050031203100030031703200030032001400080032386500090033100200070034003500100
0347801001800357#v55n1#V:\SciELO\serial\abem\v55n1\markup\07.htm#S#c#195#35#arti
cle#39#35#^rND^sde Jongh^nS#^rND^sLilien^nMR#^rND^sop't Roodt^nJ#^rND^sStroes^nE
S#^rND^sBakker^nHD#^rND^sKastelein^nJJ#Early statin theraphy restores endothelia
l function in children with familial hypercholesterolemia^len#J Am Coll Cardiol#
20020000#2002#40#12#2117-21#20110200#07.htm#0735-1097#J Am Coll Cardiol##
00561000000000289000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100018000730100016000910110
03100107012005900138030001100197065000900208064000500217031000400222014000800226
865000900234002000700243035001000250801001100260#v55n1#V:\SciELO\serial\abem\v55
n1\markup\07.htm#S#c#196#36#article#39#36#^rND^sDaniels^nSR#^rND^sGreer^nFR#and 
the Committee on Nutrition#Lipid screening and Cardiovascular Health in Childhoo
d^len#Pediatrics#20080000#2008#122#198-208#20110200#07.htm#0031-4005#Pediatrics#
#
00605000000000325000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100015000730100015000880100
01400103010001800117010001900135010001500154810000600169012005000175030001200225
71000020023706500090023906400050024803100040025301400060025786500090026300200070
0272#v55n1#V:\SciELO\serial\abem\v55n1\markup\07.htm#S#c#197#37#article#39#37#^r
ND^sOral^nEA#^rND^sSimha^nV#^rND^sRuiz^nE#^rND^sAndewelt^nA#^rND^sPremkumar^nA#^
rND^sSnell^nP#et al#Leptin replacement theraphy for lipodystrophy^len#N EnglJ Me
d#2#20020000#2002#346#570-8#20110200#07.htm##
00593000000000301000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730100016000890100
01800105010001600123012007700139030001300216065000900229064000500238031000300243
014000600246865000900252002000700261035001000268801001300278#v55n1#V:\SciELO\ser
ial\abem\v55n1\markup\07.htm#S#c#198#38#article#39#38#^rND^sChong^nAY#^rND^sLups
a^nBC#^rND^sCochran^nEK#^rND^sGorden^nP#Efficacy of leptin therapy in the differ
ent forms of human lipodystrophy^len#Diabetologia#20100000#2010#53#27-35#2011020
0#07.htm#0012-186X#Diabetologia##
00729000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100018000730100016000910100
02400107010001500131010001400146010001500160810000600175012012400181030001700305
06500090032206400050033103100040033601400080034086500090034800200070035703500100
0364801001700374#v55n1#V:\SciELO\serial\abem\v55n1\markup\07.htm#S#c#199#39#arti
cle#39#39#^rND^sBeltrand^nJ#^rND^sLahlou^nN#^rND^sLe Charpentier^nT#^rND^sSebag^
nG#^rND^sLeka^nS#^rND^sPolak^nM#et al#Resistance to leptin replacement theraphy 
in Berardinelli-Seip congenital lipodystrophy (BSCL): An immunological origin^le
n#Eur J Endocrinol#20100000#2010#162#1083-91#20110200#07.htm#0804-4643#Eur J End
ocrinol##
00262000000000169000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640910009000660920007000750020007000827030
00300089#v55n1#V:\SciELO\serial\abem\v55n1\markup\11.htm#S#o#1#1#article#1#20110
406#124312#11.htm#82##
02368000000000541000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640710003000660400003000690010006000720420
00200078120000400080038000500084038000400089121000300093049000800096158000300104
03000260010703100030013303200020013606500090013801400090014703500100015601201240
01660120106002900100043003960100032004390100042004710100043005130100028005560100
03800584070008100622070008300703083046000786083052201246117000601768072000201774
112000901776111001301785114000901798113001201807002000701819#v55n1#V:\SciELO\ser
ial\abem\v55n1\markup\11.htm#S#h#2#1#article#1#cr#pt#br1.1#1#4.0#ILUS#TAB#11#ABE
M060#nd#Arq Bras Endocrinol Metab#55#1#20110200#^f78^l80#0004-2730#Hormônio de c
rescimento e hipersensibilidade por imunocomplexo (Tipo III): uma contraindicaçã
o para a dessensibilização^lpt#Growth hormone therapy and hypersensitivity type 
III reaction: a contraindication for desensitization^len#^rND^1A01 A02^nWilma Ca
rvalho Neves^sForte#^rND^1A01 A02^nCristiane^sKochi#^rND^1A01^nClaudia Dutra Cos
tantin^sFaria#^rND^1A01^nLuis Eduardo Procópio^sCalliari#^rND^1A01 A02^nOsmar^sM
onte#^rND^1A01 A02^nCarlos Alberto^sLongui#Irmandade da Santa Casa de Misericórd
ia de São Paulo^iA01^cSão Paulo^sSP^pBrasil#Santa Casa de São Paulo^iA02^1Faculd
ade de Ciências Médicas^cSão Paulo^sSP^pBrasil#^lpt^aAs reações alérgicas ao GH 
são raras e usualmente representadas por reações de hipersensibilidade tipo I (I
gE mediadas), passíveis de tratamento por dessensibilização. Neste relato de cas
o, descrevemos a presença de reação alérgica ao GH mediada por imunocomplexo (hi
persensibilidade tipo III). Nesta situação, a tentativa de dessensibilização pod
e perpetuar a formação de imunocomplexo, cujo depósito pode determinar insuficiê
ncia renal e respiratória.#^len^aAllergic reactions against GH are rare, and usu
ally represented by the hypersensitivity type I (IgE-mediated). This type of rea
ction can be treated by desensitization. In this case report, we present a patie
nt showing an allergic reaction soon after starting GH therapy mediated by immun
e complex (hypersensitivity type III reaction). In this condition, the attempt t
o perform the desensitization procedure can perpetuate immune complex deposition
 determining a life threatening renal and respiratory insufficiency.#other#6#201
00519#19/Mail/2010#20101111#11/Nov/2010#11.htm##
02396000000000541000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640710003000660400003000690010006000720420
00200078120000400080038000500084038000400089121000300093049000800096158000300104
03000260010703100030013303200020013606500090013801400090014703500100015601201380
01660120120003040100043004240100032004670100042004990100043005410100028005840100
03800612070008100650070008300731083046000814083052201274117000601796072000201802
112000901804111001301813114000901826113001201835002000701847#v55n1#V:\SciELO\ser
ial\abem\v55n1\markup\11.htm#S#f#3#1#article#1#cr#pt#br1.1#1#4.0#ILUS#TAB#11#ABE
M060#nd#Arq Bras Endocrinol Metab#55#1#20110200#^f78^l80#0004-2730#<b>Hormônio d
e crescimento e hipersensibilidade por imunocomplexo (Tipo III)</b>: <b>uma cont
raindicação para a dessensibilização</b>^lpt#<b>Growth hormone therapy and hyper
sensitivity type III reaction</b>: <b>a contraindication for desensitization</b>
^len#^rND^1A01 A02^nWilma Carvalho Neves^sForte#^rND^1A01 A02^nCristiane^sKochi#
^rND^1A01^nClaudia Dutra Costantin^sFaria#^rND^1A01^nLuis Eduardo Procópio^sCall
iari#^rND^1A01 A02^nOsmar^sMonte#^rND^1A01 A02^nCarlos Alberto^sLongui#Irmandade
 da Santa Casa de Misericórdia de São Paulo^iA01^cSão Paulo^sSP^pBrasil#Santa Ca
sa de São Paulo^iA02^1Faculdade de Ciências Médicas^cSão Paulo^sSP^pBrasil#^lpt^
aAs reações alérgicas ao GH são raras e usualmente representadas por reações de 
hipersensibilidade tipo I (IgE mediadas), passíveis de tratamento por dessensibi
lização. Neste relato de caso, descrevemos a presença de reação alérgica ao GH m
ediada por imunocomplexo (hipersensibilidade tipo III). Nesta situação, a tentat
iva de dessensibilização pode perpetuar a formação de imunocomplexo, cujo depósi
to pode determinar insuficiência renal e respiratória.#^len^aAllergic reactions 
against GH are rare, and usually represented by the hypersensitivity type I (IgE
-mediated). This type of reaction can be treated by desensitization. In this cas
e report, we present a patient showing an allergic reaction soon after starting 
GH therapy mediated by immune complex (hypersensitivity type III reaction). In t
his condition, the attempt to perform the desensitization procedure can perpetua
te immune complex deposition determining a life threatening renal and respirator
y insufficiency.#other#6#20100519#19/Mail/2010#20101111#11/Nov/2010#11.htm##
02501000000000565000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640640013000660710003000790400003000820010
00600085042000200091120000400093038000500097038000400102121000300106049000800109
15800030011703000290012003100030014903200020015206500090015401400090016303500100
01720120124001820120106003060100043004120100032004550100042004870100043005290100
02800572010003800600070008300638070008500721083046000806083052201266117000601788
07200020179411200090179611100130180511400090181811300120182700200070183900800890
1846#v55n1#V:\SciELO\serial\abem\v55n1\markup\11.htm#S#l#4#1#article#1#^mfev.^a2
011#cr#pt#br1.1#1#4.0#ilus#tab#11#ABEM060#nd#Arq. bras. endocrinol. metab#55#1#2
0110200#^f78^l80#0004-2730#Hormônio de crescimento e hipersensibilidade por imun
ocomplexo (Tipo III): uma contraindicação para a dessensibilização^lpt#Growth ho
rmone therapy and hypersensitivity type III reaction: a contraindication for des
ensitization^len#^rND^1A01 A02^nWilma Carvalho Neves^sForte#^rND^1A01 A02^nCrist
iane^sKochi#^rND^1A01^nClaudia Dutra Costantin^sFaria#^rND^1A01^nLuis Eduardo Pr
ocópio^sCalliari#^rND^1A01 A02^nOsmar^sMonte#^rND^1A01 A02^nCarlos Alberto^sLong
ui#^iA01^1Irmandade da Santa Casa de Misericórdia de São Paulo^cSão Paulo^sSP^pB
rasil#^iA02^1Santa Casa de São Paulo^2Faculdade de Ciências Médicas^cSão Paulo^s
SP^pBrasil#^lpt^aAs reações alérgicas ao GH são raras e usualmente representadas
 por reações de hipersensibilidade tipo I (IgE mediadas), passíveis de tratament
o por dessensibilização. Neste relato de caso, descrevemos a presença de reação 
alérgica ao GH mediada por imunocomplexo (hipersensibilidade tipo III). Nesta si
tuação, a tentativa de dessensibilização pode perpetuar a formação de imunocompl
exo, cujo depósito pode determinar insuficiência renal e respiratória.#^len^aAll
ergic reactions against GH are rare, and usually represented by the hypersensiti
vity type I (IgE-mediated). This type of reaction can be treated by desensitizat
ion. In this case report, we present a patient showing an allergic reaction soon
 after starting GH therapy mediated by immune complex (hypersensitivity type III
 reaction). In this condition, the attempt to perform the desensitization proced
ure can perpetuate immune complex deposition determining a life threatening rena
l and respiratory insufficiency.#other#6#20100519#19/Mail/2010#20101111#11/Nov/2
010#11.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S000
4-27302011000100011##
00361000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000300064704014100067002000700208#v55n1#V:\SciELO
\serial\abem\v55n1\markup\11.htm#S#p#5#1#article#72#<p align="right"><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>APRESENTA&Ccedil;&Atilde;O  
  DE CASO</b></font></p>     ^cY#11.htm##
00242000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000300064704002200067002000700089#v55n1#V:\SciELO
\serial\abem\v55n1\markup\11.htm#S#p#6#2#article#72#<p>&nbsp;</p>     ^cY#11.htm
##
00487000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000300064704026700067002000700334#v55n1#V:\SciELO
\serial\abem\v55n1\markup\11.htm#S#p#7#3#article#72#<p><a name="top"></a><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="4"><b>Horm&ocirc;nio    de cre
scimento e hipersensibilidade por imunocomplexo (Tipo III): uma contraindica&cce
dil;&atilde;o    para a dessensibiliza&ccedil;&atilde;o</b></font></p>     ^cY#1
1.htm##
00242000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000300064704002200067002000700089#v55n1#V:\SciELO
\serial\abem\v55n1\markup\11.htm#S#p#8#4#article#72#<p>&nbsp;</p>     ^cY#11.htm
##
00414000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000300064704019400067002000700261#v55n1#V:\SciELO
\serial\abem\v55n1\markup\11.htm#S#p#9#5#article#72#<p><font face="Verdana, Aria
l, Helvetica, sans-serif" size="3"><b>Growth hormone    therapy and hypersensiti
vity type III reaction: a contraindication for desensitization</b></font></p>   
  ^cY#11.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000300065704002200068002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\11.htm#S#p#10#6#article#72#<p>&nbsp;</p>     ^cY#11.ht
m##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000300065704002200068002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\11.htm#S#p#11#7#article#72#<p>&nbsp;</p>     ^cY#11.ht
m##
00557000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000300065704033600068002000700404#v55n1#V:\SciELO
\serial\abem\v55n1\markup\11.htm#S#p#12#8#article#72#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="2"><b>Wilma Carvalho    Neves Forte<sup>I, II</
sup>; Cristiane Kochi<sup>I, II</sup>; Claudia Dutra    Costantin Faria<sup>I</s
up>; Luis Eduardo Proc&oacute;pio Calliari<sup>I</sup>;    Osmar Monte<sup>I, II
</sup>; Carlos Alberto Longui<sup>I, II</sup></b></font></p>     ^cY#11.htm##
00415000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000300065704019400068002000700262#v55n1#V:\SciELO
\serial\abem\v55n1\markup\11.htm#S#p#13#9#article#72#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="2"><sup>I</sup>Irmandade    da Santa Casa de Mi
seric&oacute;rdia de S&atilde;o Paulo (ISCMSP), S&atilde;o    Paulo, SP, Brasil 
   ^cY#11.htm##
00381000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704015900069002000700228#v55n1#V:\SciELO
\serial\abem\v55n1\markup\11.htm#S#p#14#10#article#72#<br>   <sup>II</sup>Faculd
ade de Ci&ecirc;ncias M&eacute;dicas da Santa Casa de S&atilde;o    Paulo (FCMSC
SP), S&atilde;o Paulo, SP, Brasil</font></p>     ^cY#11.htm##
00352000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704013000069002000700199#v55n1#V:\SciELO
\serial\abem\v55n1\markup\11.htm#S#p#15#11#article#72#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><a href="#back">Correspond&ecirc;ncia  para
</a></font></p>     ^cY#11.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\11.htm#S#p#16#12#article#72#<p>&nbsp;</p>     ^cY#11.h
tm##
00266000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704004400069002000700113#v55n1#V:\SciELO
\serial\abem\v55n1\markup\11.htm#S#p#17#13#article#72#<p>&nbsp;</p> <hr size="1"
 noshade>     ^cY#11.htm##
00326000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704010400069002000700173#v55n1#V:\SciELO
\serial\abem\v55n1\markup\11.htm#S#p#18#14#article#72#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>SUM&Aacute;RIO</b></font></p>     ^cY#11
.htm##
00954000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704073200069002000700801#v55n1#V:\SciELO
\serial\abem\v55n1\markup\11.htm#S#p#19#15#article#72#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">As rea&ccedil;&otilde;es    al&eacute;rgica
s ao GH s&atilde;o raras e usualmente representadas por rea&ccedil;&otilde;es   
 de hipersensibilidade tipo I (IgE mediadas), pass&iacute;veis de tratamento    
por dessensibiliza&ccedil;&atilde;o. Neste relato de caso, descrevemos a presen&
ccedil;a    de rea&ccedil;&atilde;o al&eacute;rgica ao GH mediada por imunocompl
exo (hipersensibilidade    tipo III). Nesta situa&ccedil;&atilde;o, a tentativa 
de dessensibiliza&ccedil;&atilde;o    pode perpetuar a forma&ccedil;&atilde;o de
 imunocomplexo, cujo dep&oacute;sito    pode determinar insufici&ecirc;ncia rena
l e respirat&oacute;ria.</font></p> <hr size="1" noshade>     ^cY#11.htm##
00319000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704009700069002000700166#v55n1#V:\SciELO
\serial\abem\v55n1\markup\11.htm#S#p#20#16#article#72#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>SUMMARY</b></font></p>     ^cY#11.htm##
00863000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704064100069002000700710#v55n1#V:\SciELO
\serial\abem\v55n1\markup\11.htm#S#p#21#17#article#72#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Allergic reactions    against GH are rare, 
and usually represented by the hypersensitivity type I    (IgE-mediated). This t
ype of reaction can be treated by desensitization. In    this case report, we pr
esent a patient showing an allergic reaction soon after    starting GH therapy m
ediated by immune complex (hypersensitivity type III reaction).    In this condi
tion, the attempt to perform the desensitization procedure can    perpetuate imm
une complex deposition determining a life threatening renal and    respiratory i
nsufficiency.</font></p> <hr size="1" noshade>     ^cY#11.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\11.htm#S#p#22#18#article#72#<p>&nbsp;</p>     ^cY#11.h
tm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\11.htm#S#p#23#19#article#72#<p>&nbsp;</p>     ^cY#11.h
tm##
00336000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704011400069002000700183#v55n1#V:\SciELO
\serial\abem\v55n1\markup\11.htm#S#p#24#20#article#72#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>INTRODU&Ccedil;&Atilde;O</b></font></p> 
    ^cY#11.htm##
00964000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704074200069002000700811#v55n1#V:\SciELO
\serial\abem\v55n1\markup\11.htm#S#p#25#21#article#72#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Rea&ccedil;&otilde;es    al&eacute;rgicas a
o horm&ocirc;nio de crescimento (GH) s&atilde;o raramente    descritas, sendo re
presentadas por rea&ccedil;&otilde;es de hipersensibilidade    tipo I ou rea&cce
dil;&otilde;es IgE mediadas (1,2). Neste tipo de rea&ccedil;&atilde;o    imune, 
o procedimento de dessensibiliza&ccedil;&atilde;o &eacute; poss&iacute;vel    ut
ilizando-se doses muito baixas, progressivamente aumentadas at&eacute; a dose   
 recomendada (2-5). Para outros horm&ocirc;nios sint&eacute;ticos, como insulina
    e horm&ocirc;nio tireoidiano (6), as rea&ccedil;&otilde;es al&eacute;rgicas 
   mais relatadas tamb&eacute;m s&atilde;o IgE mediadas.</font></p>     ^cY#11.h
tm##
00725000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704050300069002000700572#v55n1#V:\SciELO
\serial\abem\v55n1\markup\11.htm#S#p#26#22#article#72#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Ainda mais raras    s&atilde;o as rea&ccedi
l;&otilde;es mediadas por imunocomplexo ou rea&ccedil;&otilde;es    de hipersens
ibilidade tipo III. Neste tipo de rea&ccedil;&atilde;o, a tentativa    de dessen
sibiliza&ccedil;&atilde;o pode perpetuar a forma&ccedil;&atilde;o de    imunocom
plexos, com risco de ocorrer dep&oacute;sito destes, determinando insufici&ecirc
;ncia    renal, respirat&oacute;ria e mesmo &oacute;bito.</font></p>     ^cY#11.
htm##
00572000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704035000069002000700419#v55n1#V:\SciELO
\serial\abem\v55n1\markup\11.htm#S#p#27#23#article#72#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">O presente relato    descreve cl&iacute;nic
a e laboratorialmente uma paciente que durante o uso de    GH apresentou rea&cce
dil;&atilde;o al&eacute;rgica e falha terap&ecirc;utica,    necessitando a disti
n&ccedil;&atilde;o entre os tipos I e III de hipersensibilidade.</font></p>     
^cY#11.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\11.htm#S#p#28#24#article#72#<p>&nbsp;</p>     ^cY#11.h
tm##
00326000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704010400069002000700173#v55n1#V:\SciELO
\serial\abem\v55n1\markup\11.htm#S#p#29#25#article#72#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>RELATO DO CASO</b></font></p>     ^cY#11
.htm##
00641000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704041900069002000700488#v55n1#V:\SciELO
\serial\abem\v55n1\markup\11.htm#S#p#30#26#article#72#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">MP, branca, nascida    em S&atilde;o Paulo,
 12 anos de idade, encaminhada por baixa estatura e obesidade.    Crian&ccedil;a
 sempre foi pequena, o que se tornou mais evidente ap&oacute;s    os 5 anos de i
dade, quando simultaneamente passou a observar maior ganho ponderal.    Apresent
ava cefaleia holocraniana espor&aacute;dica e miopia.</font></p>     ^cY#11.htm#
#
01348000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704112600069002000701195#v55n1#V:\SciELO
\serial\abem\v55n1\markup\11.htm#S#p#31#27#article#72#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Nascida a termo,    parto ces&aacute;rio po
r apresenta&ccedil;&atilde;o p&eacute;lvica, Apgar 4    e 9, referido como adequ
ada para a idade gestacional. Teve hipoglicemia transit&oacute;ria    e icter&ia
cute;cia neonatal tratada apenas com fototerapia. Alta hospitalar    com cinco d
ias de vida. Apresentou luxa&ccedil;&atilde;o cong&ecirc;nita bilateral    dos q
uadris associada a p&eacute;s tortos cong&ecirc;nitos, frouxid&atilde;o    ligam
entar dos joelhos e rota&ccedil;&atilde;o interna da t&iacute;bia esquerda.    S
ubmetida &agrave; imobiliza&ccedil;&atilde;o gessada seguida de tr&ecirc;s    co
rre&ccedil;&otilde;es cir&uacute;rgicas dos p&eacute;s durante os primeiros    a
nos de vida. Entre os 3 e 10 anos de idade, foi submetida a seis procedimentos  
  ortop&eacute;dicos para corre&ccedil;&atilde;o do quadril e membros inferiores
,    com resultado cir&uacute;rgico satisfat&oacute;rio. Identificado ainda espo
ndilolistese    ao n&iacute;vel da v&eacute;rtebra L5, sem necessidade de interv
en&ccedil;&atilde;o    cir&uacute;rgica.</font></p>     ^cY#11.htm##
00686000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704046400069002000700533#v55n1#V:\SciELO
\serial\abem\v55n1\markup\11.htm#S#p#32#28#article#72#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Antecedentes familiais:    m&atilde;e com e
statura de 158 cm, quatro gesta&ccedil;&otilde;es, um parto,    tr&ecirc;s abort
amentos espont&acirc;neos relacionados a &uacute;tero bicorno.    Pai com estatu
ra de 173 cm, referindo hipertens&atilde;o arterial e dislipidemia.    Hist&oacu
te;rico familiar de diabetes melito tipo 2 e hipertens&atilde;o arterial.    Neg
a consanguinidade.</font></p>     ^cY#11.htm##
00784000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704056200069002000700631#v55n1#V:\SciELO
\serial\abem\v55n1\markup\11.htm#S#p#33#29#article#72#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">O exame f&iacute;sico    inicial evidenciou
 peso = 50,7 kg (p = 75) e estatura de 132,3 cm (p = 3); com    &iacute;ndice de
 massa corporal de 29,1 (&gt; p95), est&aacute;gio puberal:    M1P1, press&atild
e;o arterial normal e sem sinais cl&iacute;nicos sugestivos    de s&iacute;ndrom
e de Cushing. Exames laboratoriais gerais normais, idade &oacute;ssea    de 10 a
nos, cari&oacute;tipo: 46,XX, CT = 190 mg/dL; HDL = 37 mg/dL; LDL = 131    mg/dL
 e triglic&eacute;rides = 108 mg/dl.</font></p>     ^cY#11.htm##
00552000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704033000069002000700399#v55n1#V:\SciELO
\serial\abem\v55n1\markup\11.htm#S#p#34#30#article#72#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Exames hormonais    basais: IGF1 = 36 ng/mL
 (RIE,VR = 110-565); IGFBP3 = 1,7 mcg/mL (RIE,VR = 1,5-4,3);    LH &lt; 0,01 mUI
/L(QL); FSH = 0,4 mUI/L(QL); E2 &lt; 10 pg/mL (RIE); T3 = 119    ng/mL; T4 = 4,6
 mcg/dL; T4L = 0,66 ng/dL; TSH = 3,3 mUI/mL.</font></p>     ^cY#11.htm##
00378000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704015600069002000700225#v55n1#V:\SciELO
\serial\abem\v55n1\markup\11.htm#S#p#35#31#article#72#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Teste da clonidina:    GH basal = 0,07 ng/m
L e pico GH = 0,08 ng/mL (QL).</font></p>     ^cY#11.htm##
00723000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704050100069002000700570#v55n1#V:\SciELO
\serial\abem\v55n1\markup\11.htm#S#p#36#32#article#72#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Teste combinado    de avalia&ccedil;&atilde
;o da fun&ccedil;&atilde;o hipofis&aacute;ria (<a href="/img/revistas/abem/v55n1
/11t01.jpg">Tabela    1</a>) evidenciando falta de resposta do GH e resposta par
cial do cortisol durante    hipoglicemia; discreta eleva&ccedil;&atilde;o da pro
lactina e hiper-resposta    do TSH, sugestiva de hipotiroidismo hipotal&acirc;mi
co. Aus&ecirc;ncia de resposta    gonadotr&oacute;fica.</font></p>     ^cY#11.ht
m##
00474000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704025200069002000700321#v55n1#V:\SciELO
\serial\abem\v55n1\markup\11.htm#S#p#37#33#article#72#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A resson&acirc;ncia    magn&eacute;tica evi
denciou intensa hipoplasia de hip&oacute;fise anterior associada    a hipersinal
 ect&oacute;pico da hip&oacute;fise posterior.</font></p>     ^cY#11.htm##
00519000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704029700069002000700366#v55n1#V:\SciELO
\serial\abem\v55n1\markup\11.htm#S#p#38#34#article#72#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A paciente foi    medicada com acetato de h
idrocortisona (15 mg/m<sup>2</sup>), dividido em duas    doses di&aacute;rias; l
evotiroxina s&oacute;dica (100 mcg/dia) e horm&ocirc;nio    de crescimento (0,1 
UI/kg/dia).</font></p>     ^cY#11.htm##
00841000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704061900069002000700688#v55n1#V:\SciELO
\serial\abem\v55n1\markup\11.htm#S#p#39#35#article#72#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Ap&oacute;s duas    semanas do in&iacute;ci
o da terapia com GH, come&ccedil;ou a apresentar les&otilde;es    de pele, refer
idas como urtic&aacute;ria, al&eacute;m de dor em joelho direito.    Ao exame f&
iacute;sico, constataram-se les&otilde;es m&aacute;culo-papulares,    de di&acir
c;metro entre 3 e 4 cm, algumas confluentes, n&atilde;o urticariformes,    princ
ipalmente em face e tronco; articula&ccedil;&otilde;es sem sinais flog&iacute;st
icos;    adenomegalia cervical, axilar, inguinal e ba&ccedil;o palp&aacute;vel (
1 cm    RCE).</font></p>     ^cY#11.htm##
01046000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704082400069002000700893#v55n1#V:\SciELO
\serial\abem\v55n1\markup\11.htm#S#p#40#36#article#72#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Diante do quadro,    foi realizada a dosage
m de IgE total, que se mostrou normal. A pesquisa de imunocomplexos    foi reali
zada em sangue perif&eacute;rico, seguindo-se o m&eacute;todo descrito    resumi
damente a seguir: ap&oacute;s coleta de 10 mL de sangue com material pr&eacute;-
aquecido,    este foi imediatamente incubado a 37ºC, separando-se o co&aacute;gu
lo ap&oacute;s    duas horas. O soro foi armazenado a 4ºC e, ap&oacute;s 10 dias
, avaliado para    constata&ccedil;&atilde;o de forma&ccedil;&atilde;o do criopr
ecipitado, que    ap&oacute;s separa&ccedil;&atilde;o em centr&iacute;fuga refri
gerada foi lavado    com soro fisiol&oacute;gico. Realizou-se a solubiliza&ccedi
l;&atilde;o do crioprecipitado    ap&oacute;s aquecimento.</font></p>     ^cY#11
.htm##
01126000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704090400069002000700973#v55n1#V:\SciELO
\serial\abem\v55n1\markup\11.htm#S#p#41#37#article#72#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">O crioprecipitado    foi colocado em placas
 de imunodifus&atilde;o radial, identificando-se a forma&ccedil;&atilde;o    de 
halos para IgM, IgG, IGA e componentes C3 e C4 do complemento. Para a identifica
&ccedil;&atilde;o    de imunocomplexo, o crioprecipitado foi colocado em tr&ecir
c;s ensaios de agarose:    um contendo o pr&oacute;prio medicamento utilizado pe
la paciente GH, outro GH    de marca diferente, e um terceiro ensaio contendo ap
enas o diluente. As amostras    do crioprecipitado foram dilu&iacute;das 1:10 e 
submetidas ao gel de agarose    1,0% e 2,4%. A imunodifus&atilde;o radial do pre
cipitado, mais bem observada    ap&oacute;s 72 horas, foi somente observada nas 
placas contendo ambas as apresenta&ccedil;&otilde;es    de GH, n&atilde;o havend
o imunodifus&atilde;o na placa contendo apenas o diluente.</font></p>     ^cY#11
.htm##
00760000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704053800069002000700607#v55n1#V:\SciELO
\serial\abem\v55n1\markup\11.htm#S#p#42#38#article#72#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Orientada a suspens&atilde;o    do GH, a re
gress&atilde;o dos sinais cl&iacute;nicos de hipersensibilidade foi    observada
 em cerca de 30 dias. Evolutivamente, a paciente foi mantida sem uso    de GH, t
endo recebido doses substitutivas de levotiroxina, prednisolona e estrog&ecirc;n
ios    conjugados, variando progressivamente de 0,15 a 0,625 mg/dia. Apresentou 
menarca    aos 17,8 anos. Doses atuais de tiroxina (88 mcg/dia) e prednisolona (
1,5 mg/dia).</font></p>     ^cY#11.htm##
00399000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704017700069002000700246#v55n1#V:\SciELO
\serial\abem\v55n1\markup\11.htm#S#p#43#39#article#72#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A evolu&ccedil;&atilde;o    p&ocirc;ndero-e
statural est&aacute; na <a href="#f1">figura 1</a>.</font></p>     ^cY#11.htm##
00255000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704003300069002000700102#v55n1#V:\SciELO
\serial\abem\v55n1\markup\11.htm#S#p#44#40#article#72#<p><a name="f1"></a></p>  
   ^cY#11.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\11.htm#S#p#45#41#article#72#<p>&nbsp;</p>     ^cY#11.h
tm##
00299000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704007700069002000700146#v55n1#V:\SciELO
\serial\abem\v55n1\markup\11.htm#S#p#46#42#article#72#<p align="center"><img src
="/img/revistas/abem/v55n1/11f01.jpg"></p>     ^cY#11.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\11.htm#S#p#47#43#article#72#<p>&nbsp;</p>     ^cY#11.h
tm##
00328000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704010600069002000700175#v55n1#V:\SciELO
\serial\abem\v55n1\markup\11.htm#S#p#48#44#article#72#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>DISCUSS&Atilde;O</b></font></p>     ^cY#
11.htm##
01952000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704173000069002000701799#v55n1#V:\SciELO
\serial\abem\v55n1\markup\11.htm#S#p#49#45#article#72#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Os dados observados    indicam a presen&cce
dil;a de hipersensibilidade tipo III (mediada por imunocomplexos).    O in&iacut
e;cio dos sintomas ap&oacute;s duas semanas de uso do GH reflete o    per&iacute
;odo de lat&ecirc;ncia para o aparecimento de imunocomplexos de tamanho    inter
medi&aacute;rio, ou seja, excesso relativo de mol&eacute;culas de ant&iacute;gen
o    em rela&ccedil;&atilde;o ao anticorpo. Os complexos pequenos n&atilde;o des
encadeiam    a ativa&ccedil;&atilde;o de complemento, enquanto os grandes s&atil
de;o rapidamente    reconhecidos pelo sistema imunol&oacute;gico e fagocitados. 
Os imunocomplexos    de tamanho intermedi&aacute;rio s&atilde;o sol&uacute;veis,
 circulando pelo    organismo; ao encontrarem barreiras, como sin&oacute;via, al
v&eacute;olos, glom&eacute;rulos,    depositam-se e a patogenia da doen&ccedil;a
 &eacute; determinada pela pr&oacute;pria    deposi&ccedil;&atilde;o, al&eacute;
m da ativa&ccedil;&atilde;o do complemento,    determinando lise do local onde h
ouve o dep&oacute;sito. Essa patogenia poderia    explicar as altera&ccedil;&oti
lde;es cut&acirc;neas e a dor articular referida    pela paciente, assim como um
a poss&iacute;vel evolu&ccedil;&atilde;o para insufici&ecirc;ncia    respirat&oa
cute;ria e/ou renal apresentada em casos de cont&iacute;nua administra&ccedil;&a
tilde;o    de ant&iacute;geno, o que n&atilde;o foi o caso do presente relato, p
ois o GH    foi prontamente suspenso. &Eacute; importante ressaltar que a dessen
sibiliza&ccedil;&atilde;o    seria totalmente contraindicada nessa situa&ccedil;
&atilde;o, uma vez que n&atilde;o    se tratava de rea&ccedil;&atilde;o IgE medi
ada.</font></p>     ^cY#11.htm##
01504000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704128200069002000701351#v55n1#V:\SciELO
\serial\abem\v55n1\markup\11.htm#S#p#50#46#article#72#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Laboratorialmente    a rea&ccedil;&atilde;o
 tipo III foi estabelecida pela presen&ccedil;a de crioprecipitado.    Tivemos o
 cuidado de afastar a presen&ccedil;a de fibrinog&ecirc;nio atrav&eacute;s    da
 solubiliza&ccedil;&atilde;o do crioprecipitado ap&oacute;s aquecimento e    pel
a confirma&ccedil;&atilde;o da presen&ccedil;a de IgM, IgG, IgA, componentes    
C3 e C4 do complemento. A constata&ccedil;&atilde;o da especificidade do criopre
cipitado    para GH foi feita atrav&eacute;s dos ensaios de dilui&ccedil;&atilde
;o. Foram    tentadas diferentes concentra&ccedil;&otilde;es e as que permitiram
 melhor visualiza&ccedil;&atilde;o    da difus&atilde;o radial do crioprecipitad
o da paciente em quest&atilde;o foi    a concentra&ccedil;&atilde;o de 1:10 em g
el de agarose 1,0% e 2,4%. A n&atilde;o    forma&ccedil;&atilde;o de halo afasta
 a possibilidade de forma&ccedil;&atilde;o    de anticorpos contra algum contami
nante do diluente. A presen&ccedil;a de imunodifus&atilde;o    do crioprecipitad
o por meio de agarose contendo GH de outra marca, bem como    contendo o pr&oacu
te;prio medicamento utilizado pela paciente, constata a especificidade    da rea
&ccedil;&atilde;o ao horm&ocirc;nio.</font></p>     ^cY#11.htm##
00491000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704026900069002000700338#v55n1#V:\SciELO
\serial\abem\v55n1\markup\11.htm#S#p#51#47#article#72#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Embora ainda n&atilde;o    dispon&iacute;ve
l no mercado em nosso pa&iacute;s, uma possibilidade terap&ecirc;utica    seria 
o uso da IGF1 recombinante para o tratamento da baixa estatura.</font></p>     ^
cY#11.htm##
00804000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704058200069002000700651#v55n1#V:\SciELO
\serial\abem\v55n1\markup\11.htm#S#p#52#48#article#72#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Conclu&iacute;mos    que a paciente apresen
tou rea&ccedil;&atilde;o de hipersensibilidade tipo III,    ou seja, mediada por
 imunocomplexo, ao horm&ocirc;nio de crescimento utilizado.    O presente relato
 &eacute; importante para ressaltar que as rea&ccedil;&otilde;es    ao GH n&atil
de;o s&atilde;o apenas mediadas por IgE, servindo de alerta para    a contraindi
ca&ccedil;&atilde;o do procedimento de dessensibiliza&ccedil;&atilde;o    nesse 
tipo de rea&ccedil;&atilde;o mediada por imunocomplexos.</font></p>     ^cY#11.h
tm##
00428000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704020600069002000700275#v55n1#V:\SciELO
\serial\abem\v55n1\markup\11.htm#S#p#53#49#article#72#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Declara&ccedil;&atilde;o:    os autores dec
laram n&atilde;o haver conflitos de interesse cient&iacute;fico    nesse estudo.
</font></p>     ^cY#11.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\11.htm#S#p#54#50#article#72#<p>&nbsp;</p>     ^cY#11.h
tm##
00329000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704010700069002000700176#v55n1#V:\SciELO
\serial\abem\v55n1\markup\11.htm#S#p#55#51#article#72#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>REFER&Ecirc;NCIAS</b></font></p>     ^cY
#11.htm##
00454000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000200069704021800071002000700289#v55
n1#V:\SciELO\serial\abem\v55n1\markup\11.htm#S#p#56#52#article#72#1#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">1. Petersen K,    Khalaf A, Z
eisel H. IgE antibodies to human growth hormone prior to and during    the treat
ment. Acta Endocrinol. 1989;121:501-4.    ^cY#11.htm##
00242000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002000069002000700089#v55n1#V:\SciELO
\serial\abem\v55n1\markup\11.htm#S#p#57#53#article#72#</font></p>     ^cY#11.htm
##
00432000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000200069704019600071002000700267#v55
n1#V:\SciELO\serial\abem\v55n1\markup\11.htm#S#p#58#54#article#72#2#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">2. Ranke MB, Bierich    JR. C
linical experience with authentic recombinant somatropin. Acta Paediatr    Scand
. 1987;331:9-17.    ^cY#11.htm##
00242000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002000069002000700089#v55n1#V:\SciELO
\serial\abem\v55n1\markup\11.htm#S#p#59#55#article#72#</font></p>     ^cY#11.htm
##
00453000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000200069704021700071002000700288#v55
n1#V:\SciELO\serial\abem\v55n1\markup\11.htm#S#p#60#56#article#72#3#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">3. Walker SB, Weiss    ME, Ta
ttoni DS. Systemic reaction to human growth hormone treated with acute    desens
itization. Pediatrics. 1992;90:108-9.    ^cY#11.htm##
00242000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002000069002000700089#v55n1#V:\SciELO
\serial\abem\v55n1\markup\11.htm#S#p#61#57#article#72#</font></p>     ^cY#11.htm
##
00492000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000200069704025600071002000700327#v55
n1#V:\SciELO\serial\abem\v55n1\markup\11.htm#S#p#62#58#article#72#4#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">4. Junprasert J,    Javier FC
, Rodriguea JA, Moore C, Sorensen RU. Successful intravenous desensitization    
of growth hormone hypersensitivity. J Ped Endocrinol Metabol. 1997;10:223-6.    
^cY#11.htm##
00242000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002000069002000700089#v55n1#V:\SciELO
\serial\abem\v55n1\markup\11.htm#S#p#63#59#article#72#</font></p>     ^cY#11.htm
##
00584000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000200069704034800071002000700419#v55
n1#V:\SciELO\serial\abem\v55n1\markup\11.htm#S#p#64#60#article#72#5#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">5. Davis JRE, Sheppard    MC,
 Shakespear RA, Lynch SS, Clayton RN. Does growth hormone releasing factor    de
sensitize the somatotroph? Interpretation of responses of growth hormone during 
   and after 10-hour infusion of grf 1-29 amide in man. Clin Endocrinol. 2008;24
:135-40.    ^cY#11.htm##
00242000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002000069002000700089#v55n1#V:\SciELO
\serial\abem\v55n1\markup\11.htm#S#p#65#61#article#72#</font></p>     ^cY#11.htm
##
00492000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000200069704025600071002000700327#v55
n1#V:\SciELO\serial\abem\v55n1\markup\11.htm#S#p#66#62#article#72#6#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">6. Shibata H, Hayakawa    H, 
Hirukawa M. Hypersensitivity caused by synthetic thyroid hormones in a hypothyro
id    patient with Hashimoto's thyroiditis. Arch Inter Med. 1986;146:1624-5.    
^cY#11.htm##
00242000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002000069002000700089#v55n1#V:\SciELO
\serial\abem\v55n1\markup\11.htm#S#p#67#63#article#72#</font></p>     ^cY#11.htm
##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\11.htm#S#p#68#64#article#72#<p>&nbsp;</p>     ^cY#11.h
tm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\11.htm#S#p#69#65#article#72#<p>&nbsp;</p>     ^cY#11.h
tm##
00421000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704019900069002000700268#v55n1#V:\SciELO
\serial\abem\v55n1\markup\11.htm#S#p#70#66#article#72#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b><a name="back"></a><a href="#top"><img s
rc="/img/revistas/abem/v55n1/seta.jpg" border="0"></a>    Correspond&ecirc;ncia 
para:    ^cY#11.htm##
00257000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704003500069002000700104#v55n1#V:\SciELO
\serial\abem\v55n1\markup\11.htm#S#p#71#67#article#72#<br>   </b> Cristiane Koch
i    ^cY#11.htm##
00260000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704003800069002000700107#v55n1#V:\SciELO
\serial\abem\v55n1\markup\11.htm#S#p#72#68#article#72#<br>   Rua Dona Veridiana,
 311    ^cY#11.htm##
00246000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002400069002000700093#v55n1#V:\SciELO
\serial\abem\v55n1\markup\11.htm#S#p#73#69#article#72#<br>   01238-010    ^cY#11
.htm##
00305000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704008300069002000700152#v55n1#V:\SciELO
\serial\abem\v55n1\markup\11.htm#S#p#74#70#article#72#<br>   <a href="mailto:cko
chi@uol.com.br">ckochi@uol.com.br</a></font></p>     ^cY#11.htm##
00317000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704009500069002000700164#v55n1#V:\SciELO
\serial\abem\v55n1\markup\11.htm#S#p#75#71#article#72#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Recebido em 19/Mail/2010    ^cY#11.htm##
00270000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704004800069002000700117#v55n1#V:\SciELO
\serial\abem\v55n1\markup\11.htm#S#p#76#72#article#72#<br>   Aceito em 11/Nov/20
10</font></p>     ^cY#11.htm##
00519000000000265000450000400060000070200420000670500020004870600020005070000030
00527010002000557090008000577080002000651180002000670100018000690100016000870100
01600103012007700119033001700196065000900213064000500222031000400227014000600231
865000900237002000700246#v55n1#V:\SciELO\serial\abem\v55n1\markup\11.htm#S#c#77#
1#article#6#1#^rND^sPetersen^nK#^rND^sKhalaf^nA#^rND^sZeisel^nH#IgE antibodies t
o human growth hormone prior to and during the treatment^len#Acta Endocrinol.#19
890000#1989#121#501-4#20110200#11.htm##
00493000000000265000450000400060000070200420000670500020004870600020005070000030
00527010002000557090008000577080002000651180002000670100016000690100018000850120
06200103030002100165710000200186065000900188064000500197031000400202014000500206
865000900211002000700220#v55n1#V:\SciELO\serial\abem\v55n1\markup\11.htm#S#c#78#
2#article#6#2#^rND^sRanke^nMB#^rND^sBierich^nJR#Clinical experience with authent
ic recombinant somatropin^len#Acta Paediatr Scand.#2#19870000#1987#331#9-17#2011
0200#11.htm##
00562000000000289000450000400060000070200420000670500020004870600020005070000030
00527010002000557090008000577080002000651180002000670100017000690100016000860100
01800102012008100120030001100201065000900212064000500221031000300226014000600229
865000900235002000700244035001000251801001100261#v55n1#V:\SciELO\serial\abem\v55
n1\markup\11.htm#S#c#79#3#article#6#3#^rND^sWalker^nSB#^rND^sWeiss^nME#^rND^sTat
toni^nDS#Systemic reaction to human growth hormone treated with acute desensitiz
ation^len#Pediatrics#19920000#1992#90#108-9#20110200#11.htm#0031-4005#Pediatrics
##
00606000000000301000450000400060000070200420000670500020004870600020005070000030
00527010002000557090008000577080002000651180002000670100020000690100017000890100
02000106010001500126010001900141012007800160030002500238710000200263065000900265
064000500274031000300279014000600282865000900288002000700297#v55n1#V:\SciELO\ser
ial\abem\v55n1\markup\11.htm#S#c#80#4#article#6#4#^rND^sJunprasert^nJ#^rND^sJavi
er^nFC#^rND^sRodriguea^nJA#^rND^sMoore^nC#^rND^sSorensen^nRU#Successful intraven
ous desensitization of growth hormone hypersensitivity^len#J Ped Endocrinol Meta
bol#2#19970000#1997#10#223-6#20110200#11.htm##
00696000000000301000450000400060000070200420000670500020004870600020005070000030
00527010002000557090008000577080002000651180002000670100017000690100019000860100
02100105010001600126010001800142012017600160030001600336710000200352065000900354
064000500363031000300368014000700371865000900378002000700387#v55n1#V:\SciELO\ser
ial\abem\v55n1\markup\11.htm#S#c#81#5#article#6#5#^rND^sDavis^nJRE#^rND^sSheppar
d^nMC#^rND^sShakespear^nRA#^rND^sLynch^nSS#^rND^sClayton^nRN#Does growth hormone
 releasing factor desensitize the somatotroph?: Interpretation of responses of g
rowth hormone during and after 10-hour infusion of grf 1-29 amide in man^len#Cli
n Endocrinol#2#20080000#2008#24#135-40#20110200#11.htm##
00571000000000277000450000400060000070200420000670500020004870600020005070000030
00527010002000557090008000577080002000651180002000670100017000690100018000860100
01800104012011200122030001600234710000200250065000900252064000500261031000400266
014000700270865000900277002000700286#v55n1#V:\SciELO\serial\abem\v55n1\markup\11
.htm#S#c#82#6#article#6#6#^rND^sShibata^nH#^rND^sHayakawa^nH#^rND^sHirukawa^nM#H
ypersensitivity caused by synthetic thyroid hormones in a hypothyroid patient wi
th Hashimoto's thyroiditis^len#Arch Inter Med.#2#19860000#1986#146#1624-5#201102
00#11.htm##
00263000000000169000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640910009000660920007000750020007000827030
00400089#v55n1#V:\SciELO\serial\abem\v55n1\markup\12.htm#S#o#1#1#article#1#20110
324#154608#12.htm#106##
02398000000000469000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640710003000660400003000690010006000720420
00200078120000400080038000400084121000300088049000800091158000300099030002600102
03100030012803200020013106500090013301400090014203500100015101201240016101201290
02850100041004140100033004550700061004880830643005490830679011921170006018710720
00301877112000901880111001101889114000901900113001201909002000701921#v55n1#V:\Sc
iELO\serial\abem\v55n1\markup\12.htm#S#h#2#1#article#1#oa#en#br1.1#1#4.0#TAB#12#
ABEM060#nd#Arq Bras Endocrinol Metab#55#1#20110200#^f81^l84#0004-2730#Increased 
levothyroxine requirement in a woman with previously well-controlled hypothyroid
ism and intestinal giardiasis^len#Aumento da necessidade de levotiroxina em uma 
paciente com hipotireoidismo previamente bem-controlado e giardíase intestinal^l
pt#^rND^1A01^nRafael de Figueiredo^sRadaeli#^rND^1A01^nLeandro Arthur^sDiehl#Uni
versidade Estadual de Londrina^iA01^cLondrina^sPR^pBrazil#^len^aThe most common 
cause of apparent inefficiency or resistance to oral therapy with levothyroxine 
for hypothyroidism is nonadhesion. However, in some subjects in whom the control
 of hypothyroidism is extremely difficult, levothyroxine bioavailability defects
 should be considered. We report here the case of a 57-year-old woman with hypot
hyroidism that was well-controlled for the previous 6 years but suddenly present
ed with poor hormonal control and abdominal symptoms, despite repeatedly reporti
ng good compliance to therapy. Adequate control of thyroid function was only obt
ained after intestinal giardiasis was diagnosed and treated.#^lpt^aA causa mais 
comum de aparente ineficácia ou resistência ao tratamento do hipotireoidismo com
 levotiroxina oral é a má adesão. No entanto, em alguns pacientes nos quais o co
ntrole do hipotireoidismo é extremamente difícil, defeitos na biodisponibilidade
 da levotiroxina devem ser considerados. Relatamos aqui o caso de uma mulher de 
57 anos de idade com hipotireoidismo que vinha previamente bem controlado durant
e 6 anos, mas que, abruptamente, começou a apresentar mau controle hormonal, ape
sar de insistentemente relatar boa adesão ao tratamento. O controle adequado da 
função tireoidiana só foi possível depois que uma giardíase intestinal foi diagn
osticada e tratada.#other#17#20100805#Aug/5/2010#20101115#Nov/15/2010#12.htm##
02412000000000469000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640710003000660400003000690010006000720420
00200078120000400080038000400084121000300088049000800091158000300099030002600102
03100030012803200020013106500090013301400090014203500100015101201310016101201360
02920100041004280100033004690700061005020830643005630830679012061170006018850720
00301891112000901894111001101903114000901914113001201923002000701935#v55n1#V:\Sc
iELO\serial\abem\v55n1\markup\12.htm#S#f#3#1#article#1#oa#en#br1.1#1#4.0#TAB#12#
ABEM060#nd#Arq Bras Endocrinol Metab#55#1#20110200#^f81^l84#0004-2730#<b>Increas
ed levothyroxine requirement in a woman with previously well-controlled hypothyr
oidism and intestinal giardiasis</b>^len#<b>Aumento da necessidade de levotiroxi
na em uma paciente com hipotireoidismo previamente bem-controlado e giardíase in
testinal</b>^lpt#^rND^1A01^nRafael de Figueiredo^sRadaeli#^rND^1A01^nLeandro Art
hur^sDiehl#Universidade Estadual de Londrina^iA01^cLondrina^sPR^pBrazil#^len^aTh
e most common cause of apparent inefficiency or resistance to oral therapy with 
levothyroxine for hypothyroidism is nonadhesion. However, in some subjects in wh
om the control of hypothyroidism is extremely difficult, levothyroxine bioavaila
bility defects should be considered. We report here the case of a 57-year-old wo
man with hypothyroidism that was well-controlled for the previous 6 years but su
ddenly presented with poor hormonal control and abdominal symptoms, despite repe
atedly reporting good compliance to therapy. Adequate control of thyroid functio
n was only obtained after intestinal giardiasis was diagnosed and treated.#^lpt^
aA causa mais comum de aparente ineficácia ou resistência ao tratamento do hipot
ireoidismo com levotiroxina oral é a má adesão. No entanto, em alguns pacientes 
nos quais o controle do hipotireoidismo é extremamente difícil, defeitos na biod
isponibilidade da levotiroxina devem ser considerados. Relatamos aqui o caso de 
uma mulher de 57 anos de idade com hipotireoidismo que vinha previamente bem con
trolado durante 6 anos, mas que, abruptamente, começou a apresentar mau controle
 hormonal, apesar de insistentemente relatar boa adesão ao tratamento. O control
e adequado da função tireoidiana só foi possível depois que uma giardíase intest
inal foi diagnosticada e tratada.#other#17#20100805#Aug/5/2010#20101115#Nov/15/2
010#12.htm##
02529000000000493000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640640013000660710003000790400003000820010
00600085042000200091120000400093038000400097121000300101049000800104158000300112
03000290011503100030014403200020014706500090014901400090015803500100016701201240
01770120129003010100041004300100033004710700063005040830643005670830679012101170
00601889072000301895112000901898111001101907114000901918113001201927002000701939
008008901946#v55n1#V:\SciELO\serial\abem\v55n1\markup\12.htm#S#l#4#1#article#1#^
mFeb.^a2011#oa#en#br1.1#1#4.0#tab#12#ABEM060#nd#Arq. bras. endocrinol. metab#55#
1#20110200#^f81^l84#0004-2730#Increased levothyroxine requirement in a woman wit
h previously well-controlled hypothyroidism and intestinal giardiasis^len#Aument
o da necessidade de levotiroxina em uma paciente com hipotireoidismo previamente
 bem-controlado e giardíase intestinal^lpt#^rND^1A01^nRafael de Figueiredo^sRada
eli#^rND^1A01^nLeandro Arthur^sDiehl#^iA01^1Universidade Estadual de Londrina^cL
ondrina^sPR^pBrazil#^len^aThe most common cause of apparent inefficiency or resi
stance to oral therapy with levothyroxine for hypothyroidism is nonadhesion. How
ever, in some subjects in whom the control of hypothyroidism is extremely diffic
ult, levothyroxine bioavailability defects should be considered. We report here 
the case of a 57-year-old woman with hypothyroidism that was well-controlled for
 the previous 6 years but suddenly presented with poor hormonal control and abdo
minal symptoms, despite repeatedly reporting good compliance to therapy. Adequat
e control of thyroid function was only obtained after intestinal giardiasis was 
diagnosed and treated.#^lpt^aA causa mais comum de aparente ineficácia ou resist
ência ao tratamento do hipotireoidismo com levotiroxina oral é a má adesão. No e
ntanto, em alguns pacientes nos quais o controle do hipotireoidismo é extremamen
te difícil, defeitos na biodisponibilidade da levotiroxina devem ser considerado
s. Relatamos aqui o caso de uma mulher de 57 anos de idade com hipotireoidismo q
ue vinha previamente bem controlado durante 6 anos, mas que, abruptamente, começ
ou a apresentar mau controle hormonal, apesar de insistentemente relatar boa ade
são ao tratamento. O controle adequado da função tireoidiana só foi possível dep
ois que uma giardíase intestinal foi diagnosticada e tratada.#other#17#20100805#
Aug/5/2010#20101115#Nov/15/2010#12.htm#Internet^ihttp://www.scielo.br/scielo.php
?script=sci_arttext&pid=S0004-27302011000100012##
00347000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000300064704012700067002000700194#v55n1#V:\SciELO
\serial\abem\v55n1\markup\12.htm#S#p#5#1#article#85#<p align="right"><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>CLINICAL    CASE REPORT</b><
/font></p>     ^cY#12.htm##
00242000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000300064704002200067002000700089#v55n1#V:\SciELO
\serial\abem\v55n1\markup\12.htm#S#p#6#2#article#85#<p>&nbsp;</p>     ^cY#12.htm
##
00453000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000300064704023300067002000700300#v55n1#V:\SciELO
\serial\abem\v55n1\markup\12.htm#S#p#7#3#article#85#<p><a name="top"></a><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="4"><b>Increased    levothyroxi
ne requirement in a woman with previously well-controlled hypothyroidism    and 
intestinal giardiasis</b></font></p>     ^cY#12.htm##
00242000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000300064704002200067002000700089#v55n1#V:\SciELO
\serial\abem\v55n1\markup\12.htm#S#p#8#4#article#85#<p>&nbsp;</p>     ^cY#12.htm
##
00447000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000300064704022700067002000700294#v55n1#V:\SciELO
\serial\abem\v55n1\markup\12.htm#S#p#9#5#article#85#<p><font face="Verdana, Aria
l, Helvetica, sans-serif" size="3"><b>Aumento da necessidade    de levotiroxina 
em uma paciente com hipotireoidismo previamente bem-controlado    e giard&iacute
;ase intestinal</b></font></p>     ^cY#12.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000300065704002200068002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\12.htm#S#p#10#6#article#85#<p>&nbsp;</p>     ^cY#12.ht
m##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000300065704002200068002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\12.htm#S#p#11#7#article#85#<p>&nbsp;</p>     ^cY#12.ht
m##
00364000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000300065704014300068002000700211#v55n1#V:\SciELO
\serial\abem\v55n1\markup\12.htm#S#p#12#8#article#85#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="2"><b>Rafael de Figueiredo    Radaeli; Leandro 
Arthur Diehl</b></font></p>     ^cY#12.htm##
00368000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000300065704014700068002000700215#v55n1#V:\SciELO
\serial\abem\v55n1\markup\12.htm#S#p#13#9#article#85#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="2">Universidade Estadual    de Londrina (UEL), 
Londrina, PR, Brazil</font></p>     ^cY#12.htm##
00345000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704012300069002000700192#v55n1#V:\SciELO
\serial\abem\v55n1\markup\12.htm#S#p#14#10#article#85#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><a href="#back">Correspondence    to</a></f
ont></p>     ^cY#12.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\12.htm#S#p#15#11#article#85#<p>&nbsp;</p>     ^cY#12.h
tm##
00266000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704004400069002000700113#v55n1#V:\SciELO
\serial\abem\v55n1\markup\12.htm#S#p#16#12#article#85#<p>&nbsp;</p> <hr size="1"
 noshade>     ^cY#12.htm##
00319000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704009700069002000700166#v55n1#V:\SciELO
\serial\abem\v55n1\markup\12.htm#S#p#17#13#article#85#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>SUMMARY</b></font></p>     ^cY#12.htm##
00987000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704076500069002000700834#v55n1#V:\SciELO
\serial\abem\v55n1\markup\12.htm#S#p#18#14#article#85#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The most common    cause of apparent ineffi
ciency or resistance to oral therapy with levothyroxine    for hypothyroidism is
 nonadhesion. However, in some subjects in whom the control    of hypothyroidism
 is extremely difficult, levothyroxine bioavailability defects    should be cons
idered. We report here the case of a 57-year-old woman with hypothyroidism    th
at was well-controlled for the previous 6 years but suddenly presented with    p
oor hormonal control and abdominal symptoms, despite repeatedly reporting good  
  compliance to therapy. Adequate control of thyroid function was only obtained 
   after intestinal giardiasis was diagnosed and treated.</font></p> <hr size="1
" noshade>     ^cY#12.htm##
00326000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704010400069002000700173#v55n1#V:\SciELO
\serial\abem\v55n1\markup\12.htm#S#p#19#15#article#85#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>SUM&Aacute;RIO</b></font></p>     ^cY#12
.htm##
01126000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704090400069002000700973#v55n1#V:\SciELO
\serial\abem\v55n1\markup\12.htm#S#p#20#16#article#85#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A causa mais comum    de aparente inefic&aa
cute;cia ou resist&ecirc;ncia ao tratamento do hipotireoidismo    com levotiroxi
na oral &eacute; a m&aacute; ades&atilde;o. No entanto, em alguns    pacientes n
os quais o controle do hipotireoidismo &eacute; extremamente dif&iacute;cil,    
defeitos na biodisponibilidade da levotiroxina devem ser considerados. Relatamos
    aqui o caso de uma mulher de 57 anos de idade com hipotireoidismo que vinha 
   previamente bem controlado durante 6 anos, mas que, abruptamente, come&ccedil
;ou    a apresentar mau controle hormonal, apesar de insistentemente relatar boa
 ades&atilde;o    ao tratamento. O controle adequado da fun&ccedil;&atilde;o tir
eoidiana s&oacute;    foi poss&iacute;vel depois que uma giard&iacute;ase intest
inal foi diagnosticada    e tratada.</font></p> <hr size="1" noshade>     ^cY#12
.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\12.htm#S#p#21#17#article#85#<p>&nbsp;</p>     ^cY#12.h
tm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\12.htm#S#p#22#18#article#85#<p>&nbsp;</p>     ^cY#12.h
tm##
00324000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704010200069002000700171#v55n1#V:\SciELO
\serial\abem\v55n1\markup\12.htm#S#p#23#19#article#85#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>INTRODUCTION</b></font></p>     ^cY#12.h
tm##
00940000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704071800069002000700787#v55n1#V:\SciELO
\serial\abem\v55n1\markup\12.htm#S#p#24#20#article#85#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The failure to    adequately control hypoth
yroidism with oral levothyroxine (L-T4) is a common    clinical problem. Nonadhe
sion is the most common cause, but other conditions    can be responsible and sh
ould be investigated in selected patients (1). Giardiasis,    a common intestina
l infection, has been rarely reported to impair the absorption    of orally inge
sted L-T4 (2). We describe here the case of a patient with long-standing    hypo
thyroidism, previously well-controlled with stable doses of L-T4, who abruptly  
  presented poor hormonal control and abdominal symptoms, which only remitted   
 after treatment for giardiasis.</font></p>     ^cY#12.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\12.htm#S#p#25#21#article#85#<p>&nbsp;</p>     ^cY#12.h
tm##
00323000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704010100069002000700170#v55n1#V:\SciELO
\serial\abem\v55n1\markup\12.htm#S#p#26#22#article#85#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>CASE REPORT</b></font></p>     ^cY#12.ht
m##
00525000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704030300069002000700372#v55n1#V:\SciELO
\serial\abem\v55n1\markup\12.htm#S#p#27#23#article#85#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A 57-year-old woman    was referred to the 
Endocrinology public clinic of the city of Londrina (Paran&aacute;,    Brazil), 
in November, 2007, due to difficult management of a previously well-controlled  
  hypothyroidism.</font></p>     ^cY#12.htm##
01068000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704084600069002000700915#v55n1#V:\SciELO
\serial\abem\v55n1\markup\12.htm#S#p#28#24#article#85#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The patient informed    that her primary ca
re physician had diagnosed her with primary hypothyroidism    9 years earlier, b
ecause of her complaints of low energy and depressed humor,    and an elevated s
erum TSH (data not available). She was started on L-T4, with    significant clin
ical and laboratorial improvement. During the next 6 years,    she remained asym
ptomatic with normal TSH levels, and a stable dose of L-T4    (150 mcg), except 
for a marked dose reduction (to 50 mcg) that was necessary    when her medicatio
n was withdrawn from the Brazilian market and she was started    on a new levoth
yroxine brand, apparently more potent than the first one. Results    for the lab
 tests are shown in <a href="/img/revistas/abem/v55n1/12t01.jpg">table    1</a>.
</font></p>     ^cY#12.htm##
01260000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704103800069002000701107#v55n1#V:\SciELO
\serial\abem\v55n1\markup\12.htm#S#p#29#25#article#85#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">About 2 years before    referral she notice
d that her symptoms (mainly fatigue) had returned, despite    that her continuin
g to take her pills as usual. Her TSH, at that time, had increased    to 84 mUI/
mL. The patient insistently denied nonadhesion. Several dose adjustments    were
 tried by the primary care physician during the next 13 months, but her    TSH o
nly became near-normal when she used a daily dose of 125 mcg, 2.5 times    great
er than her previous usual dosage (<a href="/img/revistas/abem/v55n1/12t01.jpg">
Table    1</a>). Interestingly, on that occasion, 9 months before her referral, 
she also    complained of diarrhea and a fecal test was ordered, which resulted 
positive    (specific agent unknown). She was treated with albendazole and in th
e next few    months she was able to gradually reduce her L-T4 to 50 mcg/day, bu
t her physician    referred her to an Endocrinology specialist due to her freque
nt need for dose    adjustments.</font></p>     ^cY#12.htm##
01458000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704123600069002000701305#v55n1#V:\SciELO
\serial\abem\v55n1\markup\12.htm#S#p#30#26#article#85#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">At her first visit    to the endocrinologis
t (November, 2007), she had no symptoms. During a careful    interrogation, she 
reassured the physician that she was taking her levothyroxine    every day, at l
east 30 minutes before breakfast. She was also in use of nifedipine    20 mg, af
ter breakfast and supper, for arterial hypertension, and amitriptyline    25 mg,
 at bedtime, for a mild depressive disorder. She denied any other diseases    or
 the use of any other drugs or medications. She was amenorrheic since the    age
 of 51 and had received postmenopausal hormone therapy until the age of 52.    O
n exam, she presented with good general appearance, weight 53 kg (BMI 22.6    kg
/m<sup>2</sup>), blood pressure 120/85 mmHg (seated), pulse 68 bpm, with a    pa
lpable normal-sized fibroelastic thyroid gland and no other abnormalities.    He
r most recent exam was a TSH 0.14 mUI/mL of 2 months before, when the primary   
 care physician had reduced her dose of L-T4 from 75 mcg to 50 mcg/day. The endo
crinologist    maintained her last dose (50 mcg) and reinforced the importance o
f adhesion,    asking her to come back in 3 months with new lab tests.</font></p
>     ^cY#12.htm##
01081000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704085900069002000700928#v55n1#V:\SciELO
\serial\abem\v55n1\markup\12.htm#S#p#31#27#article#85#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">In March 2008,    she returned with fatigue
, myalgia, muscle cramps, frequent dyspeptic symptoms    and diarrhea. She had g
ained weight (2 kg), her blood pressure was 140/70 mmHg,    and her new tests re
vealed very high TSH levels (&gt; 100 m UI/mL) and a slightly    low free T4, al
ong with a small decrease in hemoglobin (<a href="/img/revistas/abem/v55n1/12t01
.jpg">Table    1</a>). On interrogation, the endocrinologist found out that she 
had been treated    for giardiasis several years before, when she presented simi
lar clinical picture    (she had not reported the use of albendazole on the prev
ious visit a few months    before). As the patient insisted that she was adheren
t, a fecal examination    for ova and parasites was ordered and L-T4 was increas
ed to 75 mcg.</font></p>     ^cY#12.htm##
00775000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704055300069002000700622#v55n1#V:\SciELO
\serial\abem\v55n1\markup\12.htm#S#p#32#28#article#85#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Two months later,    the patient returned r
eporting remission of muscle cramps and fatigue. Fecal    test resulted positive
 for <i>Giardia lamblia</i> and partial improvement in    thyroid function was a
lso noticed (<a href="/img/revistas/abem/v55n1/12t01.jpg">Table    1</a>). The p
atient was prescribed single-dose secnidazole and 2-week metronidazole    PO. Af
ter that treatment, a new fecal test resulted negative, and the diarrhea    and 
abdominal pain disappeared.</font></p>     ^cY#12.htm##
00648000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704042600069002000700495#v55n1#V:\SciELO
\serial\abem\v55n1\markup\12.htm#S#p#33#29#article#85#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The dose of L-T4    was increased to 88 mcg
 a few months later since her TSH still persisted slightly    high. After that, 
the patient presented gradual improvement of thyroid function    tests, without 
further L-T4 dose adjustment and remained asymptomatic for the    next 18 months
 (<a href="/img/revistas/abem/v55n1/12t01.jpg">Table 1</a>).</font></p>     ^cY#
12.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\12.htm#S#p#34#30#article#85#<p>&nbsp;</p>     ^cY#12.h
tm##
00322000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704010000069002000700169#v55n1#V:\SciELO
\serial\abem\v55n1\markup\12.htm#S#p#35#31#article#85#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>DISCUSSION</b></font></p>     ^cY#12.htm
##
01090000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704086800069002000700937#v55n1#V:\SciELO
\serial\abem\v55n1\markup\12.htm#S#p#36#32#article#85#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Adequate intestinal    absorption of levoth
yroxine is essential for the successful management of hypothyroidism.    In clin
ical practice, we often observe patients who remain symptomatic and with    elev
ated TSH levels although they have been prescribed L-T4 in presumably appropriat
e    dosages (about 1.6 to 1.8 mcg/kg/day in the adult). Noncompliance to therap
y    ("pseudomalabsorption") is the main reason for this situation (1,3,4). Othe
r    possibilities are far less common and include the use of other substances t
hat    could interfere with absorption or metabolism of L-T4, or intestinal dise
ases    which could determine true malabsorption of orally ingested thyroid horm
one.    An extensive review on this matter has been recently published in this J
ournal    by Ward (1).</font></p>     ^cY#12.htm##
00615000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704039300069002000700462#v55n1#V:\SciELO
\serial\abem\v55n1\markup\12.htm#S#p#37#33#article#85#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The first step    in the assessment of subj
ects with poorly controlled hypothyroidism should be    to reinforce the importa
nce of adhesion through the daily ingestion of the medication    in the fasting 
state. Some studies show that most patients can be brought to    euthyroidism wi
th this simple measure (5).</font></p>     ^cY#12.htm##
00962000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704074000069002000700809#v55n1#V:\SciELO
\serial\abem\v55n1\markup\12.htm#S#p#38#34#article#85#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">However, in some    cases, TSH levels may p
ersist elevated. In this situation, additional tests    can be performed to eval
uate if there is an identifiable cause for L-T4 malabsorption.    Routinely orde
red tests include: anti-gliadin antibodies (for celiac disease),    inflammation
 markers (for inflammatory intestinal disease), lactose tolerance    test (for l
actose intolerance) (6,7), and, occasionally, anti-T4 antibodies    (8). Short b
owel syndrome after intestinal or bariatric surgery, hepatic cirrhosis    and co
ngestive heart failure can also impair L-T4 intestinal absorption, and    should
 be investigated if there is clinical suspicion (3,6).</font></p>     ^cY#12.htm
##
00670000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704044800069002000700517#v55n1#V:\SciELO
\serial\abem\v55n1\markup\12.htm#S#p#39#35#article#85#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">In our patient,    we decided to search for
 intestinal parasitosis because of her history of giardiasis    and her abdomina
l complaints (dyspepsia, diarrhea). Fecal test, which confirmed    <i>Giardia</i
> infection, is the most often used diagnostic test, although its    sensitivity
 is known to be suboptimal (73% for one sample, and 85% for three    samples) (9
).</font></p>     ^cY#12.htm##
01454000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704123200069002000701301#v55n1#V:\SciELO
\serial\abem\v55n1\markup\12.htm#S#p#40#36#article#85#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><i>Giardia lamblia</i>    is the most preva
lent human intestinal parasitic protist (10). Giardiasis is    probably subdiagn
osed, but it affects 5%-29% of Brazilian children, more commonly    in environme
nts with poor sanitary conditions (11-13). Infected patients may    present diar
rhea, flatulence, and abdominal pain, but most are asymptomatic    (14,15). A kn
own complication of chronic intestinal giardiasis is malabsorption    of drugs a
nd nutrients (leading to anemia, growth retardation, and weight loss).    The pr
esence of trophozoites activates intestinal T lymphocytes, which induce    infla
mmatory epithelial damage, shown by diffuse shortening of microvilli, maldigesti
on    and malabsorption. In addition, <i>Giardia</i> disrupts epithelial tight j
unctions    and induces enterocitic apoptosis resulting in loss of epithelial ba
rrier, increased    intestinal permeability, and diarrhea (10,15). Similar chron
ic malabsorptive    syndromes related to mucosal inflammation have been describe
d with other common    intestinal infection agents such as <i>Strongyloides</i>,
 <i>Clostridium difficile,</i>    and <i>Cryptosporidium</i> (16).</font></p>   
  ^cY#12.htm##
01156000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704093400069002000701003#v55n1#V:\SciELO
\serial\abem\v55n1\markup\12.htm#S#p#41#37#article#85#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Despite the high    frequency of giardiasis
, we found only one report of levothyroxine malabsorption    associated to <i>Gi
ardia lamblia</i> infection in the literature, describing    a patient with pers
istently high TSH while taking a high dose of L-T4 (2). Our    patient presented
 a similar evolution: she had been euthyroid during 6 years    with stable doses
 of L-T4 but presented TSH elevation and increased requirement    of L-T4 coinci
dent with the onset of abdominal symptoms suggestive of <i>Giardia</i>    infect
ion, as well as reduction of that requirement soon after antiparasitic    treatm
ent, at least in two separate occasions. Metronidazole (for a week), or    singl
e-dose secnidazole or tinidazole are the drugs of choice for giardiasis,    with
 &gt; 90% of cure; other options are albendazole, paromomycin, and nitazoxanide 
   (17).</font></p>     ^cY#12.htm##
01012000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704079000069002000700859#v55n1#V:\SciELO
\serial\abem\v55n1\markup\12.htm#S#p#42#38#article#85#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Although it cannot    be totally ruled out,
 nonadhesion was considered an unlikely explanation based    on careful and thor
ough interrogation, suppression of TSH sporadically observed,    and the lack of
 response to the adhesion-stimulant guidance given by the physician.    Drug or 
food interference with L-T4 absorption was also regarded improbable    since ser
um TSH and L-T4 requirement fluctuated significantly while the patient    had no
t changed her habits. Finally, reduction of L-T4 requirement and stabilization  
  of thyroid function was only possible after eradication of the parasite. Due  
  to the good clinical response, the search for other causes of nonabsorption   
 was deemed unnecessary.</font></p>     ^cY#12.htm##
00852000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704063000069002000700699#v55n1#V:\SciELO
\serial\abem\v55n1\markup\12.htm#S#p#43#39#article#85#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">In conclusion,    we suggest that giardiasi
s should also be considered in the assessment of the    "difficult patient" with
 hypothyroidism, after ruling out nonadhesion and use    of interfering drugs, s
pecially in areas with high prevalence of the infection    (Brazil and other dev
eloping countries). Potential candidates to investigation    should include pati
ents with previously well-controlled hypothyroidism, with    symptoms of giardia
sis (weight loss, diarrhea, abdominal pain, anemia) or with    personal or famil
y history of giardiasis.</font></p>     ^cY#12.htm##
00392000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704017000069002000700239#v55n1#V:\SciELO
\serial\abem\v55n1\markup\12.htm#S#p#44#40#article#85#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Disclosure: no    potential conflict of int
erest relevant to this article was reported.</font></p>     ^cY#12.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\12.htm#S#p#45#41#article#85#<p>&nbsp;</p>     ^cY#12.h
tm##
00322000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704010000069002000700169#v55n1#V:\SciELO
\serial\abem\v55n1\markup\12.htm#S#p#46#42#article#85#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>REFERENCES</b></font></p>     ^cY#12.htm
##
00486000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000200069704025000071002000700321#v55
n1#V:\SciELO\serial\abem\v55n1\markup\12.htm#S#p#47#43#article#85#1#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">1. Ward, LS. The    difficult
 patient: drug interaction and the influence of concomitant diseases    on the t
reatment of hypothyroidism. Arq Bras Endocrinol Metab. 2010;54:435-42.    ^cY#12
.htm##
00242000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002000069002000700089#v55n1#V:\SciELO
\serial\abem\v55n1\markup\12.htm#S#p#48#44#article#85#</font></p>     ^cY#12.htm
##
00579000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000200069704034300071002000700414#v55
n1#V:\SciELO\serial\abem\v55n1\markup\12.htm#S#p#49#45#article#85#2#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">2. Seppel T, Rose    F, Schla
ghecke R. Chronic intestinal giardiasis with isolated levothyroxine    malabsorp
tion as reason for severe hypothyroidism - implications for localization    of t
hyroid hormone absorption in the gut. Exp Clin Endocrinol Diabetes. 1996;104:180
-2.    ^cY#12.htm##
00242000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002000069002000700089#v55n1#V:\SciELO
\serial\abem\v55n1\markup\12.htm#S#p#50#46#article#85#</font></p>     ^cY#12.htm
##
00449000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000200069704021300071002000700284#v55
n1#V:\SciELO\serial\abem\v55n1\markup\12.htm#S#p#51#47#article#85#3#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">3. Pedrosa W, Santana    G. P
seudomalabsor&ccedil;&atilde;o de levotiroxina - relato de um caso. Arq    Bras 
Endocrinol Metab. 2004;49:308-13.    ^cY#12.htm##
00242000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002000069002000700089#v55n1#V:\SciELO
\serial\abem\v55n1\markup\12.htm#S#p#52#48#article#85#</font></p>     ^cY#12.htm
##
00416000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000200069704018000071002000700251#v55
n1#V:\SciELO\serial\abem\v55n1\markup\12.htm#S#p#53#49#article#85#4#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">4. Ain KB, Refetoff    S, Fei
n HG, Weintraub BD. Pseudomalabsortion of levothyroxine. JAMA. 1991;266:2118-20.
    ^cY#12.htm##
00242000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002000069002000700089#v55n1#V:\SciELO
\serial\abem\v55n1\markup\12.htm#S#p#54#50#article#85#</font></p>     ^cY#12.htm
##
00457000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000200069704022100071002000700292#v55
n1#V:\SciELO\serial\abem\v55n1\markup\12.htm#S#p#55#51#article#85#5#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">5. Bagattoli RM,    Vaisman M
, Lima JS, Ward LS. Estudo de ades&atilde;o ao tratamento do hipotiroidismo.    
Arq Bras Endocrinol Metab. 2000;44:483-7.    ^cY#12.htm##
00242000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002000069002000700089#v55n1#V:\SciELO
\serial\abem\v55n1\markup\12.htm#S#p#56#52#article#85#</font></p>     ^cY#12.htm
##
00435000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000200069704019900071002000700270#v55
n1#V:\SciELO\serial\abem\v55n1\markup\12.htm#S#p#57#53#article#85#6#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">6. Singh N, Hershman    JM. I
nterference with the absorption of levothyroxine. Curr Opin Endocrinol    Diabet
es. 2003;10:347-52.    ^cY#12.htm##
00242000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002000069002000700089#v55n1#V:\SciELO
\serial\abem\v55n1\markup\12.htm#S#p#58#54#article#85#</font></p>     ^cY#12.htm
##
00469000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000200069704023300071002000700304#v55
n1#V:\SciELO\serial\abem\v55n1\markup\12.htm#S#p#59#55#article#85#7#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">7. Mu&ntilde;oz-Torres    M, 
Varsavsky M, Alonso G. Lactose intolerance revealed by severe resistance    to t
reatment with levothyroxine. Thyroid. 2006;11:1171-3.    ^cY#12.htm##
00242000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002000069002000700089#v55n1#V:\SciELO
\serial\abem\v55n1\markup\12.htm#S#p#60#56#article#85#</font></p>     ^cY#12.htm
##
00530000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000200069704029400071002000700365#v55
n1#V:\SciELO\serial\abem\v55n1\markup\12.htm#S#p#61#57#article#85#8#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">8. Suzuki Y, Takeshita    E, 
Kano S, Hirata S, Sato S. Impaired intestinal absorption of thyroid hormone    i
n a case of Hashimoto&acute;s disease with anti-T3 and anti-T4. Nippon Naibunpi 
   Gakkai Zasshi. 1982:58:1487-97.    ^cY#12.htm##
00242000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002000069002000700089#v55n1#V:\SciELO
\serial\abem\v55n1\markup\12.htm#S#p#62#58#article#85#</font></p>     ^cY#12.htm
##
00492000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000200069704025600071002000700327#v55
n1#V:\SciELO\serial\abem\v55n1\markup\12.htm#S#p#63#59#article#85#9#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">9. Goka AK, Rolston    DD, Ma
than VI, Farthing MJ. The relative merits of faecal and duodenal juice    micros
copy in the diagnosis of giardiasis. Trans R Soc Trop Med Hyg. 1990;84:66-7.    
^cY#12.htm##
00242000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002000069002000700089#v55n1#V:\SciELO
\serial\abem\v55n1\markup\12.htm#S#p#64#60#article#85#</font></p>     ^cY#12.htm
##
00412000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000300069704017500072002000700247#v55
n1#V:\SciELO\serial\abem\v55n1\markup\12.htm#S#p#65#61#article#85#10#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">10. Buret AG. Pathophysiolog
y    of enteric infections with Giardia duodenalis. Parasite. 2008;15:261-5.    
^cY#12.htm##
00242000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002000069002000700089#v55n1#V:\SciELO
\serial\abem\v55n1\markup\12.htm#S#p#66#62#article#85#</font></p>     ^cY#12.htm
##
00555000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000300069704031800072002000700390#v55
n1#V:\SciELO\serial\abem\v55n1\markup\12.htm#S#p#67#63#article#85#11#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">11. Pereira MGC,    Atwill E
R, Barbosa AP. Prevalence and associated risk factors for Giardia lamblia    inf
ection among children hospitalized for diarrhea in Goi&acirc;nia, Goi&aacute;s  
  State, Brazil. Rev Inst Med Trop S Paulo. 2007;49:139-45.    ^cY#12.htm##
00242000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002000069002000700089#v55n1#V:\SciELO
\serial\abem\v55n1\markup\12.htm#S#p#68#64#article#85#</font></p>     ^cY#12.htm
##
00604000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000300069704036700072002000700439#v55
n1#V:\SciELO\serial\abem\v55n1\markup\12.htm#S#p#69#65#article#85#12#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">12. Carvalho-Costa    FA, Go
n&ccedil;alves AQ, Lassance SL, Silva Neto LM, Salmazo CAA, B&oacute;ia    MN. G
iardia lamblia and other intestinal parasitic infections and their relationships
    with nutritional status in children from Brazilian Amazon. Rev Inst Med Trop
    S Paulo. 2007;49:147-53.    ^cY#12.htm##
00242000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002000069002000700089#v55n1#V:\SciELO
\serial\abem\v55n1\markup\12.htm#S#p#70#66#article#85#</font></p>     ^cY#12.htm
##
00527000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000300069704029000072002000700362#v55
n1#V:\SciELO\serial\abem\v55n1\markup\12.htm#S#p#71#67#article#85#13#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">13. Ferreira MU,    Ferreira
 CS, Monteiro CA. Tend&ecirc;ncia secular das parasitoses intestinais    na inf&
acirc;ncia na cidade de S&atilde;o Paulo (1984-1996). Rev Sa&uacute;de    P&uacu
te;bl (S Paulo). 2000;34:73-82.    ^cY#12.htm##
00242000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002000069002000700089#v55n1#V:\SciELO
\serial\abem\v55n1\markup\12.htm#S#p#72#68#article#85#</font></p>     ^cY#12.htm
##
00430000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000300069704019300072002000700265#v55
n1#V:\SciELO\serial\abem\v55n1\markup\12.htm#S#p#73#69#article#85#14#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">14. Castro H. Giard&iacute;a
se:    considera&ccedil;&otilde;es pr&aacute;ticas. Rev Port Cl&iacute;n Geral. 
2001;17:57-61.    ^cY#12.htm##
00242000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002000069002000700089#v55n1#V:\SciELO
\serial\abem\v55n1\markup\12.htm#S#p#74#70#article#85#</font></p>     ^cY#12.htm
##
00391000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000300069704015400072002000700226#v55
n1#V:\SciELO\serial\abem\v55n1\markup\12.htm#S#p#75#71#article#85#15#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">15. Ali SA, Hill    DR. Giar
dia intestinalis. Curr Opin Infect Dis. 2003;16:453-60.    ^cY#12.htm##
00242000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002000069002000700089#v55n1#V:\SciELO
\serial\abem\v55n1\markup\12.htm#S#p#76#72#article#85#</font></p>     ^cY#12.htm
##
00407000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000300069704017000072002000700242#v55
n1#V:\SciELO\serial\abem\v55n1\markup\12.htm#S#p#77#73#article#85#16#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">16. Aubry P. Malabsorption  
  syndrome and intestinal parasitosis. Med Trop (Mars). 1983;43:317-24.    ^cY#1
2.htm##
00242000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002000069002000700089#v55n1#V:\SciELO
\serial\abem\v55n1\markup\12.htm#S#p#78#74#article#85#</font></p>     ^cY#12.htm
##
00396000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000300069704015900072002000700231#v55
n1#V:\SciELO\serial\abem\v55n1\markup\12.htm#S#p#79#75#article#85#17#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">17. Gardner TB,    Hill DR. 
Treatment of giardiasis. Clin Microbiol Rev. 2001;14:114-28.    ^cY#12.htm##
00242000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002000069002000700089#v55n1#V:\SciELO
\serial\abem\v55n1\markup\12.htm#S#p#80#76#article#85#</font></p>     ^cY#12.htm
##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\12.htm#S#p#81#77#article#85#<p>&nbsp;</p>     ^cY#12.h
tm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\12.htm#S#p#82#78#article#85#<p>&nbsp;</p>     ^cY#12.h
tm##
00417000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704019500069002000700264#v55n1#V:\SciELO
\serial\abem\v55n1\markup\12.htm#S#p#83#79#article#85#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><a name="back"></a><a href="#top"><img src=
"/img/revistas/abem/v55n1/seta.jpg" border="0"></a>    <b>Correspondence to:</b>
     ^cY#12.htm##
00265000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704004300069002000700112#v55n1#V:\SciELO
\serial\abem\v55n1\markup\12.htm#S#p#84#80#article#85#<br>   Rafael de Figueired
o Radaeli    ^cY#12.htm##
00271000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704004900069002000700118#v55n1#V:\SciELO
\serial\abem\v55n1\markup\12.htm#S#p#85#81#article#85#<br>   Rua Marechal Floria
no Peixoto, 713    ^cY#12.htm##
00270000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704004800069002000700117#v55n1#V:\SciELO
\serial\abem\v55n1\markup\12.htm#S#p#86#82#article#85#<br>   14701-360 - Bebedou
ro, SP, Brazil    ^cY#12.htm##
00323000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704010100069002000700170#v55n1#V:\SciELO
\serial\abem\v55n1\markup\12.htm#S#p#87#83#article#85#<br>   <a href="mailto:raf
ael_radaeli@hotmail.com">rafael_radaeli@hotmail.com</a></font></p>     ^cY#12.ht
m##
00315000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704009300069002000700162#v55n1#V:\SciELO
\serial\abem\v55n1\markup\12.htm#S#p#88#84#article#85#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Received on Aug/5/2010    ^cY#12.htm##
00272000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704005000069002000700119#v55n1#V:\SciELO
\serial\abem\v55n1\markup\12.htm#S#p#89#85#article#85#<br>   Accepted on Nov/15/
2010</font></p>     ^cY#12.htm##
00528000000000253000450000400060000070200420000670500020004870600020005070000030
00527010002000557090008000577080003000651180002000680100015000700120121000850300
02600206710000200232065000900234064000500243031000300248014000700251865000900258
002000700267#v55n1#V:\SciELO\serial\abem\v55n1\markup\12.htm#S#c#90#1#article#17
#1#^rND^sWard^nLS#The difficult patient: drug interaction and the influence of c
oncomitant diseases on the treatment of hypothyroidism^len#Arq Bras Endocrinol M
etab#2#20100000#2010#54#435-42#20110200#12.htm##
00703000000000289000450000400060000070200420000670500020004870600020005070000030
00527010002000557090008000577080003000651180002000680100016000700100014000860100
02100100012018400121030002900305065000900334064000500343031000400348014000600352
865000900358002000700367035001000374801002900384#v55n1#V:\SciELO\serial\abem\v55
n1\markup\12.htm#S#c#91#2#article#17#2#^rND^sSeppel^nT#^rND^sRose^nF#^rND^sSchla
ghecke^nR#Chronic intestinal giardiasis with isolated levothyroxine malabsorptio
n as reason for severe hypothyroidism: implications for localization of thyroid 
hormone absorption in the gut^len#Exp Clin Endocrinol Diabetes#19960000#1996#104
#180-2#20110200#12.htm#0947-7349#Exp Clin Endocrinol Diabetes##
00495000000000265000450000400060000070200420000670500020004870600020005070000030
00527010002000557090008000577080003000651180002000680100017000700100017000870120
05700104030002600161710000200187065000900189064000500198031000300203014000700206
865000900213002000700222#v55n1#V:\SciELO\serial\abem\v55n1\markup\12.htm#S#c#92#
3#article#17#3#^rND^sPedrosa^nW#^rND^sSantana^nG#Pseudomalabsorção de levotiroxi
na: relato de um caso^lpt#Arq Bras Endocrinol Metab#2#20040000#2004#49#308-13#20
110200#12.htm##
00541000000000301000450000400060000070200420000670500020004870600020005070000030
00527010002000557090008000577080003000651180002000680100014000700100018000840100
01500102010002000117012004000137030000500177065000900182064000500191031000400196
014000800200865000900208002000700217035001000224801000500234#v55n1#V:\SciELO\ser
ial\abem\v55n1\markup\12.htm#S#c#93#4#article#17#4#^rND^sAin^nKB#^rND^sRefetoff^
nS#^rND^sFein^nHG#^rND^sWeintraub^nBD#Pseudomalabsortion of levothyroxine^len#JA
MA#19910000#1991#266#2118-20#20110200#12.htm#0098-7484#JAMA##
00547000000000289000450000400060000070200420000670500020004870600020005070000030
00527010002000557090008000577080003000651180002000680100020000700100017000900100
01500107010001500122012005300137030002600190710000200216065000900218064000500227
031000300232014000600235865000900241002000700250#v55n1#V:\SciELO\serial\abem\v55
n1\markup\12.htm#S#c#94#5#article#17#5#^rND^sBagattoli^nRM#^rND^sVaisman^nM#^rND
^sLima^nJS#^rND^sWard^nLS#Estudo de adesão ao tratamento do hipotiroidismo^lpt#A
rq Bras Endocrinol Metab#2#20000000#2000#44#483-7#20110200#12.htm##
00496000000000265000450000400060000070200420000670500020004870600020005070000030
00527010002000557090008000577080003000651180002000680100015000700100019000850120
05400104030003000158710000200188065000900190064000500199031000300204014000700207
865000900214002000700223#v55n1#V:\SciELO\serial\abem\v55n1\markup\12.htm#S#c#95#
6#article#17#6#^rND^sSingh^nN#^rND^sHershman^nJM#Interference with the absorptio
n of levothyroxine^len#Curr Opin Endocrinol Diabetes#2#20030000#2003#10#347-52#2
0110200#12.htm##
00569000000000289000450000400060000070200420000670500020004870600020005070000030
00527010002000557090008000577080003000651180002000680100022000700100019000920100
01600111012008600127030000800213065000900221064000500230031000300235014000700238
865000900245002000700254035001000261801000800271#v55n1#V:\SciELO\serial\abem\v55
n1\markup\12.htm#S#c#96#7#article#17#7#^rND^sMuñoz-Torres^nM#^rND^sVarsavsky^nM#
^rND^sAlonso^nG#Lactose intolerance revealed by severe resistance to treatment w
ith levothyroxine^len#Thyroid#20060000#2006#11#1171-3#20110200#12.htm#1050-7256#
Thyroid##
00686000000000313000450000400060000070200420000670500020004870600020005070000030
00527010002000557090008000577080003000651180002000680100016000700100019000860100
01400105010001600119010001400135012011200149030003000261065000900291064000500300
031000300305014000800308865000900316002000700325035001000332801003000342#v55n1#V
:\SciELO\serial\abem\v55n1\markup\12.htm#S#c#97#8#article#17#8#^rND^sSuzuki^nY#^
rND^sTakeshita^nE#^rND^sKano^nS#^rND^sHirata^nS#^rND^sSato^nS#Impaired intestina
l absorption of thyroid hormone in a case of Hashimoto´s disease with anti-T3 an
d anti-T4^len#Nippon Naibunpi Gakkai Zasshi#19820000#1982#58#1487-97#20110200#12
.htm#0029-0661#Nippon Naibunpi Gakkai Zasshi##
00634000000000301000450000400060000070200420000670500020004870600020005070000030
00527010002000557090008000577080003000651180002000680100015000700100018000850100
01700103010001900120012009500139030002500234065000900259064000500268031000300273
014000500276865000900281002000700290035001000297801002500307#v55n1#V:\SciELO\ser
ial\abem\v55n1\markup\12.htm#S#c#98#9#article#17#9#^rND^sGoka^nAK#^rND^sRolston^
nDD#^rND^sMathan^nVI#^rND^sFarthing^nMJ#The relative merits of faecal and duoden
al juice microscopy in the diagnosis of giardiasis^len#Trans R Soc Trop Med Hyg#
19900000#1990#84#66-7#20110200#12.htm#0035-9203#Trans R Soc Trop Med Hyg##
00487000000000265000450000400060000070200420000670500020004870600020005070000030
00527010003000557090008000587080003000661180003000690100016000720120066000880300
00900154065000900163064000500172031000300177014000600180865000900186002000700195
035001000202801000900212#v55n1#V:\SciELO\serial\abem\v55n1\markup\12.htm#S#c#99#
10#article#17#10#^rND^sBuret^nAG#Pathophysiology of enteric infections with Giar
dia duodenalis^len#Parasite#20080000#2008#15#261-5#20110200#12.htm#1252-607X#Par
asite##
00665000000000289000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100019000730100017000920100
01800109012014600127030002600273065000900299064000500308031000300313014000700316
865000900323002000700332035001000339801002600349#v55n1#V:\SciELO\serial\abem\v55
n1\markup\12.htm#S#c#100#11#article#17#11#^rND^sPereira^nMGC#^rND^sAtwill^nER#^r
ND^sBarbosa^nAP#Prevalence and associated risk factors for Giardia lamblia infec
tion among children hospitalized for diarrhea in Goiânia, Goiás State, Brazil^le
n#Rev Inst Med Trop S Paulo#20070000#2007#49#139-45#20110200#12.htm#0036-4665#Re
v Inst Med Trop S Paulo##
00764000000000325000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100025000730100020000980100
01900118010002100137010001900158010001500177012014400192030002600336065000900362
06400050037103100030037601400070037986500090038600200070039503500100040280100260
0412#v55n1#V:\SciELO\serial\abem\v55n1\markup\12.htm#S#c#101#12#article#17#12#^r
ND^sCarvalho-Costa^nFA#^rND^sGonçalves^nAQ#^rND^sLassance^nSL#^rND^sSilva Neto^n
LM#^rND^sSalmazo^nCAA#^rND^sBóia^nMN#Giardia lamblia and other intestinal parasi
tic infections and their relationships with nutritional status in children from 
Brazilian Amazon^len#Rev Inst Med Trop S Paulo#20070000#2007#49#147-53#20110200#
12.htm#0036-4665#Rev Inst Med Trop S Paulo##
00571000000000277000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100019000730100019000920100
01900111012009700130030002500227710000200252065000900254064000500263031000300268
014000600271865000900277002000700286#v55n1#V:\SciELO\serial\abem\v55n1\markup\12
.htm#S#c#102#13#article#17#13#^rND^sFerreira^nMU#^rND^sFerreira^nCS#^rND^sMontei
ro^nCA#Tendência secular das parasitoses intestinais na infância na cidade de Sã
o Paulo (1984-1996)^lpt#Rev Saúde Públ (S Paulo)#2#20000000#2000#34#73-82#201102
00#12.htm##
00442000000000253000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730120038000890300
02000127710000200147065000900149064000500158031000300163014000600166865000900172
002000700181#v55n1#V:\SciELO\serial\abem\v55n1\markup\12.htm#S#c#103#14#article#
17#14#^rND^sCastro^nH#Giardíase: considerações práticas^lpt#Rev Port Clín Geral#
2#20010000#2001#17#57-61#20110200#12.htm##
00456000000000265000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100014000730100015000870120
02500102030002100127710000200148065000900150064000500159031000300164014000700167
865000900174002000700183#v55n1#V:\SciELO\serial\abem\v55n1\markup\12.htm#S#c#104
#15#article#17#15#^rND^sAli^nSA#^rND^sHill^nDR#Giardia intestinalis^len#Curr Opi
n Infect Dis#2#20030000#2003#16#453-60#20110200#12.htm##
00490000000000265000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100015000730120054000880300
01600142065000900158064000500167031000300172014000700175865000900182002000700191
035001000198801001600208#v55n1#V:\SciELO\serial\abem\v55n1\markup\12.htm#S#c#105
#16#article#17#16#^rND^sAubry^nP#Malabsorption syndrome and intestinal parasitos
is^len#Med Trop (Mars)#19830000#1983#43#317-24#20110200#12.htm#0025-682X#Med Tro
p (Mars)##
00500000000000277000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100018000730100015000910120
02800106030001900134065000900153064000500162031000300167014000700170865000900177
002000700186035001000193801001900203#v55n1#V:\SciELO\serial\abem\v55n1\markup\12
.htm#S#c#106#17#article#17#17#^rND^sGardner^nTB#^rND^sHill^nDR#Treatment of giar
diasis^len#Clin Microbiol Rev#20010000#2001#14#114-28#20110200#12.htm#0893-8512#
Clin Microbiol Rev##
00262000000000169000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640910009000660920007000750020007000827030
00300089#v55n1#V:\SciELO\serial\abem\v55n1\markup\13.htm#S#o#1#1#article#1#20110
324#154611#13.htm#98##
02310000000000517000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640710003000660400003000690010006000720420
00200078120000400080038000500084121000300089049000800092158000300100030002600103
03100030012903200020013206500090013401400090014303500100015201200760016201200800
02380100039003180100031003570100045003880100037004330100035004700100026005050700
12600531083054600657083053101203117000601734072000201740112000901742111001301751
114000901764113001201773002000701785#v55n1#V:\SciELO\serial\abem\v55n1\markup\13
.htm#S#h#2#1#article#1#oa#en#br1.1#1#4.0#ILUS#13#ABEM060#nd#Arq Bras Endocrinol 
Metab#55#1#20110200#^f85^l88#0004-2730#Orbital pseudotumor: a differential diagn
osis of Graves' ophthalmopathy^len#Pseudotumor de órbita: um diagnóstico diferen
cial de oftalmopatia de Graves^lpt#^rND^1A01^nLuciana Souza Cruz^sCaminha#^rND^1
A01^nElisa Rebelo^sPinto#^rND^1A01^nPriscila Alves Medeiros de^sSousa#^rND^1A01^
nRicardo Andrade^sOliveira#^rND^1A01^nFlavia Lucia^sConceiçao#^rND^1A01^nMario^s
Vaisman#Universidade Federal do Rio de Janeiro^iA01^1Hospital Universitário Clem
entino Fraga Filho^2Endocrinology Service^sRJ^pBrazil#^len^aThe objective of thi
s study is to report and discuss a rare and inflammatory cause of exophthalmos. 
This report describes a patient with exophthalmos, who was initially diagnosed w
ith euthyroid Graves' with good response to therapy. After 8 years of follow-up,
 she had recurrence of symptoms and a new evaluation revealed the final diagnosi
s of orbital pseudotumor. Orbital pseudotumor is an uncommon disorder that both 
radiologically and clinically mimics a malignant process or other inflammatory d
isease, such as Graves' ophthalmopathy.#^lpt^aO objetivo deste estudo é relatar 
e discutir uma causa de exoftalmia rara e inflamatória. Este artigo relata uma p
aciente com exoftalmia que recebeu diagnóstico inicial de oftalmopatia de Graves
 eutireoideana com boa resposta à terapia. Após oito anos de seguimento, houve r
ecorrência dos sintomas e uma nova avaliação revelou o diagnóstico final de pseu
dotumor orbitário. Pseudotumor orbitário é uma condição incomum que mimetiza clí
nica e radiologicamente uma doença maligna ou inflamatória, como a oftalmopatia 
de Graves.#other#8#20100926#Sept/26/2010#20101119#Nov/19/2010#13.htm##
02338000000000517000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640710003000660400003000690010006000720420
00200078120000400080038000500084121000300089049000800092158000300100030002600103
03100030012903200020013206500090013401400090014303500100015201200900016201200940
02520100039003460100031003850100045004160100037004610100035004980100026005330700
12600559083054600685083053101231117000601762072000201768112000901770111001301779
114000901792113001201801002000701813#v55n1#V:\SciELO\serial\abem\v55n1\markup\13
.htm#S#f#3#1#article#1#oa#en#br1.1#1#4.0#ILUS#13#ABEM060#nd#Arq Bras Endocrinol 
Metab#55#1#20110200#^f85^l88#0004-2730#<b>Orbital pseudotumor</b>: <b>a differen
tial diagnosis of Graves' ophthalmopathy</b>^len#<b>Pseudotumor de órbita</b>: <
b>um diagnóstico diferencial de oftalmopatia de Graves</b>^lpt#^rND^1A01^nLucian
a Souza Cruz^sCaminha#^rND^1A01^nElisa Rebelo^sPinto#^rND^1A01^nPriscila Alves M
edeiros de^sSousa#^rND^1A01^nRicardo Andrade^sOliveira#^rND^1A01^nFlavia Lucia^s
Conceiçao#^rND^1A01^nMario^sVaisman#Universidade Federal do Rio de Janeiro^iA01^
1Hospital Universitário Clementino Fraga Filho^2Endocrinology Service^sRJ^pBrazi
l#^len^aThe objective of this study is to report and discuss a rare and inflamma
tory cause of exophthalmos. This report describes a patient with exophthalmos, w
ho was initially diagnosed with euthyroid Graves' with good response to therapy.
 After 8 years of follow-up, she had recurrence of symptoms and a new evaluation
 revealed the final diagnosis of orbital pseudotumor. Orbital pseudotumor is an 
uncommon disorder that both radiologically and clinically mimics a malignant pro
cess or other inflammatory disease, such as Graves' ophthalmopathy.#^lpt^aO obje
tivo deste estudo é relatar e discutir uma causa de exoftalmia rara e inflamatór
ia. Este artigo relata uma paciente com exoftalmia que recebeu diagnóstico inici
al de oftalmopatia de Graves eutireoideana com boa resposta à terapia. Após oito
 anos de seguimento, houve recorrência dos sintomas e uma nova avaliação revelou
 o diagnóstico final de pseudotumor orbitário. Pseudotumor orbitário é uma condi
ção incomum que mimetiza clínica e radiologicamente uma doença maligna ou inflam
atória, como a oftalmopatia de Graves.#other#8#20100926#Sept/26/2010#20101119#No
v/19/2010#13.htm##
02441000000000541000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640640013000660710003000790400003000820010
00600085042000200091120000400093038000500097121000300102049000800105158000300113
03000290011603100030014503200020014806500090015001400090015903500100016801200760
01780120080002540100039003340100031003730100045004040100037004490100035004860100
02600521070012800547083054600675083053101221117000601752072000201758112000901760
111001301769114000901782113001201791002000701803008008901810#v55n1#V:\SciELO\ser
ial\abem\v55n1\markup\13.htm#S#l#4#1#article#1#^mFeb.^a2011#oa#en#br1.1#1#4.0#il
us#13#ABEM060#nd#Arq. bras. endocrinol. metab#55#1#20110200#^f85^l88#0004-2730#O
rbital pseudotumor: a differential diagnosis of Graves' ophthalmopathy^len#Pseud
otumor de órbita: um diagnóstico diferencial de oftalmopatia de Graves^lpt#^rND^
1A01^nLuciana Souza Cruz^sCaminha#^rND^1A01^nElisa Rebelo^sPinto#^rND^1A01^nPris
cila Alves Medeiros de^sSousa#^rND^1A01^nRicardo Andrade^sOliveira#^rND^1A01^nFl
avia Lucia^sConceiçao#^rND^1A01^nMario^sVaisman#^iA01^1Universidade Federal do R
io de Janeiro^2Hospital Universitário Clementino Fraga Filho^3Endocrinology Serv
ice^sRJ^pBrazil#^len^aThe objective of this study is to report and discuss a rar
e and inflammatory cause of exophthalmos. This report describes a patient with e
xophthalmos, who was initially diagnosed with euthyroid Graves' with good respon
se to therapy. After 8 years of follow-up, she had recurrence of symptoms and a 
new evaluation revealed the final diagnosis of orbital pseudotumor. Orbital pseu
dotumor is an uncommon disorder that both radiologically and clinically mimics a
 malignant process or other inflammatory disease, such as Graves' ophthalmopathy
.#^lpt^aO objetivo deste estudo é relatar e discutir uma causa de exoftalmia rar
a e inflamatória. Este artigo relata uma paciente com exoftalmia que recebeu dia
gnóstico inicial de oftalmopatia de Graves eutireoideana com boa resposta à tera
pia. Após oito anos de seguimento, houve recorrência dos sintomas e uma nova ava
liação revelou o diagnóstico final de pseudotumor orbitário. Pseudotumor orbitár
io é uma condição incomum que mimetiza clínica e radiologicamente uma doença mal
igna ou inflamatória, como a oftalmopatia de Graves.#other#8#20100926#Sept/26/20
10#20101119#Nov/19/2010#13.htm#Internet^ihttp://www.scielo.br/scielo.php?script=
sci_arttext&pid=S0004-27302011000100013##
00347000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000300064704012700067002000700194#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#5#1#article#86#<p align="right"><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>CLINICAL    CASE REPORT</b><
/font></p>     ^cY#13.htm##
00242000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000300064704002200067002000700089#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#6#2#article#86#<p>&nbsp;</p>     ^cY#13.htm
##
00402000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000300064704018200067002000700249#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#7#3#article#86#<p><a name="top"></a><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="4"><b>Orbital    pseudotumor: 
a differential diagnosis of Graves' ophthalmopathy</b></font></p>     ^cY#13.htm
##
00242000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000300064704002200067002000700089#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#8#4#article#86#<p>&nbsp;</p>     ^cY#13.htm
##
00402000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000300064704018200067002000700249#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#9#5#article#86#<p><font face="Verdana, Aria
l, Helvetica, sans-serif" size="3"><b>Pseudotumor    de &oacute;rbita: um diagn&
oacute;stico diferencial de oftalmopatia de Graves</b></font></p>     ^cY#13.htm
##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000300065704002200068002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#10#6#article#86#<p>&nbsp;</p>     ^cY#13.ht
m##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000300065704002200068002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#11#7#article#86#<p>&nbsp;</p>     ^cY#13.ht
m##
00469000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000300065704024800068002000700316#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#12#8#article#86#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="2"><b>Luciana Souza    Cruz Caminha; Elisa Rebe
lo Pinto; Priscila Alves Medeiros de Sousa; Ricardo    Andrade Oliveira; Flavia 
Lucia Concei&ccedil;ao; Mario Vaisman</b></font></p>     ^cY#13.htm##
00452000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000300065704023100068002000700299#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#13#9#article#86#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="2">Endocrinology Service,    Hospital Universit
&aacute;rio Clementino Fraga Filho (HUCFF), Universidade Federal    do Rio de Ja
neiro (UFRJ), RJ, Brazil</font></p>     ^cY#13.htm##
00345000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704012300069002000700192#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#14#10#article#86#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><a href="#back">Correspondence    to</a></f
ont></p>     ^cY#13.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#15#11#article#86#<p>&nbsp;</p>     ^cY#13.h
tm##
00266000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704004400069002000700113#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#16#12#article#86#<p>&nbsp;</p> <hr size="1"
 noshade>     ^cY#13.htm##
00319000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704009700069002000700166#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#17#13#article#86#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>SUMMARY</b></font></p>     ^cY#13.htm##
00887000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704066500069002000700734#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#18#14#article#86#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The objective of    this study is to report
 and discuss a rare and inflammatory cause of exophthalmos.    This report descr
ibes a patient with exophthalmos, who was initially diagnosed    with euthyroid 
Graves' with good response to therapy. After 8 years of follow-up,    she had re
currence of symptoms and a new evaluation revealed the final diagnosis    of orb
ital pseudotumor. Orbital pseudotumor is an uncommon disorder that both    radio
logically and clinically mimics a malignant process or other inflammatory    dis
ease, such as Graves' ophthalmopathy.</font></p> <hr size="1" noshade>     ^cY#1
3.htm##
00326000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704010400069002000700173#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#19#15#article#86#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>SUM&Aacute;RIO</b></font></p>     ^cY#13
.htm##
00993000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704077100069002000700840#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#20#16#article#86#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">O objetivo deste    estudo &eacute; relatar
 e discutir uma causa de exoftalmia rara e inflamat&oacute;ria.    Este artigo r
elata uma paciente com exoftalmia que recebeu diagn&oacute;stico    inicial de o
ftalmopatia de Graves eutireoideana com boa resposta &agrave; terapia.    Ap&oac
ute;s oito anos de seguimento, houve recorr&ecirc;ncia dos sintomas e    uma nov
a avalia&ccedil;&atilde;o revelou o diagn&oacute;stico final de pseudotumor    o
rbit&aacute;rio. Pseudotumor orbit&aacute;rio &eacute; uma condi&ccedil;&atilde;
o    incomum que mimetiza cl&iacute;nica e radiologicamente uma doen&ccedil;a ma
ligna    ou inflamat&oacute;ria, como a oftalmopatia de Graves.</font></p> <hr s
ize="1" noshade>     ^cY#13.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#21#17#article#86#<p>&nbsp;</p>     ^cY#13.h
tm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#22#18#article#86#<p>&nbsp;</p>     ^cY#13.h
tm##
00324000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704010200069002000700171#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#23#19#article#86#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>INTRODUCTION</b></font></p>     ^cY#13.h
tm##
00819000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704059700069002000700666#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#24#20#article#86#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The most common    cause of proptosis, unil
ateral or bilateral, is Graves' ophthalmopathy. It is    usually bilateral and a
ssociated with hyperthyroidism, but it can also be asymmetric    or unilateral. 
The ophtalmopathy may precede (euthyroid Graves' disease), follow    or occur si
multaneously with hyperthyroidism (1,2). Diagnosis is straightforward    in pati
ents with hyperthyroidism and bilateral disease, but it should also be    consid
ered in patients with no thyroid dysfunction or unilateral disease (3).</font></
p>     ^cY#13.htm##
00885000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704066300069002000700732#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#25#21#article#86#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Since several conditions    can cause exoph
thalmos when diagnosis is uncertain orbital imaging (computed    tomography - CT
 or magnetic resonance - MRI) should be done. Measurement of    thyrotropin-rece
ptor antibodies (TRAb) should be performed due to their high    specificity and 
sensitivity in Graves' disease. These conditions include orbital    pseudotumor,
 Cushing's syndrome, obesity, idiopathic miositis and cellulitis,    granulomato
us disorders, primary or metastatic tumors, fistulas in the cavernous    portion
 of the carotid artery and other vascular conditions (3).</font></p>     ^cY#13.
htm##
00510000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704028800069002000700357#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#26#22#article#86#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">This report describes    a patient with exo
phthalmos, who was initially diagnosed with euthyroid Graves'    ophthalmopathy 
but had the final diagnosis of orbital pseudotumor, after 8 years    of follow-u
p.</font></p>     ^cY#13.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#27#23#article#86#<p>&nbsp;</p>     ^cY#13.h
tm##
00323000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704010100069002000700170#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#28#24#article#86#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>CASE REPORT</b></font></p>     ^cY#13.ht
m##
01267000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704104500069002000701114#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#29#25#article#86#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">In 2000, a 39-year-old    woman came to the
 hospital for evaluation of unilateral proptosis in the right    eye, which had 
developed 2 years before. At this time, she complained of tearing    and grittin
ess with no decrease in visual acuity. There was no sign/symptom    of thyroid d
ysfunction; she had been taking propylthiouracil for 3 months despite    normal 
hormone levels. She had a history of peripartum cardiomyopathy in 1998.    Clini
cal examination showed proptosis in the right eye, associated with mild    swell
ing, redness, and normal eye movements; no pain, diplopia or goiter. Lab    test
s showed normal thyroid function tests, negative antithyroglobulin and antithyro
id    peroxidase antibodies. Orbital CT and ultrasound revealed enlargement of l
ateral    rectus muscle and higher density of orbital fat, suggesting Graves' op
htalmopathy.    Intravenous corticosteroid followed by oral prednisone was admin
istered with    good clinical response.</font></p>     ^cY#13.htm##
01236000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704101400069002000701083#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#30#26#article#86#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">During 7 years    of follow-up she did not 
show any signs or symptoms of recurrence (2001-2008).    In March, 2008 she pres
ented mild proptosis, redness, and swelling of the left    eye. She continued to
 show no decrease in visual acuity or limitation of eye    movements. A new orbi
tal CT revealed a retrobulbar mass which involved the optic    nerve (without af
fecting it), exhibiting enhancement post contrast media injection.    Muscle and
 orbital fat were normal (<a href="#f1">Figure 1</a>). MRI showed    isointense 
images on T1 and T2 (<a href="#f2">Figure 2</a>). Lab tests showed    euthyroidi
sm. TRAb and anti-TPO were negative. Retrobulbar biopsy was performed    and rev
ealed chronic inflammatory infiltrate. A sample of striated muscle taken    was 
normal, excluding Graves' ophthalmopathy. During clinical investigation    the p
roptosis, periorbital swelling, and ecchymosis worsened (<a href="#f3">Figure   
 3</a>).</font></p>     ^cY#13.htm##
00255000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704003300069002000700102#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#31#27#article#86#<p><a name="f1"></a></p>  
   ^cY#13.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#32#28#article#86#<p>&nbsp;</p>     ^cY#13.h
tm##
00299000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704007700069002000700146#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#33#29#article#86#<p align="center"><img src
="/img/revistas/abem/v55n1/13f01.jpg"></p>     ^cY#13.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#34#30#article#86#<p>&nbsp;</p>     ^cY#13.h
tm##
00255000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704003300069002000700102#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#35#31#article#86#<p><a name="f2"></a></p>  
   ^cY#13.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#36#32#article#86#<p>&nbsp;</p>     ^cY#13.h
tm##
00299000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704007700069002000700146#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#37#33#article#86#<p align="center"><img src
="/img/revistas/abem/v55n1/13f02.jpg"></p>     ^cY#13.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#38#34#article#86#<p>&nbsp;</p>     ^cY#13.h
tm##
00255000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704003300069002000700102#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#39#35#article#86#<p><a name="f3"></a></p>  
   ^cY#13.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#40#36#article#86#<p>&nbsp;</p>     ^cY#13.h
tm##
00299000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704007700069002000700146#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#41#37#article#86#<p align="center"><img src
="/img/revistas/abem/v55n1/13f03.jpg"></p>     ^cY#13.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#42#38#article#86#<p>&nbsp;</p>     ^cY#13.h
tm##
00627000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704040500069002000700474#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#43#39#article#86#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Considering the    clinical history and his
topathological examination, diagnosis of orbital pseudotumor    was made and int
ravenous glucocorticoid followed by oral prednisone was prescribed.    Administr
ation of intravenous methylprednisolone resulted in marked improvement    within
 24 hours (<a href="#f4">Figure 4</a>).</font></p>     ^cY#13.htm##
00255000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704003300069002000700102#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#44#40#article#86#<p><a name="f4"></a></p>  
   ^cY#13.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#45#41#article#86#<p>&nbsp;</p>     ^cY#13.h
tm##
00299000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704007700069002000700146#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#46#42#article#86#<p align="center"><img src
="/img/revistas/abem/v55n1/13f04.jpg"></p>     ^cY#13.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#47#43#article#86#<p>&nbsp;</p>     ^cY#13.h
tm##
00631000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704040900069002000700478#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#48#44#article#86#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Considering the    clinical history and his
topathological examination, the diagnosis of orbital    pseudotumor was made and
 intravenous glucocorticoid followed by oral prednisone    was prescribed. Admin
istration of intravenous methylprednisolone resulted in    marked improvement wi
thin 24 hours (<a href="#f4">Figure 4</a>).</font></p>     ^cY#13.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#49#45#article#86#<p>&nbsp;</p>     ^cY#13.h
tm##
00322000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704010000069002000700169#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#50#46#article#86#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>DISCUSSION</b></font></p>     ^cY#13.htm
##
00602000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704038000069002000700449#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#51#47#article#86#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Orbital pseudotumor    (OP) or idiopathic o
rbital inflammatory disease was first described in 1903    by Gleason and by Bus
se and Hochheim (4). Inflammatory pseudotumor most often    occurs in the lung, 
liver, and orbit but it has been reported to occur in nearly    every organ in t
he body (5,6).</font></p>     ^cY#13.htm##
00650000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704042800069002000700497#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#52#48#article#86#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">It is an uncommon    disease and is defined
 as a benign, non-infectious, space-occupying orbital    lesion without identifi
able local or systemic cause. The inflammatory process    may involve any orbit 
tissue and it has variable clinical features (myositis,    dacryoadenitis, perin
euritis, tendonitis, episcleritis, and localized mass)    (5).</font></p>     ^c
Y#13.htm##
00811000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704058900069002000700658#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#53#49#article#86#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The pathogenesis    is not clear. It has be
en associated with infection, trauma, and surgery. Several    lines of evidence 
suggest an immune-mediated process. An association with systemic    immunologic 
disorders including Crohn's disease, Sjogren's syndrome, Becet's    disease, lup
us, rheumatoid arthritis, <i>diabetes mellitus</i>, myasthenia gravis,    and an
kylosing spondylitis have been reported (5,6). Moreover, OP favorably    respond
s to glucocorticoid therapy and other immunosuppressive agents.</font></p>     ^
cY#13.htm##
00952000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704073000069002000700799#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#54#50#article#86#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Orbital pseudotumor    occurs more often in
 the third to sixth decades (5) with no strong sex predilection    (4); it accou
nts for 4.7% to 6.3% of orbital disorders and is the third most    common orbita
l disease (following Graves' orbitopathy and lymphoproliferative    disease) (4,
7). Unilateral disease is the rule but bilateral presentations are    not uncomm
on, especially in children. Symptoms most commonly develop acutely    (hours or 
days) but may be subacute or chronic and present with proptosis and    inflammat
ory signs (pain, swelling and erythema); ptosis, chemosis, motility    dysfuncti
on, and optic neurophaty may also occur (5).</font></p>     ^cY#13.htm##
01029000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704080700069002000700876#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#55#51#article#86#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Clinical diagnosis    of orbital pseudotumo
r is made by exclusion of other conditions. A biopsy must    be considered when 
the diagnosis is uncertain after clinical examination and    images; when the di
sease involves the anterior orbital (easy approach); in recurrent    episodes or
 when the patient is refractory to treatment (5,8). The main differential    dia
gnoses that should be excluded are: infections, inflammatory reaction to    trau
ma or foreign body, thyroid dysfunction, vasculitis (Wegner's granulomatosis,   
 polyarteritis nodosa and giant cell arteritis), sarcoidosis, neoplasia (primary
    and metastatic tumors of breast, lung, prostate or kidney), lymphoma, arteri
ovenous    fistula and malformations (4).</font></p>     ^cY#13.htm##
01153000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704093100069002000701000#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#56#52#article#86#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Orbital imaging    is an essential tool bec
ause it allows for the characterization and localization    of disorder without 
surgical intervention. On CT scan, a moderately enhanced    focal or diffuse mas
s frequently accompanied by infiltration of retrobulbar    fat is usually seen. 
On MRI images, OP is usually isointense to hypointense    in relation to muscle 
on T1-weighted images, with a relative isointense T2 signal.    It can also show
 proptosis, optic nerve thickening, uveal-scleral thickening,    lachrymal gland
 infiltration and extraocular muscle enlargement (with muscle    tendon or sheat
h enlargement). This radiologic feature is useful to differentiate    OP from Gr
aves' ophtalmophaty, since the latter is commonly bilateral and mainly    involv
es orbital fat and extraocular muscle with tendon sparing (spindle-shapped)    (
2-4).</font></p>     ^cY#13.htm##
00480000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704025800069002000700327#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#57#53#article#86#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Histopathological    analysis reveals pleom
orphic inflammatory cell infiltration followed by reactive    fibrosis. The scle
rotic form is considered to have poor prognosis (4).</font></p>     ^cY#13.htm##
01281000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704105900069002000701128#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#58#54#article#86#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Primary treatment    consists of systemic s
teroid therapy. Observation can be considered for mild    disease because sponta
neous remission has been reported after a few weeks. Some    authors suggest tha
t the use of oral non-steroidal anti-inflammatory (ibuprofen,    for example) sh
ould precede steroid therapy since it is often effective (4,5,8).    For moderat
e to severe clinical presentation, oral prednisone can be started    with an ini
tial dosage of 60 mg to 100 mg per day for 1 to 2 weeks followed    by progressi
ve reduction, depending on clinical response (4,5). Intravenous    corticosteroi
d should be initiated if optic nerve dysfunction occurs (2). In    general, the 
treatment results in dramatic improvement within 48-72 hours, mainly    of infla
mmatory signs and pain (6). Although many patients do have a favorable    respon
se to corticosteroids, incomplete resolution and recurrence are common.    Recur
rence rates as high 25%-52% have been reported (4,5).</font></p>     ^cY#13.htm#
#
00886000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704066400069002000700733#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#59#55#article#86#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Orbital irradiation    may be useful as an 
additional therapy and may be considered when there is no    clinical improvemen
t after 2 weeks of adequate therapy or if the patient becomes    steroid-depende
nt, or had a serious adverse reaction to the steroid. Even a    low dose treatme
nt (10-20 Gy fractioned over 10 days) may produce long term    remission. Becaus
e recurrence/resistance is common other immunosuppressive agents    have been us
ed with variable results. Cyclophosphamide, chlorambucil, mycophenolate    mofet
il, methotrexate have been used in refractory cases (4,5).</font></p>     ^cY#13
.htm##
00530000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704030800069002000700377#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#60#56#article#86#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Surgical debulking    is indicated for pati
ents with severely progressive and disabling clinical course    (e.g., orbital a
pex syndrome with optic nerve compression) or when the lesion    is focal and ea
sily approachable (4).</font></p>     ^cY#13.htm##
00770000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704054800069002000700617#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#61#57#article#86#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">In conclusion,    orbital pseudotumor is an
 uncommon disorder that radiologically and clinically    mimics a malignant proc
ess or other inflammatory diseases. In this reported    case, there was probably
 a recurrence after 7 years of remission. She had a    favorable response to ste
roid therapy, as in the first episode. The patient    has a history of peripartu
m cardiomyopathy, a disorder of uncertain etiology,    but autoimmunity has been
 implicated, as in OP.</font></p>     ^cY#13.htm##
00392000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704017000069002000700239#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#62#58#article#86#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Disclosure: no    potential conflict of int
erest relevant to this article was reported.</font></p>     ^cY#13.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#63#59#article#86#<p>&nbsp;</p>     ^cY#13.h
tm##
00322000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704010000069002000700169#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#64#60#article#86#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>REFERENCES</b></font></p>     ^cY#13.htm
##
00400000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000200069704016400071002000700235#v55
n1#V:\SciELO\serial\abem\v55n1\markup\13.htm#S#p#65#61#article#86#1#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">1. Vilar L. Endocrinologia   
 cl&iacute;nica. 3rd ed. Rio de Janeiro: Guanabara Koogan; 2006.    ^cY#13.htm##
00242000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002000069002000700089#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#66#62#article#86#</font></p>     ^cY#13.htm
##
00389000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000200069704015300071002000700224#v55
n1#V:\SciELO\serial\abem\v55n1\markup\13.htm#S#p#67#63#article#86#2#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">2. Winn R. Youmans.    Neurol
ogical surgery. 5th ed. Philadelphia: Saunders; 2004.    ^cY#13.htm##
00242000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002000069002000700089#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#68#64#article#86#</font></p>     ^cY#13.htm
##
00392000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000200069704015600071002000700227#v55
n1#V:\SciELO\serial\abem\v55n1\markup\13.htm#S#p#69#65#article#86#3#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">3. Bartalena L.    Tanda AM. 
Graves' Ophthalmopathy. N Engl J Med. 2006;360:994-1001.    ^cY#13.htm##
00242000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002000069002000700089#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#70#66#article#86#</font></p>     ^cY#13.htm
##
00456000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000200069704022000071002000700291#v55
n1#V:\SciELO\serial\abem\v55n1\markup\13.htm#S#p#71#67#article#86#4#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">4. Yuen SJ, Rubin    PA. Idio
pathic orbital inflammation: distribution, clinical features, and treatment    o
utcome. Arch Ophthalmol. 2003;121:491-9.    ^cY#13.htm##
00242000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002000069002000700089#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#72#68#article#86#</font></p>     ^cY#13.htm
##
00408000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000200069704017200071002000700243#v55
n1#V:\SciELO\serial\abem\v55n1\markup\13.htm#S#p#73#69#article#86#5#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">5. Kanski JJ. Clinical    oph
thalmology: a systematic approach. 6th ed. Philadelphia: Elsevier; 2008.    ^cY#
13.htm##
00242000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002000069002000700089#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#74#70#article#86#</font></p>     ^cY#13.htm
##
00456000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000200069704022000071002000700291#v55
n1#V:\SciELO\serial\abem\v55n1\markup\13.htm#S#p#75#71#article#86#6#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">6. McCall T, Fassett    DR, L
yons G, Couldwell WT. Inflammatory pseudotumor of the cavernous sinus and    sku
ll base. Neurosurg Rev. 2006;29:194-200.    ^cY#13.htm##
00242000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002000069002000700089#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#76#72#article#86#</font></p>     ^cY#13.htm
##
00424000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000200069704018800071002000700259#v55
n1#V:\SciELO\serial\abem\v55n1\markup\13.htm#S#p#77#73#article#86#7#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">7. Narla L, Newman    B, Spot
tswood SS, Narla S, Kolli R. Inflammatory pseudotumor. Radiographics.    2003;23
:719-29.    ^cY#13.htm##
00242000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002000069002000700089#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#78#74#article#86#</font></p>     ^cY#13.htm
##
00499000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000200069704026300071002000700334#v55
n1#V:\SciELO\serial\abem\v55n1\markup\13.htm#S#p#79#75#article#86#8#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">8. Nunes TP, Roizemblatt    R
, Miki G, Garcia R, Santo RM, Olivalves E, et al. Idiopathic orbital inflammatio
n    with extraorbital extension: case report. Arq Bras Oftalmol. 2007;70(3):540
-3.    ^cY#13.htm##
00242000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002000069002000700089#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#80#76#article#86#</font></p>     ^cY#13.htm
##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#81#77#article#86#<p>&nbsp;</p>     ^cY#13.h
tm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#82#78#article#86#<p>&nbsp;</p>     ^cY#13.h
tm##
00417000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704019500069002000700264#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#83#79#article#86#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><a name="back"></a><a href="#top"><img src=
"/img/revistas/abem/v55n1/seta.jpg" border="0"></a>    <b>Correspondence to:</b>
     ^cY#13.htm##
00263000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704004100069002000700110#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#84#80#article#86#<br>   Luciana Souza Cruz 
Caminha    ^cY#13.htm##
00281000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704005900069002000700128#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#85#81#article#86#<br>   Servi&ccedil;o de E
ndocrinologia, HUCFF-UFRJ    ^cY#13.htm##
00272000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704005000069002000700119#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#86#82#article#86#<br>   Av. Brigadeiro Trom
povski, 9º andar    ^cY#13.htm##
00275000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704005300069002000700122#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#87#83#article#86#<br>   21941-590 - Rio de 
Janeiro, RJ, Brazil    ^cY#13.htm##
00323000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704010100069002000700170#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#88#84#article#86#<br>   <a href="mailto:luc
ianacaminha@hotmail.com">lucianacaminha@hotmail.com</a></font></p>     ^cY#13.ht
m##
00317000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704009500069002000700164#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#89#85#article#86#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Received on Sept/26/2010    ^cY#13.htm##
00272000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704005000069002000700119#v55n1#V:\SciELO
\serial\abem\v55n1\markup\13.htm#S#p#90#86#article#86#<br>   Accepted on Nov/19/
2010</font></p>     ^cY#13.htm##
00417000000000241000450000400060000070200420000670500020004870600020005070000030
00527010002000557090008000577080002000651180002000670160015000690180027000840630
00200111066001500113062001700128065000900145064000500154865000900159002000700168
#v55n1#V:\SciELO\serial\abem\v55n1\markup\13.htm#S#c#91#1#article#8#1#^rND^sVila
r^nL#Endocrinologia clínica^lpt#3#Rio de Janeiro#Guanabara Koogan#20060000#2006#
20110200#13.htm##
00413000000000241000450000400060000070200420000670500020004870600020005070000030
00527010002000557090008000577080002000651180002000670160014000690180034000830630
00200117066001300119062000900132065000900141064000500150865000900155002000700164
#v55n1#V:\SciELO\serial\abem\v55n1\markup\13.htm#S#c#92#2#article#8#2#^rND^sWinn
^nR#Youmans: Neurological surgery^len#5#Philadelphia#Saunders#20040000#2004#2011
0200#13.htm##
00488000000000277000450000400060000070200420000670500020004870600020005070000030
00527010002000557090008000577080002000651180002000670100019000690100016000880120
02700104030001300131065000900144064000500153031000400158014000900162865000900171
002000700180035001000187801001300197#v55n1#V:\SciELO\serial\abem\v55n1\markup\13
.htm#S#c#93#3#article#8#3#^rND^sBartalena^nL#^rND^sTanda^nAM#Graves' Ophthalmopa
thy^len#N Engl J Med#20060000#2006#360#994-1001#20110200#13.htm#0028-4793#N Engl
 J Med##
00552000000000277000450000400060000070200420000670500020004870600020005070000030
00527010002000557090008000577080002000651180002000670100015000690100016000840120
09200100030001600192065000900208064000500217031000400222014000600226865000900232
002000700241035001000248801001600258#v55n1#V:\SciELO\serial\abem\v55n1\markup\13
.htm#S#c#94#4#article#8#4#^rND^sYuen^nSJ#^rND^sRubin^nPA#Idiopathic orbital infl
ammation: distribution, clinical features, and treatment outcome^len#Arch Ophtha
lmol#20030000#2003#121#491-9#20110200#13.htm#0003-9950#Arch Ophthalmol##
00432000000000241000450000400060000070200420000670500020004870600020005070000030
00527010002000557090008000577080002000651180002000670160017000690180050000860630
00200136066001300138062000900151065000900160064000500169865000900174002000700183
#v55n1#V:\SciELO\serial\abem\v55n1\markup\13.htm#S#c#95#5#article#8#5#^rND^sKans
ki^nJJ#Clinical ophthalmology: a systematic approach^len#6#Philadelphia#Elsevier
#20080000#2008#20110200#13.htm##
00586000000000301000450000400060000070200420000670500020004870600020005070000030
00527010002000557090008000577080002000651180002000670100016000690100018000850100
01500103010002000118012006700138030001400205065000900219064000500228031000300233
014000800236865000900244002000700253035001000260801001400270#v55n1#V:\SciELO\ser
ial\abem\v55n1\markup\13.htm#S#c#96#6#article#8#6#^rND^sMcCall^nT#^rND^sFassett^
nDR#^rND^sLyons^nG#^rND^sCouldwell^nWT#Inflammatory pseudotumor of the cavernous
 sinus and skull base^len#Neurosurg Rev#20060000#2006#29#194-200#20110200#13.htm
#0344-5607#Neurosurg Rev##
00572000000000313000450000400060000070200420000670500020004870600020005070000030
00527010002000557090008000577080002000651180002000670100015000690100016000840100
02100100010001500121010001500136012002900151030001400180065000900194064000500203
031000300208014000700211865000900218002000700227035001000234801001400244#v55n1#V
:\SciELO\serial\abem\v55n1\markup\13.htm#S#c#97#7#article#8#7#^rND^sNarla^nL#^rN
D^sNewman^nB#^rND^sSpottswood^nSS#^rND^sNarla^nS#^rND^sKolli^nR#Inflammatory pse
udotumor^len#Radiographics#20030000#2003#23#719-29#20110200#13.htm#0271-5333#Rad
iographics##
00691000000000349000450000400060000070200420000670500020004870600020005070000030
00527010002000557090008000577080002000651180002000670100016000690100021000850100
01400106010001600120010001600136010001900152810000600171012007700177030001800254
06500090027206400050028103100030028603200020028901400060029186500090029700200070
0306035001000313801001800323#v55n1#V:\SciELO\serial\abem\v55n1\markup\13.htm#S#c
#98#8#article#8#8#^rND^sNunes^nTP#^rND^sRoizemblatt^nR#^rND^sMiki^nG#^rND^sGarci
a^nR#^rND^sSanto^nRM#^rND^sOlivalves^nE#et al#Idiopathic orbital inflammation wi
th extraorbital extension: case report^len#Arq Bras Oftalmol#20070000#2007#70#3#
540-3#20110200#13.htm#0004-2749#Arq Bras Oftalmol##
00259000000000169000450000400060000070200420000670500020004870600020005070000020
00527010002000547090005000567080002000610910009000630920007000720020007000797030
00300086#v55n1#V:\SciELO\serial\abem\v55n1\markup\14.htm#S#o#1#1#text#1#20110324
#154614#14.htm#53##
01030000000000421000450000400060000070200420000670500020004870600020005070000020
00527010002000547090005000567080002000610710003000630400003000660010006000690420
00200075120000400077038000300081121000300084049000800087158000300095030002600098
03100030012403200020012706500090012901400090013803500100014712300020015701200830
01590120077002420100031003190100028003500700133003780700082005111170006005930720
00200599002000700601#v55n1#V:\SciELO\serial\abem\v55n1\markup\14.htm#S#h#2#1#tex
t#1#le#pt#br1.1#1#4.0#ND#14#ABEM080#nd#Arq Bras Endocrinol Metab#55#1#20110200#^
f89^l90#0004-2730#1#Metformina: mais uma interação medicamentosa no tratamento d
o hipotireoidismo?^lpt#Metformin: one more drug interaction in the treatment of 
hypothyroidism?^len#^rND^1A01^nRodrigo O.^sMoreira#^rND^1A02^nGeni O.^sMoreira#P
ontifícia Universidade Católica do Rio de Janeiro^iA01^1Instituto Estadual de Di
abetes e Endocrinologia^cRio de Janeiro^sRJ^pBrasil#Universidade Federal do Esta
do do Rio de Janeiro^iA02^cRio de Janeiro^sRJ^pBrasil#other#6#14.htm##
01058000000000421000450000400060000070200420000670500020004870600020005070000020
00527010002000547090005000567080002000610710003000630400003000660010006000690420
00200075120000400077038000300081121000300084049000800087158000300095030002600098
03100030012403200020012706500090012901400090013803500100014712300020015701200970
01590120091002560100031003470100028003780700133004060700082005391170006006210720
00200627002000700629#v55n1#V:\SciELO\serial\abem\v55n1\markup\14.htm#S#f#3#1#tex
t#1#le#pt#br1.1#1#4.0#ND#14#ABEM080#nd#Arq Bras Endocrinol Metab#55#1#20110200#^
f89^l90#0004-2730#1#<b>Metformina</b>: <b>mais uma interação medicamentosa no tr
atamento do hipotireoidismo?</b>^lpt#<b>Metformin</b>: <b>one more drug interact
ion in the treatment of hypothyroidism?</b>^len#^rND^1A01^nRodrigo O.^sMoreira#^
rND^1A02^nGeni O.^sMoreira#Pontifícia Universidade Católica do Rio de Janeiro^iA
01^1Instituto Estadual de Diabetes e Endocrinologia^cRio de Janeiro^sRJ^pBrasil#
Universidade Federal do Estado do Rio de Janeiro^iA02^cRio de Janeiro^sRJ^pBrasi
l#other#6#14.htm##
01146000000000433000450000400060000070200420000670500020004870600020005070000020
00527010002000547090005000567080002000610640013000630710003000760400003000790010
00600082042000200088120000400090121000300094049000800097158000300105030002900108
03100030013703200020014006500090014201400090015103500100016012300020017001200830
01720120077002550100030003320100027003620700135003890700084005241170006006080720
00200614002000700616008008900623#v55n1#V:\SciELO\serial\abem\v55n1\markup\14.htm
#S#l#4#1#text#1#^mfev.^a2011#le#pt#br1.1#1#4.0#14#ABEM080#nd#Arq. bras. endocrin
ol. metab#55#1#20110200#^f89^l90#0004-2730#1#Metformina: mais uma interação medi
camentosa no tratamento do hipotireoidismo?^lpt#Metformin: one more drug interac
tion in the treatment of hypothyroidism?^len#^rND^1A01^nRodrigo O^sMoreira#^rND^
1A02^nGeni O^sMoreira#^iA01^1Pontifícia Universidade Católica do Rio de Janeiro^
2Instituto Estadual de Diabetes e Endocrinologia^cRio de Janeiro^sRJ^pBrasil#^iA
02^1Universidade Federal do Estado do Rio de Janeiro^cRio de Janeiro^sRJ^pBrasil
#other#6#14.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid
=S0004-27302011000100014##
00339000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000500056708000300061704012200064002000700186#v55n1#V:\SciELO
\serial\abem\v55n1\markup\14.htm#S#p#5#1#text#43#<p align="right"><font face="Ve
rdana, Arial, Helvetica, sans-serif" size="2"><b>CARTA    AO EDITOR</b></font></
p>     ^cY#14.htm##
00239000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000500056708000300061704002200064002000700086#v55n1#V:\SciELO
\serial\abem\v55n1\markup\14.htm#S#p#6#2#text#43#<p>&nbsp;</p>     ^cY#14.htm##
00420000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000500056708000300061704020300064002000700267#v55n1#V:\SciELO
\serial\abem\v55n1\markup\14.htm#S#p#7#3#text#43#<p><a name="top"></a><font face
="Verdana, Arial, Helvetica, sans-serif" size="4"><b>Metformina:    mais uma int
era&ccedil;&atilde;o medicamentosa no tratamento do hipotireoidismo?</b></font><
/p>     ^cY#14.htm##
00239000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000500056708000300061704002200064002000700086#v55n1#V:\SciELO
\serial\abem\v55n1\markup\14.htm#S#p#8#4#text#43#<p>&nbsp;</p>     ^cY#14.htm##
00382000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000500056708000300061704016500064002000700229#v55n1#V:\SciELO
\serial\abem\v55n1\markup\14.htm#S#p#9#5#text#43#<p><font face="Verdana, Arial, 
Helvetica, sans-serif" size="3"><b>Metformin: one    more drug interaction in th
e treatment of hypothyroidism?</b></font></p>     ^cY#14.htm##
00240000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000500057708000300062704002200065002000700087#v55n1#V:\SciELO
\serial\abem\v55n1\markup\14.htm#S#p#10#6#text#43#<p>&nbsp;</p>     ^cY#14.htm##
00240000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000500057708000300062704002200065002000700087#v55n1#V:\SciELO
\serial\abem\v55n1\markup\14.htm#S#p#11#7#text#43#<p>&nbsp;</p>     ^cY#14.htm##
00371000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000500057708000300062704015300065002000700218#v55n1#V:\SciELO
\serial\abem\v55n1\markup\14.htm#S#p#12#8#text#43#<p><font face="Verdana, Arial,
 Helvetica, sans-serif" size="2"><b>Rodrigo O. Moreira<sup>I</sup>;    Geni O. M
oreira<sup>II</sup></b></font></p>     ^cY#14.htm##
00465000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000500057708000300062704024700065002000700312#v55n1#V:\SciELO
\serial\abem\v55n1\markup\14.htm#S#p#13#9#text#43#<p><font face="Verdana, Arial,
 Helvetica, sans-serif" size="2"><sup>I</sup>Instituto    Estadual de Diabetes e
 Endocrinologia (IEDE) e Pontif&iacute;cia Universidade    Cat&oacute;lica do Ri
o de Janeiro (PUC-RJ), Rio de Janeiro, RJ, Brasil    ^cY#14.htm##
00347000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704012800066002000700194#v55n1#V:\SciELO
\serial\abem\v55n1\markup\14.htm#S#p#14#10#text#43#<br>   <sup>II</sup>Universid
ade Federal do Estado do Rio de Janeiro (UNIRIO), Rio    de Janeiro, RJ, Brasil<
/font></p>     ^cY#14.htm##
00351000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704013200066002000700198#v55n1#V:\SciELO
\serial\abem\v55n1\markup\14.htm#S#p#15#11#text#43#<p><font face="Verdana, Arial
, Helvetica, sans-serif" size="2"><a href="#back">Correspond&ecirc;ncia    para<
/a></font></p>     ^cY#14.htm##
00241000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704002200066002000700088#v55n1#V:\SciELO
\serial\abem\v55n1\markup\14.htm#S#p#16#12#text#43#<p>&nbsp;</p>     ^cY#14.htm#
#
00241000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704002200066002000700088#v55n1#V:\SciELO
\serial\abem\v55n1\markup\14.htm#S#p#17#13#text#43#<p>&nbsp;</p>     ^cY#14.htm#
#
01440000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704122100066002000701287#v55n1#V:\SciELO
\serial\abem\v55n1\markup\14.htm#S#p#18#14#text#43#<p><font face="Verdana, Arial
, Helvetica, sans-serif" size="2">Na edi&ccedil;&atilde;o    dos <i>Arquivos Bra
sileiros de Endocrinologia e Metabologia</i> de julho de    2010, a Dra. Laura S
. Ward apresentou uma excelente revis&atilde;o sobre intera&ccedil;&atilde;o    
medicamentosa e o impacto de doen&ccedil;as concomitantes no tratamento do hipot
ireoidismo    (1). Por ser uma doen&ccedil;a com elevada preval&ecirc;ncia e de 
tratamento    relativamente simples, &eacute; necess&aacute;rio que todos os m&e
acute;dicos    que tratem pacientes com hipotireoidismo conhe&ccedil;am todos (o
u a maioria)    dos medicamentos que possam interferir na absor&ccedil;&atilde;o
 e/ou no metabolismo    da levotiroxina (LT4). Na sua revis&atilde;o, a autora a
presenta alguns dos    medicamentos e situa&ccedil;&otilde;es mais importantes d
essa intera&ccedil;&atilde;o,    incluindo doen&ccedil;as g&aacute;stricas, ciru
rgia bari&aacute;trica e amiodarona.    Entretanto, nos &uacute;ltimos anos, alg
umas evid&ecirc;ncias v&ecirc;m sendo    publicadas sobre os efeitos no hipotire
oidismo de um dos medicamentos mais utilizados    pelos endocrinologistas para o
 tratamento do diabetes melito tipo 2: a metformina.</font></p>     ^cY#14.htm##
01733000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704151400066002000701580#v55n1#V:\SciELO
\serial\abem\v55n1\markup\14.htm#S#p#19#15#text#43#<p><font face="Verdana, Arial
, Helvetica, sans-serif" size="2">Existem, at&eacute;    o presente momento, tr&
ecirc;s artigos publicados que sugerem que a metformina    pode interferir no tr
atamento do hipotireoidismo. O primeiro artigo &eacute;    composto por uma s&ea
cute;rie de casos e foi publicado em 2006 por Vigersky    e cols. (2). No manusc
rito, os autores apresentam o caso de uma paciente com    hipotireoidismo contro
lado com uma dose est&aacute;vel de LT4 que apresentou    supress&atilde;o da co
ncentra&ccedil;&atilde;o s&eacute;rica de TSH ap&oacute;s    a introdu&ccedil;&a
tilde;o da metformina de libera&ccedil;&atilde;o prolongada    para tratamento d
e esteatose hep&aacute;tica. A concentra&ccedil;&atilde;o plasm&aacute;tica    d
o TSH retornou ao normal ap&oacute;s a suspens&atilde;o da metformina e novament
e    foi suprimida com o rein&iacute;cio da medica&ccedil;&atilde;o. Durante tod
o    o per&iacute;odo, a dose da LT4 se manteve est&aacute;vel. Neste mesmo arti
go,    mais quatro pacientes s&atilde;o apresentados com evolu&ccedil;&atilde;o 
cl&iacute;nica    semelhante: um com hipotireoidismo p&oacute;s-tratamento de do
en&ccedil;a de    Graves com <sup>131</sup>I; um com tireoidite de Hashimoto e d
ois com hipotireoidismo    p&oacute;s-cir&uacute;rgico. Em todos os casos, houve
 redu&ccedil;&atilde;o    da concentra&ccedil;&atilde;o s&eacute;rica do TSH ap&
oacute;s a introdu&ccedil;&atilde;o    da metformina, inclusive com necessidade 
de ajuste da dose da LT4.</font></p>     ^cY#14.htm##
02588000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704236900066002000702435#v55n1#V:\SciELO
\serial\abem\v55n1\markup\14.htm#S#p#20#16#text#43#<p><font face="Verdana, Arial
, Helvetica, sans-serif" size="2">Os dois artigos    publicados posteriormente j
&aacute; envolvem um n&uacute;mero um pouco maior    de pacientes. No artigo de 
Isidro e cols. de 2007 (3), os autores investigam    os efeitos da introdu&ccedi
l;&atilde;o da metformina em oito pacientes com hipotireoidismo    e dose est&aa
cute;vel de LT4. Os autores observaram uma redu&ccedil;&atilde;o    estatisticam
ente significativa da concentra&ccedil;&atilde;o plasm&aacute;tica    do TSH ap&
oacute;s tr&ecirc;s meses de tratamento com metformina (de 3,11 &plusmn;    0,50
 para 1,18 &plusmn; 0,36 microUI/ml; p &lt; 0,05), com um posterior aumento    d
o TSH tr&ecirc;s meses ap&oacute;s a suspens&atilde;o da medica&ccedil;&atilde;o
    (para 2,21 &plusmn; 0,37 microUI/ml). No &uacute;ltimo artigo publicado sobr
e    o assunto por Cappelli e cols. em 2009 (4), os autores investigam dois grup
os    de pacientes. No primeiro grupo, os autores avaliam a varia&ccedil;&atilde
;o    do TSH em 11 pacientes com hipotireoidismo e dose est&aacute;vel de LT4 tr
atados    por metformina por seis meses. Embora tenha sido observada apenas uma 
modesta    e n&atilde;o significativa redu&ccedil;&atilde;o do TSH (de 2,11 &plu
smn; 0,55    para 1,5 &plusmn; 0,36; p = NS), um dos pacientes apresentou uma su
press&atilde;o    da concentra&ccedil;&atilde;o plasm&aacute;tica de TSH, que re
tornou ao normal    ap&oacute;s a suspens&atilde;o da metformina. Na segunda par
te do trabalho,    os autores observam tr&ecirc;s resultados em tr&ecirc;s grupo
s de pacientes    acompanhados por um ano: (1) em pacientes com hipotireoidismo 
adequadamente    compensado com uma dose est&aacute;vel de LT4, houve redu&ccedi
l;&atilde;o significativa    da concentra&ccedil;&atilde;o s&eacute;rica de TSH 
(de 2,37 &plusmn; 1,17 para    1,41 &plusmn; 1,21 microUI/ml; p &lt; 0,001); (2)
 em pacientes com hipotireoidismo    subcl&iacute;nico sem tratamento, houve uma
 redu&ccedil;&atilde;o significativa    da concentra&ccedil;&atilde;o plasm&aacu
te;tica de TSH (de 4,5 &plusmn; 0,37    para 2,93 &plusmn; 1,48 microUI/ml; p &l
t; 0,001) e (3) num grupo controle sem    qualquer evid&ecirc;ncia de doen&ccedi
l;a tireoidiana n&atilde;o houve diferen&ccedil;a    na concentra&ccedil;&atilde
;o s&eacute;rica do TSH (2,74 &plusmn; 0,82 para    2,56 &plusmn; 1,16; p = NS).
</font></p>     ^cY#14.htm##
03042000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704282300066002000702889#v55n1#V:\SciELO
\serial\abem\v55n1\markup\14.htm#S#p#21#17#text#43#<p><font face="Verdana, Arial
, Helvetica, sans-serif" size="2">N&atilde;o existe    ainda uma explica&ccedil;
&atilde;o para esses efeitos, embora algumas hip&oacute;teses    j&aacute; tenha
m sido aventadas. Uma das explica&ccedil;&otilde;es poderia envolver    uma alte
ra&ccedil;&atilde;o na absor&ccedil;&atilde;o da LT4 induzida pela metformina.  
  Entretanto, em consequ&ecirc;ncia dos conhecidos efeitos gastrointestinais da 
   metformina, seria esperada uma diminui&ccedil;&atilde;o da absor&ccedil;&atil
de;o    da LT4, com um aumento da concentra&ccedil;&atilde;o plasm&aacute;tica d
e TSH.    Al&eacute;m disso, essa explica&ccedil;&atilde;o n&atilde;o justifica 
o achado    de Capelli e cols. (4) da supress&atilde;o do TSH em pacientes com h
ipotireoidismo    subcl&iacute;nico ainda sem tratamento. Outra hip&oacute;tese 
seria a exist&ecirc;ncia    de efeitos anti-inflamat&oacute;rios da metformina d
iretamente sobre a tireoide.    Entretanto, devemos lembrar que, no estudo inici
al de Vigersky e cols. (2),    dois pacientes apresentavam hipotireoidismo p&oac
ute;s-cir&uacute;rgico (incluindo    um com tireoidectomia total por carcinoma d
iferenciado da tireoide). Uma terceira    explica&ccedil;&atilde;o seria um efei
to direto da metformina sobre o hipot&aacute;lamo    e/ou hip&oacute;fise, alter
ando de forma significativa os mecanismos de <i>feedback</i>    do eixo tireoidi
ano. Da mesma forma, poderia se especular que a redu&ccedil;&atilde;o    na conc
entra&ccedil;&atilde;o plasm&aacute;tica do TSH seria secund&aacute;ria    a uma
 redu&ccedil;&atilde;o do peso corporal induzida pela metformina. Em nenhum    d
os artigos, entretanto, foi evidenciada qualquer altera&ccedil;&atilde;o signifi
cativa    do peso que pudesse justificar essa hip&oacute;tese. Finalmente, poder
ia existir    algum efeito da metformina que comprometesse o metabolismo hep&aac
ute;tico da    LT4. Essa hip&oacute;tese tamb&eacute;m parece improv&aacute;vel,
 j&aacute;    que a metformina n&atilde;o sofre metaboliza&ccedil;&atilde;o hep&
aacute;tica    e n&atilde;o foi encontrada nenhuma evid&ecirc;ncia que sugira qu
e a metformina    possa interferir na atividade das deiodinases, com a liga&cced
il;&atilde;o da    tiroxina a TBG ("<i>Thyroxine-Binding Globulin</i>") ou com o
 processo de degrada&ccedil;&atilde;o    da tiroxina (especificamente com as rea
&ccedil;&otilde;es hep&aacute;ticas de    sulfata&ccedil;&atilde;o ou glicorunid
a&ccedil;&atilde;o) (5). &Eacute; importante    ressaltar que os &uacute;nicos e
feitos identific&aacute;veis da metformina foram    sobre a concentra&ccedil;&at
ilde;o s&eacute;rica do TSH. Os estudos tamb&eacute;m    avaliaram os outros hor
m&ocirc;nios e n&atilde;o foram encontradas diferen&ccedil;as    significativas 
nos n&iacute;veis de T3 e T4 livre, assim como da TBG.</font></p>     ^cY#14.htm
##
01647000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704142800066002000701494#v55n1#V:\SciELO
\serial\abem\v55n1\markup\14.htm#S#p#22#18#text#43#<p><font face="Verdana, Arial
, Helvetica, sans-serif" size="2">A exist&ecirc;ncia    de uma poss&iacute;vel i
ntera&ccedil;&atilde;o da metformina sobre o tratamento    do hipotireoidismo &e
acute; de enorme import&acirc;ncia cl&iacute;nica, assim    como de diversos out
ros medicamentos utilizados na pr&aacute;tica cl&iacute;nica    (6). A relev&aci
rc;ncia dessa associa&ccedil;&atilde;o baseia-se no fato de    o DM tipo 2 e o h
ipotireoidismo serem as duas doen&ccedil;as mais prevalentes    da endocrinologi
a e de frequentemente coexistirem em um mesmo paciente. At&eacute;    o presente
 momento, n&atilde;o existe uma evid&ecirc;ncia concreta de que essa    intera&c
cedil;&atilde;o exista. Entretanto, os trabalhos acima s&atilde;o geradores    d
e hip&oacute;teses, o que provavelmente levar&aacute; a novos trabalhos, com    
mais pacientes e metodologia mais adequada, para que essa intera&ccedil;&atilde;
o    possa ser adequadamente investigada. Al&eacute;m disso, o pr&oacute;prio me
canismo    dessa poss&iacute;vel intera&ccedil;&atilde;o ainda permanece obscuro
 e precisa    ser mais bem compreendido, se realmente existir. Entretanto, o end
ocrinologista    precisa estar ciente de que tal intera&ccedil;&atilde;o pode ex
istir e, copiando    o t&iacute;tulo da revis&atilde;o da Dra. Laura S. Ward (1)
, de que o paciente    com hipotireoidismo e DM pode ser ainda mais "dif&iacute;
cil" do que parece.</font></p>     ^cY#14.htm##
00425000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704020600066002000700272#v55n1#V:\SciELO
\serial\abem\v55n1\markup\14.htm#S#p#23#19#text#43#<p><font face="Verdana, Arial
, Helvetica, sans-serif" size="2">Declara&ccedil;&atilde;o:    os autores declar
am n&atilde;o haver conflitos de interesse cient&iacute;fico    neste estudo.</f
ont></p>     ^cY#14.htm##
00241000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704002200066002000700088#v55n1#V:\SciELO
\serial\abem\v55n1\markup\14.htm#S#p#24#20#text#43#<p>&nbsp;</p>     ^cY#14.htm#
#
00326000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704010700066002000700173#v55n1#V:\SciELO
\serial\abem\v55n1\markup\14.htm#S#p#25#21#text#43#<p><font face="Verdana, Arial
, Helvetica, sans-serif" size="3"><b>REFER&Ecirc;NCIAS</b></font></p>     ^cY#14
.htm##
00485000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063888000200066704025200068002000700320#v55
n1#V:\SciELO\serial\abem\v55n1\markup\14.htm#S#p#26#22#text#43#1#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="2">1. Ward LS. The    difficult pat
ient: drug interaction and the influence of concomitant diseases    on the treat
ment of hypothyroidism. Arq Bras Endocrinol Metab. 2010;54(5):435-42.    ^cY#14.
htm##
00239000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704002000066002000700086#v55n1#V:\SciELO
\serial\abem\v55n1\markup\14.htm#S#p#27#23#text#43#</font></p>     ^cY#14.htm##
00434000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063888000200066704020100068002000700269#v55
n1#V:\SciELO\serial\abem\v55n1\markup\14.htm#S#p#28#24#text#43#2#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="2">2. Vigersky RA,    Filmore-Nassa
r A, Glass AR. Thyrotropin suppression by metformin. J Clin Endocrinol    Metab.
 2006;91(1):225-7.    ^cY#14.htm##
00239000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704002000066002000700086#v55n1#V:\SciELO
\serial\abem\v55n1\markup\14.htm#S#p#29#25#text#43#</font></p>     ^cY#14.htm##
00527000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063888000200066704029400068002000700362#v55
n1#V:\SciELO\serial\abem\v55n1\markup\14.htm#S#p#30#26#text#43#3#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="2">3. 3. Isidro ML,    Pen&iacute;n
 MA, Nemi&ntilde;a R, Cordido F. Metformin reduces thyrotropin levels    in obes
e, diabetic women with primary hypothyroidism on thyroxine replacement    therap
y. Endocrine. 2007;32(1):79-82.    ^cY#14.htm##
00239000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704002000066002000700086#v55n1#V:\SciELO
\serial\abem\v55n1\markup\14.htm#S#p#31#27#text#43#</font></p>     ^cY#14.htm##
00584000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063888000200066704035100068002000700419#v55
n1#V:\SciELO\serial\abem\v55n1\markup\14.htm#S#p#32#28#text#43#4#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="2">4. Cappelli C,    Rotondi M, Pir
ola I, Agosti B, Gandossi E, Valentini U, et al. TSH-lowering    effect of metfo
rmin in type 2 diabetic patients: differences between euthyroid,    untreated hy
pothyroid, and euthyroid on L-T4 therapy patients. Diabetes Care.    2009;32(9):
1589-90.    ^cY#14.htm##
00239000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704002000066002000700086#v55n1#V:\SciELO
\serial\abem\v55n1\markup\14.htm#S#p#33#29#text#43#</font></p>     ^cY#14.htm##
00520000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063888000200066704028700068002000700355#v55
n1#V:\SciELO\serial\abem\v55n1\markup\14.htm#S#p#34#30#text#43#5#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="2">5. Farwell AP,    Braverman LE. 
Thyroid and antithyroid drugs. In: Goodman &amp; Gilman's. The    pharmacologica
l basis of therapeutics. Hardman Gilman AG, JG, Limbird LE. 9th    edition. New 
York: McGraw-Hill; 1996.    ^cY#14.htm##
00239000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704002000066002000700086#v55n1#V:\SciELO
\serial\abem\v55n1\markup\14.htm#S#p#35#31#text#43#</font></p>     ^cY#14.htm##
00438000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063888000200066704020500068002000700273#v55
n1#V:\SciELO\serial\abem\v55n1\markup\14.htm#S#p#36#32#text#43#6#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="2">6. Haugen BR. Drugs    that supp
ress TSH or cause central hypothyroidism. Best Pract Res Clin Endocrinol    Meta
b. 2009;23(6):793-800.    ^cY#14.htm##
00239000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704002000066002000700086#v55n1#V:\SciELO
\serial\abem\v55n1\markup\14.htm#S#p#37#33#text#43#</font></p>     ^cY#14.htm##
00241000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704002200066002000700088#v55n1#V:\SciELO
\serial\abem\v55n1\markup\14.htm#S#p#38#34#text#43#<p>&nbsp;</p>     ^cY#14.htm#
#
00241000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704002200066002000700088#v55n1#V:\SciELO
\serial\abem\v55n1\markup\14.htm#S#p#39#35#text#43#<p>&nbsp;</p>     ^cY#14.htm#
#
00418000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704019900066002000700265#v55n1#V:\SciELO
\serial\abem\v55n1\markup\14.htm#S#p#40#36#text#43#<p><font face="Verdana, Arial
, Helvetica, sans-serif" size="2"><b><a name="back"></a><a href="#top"><img src=
"/img/revistas/abem/v55n1/seta.jpg" border="0"></a>    Correspond&ecirc;ncia par
a:    ^cY#14.htm##
00257000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704003800066002000700104#v55n1#V:\SciELO
\serial\abem\v55n1\markup\14.htm#S#p#41#37#text#43#<br>   </b> Rodrigo O. Moreir
a    ^cY#14.htm##
00281000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704006200066002000700128#v55n1#V:\SciELO
\serial\abem\v55n1\markup\14.htm#S#p#42#38#text#43#<br>   Instituto Estadual de 
Diabetes e Endocrinologia    ^cY#14.htm##
00256000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704003700066002000700103#v55n1#V:\SciELO
\serial\abem\v55n1\markup\14.htm#S#p#43#39#text#43#<br>   Rua Moncorvo Filho, 90
    ^cY#14.htm##
00272000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704005300066002000700119#v55n1#V:\SciELO
\serial\abem\v55n1\markup\14.htm#S#p#44#40#text#43#<br>   20211-340 - Rio de Jan
eiro, RJ, Brasil    ^cY#14.htm##
00300000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704008100066002000700147#v55n1#V:\SciELO
\serial\abem\v55n1\markup\14.htm#S#p#45#41#text#43#<br>   <a href="mailto:rom_br
@yahoo.com">rom_br@yahoo.com</a></font></p>     ^cY#14.htm##
00314000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704009500066002000700161#v55n1#V:\SciELO
\serial\abem\v55n1\markup\14.htm#S#p#46#42#text#43#<p><font face="Verdana, Arial
, Helvetica, sans-serif" size="2">Recebido em 14/Agol/2010    ^cY#14.htm##
00266000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704004700066002000700113#v55n1#V:\SciELO
\serial\abem\v55n1\markup\14.htm#S#p#47#43#text#43#<br>   Aceito em 5/Jan/2011</
font></p>     ^cY#14.htm##
00538000000000265000450000400060000070200420000670500020004870600020005070000030
00527010002000557090005000577080002000621180002000640100015000660120121000810300
02600202710000200228065000900230064000500239031000300244032000200247014000700249
865000900256002000700265#v55n1#V:\SciELO\serial\abem\v55n1\markup\14.htm#S#c#48#
1#text#6#1#^rND^sWard^nLS#The difficult patient: drug interaction and the influe
nce of concomitant diseases on the treatment of hypothyroidism^len#Arq Bras Endo
crinol Metab#2#20100000#2010#54#5#435-42#20110200#14.htm##
00567000000000301000450000400060000070200420000670500020004870600020005070000030
00527010002000557090005000577080002000621180002000640100019000660100024000850100
01600109012004100125030002400166065000900190064000500199031000300204032000200207
014000600209865000900215002000700224035001000231801002400241#v55n1#V:\SciELO\ser
ial\abem\v55n1\markup\14.htm#S#c#49#2#text#6#2#^rND^sVigersky^nRA#^rND^sFilmore-
Nassar^nA#^rND^sGlass^nAR#Thyrotropin suppression by metformin^len#J Clin Endocr
inol Metab#20060000#2006#91#1#225-7#20110200#14.htm#0021-972X#J Clin Endocrinol 
Metab##
00644000000000313000450000400060000070200420000670500020004870600020005070000030
00527010002000557090005000577080002000621180002000640100017000660100016000830100
01600099010001700115012012700132030001000259065000900269064000500278031000300283
032000200286014000600288865000900294002000700303035001000310801001000320#v55n1#V
:\SciELO\serial\abem\v55n1\markup\14.htm#S#c#50#3#text#6#3#^rND^sIsidro^nML#^rND
^sPenín^nMA#^rND^sNemiña^nR#^rND^sCordido^nF#Metformin reduces thyrotropin level
s in obese, diabetic women with primary hypothyroidism on thyroxine replacement 
therapy^len#Endocrine#20070000#2007#32#1#79-82#20110200#14.htm#0969-711X#ENDOCRI
NE##
00766000000000349000450000400060000070200420000670500020004870600020005070000030
00527010002000557090005000577080002000621180002000640100018000660100017000840100
01600101010001600117010001800133010001900151810000600170012015900176030001400335
06500090034906400050035803100030036303200020036601400080036886500090037600200070
0385035001000392801001400402#v55n1#V:\SciELO\serial\abem\v55n1\markup\14.htm#S#c
#51#4#text#6#4#^rND^sCappelli^nC#^rND^sRotondi^nM#^rND^sPirola^nI#^rND^sAgosti^n
B#^rND^sGandossi^nE#^rND^sValentini^nU#et al#TSH-lowering effect of metformin in
 type 2 diabetic patients: differences between euthyroid, untreated hypothyroid,
 and euthyroid on L-T4 therapy patients^len#Diabetes Care#20090000#2009#32#9#158
9-90#20110200#14.htm#0149-5992#Diabetes Care##
00540000000000277000450000400060000070200420000670500020004870600020005070000030
00527010002000557090005000577080002000621180002000640100018000660100020000840120
03400104016002500138018004600163063000200209066000900211062001200220065000900232
064000500241865000900246002000700255#v55n1#V:\SciELO\serial\abem\v55n1\markup\14
.htm#S#c#52#5#text#6#5#^rND^sFarwell^nAP#^rND^sBraverman^nLE#Thyroid and antithy
roid drugs^len#^rND^sGoodman & Gilman's#The pharmacological basis of therapeutic
s^len#9#New York#McGraw-Hill#19960000#1996#20110200#14.htm##
00491000000000265000450000400060000070200420000670500020004870600020005070000030
00527010002000557090005000577080002000621180002000640100017000660120060000830300
03700143710000200180065000900182064000500191031000300196032000200199014000800201
865000900209002000700218#v55n1#V:\SciELO\serial\abem\v55n1\markup\14.htm#S#c#53#
6#text#6#6#^rND^sHaugen^nBR#Drugs that suppress TSH or cause central hypothyroid
ism^len#Best Pract Res Clin Endocrinol Metab#2#20090000#2009#23#6#793-800#201102
00#14.htm##
00263000000000169000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640910009000660920007000750020007000827030
00400089#v55n1#V:\SciELO\serial\abem\v55n1\markup\08.htm#S#o#1#1#article#1#20110
406#124301#08.htm#130##
03528000000000577000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640710003000660400003000690010006000720420
00200078120000400080038000500084038000400089121000300093049000800096158000300104
03000260010703100030013303200020013606500090013801400090014703500100015601201190
01660120111002850100045003960100024004410100030004650100032004950100029005270100
02800556010003100584010002700615010002700642070012900669070011000798083099400908
08309900190211700060289207200030289811200090290111100120291011400090292211300120
2931002000702943#v55n1#V:\SciELO\serial\abem\v55n1\markup\08.htm#S#h#2#1#article
#1#oa#en#br1.1#1#4.0#ILUS#TAB#08#ABEM430#nd#Arq Bras Endocrinol Metab#55#1#20110
200#^f60^l66#0004-2730#Novel mutation in MCT8 gene in a Brazilian boy with thyro
id hormone resistance and severe neurologic abnormalities^len#Mutação nova do ge
ne MCT8 em menino Brasileiro com resistência ao hormônio tireioidiano e neuropat
ia grave^lpt#^rND^1A01^nHamilton Cabral de^sMenezes Filho#^rND^1A02^nSuemi^sMaru
i#^rND^1A01^nThais Della^sManna#^rND^1A02^nEster Saraiva^sBrust#^rND^1A01^nVanes
sa^sRadonsky#^rND^1A01^nHilton^sKuperman#^rND^1A01^nVaê^sDichtchekenian#^rND^1A0
1^nNuvarte^sSetian#^rND^1A01^nDurval^sDamiani#Universidade de São Paulo^iA01^1Fa
culdade de Medicina^2Instituto da Criança^3Pediatric Endocrinology Unit^cSão Pau
lo^sSP^pBrazil#USP^iA02^1FM^2Division of Endocrinology^3Laboratory of Molecular 
Genetics and Hormones^cSão Paulo^sSP^pBrazil#^lpt^aO MCT8 é um transportador cel
ular de hormônios tireoidianos, importante para sua ação e metabolização. Relata
mos o caso de um menino com a nova mutação inativadora 630insG no éxon 1 do MCT8
. O paciente caracterizou-se por grave comprometimento neurológico (inicialmente
 com hipotonia global, evoluindo com hipertonia generalizada), crescimento norma
l nos dois primeiros anos de vida, reduzido ganho ponderal e ausência dos sinais
 e sintomas típicos de hipotireoidismo. A sua avaliação sérica revelou elevação 
do T3, redução do T4 total e livre e TSH levemente aumentado. O tratamento com l
evotiroxina melhorou o perfil hormonal tireoidiano, mas não modificou o quadro c
línico do paciente. Esses dados reforçam o conceito de que o papel do MCT8 é tec
ido-dependente: enquanto os neurônios são altamente dependentes do MCT8, o osso,
 o tecido adiposo, o músculo e o fígado são menos dependentes do MCT8 e, portant
o, podem sofrer as consequências da exposição a níveis séricos elevados de T3.#^
len^aMCT8 is a cellular transporter of thyroid hormones important in their actio
n and metabolization. We report a male patient with the novel inactivating mutat
ion 630insG in the coding region in exon 1 of MCT8. He was characterized clinica
lly by severe neurologic impairment (initially with global hypotonia, later evol
ving with generalized hypertonia), normal growth during infancy, reduced weight 
gain, and absence of typical signs and symptoms of hypothyroidism, while the lab
oratory evaluation disclosed elevated T3, low total and free T4, and mildly elev
ated TSH serum levels. Treatment with levothyroxine improved thyroid hormone pro
file but was not able to alter the clinical picture of the patient. These data r
einforce the concept that the role of MCT8 is tissue-dependent: while neurons ar
e highly dependent on MCT8, bone tissue, adipose tissue, muscle, and liver are l
ess dependent on MCT8 and, therefore, may suffer the consequences of the exposit
ion to high serum T3 levels.#other#17#20100730#Jul/30/2010#20101214#Dec/14/2010#
08.htm##
03570000000000577000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640710003000660400003000690010006000720420
00200078120000400080038000500084038000400089121000300093049000800096158000300104
03000260010703100030013303200020013606500090013801400090014703500100015601201330
01660120125002990100045004240100024004690100030004930100032005230100029005550100
02800584010003100612010002700643010002700670070012900697070011000826083100100936
08309970193711700060293407200030294011200090294311100120295211400090296411300120
2973002000702985#v55n1#V:\SciELO\serial\abem\v55n1\markup\08.htm#S#f#3#1#article
#1#oa#en#br1.1#1#4.0#ILUS#TAB#08#ABEM430#nd#Arq Bras Endocrinol Metab#55#1#20110
200#^f60^l66#0004-2730#<b>Novel mutation in <i>MCT8</i> gene in a Brazilian boy 
with thyroid hormone resistance and severe neurologic abnormalities</b>^len#<b>M
utação nova do gene <i>MCT8</i> em menino Brasileiro com resistência ao hormônio
 tireioidiano e neuropatia grave</b>^lpt#^rND^1A01^nHamilton Cabral de^sMenezes 
Filho#^rND^1A02^nSuemi^sMarui#^rND^1A01^nThais Della^sManna#^rND^1A02^nEster Sar
aiva^sBrust#^rND^1A01^nVanessa^sRadonsky#^rND^1A01^nHilton^sKuperman#^rND^1A01^n
Vaê^sDichtchekenian#^rND^1A01^nNuvarte^sSetian#^rND^1A01^nDurval^sDamiani#Univer
sidade de São Paulo^iA01^1Faculdade de Medicina^2Instituto da Criança^3Pediatric
 Endocrinology Unit^cSão Paulo^sSP^pBrazil#USP^iA02^1FM^2Division of Endocrinolo
gy^3Laboratory of Molecular Genetics and Hormones^cSão Paulo^sSP^pBrazil#^lpt^aO
 MCT8 é um transportador celular de hormônios tireoidianos, importante para sua 
ação e metabolização. Relatamos o caso de um menino com a nova mutação inativado
ra 630insG no éxon 1 do <i>MCT8</i>. O paciente caracterizou-se por grave compro
metimento neurológico (inicialmente com hipotonia global, evoluindo com hiperton
ia generalizada), crescimento normal nos dois primeiros anos de vida, reduzido g
anho ponderal e ausência dos sinais e sintomas típicos de hipotireoidismo. A sua
 avaliação sérica revelou elevação do T3, redução do T4 total e livre e TSH leve
mente aumentado. O tratamento com levotiroxina melhorou o perfil hormonal tireoi
diano, mas não modificou o quadro clínico do paciente. Esses dados reforçam o co
nceito de que o papel do MCT8 é tecido-dependente: enquanto os neurônios são alt
amente dependentes do MCT8, o osso, o tecido adiposo, o músculo e o fígado são m
enos dependentes do MCT8 e, portanto, podem sofrer as consequências da exposição
 a níveis séricos elevados de T3.#^len^aMCT8 is a cellular transporter of thyroi
d hormones important in their action and metabolization. We report a male patien
t with the novel inactivating mutation 630insG in the coding region in exon 1 of
 <i>MCT8</i>. He was characterized clinically by severe neurologic impairment (i
nitially with global hypotonia, later evolving with generalized hypertonia), nor
mal growth during infancy, reduced weight gain, and absence of typical signs and
 symptoms of hypothyroidism, while the laboratory evaluation disclosed elevated 
T3, low total and free T4, and mildly elevated TSH serum levels. Treatment with 
levothyroxine improved thyroid hormone profile but was not able to alter the cli
nical picture of the patient. These data reinforce the concept that the role of 
MCT8 is tissue-dependent: while neurons are highly dependent on MCT8, bone tissu
e, adipose tissue, muscle, and liver are less dependent on MCT8 and, therefore, 
may suffer the consequences of the exposition to high serum T3 levels.#other#17#
20100730#Jul/30/2010#20101214#Dec/14/2010#08.htm##
03661000000000601000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640640013000660710003000790400003000820010
00600085042000200091120000400093038000500097038000400102121000300106049000800109
15800030011703000290012003100030014903200020015206500090015401400090016303500100
01720120119001820120111003010100045004120100024004570100030004810100032005110100
02900543010002800572010003100600010002700631010002700658070013100685070011200816
08309940092808309900192211700060291207200030291811200090292111100120293011400090
2942113001202951002000702963008008902970#v55n1#V:\SciELO\serial\abem\v55n1\marku
p\08.htm#S#l#4#1#article#1#^mFeb.^a2011#oa#en#br1.1#1#4.0#ilus#tab#08#ABEM430#nd
#Arq. bras. endocrinol. metab#55#1#20110200#^f60^l66#0004-2730#Novel mutation in
 MCT8 gene in a Brazilian boy with thyroid hormone resistance and severe neurolo
gic abnormalities^len#Mutação nova do gene MCT8 em menino Brasileiro com resistê
ncia ao hormônio tireioidiano e neuropatia grave^lpt#^rND^1A01^nHamilton Cabral 
de^sMenezes Filho#^rND^1A02^nSuemi^sMarui#^rND^1A01^nThais Della^sManna#^rND^1A0
2^nEster Saraiva^sBrust#^rND^1A01^nVanessa^sRadonsky#^rND^1A01^nHilton^sKuperman
#^rND^1A01^nVaê^sDichtchekenian#^rND^1A01^nNuvarte^sSetian#^rND^1A01^nDurval^sDa
miani#^iA01^1Universidade de São Paulo^2Faculdade de Medicina^3Instituto da Cria
nça. Pediatric Endocrinology Unit^cSão Paulo^sSP^pBrazil#^iA02^1USP^2FM^3Divisio
n of Endocrinology. Laboratory of Molecular Genetics and Hormones^cSão Paulo^sSP
^pBrazil#^lpt^aO MCT8 é um transportador celular de hormônios tireoidianos, impo
rtante para sua ação e metabolização. Relatamos o caso de um menino com a nova m
utação inativadora 630insG no éxon 1 do MCT8. O paciente caracterizou-se por gra
ve comprometimento neurológico (inicialmente com hipotonia global, evoluindo com
 hipertonia generalizada), crescimento normal nos dois primeiros anos de vida, r
eduzido ganho ponderal e ausência dos sinais e sintomas típicos de hipotireoidis
mo. A sua avaliação sérica revelou elevação do T3, redução do T4 total e livre e
 TSH levemente aumentado. O tratamento com levotiroxina melhorou o perfil hormon
al tireoidiano, mas não modificou o quadro clínico do paciente. Esses dados refo
rçam o conceito de que o papel do MCT8 é tecido-dependente: enquanto os neurônio
s são altamente dependentes do MCT8, o osso, o tecido adiposo, o músculo e o fíg
ado são menos dependentes do MCT8 e, portanto, podem sofrer as consequências da 
exposição a níveis séricos elevados de T3.#^len^aMCT8 is a cellular transporter 
of thyroid hormones important in their action and metabolization. We report a ma
le patient with the novel inactivating mutation 630insG in the coding region in 
exon 1 of MCT8. He was characterized clinically by severe neurologic impairment 
(initially with global hypotonia, later evolving with generalized hypertonia), n
ormal growth during infancy, reduced weight gain, and absence of typical signs a
nd symptoms of hypothyroidism, while the laboratory evaluation disclosed elevate
d T3, low total and free T4, and mildly elevated TSH serum levels. Treatment wit
h levothyroxine improved thyroid hormone profile but was not able to alter the c
linical picture of the patient. These data reinforce the concept that the role o
f MCT8 is tissue-dependent: while neurons are highly dependent on MCT8, bone tis
sue, adipose tissue, muscle, and liver are less dependent on MCT8 and, therefore
, may suffer the consequences of the exposition to high serum T3 levels.#other#1
7#20100730#Jul/30/2010#20101214#Dec/14/2010#08.htm#Internet^ihttp://www.scielo.b
r/scielo.php?script=sci_arttext&pid=S0004-27302011000100008##
00351000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704013000068002000700198#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#5#1#article#109#<p align="right"><font face
="Verdana, Arial, Helvetica, sans-serif" size="2"><b>MOLECULAR    CLINICAL CASE<
/b></font></p>     ^cY#08.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704002200068002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#6#2#article#109#<p>&nbsp;</p>     ^cY#08.ht
m##
00456000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704023500068002000700303#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#7#3#article#109#<p><a name="top"></a><font 
face="Verdana, Arial, Helvetica, sans-serif" size="4"><b>Novel    mutation in <i
>MCT8</i> gene in a Brazilian boy with thyroid hormone resistance    and severe 
neurologic abnormalities</b></font></p>     ^cY#08.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704002200068002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#8#4#article#109#<p>&nbsp;</p>     ^cY#08.ht
m##
00456000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704023500068002000700303#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#9#5#article#109#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="3"><b>Muta&ccedil;&atilde;o    nova do gene <i>
MCT8</i> em menino Brasileiro com resist&ecirc;ncia ao horm&ocirc;nio    tireioi
diano e neuropatia grave</b></font></p>     ^cY#08.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000400065704002200069002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#10#6#article#109#<p>&nbsp;</p>     ^cY#08.h
tm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000400065704002200069002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#11#7#article#109#<p>&nbsp;</p>     ^cY#08.h
tm##
00609000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000400065704038700069002000700456#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#12#8#article#109#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>Hamilton Cabral    de Menezes Filho<sup>
I</sup>; Suemi Marui<sup>II</sup>; Thais Della Manna<sup>I</sup>;    Ester Sarai
va Brust<sup>II</sup>; Vanessa Radonsky<sup>I</sup>; Hilton Kuperman<sup>I</sup>
;    Va&ecirc; Dichtchekenian<sup>I</sup>, Nuvarte Setian<sup>I</sup>, Durval Da
miani<sup>I</sup></b></font></p>     ^cY#08.htm##
00505000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000400065704028300069002000700352#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#13#9#article#109#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><sup>I</sup>Pediatric    Endocrinology Unit
, Instituto da Crian&ccedil;a, Hospital das Cl&iacute;nicas,    Faculdade de Med
icina da Universidade de S&atilde;o Paulo (ICr-HC-FMUSP), S&atilde;o    Paulo, S
P, Brazil    ^cY#08.htm##
00398000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704017500070002000700245#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#14#10#article#109#<br>   <sup>II</sup>Thyro
id Unit, Laboratory of Molecular Genetics and Hormones (LIM-25),    Division of 
Endocrinology, FMUSP, S&atilde;o Paulo, SP, Brazil</font></p>     ^cY#08.htm##
00346000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704012300070002000700193#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#15#11#article#109#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><a href="#back">Correspondence    to</a></
font></p>     ^cY#08.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#16#12#article#109#<p>&nbsp;</p>     ^cY#08.
htm##
00267000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704004400070002000700114#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#17#13#article#109#<p>&nbsp;</p> <hr size="1
" noshade>     ^cY#08.htm##
00320000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704009700070002000700167#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#18#14#article#109#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>SUMMARY</b></font></p>     ^cY#08.htm##
01357000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704113400070002000701204#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#19#15#article#109#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">MCT8 is a cellular    transporter of thyro
id hormones important in their action and metabolization.    We report a male pa
tient with the novel inactivating mutation 630insG in the    coding region in ex
on 1 of <i>MCT8</i>. He was characterized clinically by severe    neurologic imp
airment (initially with global hypotonia, later evolving with    generalized hyp
ertonia), normal growth during infancy, reduced weight gain,    and absence of t
ypical signs and symptoms of hypothyroidism, while the laboratory    evaluation 
disclosed elevated T3, low total and free T4, and mildly elevated    TSH serum l
evels. Treatment with levothyroxine improved thyroid hormone profile    but was 
not able to alter the clinical picture of the patient. These data reinforce    t
he concept that the role of MCT8 is tissue-dependent: while neurons are highly  
  dependent on MCT8, bone tissue, adipose tissue, muscle, and liver are less dep
endent    on MCT8 and, therefore, may suffer the consequences of the exposition 
to high    serum T3 levels.</font></p> <hr size="1" noshade>     ^cY#08.htm##
00327000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704010400070002000700174#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#20#16#article#109#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>SUM&Aacute;RIO</b></font></p>     ^cY#0
8.htm##
01594000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704137100070002000701441#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#21#17#article#109#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">O MCT8 &eacute;    um transportador celula
r de horm&ocirc;nios tireoidianos, importante para sua    a&ccedil;&atilde;o e m
etaboliza&ccedil;&atilde;o. Relatamos o caso de um menino    com a nova muta&cce
dil;&atilde;o inativadora 630insG no &eacute;xon 1 do <i>MCT8</i>.    O paciente
 caracterizou-se por grave comprometimento neurol&oacute;gico (inicialmente    c
om hipotonia global, evoluindo com hipertonia generalizada), crescimento normal 
   nos dois primeiros anos de vida, reduzido ganho ponderal e aus&ecirc;ncia dos
    sinais e sintomas t&iacute;picos de hipotireoidismo. A sua avalia&ccedil;&at
ilde;o    s&eacute;rica revelou eleva&ccedil;&atilde;o do T3, redu&ccedil;&atild
e;o do    T4 total e livre e TSH levemente aumentado. O tratamento com levotirox
ina melhorou    o perfil hormonal tireoidiano, mas n&atilde;o modificou o quadro
 cl&iacute;nico    do paciente. Esses dados refor&ccedil;am o conceito de que o 
papel do MCT8 &eacute;    tecido-dependente: enquanto os neur&ocirc;nios s&atild
e;o altamente dependentes    do MCT8, o osso, o tecido adiposo, o m&uacute;sculo
 e o f&iacute;gado s&atilde;o    menos dependentes do MCT8 e, portanto, podem so
frer as consequ&ecirc;ncias da    exposi&ccedil;&atilde;o a n&iacute;veis s&eacu
te;ricos elevados de T3.</font></p> <hr size="1" noshade>     ^cY#08.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#22#18#article#109#<p>&nbsp;</p>     ^cY#08.
htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#23#19#article#109#<p>&nbsp;</p>     ^cY#08.
htm##
00325000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704010200070002000700172#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#24#20#article#109#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="3"><b>INTRODUCTION</b></font></p>     ^cY#08.
htm##
01518000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704129500070002000701365#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#25#21#article#109#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Iodothyronine deiodinases    are capable o
f activating or inactivating thyroid hormones (TH) (1). Type 2    deiodinase (D2
) removes an outer ring iodine atom, allowing the conversion of    tetraiodothyr
onine (T4, or thyroxine) into triiodothyronine (T3), the active    form of TH (1
). On the other hand, the inactivation of T4 to reverse T3 (rT3)    and of T3 to
 T2 depends on the internal ring deiodination by type 3 iodothyronine    deiodin
ase (D3). Type 1 iodothyronine deiodinase (D1) catalyzes the removal    of inner
 or outer ring iodine atoms and therefore generates T3, rT3, or T2,    depending
 on the substrate (1). In humans most circulating T3 arises from T4    by the ac
tions of D1 in the liver and kidney, although D2 in the skeletal muscle    also 
contributes (1). Hepatic D1 is involved in the clearance of rT3 into T2,    whil
e D2 controls the intracellular concentration of T3 (1). D2 is responsible    fo
r the local generation of T3 when there is deprivation of T4, protecting vital  
  organs (like the brain, for example) during periods of hypothyroidism (1). D3 
   is the only enzyme capable of degrading TH with an important role in the nega
tive    control of tissue and serum T3 levels (2).</font></p>     ^cY#08.htm##
01675000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704145200070002000701522#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#26#22#article#109#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">The biological    activity of TH is relate
d to intracellular T3 concentration, which depends on    the concentration of ci
rculating T4 and T3, the activity of deiodinases D1 and    D2, and the activity 
of transporters responsible for the influx and/or efflux    of T3 and T4 (2). Th
e monocarboxylate transporter 8 (MCT8) is an active transporter    highly specif
ic for TH present in different tissues, including the brain, where    it is expr
essed specifically by TH-sensitive neuronal populations (2). Friesema    and col
s. were the first to demonstrate that rat MCT8 facilitates the transport    of i
odothyronines into <i>Xenopus laevis</i> oocytes injected with the mRNA    codin
g for this transporter (3). Subsequent studies demonstrated the role of    MCT8 
in the TH transport in human tissues, particularly the brain (4,5). Later,    Fr
iesema and cols. showed that human MCT8 stimulates cellular uptake of T4 and    
T3, but does not seem to be important for rT3 and T2 transportation (6). Importa
ntly,    they also demonstrated that MCT8 increases iodothyronine metabolism by 
deiodinases,    a direct evidence that MCT8 increases the intracellular availabi
lity of these    substrates (6). MCT8 and D2 seem to act synchronically since th
e treatment with    T4 of cells co-expressing MCT8 and D2 results in increased T
3 production and    hormone responsiveness (1).</font></p>     ^cY#08.htm##
01348000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704112500070002000701195#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#27#23#article#109#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">The expression    of <i>MCT8</i> in the ch
oroid plexus and in large capillaries indicates that    it is involved in the tr
ansport of TH across the blood-brain barrier and the    blood-cerebrospinal flui
d barrier (2). MCT8 is present in neurons and astrocytes    of the paraventricul
ar and infundibular nuclei, and in tanycytes located in    the central lining of
 the third ventricle (these cells are in close contact    with the cerebrospinal
 fluid, hypothalamus and median eminence and probably    supply T3 to the centra
l nervous system) (2). In neurons, MCT8 is important    for the uptake of T3 pro
duced from T4 in neighboring astrocytes that express    D2. Neurons are the prim
ary targets for TH action in the developing brain, and    mutations in gene <i>M
CT8</i> deprive neurons of essential T3 and result in    psychomotor retardation
 (2). The action of T3 on neurons is controlled by the    local inactivation of 
T3 by D3. Therefore a defect in MCT8 also reduces the    inactivation of T3, res
ulting in increased serum T3 levels (2).</font></p>     ^cY#08.htm##
00629000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704040600070002000700476#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#28#24#article#109#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">The <i>MCT8</i>    gene consisting of six 
exons is located on the X chromosome (Xq13.2) and codes    for a protein of 539 
or 613 aminoacids depending on which of the two possible    translation start si
tes is used. <i>MCT8</i> has 12 putative transmembrane domains    (2). The human
 <i>MCT8</i> gene was cloned in 1994 (2).</font></p>     ^cY#08.htm##
00639000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704041600070002000700486#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#29#25#article#109#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">The inactivating    mutations of <i>MCT8</
i> are associated to a severe neurologic dysfunction and    high serum T3, that 
constitute the Allan-Herndon-Dudley syndrome (MIM 309600)    (7). In addition to
 mutations in thyroid hormone receptor, the inactivating    mutations of <i>MCT8
</i> constitute another cause of TH resistance (2).</font></p>     ^cY#08.htm##
00464000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704024100070002000700311#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#30#26#article#109#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">In this article    we describe a new <i>MC
T8</i> mutation identified on a male patient with severe    neurological impairm
ent and high serum T3 concentration.</font></p>     ^cY#08.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#31#27#article#109#<p>&nbsp;</p>     ^cY#08.
htm##
00335000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704011200070002000700182#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#32#28#article#109#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="3"><b>SUBJECT AND    METHODS</b></font></p>  
   ^cY#08.htm##
02040000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704181700070002000701887#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#33#29#article#109#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">A male patient    aged 12.25 years was fir
st evaluated at our Unit of Pediatric Endocrinology    when he was 9 months old.
 The patient was referred to us due to neurologic delay,    generalized hypotoni
a, strabismus, brain malformation, and abnormal thyroid    profile. His mother w
as 22 years old when she became pregnant. Pregnancy and    delivery were unevent
ful. Gestational age was of 40 weeks and the Apgar score    in the first and fif
th minutes was respectively 8 and 9. His birth weight (3096    g), body length (
51 cm), and head circumference (35 cm) were normal. His parents    are healthy a
nd nonconsanguineous. His two brothers are healthy. There was no    familial his
tory of neurological impairment or of thyroid diseases. His neurological    deve
lopment was impaired since the first months of life: the patient has never    be
en able to control his head or to sit, showed few reactions to external stimuli 
   and little communication with his parents and medical personnel. On the other
    hand, he could breast-feed efficiently. His parents described that he slept 
   during the day and was awake at night what suggested a disruption of the wake
-sleep    cycle. His movements were uncoordinated. The auxological evaluation at
 the age    of 9 months showed normal body length (74.5 cm; + 0.89 SDS), poor we
ight gain    (9.0 kg; - 0.36 SDS), and normal head circumference (46 cm; +0.50 S
DS). The    disproportion between his stature and weight resulted in a thin appe
arance.    Physical exam showed asymmetry of the skull. In spite of a global hyp
otonia    his upper right limb was hypertonic. No goiter was found, nor were any
 clinical    characteristic of hypothyroidism noted. His cardiac rhythm was norm
al (76 bpm).</font></p>     ^cY#08.htm##
00946000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704072300070002000700793#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#34#30#article#109#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">The global hypotonia    noted during the f
irst year of life gave rise to a generalized hypertonia with    spastic quadripl
egia. During his follow-up a severe visual impairment was identified.    The pat
ient evolved with a crisis first noted when he was 2 years old characterized    
by fixed and deviated eyes, deviation of his head, loss of consciousness, and   
 hypertonia of all four limbs. The crises were provoked by emotional stress or  
  by crying. Initially, the crises occurred two to three times per week but the 
   frequency increased up to two to three times per day, which prompted the intr
oduction    of anticonvulsant therapy.</font></p>     ^cY#08.htm##
00627000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704040400070002000700474#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#35#31#article#109#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">While his growth    was normal during the 
first 20 months of life (stature at 20 months = 85.0 cm;    + 0.33 SDS), his wei
ght-gain worsened continuously (weight at 20 months = 10.0    kg; - 1.82 SDS). H
owever, from 20 months on both growth and weight-gain were    impaired. The firs
t teeth eroded after 16 months of life.</font></p>     ^cY#08.htm##
00517000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704029400070002000700364#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#36#32#article#109#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">His first thyroid    evaluation, performed
 when he was 7 months old, disclosed high serum T3, reduced    total and free T4
, and TSH mildly increased (<a href="/img/revistas/abem/v55n1/08t01.jpg">Table  
  1</a>).</font></p>     ^cY#08.htm##
00792000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704056900070002000700639#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#37#33#article#109#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">As clinical and    hormonal features sugge
sted a mutation of <i>MCT8</i> a molecular study was    performed on the patient
, his mother, and his brother, after informed consent    was obtained from his p
arents. Genomic DNA was isolated from peripheral blood    according to standard 
procedures (8). PCR from all exons were amplified individually,    as previously
 described and directly sequenced (ABI PRISM 3130 xl, Perkin-Elmer    Applied Bi
osystems, Foster City, California, USA) (5).</font></p>     ^cY#08.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#38#34#article#109#<p>&nbsp;</p>     ^cY#08.
htm##
00320000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704009700070002000700167#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#39#35#article#109#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="3"><b>RESULTS</b></font></p>     ^cY#08.htm##
00597000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704037400070002000700444#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#40#36#article#109#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">In the neonatal    period, screening for c
ongenital hypothyroidism was normal. Laboratory evaluations    ruled out cytomeg
alovirus infection, infectious mononucleosis, syphilis, toxoplasmosis,    rubell
a, and HIV. There was mild anemia (Hb = 10.6 g/dL; mean corpuscular volume    = 
74.3 fL).</font></p>     ^cY#08.htm##
00594000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704037100070002000700441#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#41#37#article#109#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Curiously, high    titles of thyroglobulin
 antibodies (1125.3 IU/mL) were detected when he was    0.87 years old. Subseque
ntly serum levels of antithyroid antibodies (thyroglobulin    and thyroperoxidas
e antibodies) were normal but since the age of 8.3 years they    have increased 
again.</font></p>     ^cY#08.htm##
00599000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704037600070002000700446#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#42#38#article#109#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Thyroid scintigraphy    with <sup>131</sup
>I showed a gland with normal position, size and morphology,    while scintigrap
hy with <sup>99m</sup>Tc identified a normal captation after    2 hours (13%; no
rmal range: 8%-18%), and a reduced captation after 24 hours    (6%; normal range
: 20%-48%).</font></p>     ^cY#08.htm##
00556000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704033300070002000700403#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#43#39#article#109#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">A brain computed    tomography showed redu
ced ventricles and a bilateral posterior hypodense extra-axial    collection. Wh
en he was 7 years old, an electroencephalogram revealed irregular    slow-wave a
ctivity compatible with diffuse brain suffering.</font></p>     ^cY#08.htm##
01736000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704151300070002000701583#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#44#40#article#109#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Re-evaluation of    thyroid function when 
he was 1.47 and 1.64 years old, identified high serum    T3, low total and free 
T4, and TSH values progressively higher (<a href="/img/revistas/abem/v55n1/08t01
.jpg">Table    1</a>). The increase of serum TSH during his follow-up prompted t
he introduction    of levothyroxine at a dose of 50.0 </font><font size="2">&#95
6;</font><font face="Verdana, Arial, Helvetica, sans-serif" size="2">g/m<sup>2</
sup>/day,    posteriorly increased to 94.9 </font><font size="2">&#956;</font><f
ont face="Verdana, Arial, Helvetica, sans-serif" size="2">g/m<sup>2</sup>/day   
 (corresponding to 3.75 </font><font size="2">&#956;</font><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2">g/kg/day    when he was 11.5 years old). 
Treatment with levothyroxine was associated to    improvement in thyroid functio
n with normalization of serum T3, progressive    increase of free T4, normalizat
ion of TSH, and maintenance of low total T4,    as showed by the laboratory eval
uation results obtained at the ages of 8.75    and 11.6 years (<a href="/img/rev
istas/abem/v55n1/08t01.jpg">Table 1</a>). On    the other hand, it was not easy 
to evaluate the clinical effects of the treatment    due to the patient's severe
 neurologic impairment. Meanwhile we noticed that    during the 10.5 years of tr
eatment with levothyroxine there was a gradual worsening    of the weight defici
t from - 1.82 to - 5.09 SDS.</font></p>     ^cY#08.htm##
00862000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704063900070002000700709#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#45#41#article#109#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Lipid profile was    evaluated when the pa
tient was 8.75 years old. At that moment he was treated    with levothyroxine (3
3 </font><font size="2">&#956;</font><font face="Verdana, Arial, Helvetica, sans
-serif" size="2">g/m<sup>2</sup>/day)    and his thyroid function was characteri
zed by T3 in the upper limit of the normal    range, low total and free T4, and 
normal TSH (<a href="/img/revistas/abem/v55n1/08t01.jpg">Table    1</a>). Lipid 
profile was normal: total cholesterol = 180 mg/dL, LDL = 101 mg/dL,    HDL = 44 
mg/dL and triglyceride = 62 mg/dL.</font></p>     ^cY#08.htm##
00790000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704056700070002000700637#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#46#42#article#109#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Molecular study    of the patient identifi
ed the insertion of a G nucleotide at the position 630    (630insG) in the codin
g region in exon 1 of <i>MCT8</i>. The mutation caused    a frameshift in exon 1
 and truncated the protein at codon 240, as shown in <a href="#f1">figure    1</
a>. His mother is heterozygous for this mutation and his asymptomatic brother   
 does not carry the mutation. As this insertion has not been seen in 50 healthy 
   control men, polymorphism was excluded.</font></p>     ^cY#08.htm##
00256000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704003300070002000700103#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#47#43#article#109#<p><a name="f1"></a></p> 
    ^cY#08.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#48#44#article#109#<p>&nbsp;</p>     ^cY#08.
htm##
00300000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704007700070002000700147#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#49#45#article#109#<p align="center"><img sr
c="/img/revistas/abem/v55n1/08f01.jpg"></p>     ^cY#08.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#50#46#article#109#<p>&nbsp;</p>     ^cY#08.
htm##
00828000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704060500070002000700675#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#51#47#article#109#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Thyroid function    serum evaluation of hi
s mother, heterozygous for the mutation and asymptomatic,    showed normal TSH (
1.82 </font><font size="2">&#956;</font><font face="Verdana, Arial, Helvetica, s
ans-serif" size="2">U/mL),    T3 in the upper limit of normality (199 ng/dL; nor
mal range: 70-200 ng/dL),    normal T4 (7.1 </font><font size="2">&#956;</font><
font face="Verdana, Arial, Helvetica, sans-serif" size="2">g/dL),    and low fre
e T4 (0.63 ng/dL; normal range: 0.7-1.5). Antithyroid antibodies    were absent.
</font></p>     ^cY#08.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#52#48#article#109#<p>&nbsp;</p>     ^cY#08.
htm##
00323000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704010000070002000700170#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#53#49#article#109#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="3"><b>DISCUSSION</b></font></p>     ^cY#08.ht
m##
01369000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704114600070002000701216#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#54#50#article#109#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">TH have crucial    roles in brain developm
ent including the control of cell proliferation, specification    of neural and 
glial cell fate, migration and synaptogenesis (9). During hypothyroid    states 
it is important that the intracellular concentration of T3, the active    TH, be
 maintained at a safe range, especially in vital organs like the brain.    In th
e brain this is achieved by means of increased brain uptake of serum T3    throu
gh increased action of transporters like MCT8, increased conversion of    T4 to 
T3 through increased action of D2 and decreased conversion of T3 to T2    throug
h reduced action of D3 (9). These compensatory mechanisms may work acutely    bu
t may fail to protect the brain during chronic deprivation of TH (9). On the    
other hand, even during the decrease of serum T4 some brain regions or cell    t
ypes, but not others, are capable of maintaining T3 levels, what raises the    c
oncept of region-specific compensation to low serum TH (9). The developing    br
ain has a very limited capacity to compensate for low TH (9).</font></p>     ^cY
#08.htm##
01299000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704107600070002000701146#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#55#51#article#109#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Friesema and cols.    were the first to re
port patients with resistance to TH due to a transporter    defect (4). The auth
ors reported mutations in <i>MCT8</i> in five young boys    aged 1.5- 6 years wi
th severe psychomotor retardation and strongly raised serum    T3 concentrations
. These patients were characterized clinically by severe proximal    hypotonia, 
poor head control, lack of verticalization, no targeted grasping,    involuntary
 writhing movements, movement-induced increase in distal muscle tone,    and sev
ere mental retardation with lack of speech development and rudimentary    commun
icative skills. This group of patients did not show any sign or symptom    of hy
pothyroidism. Their thyroid laboratory evaluations showed serum levels    of T4 
and free T4 at the lower limit of the normal range, TSH concentrations    varyin
g from normal to high and remarkably increased serum T3. The five patients    ha
rbored loss-of-function mutations of the X-linked <i>MCT8</i> gene (4).</font></
p>     ^cY#08.htm##
01363000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704114000070002000701210#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#56#52#article#109#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">The neurologic    characteristics of our p
atient have been described in association to inactivating    mutations of <i>MCT
8</i>, specially the substitution of global hypotonia for    a global hypertonia
. Schwartz and cols., studying six families with Allan-Herndon-Dudley    syndrom
e stated that the progression to spastic paraplegia is notable (7). During    in
fancy and early childhood the main neuromuscular findings are hypotonia and    d
ecreased muscle mass, affecting specially the neck. Truncal hypotonia persists  
  into adolescence and adult life whereas the limbs, hands, and feet become hype
rtonic,    spastic, and contracted, and/or dystonic and fixed in position (10). 
At this    point a neurologic exam may identify hyperreflexia at the large joint
s, clonus,    and Babinski signs (7). With respect to the crisis observed in our
 patient,    they seem to be common in patients with the syndrome and are classi
fied by some    authors as paroxysmal kinesigenic dyskinesias that may be provok
ed by stimuli    like changing clothes or diapers (11).</font></p>     ^cY#08.ht
m##
01497000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704127400070002000701344#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#57#53#article#109#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">We observed that    the growth of our pati
ent, who was born with normal length (51 cm), was normal    during the first 20 
months of age. These data were also reported by others and    suggest that MCT8 
is not important for TH transport in bone cells (7,12,13).    Similarly, the pat
ient evaluated by Herzovich and cols. grew normally during    the first two year
s of life, and his bone maturation was advanced (bone age    was 30 months when 
his chronologic age was 18 months) (14). In agreement with    these results, the
 study of Williams and cols. identified that although MCT8    mRNA is expressed 
in chondrocytes, osteoblasts and osteoclasts at all stages    of cell differenti
ation, T3 availability during skeletal development seems to    be limited by D3-
mediated catabolism rather than by MCT8-mediated cellular uptake    or D2-depend
ent T3 production (1). The advanced bone maturation is one characteristic    of 
hyperthyroidism in children and adolescents. Therefore the increased bone    mat
uration identified by Herzovich and cols. suggests that the inactivation    of <
i>MCT8</i> and the consequent increase of serum T3 creates a hyperthyroid-like  
  state for bone tissue (14).</font></p>     ^cY#08.htm##
02331000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704210800070002000702178#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#58#54#article#109#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">We also noted a    disproportion between t
he height and the weight of our patient. This disproportion    was characterized
 by superior height in relation to his weight as exemplified    by the discrepan
cy between the height and weight SDs at the ages of 9 months    (+ 0.89 and - 0.
36, respectively), and 20 months (+ 0.33 and - 1.82, respectively).    In the si
x families with Allan-Herndon-Dudley Syndrome studied by Schwartz and    cols. t
he authors observed that in 19 out of 29 male patients (65.5%) at all    ages th
e weight percentile was below the third percentile (7). Herzovich and    cols. f
ound increased levels of muscle metabolism markers (serum ammonium and    lactic
 acid) in their patient with inactive <i>MCT8</i> (14). Aiming to evaluate    th
e influence of serum T3 on the body mass index W&eacute;meau and cols. studied  
  the effects of treatment with propylthiouracil (PTU) (200 mg/day) in an undern
ourished    16 year-old boy with a loss of function mutation of <i>MCT8</i> (15)
. After    a period of treatment with PTU levothyroxine was added to the treatme
nt at doses    of 50, 75, and 100 </font><font size="2">&#956;</font><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">g/day    (15). While treatment 
with PTU alone reduced free T4, normalized free T3, and    increased TSH serum l
evels, the introduction of levothyroxine, especially in    the 100 </font><font 
size="2">&#956;</font><font face="Verdana, Arial, Helvetica, sans-serif" size="2
">g/day    dose, allowed TSH and free T4 levels return to those levels obtained 
before    the introduction of PTU (15). More importantly, this strategy improved
 body    mass index as a consequence of the increase in the rate of weight gain 
from    200 g/year to 3 kg/year (this treatment had no effect on cerebral distur
bances    and the psychomotor retardation) (15). Thus we can speculate that incr
eased    serum T3 also generates a hyperthyroid-like state in the muscle and adi
pose    tissue, capable of preventing the adequate weight gain.</font></p>     ^
cY#08.htm##
00835000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704061200070002000700682#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#59#55#article#109#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">In our patient    the normal lipid profile
 in spite of low total and free serum T4 levels suggests    an increased action 
of T3 in the liver. We can speculate that the increased    action of T3 in the l
iver hindered the elevation of serum LDL and triglyceride    that could be expec
ted in the context of hypothyroidism. Interestingly, serum    levels of sex horm
one-binding protein, a protein synthesized in the liver under    the stimulus of
 TH, was persistently elevated in the patient described by Herzovich    and cols
. (14).</font></p>     ^cY#08.htm##
00765000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704054200070002000700612#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#60#56#article#109#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">The patient we    have described, like oth
er patients with inactivating mutations of <i>MCT8,</i>    had no signs or sympt
oms typically associated to congenital hypothyroidism (prolonged    jaundice, um
bilical hernia, bradycardia, growth retardation, myxedema and tendency    to ove
rweight or obesity) (12). This clinical finding reinforces the concept    that t
issues like bone, fat and liver are not as dependent on MCT8 for TH transport   
 as the brain is.</font></p>     ^cY#08.htm##
01980000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704175700070002000701827#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#61#57#article#109#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">In our patient,    and also in those descr
ibed by other authors, the high serum values of TSH associated    to high serum 
T3 suggest that the negative feedback of T3 on the pituitary is    compromised p
robably because a smaller amount of T3 is capable to reach its    nuclear recept
ors. Maranduba and cols. studied four adult Brazilian patients    of the same fa
mily and showed that the protein originated from the mutated <i>MCT8</i>    has 
a low capacity to promote T3 transport into the cells (16). This finding    may 
have severe consequences to the brain, a tissue which is very dependent    on MC
T8 for T3 transport into cells. It is noteworthy that the introduction    of lev
othyroxine resulted in reduction of T3 and TSH serum levels. We believe    that 
the effect of levothyroxine may be attributed to a better pituitary negative    
feedback capable of reducing TSH secretion and consequently the conversion of   
 T4 to T3. We must remember that in the pituitary almost three quarters of intra
cellular    T3 originates from the conversion of T4 and the remainder derives fr
om circulation.    However, alterations in thyroid profile associated to mutatio
ns in <i>MCT8</i>    are still a reason for debate. Maranduba and cols. identifi
ed that the increase    of serum T3 is related to the reduction of its intracell
ular clearance as a    result of decreased entry of the hormone into cells that 
metabolize it through    D3 (16). However, studies in <i>Mct8</i> knockout mice 
show that T3 generation    by D1 and D2 is increased, which has a consumptive ef
fect on serum total and    free T4 levels. In these mice pituitary resistance to
 T3 was also identified    (15).</font></p>     ^cY#08.htm##
01304000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704108100070002000701151#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#62#58#article#109#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">In our patient    the novel mutation 630in
sG in the coding region at exon 1 of <i>MCT8</i> resulted    in a frameshift wit
h truncation of the protein at codon 240. Probably the mutation    630insG inact
ivated <i>MCT8</i> completely. As the insertion was not observed    in 50 health
y control men polymorphism was excluded. The functional effect of    this novel 
mutation has still to be determined. On the other hand, Frints and    cols. repo
rted a similar mutation 630insA in one among the 13 families studied    with ind
ividuals affected by X-linked mental retardation (17). Mutation 629insA    cause
d a frameshift in exon 1 and introduced a premature termination codon in    exon
 2 of <i>MCT8</i> (17). The mutations of <i>MCT8</i> encompass large deletions, 
   smaller frameshift deletions, deletions or insertions of 1-amino acid, nonsen
se    mutations and missense mutations (2). Studies suggest that there is a geno
type-phenotype    correlation in patients with mutations in <i>MCT8</i> (2).</fo
nt></p>     ^cY#08.htm##
01374000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704115100070002000701221#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#63#59#article#109#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Our patient evolved    with variable level
s of antithyroid antibodies. Both thyroglobulin and thyroperoxidase    antibodie
s were detected at the age of 9 months and again when he was older    than 8.3 y
ears. One male patient with inactivating mutation of <i>MCT8</i> described    by
 Dumitrescu and cols. had been diagnosed with insulin-dependent <i>diabetes    m
ellitus</i> at 3 years of age, and the patient had a maternal aunt, an uncle    
and one grandmother with autoimmune thyroid disease, evidenced by positive thyro
globulin    and thyroperoxidase antibodies (5). The other patient studied by the
 same group    had a maternal grandfather with mild TSH elevation due to autoimm
une thyroid    disease confirmed by positive thyroperoxidase antibodies (5). We 
believe that    current knowledge does not allow us to associate the inactivatio
n of <i>MCT8</i>    to the risk of autoimmunity. Probably the description of new
 patients with inactivation    of <i>MCT8</i> and a deeper understanding about <
i>MCT8</i> functions and interactions    will help in this matter.</font></p>   
  ^cY#08.htm##
01640000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704141700070002000701487#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#64#60#article#109#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">The mother of the    patient is heterozygo
us for the mutation of <i>MCT8</i> and, although clinically    asymptomatic, sho
wed mild thyroid function abnormalities (normal serum TSH and    total T4, serum
 T3 in the upper limit of normality and low free T4). Abnormal    thyroid profil
e with high serum T3 levels may be present in 25% of female carriers    of the <
i>MCT8</i> mutation (17). Studies performed by Dumitrescu and cols.    to clarif
y the reason for the thyroid phenotype in heterozygous women suggested    that b
oth dominant-negative effect and haploinsufficiency are mechanisms responsible  
  for the dominant expression of the thyroid phenotype (5). The authors observed
    that apparently there is no preferential X inactivation of the two alleles (
5).    The phenotype of heterozygous females for mutations of <i>MCT8</i> encomp
asses    from asymptomatic patients to those with mild mental retardation (5,14,
17).    However, Frints and cols. reported the first female patient with the All
an-Herndon-Dudley    syndrome (17). This patient was severely developmentally re
tarded and showed    elevated serum T3 and free T3 due to a <i>de novo</i> balan
ced 46,X,t(X;9)(q13.2;p24)    translocation (17). In this patient the complete n
onrandom inactivation of normal    X chromosome impinged the expression of <i>MC
T8</i> (17).</font></p>     ^cY#08.htm##
01172000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704094900070002000701019#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#65#61#article#109#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Although new cases    of mutations of <i>M
CT8</i> have been described, the scarce number of patients    precludes knowledg
e about prevalence, clinical manifestations and genotype-phenotype    correlatio
n of the disease. X-linked mental retardation has an estimated prevalence    of 
0.1% in males and is related to disturbances in a group of 82 genes, including  
  <i>MCT8</i> (2). Currently, in view of the difficult clinical definition of   
 X-linked mental retardation, it is suggested that mutations of <i>MCT8</i> be  
  suspected in the context of an abnormal thyroid profile characterized by incre
ased    T3, low-normal to low free T4, low rT3, and normal to elevated TSH serum
 levels    (2). The measurement of serum free T3 is considered the better method
 for screening    high-risk populations, such as children with developmental del
ay and hypotonia    (7).</font></p>     ^cY#08.htm##
01470000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704124700070002000701317#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#66#62#article#109#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">In summary, we    describe a male patient 
with a novel inactivating mutation of <i>MCT8.</i> The    patient was characteri
zed clinically by severe neurologic impairment (initially    manifested as globa
l hypotonia later evolving with generalized hypertonia and    spastic quadripleg
ia), normal growth during the first two years of life, reduced    weight gain du
ring his infancy and childhood and absence of the typical signs    and symptoms 
of hypothyroidism. His laboratory evaluations disclosed high T3,    low total an
d free T4, and mildly elevated TSH serum levels. Treatment with    levothyroxine
 resulted in better thyroid function tests (with normalization    of total T3 an
d TSH, a progressive increase in free T4, and the maintenance    of low total T4
 levels) but no clear clinical benefit could be recognized. Our    results reinf
orce the concept that the role of MCT8 in the intracellular transport    of TH i
s tissue-dependent: neurons seem to be highly dependent on MCT8, while    the bo
ne, adipose tissue, muscle and liver are clearly less dependent on MCT8    and m
ay therefore suffer the consequences of the exposition to high serum T3    level
s.</font></p>     ^cY#08.htm##
00461000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704023800070002000700308#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#67#63#article#109#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Acknowledgements:    We thank Professor Th
eo Visser for evaluating the sequence of <i>MCT8</i> gene    and for encouraging
 us to study this novel mutation.</font></p>     ^cY#08.htm##
00392000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704016900070002000700239#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#68#64#article#109#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Disclosure: no    potential conflict of in
terest relevant to this articlewas reported.</font></p>     ^cY#08.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#69#65#article#109#<p>&nbsp;</p>     ^cY#08.
htm##
00323000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704010000070002000700170#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#70#66#article#109#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="3"><b>REFERENCES</b></font></p>     ^cY#08.ht
m##
00472000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704023500072002000700307#v55
n1#V:\SciELO\serial\abem\v55n1\markup\08.htm#S#p#71#67#article#109#1#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">1. Williams AJ,    Robson H,
 Kester MHA, van Leeuwen JPTM, Shalet SM, Visser TJ, et al. Iodothyronine    dei
odinase enzyme activities in bone. Bone. 2008;43:126-34.    ^cY#08.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002000070002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#72#68#article#109#</font></p>     ^cY#08.ht
m##
00451000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704021400072002000700286#v55
n1#V:\SciELO\serial\abem\v55n1\markup\08.htm#S#p#73#69#article#109#2#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">2. Friesema ECH,    Visser W
E, Visser TJ. Genetics and phenomics of thyroid hormone transport by    MCT8. Mo
l Cell Endocrinol. 2010;322:107-13.    ^cY#08.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002000070002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#74#70#article#109#</font></p>     ^cY#08.ht
m##
00520000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704028300072002000700355#v55
n1#V:\SciELO\serial\abem\v55n1\markup\08.htm#S#p#75#71#article#109#3#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">3. Friesema EC,    Ganguly S
, Abdalla A, Manning Fox JE, Halestrap AP, Visser TJ. Identification    of monoc
arboxylate transporter 8 as a specific thyroid hormone transporter.    J Biol Ch
em. 2003;278(40):128-35.    ^cY#08.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002000070002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#76#72#article#109#</font></p>     ^cY#08.ht
m##
00530000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704029300072002000700365#v55
n1#V:\SciELO\serial\abem\v55n1\markup\08.htm#S#p#77#73#article#109#4#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">4. Friesema EC,    Grueters 
A, Biebermann H, Krude H, von Moers A, Reeser M, et al. Association    between m
utations in a thyroid hormone transporter and severe X-linked psychomotor    ret
ardation. Lancet. 2004;364:1435-7.    ^cY#08.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002000070002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#78#74#article#109#</font></p>     ^cY#08.ht
m##
00543000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704030600072002000700378#v55
n1#V:\SciELO\serial\abem\v55n1\markup\08.htm#S#p#79#75#article#109#5#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">5. Dumitrescu AM,    Liao XH
, Best TB, Brockmann K, Refetoff S. A novel syndrome combining thyroid    and ne
urological abnormalities is associated with mutations in a monocarboxylate    tr
ansporter gene. Am J Hum Genet. 2004;74:168-75.    ^cY#08.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002000070002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#80#76#article#109#</font></p>     ^cY#08.ht
m##
00535000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704029800072002000700370#v55
n1#V:\SciELO\serial\abem\v55n1\markup\08.htm#S#p#81#77#article#109#6#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">6. Friesema ECH,    Kuipe GG
JM, Jansen J, Visser TJ, Kester MHA. Thyroid hormone transport by the    human m
onocarboxylate transporter 8 and its rate-limiting role in intracellular    meta
bolism. Mol Endocrinol. 2006;20:2761-7.    ^cY#08.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002000070002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#82#78#article#109#</font></p>     ^cY#08.ht
m##
00505000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704026800072002000700340#v55
n1#V:\SciELO\serial\abem\v55n1\markup\08.htm#S#p#83#79#article#109#7#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">7. Schwartz CE,    May MM, C
arpenter NJ, Rogers RC, Martin J, Bialer MG, et al. Allan-Herndon-Dudley    synd
rome and the monocarboxylate transporter 8 (MCT8) gene. Am J Hum Genet.    2005;
77:41-53.    ^cY#08.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002000070002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#84#80#article#109#</font></p>     ^cY#08.ht
m##
00463000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704022600072002000700298#v55
n1#V:\SciELO\serial\abem\v55n1\markup\08.htm#S#p#85#81#article#109#8#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">8. Miller SA, Dykes    DD, P
olesky HA. A simple salting out procedure for extracting DNA from human    nucle
ated cells. Nucleic Acids Res. 1988;16(3):1215.    ^cY#08.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002000070002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#86#82#article#109#</font></p>     ^cY#08.ht
m##
00502000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704026500072002000700337#v55
n1#V:\SciELO\serial\abem\v55n1\markup\08.htm#S#p#87#83#article#109#9#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">9. Sharlin DS,    Gilbert ME
, Taylor MA, Ferguson DC, Zoeller RT. The nature of the compensatory    response
 to low thyroid hormone in the developing brain. J Neuroendocrinol.    2010;22:1
53-65.    ^cY#08.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002000070002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#88#84#article#109#</font></p>     ^cY#08.ht
m##
00519000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000300070704028100073002000700354#v55
n1#V:\SciELO\serial\abem\v55n1\markup\08.htm#S#p#89#85#article#109#10#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">10. Holden KR,    Z&uacute;
&ntilde;iga OF, May MM, Su H, Molinero MR, Rogers RC, et al. X-linked    MCT8 ge
ne mutations: characterization of the pediatric neurologic phenotype.    J Child
 Neurol. 2005;20:852-7.    ^cY#08.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002000070002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#90#86#article#109#</font></p>     ^cY#08.ht
m##
00497000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000300070704025900073002000700332#v55
n1#V:\SciELO\serial\abem\v55n1\markup\08.htm#S#p#91#87#article#109#11#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">11. Brockmann K,    Dumitre
scu AM, Best TT, Hanefeld F, Refetoff S. X-linked paroxysmal dyskinesia    and s
evere global retardation caused by defective MCT8 gene. J Neurol. 2005;252:663-6
.    ^cY#08.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002000070002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#92#88#article#109#</font></p>     ^cY#08.ht
m##
00598000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000300070704036000073002000700433#v55
n1#V:\SciELO\serial\abem\v55n1\markup\08.htm#S#p#93#89#article#109#12#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">12. Biebermann    H, Ambrug
ger P, Tarnow P, von Moers A, Schweizer U, Grueters A. Extended clinical    phen
otype, endocrine investigations and functional studies of a loss-of-function    
mutation A150V in the thyroid hormone specific transporter MCT8. Eur J Endocrino
l.    2005;153:359-66.    ^cY#08.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002000070002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#94#90#article#109#</font></p>     ^cY#08.ht
m##
00547000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000300070704030900073002000700382#v55
n1#V:\SciELO\serial\abem\v55n1\markup\08.htm#S#p#95#91#article#109#13#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">13. Namba N, Etani    Y, Ki
taoka T, Nakamoto Y, Nakacho M, Bessho K, et al. Clinical phenotype and    endoc
rinological investigations in a patient with a mutation in the MCT8 thyroid    h
ormone transporter. Eur J Pediatr. 2008;167:785-91.    ^cY#08.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002000070002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#96#92#article#109#</font></p>     ^cY#08.ht
m##
00550000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000300070704031200073002000700385#v55
n1#V:\SciELO\serial\abem\v55n1\markup\08.htm#S#p#97#93#article#109#14#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">14. Herzovich V,    Vaiani 
E, Marino R, Dratler G, Lazzati JM, Tilitzky S, et al. Unexpected peripheral    
markers of thyroid function in a patient with a novel mutation of the MCT8 thyro
id    hormone transporter gene. Horm Res. 2007;67:1-6.    ^cY#08.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002000070002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#98#94#article#109#</font></p>     ^cY#08.ht
m##
00556000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000300070704031800073002000700391#v55
n1#V:\SciELO\serial\abem\v55n1\markup\08.htm#S#p#99#95#article#109#15#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">15. W&eacute;meau    JL, Pi
geyre M, Proust-Lemoine E, d'Herbomez M, Gottrand F, Jansen T, et al.    Benefic
ial effects of propylthiouracil plus l-thyroxine treatment in a patient    with 
a mutation in MCT8. J Clin Endocrinol Metab. 2008;93:2084-8.    ^cY#08.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000300056709000800059708000400067704002000071002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#100#96#article#109#</font></p>     ^cY#08.h
tm##
00580000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000300056709000800059708000400067888000300071704034100074002000700415#v55
n1#V:\SciELO\serial\abem\v55n1\markup\08.htm#S#p#101#97#article#109#16#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">16. Maranduba CMC,    Frie
sema ECH, Kok F, Kester MHA, Jansen J, Serti&eacute; AL, et al. Decreased    cel
lular uptake and metabolism in Allan-Herndon-Dudley syndrome (AHDS) due to    a 
novel mutation in the MCT8 thyroid hormone transporter. J Med Genet. 2006;43:457
-60.    ^cY#08.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000300056709000800059708000400067704002000071002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#102#98#article#109#</font></p>     ^cY#08.h
tm##
00562000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000300056709000800059708000400067888000300071704032300074002000700397#v55
n1#V:\SciELO\serial\abem\v55n1\markup\08.htm#S#p#103#99#article#109#17#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">17. Frints SG,    Lenzner 
S, Bauters M, Jensen LR, Van Esch H, des Portes V, et al. MCT8 mutation    analy
sis and identification of the first female with Allan-Herndon-Dudley syndrome   
 due to loss of MCT8 expression. Eur J Hum Genet. 2008;16:1029-37.    ^cY#08.htm
##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#104#100#article#109#</font></p>     ^cY#08.
htm##
00247000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002200072002000700094#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#105#101#article#109#<p>&nbsp;</p>     ^cY#0
8.htm##
00247000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002200072002000700094#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#106#102#article#109#<p>&nbsp;</p>     ^cY#0
8.htm##
00420000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704019500072002000700267#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#107#103#article#109#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2"><a name="back"></a><a href="#top"><img s
rc="/img/revistas/abem/v55n1/seta.jpg" border="0"></a>    <b>Correspondence to:<
/b>     ^cY#08.htm##
00272000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704004700072002000700119#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#108#104#article#109#<br>   Hamilton Cabral 
de Menezes Filho    ^cY#08.htm##
00267000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704004200072002000700114#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#109#105#article#109#<br>   Rua Joinville, 6
37, ap. 701    ^cY#08.htm##
00280000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704005500072002000700127#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#110#106#article#109#<br>   04008-011 " S&at
ilde;o Paulo, SP, Brazil    ^cY#08.htm##
00316000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704009100072002000700163#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#111#107#article#109#<br>   <a href="mailto:
hamiltoncm@uol.com.br">hamiltoncm@uol.com.br</a></font></p>     ^cY#08.htm##
00319000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704009400072002000700166#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#112#108#article#109#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2">Received on Jul/30/2010    ^cY#08.htm##
00275000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704005000072002000700122#v55n1#V:\SciELO
\serial\abem\v55n1\markup\08.htm#S#p#113#109#article#109#<br>   Accepted on Dec/
14/2010</font></p>     ^cY#08.htm##
00641000000000337000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100019000710100016000900100
01800106010002400124010001700148010001700165810000600182012005500188030000500243
06500090024806400050025703100030026201400070026586500090027200200070028103500100
0288801000500298#v55n1#V:\SciELO\serial\abem\v55n1\markup\08.htm#S#c#114#1#artic
le#17#1#^rND^sWilliams^nAJ#^rND^sRobson^nH#^rND^sKester^nMHA#^rND^svan Leeuwen^n
JPTM#^rND^sShalet^nSM#^rND^sVisser^nTJ#et al#Iodothyronine deiodinase enzyme act
ivities in bone^len#Bone#20080000#2008#43#126-34#20110200#08.htm#8756-3282#Bone#
#
00570000000000289000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100020000710100017000910100
01700108012006400125030002000189065000900209064000500218031000400223014000700227
865000900234002000700243035001000250801002000260#v55n1#V:\SciELO\serial\abem\v55
n1\markup\08.htm#S#c#115#2#article#17#2#^rND^sFriesema^nECH#^rND^sVisser^nWE#^rN
D^sVisser^nTJ#Genetics and phenomics of thyroid hormone transport by MCT8^len#Mo
l Cell Endocrinol#20100000#2010#322#107-13#20110200#08.htm#0303-7207#Mol Cell En
docrinol##
00693000000000337000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100019000710100017000900100
01700107010002200124010002000146010001700166012009400183030001200277065000900289
06400050029803100040030303200030030701400070031086500090031700200070032603500100
0333801001200343#v55n1#V:\SciELO\serial\abem\v55n1\markup\08.htm#S#c#116#3#artic
le#17#3#^rND^sFriesema^nEC#^rND^sGanguly^nS#^rND^sAbdalla^nA#^rND^sManning Fox^n
JE#^rND^sHalestrap^nAP#^rND^sVisser^nTJ#Identification of monocarboxylate transp
orter 8 as a specific thyroid hormone transporter^len#J Biol Chem#20030000#2003#
278#40#128-35#20110200#08.htm#0021-9258#J Biol Chem##
00698000000000337000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100019000710100018000900100
02000108010001500128010001900143010001600162810000600178012011100184030000700295
06500090030206400050031103100040031601400070032086500090032700200070033603500100
0343801000700353#v55n1#V:\SciELO\serial\abem\v55n1\markup\08.htm#S#c#117#4#artic
le#17#4#^rND^sFriesema^nEC#^rND^sGrueters^nA#^rND^sBiebermann^nH#^rND^sKrude^nH#
^rND^svon Moers^nA#^rND^sReeser^nM#et al#Association between mutations in a thyr
oid hormone transporter and severe X-linked psychomotor retardation^len#Lancet#2
0040000#2004#364#1435-7#20110200#08.htm#0099-5355#Lancet##
00690000000000313000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100021000710100015000920100
01500107010001900122010001800141012013700159030001500296065000900311064000500320
031000300325014000700328865000900335002000700344035001000351801001500361#v55n1#V
:\SciELO\serial\abem\v55n1\markup\08.htm#S#c#118#5#article#17#5#^rND^sDumitrescu
^nAM#^rND^sLiao^nXH#^rND^sBest^nTB#^rND^sBrockmann^nK#^rND^sRefetoff^nS#A novel 
syndrome combining thyroid and neurological abnormalities is associated with mut
ations in a monocarboxylate transporter gene^len#Am J Hum Genet#20040000#2004#74
#168-75#20110200#08.htm#0002-9297#Am J Hum Genet##
00682000000000313000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100020000710100018000910100
01600109010001700125010001800142012012800160030001500288065000900303064000500312
031000300317014000700320865000900327002000700336035001000343801001500353#v55n1#V
:\SciELO\serial\abem\v55n1\markup\08.htm#S#c#119#6#article#17#6#^rND^sFriesema^n
ECH#^rND^sKuipe^nGGJM#^rND^sJansen^nJ#^rND^sVisser^nTJ#^rND^sKester^nMHA#Thyroid
 hormone transport by the human monocarboxylate transporter 8 and its rate-limit
ing role in intracellular metabolism^len#Mol Endocrinol#20060000#2006#20#2761-7#
20110200#08.htm#0888-8809#Mol Endocrinol##
00681000000000337000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100019000710100014000900100
02000104010001700124010001600141010001700157810000600174012008400180030001500264
06500090027906400050028803100030029301400060029686500090030200200070031103500100
0318801001500328#v55n1#V:\SciELO\serial\abem\v55n1\markup\08.htm#S#c#120#7#artic
le#17#7#^rND^sSchwartz^nCE#^rND^sMay^nMM#^rND^sCarpenter^nNJ#^rND^sRogers^nRC#^r
ND^sMartin^nJ#^rND^sBialer^nMG#et al#Allan-Herndon-Dudley syndrome and the monoc
arboxylate transporter 8 (MCT8) gene^len#Am J Hum Genet#20050000#2005#77#41-53#2
0110200#08.htm#0002-9297#Am J Hum Genet##
00591000000000301000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100017000710100016000880100
01800104012008100122030001800203065000900221064000500230031000300235032000200238
014000500240865000900245002000700254035001000261801001800271#v55n1#V:\SciELO\ser
ial\abem\v55n1\markup\08.htm#S#c#121#8#article#17#8#^rND^sMiller^nSA#^rND^sDykes
^nDD#^rND^sPolesky^nHA#A simple salting out procedure for extracting DNA from hu
man nucleated cells^len#Nucleic Acids Res#19880000#1988#16#3#1215#20110200#08.ht
m#0305-1048#Nucleic Acids Res##
00652000000000313000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100018000710100018000890100
01700107010001900124010001800143012009100161030001800252065000900270064000500279
031000300284014000700287865000900294002000700303035001000310801001800320#v55n1#V
:\SciELO\serial\abem\v55n1\markup\08.htm#S#c#122#9#article#17#9#^rND^sSharlin^nD
S#^rND^sGilbert^nME#^rND^sTaylor^nMA#^rND^sFerguson^nDC#^rND^sZoeller^nRT#The na
ture of the compensatory response to low thyroid hormone in the developing brain
^len#J Neuroendocrinol#20100000#2010#22#153-65#20110200#08.htm#0953-8194#J Neuro
endocrinol##
00681000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730100017000900100
01400107010001200121010001900133010001700152810000600169012008900175030001500264
06500090027906400050028803100030029301400060029686500090030200200070031103500100
0318801001500328#v55n1#V:\SciELO\serial\abem\v55n1\markup\08.htm#S#c#123#10#arti
cle#17#10#^rND^sHolden^nKR#^rND^sZúñiga^nOF#^rND^sMay^nMM#^rND^sSu^nH#^rND^sMoli
nero^nMR#^rND^sRogers^nRC#et al#X-linked MCT8 gene mutations: characterization o
f the pediatric neurologic phenotype^len#J Child Neurol#20050000#2005#20#852-7#2
0110200#08.htm#0883-0738#J Child Neurol##
00641000000000313000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100019000730100021000920100
01500113010001800128010001800146012009500164030000900259065000900268064000500277
031000400282014000600286865000900292002000700301035001000308801000900318#v55n1#V
:\SciELO\serial\abem\v55n1\markup\08.htm#S#c#124#11#article#17#11#^rND^sBrockman
n^nK#^rND^sDumitrescu^nAM#^rND^sBest^nTT#^rND^sHanefeld^nF#^rND^sRefetoff^nS#X-l
inked paroxysmal dyskinesia and severe global retardation caused by defective MC
T8 gene^len#J Neurol#20050000#2005#252#663-6#20110200#08.htm#0340-5354#J Neurol#
#
00762000000000325000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100020000730100019000930100
01600112010001900128010001900147010001800166012016700184030001700351065000900368
06400050037703100040038201400070038686500090039300200070040203500100040980100170
0419#v55n1#V:\SciELO\serial\abem\v55n1\markup\08.htm#S#c#125#12#article#17#12#^r
ND^sBiebermann^nH#^rND^sAmbrugger^nP#^rND^sTarnow^nP#^rND^svon Moers^nA#^rND^sSc
hweizer^nU#^rND^sGrueters^nA#Extended clinical phenotype, endocrine investigatio
ns and functional studies of a loss-of-function mutation A150V in the thyroid ho
rmone specific transporter MCT8^len#Eur J Endocrinol#20050000#2005#153#359-66#20
110200#08.htm#0804-4643#Eur J Endocrinol##
00722000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100015000730100015000880100
01700103010001800120010001700138010001600155810000600171012012800177030001400305
06500090031906400050032803100040033301400070033786500090034400200070035303500100
0360801001400370#v55n1#V:\SciELO\serial\abem\v55n1\markup\08.htm#S#c#126#13#arti
cle#17#13#^rND^sNamba^nN#^rND^sEtani^nY#^rND^sKitaoka^nT#^rND^sNakamoto^nY#^rND^
sNakacho^nM#^rND^sBessho^nK#et al#Clinical phenotype and endocrinological invest
igations in a patient with a mutation in the MCT8 thyroid hormone transporter^le
n#Eur J Pediatr#20080000#2008#167#785-91#20110200#08.htm#0340-6199#Eur J Pediatr
##
00720000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100019000730100016000920100
01600108010001700124010001800141010001800159810000600177012013400183030000900317
06500090032606400050033503100030034001400040034386500090034700200070035603500100
0363801000900373#v55n1#V:\SciELO\serial\abem\v55n1\markup\08.htm#S#c#127#14#arti
cle#17#14#^rND^sHerzovich^nV#^rND^sVaiani^nE#^rND^sMarino^nR#^rND^sDratler^nG#^r
ND^sLazzati^nJM#^rND^sTilitzky^nS#et al#Unexpected peripheral markers of thyroid
 function in a patient with a novel mutation of the MCT8 thyroid hormone transpo
rter gene^len#Horm Res#20070000#2007#67#1-6#20110200#08.htm#0301-0163#Horm Res##
00734000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730100017000900100
02400107010002000131010001800151010001600169810000600185012010700191030002400298
06500090032206400050033103100030033601400070033986500090034600200070035503500100
0362801002400372#v55n1#V:\SciELO\serial\abem\v55n1\markup\08.htm#S#c#128#15#arti
cle#17#15#^rND^sWémeau^nJL#^rND^sPigeyre^nM#^rND^sProust-Lemoine^nE#^rND^sd'Herb
omez^nM#^rND^sGottrand^nF#^rND^sJansen^nT#et al#Beneficial effects of propylthio
uracil plus l-thyroxine treatment in a patient with a mutation in MCT8^len#J Cli
n Endocrinol Metab#20080000#2008#93#2084-8#20110200#08.htm#0021-972X#J Clin Endo
crinol Metab##
00745000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100021000730100020000940100
01300114010001800127010001600145010001700161810000600178012014900184030001200333
06500090034506400050035403100030035901400070036286500090036900200070037803500100
0385801001200395#v55n1#V:\SciELO\serial\abem\v55n1\markup\08.htm#S#c#129#16#arti
cle#17#16#^rND^sMaranduba^nCMC#^rND^sFriesema^nECH#^rND^sKok^nF#^rND^sKester^nMH
A#^rND^sJansen^nJ#^rND^sSertié^nAL#et al#Decreased cellular uptake and metabolis
m in Allan-Herndon-Dudley syndrome (AHDS) due to a novel mutation in the MCT8 th
yroid hormone transporter^len#J Med Genet#20060000#2006#43#457-60#20110200#08.ht
m#0022-2593#J Med Genet##
00738000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730100017000900100
01700107010001700124010001800141010002000159810000600179012013200185030001600317
06500090033306400050034203100030034701400080035086500090035800200070036703500100
0374801001600384#v55n1#V:\SciELO\serial\abem\v55n1\markup\08.htm#S#c#130#17#arti
cle#17#17#^rND^sFrints^nSG#^rND^sLenzner^nS#^rND^sBauters^nM#^rND^sJensen^nLR#^r
ND^sVan Esch^nH#^rND^sdes Portes^nV#et al#MCT8 mutation analysis and identificat
ion of the first female with Allan-Herndon-Dudley syndrome due to loss of MCT8 e
xpression^len#Eur J Hum Genet#20080000#2008#16#1029-37#20110200#08.htm#1018-4813
#Eur J Hum Genet##
00262000000000169000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640910009000660920007000750020007000827030
00300089#v55n1#V:\SciELO\serial\abem\v55n1\markup\09.htm#S#o#1#1#article#1#20110
324#154556#09.htm#87##
03462000000000565000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640710003000660400003000690010006000720420
00200078120000400080038000500084038000400089038000400093121000300097049000800100
15800030010803000260011103100030013703200020014006500090014201400090015103500100
01600120142001700120139003120100034004510100035004850100035005200100029005550100
03000584010004300614010003600657070012700693070005200820083099800872083096901870
11700060283907200020284511200090284711100120285611400090286811300120287700200070
2889#v55n1#V:\SciELO\serial\abem\v55n1\markup\09.htm#S#h#2#1#article#1#oa#en#br1
.1#1#4.0#ILUS#GRA#TAB#09#ABEM430#nd#Arq Bras Endocrinol Metab#55#1#20110200#^f67
^l71#0004-2730#New mutation in the CASR gene in a family with familial hypocalci
uric hypercalcemia (FHH) and neonatal severe hyperparathyroidism (NSHPT)^len#Nov
a mutação no gene CASR em uma família com hipercalcemia hipocalciúrica familiar 
(HHF) e hiperparatireoidismo neonatal grave (HPTNG)^lpt#^rND^1A01^nLuiza Souza^s
Rodrigues#^rND^1A02^nAna Carolina Arias^sCáu#^rND^1A01^nLuciane Zgoda^sBussmann#
^rND^1A02^nGabriela^sBastida#^rND^1A02^nOscar H.^sBrunetto#^rND^1A01^nPedro Henr
ique Silveira^sCorrêa#^rND^1A01^nRegina Matsunaga^sMartin#Universidade de São Pa
ulo^iA01^1Faculdade de Medicina^2Hospital das Clínicas^3Division of Endocrinolog
y^cSão Paulo^sSP^pBrazil#Hospital de Niños Pedro de Elizalde^iA02^pArgentina#^le
n^aA loss of calcium-sensing receptor (CASR) function due to inactivating mutati
ons can cause familial hypocalciuric hypercalcemia (FHH) or neonatal severe hype
rparathyroidism (NSHPT). NSHPT represents the most severe expression of FHH and 
courses as a life-threatening condition. The aim of this study was to identify a
nd characterize a CASR mutation in a female infant brought to the health service
 due to dehydration, apathy, lack of breast feeding and severe hypercalcemia. Mo
lecular analysis was performed on genomic DNA of the index case and her parents.
 A novel homozygous mutation (p.E519X) in CASR was identified in the proband; bo
th mother and father had the same mutation in heterozygous state, confirming the
ir FHH condition. The mutation results in a truncated and inactive protein due t
o the lack of transmembrane and intracellular domains. The identification of thi
s novel CASR gene mutation established the basis of hypercalcemia in this family
 and allowed a genetic counseling.#^lpt^aMutações inativadoras no gene do sensor
 do cálcio (CASR) podem causar hipercalcemia hipocalciúrica familiar (HHF) ou hi
perparatireoidismo neonatal grave (HPTNSG). A HPTNS representa a forma mais grav
e da HHF cursando com risco de vida. O objetivo deste estudo foi identificar e c
aracterizar uma mutação no gene CASR de uma criança do sexo feminino levada ao h
ospital em decorrência de desidratação, apatia, dificuldade para mamar e hiperca
lcemia grave. A análise molecular foi realizada a partir do DNA genômico do caso
 índice e de seus pais. Uma nova mutação em homozigose (p.E519X) foi identificad
a no caso índice; ambos, mãe e pai, apresentaram a mesma mutação em heterozigose
, o que os caracteriza como portadores de HHF. Essa alteração resulta em uma pro
teína truncada e inativa devido à falta dos domínios transmembrana e intracelula
r. A identificação dessa nova mutação estabeleceu a causa da hipercalcemia na fa
mília e permitiu o aconselhamento genético.#other#6#20100731#Jul/31/2010#2011011
9#Jan/19/2011#09.htm##
03525000000000565000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640710003000660400003000690010006000720420
00200078120000400080038000500084038000400089038000400093121000300097049000800100
15800030010803000260011103100030013703200020014006500090014201400090015103500100
01600120156001700120153003260100034004790100035005130100035005480100029005830100
03000612010004300642010003600685070012700721070005200848083101900900083098301919
11700060290207200020290811200090291011100120291911400090293111300120294000200070
2952#v55n1#V:\SciELO\serial\abem\v55n1\markup\09.htm#S#f#3#1#article#1#oa#en#br1
.1#1#4.0#ILUS#GRA#TAB#09#ABEM430#nd#Arq Bras Endocrinol Metab#55#1#20110200#^f67
^l71#0004-2730#<b>New mutation in the <i>CASR</i> gene in a family with familial
 hypocalciuric hypercalcemia (FHH) and neonatal severe hyperparathyroidism (NSHP
T)</b>^len#<b>Nova mutação no gene <i>CASR</i> em uma família com hipercalcemia 
hipocalciúrica familiar (HHF) e hiperparatireoidismo neonatal grave (HPTNG)</b>^
lpt#^rND^1A01^nLuiza Souza^sRodrigues#^rND^1A02^nAna Carolina Arias^sCáu#^rND^1A
01^nLuciane Zgoda^sBussmann#^rND^1A02^nGabriela^sBastida#^rND^1A02^nOscar H.^sBr
unetto#^rND^1A01^nPedro Henrique Silveira^sCorrêa#^rND^1A01^nRegina Matsunaga^sM
artin#Universidade de São Paulo^iA01^1Faculdade de Medicina^2Hospital das Clínic
as^3Division of Endocrinology^cSão Paulo^sSP^pBrazil#Hospital de Niños Pedro de 
Elizalde^iA02^pArgentina#^len^aA loss of calcium-sensing receptor (CASR) functio
n due to inactivating mutations can cause familial hypocalciuric hypercalcemia (
FHH) or neonatal severe hyperparathyroidism (NSHPT). NSHPT represents the most s
evere expression of FHH and courses as a life-threatening condition. The aim of 
this study was to identify and characterize a <i>CASR</i> mutation in a female i
nfant brought to the health service due to dehydration, apathy, lack of breast f
eeding and severe hypercalcemia. Molecular analysis was performed on genomic DNA
 of the index case and her parents. A novel homozygous mutation (p.E519X) in <i>
CASR</i> was identified in the proband; both mother and father had the same muta
tion in heterozygous state, confirming their FHH condition. The mutation results
 in a truncated and inactive protein due to the lack of transmembrane and intrac
ellular domains. The identification of this novel <i>CASR</i> gene mutation esta
blished the basis of hypercalcemia in this family and allowed a genetic counseli
ng.#^lpt^aMutações inativadoras no gene do sensor do cálcio (<i>CASR</i>) podem 
causar hipercalcemia hipocalciúrica familiar (HHF) ou hiperparatireoidismo neona
tal grave (HPTNSG). A HPTNS representa a forma mais grave da HHF cursando com ri
sco de vida. O objetivo deste estudo foi identificar e caracterizar uma mutação 
no gene <i>CASR</i> de uma criança do sexo feminino levada ao hospital em decorr
ência de desidratação, apatia, dificuldade para mamar e hipercalcemia grave. A a
nálise molecular foi realizada a partir do DNA genômico do caso índice e de seus
 pais. Uma nova mutação em homozigose (p.E519X) foi identificada no caso índice;
 ambos, mãe e pai, apresentaram a mesma mutação em heterozigose, o que os caract
eriza como portadores de HHF. Essa alteração resulta em uma proteína truncada e 
inativa devido à falta dos domínios transmembrana e intracelular. A identificaçã
o dessa nova mutação estabeleceu a causa da hipercalcemia na família e permitiu 
o aconselhamento genético.#other#6#20100731#Jul/31/2010#20110119#Jan/19/2011#09.
htm##
03594000000000589000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640640013000660710003000790400003000820010
00600085042000200091120000400093038000500097038000400102038000400106121000300110
04900080011315800030012103000290012403100030015303200020015606500090015801400090
01670350010001760120142001860120139003280100034004670100035005010100035005360100
02900571010002900600010004300629010003600672070012900708070005400837083099800891
08309690188911700060285807200020286411200090286611100120287511400090288711300120
2896002000702908008008902915#v55n1#V:\SciELO\serial\abem\v55n1\markup\09.htm#S#l
#4#1#article#1#^mFeb.^a2011#oa#en#br1.1#1#4.0#ilus#gra#tab#09#ABEM430#nd#Arq. br
as. endocrinol. metab#55#1#20110200#^f67^l71#0004-2730#New mutation in the CASR 
gene in a family with familial hypocalciuric hypercalcemia (FHH) and neonatal se
vere hyperparathyroidism (NSHPT)^len#Nova mutação no gene CASR em uma família co
m hipercalcemia hipocalciúrica familiar (HHF) e hiperparatireoidismo neonatal gr
ave (HPTNG)^lpt#^rND^1A01^nLuiza Souza^sRodrigues#^rND^1A02^nAna Carolina Arias^
sCáu#^rND^1A01^nLuciane Zgoda^sBussmann#^rND^1A02^nGabriela^sBastida#^rND^1A02^n
Oscar H^sBrunetto#^rND^1A01^nPedro Henrique Silveira^sCorrêa#^rND^1A01^nRegina M
atsunaga^sMartin#^iA01^1Universidade de São Paulo^2Faculdade de Medicina^3Hospit
al das Clínicas. Division of Endocrinology^cSão Paulo^sSP^pBrazil#^iA02^1Hospita
l de Niños Pedro de Elizalde^pArgentina#^len^aA loss of calcium-sensing receptor
 (CASR) function due to inactivating mutations can cause familial hypocalciuric 
hypercalcemia (FHH) or neonatal severe hyperparathyroidism (NSHPT). NSHPT repres
ents the most severe expression of FHH and courses as a life-threatening conditi
on. The aim of this study was to identify and characterize a CASR mutation in a 
female infant brought to the health service due to dehydration, apathy, lack of 
breast feeding and severe hypercalcemia. Molecular analysis was performed on gen
omic DNA of the index case and her parents. A novel homozygous mutation (p.E519X
) in CASR was identified in the proband; both mother and father had the same mut
ation in heterozygous state, confirming their FHH condition. The mutation result
s in a truncated and inactive protein due to the lack of transmembrane and intra
cellular domains. The identification of this novel CASR gene mutation establishe
d the basis of hypercalcemia in this family and allowed a genetic counseling.#^l
pt^aMutações inativadoras no gene do sensor do cálcio (CASR) podem causar hiperc
alcemia hipocalciúrica familiar (HHF) ou hiperparatireoidismo neonatal grave (HP
TNSG). A HPTNS representa a forma mais grave da HHF cursando com risco de vida. 
O objetivo deste estudo foi identificar e caracterizar uma mutação no gene CASR 
de uma criança do sexo feminino levada ao hospital em decorrência de desidrataçã
o, apatia, dificuldade para mamar e hipercalcemia grave. A análise molecular foi
 realizada a partir do DNA genômico do caso índice e de seus pais. Uma nova muta
ção em homozigose (p.E519X) foi identificada no caso índice; ambos, mãe e pai, a
presentaram a mesma mutação em heterozigose, o que os caracteriza como portadore
s de HHF. Essa alteração resulta em uma proteína truncada e inativa devido à fal
ta dos domínios transmembrana e intracelular. A identificação dessa nova mutação
 estabeleceu a causa da hipercalcemia na família e permitiu o aconselhamento gen
ético.#other#6#20100731#Jul/31/2010#20110119#Jan/19/2011#09.htm#Internet^ihttp:/
/www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27302011000100009##
00350000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000300064704013000067002000700197#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#5#1#article#77#<p align="right"><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>MOLECULAR    CLINICAL CASE</
b></font></p>     ^cY#09.htm##
00242000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000300064704002200067002000700089#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#6#2#article#77#<p>&nbsp;</p>     ^cY#09.htm
##
00478000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000300064704025800067002000700325#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#7#3#article#77#<p><a name="top"></a><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="4"><b>New    mutation in the <
i>CASR</i> gene in a family with familial hypocalciuric hypercalcemia    (FHH) a
nd neonatal severe hyperparathyroidism (NSHPT)</b></font></p>     ^cY#09.htm##
00242000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000300064704002200067002000700089#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#8#4#article#77#<p>&nbsp;</p>     ^cY#09.htm
##
00485000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000300064704026500067002000700332#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#9#5#article#77#<p><font face="Verdana, Aria
l, Helvetica, sans-serif" size="3"><b>Nova muta&ccedil;&atilde;o    no gene <i>C
ASR</i> em uma fam&iacute;lia com hipercalcemia hipocalci&uacute;rica    familia
r (HHF) e hiperparatireoidismo neonatal grave (HPTNG)</b></font></p>     ^cY#09.
htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000300065704002200068002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#10#6#article#77#<p>&nbsp;</p>     ^cY#09.ht
m##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000300065704002200068002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#11#7#article#77#<p>&nbsp;</p>     ^cY#09.ht
m##
00587000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000300065704036600068002000700434#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#12#8#article#77#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="2"><b>Luiza Souza    Rodrigues<sup>I</sup>; Ana
 Carolina Arias C&aacute;u<sup>II</sup>; Luciane Zgoda    Bussmann<sup>I</sup>; 
Gabriela Bastida<sup>II</sup>; Oscar H. Brunetto<sup>II</sup>;    Pedro Henrique
 Silveira Corr&ecirc;a<sup>III</sup>; Regina Matsunaga Martin<sup>III</sup></b><
/font></p>     ^cY#09.htm##
00522000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000300065704030100068002000700369#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#13#9#article#77#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="2"><sup>I</sup>Laboratory    of Molecular Genet
ics and Hormones (LIM/42), Division of Endocrinology, Hospital    das Cl&iacute;
nicas, Faculdade de Medicina, Universidade de S&atilde;o Paulo    (HC-FMUSP), S&
atilde;o Paulo, SP, Brazil    ^cY#09.htm##
00303000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704008100069002000700150#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#14#10#article#77#<br>   <sup>II</sup>Hospit
al de Ni&ntilde;os Pedro de Elizalde, Argentina    ^cY#09.htm##
00361000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704013900069002000700208#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#15#11#article#77#<br>   <sup>III</sup>Disea
ses Unit Osteometabolic, Division of Endocrinology, HC-FMUSP,    S&atilde;o Paul
o, SP, Brazil</font></p>     ^cY#09.htm##
00345000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704012300069002000700192#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#16#12#article#77#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><a href="#back">Correspondence    to</a></f
ont></p>     ^cY#09.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#17#13#article#77#<p>&nbsp;</p>     ^cY#09.h
tm##
00266000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704004400069002000700113#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#18#14#article#77#<p>&nbsp;</p> <hr size="1"
 noshade>     ^cY#09.htm##
00319000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704009700069002000700166#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#19#15#article#77#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>SUMMARY</b></font></p>     ^cY#09.htm##
01378000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704115600069002000701225#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#20#16#article#77#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A loss of calcium-sensing    receptor (CASR
) function due to inactivating mutations can cause familial hypocalciuric    hyp
ercalcemia (FHH) or neonatal severe hyperparathyroidism (NSHPT). NSHPT represent
s    the most severe expression of FHH and courses as a life-threatening conditi
on.    The aim of this study was to identify and characterize a <i>CASR</i> muta
tion    in a female infant brought to the health service due to dehydration, apa
thy,    lack of breast feeding and severe hypercalcemia. Molecular analysis was 
performed    on genomic DNA of the index case and her parents. A novel homozygou
s mutation    (p.E519X) in <i>CASR</i> was identified in the proband; both mothe
r and father    had the same mutation in heterozygous state, confirming their FH
H condition.    The mutation results in a truncated and inactive protein due to 
the lack of    transmembrane and intracellular domains. The identification of th
is novel <i>CASR</i>    gene mutation established the basis of hypercalcemia in 
this family and allowed    a genetic counseling.</font></p> <hr size="1" noshade
>     ^cY#09.htm##
00326000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704010400069002000700173#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#21#17#article#77#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>SUM&Aacute;RIO</b></font></p>     ^cY#09
.htm##
01556000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704133400069002000701403#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#22#18#article#77#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Muta&ccedil;&otilde;es    inativadoras no g
ene do sensor do c&aacute;lcio (<i>CASR</i>) podem causar hipercalcemia    hipoc
alci&uacute;rica familiar (HHF) ou hiperparatireoidismo neonatal grave    (HPTNS
G). A HPTNS representa a forma mais grave da HHF cursando com risco de    vida. 
O objetivo deste estudo foi identificar e caracterizar uma muta&ccedil;&atilde;o
    no gene <i>CASR</i> de uma crian&ccedil;a do sexo feminino levada ao hospita
l    em decorr&ecirc;ncia de desidrata&ccedil;&atilde;o, apatia, dificuldade par
a    mamar e hipercalcemia grave. A an&aacute;lise molecular foi realizada a par
tir    do DNA gen&ocirc;mico do caso &iacute;ndice e de seus pais. Uma nova muta
&ccedil;&atilde;o    em homozigose (p.E519X) foi identificada no caso &iacute;nd
ice; ambos, m&atilde;e    e pai, apresentaram a mesma muta&ccedil;&atilde;o em h
eterozigose, o que os    caracteriza como portadores de HHF. Essa altera&ccedil;
&atilde;o resulta em    uma prote&iacute;na truncada e inativa devido &agrave; f
alta dos dom&iacute;nios    transmembrana e intracelular. A identifica&ccedil;&a
tilde;o dessa nova muta&ccedil;&atilde;o    estabeleceu a causa da hipercalcemia
 na fam&iacute;lia e permitiu o aconselhamento    gen&eacute;tico.</font></p> <h
r size="1" noshade>     ^cY#09.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#23#19#article#77#<p>&nbsp;</p>     ^cY#09.h
tm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#24#20#article#77#<p>&nbsp;</p>     ^cY#09.h
tm##
00324000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704010200069002000700171#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#25#21#article#77#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>INTRODUCTION</b></font></p>     ^cY#09.h
tm##
01331000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704110900069002000701178#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#26#22#article#77#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The calcium sensing    receptor (CASR) is a
 G-protein coupled receptor well expressed in parathyroid    and renal tubule ce
lls that plays an essential role in calcium homeostasis.    About 200 mutations 
have previously been described in the <i>CASR</i> gene which    result in loss o
r gain of function. The most common are missense mutations.    Familial hypocalc
iuric hypercalcemia (FHH) and neonatal severe hyperparathyroidism    (NSHPT) can
 be associated with loss of CASR function. The first condition is    an autosoma
l dominant disease characterized by mild elevations of serum calcium    concentr
ation, lower urinary calcium, excretion and inappropriately normal PTH    levels
. Individuals with FHH are usually asymptomatic and the disorder is considered  
  benign. NSHPT represents the most severe expression of FHH and courses as a   
 life-threatening condition with severe hypercalcemia, hypotonia, bone demineral
ization,    fractures, and respiratory distress. Parathyroidectomy is essential 
for treatment    (1,2).</font></p>     ^cY#09.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#27#23#article#77#<p>&nbsp;</p>     ^cY#09.h
tm##
00323000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704010100069002000700170#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#28#24#article#77#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>CASE REPORT</b></font></p>     ^cY#09.ht
m##
00891000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704066900069002000700738#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#29#25#article#77#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A 36-day-old female    infant was brought t
o the health care service with dehydration, apathy, and    lack of breast feedin
g. She presented severe hypercalcemia, hypophosphatemia,    high levels of PTH w
ith normal renal function (<a href="/img/revistas/abem/v55n1/09t01.jpg">Table   
 1</a>). Chest X-ray showed a narrowed, bell-shaped rib cage (<a href="#f1">Figu
re    1</a>). The baby underwent subtotal parathyroidectomy because she remained
 hipercalcemic    despite of hydratation, furosemide and biphosphonate administr
ation. At that    moment, the diagnosis of NSHPT was suspected.</font></p>     ^
cY#09.htm##
00255000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704003300069002000700102#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#30#26#article#77#<p><a name="f1"></a></p>  
   ^cY#09.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#31#27#article#77#<p>&nbsp;</p>     ^cY#09.h
tm##
00299000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704007700069002000700146#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#32#28#article#77#<p align="center"><img src
="/img/revistas/abem/v55n1/09f01.jpg"></p>     ^cY#09.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#33#29#article#77#<p>&nbsp;</p>     ^cY#09.h
tm##
00812000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704059000069002000700659#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#34#30#article#77#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">After two months,    the infant returned to
 the Hospital de Ni&ntilde;os Pedro de Elizalde presenting    hypercalcemia recu
rrence and a skin lesion which rapidly evaluated to sepsis.    She was transferr
ed to the intensive care unit where she received appropriate    antibiotics and 
three doses of pamidronate to control hypercalcemia until a    total parathyroid
ectomy was possible (<a href="/img/revistas/abem/v55n1/09t01.jpg">Table    1</a>
 and <a href="/img/revistas/abem/v55n1/09f02.jpg">Figure 2</a>).</font></p>     
^cY#09.htm##
00680000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704045800069002000700527#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#35#31#article#77#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The second surgery    occurred when the pat
ient was 7 months of age and although the goal was to permamnently    correct hy
percalcemia, her follow-up lab tests showed mild elevated serum calcium    conce
ntrations and inappropriately normal PTH levels, probably due to an extra    num
bered or remained parathyroid (<a href="/img/revistas/abem/v55n1/09t01.jpg">Tabl
e    1</a>).</font></p>     ^cY#09.htm##
00684000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704046200069002000700531#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#36#32#article#77#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Nowadays, the child    is 6 years old, 101 
cm tall (SD -2.17), has normal bone age and she weighs 15.3    kg (SD -2.06). Fo
r the last 3 years to date, her diet has been hypocalcemic    (around 500 mg of 
calcium per day) and supplemented by 800 U/d of vitamin D.    There was no sign 
of nephrocalcinosis at renal ultrasonography, neither was    there any episode o
f bone fracture.</font></p>     ^cY#09.htm##
00555000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704033300069002000700402#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#37#33#article#77#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Her parents are    healthy, asymptomatic fo
r the disease, denied medication intake, consanguinity    or any similar case in
 the family. Almost all of their lab tests were normal,    although measurement 
was done only once (<a href="#t2">Table 2</a>).</font></p>     ^cY#09.htm##
00255000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704003300069002000700102#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#38#34#article#77#<p><a name="t2"></a></p>  
   ^cY#09.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#39#35#article#77#<p>&nbsp;</p>     ^cY#09.h
tm##
00299000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704007700069002000700146#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#40#36#article#77#<p align="center"><img src
="/img/revistas/abem/v55n1/09t02.jpg"></p>     ^cY#09.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#41#37#article#77#<p>&nbsp;</p>     ^cY#09.h
tm##
00570000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704034800069002000700417#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#42#38#article#77#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">In order to confirm    in the baby NSHPT di
sease caused by a CASR loss-of-function, its coding region    was analyzed from 
her genomic DNA. The parents' genomic DNAs were also studied    with the aim of 
knowing if the child's genetic condition was inherited or not.</font></p>     ^c
Y#09.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#43#39#article#77#<p>&nbsp;</p>     ^cY#09.h
tm##
00334000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704011200069002000700181#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#44#40#article#77#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>METHODS AND    RESULTS</b></font></p>   
  ^cY#09.htm##
01065000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704084300069002000700912#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#45#41#article#77#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The study protocol    was approved by the E
thics Committee, and informed consent was obtained from    the parents. Genomic 
DNA was extracted from peripheral blood leukocytes from    the patient and her p
arents. Ten intronic primer pairs were used to amplify    exons 2-7 from the <i>
CASR</i> gene, which encode the CASR protein. After amplification    confirmatio
n by electrophoresis in agarosis gel, PCR products were submitted    to automati
c sequencing reaction. A homozygous mutation (p.E519X) was identified    at exon
 5 of <i>CASR</i> in the DNA of the index case. Both mother and father    had th
e same mutation in heterozygous state (<a href="/img/revistas/abem/v55n1/09f03.j
pg">Figures    3</a> and <a href="/img/revistas/abem/v55n1/09f04.jpg">4</a>).</f
ont></p>     ^cY#09.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#46#42#article#77#<p>&nbsp;</p>     ^cY#09.h
tm##
00341000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704011900069002000700188#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#47#43#article#77#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>DISCUSSION AND    CONCLUSIONS</b></font>
</p>     ^cY#09.htm##
00893000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704067100069002000700740#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#48#44#article#77#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Although NSHPT    is a rare disease the sur
vival of children depends on early diagnosis and appropriate    treatment, usual
ly involving parathyroidectomy (3). In this case, it was decided    to perform a
 subtotal parathyroidectomy because the family belongs to a native    Indian com
munity located far from a any health care service and hypocalcemia    after tota
l parathyroidectomy could be more deleterious than mild hypercalcemia.    Howeve
r, follow-up of this case showed quick relapse with severe clinical repercussion
s    and a second surgery was necessary to control hypercalcemia.</font></p>    
 ^cY#09.htm##
00499000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704027700069002000700346#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#49#45#article#77#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The molecular basis    of NSHPT is a lack o
f <i>CASR</i> function that can be inherited (in this situation,    it was expec
ted that the parents were FHH) or secondary to <i>de novo</i> mutation.</font></
p>     ^cY#09.htm##
00893000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704067100069002000700740#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#50#46#article#77#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">FHH is characterized    by a persistent, no
n-progressive mild to moderate hypercalcemia, relative hypocalciuria,    and abs
ence of classical clinical features of primary hyperparathyroidism (PHTP).    Be
sides the suspected diagnosis after routine biochemical screening showing    hig
h blood calcium levels, another hint of FHH is the persistence or recurrence    
of hypercalcemia after surgical treatment of PHPT in members of the same kindred
    (4). It is a benign condition in which the patients may have nonspecific sym
ptoms    such as fatigue, weakness, painful joints, and headache.</font></p>    
 ^cY#09.htm##
00548000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704032600069002000700395#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#51#47#article#77#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">In this case, even    though the child's pa
rents had normal levels of total calcium we do not know    the values of ionized
 calcium neither the values of calcium albumin-adjusted.    Moreover there was o
nly one measurement for each individual.</font></p>     ^cY#09.htm##
00898000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704067600069002000700745#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#52#48#article#77#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Generally, PTH    levels in FHH are not sup
pressed by hypercalcemia and are inappropriately normal.    In a family studied 
by Zajickova and cols. it was demonstrated that the vitamin    D deficiency of p
roband, determined high levels of PTH which were normalized    after vitamin D r
epletion (5). In this family, at first glance, the mother's    PTH suggests seco
ndary hyperparathyroidism but, as she has FHH, probably her    vitamin D replace
ment should result in hypercalcemia with PTH in the upper limit.    In other wor
ds, her normocalcemia could be underestimated by vitamin D deficiency.</font></p
>     ^cY#09.htm##
00930000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704070800069002000700777#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#53#49#article#77#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">To assess relative    hypocalciuria, the ra
tio of renal calcium clearance to creatinine clearance    (Cl Ca/Cr) is determin
ed classically. In hypercalcemic cases, this clearance    ratio in FHH averages 
one third of that found in typical PHPT and a cut-off    value &lt; 0.01 is help
ful for diagnosis. This index was based on meta-analysis    showing a sensitivit
y of 81% for diagnosing FHH, with a specificity of 88% for    excluding PHPT (4)
. Our patient's parents disclosed normal ratios of Cl Ca/Cr    (<a href="#t2">Ta
ble 2</a>). Thus, based exclusively on their lab data, hardly    a FHH hypothesi
s could be considered.</font></p>     ^cY#09.htm##
00745000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704052300069002000700592#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#54#50#article#77#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The presence of    p.E519X mutation in the 
<i>CASR</i> of the infant patient, in homozygous state,    justifies the NSHPT p
henotype. The same mutation in her parents' DNAs, in heterozygous,    revealed t
he diagnosis of FHH and surprisingly confirmed its inherited origin.    Even if 
the parents denied consanguinity, the fact of belonging to a restricted    commu
nity in Argentina's southwestern (Mapuche tribe) suggests blood relationship.</f
ont></p>     ^cY#09.htm##
00823000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704060100069002000700670#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#55#51#article#77#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">When the study    was being carried out the
 couple had another child who died in early infancy    after presenting similar 
symptoms of the index case, probably in consequence    of hypercalcemia. On the 
other hand, calcium metabolism of the sister child    was only performed recentl
y and no abnormalities were found; her Cl Ca/Cr ratio    is 0.06 (<a href="/img/
revistas/abem/v55n1/09f03.jpg">Figure 3</a>). Although    late, the results of t
his research enable genetic counseling for future cases    of NSHPT or FHH.</fon
t></p>     ^cY#09.htm##
00853000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704063100069002000700700#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#56#52#article#77#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The p.E519X mutation    in the <i>CASR</i> 
has not been previously described and although it has not    been done an <i>in 
vitro</i> study we believe it is the cause of NSHPT phenotype    in our patient 
and of the FHH in her parents because the substitution of guanine    by thymine 
at nucleotide 1993 of the <i>CASR</i> gene predicts a stop codon    at 519 aa re
sulting in a truncated and inactive protein as consequence of loss    of the ful
l transmembrane and intracellular domains (<a href="/img/revistas/abem/v55n1/09f
04.jpg">Figure    4</a>).</font></p>     ^cY#09.htm##
00392000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704017000069002000700239#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#57#53#article#77#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Disclosure: no    potential conflict of int
erest relevant to this article was reported.</font></p>     ^cY#09.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#58#54#article#77#<p>&nbsp;</p>     ^cY#09.h
tm##
00322000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704010000069002000700169#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#59#55#article#77#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>REFERENCES</b></font></p>     ^cY#09.htm
##
00429000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000200069704019300071002000700264#v55
n1#V:\SciELO\serial\abem\v55n1\markup\09.htm#S#p#60#56#article#77#1#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">1. Thakker RV.    Diseases as
sociated with the extracellular calcium-sensing receptor. Cell Calcium.    2004;
35(3):275-82.    ^cY#09.htm##
00242000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002000069002000700089#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#61#57#article#77#</font></p>     ^cY#09.htm
##
00428000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000200069704019200071002000700263#v55
n1#V:\SciELO\serial\abem\v55n1\markup\09.htm#S#p#62#58#article#77#2#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">2. D'Souza-Li L.    The calci
um-sensing receptor and related diseases. Arq Bras Endocrinol Metabol.    2006;5
0(4):628-39.    ^cY#09.htm##
00242000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002000069002000700089#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#63#59#article#77#</font></p>     ^cY#09.htm
##
00542000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000200069704030600071002000700377#v55
n1#V:\SciELO\serial\abem\v55n1\markup\09.htm#S#p#64#60#article#77#3#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">3. Waller S, Kurzawinski    T
, Spitz L, Thakker R, Cranston T, Pearce S, et al. Neonatal severe hyperparathyr
oidism:    genotype/phenotype correlation and the use of pamidronate as rescue t
herapy.    Eur J Pediatr. 2004;163(10):589-94.    ^cY#09.htm##
00242000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002000069002000700089#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#65#61#article#77#</font></p>     ^cY#09.htm
##
00468000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000200069704023200071002000700303#v55
n1#V:\SciELO\serial\abem\v55n1\markup\09.htm#S#p#66#62#article#77#4#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">4. Gunn IR, Gaffney    D. Cli
nical and laboratory features of calcium-sensing receptor disorders: a    system
atic review. Ann Clin Biochem. 2004;41(Pt 6):441-58.    ^cY#09.htm##
00242000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002000069002000700089#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#67#63#article#77#</font></p>     ^cY#09.htm
##
00633000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000200069704039700071002000700468#v55
n1#V:\SciELO\serial\abem\v55n1\markup\09.htm#S#p#68#64#article#77#5#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">5. Zajickova K,    Vrbikova J
, Canaff L, Pawelek PD, Goltzman D, Hendy GN. Identification and functional    c
haracterization of a novel mutation in the calcium-sensing receptor gene in    f
amilial hypocalciuric hypercalcemia: modulation of clinical severity by vitamin 
   D status. J Clin Endocrinol Metab. 2007;92(7):2616-23.    ^cY#09.htm##
00242000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002000069002000700089#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#69#65#article#77#</font></p>     ^cY#09.htm
##
00494000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000200069704025800071002000700329#v55
n1#V:\SciELO\serial\abem\v55n1\markup\09.htm#S#p#70#66#article#77#6#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">6. Rodriguez M,    Nemeth E, 
Martin D. The calcium-sensing receptor: a key factor in the pathogenesis    of s
econdary hyperparathyroidism. Am J Physiol Renal Physiol. 2005;288(2):F253-64.  
  ^cY#09.htm##
00242000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002000069002000700089#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#71#67#article#77#</font></p>     ^cY#09.htm
##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#72#68#article#77#<p>&nbsp;</p>     ^cY#09.h
tm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#73#69#article#77#<p>&nbsp;</p>     ^cY#09.h
tm##
00417000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704019500069002000700264#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#74#70#article#77#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><a name="back"></a><a href="#top"><img src=
"/img/revistas/abem/v55n1/seta.jpg" border="0"></a>    <b>Correspondence to:</b>
     ^cY#09.htm##
00260000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704003800069002000700107#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#75#71#article#77#<br>   Regina Matsunaga Ma
rtin    ^cY#09.htm##
00274000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704005200069002000700121#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#76#72#article#77#<br>   Av. Dr. Eneas de Ca
rvalho Aguiar, 155    ^cY#09.htm##
00260000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704003800069002000700107#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#77#73#article#77#<br>   PAMB, 2º andar, Blo
co 6    ^cY#09.htm##
00277000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704005500069002000700124#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#78#74#article#77#<br>   05403-900 - S&atild
e;o Paulo, SP, Brazil    ^cY#09.htm##
00301000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704007900069002000700148#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#79#75#article#77#<br>   <a href="mailto:reg
inamm@usp.br">reginamm@usp.br</a></font></p>     ^cY#09.htm##
00316000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704009400069002000700163#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#80#76#article#77#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Received on Jul/31/2010    ^cY#09.htm##
00272000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704005000069002000700119#v55n1#V:\SciELO
\serial\abem\v55n1\markup\09.htm#S#p#81#77#article#77#<br>   Accepted on Jan/19/
2011</font></p>     ^cY#09.htm##
00515000000000277000450000400060000070200420000670500020004870600020005070000030
00527010002000557090008000577080002000651180002000670100018000690120072000870300
01300159065000900172064000500181031000300186032000200189014000700191865000900198
002000700207035001000214801001300224#v55n1#V:\SciELO\serial\abem\v55n1\markup\09
.htm#S#c#82#1#article#6#1#^rND^sThakker^nRV#Diseases associated with the extrace
llular calcium-sensing receptor^len#Cell Calcium#20040000#2004#35#3#275-82#20110
200#09.htm#0143-4160#Cell Calcium##
00529000000000277000450000400060000070200420000670500020004870600020005070000030
00527010002000557090008000577080002000651180002000670100020000690120054000890300
02800143065000900171064000500180031000300185032000200188014000700190865000900197
002000700206035001000213801002800223#v55n1#V:\SciELO\serial\abem\v55n1\markup\09
.htm#S#c#83#2#article#6#2#^rND^sD'Souza-Li^nL#The calcium-sensing receptor and r
elated diseases^len#Arq Bras Endocrinol Metabol#20060000#2006#50#4#628-39#201102
00#09.htm#0004-2730#Arq Bras Endocrinol Metabol##
00727000000000349000450000400060000070200420000670500020004870600020005070000030
00527010002000557090008000577080002000651180002000670100016000690100021000850100
01500106010001700121010001800138010001600156810000600172012011700178030001400295
06500090030906400050031803100040032303200030032701400070033086500090033700200070
0346035001000353801001400363#v55n1#V:\SciELO\serial\abem\v55n1\markup\09.htm#S#c
#84#3#article#6#3#^rND^sWaller^nS#^rND^sKurzawinski^nT#^rND^sSpitz^nL#^rND^sThak
ker^nR#^rND^sCranston^nT#^rND^sPearce^nS#et al#Neonatal severe hyperparathyroidi
sm: genotype/phenotype correlation and the use of pamidronate as rescue therapy^
len#Eur J Pediatr#20040000#2004#163#10#589-94#20110200#09.htm#0340-6199#Eur J Pe
diatr##
00559000000000277000450000400060000070200420000670500020004870600020005070000030
00527010002000557090008000577080002000651180002000670100015000690100017000840120
09600101030001700197065000900214064000500223031000300228014000700231865000900238
002000700247035001000254801001700264#v55n1#V:\SciELO\serial\abem\v55n1\markup\09
.htm#S#c#85#4#article#6#4#^rND^sGunn^nIR#^rND^sGaffney^nD#Clinical and laborator
y features of calcium-sensing receptor disorders: a systematic review^len#Ann Cl
in Biochem#20040000#2004#41#441-58#20110200#09.htm#0004-5632#Ann Clin Biochem##
00814000000000337000450000400060000070200420000670500020004870600020005070000030
00527010002000557090008000577080002000651180002000670100019000690100018000880100
01600106010001800122010001800140010001600158012020100174030002400375065000900399
06400050040803100030041303200020041601400080041886500090042600200070043503500100
0442801002400452#v55n1#V:\SciELO\serial\abem\v55n1\markup\09.htm#S#c#86#5#articl
e#6#5#^rND^sZajickova^nK#^rND^sVrbikova^nJ#^rND^sCanaff^nL#^rND^sPawelek^nPD#^rN
D^sGoltzman^nD#^rND^sHendy^nGN#Identification and functional characterization of
 a novel mutation in the calcium-sensing receptor gene in familial hypocalciuric
 hypercalcemia: modulation of clinical severity by vitamin D status^len#J Clin E
ndocrinol Metab#20070000#2007#92#7#2616-23#20110200#09.htm#0021-972X#J Clin Endo
crinol Metab##
00583000000000289000450000400060000070200420000670500020004870600020005070000030
00527010002000557090008000577080002000651180002000670100019000690100016000880100
01600104012010000120030002700220710000200247065000900249064000500258031000400263
032000200267014000800269865000900277002000700286#v55n1#V:\SciELO\serial\abem\v55
n1\markup\09.htm#S#c#87#6#article#6#6#^rND^sRodriguez^nM#^rND^sNemeth^nE#^rND^sM
artin^nD#The calcium-sensing receptor: a key factor in the pathogenesis of secon
dary hyperparathyroidism^len#Am J Physiol Renal Physiol#2#20050000#2005#288#2#F2
53-64#20110200#09.htm##
00263000000000169000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640910009000660920007000750020007000827030
00400089#v55n1#V:\SciELO\serial\abem\v55n1\markup\10.htm#S#o#1#1#article#1#20110
324#154600#10.htm#140##
03801000000000565000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640710003000660400003000690010006000720420
00200078120000400080038000500084038000400089121000300093049000800096158000300104
03000260010703100030013303200020013606500090013801400090014703500100015601200840
01660120083002500100036003330100038003690100036004070100032004430100035004750100
02900510010003400539010004100573010005200614070013300666083118400799083119401983
11700060317707200030318311200090318611100120319511400090320711300120321600200070
3228#v55n1#V:\SciELO\serial\abem\v55n1\markup\10.htm#S#h#2#1#article#1#oa#en#br1
.1#1#4.0#ILUS#TAB#10#ABEM430#nd#Arq Bras Endocrinol Metab#55#1#20110200#^f72^l77
#0004-2730#Clinical and molecular aspects of a pediatric metachronous adrenocort
ical tumor^len#Aspectos clínicos e moleculares de tumor adrenocortical metacrôni
co pediátrico^lpt#^rND^1A01^nLorena de Oliveira^sLima#^rND^1A01^nAntonio Marcond
es^sLerario#^rND^1A01^nGuilherme Asmar^sAlencar#^rND^1A01^nLuciana Pinto^sBrito#
^rND^1A01^nMadson Queiroz^sAlmeida#^rND^1A01^nSorahia^sDomenice#^rND^1A01^nAna C
laudia^sLatronico#^rND^1A01^nBerenice Bilharinho^sMendonca#^rND^1A01^nMaria Cand
ida Barrison Villares^sFragoso#Universidade de São Paulo^iA01^1Faculdade de Medi
cina^2Hospital das Clínicas^3Department of Internal Medicine^cSão Paulo^sSP^pBra
zil#^len^aThe occurrence of metachronous adrenocortical carcinoma has rarely bee
n described. We report a case of a child with virilizing adrenocortical metachro
nous tumors that, despite several metastases, presented long-term survival (15 y
ears). We analyzed in this tumor IGF2, IGF1R and FGFR4 gene expression, and eval
uated the presence of p.R337H germline p53 mutation and somatic CTNNB1 mutation.
 IGF2 gene was over-expressed in both left (Weiss score 5) and right (Weiss 7) a
drenocortical tumors. IGF1R expression levels were higher in the right adrenocor
tical tumor. FGFR4 over-expression was also detected in the right adrenocortical
 tumor. In addition, this patient harbors the germline p.R337H p53 mutation and 
loss of heterozygosity (LOH) was detected in the tumors. No somatic CTNNB1 mutat
ions were found in both tumors. In conclusion, we demonstrated in this unusual c
ase the over-expression of growth signaling pathways, which are molecular mechan
isms previously related to adrenocortical tumorigenesis. Furthermore, the absenc
e of somatic CTNNB1 mutations, which is a molecular marker of poor prognosis in 
adults, might be related to the long-term survival of this patient.#^lpt^aA ocor
rência de carcinomas adrenocorticais metacrônicos é raramente relatada. Descreve
mos o caso de uma criança portadora de tumor adrenocortical virilizante metacrôn
ico que, apesar das inúmeras metástases, apresentou uma longa sobrevida (15 anos
). Analisamos nesse tumor a expressão gênica de IGF2, IGF1R e FGFR4 e avaliamos 
a presença da mutação germinativa R337H no p53 e mutação somática no gene CTNNB1
. O gene IGF2 foi hiperexpresso nos tumores adrenocorticais esquerdo (Weiss 5) e
 direito (Weiss 7). Os níveis de expressão de IGF1R foram maiores no tumor direi
to. Hiperexpressão do gene FGFR4 também foi observada no tumor adrenocortical di
reito. Esse paciente é portador da mutação germinativa R337H no p53, e perda de 
heterozigose (LOH) foi observada em ambos os tumores. Não foram encontradas muta
ções no gene CTNNB1 nos tumores. Em conclusão, demonstramos neste caso a hiperex
pressão de vias moleculares de crescimento, que são mecanismos previamente relac
ionados à tumorigênese adrenocortical. Além disso, não encontramos mutações somá
ticas no gene CTNNB1, que é um marcador molecular de mau prognóstico em adultos 
e poderia estar relacionado à longa sobrevida desse paciente.#other#19#20100902#
Sept/2/2010#20101228#Dec/28/2010#10.htm##
03920000000000565000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640710003000660400003000690010006000720420
00200078120000400080038000500084038000400089121000300093049000800096158000300104
03000260010703100030013303200020013606500090013801400090014703500100015601200910
01660120090002570100036003470100038003830100036004210100032004570100035004890100
02900524010003400553010004100587010005200628070013300680083124000813083124302053
11700060329607200030330211200090330511100120331411400090332611300120333500200070
3347#v55n1#V:\SciELO\serial\abem\v55n1\markup\10.htm#S#f#3#1#article#1#oa#en#br1
.1#1#4.0#ILUS#TAB#10#ABEM430#nd#Arq Bras Endocrinol Metab#55#1#20110200#^f72^l77
#0004-2730#<b>Clinical and molecular aspects of a pediatric metachronous adrenoc
ortical tumor</b>^len#<b>Aspectos clínicos e moleculares de tumor adrenocortical
 metacrônico pediátrico</b>^lpt#^rND^1A01^nLorena de Oliveira^sLima#^rND^1A01^nA
ntonio Marcondes^sLerario#^rND^1A01^nGuilherme Asmar^sAlencar#^rND^1A01^nLuciana
 Pinto^sBrito#^rND^1A01^nMadson Queiroz^sAlmeida#^rND^1A01^nSorahia^sDomenice#^r
ND^1A01^nAna Claudia^sLatronico#^rND^1A01^nBerenice Bilharinho^sMendonca#^rND^1A
01^nMaria Candida Barrison Villares^sFragoso#Universidade de São Paulo^iA01^1Fac
uldade de Medicina^2Hospital das Clínicas^3Department of Internal Medicine^cSão 
Paulo^sSP^pBrazil#^len^aThe occurrence of metachronous adrenocortical carcinoma 
has rarely been described. We report a case of a child with virilizing adrenocor
tical metachronous tumors that, despite several metastases, presented long-term 
survival (15 years). We analyzed in this tumor <i>IGF2, IGF1R</i> and <i>FGFR4</
i> gene expression, and evaluated the presence of p.R337H germline p53 mutation 
and somatic <i>CTNNB1</i> mutation. <i>IGF2</i> gene was over-expressed in both 
left (Weiss score 5) and right (Weiss 7) adrenocortical tumors. <i>IGF1R</i> exp
ression levels were higher in the right adrenocortical tumor. <i>FGFR4</i> over-
expression was also detected in the right adrenocortical tumor. In addition, thi
s patient harbors the germline p.R337H p53 mutation and loss of heterozygosity (
LOH) was detected in the tumors. No somatic <i>CTNNB1</i> mutations were found i
n both tumors. In conclusion, we demonstrated in this unusual case the over-expr
ession of growth signaling pathways, which are molecular mechanisms previously r
elated to adrenocortical tumorigenesis. Furthermore, the absence of somatic <i>C
TNNB1</i> mutations, which is a molecular marker of poor prognosis in adults, mi
ght be related to the long-term survival of this patient.#^lpt^aA ocorrência de 
carcinomas adrenocorticais metacrônicos é raramente relatada. Descrevemos o caso
 de uma criança portadora de tumor adrenocortical virilizante metacrônico que, a
pesar das inúmeras metástases, apresentou uma longa sobrevida (15 anos). Analisa
mos nesse tumor a expressão gênica de <i>IGF2, IGF1R e FGFR4</i> e avaliamos a p
resença da mutação germinativa R337H no p53 e mutação somática no gene <i>CTNNB1
</i>. O gene <i>IGF2</i> foi hiperexpresso nos tumores adrenocorticais esquerdo 
(Weiss 5) e direito (Weiss 7). Os níveis de expressão de <i>IGF1R</i> foram maio
res no tumor direito. Hiperexpressão do gene <i>FGFR4</i> também foi observada n
o tumor adrenocortical direito. Esse paciente é portador da mutação germinativa 
R337H no p53, e perda de heterozigose (LOH) foi observada em ambos os tumores. N
ão foram encontradas mutações no gene <i>CTNNB1</i> nos tumores. Em conclusão, d
emonstramos neste caso a hiperexpressão de vias moleculares de crescimento, que 
são mecanismos previamente relacionados à tumorigênese adrenocortical. Além diss
o, não encontramos mutações somáticas no gene <i>CTNNB1</i>, que é um marcador m
olecular de mau prognóstico em adultos e poderia estar relacionado à longa sobre
vida desse paciente.#other#19#20100902#Sept/2/2010#20101228#Dec/28/2010#10.htm##
03932000000000589000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640640013000660710003000790400003000820010
00600085042000200091120000400093038000500097038000400102121000300106049000800109
15800030011703000290012003100030014903200020015206500090015401400090016303500100
01720120084001820120083002660100036003490100038003850100036004230100032004590100
03500491010002900526010003400555010004100589010005200630070013500682083118400817
08311940200111700060319507200030320111200090320411100120321311400090322511300120
3234002000703246008008903253#v55n1#V:\SciELO\serial\abem\v55n1\markup\10.htm#S#l
#4#1#article#1#^mFeb.^a2011#oa#en#br1.1#1#4.0#ilus#tab#10#ABEM430#nd#Arq. bras. 
endocrinol. metab#55#1#20110200#^f72^l77#0004-2730#Clinical and molecular aspect
s of a pediatric metachronous adrenocortical tumor^len#Aspectos clínicos e molec
ulares de tumor adrenocortical metacrônico pediátrico^lpt#^rND^1A01^nLorena de O
liveira^sLima#^rND^1A01^nAntonio Marcondes^sLerario#^rND^1A01^nGuilherme Asmar^s
Alencar#^rND^1A01^nLuciana Pinto^sBrito#^rND^1A01^nMadson Queiroz^sAlmeida#^rND^
1A01^nSorahia^sDomenice#^rND^1A01^nAna Claudia^sLatronico#^rND^1A01^nBerenice Bi
lharinho^sMendonca#^rND^1A01^nMaria Candida Barrison Villares^sFragoso#^iA01^1Un
iversidade de São Paulo^2Faculdade de Medicina^3Hospital das Clínicas. Departmen
t of Internal Medicine^cSão Paulo^sSP^pBrazil#^len^aThe occurrence of metachrono
us adrenocortical carcinoma has rarely been described. We report a case of a chi
ld with virilizing adrenocortical metachronous tumors that, despite several meta
stases, presented long-term survival (15 years). We analyzed in this tumor IGF2,
 IGF1R and FGFR4 gene expression, and evaluated the presence of p.R337H germline
 p53 mutation and somatic CTNNB1 mutation. IGF2 gene was over-expressed in both 
left (Weiss score 5) and right (Weiss 7) adrenocortical tumors. IGF1R expression
 levels were higher in the right adrenocortical tumor. FGFR4 over-expression was
 also detected in the right adrenocortical tumor. In addition, this patient harb
ors the germline p.R337H p53 mutation and loss of heterozygosity (LOH) was detec
ted in the tumors. No somatic CTNNB1 mutations were found in both tumors. In con
clusion, we demonstrated in this unusual case the over-expression of growth sign
aling pathways, which are molecular mechanisms previously related to adrenocorti
cal tumorigenesis. Furthermore, the absence of somatic CTNNB1 mutations, which i
s a molecular marker of poor prognosis in adults, might be related to the long-t
erm survival of this patient.#^lpt^aA ocorrência de carcinomas adrenocorticais m
etacrônicos é raramente relatada. Descrevemos o caso de uma criança portadora de
 tumor adrenocortical virilizante metacrônico que, apesar das inúmeras metástase
s, apresentou uma longa sobrevida (15 anos). Analisamos nesse tumor a expressão 
gênica de IGF2, IGF1R e FGFR4 e avaliamos a presença da mutação germinativa R337
H no p53 e mutação somática no gene CTNNB1. O gene IGF2 foi hiperexpresso nos tu
mores adrenocorticais esquerdo (Weiss 5) e direito (Weiss 7). Os níveis de expre
ssão de IGF1R foram maiores no tumor direito. Hiperexpressão do gene FGFR4 també
m foi observada no tumor adrenocortical direito. Esse paciente é portador da mut
ação germinativa R337H no p53, e perda de heterozigose (LOH) foi observada em am
bos os tumores. Não foram encontradas mutações no gene CTNNB1 nos tumores. Em co
nclusão, demonstramos neste caso a hiperexpressão de vias moleculares de crescim
ento, que são mecanismos previamente relacionados à tumorigênese adrenocortical.
 Além disso, não encontramos mutações somáticas no gene CTNNB1, que é um marcado
r molecular de mau prognóstico em adultos e poderia estar relacionado à longa so
brevida desse paciente.#other#19#20100902#Sept/2/2010#20101228#Dec/28/2010#10.ht
m#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-2730201
1000100010##
00351000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704013000068002000700198#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#5#1#article#117#<p align="right"><font face
="Verdana, Arial, Helvetica, sans-serif" size="2"><b>MOLECULAR    CLINICAL CASE<
/b></font></p>     ^cY#10.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704002200068002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#6#2#article#117#<p>&nbsp;</p>     ^cY#10.ht
m##
00411000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704019000068002000700258#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#7#3#article#117#<p><a name="top"></a><font 
face="Verdana, Arial, Helvetica, sans-serif" size="4"><b>Clinical    and molecul
ar aspects of a pediatric metachronous adrenocortical tumor</b></font></p>     ^
cY#10.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704002200068002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#8#4#article#117#<p>&nbsp;</p>     ^cY#10.ht
m##
00412000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704019100068002000700259#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#9#5#article#117#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="3"><b>Aspectos cl&iacute;nicos    e moleculares
 de tumor adrenocortical metacr&ocirc;nico pedi&aacute;trico</b></font></p>     
^cY#10.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000400065704002200069002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#10#6#article#117#<p>&nbsp;</p>     ^cY#10.h
tm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000400065704002200069002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#11#7#article#117#<p>&nbsp;</p>     ^cY#10.h
tm##
00553000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000400065704033100069002000700400#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#12#8#article#117#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>Lorena de Oliveira    Lima; Antonio Marc
ondes Lerario; Guilherme Asmar Alencar; Luciana Pinto Brito;    Madson Queiroz A
lmeida; Sorahia Domenice; Ana Claudia Latronico; Berenice Bilharinho    Mendonca
; Maria Candida Barrison Villares Fragoso</b></font></p>     ^cY#10.htm##
00534000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000400065704031200069002000700381#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#13#9#article#117#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Endocrinology Development    Unit, Division
 of Endocrinology, Department of Internal Medicine, Hospital das    Cl&iacute;ni
cas, Faculdade de Medicina da Universidade de S&atilde;o Paulo (HC-FMUSP),    S&
atilde;o Paulo, SP, Brazil</font></p>     ^cY#10.htm##
00346000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704012300070002000700193#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#14#10#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><a href="#back">Correspondence    to</a></
font></p>     ^cY#10.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#15#11#article#117#<p>&nbsp;</p>     ^cY#10.
htm##
00267000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704004400070002000700114#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#16#12#article#117#<p>&nbsp;</p> <hr size="1
" noshade>     ^cY#10.htm##
00320000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704009700070002000700167#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#17#13#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>SUMMARY</b></font></p>     ^cY#10.htm##
01609000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704138600070002000701456#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#18#14#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">The occurrence    of metachronous adrenoco
rtical carcinoma has rarely been described. We report    a case of a child with 
virilizing adrenocortical metachronous tumors that, despite    several metastase
s, presented long-term survival (15 years). We analyzed in    this tumor <i>IGF2
, IGF1R</i> and <i>FGFR4</i> gene expression, and evaluated    the presence of p
.R337H germline p53 mutation and somatic <i>CTNNB1</i> mutation.    <i>IGF2</i> 
gene was over-expressed in both left (Weiss score 5) and right (Weiss    7) adre
nocortical tumors. <i>IGF1R</i> expression levels were higher in the    right ad
renocortical tumor. <i>FGFR4</i> over-expression was also detected in    the rig
ht adrenocortical tumor. In addition, this patient harbors the germline    p.R33
7H p53 mutation and loss of heterozygosity (LOH) was detected in the tumors.    
No somatic <i>CTNNB1</i> mutations were found in both tumors. In conclusion,    
we demonstrated in this unusual case the over-expression of growth signaling    
pathways, which are molecular mechanisms previously related to adrenocortical   
 tumorigenesis. Furthermore, the absence of somatic <i>CTNNB1</i> mutations,    
which is a molecular marker of poor prognosis in adults, might be related to    
the long-term survival of this patient.</font></p> <hr size="1" noshade>     ^cY
#10.htm##
00327000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704010400070002000700174#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#19#15#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>SUM&Aacute;RIO</b></font></p>     ^cY#1
0.htm##
01879000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704165600070002000701726#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#20#16#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">A ocorr&ecirc;ncia    de carcinomas adreno
corticais metacr&ocirc;nicos &eacute; raramente relatada.    Descrevemos o caso 
de uma crian&ccedil;a portadora de tumor adrenocortical virilizante    metacr&oc
irc;nico que, apesar das in&uacute;meras met&aacute;stases, apresentou    uma lo
nga sobrevida (15 anos). Analisamos nesse tumor a express&atilde;o g&ecirc;nica 
   de <i>IGF2, IGF1R e FGFR4</i> e avaliamos a presen&ccedil;a da muta&ccedil;&a
tilde;o    germinativa R337H no p53 e muta&ccedil;&atilde;o som&aacute;tica no g
ene <i>CTNNB1</i>.    O gene <i>IGF2</i> foi hiperexpresso nos tumores adrenocor
ticais esquerdo (Weiss    5) e direito (Weiss 7). Os n&iacute;veis de express&at
ilde;o de <i>IGF1R</i>    foram maiores no tumor direito. Hiperexpress&atilde;o 
do gene <i>FGFR4</i> tamb&eacute;m    foi observada no tumor adrenocortical dire
ito. Esse paciente &eacute; portador    da muta&ccedil;&atilde;o germinativa R33
7H no p53, e perda de heterozigose (LOH)    foi observada em ambos os tumores. N
&atilde;o foram encontradas muta&ccedil;&otilde;es    no gene <i>CTNNB1</i> nos 
tumores. Em conclus&atilde;o, demonstramos neste caso    a hiperexpress&atilde;o
 de vias moleculares de crescimento, que s&atilde;o mecanismos    previamente re
lacionados &agrave; tumorig&ecirc;nese adrenocortical. Al&eacute;m    disso, n&a
tilde;o encontramos muta&ccedil;&otilde;es som&aacute;ticas no gene    <i>CTNNB1
</i>, que &eacute; um marcador molecular de mau progn&oacute;stico    em adultos
 e poderia estar relacionado &agrave; longa sobrevida desse paciente.</font></p>
 <hr size="1" noshade>     ^cY#10.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#21#17#article#117#<p>&nbsp;</p>     ^cY#10.
htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#22#18#article#117#<p>&nbsp;</p>     ^cY#10.
htm##
00325000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704010200070002000700172#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#23#19#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="3"><b>INTRODUCTION</b></font></p>     ^cY#10.
htm##
01383000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704116000070002000701230#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#24#20#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Adrenocortical    carcinoma is a rare tumo
r in childhood. However, the incidence of adrenocortical    tumors in children u
nder the age of 15 years (mostly diagnosed before the age    of 4) in Southeast 
Brazil is approximately 10 times greater than the worldwide    incidence that ra
nges from only 0.3-0.38 million per year (1). A unique germline    mutation of <
i>TP53</i> (R337H) underlies the genetic predisposition in this    population (1
-3). Pediatric adrenocortical tumors appear to behave differently    than histol
ogically similar tumors in the adult population (4). Unlike the dismal    surviv
al statistics in adult adrenocortical carcinoma series, pediatric adrenocortical
    tumors with apparent poor prognosis on the basis of histopathological featur
es    may often have a better outcome (5). Unfortunately, there are no histologi
cal    or molecular markers so far that can reliably distinguish benign from mal
ignant    adrenocortical tumors and define the prognosis. Clearly, the extent of
 surgical    resection is the most important factor in patient outcome (6).</fon
t></p>     ^cY#10.htm##
01101000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704087800070002000700948#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#25#21#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">The mechanisms    of adrenocortical tumori
genesis are still not fully understood, but several    data suggest that maligna
nt transformation is a multistep process (7). Molecular    studies of sporadic a
drenocortical tumors in the pediatric age group are limited    due to the rarity
 of this condition, however, since children seem to have a    better prognosis, 
it is important to determine whether the same molecular alterations    described
 in adults are also present in children, and whether this is related    to the o
utcome. We report the case of adrenocortical metachronous tumors presenting    i
n a child with long-term survival, emphasizing different molecular pathways    t
hat could be involved in the adrenocortical tumorigenesis and related to the    
benign evolution of this patient.</font></p>     ^cY#10.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#26#22#article#117#<p>&nbsp;</p>     ^cY#10.
htm##
00324000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704010100070002000700171#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#27#23#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="3"><b>CASE REPORT</b></font></p>     ^cY#10.h
tm##
01808000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704158500070002000701655#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#28#24#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">This study was    approved by the Ethics C
ommittee of Hospital das Cl&iacute;nicas (S&atilde;o    Paulo, Brazil). The pare
nts of this child provided informed consent, including    for the use of the pho
tographs, images and the report that follows. The patient    was born full term 
after an uncomplicated pregnancy and delivery. At 2 years    and 2 months of age
, the child presented with signs of virilization (pubic hair,    penis enlargeme
nt, growth acceleration and aggressiveness) (<a href="#f1">Figure    1</a>). At 
that time, his weight and height were 18.0 kg and 100.0 cm respectively    (heig
ht SD + 3.74). At physical examination he was found to have virilization    desc
ribed as prepubertal testis and more recent facial acne, deepening of the    voi
ce, and increased muscle mass, but no abdominal mass was palpable. The family   
 history was unremarkable. Laboratory evaluation demonstrated undetectable gonad
otropins    and abnormally elevated adrenal steroid levels: DHEA-S, 1790 ng/mL &
#91;normal    range &lt; 194 ng/mL&#93;; androstenedione, 2.0 ng/mL &#91;normal 
range &lt;    0.3-2.9 ng/mL&#93;, and testosterone, 395 ng/dL &#91;normal range 
&lt; 19 ng/dL&#93;,    characterizing isosexual precocious puberty independent o
f gonadotropins. Abdominal    computerized tomography (CT) showed a 2.0 cm mass 
in the left adrenal gland    (<a href="#f2">Figure 2</a>). The patient underwent
 surgical procedure and an    adrenal mass with 3.0 g of weight and 2.5 cm of di
ameter was resected.</font></p>     ^cY#10.htm##
00256000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704003300070002000700103#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#29#25#article#117#<p><a name="f1"></a></p> 
    ^cY#10.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#30#26#article#117#<p>&nbsp;</p>     ^cY#10.
htm##
00300000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704007700070002000700147#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#31#27#article#117#<p align="center"><img sr
c="/img/revistas/abem/v55n1/10f01.jpg"></p>     ^cY#10.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#32#28#article#117#<p>&nbsp;</p>     ^cY#10.
htm##
00256000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704003300070002000700103#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#33#29#article#117#<p><a name="f2"></a></p> 
    ^cY#10.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#34#30#article#117#<p>&nbsp;</p>     ^cY#10.
htm##
00300000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704007700070002000700147#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#35#31#article#117#<p align="center"><img sr
c="/img/revistas/abem/v55n1/10f02.jpg"></p>     ^cY#10.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#36#32#article#117#<p>&nbsp;</p>     ^cY#10.
htm##
00636000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704041300070002000700483#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#37#33#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">The adrenocortical    tumor had a histolog
ical Weiss score of 5 (8) and the MacFarlane modified by    Sullivan staging was
 I (9) (<a href="#t1">Table 1</a>). Postoperatively, the    signs of virilizatio
n disappeared and all tumor markers returned to their normal    ranges. At that 
time, the patient received no further treatment.</font></p>     ^cY#10.htm##
00256000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704003300070002000700103#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#38#34#article#117#<p><a name="t1"></a></p> 
    ^cY#10.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#39#35#article#117#<p>&nbsp;</p>     ^cY#10.
htm##
00300000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704007700070002000700147#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#40#36#article#117#<p align="center"><img sr
c="/img/revistas/abem/v55n1/10t01.jpg"></p>     ^cY#10.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#41#37#article#117#<p>&nbsp;</p>     ^cY#10.
htm##
02057000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704183400070002000701904#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#42#38#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Two years after    surgery the patient pre
sented signs of virilization all over again and, in addition,    frequent erecti
ons. Hormonal studies revealed elevated androgen levels (DHEA-S,    6,905 ng/mL 
&#91;normal range, &lt; 194 ng/mL&#93;; androstenedione, 8.1 ng/mL    &#91;norma
l range, 0.3-2.9 ng/mL&#93;, and testosterone, 403 ng/dL &#91;normal    range &l
t; 19 ng/dL&#93;). A novel right adrenal mass was discovered by an abdominal    
CT (<a href="#f3">Figure 3</a>). No secondary lesions were detected by radiologi
cal    studies at this time. The patient underwent surgical resection and intrao
perative    findings revealed a large (8.5 cm) tumor in the right adrenal gland.
 The mass    was apparently adherent to the kidney and a freezing biopsy showed 
invasion    of the capsule of the liver. The tumor was removed together with the
 right kidney    and with a small portion of the right lobe of the liver. The we
ight of the tumor    was 30.0 g and histological analysis revealed a Weiss score
 7. Although no signs    of invasion of the liver itself or the kidney were obse
rved the tumor was classified    as a carcinoma (MacFarlane modified by Sullivan
 staging III) (Table 1). Due    to the poor prognosis associated with this diagn
osis by the observation of invasion    of the liver capsule by freezing biopsy, 
the patient was immediately started    on mitotane. The dose was gradually incre
ased to 1 g/d. The patient was also    treated with replacement doses of cortiso
ne acetate and fludrocortisone. Five    months after tumor resection, the patien
t developed gynecomastia and severe    neurologic side effects, and mitotane was
 discontinued. He continued to receive    steroid replacement, and his adrenal m
arkers remained undetectable.</font></p>     ^cY#10.htm##
00256000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704003300070002000700103#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#43#39#article#117#<p><a name="f3"></a></p> 
    ^cY#10.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#44#40#article#117#<p>&nbsp;</p>     ^cY#10.
htm##
00300000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704007700070002000700147#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#45#41#article#117#<p align="center"><img sr
c="/img/revistas/abem/v55n1/10f03.jpg"></p>     ^cY#10.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#46#42#article#117#<p>&nbsp;</p>     ^cY#10.
htm##
00803000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704058000070002000700650#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#47#43#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">At 7 years and    8 months of age, his DHE
A-S levels increased to 272 ng/mL. This relapse was    secondary to a pulmonary 
metastasis, which was treated by surgery. Histology    confirmed metastatic nodu
le of adrenocortical carcinoma. Seven months after    this surgery, a novel elev
ation of DHEA-S levels was observed. A Positron emission    tomography-fludeoxyg
lucose (PET-FDG) scan and a chest CT showed a left hilar    pulmonary metastasis
, which was successfully removed by surgical procedure.</font></p>     ^cY#10.ht
m##
00425000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704020200070002000700272#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#48#44#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Nowadays, the patient    is 17 years old w
ith no evidence of new metastasis based on radiological imaging    follow-up.</f
ont></p>     ^cY#10.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#49#45#article#117#<p>&nbsp;</p>     ^cY#10.
htm##
00335000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704011200070002000700182#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#50#46#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="3"><b>METHODS AND    RESULTS</b></font></p>  
   ^cY#10.htm##
00331000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704010800070002000700178#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#51#47#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Molecular analysis</b></font></p>     ^
cY#10.htm##
01229000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704100600070002000701076#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#52#48#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">We have studied    different molecular pat
hways related to the pathophysiology in a male pediatric    case of metastatic a
drenocortical carcinoma with long-term follow-up and insidious    evolution. In 
trying to clarify the atypical tumor behavior in this case we    investigated th
e expression of different genes in the tumor's tissue: insulin    growth factor 
2 (<i>IGF2</i>, Taqman assay Hs01005963_m<sub>1</sub>, Applied    Biosystems, Fo
ster City, CA, USA) and its receptor (<i>IGF1R,</i> assay Hs00181385_m<sub>1</su
b>)    and fibroblast growth factor receptor 4 (<i>FGFR4</i>, assay Hs00242558_m
<sub>1</sub>).    Quantitative real-time PCR was performed as previously describ
ed (10,11). <i>IGF2</i>    gene was over-expressed in both left (Weiss score 5) 
and right (Weiss 7) adrenocortical    tumors. <i>IGF1R</i> expression levels wer
e higher in the right adrenocortical    tumor (fold change, 7.4 <i>vs.</i> 3.32)
.</font></p>     ^cY#10.htm##
00495000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704027200070002000700342#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#53#49#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">We also analyzed    the presence of mutati
ons in a particular region of genes coding for p53, a    tumor suppressor, and f
or beta-catenin (<i>CTNNB1</i>), a key component of Wnt    pathway.</font></p>  
   ^cY#10.htm##
01484000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704126100070002000701331#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#54#50#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Tumor DNA was extracted    according to st
andard procedures. Mutational analysis involving exon 3 of the    <i>CTNNB1</i> 
gene, which encodes beta-catenin, was performed using flaking    intronic sequen
ces of this exon. The primers used were 5' TGGGTCATATCACAGATTCTTTTTTT    3' and 
3'TCAAAACTGCATTCTGACTTTCA 5'. PCR was performed employing TAQ DNA polymerase    
(Promega). The amplified product was submitted to direct sequencing on an automa
ted    sequencer (ABI 7000 sequencer detection system - Applied Biosystems). Mut
ations    were verified in both sense and anti-sense directions. The entire exon
 10 of    the <i>TP53</i> gene was amplified and sequenced. In addition loss of 
heterozygosity    (LOH) was studied in both tumors as previously described (1,2)
. The patient    was found to be a carrier of the <i>TP53</i> R337H germinal mut
ation in a heterozygosis    pattern, which seems to be associated with a predisp
osition to adrenocortical    tumors without prognostic implications (2). In addi
tion, LOH was detected in    the left and right tumors. Analysis of <i>CTNNB1</i
> exon 3 showed no alterations    in both left and right tumors in comparison to
 wild type gene.</font></p>     ^cY#10.htm##
00344000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704012100070002000700191#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#55#51#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Immunohistochemical    analysis</b></fo
nt></p>     ^cY#10.htm##
00694000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704047100070002000700541#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#56#52#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">To investigate    the role of Wnt/beta-cat
enin signaling in tumorigenesis, beta-catenin expression    was studied by immun
ohistochemistry using a monoclonal mouse anti-human beta-catenin    antibody at 
the dilution of 1:200 (code: M3539 - Dakocytomation). In addition,    we perform
ed immunohistochemistry of p53, by P53 antibody at the dilution of    1:1000 (Cl
one DO7 - Dakocytomation).</font></p>     ^cY#10.htm##
00722000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704049900070002000700569#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#57#53#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">The usual distribution    of beta-catenin 
at the plasma membrane was demonstrated with no nucleus/cytoplasmic    staining,
 which is the normal pattern, since beta-catenin plays a role in the    cell-cel
l adhesion with cadherin (12). P53 immunohistochemistry analyzes showed    abnor
mal nuclear staining as expected, as the patient is a carrier of R337H    mutati
on in <i>TP53</i> (1,13) (<a href="#f4">Figure 4</a>).</font></p>     ^cY#10.htm
##
00256000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704003300070002000700103#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#58#54#article#117#<p><a name="f4"></a></p> 
    ^cY#10.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#59#55#article#117#<p>&nbsp;</p>     ^cY#10.
htm##
00300000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704007700070002000700147#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#60#56#article#117#<p align="center"><img sr
c="/img/revistas/abem/v55n1/10f04.jpg"></p>     ^cY#10.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#61#57#article#117#<p>&nbsp;</p>     ^cY#10.
htm##
00323000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704010000070002000700170#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#62#58#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="3"><b>DISCUSSION</b></font></p>     ^cY#10.ht
m##
02558000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704233500070002000702405#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#63#59#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">The diagnosis of    adrenocortical tumors 
in children is suspected mainly based on clinical signs    and symptoms of andro
gen hormones in excess, causing precocious pubarche. The    occurrence of isolat
ed Cushing's Syndrome due to the production of glucocorticoid    by an adrenocor
tical tumor is infrequent (3). Routine evaluation for suspected    adrenocortica
l tumors consists in the measurement of: DHEA-S, testosterone,    estradiol, LH,
 FSH, ACTH, androstenedione, 17-hydroxyprogesterone, aldosterone,    renin activ
ity, 11-deoxycortisol, and cortisol after low dose of overnight dexamethasone   
 (5). To date, adrenocortical tumors in children are unequivocally established  
  as carcinomas due to local recurrence or metastasis development. However, dist
inction    between adenoma and carcinoma can be very difficult to accomplish whe
n adrenocortical    neoplasms are diagnosed in the early stages, since there is 
yet no reliable    marker to predict tumor recurrence or dissemination. Pediatri
c adrenocortical    tumors classified as carcinomas based solely on histopatholo
gical Weiss criteria    often have favorable prognosis (14). Wieneke and cols. (
4) described some factors    that when identified in the aggregate appear to acc
urately predict a more aggressive    biologic behavior, which includes: tumor we
ight &gt; 400 g, tumor size &gt;    10.5 cm, extension into periadrenal soft tis
sues and/or adjacent organs, invasion    into the vena cava, venous invasion, ca
psular invasion, presence of tumor necrosis,    &gt; 15 mitoses per 20 HPF, and 
presence of atypical mitosis figures (4). Of    note is the presence of some of 
these histopathological criteria in both tumors    presented by the child (Table
 1), however, the tumors' weights and sizes are    beneath these ranges. Among v
arious clinical parameters that have been shown    to impact adrenocortical carc
inoma prognosis, tumor staging has been demonstrated    as one of the most impor
tant (13). The staging system for adrenocortical carcinomas    depends upon tumo
r size, nodal involvement, invasion of adjacent organs, and    presence of dista
nt metastasis (9). However, it is important to know that is    not uncommon for 
patients with small tumors to experience relapses.</font></p>     ^cY#10.htm##
01746000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704152300070002000701593#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#64#60#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">The pathophysiological    study of the adr
enocortical carcinoma is important to improve diagnosis, prognostic    evaluatio
n, and treatment. Analysis of exon 10 of the <i>TP53</i> gene revealed    that o
ur patient is a carrier of <i>TP53</i> R337H germinal mutation as is the    majo
rity of pediatric Brazilian patients with adrenocortical tumors. This mutation  
  is not related to a dismal behavior of this disease (2). <i>IGF2</i> overexpre
ssion    has been consistently demonstrated in adult sporadic adrenocortical car
cinomas.    <i>IGF2</i> exerts its mitogenic effects through interaction with <i
>IGF1R</i>    (15). Almeida and cols. (10) reported overexpression of <i>IGF2</i
> in both    pediatric adrenocortical adenomas and carcinomas; on the other hand
, <i>IGF1R</i>    m RNA levels were significantly higher in childhood adrenocort
ical carcinomas.    Both adrenocortical tumors reported here had a high expressi
on of <i>IGF2</i>    and <i>IGF1R</i>, but <i>IGF1R</i> expression was higher in
 the right tumor.    Studies have demonstrated that antagonizing the IGF signali
ng pathway with pharmacological    agents results in the inhibition of <i>in vit
ro</i> and <i>in vivo</i> tumor    cell growth. This raises the prospect of usin
g target disruption of the <i>IGF1R</i>    signaling pathway as a therapeutic ag
ent since this targeted inhibition was    apparently more potent than the use of
 mitotane in xenograft growth (10,15).</font></p>     ^cY#10.htm##
01370000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704114700070002000701217#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#65#61#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Tissier and cols.    (16) reported beta-ca
tenin anomalous staining at the nucleus and/or cytoplasm    in a high frequency 
of adult adrenocortical tumors, mainly in carcinomas. However,    the pattern di
ffered between these tumors. The abnormal beta-catenin immunostaining    was foc
al in most adrenocortical adenomas and diffuse in adrenocortical carcinomas.    
Until now, there is little information in medical literature about the participa
tion    of the Wnt pathway in pediatric adrenocortical tumorigenesis. Pusantisam
pan    T and cols. (17) reported a case of a child with metastatic adrenocortica
l carcinoma    presenting a somatic mutation of beta-catenin. Recently, somatic 
activating    mutations of the <i>CTNNB1</i> gene were associated as a poor prog
nostic factor    in adult adrenocortical carcinomas (18). In the present case, n
either abnormal    beta-catenin staining, nor mutation in the exon 3 beta cateni
n gene was observed.    The absence of this somatic molecular alteration might b
e related to the indolent    behavior of the patient's tumors.</font></p>     ^c
Y#10.htm##
00529000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704030600070002000700376#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#66#62#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">A previous microarray    analysis of pedia
tric adrenocortical tumors demonstrated high of expression    of <i>FGFR4</i> (1
9). In fact, an overexpression of <i>FGFR4</i> was observed    in the tumors of 
the patient reported.</font></p>     ^cY#10.htm##
01102000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704087900070002000700949#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#67#63#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Surgical resection    is the treatment of 
choice for patients with resectable primary and even metastatic    lesions (6). 
In addition, adjuvant mitotane therapy may be given to patients    in MacFarlane
 stage III and IV to increase the length of time between recurrences.    Mitotan
e has a cytotoxic effect on adrenocortical cells and it is effective    in contr
olling steroid excess in patients with secreting adrenocortical carcinoma;    bu
t patients often present symptoms due to the toxicity of this drug, which    is 
largely related to mitotane blood levels. Mitotane has been extensively used    
in adults, but there is little knowledge of its efficacy and long-term effects  
  in children. The role of chemotherapy in the management of adrenocortical carc
inoma    in children is not clear.</font></p>     ^cY#10.htm##
01040000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704081700070002000700887#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#68#64#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">After surgical    procedures the patient p
resented good evolution and to date he is receiving    glycocorticoid and minera
locorticoid replacement. Puberty has developed at the    expected age and the pa
tient achieved the target high. It is important to emphasize    that the cure ac
hieved for this particular patient may be related to total resection    of the t
umors and also of the metastasis. Of note, there is a risk for recurrence    eve
n after 10-12 years and complete resection of both adrenocortical tumors    and 
metastasis. Continued surveillance is still required. Also, we do not recommend 
   this patient, being a carrier of the <i>TP53</i> mutation, to smoke or have  
  contact with substances that might damage his DNA.</font></p>     ^cY#10.htm##
00393000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704017000070002000700240#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#69#65#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Disclosure: no    potential conflict of in
terest relevant to this article was reported.</font></p>     ^cY#10.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#70#66#article#117#<p>&nbsp;</p>     ^cY#10.
htm##
00323000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704010000070002000700170#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#71#67#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="3"><b>REFERENCES</b></font></p>     ^cY#10.ht
m##
00559000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704032200072002000700394#v55
n1#V:\SciELO\serial\abem\v55n1\markup\10.htm#S#p#72#68#article#117#1#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">1. Ribeiro RC,    Sandrini F
, Figueiredo B, Zambetti GP, Michalkiewicz E, Lafferty AR, et al.    An inherite
d p53 mutation that contributes in a tissue-specific manner to pediatric    adre
nal cortical carcinoma. Proc Natl Acad Sci. 2001;98(16):9330-5.    ^cY#10.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002000070002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#73#69#article#117#</font></p>     ^cY#10.ht
m##
00612000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704037500072002000700447#v55
n1#V:\SciELO\serial\abem\v55n1\markup\10.htm#S#p#74#70#article#117#2#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">2. Latronico AC,    Pinto EM
, Domenice S, Fragoso MCBV, Martin RM, Zerbini MC, et al. An inherited    mutati
on outside the highly conserved DNA-binding domain of the p53 tumor supressor   
 protein in children and adults with sporadic adrenocortical tumors. J Clin Endo
crinol    Metab. 2001;86(10):4970-3.    ^cY#10.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002000070002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#75#71#article#117#</font></p>     ^cY#10.ht
m##
00436000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704019900072002000700271#v55
n1#V:\SciELO\serial\abem\v55n1\markup\10.htm#S#p#76#72#article#117#3#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">3. Almeida MQ,    Latronico 
AC. The molecular pathogenesis of childhood adrenocortical tumors.    Horm Metab
 Res. 2007;39:461-6.    ^cY#10.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002000070002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#77#73#article#117#</font></p>     ^cY#10.ht
m##
00516000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704027900072002000700351#v55
n1#V:\SciELO\serial\abem\v55n1\markup\10.htm#S#p#78#74#article#117#4#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">4. Wieneke JA,    Thompson L
DR, Heffess CS. Adrenal cortical neoplasms in the pediatric population:    a cli
nicopathologic and immunophenotypic analysis of 83 patients. Am J Surg    Pathol
. 2003;27(7):867-81.    ^cY#10.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002000070002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#79#75#article#117#</font></p>     ^cY#10.ht
m##
00444000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704020700072002000700279#v55
n1#V:\SciELO\serial\abem\v55n1\markup\10.htm#S#p#80#76#article#117#5#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">5. Latronico AC,    Chrousos
 GP. Extensive personal experience: adrenocortical tumors. J Clin Endocrinol    
Metabol. 1997;82(5):1317-24.    ^cY#10.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002000070002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#81#77#article#117#</font></p>     ^cY#10.ht
m##
00432000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704019500072002000700267#v55
n1#V:\SciELO\serial\abem\v55n1\markup\10.htm#S#p#82#78#article#117#6#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">6. Barlaskar FM,    Hammer G
D. The molecular genetics of adrenocortical carcinoma. Rev Endocr Metab    Disor
d. 2007;8:343-8.    ^cY#10.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002000070002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#83#79#article#117#</font></p>     ^cY#10.ht
m##
00502000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704026500072002000700337#v55
n1#V:\SciELO\serial\abem\v55n1\markup\10.htm#S#p#84#80#article#117#7#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">7. Bernard MH,    Sidhu S, B
erger N, Peix JL, Marsh DJ, Robinson BG, et al. A case report in favor    of a m
ultistep adrenocortical tumorigenesis. J Clin Endocrinol Metabol. 2003;88(3):998
-1001.    ^cY#10.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002000070002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#85#81#article#117#</font></p>     ^cY#10.ht
m##
00528000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704029100072002000700363#v55
n1#V:\SciELO\serial\abem\v55n1\markup\10.htm#S#p#86#82#article#117#8#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">8. Augbert S, Wacrenier    A
, Leroy X, Devos P, Carnaille B, Proye C, et al. Weiss system revisited: a    cl
inicopathologic and immunohistochemical study of 49 adrenocortical tumors.    An
n J Surg Pathol. 2002;26:1612-9.    ^cY#10.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002000070002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#87#83#article#117#</font></p>     ^cY#10.ht
m##
00399000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704016200072002000700234#v55
n1#V:\SciELO\serial\abem\v55n1\markup\10.htm#S#p#88#84#article#117#9#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">9. Sullivan M,    Boileau M,
 Hodges CV. Adrenal cortical carcinoma. J Urol. 1978;120:660-5.    ^cY#10.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002000070002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#89#85#article#117#</font></p>     ^cY#10.ht
m##
00548000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000300070704031000073002000700383#v55
n1#V:\SciELO\serial\abem\v55n1\markup\10.htm#S#p#90#86#article#117#10#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">10. Almeida MQ,    Fragoso 
MCBV, Lofti CFP, Santos MG, Nishi MY, Costa MHS, et al. Expression of    insulin
-like growth factor-II and its receptor pediatric and adult adrenocortical    tu
mors. J Clin Endocrinol Metabol. 2008;93(9):3524-31.    ^cY#10.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002000070002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#91#87#article#117#</font></p>     ^cY#10.ht
m##
00567000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000300070704032900073002000700402#v55
n1#V:\SciELO\serial\abem\v55n1\markup\10.htm#S#p#92#88#article#117#11#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">11. Brito LP, Lerario    AM
, Bronstein MD, Soares IC, Medon&ccedil;a BB, Fragoso MCBV. Influence of the    
fibroblast growth factor receptor 4 expression and the G388R polymorphism on    
cushing disease outcome. J Clin Endocrinol Metabol. 2010;95(10):E271-9.    ^cY#1
0.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002000070002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#93#89#article#117#</font></p>     ^cY#10.ht
m##
00444000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000300070704020600073002000700279#v55
n1#V:\SciELO\serial\abem\v55n1\markup\10.htm#S#p#94#90#article#117#12#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">12. Kikuchi A.    Tumor for
mation by genetic mutations in the components of the wnt signaling    pathway. C
ancer Sci. 2003;94(3):225-9.    ^cY#10.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002000070002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#95#91#article#117#</font></p>     ^cY#10.ht
m##
00565000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000300070704032700073002000700400#v55
n1#V:\SciELO\serial\abem\v55n1\markup\10.htm#S#p#96#92#article#117#13#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">13. Lib&egrave;    R, Grous
sin L, Tissier F, Elie C, Ren&eacute;-Corail F, Fratticci A, et al.    Somatic T
P53 mutations are relatively rare among adrenocortical cancers with    the frequ
ent 17p13 loss of heterozygosity. Clin Cancer Res. 2007;13(3):844-50.    ^cY#10.
htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002000070002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#97#93#article#117#</font></p>     ^cY#10.ht
m##
00551000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000300070704031300073002000700386#v55
n1#V:\SciELO\serial\abem\v55n1\markup\10.htm#S#p#98#94#article#117#14#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">14. Mendonca BB,    Lucon A
M, Menezes CAV, Saldanha LB, Latronico AC, Zerbini C, et al. Clinical,    hormon
al and pathological findings in a comparative study of adrenocortical    neoplas
ms in childhood and adulthood. J Urol. 1995;154:2004-9.    ^cY#10.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002000070002000700090#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#99#95#article#117#</font></p>     ^cY#10.ht
m##
00542000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000300056709000800059708000400067888000300071704030300074002000700377#v55
n1#V:\SciELO\serial\abem\v55n1\markup\10.htm#S#p#100#96#article#117#15#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">15. Barlaskar FM,    Spald
ing AC, Heaton JH, Kuick R, Kim AC, Thomas DG, et al. Preclinical targeting    o
f the type I insulin-like growth factor receptor in adrenocortical carcinoma.   
 J Clin Endocrinol Metabol. 2009;94(1):204-12.    ^cY#10.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000300056709000800059708000400067704002000071002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#101#97#article#117#</font></p>     ^cY#10.h
tm##
00603000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000300056709000800059708000400067888000300071704036400074002000700438#v55
n1#V:\SciELO\serial\abem\v55n1\markup\10.htm#S#p#102#98#article#117#16#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">16. Tissier F,    Cavard C
, Groussin L, Perlemoine K, Fumey G, Hagner&eacute; AM, et al. Mutations    of b
eta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway   
 is a frequent event in both benign and malignant adrenocortical tumors. Cancer 
   Res. 2005;65(17):7622-7.    ^cY#10.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000300056709000800059708000400067704002000071002000700091#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#103#99#article#117#</font></p>     ^cY#10.h
tm##
00583000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704034300075002000700418#v55
n1#V:\SciELO\serial\abem\v55n1\markup\10.htm#S#p#104#100#article#117#17#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">17. Pusantisampan    T, S
angkhathat S, Kanngurn S, Kayasut K, Jaruratanasirikul S, Chotsampancharoan    T
, et al. Cushing's syndrome in an infant secondary to malignant adrenocortical  
  tumors with somatic mutation of beta-catenin. Pediatri Dev Pathol. 2009;13(3):
238-42.    ^cY#10.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#105#101#article#117#</font></p>     ^cY#10.
htm##
00657000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704041700075002000700492#v55
n1#V:\SciELO\serial\abem\v55n1\markup\10.htm#S#p#106#102#article#117#18#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">18. Ragazzon B,    Lib&ea
cute; R, Gaujoux S, Assi&eacute; G, Fratticci A, Launay P, et al. Transcriptome 
   analysis reveals that p53 and </font><font size="2">&#946;</font><font face="
Verdana, Arial, Helvetica, sans-serif" size="2">-catenin    alterations occur in
 a group of agressive adrenocortical cancers. Cancer Res.    2010;70(21):8276-81
.    ^cY#10.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#107#103#article#117#</font></p>     ^cY#10.
htm##
00488000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704024800075002000700323#v55
n1#V:\SciELO\serial\abem\v55n1\markup\10.htm#S#p#108#104#article#117#19#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">19. West AN, Neale    GA,
 Pounds S, Figueredo BC, Galindo CR, Pianovski MAD, et al. Gene expresion    pro
filing of childhood adrenocortical tumors. Cancer Res. 2007;67(2):600-8.    ^cY#
10.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002000072002000700092#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#109#105#article#117#</font></p>     ^cY#10.
htm##
00247000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002200072002000700094#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#110#106#article#117#<p>&nbsp;</p>     ^cY#1
0.htm##
00247000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002200072002000700094#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#111#107#article#117#<p>&nbsp;</p>     ^cY#1
0.htm##
00420000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704019500072002000700267#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#112#108#article#117#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2"><a name="back"></a><a href="#top"><img s
rc="/img/revistas/abem/v55n1/seta.jpg" border="0"></a>    <b>Correspondence to:<
/b>     ^cY#10.htm##
00263000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704003800072002000700110#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#113#109#article#117#<br>   Lorena de Olivei
ra Lima    ^cY#10.htm##
00248000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002300072002000700095#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#114#110#article#117#<br>   HC-FMUSP    ^cY#
10.htm##
00282000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704005700072002000700129#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#115#111#article#117#<br>   Disciplina de En
docrinologia e Metabologia    ^cY#10.htm##
00311000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704008600072002000700158#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#116#112#article#117#<br>   Laborat&oacute;r
io de Horm&ocirc;nios e Gen&eacute;tica Molecular LIM42    ^cY#10.htm##
00299000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704007400072002000700146#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#117#113#article#117#<br>   Av. Dr. Eneas de
 Carvalho Aguiar, 155 2&deg; andar, Bloco 6    ^cY#10.htm##
00279000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704005400072002000700126#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#118#114#article#117#<br>   05403-900, S&ati
lde;o Paulo, SP, Brazil    ^cY#10.htm##
00308000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704008300072002000700155#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#119#115#article#117#<br>   <a href="mailto:
lorenalima@usp.br">lorenalima@usp.br</a></font></p>     ^cY#10.htm##
00319000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704009400072002000700166#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#120#116#article#117#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2">Received on Sept/2/2010    ^cY#10.htm##
00275000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704005000072002000700122#v55n1#V:\SciELO
\serial\abem\v55n1\markup\10.htm#S#p#121#117#article#117#<br>   Accepted on Dec/
28/2010</font></p>     ^cY#10.htm##
00750000000000349000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100018000710100018000890100
02000107010001900127010002300146010001900169810000600188012011500194030001900309
06500090032806400050033703100030034203200030034501400070034886500090035500200070
0364035001000371801001900381#v55n1#V:\SciELO\serial\abem\v55n1\markup\10.htm#S#c
#122#1#article#19#1#^rND^sRibeiro^nRC#^rND^sSandrini^nF#^rND^sFigueiredo^nB#^rND
^sZambetti^nGP#^rND^sMichalkiewicz^nE#^rND^sLafferty^nAR#et al#An inherited p53 
mutation that contributes in a tissue-specific manner to pediatric adrenal corti
cal carcinoma^len#Proc Natl Acad Sci#20010000#2001#98#16#9330-5#20110200#10.htm#
0027-8424#Proc Natl Acad Sci##
00805000000000349000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100020000710100016000910100
01800107010002000125010001700145010001800162810000600180012016800186030002400354
06500090037806400050038703100030039203200030039501400070039886500090040500200070
0414035001000421801002400431#v55n1#V:\SciELO\serial\abem\v55n1\markup\10.htm#S#c
#123#2#article#19#2#^rND^sLatronico^nAC#^rND^sPinto^nEM#^rND^sDomenice^nS#^rND^s
Fragoso^nMCBV#^rND^sMartin^nRM#^rND^sZerbini^nMC#et al#An inherited mutation out
side the highly conserved DNA-binding domain of the p53 tumor supressor protein 
in children and adults with sporadic adrenocortical tumors^len#J Clin Endocrinol
 Metab#20010000#2001#86#10#4970-3#20110200#10.htm#0021-972X#J Clin Endocrinol Me
tab##
00532000000000277000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100018000710100020000890120
06600109030001500175065000900190064000500199031000300204014000600207865000900213
002000700222035001000229801001500239#v55n1#V:\SciELO\serial\abem\v55n1\markup\10
.htm#S#c#124#3#article#19#3#^rND^sAlmeida^nMQ#^rND^sLatronico^nAC#The molecular 
pathogenesis of childhood adrenocortical tumors^len#Horm Metab Res#20070000#2007
#39#461-6#20110200#10.htm#0018-5043#Horm Metab Res##
00640000000000301000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100018000710100020000890100
01800109012012500127030001700252065000900269064000500278031000300283032000200286
014000700288865000900295002000700304035001000311801001700321#v55n1#V:\SciELO\ser
ial\abem\v55n1\markup\10.htm#S#c#125#4#article#19#4#^rND^sWieneke^nJA#^rND^sThom
pson^nLDR#^rND^sHeffess^nCS#Adrenal cortical neoplasms in the pediatric populati
on: a clinicopathologic and immunophenotypic analysis of 83 patients^len#Am J Su
rg Pathol#20030000#2003#27#7#867-81#20110200#10.htm#0147-5185#Am J Surg Pathol##
00516000000000277000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100020000710100019000910120
05700110030002600167710000200193065000900195064000500204031000300209032000200212
014000800214865000900222002000700231#v55n1#V:\SciELO\serial\abem\v55n1\markup\10
.htm#S#c#126#5#article#19#5#^rND^sLatronico^nAC#^rND^sChrousos^nGP#Extensive per
sonal experience: adrenocortical tumors^len#J Clin Endocrinol Metabol#2#19970000
#1997#82#5#1317-24#20110200#10.htm##
00493000000000265000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100020000710100017000910120
05500108030002400163710000200187065000900189064000500198031000200203014000600205
865000900211002000700220#v55n1#V:\SciELO\serial\abem\v55n1\markup\10.htm#S#c#127
#6#article#19#6#^rND^sBarlaskar^nFM#^rND^sHammer^nGD#The molecular genetics of a
drenocortical carcinoma^len#Rev Endocr Metab Disord#2#20070000#2007#8#343-8#2011
0200#10.htm##
00657000000000337000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100018000710100015000890100
01600104010001500120010001600135010001900151810000600170012007100176030002600247
71000020027306500090027506400050028403100030028903200020029201400090029486500090
0303002000700312#v55n1#V:\SciELO\serial\abem\v55n1\markup\10.htm#S#c#128#7#artic
le#19#7#^rND^sBernard^nMH#^rND^sSidhu^nS#^rND^sBerger^nN#^rND^sPeix^nJL#^rND^sMa
rsh^nDJ#^rND^sRobinson^nBG#et al#A case report in favor of a multistep adrenocor
tical tumorigenesis^len#J Clin Endocrinol Metabol#2#20030000#2003#88#3#998-1001#
20110200#10.htm##
00669000000000325000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100017000710100019000880100
01500107010001500122010001900137010001500156810000600171012010600177030001800283
71000020030106500090030306400050031203100030031701400070032086500090032700200070
0336#v55n1#V:\SciELO\serial\abem\v55n1\markup\10.htm#S#c#129#8#article#19#8#^rND
^sAugbert^nS#^rND^sWacrenier^nA#^rND^sLeroy^nX#^rND^sDevos^nP#^rND^sCarnaille^nB
#^rND^sProye^nC#et al#Weiss system revisited: a clinicopathologic and immunohist
ochemical study of 49 adrenocortical tumors^len#Ann J Surg Pathol#2#20020000#200
2#26#1612-9#20110200#10.htm##
00508000000000289000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100018000710100017000890100
01700106012003100123030000700154065000900161064000500170031000400175014000600179
865000900185002000700194035001000201801000700211#v55n1#V:\SciELO\serial\abem\v55
n1\markup\10.htm#S#c#130#9#article#19#9#^rND^sSullivan^nM#^rND^sBoileau^nM#^rND^
sHodges^nCV#Adrenal cortical carcinoma^lpt#J Urol#19780000#1978#120#660-5#201102
00#10.htm#0022-5347#J Urol##
00700000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100018000730100020000910100
01700111010001700128010001600145010001700161810000600178012010700184030002600291
71000020031706500090031906400050032803100030033303200020033601400080033886500090
0346002000700355#v55n1#V:\SciELO\serial\abem\v55n1\markup\10.htm#S#c#131#10#arti
cle#19#10#^rND^sAlmeida^nMQ#^rND^sFragoso^nMCBV#^rND^sLofti^nCFP#^rND^sSantos^nM
G#^rND^sNishi^nMY#^rND^sCosta^nMHS#et al#Expression of insulin-like growth facto
r-II and its receptor pediatric and adult adrenocortical tumors^len#J Clin Endoc
rinol Metabol#2#20080000#2008#93#9#3524-31#20110200#10.htm##
00701000000000325000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730100018000890100
02000107010001700127010001800144010002000162012012200182030002600304710000200330
06500090033206400050034103100030034603200030034901400070035286500090035900200070
0368#v55n1#V:\SciELO\serial\abem\v55n1\markup\10.htm#S#c#132#11#article#19#11#^r
ND^sBrito^nLP#^rND^sLerario^nAM#^rND^sBronstein^nMD#^rND^sSoares^nIC#^rND^sMedon
ça^nBB#^rND^sFragoso^nMCBV#Influence of the fibroblast growth factor receptor 4 
expression and the G388R polymorphism on cushing disease outcome^len#J Clin Endo
crinol Metabol#2#20100000#2010#95#10#E271-9#20110200#10.htm##
00498000000000265000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730120088000900300
01100178710000200189065000900191064000500200031000300205032000200208014000600210
865000900216002000700225#v55n1#V:\SciELO\serial\abem\v55n1\markup\10.htm#S#c#133
#12#article#19#12#^rND^sKikuchi^nA#Tumor formation by genetic mutations in the c
omponents of the wnt signaling pathway^len#Cancer Sci#2#20030000#2003#94#3#225-9
#20110200#10.htm##
00739000000000349000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100014000730100018000870100
01700105010001400122010002100136010001900157810000600176012012300182030001600305
06500090032106400050033003100030033503200020033801400070034086500090034700200070
0356035001000363801001600373#v55n1#V:\SciELO\serial\abem\v55n1\markup\10.htm#S#c
#134#13#article#19#13#^rND^sLibè^nR#^rND^sGroussin^nL#^rND^sTissier^nF#^rND^sEli
e^nC#^rND^sRené-Corail^nF#^rND^sFratticci^nA#et al#Somatic TP53 mutations are re
latively rare among adrenocortical cancers with the frequent 17p13 loss of heter
ozygosity^len#Clin Cancer Res#20070000#2007#13#3#844-50#20110200#10.htm#1078-043
2#Clin Cancer Res##
00719000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100019000730100016000920100
01900108010001900127010002000146010001700166810000600183012012700189030000700316
06500090032306400050033203100040033701400070034186500090034800200070035703500100
0364801000700374#v55n1#V:\SciELO\serial\abem\v55n1\markup\10.htm#S#c#135#14#arti
cle#19#14#^rND^sMendonca^nBB#^rND^sLucon^nAM#^rND^sMenezes^nCAV#^rND^sSaldanha^n
LB#^rND^sLatronico^nAC#^rND^sZerbini^nC#et al#Clinical, hormonal and pathologica
l findings in a comparative study of adrenocortical neoplasms in childhood and a
dulthood^len#J Urol#19950000#1995#154#2004-9#20110200#10.htm#0022-5347#J Urol##
00693000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100020000730100019000930100
01700112010001500129010001400144010001700158810000600175012010400181030002600285
71000020031106500090031306400050032203100030032703200020033001400070033286500090
0339002000700348#v55n1#V:\SciELO\serial\abem\v55n1\markup\10.htm#S#c#136#15#arti
cle#19#15#^rND^sBarlaskar^nFM#^rND^sSpalding^nAC#^rND^sHeaton^nJH#^rND^sKuick^nR
#^rND^sKim^nAC#^rND^sThomas^nDG#et al#Preclinical targeting of the type I insuli
n-like growth factor receptor in adrenocortical carcinoma^len#J Clin Endocrinol 
Metabol#2#20090000#2009#94#1#204-12#20110200#10.htm##
00775000000000349000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730100016000900100
01800106010002000124010001500144010001800159810000600177012016700183030001100350
06500090036106400050037003100030037503200030037801400070038186500090038800200070
0397035001000404801001100414#v55n1#V:\SciELO\serial\abem\v55n1\markup\10.htm#S#c
#137#16#article#19#16#^rND^sTissier^nF#^rND^sCavard^nC#^rND^sGroussin^nL#^rND^sP
erlemoine^nK#^rND^sFumey^nG#^rND^sHagneré^nAM#et al#Mutations of beta-catenin in
 adrenocortical tumors: activation of the Wnt signaling pathway is a frequent ev
ent in both benign and malignant adrenocortical tumors^len#Cancer Res#20050000#2
005#65#17#7622-7#20110200#10.htm#0008-5472#Cancer res##
00733000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100023000730100021000960100
01800117010001700135010002700152010002700179810000600206012011900212030002000331
71000020035106500090035306400050036203100030036703200020037001400070037286500090
0379002000700388#v55n1#V:\SciELO\serial\abem\v55n1\markup\10.htm#S#c#138#17#arti
cle#19#17#^rND^sPusantisampan^nT#^rND^sSangkhathat^nS#^rND^sKanngurn^nS#^rND^sKa
yasut^nK#^rND^sJaruratanasirikul^nS#^rND^sChotsampancharoan^nT#et al#Cushing's s
yndrome in an infant secondary to malignant adrenocortical tumors with somatic m
utation of beta-catenin^len#Pediatri Dev Pathol#2#20090000#2009#13#3#238-42#2011
0200#10.htm##
00732000000000349000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100018000730100014000910100
01700105010001500122010001900137010001600156810000600172012012800178030001100306
06500090031706400050032603100030033103200030033401400080033786500090034500200070
0354035001000361801001100371#v55n1#V:\SciELO\serial\abem\v55n1\markup\10.htm#S#c
#139#18#article#19#18#^rND^sRagazzon^nB#^rND^sLibé^nR#^rND^sGaujoux^nS#^rND^sAss
ié^nG#^rND^sFratticci^nA#^rND^sLaunay^nP#et al#Transcriptome analysis reveals th
at p53 and &#946;-catenin alterations occur in a group of agressive adrenocortic
al cancers^len#Cancer Res#20100000#2010#70#21#8276-81#20110200#10.htm#0008-5472#
Cancer res##
00672000000000349000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100015000730100016000880100
01600104010002000120010001800140010002100158810000600179012006400185030001100249
06500090026006400050026903100030027403200020027701400060027986500090028500200070
0294035001000301801001100311#v55n1#V:\SciELO\serial\abem\v55n1\markup\10.htm#S#c
#140#19#article#19#19#^rND^sWest^nAN#^rND^sNeale^nGA#^rND^sPounds^nS#^rND^sFigue
redo^nBC#^rND^sGalindo^nCR#^rND^sPianovski^nMAD#et al#Gene expresion profiling o
f childhood adrenocortical tumors^len#Cancer Res#20070000#2007#67#2#600-8#201102
00#10.htm#0008-5472#Cancer res##
